{"title": "[Program, International Conference on AIDS (5th: 1989: Montreal, Canada)]", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2004-01-01", "cleaned_text": "_ ') LO [Page [unnumbered]](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/2) La Confirence organismes suivants pour leur ge'nreuse contribution: The V International Conference on AIDS thanks thefollowing organizations for their generous contributions: Santd et Bien-&tre social Canada Health and Welfare Canada L'Agence canadienne de ddveloppement international Canadian International Development Agency Le Centre de recherches pour le ddveloppement international International Development Research Centre L'Organisation mondiale de la sant6/World Health Organization Le Gouvemrnement du Qu6bec - Ministere de la Sant6 et des Services sociaux Le Secr6tariat d'ttat du Canada/Secretary of State of Canada Sandoz Australian International Development Agency La Soci6t6 canadienne de la Croix Rouge The Canadian Red Cross Society La Commission des Communaut6s europ6ennes Commission of the European Communities Overseas Development Administration-Britain L'Industrie des assurances de personnes au Canada The Life and Health Insurance Companies in Canada Organon-Teknika Le Gouvemrnement du Qu6bec - Ministbre du Tourisme Admiral Travel Agencies Ltd. Voyageur Travel Services The Upjohn Company Schering Canada, Inc. Genentech Inc. Syntex SI Lidl 0 1~ en M SECTION A SECTION B SECTION C SECTIOND SECTION E SECTION F SECTION G SECTION H SECTION I Medias Media Retransmission Overflow Affiches Posters [Page 1](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/3) Ve Conf6rence internationale sur le V International Conference on S BA~X AILS Le d6fi scientifique et social Montreal (Quebec) Canada du 4 au 9 juin 1989 Parrainde par le Centre de recherches pour le ddveloppement international, Santd et Bien-&tre social Canada, et I'Organisation mondiale de la sant6 En association avec: La Socidt6 internationale sur le SIDA The Scientific and Social Challenge Montreal, Quebec, Canada June 4 - 9, 1989 Sponsored by the International Development Research Centre, Health and Welfare Canada, and the World Health Organization In association with: The International AIDS Society PROGRAMME [Page 2](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/4) Table des matieres MESSAGES..................................................... 7 Message du Ministre de Sant6 et Bien-&tre social Canada.................................... 8 Message du Pr6sident du Centre de recherches pour le developpement international.................... 10 Message du directeur g6n6ral de l'organisation mondiale de la sant6...................... DE LA CONF~RENCE...................... 15 RENSEIGNEMENTS GtNtRAUX.............................. 23 Emplacement des services de la 24 par une universit6........................... 24 Aires de P.A.S. P.A.V.I.H........... 25 Assurances............................................................ 25 Autobus navette.......................................... 25 Bureau d'information............................................ 25 Bureau de change et services bancaires............... 26 Bureau de poste............................................. 26 Cassettes audio.......................................... 26 Cassettes vid6o...................................o........ 26 Centre de diffusion............................................. 26 Centre des m6dias................................. 26 Excursions touristiques......................................... 27 Exposition....................................o.........o... 27 H6bergement....................................................... 27 Information 7 Interpr6tation simultanee................................... 28 Journaux de la Conf6rence....................o............. 28 Messages (Bell Canada)....................................... 28 Pictogrammes............................... 29 Premiers soins........o................................... 30 Pr6sentations d'affiches...................................... 30 R6glementation l'usage du tabac................... 30 Restaurants....................................... 30 Service de rdservation de restaurants........ 31 R6servations de vols.................. 31 Retransmission 41 CARTES..................................................... 45 et centre-ville..................................... 46 Coupe du Palais..................................................... 48 ler dtage: inscription............................................ 50 ler dtage: affiches, retransmission, exposition.... GtNtRALES.................................. Auteurs 66 Auteurs de films et 67 Confdrenciers..................................... 67 Services offerts...................... 67 Pr6sidents d'assembl6es........................................ 68 PROGRAMME.................................................. 73 du Systeme numdrotation................................ 93 C6r6monie Lundi............................................... 659 Cer6monie prdsentateurs......................................... 664 vid o...........................692 [Page 4](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/6) Table of Contents M ESSAGES.................................................................... 7 A Message From the Minister of Health and Welfare Canada.............................. 9 A Message From The President of the International Research Centre.................... 11 A Message From the Director General of the Workd Health Organization....................... 13 COMMITTEES AND CONFERENCE PERSONNEL...................................... 15 GENERAL INFORMATION...................................... 23 Location of Conference Services......................... 33 Airline Reservations........................ 33 Audio Tapes................................................ 33 Broadcast Centre.......................................... 33 Conference News................................ 33 Exhibits................................................. 34 First Aid.............................................. 34 Foreign Exchange and Banking Facilities............ 34 Housing............................................. 34 Information Desk........................................... 34 Insurance.............................................. 35 Local Tours Desk........................................ 35 Media Centre.................................................. 35 Messages (Bell Canada)........................................ 35 Name Badges............................................ 35 Parking............................................ 35 Pictograms........................................... 36 Post-Conference Enquiries............................... 37 Post Office........................................... 37 Poster Presentation.................................. 37 Public Telephones............................................ 37 Public Transportation........................................... 37 Refreshments/Meals............................ 38 Registration Desk......................................... 38 Rest Areas for People with HIV/AIDS................. 38 Restaurants................................................. 38 Restaurant Reservation Service................. 39 Secretarial Services for Delegates..................... 39 Shuttle Buses............................................... 39 Simultaneous Interpretation................................. 39 Smoking Policy............................................ 39 University Accreditation...................................... 40 Video Overflow.......................................... 40 Video Tapes................................................ 40 4 [Page 5](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/7) SOCIAL ACTIVITIES................................................... 41 M A PS.............................................................................. 45 Hotels and Downtown...................................... 46 Cross section of Palais...................................... 48 1st floor: Registration....................................... 50 1st floor: Posters, overflow, exhibition................ 52 1st floor: Exhibition........................................ 54 4th floor: Convention floor................................... 56 6th floor: Cafeterias and overflow..................... 58 Guy-Favreau: Audiovisual programme................ 60 SIDART...................................... 62 GENERAL INSTRUCTIONS..................................... 65 Chairpersons........................................................ 69 Poster Presenters.......................................... 69 Speakers................................................ 70 Services Provided........................................ 71 Videotape Presenters............................ 71 PROGRAMME................................................. 73 Programme Summary....................................... 75 Key to Numbering.............................................. 93 Opening Ceremonies............................................. 95 Monday.................................................. 97 Tuesday..................................... 239 Wednesday......................................................... 377 Thursday............................. 519 Friday..................................... 659 Closing Ceremonies.............................................. 663 Presenting Authors Index.................................. - [Page 7](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/9) Mesae [Page 8](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/10) Message du Ministre de Sante et Bien-etre social Canada La V Confirence internationale sur le SIDA est un 6vdnement d6terminant de la r6ponse de ne s'6taient r6unis. Comme le combat nous donnera des forces. Au nom du gouvernement du Canada, je vous souhaite la bienvenue a la nous rentrera bagage de connaissances. Dans un esprit k apprendre SIDA. Perrin Beatty [Page 9](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/11) The Vlnternational Conference on AIDS is a milestone in humanity's response to AIDS. An unprecedented number of scientists, artists, educators, writers, policy makers and community-based AIDS organizations from around the world are taking part in this Conference. Like the fight against AIDS itself, this Conference is an international effort. Planning has taken place in every region of the world. Together we will face the challenge of AIDS. Our efforts will be strengthened by the urgent need for answers. On behalf of the Canadian government, I welcome all of you to the V International Conference on AIDS. The knowledge we share and gain here will return with each and every one of us to our respective communities and families. In the spirit of universal cooperation and compassion, we are ready to listen, to learn, and to work together in the fight against AIDS. Perrin Beatty A Message From the Minister of Health and Welfare Canada [Page 10](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/12) Message du president du Centre de recherches pour le developpement international Je vous remercie d'avoir accept6 notre invitation t V' le SIDA et pour le d6veloppement international, j'ai eu l'occasion de constater que la mise en commun de nos capacit6s intellectuelles cr6atrices va pair avec l'une des humaines les plus pr6cieuses: la entre le mandat du CRDI et le mandat qui unit ici tous les participants a cette V Confdrence internationale sur le SIDA. L'objectif est le meme: combattre l'ignorance, ou plut6t multiplier la connaissance en La menace du SIDA a d6clench6 l'6tat d'urgence et action doit A la fois ressortir le pire et le trag6die Cette conf6rence est une gageure sur la volont6 de communication et de collaboration, non seulement entre les pays du globe, mais aussi entre angoiss6e qui vit au jour le jour avec le SIDA. Ivan L. Head 10 [Page 11](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/13) I welcome you warmly to this extraordinary gathering, and express the thanks of the Steering Group for your participation in the V International Conference on AIDS. In preparing for this event, my associates and I have been privileged witnesses to the immense energies deployed by men and women in all parts of the world as they seek to understand and to come to grips with this pandemic of planetary proportions. The commitment to work and to share is a critical component of success. But it is more. My lengthy involvement with the International Develpment Research Centre has convinced me that the sharing of intellectual and creative effort is a reflection of one of the most precious of human traits the conviction that, working together, we are able to overcome adversity and to shape our future. The involvement of IDRC in this enterprise flows naturally from one of the Centre's key objectives, one which is remarkably similar to a major goal of this Conference: the overcoming of ignorance. More accurately, the broadening of knowledge through exchange and cooperation. The urgency of the AIDS tragedy demands a twofold reponse: the first, a campaign to counter the virus, and the second, an undertaking to sweep away the misinformation surrounding it. Such a response is not unprecendented. In each of the sectors essential to human wellbeing food, shelter, education, a wholesome environment, as well as in health problems are solved and standards of living raised only through the wise applications of knowledge broadly shared and disseminated. It is to that end that this Conference is dedicated. Through history, the great scourges have stimulated the best and the worst of human qualities. The AIDS pandemic is no exception. Daily, the media reflects the fear, the ignorance, the intolerance, and the resulting ostracism and regimentation of human distress that continue, sadly, to be present in so many communities. Yet coincidentally one finds increasing evidence of one compassion, sensitivity, understanding, and a collective commitment to humanitarian responses and to scientific research. This Conference is a testament to the willingness of human beings to communicate and cooperate at all levels of society, in all regions of the world. The V Conference theme takes the form of a challenge, one addressed to scientists in the biomedical and the other disciplines; one addressed to community organizations; one addressed to governments. That challenge reflects as well, we must never forget, one other: the struggle faced daily by those solitary, anguished individuals living with AIDS. Ivan L. Head A Message From the President of the International Research Centre 11 [Page 12](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/14) Message du directeur g6ndral la 6v6nement d'importance majeure dans le cadre monde pour connaitre, pr6venir communaut6 scientifique internationale est en train de construire au-deli et l'ouverture sa premibre r6union en mars 1989, la Commission mondiale du SIDA a d6nonc6 le danger de relachement. Elle a exprim6 son voir combattre les attitudes de rejet, car il ne faut pas que diminue pr6venir l'infection d'unifier les d6ploy6s a l'6chelon national et international pour contre le En temps, complexes, d6jA anciens et pr6existants que le SIDA a mis en relief au sein de nos systhmes sanitaires et sociaux. Au moment oii la sur pr6vention la lutte contre le SIDA. Notre tache aujourd'hui consiste a miser sur nos ressources et notre exp6rience, h identifier les lacunes les plus i partager r6serve propre Dr. Hiroshi Nakajima 12 [Page 13](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/15) As the specialized agency of the United Nations responsible for directing and coordinating international health work, the World Health Organization is pleased, once again, to co-sponsor this Conference. Each year, the International Conference on AIDS represents a key event in the global effort to understand, and to prevent and control, AIDS. The past four conferences have become landmarks -each in its own say - as the international scientific community forges new lines of communication across geographical boundaries and across disciplines - behavioural, clinical, biomedical, social, economic and political. We have also seen that, as knowledge of AIDS has grown, the issues and concerns it generates become increasingly complex, far exceeding the level usually seen in health programmes. The danger of complacency was voiced by the Global Commission on AIDS at its inaugural meeting in Geneva in March 1989. The Commission was concerned that, in some areas, there had been a decline in official and individual appreciation of the urgency of AIDS. We must all continue to fight denial, for we must not diminish our commitment to preventing HIV infection, reducing its personal and social impact, and unifying national and international efforts against AIDS. At the same time we must utilize the opportunity to re-examine some of the complex,long-standing and pre-existing problems that AIDS has highlighted in our health and social systems. As you commence the V International Conference on AIDS, you are challenged by the past, and by the uncharted future of global AIDS prevention and control. Our challenge now is to build on existing strengths and experience, to identify critical gaps, and to share openly our successes and failures with the confidence that we can all learn from each other and thereby strengthen our own contribution to the global effort against AIDS. Dr. Hiroshi Nakajima A Message From the Director General of the World Health Organization 13 tous ceux qui ont contribud de leur temps de leurs energies a la r\"alisation de cet evednement The VInternational Conference on AIDS wishes to express its gratitude to all those who have contributed to this event's success. Groupe directeur Steering Group Comit6 de programme Programme Committee Prdsident/Chairman Jonathan M. Mann Ivan L. Head Richard A. Morisset Martin T. Schechter Marie Berlinguet Manuel Carballo Directeur general Alastair J. Clayton Executive Director Joel Finlay Claude Paul Boivin Lars Olof Kallings Prdsident/Chairman Richard A. Morisset A. tpid6miologie et sant6 publique Epidemiology and Public Health Coordonnateur Coordinator Robert S. Remis Michel Alary Randall A. Coates Richard Lessard Francis A. Plummer Michael Rekart B. Aspects cliniques Clinical Aspects Coordonnateur Coordinator Michel G. Bergeron Mary M. Fanning Norbert J. Gilmore Sabih R. Khan Diane Lalande Normand Jolicoeur Jean Latreille Michael V. O'Shaughnessy Louis F. Qualtiere Stanley E. Read D. Le SIDA et l'individu AIDS and the Individual Coordonnateurs Coordinators Catherine Morissette Alix Smith Margaret Somerville 16 [Page 17](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/19) E. Le SIDA, la soci6t6 et le comportement AIDS, Society and Behaviour Coordonnateur Coordinator Pierre Dionne David Bennett Gilles Bibeau Richard Burzynski Elaine Carey-B6langer Guy R. Miriam Jean Usher Anne V. Whyte H. R6percussions 6conomiques du SIDA The Impact of AIDS Coordonnateurs Coordinators Margaret Duckett Andr6-Pierre Contandriopoulos Rod Jacques Ross I. Pr6sentations audiovisuelles Audiovisual Presentations Coordonnateur Morrison Greyson Colette Lachance Ren6 Lavoie Guy Lonergan Georges Tarjan Tom F. Droit et 6thique Ethics and Law Coordonnateurs Coordinators David Bernard Dickens Jean-Louis Krever T. Implications Issues Coordonnateurs Coordinators Allan R. Ronald Pierre Viens lona V. Campagnolo Stephen Simon Richard Wilson 17 [Page 18](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/20) Comit6 du programme Membres internationaux Programme Committee International Members President/Chairman Dr. Richard A. Morisset SECTION A Roy M. Anderson (United Kingdom) June Balthazar (Philippines) C. Bartholomew (Trinidad and Tobago) Jean-Baptiste Brunet (France) John Chipanghwe (Malawi) James Chin (WHO) James Curran (USA) Donald Francis (USA) Neal Halsey (USA) Harold W. Jaffe (USA) Richard A. Kaslow (USA) Mads Melbye (Denmark) Gary R. Noble (USA) S.I. Okware (Uganda) June Osbom (USA) Jean Pape (Haiti) (Thailand) Bertino Somaini (Switzerland) SECTION B Robert E. Allen (USA) Nathan Clumeck (Belgium) David Cooper (Australia) J.P. Coulaud (France) Peter Eriki (Sweden) J. Goudsmit (The Netherlands) H. Husrev Hatemi (Turkey) Martin S. Hirsch (USA) King K. Holmes (USA) Leteiev Jemni Helen I. Joller-Jemelka (Switzerland) Bila M. Kaplan (USA) Victor Lorian (USA) Andr6 Lefesvre (France) David Miller (United Kingdom) Yves Mouton (France) Abraham Morag (Israel) Rafael Najera (Spain) B. Oberg (Sweden) Roger (Guyanne Germany) Willy Rozenbaum (France) (Israel) Merle Sande (USA) Gary Slutkin Giuseppe Visco Paul Volberding (USA) Hetty Waskin (USA) Wofsy (USA) De The (France) Peter Ebbensen (Denmark) Jos6 Esparza (WHO) Myron Essex (USA) Anthony S. Fauci (USA) Eva-Maria Fenyo (Sweden) Robert C. Gallo (Brazil) Gaetano Giraldo (Italy) Jean-Claude Gluckman (France) Ian D. Gust (Australia) William A. Haseltine (USA) Yorio Hinuma (Japan) Takashi Kitamura (Japan) David Klatzmann (France) George Klein (Sweden) Kai Krohn (USA) Jay A. Levy (USA) Souleymane M'Boup (Senegal) Fred Mhalu (Tanzania) Luc Montagnier (France) James Mullins (USA) Akira Oya (Japan) Gerald V. Quinnan (USA) Giovanni B. Rossi (Italy) 18 [Page 19](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/21) Geoffrey C. Schild (United Kingdom) Pei-zhen Tao (People Republic of China) Simon Wain-Hobson (France) Robin A. Weiss (United Kingdom) Flossie Wong-Staal (USA) Daniel Zagury (France) SECTION D Lawrence Adeookun (Nigeria) Ernst Buning (USA) Manuel Carballo (WHO) Judith B. Cohen (USA) Roel Coutinho (The Netherlands) Robert G. Covell (United Kingdom) William Darrow (USA) Daniel Defert (France) Don C. Des Jarlais (USA) Michiko Fakazawa (Japan) Timothy W. Harding (WHO) Fathia Mahmoud (Sudan) Leonardo Mata (Costa Rica) Amir Mehryar (Iran) David Miller (New Zealand) Janet Mitchell (USA) Jan-Olaf Morfeldt (Sweden) Eustace Muhondwa (Tanzania) David Nabarro (United Kingdom) Elizabeth Ngugi (Kenya) D.S. Obikeze (Nigeria) Willie Pasini (Switzerland) Peter Selwyn (USA) Fritz Van Dam (Holland) Frangoise Weil-Halpem (France) SECTION E Donald Abrams (USA) Maxine Ankrah (Uganda) Jacqueline Bonneau (France) Doreen Boyd (Switzerland) Jeffrey L. Carples (USA) Maria Da Penha Silva R. Franco (Brazil) Iris L. Davis (USA) Fod6 Diouf (Senegal) William Hartley (New South Wales) Aart Hendriks (Denmark) Paul Kawata (USA) Andr6 Rauget (France) Ryan (USA) Ren6e Sabatier (United Kingdom) Inon Schenker (Israel) Kathleen Toomey (USA) Vincke (Belgium) Akiko Yagi (Japan) SECTION F John Arras (USA) Ronald Bayer (USA) Vera Boltho-Massarelli (France) Edouard Bon6 (Belgium) Susan S. Connor (USA) Robert Delizee (Belgium) Netherlands) De Sweener (Senegal) Sev S. Fluss (WHO) Raanan Gillon (United Kingdom) Kevin Gordon (USA) Larry Gostin (USA) Albert R. Jonsen (USA) Ian M. Kennedy (United Kingdom) Rihito Kimura (Japan) Michael Kirby (Australia) Nancy Lee Jones (USA) Robert Levine (USA) Ruth Macklin (USA) Wendy K. Mariner (USA) Vivienne H. Nathanson (United Kingdom) Henriette D.C. Roscam Abbing (The Netherlands) Earl E. Shelp (USA) Manfred Steinbach (Federal Republic of Germany) Pere Paul Sye (Korea) SECTION G G. P. Acharya (Nepal) Kazem Ngaly Geoffrey Carliner (USA) M. Chakravarty (India) C. S. Chutani (India) Vincent Dan (Benin) 19 [Page 20](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/22) Gloria Echeverria de Perez (Venezuela) Oscar Fay (Argentina) A. J. Georges (Central Africa Republic) Lair Guerra de Macedo Rodriguez (Brazil) Ali Guindo (Mali) Indira Kapoor (India) Lazare Kaptue (Cameroun) Ong Kok Hai (Malaysia) Yamil H. Kouri (USA) A. S. Lalif (Zimbabwe) Francisco A. Machado Ramirez (Cuba) A. N. Malaviya Mguemby C. Ofelia Bemardin Niragira (Burundi) Didace Nzaramba (Rwanda) Patricia O'Connor (Costa Rica) A. O. Osoba (Saudi Arabia) A. Outtara (Cote Swaminathan (India) Daniel Tarantola (WHO) Amnuay Traisupa (Thailand) J. L. Valdespino (Mexico) Jack Wirima (Malawi) Ong Yong Wan (Singapore) SECTION H Dennis Andrulis (USA) Jacques Baudouy (USA) Gabriel Bez (France) Geoffrey Carliner (USA) Nick Drager (WHO) Anne Johnson (United Kingdom) Kenneth Kizer (USA) Guiseppe Marasca (Italy) Mary Pittman-Lindeman (USA) SECTION I Christa Brunswicher (Switzerland) Jan Zita Len Hilgermann Sahlsberg (FRG) Wieland Speck (West Germany) 20 [Page 21](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/23) Claude Paul Boivin Bernard Dagenais Tom Elmslie Anne Kern Carole Peacock Jean Robert Serge Turgeon Directrice des communications Director of Communications Committee Comit6 Op6rationnel Executive de gestion Management Team 21 [Page 22](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/24) Personnel de la conf6rence Conference Personnel Secretariat g6neral Office CLEROUX, Chantal GOLTZ, Diane LEMIEUX, Patrick MORAND, Helene WARING, Bruce des communications Communications Secretariat des medias Media Secretariat DURDIN, Martha GOSSAGE, Patrick IMRIE, Anne MERCER, Alison SHANNON, Kristin SWITOCZ, Alice Coordonnatrice Coordinator: FOX, Marie-Hel6ne Secr6tariat de la CRISTEL, Robert Sally CORNEAU, Francine DELLI COLLI, Sylvia GUILLEMET, Coordinator: FELICISSIMO, Lucy ARA NO'VO DESIGN INC.; CENTRE FEDERAL SUR LE SIDA FEDERAL CENTER FOR AIDS; CORPAV; C.R.D.I./I.D.R.C.: Bureau du tr6sorier/Office of the Treasurer, Service de l'administration Administration Services, Division des communications/Communications Division, Bureau du conseillerjuridique/Office of the General Counsel; Diffuseur-hote, SOCIETE RADIO CANADA/Host Broadcaster, BROADCASTING CORPORATION; DU CANADA/ROYAL EXPOSITIONS INC.; MULTICOM INTERNATIONAL MONTREAL; OFFICE DU TOURISME DU GRAND MONTREAL GREATER MONTREAL CONVENTION AND TOURISM BUREAU; SERVICE DE TRADUCTION SIMULTANEE Bureau de m6dical permanent de i'Universit6 accordent a d'6ducation permanente un de d'6tude et 24 heures de cr6dits de cat6gorie I du Physicians Recognition Award de l'American Medical Association. Pour obtenir votre certificat de dans hall d'accueil. Services de l'6ducation permanente d'agr6ment Le Salon d'accueil pour personnes atteintes du VIH ou du Lorraine. Les deux salles trouvent a du Basiliaire du Complexe Desjardins. Un service de navette entre le Palais des Congres (a partir de la rue Viger, niveau Socidt6 canadienne de la Croix rouge en collaboration avec le AIDS sont responsables du fonctionnement des deux aires de repos. Assurances sur le n'est d'aucune blessure la suite d'un accident ou ' la suite celle-ci. Congres. d'information peut obtenir des renseignements sur la ville de Montr6al, les restaurants, les boutiques, les 6glises, le transport en commun, les th6 du hall 25 [Page 26](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/28) Bureau de change et services bancaires (Bank of America) Un bureau de change est situ6 dans le hall d'accueil. guichets Commerce Guy-Favreau Banque de Montr6al (Service Cirrus) 355, rue Ste-Catherine Banque de Nouvelle-tcosse 437, rue St-Jacques Banque Nationale du Canada Complexe guichet est situ6 d'un bureau de poste situd au 6tage. Cassettes audio Les sessions du programme sont enregistr6es sur bandes audio et les cassettes sont vendues le foyer du quatrieme 6tage au prix de 10,00 $ CAN l'unit6. Cassettes video Les sessions de la Conf6rence ayant lieu dans les salles 407A, Centre de diffusion est les diverses excursions touristiques est assur6e par le Bureau des Tours Maestro Plus situ6e dans le hall d'accueil. Exposition La salle d'exposition est au ler etage du Palais des encourageons plus r6cents equipements, suivantes: du \"Cartes\" des avec un plan de l'exposition. Hebergement Le Bureau d'h6bergement de la Conf6rence est hall service foumrni par l'Office des congres et du tourisme du Grand Montreal. Information la conference Pour tout renseignement, veuillez vous adresser au: 4 bureau d'inscription est situ6 ' la salle 100-A. Pour tout le reste de la semaine, de de de de Centre de diffusion et aux conf6rences de presse. Le personnel de l'exposition est tenu la salle 100 A et dans les deux caf6t6rias du Palais des Congrbs. Tous les de plaisir est jour de la Conf6rence retransmis, le matin avant les sessions pl6nibres, dans le Palais Congrbs (aires de retransmission) et A la t616vision montr6alaise, au canal 23 (cable). Messages (Bell Canada) Pendant la Conf6rence, vous pouvez laisser des messages au Centre de message Bell Canada, qui est situ6 dans le foyer, au 4e 6tage du Palais identifi6s En voici la description: dans salle 314, Congres. Elle est ouverte du dimanche au vendredi pendant les droit en haut de leur nom. Exemple M. A. P. 18 Le suivi immunologique L. Tremblay, R. Smith, L. Caruso Jour A tous discuter des presentations des Congres. Il y a aussi un restaurant et un bar sur les terrasses au niveau du 6e 6tage. Reglementation de l'usage Congres que dans la tente du Centre de diffusion pendant toute la dur6e de la Conf6rence. Restaurants Plusieurs sont Palais des Congres. 30 [Page Service de restaurants qui correspondent le mieux vos gouits et A votre budget, nous avons pr6vu un les diff6rentes cuisines offertes \" Montr6al. Conf6rence sont film6es et retransmises en direct dans et les deux au 6e 6tage du Palais. connaitre l'endroit diffusion sessions, veuillez consulter le quotidien de la Conf6rence. Service de de stationnement dont une est situ6e sous le Palais. tarif de 8,50 $ par jour. L'autre aire de stationnement est situ6e sur la rue Bleury, entre les rues Ste-Antoine et Viger. Le tarif est de 1,50 $ par demi-heure, maximum 5 $ des Congres. Pour effectuer un appel local, d6poser 25 cents et composer le num6ro voulu. Pour 6tablir une communication interurbaine, il communication vir6s. ses Pour de CAN dans le hall d'accueil. Le service de transport en commun de Montr6al propre, et s6curitaire est exploit6 de transport de la communaut6 urbaine de Montr6al). Les stations de m6tro pour le Palais des Congres, et pour la plupart des h6tels ainsi que les r6sidences, sont les l'h6tel M6ridien L'h6tel Grand, Le Reine Elizabeth et le Chateau Champlain Le Holiday Inn Crowne Plaza Le Baccarat et les r6sidences de l'universit6 McGill Le Holiday Inn Richelieu Le Holiday Inn Place Dupuis Les residences de l'Universit6 Les r6sidences de l'Universit6 de Montr6al 32 [Page 33](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/35) Location of Conference Services General Information (Convention Centre) Broadcast Centre: Conference Secretariat (Kenness Canada Inc.): Canada): Photocopier (Sandoz): Post Office: Registration Desk: Rest areas for people with HIV/AIDS: Secretarial Services for delegates (Sandoz): Slide Preview: Speakers Centre: University Accreditation: Tent, front terrace 4th Floor, 402-C Main Entrance Hall Lobby, 4th Floor Main Floor Third Floor, 314 Main Entrance Hall Main Entrance Hall Main Entrance Hall Main floor, 100-A Lobby, 4th Floor Lobby, 4th Floor Lobby, 4th Floor Main Entrance Hall M6ridien Hotel Lobby, 4th Floor 4th Floor, 402-A 4th Floor, 402-A Main Entrance Hall Airline Reservations Air Canada and Parthenon Travel will assist passengers who need to make changes in their reservations. Their desk is located in the Main Entrance Hall. You may also refer to your Delegate guide for the phone numbers of various airlines in order to reconfirm directly your onward flights. Audio Tapes Conference sessions will be taped on audio cassettes which will be sold on the 4th floor, lobby area, for the price of $10.00 CAN. Broadcast Centre The Conference is providing broadcast services to electronic media in a tent situated in front of the Palais on the terrace. Only accredited media wearing green badges will be allowed access. Conference News A Daily newspaper, \"DIMENSIONS\", is produced throughout the week of the Conference. It contains information pertaining to the schedule of sessions and Conference activities as well as summaries of scientific presentations. A televised news show will also be produced every day of the Conference. It will be broadcasted in the mornings before the plenary sessions throughout the Palais (overflow areas) and on the Montreal cable television network (Channel 23). 33 [Page 34](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/36) Exhibits Exhibits are located in the Exhibit Hall on the main floor of the Palais des Congres. Participants are encouraged to visit these exhibits and see the latest equipment, supplies, products and publications covering the subject of the Conference. Exhibits will be open during the following hours: Monday, June 5 to Wednesday, June 7 - 9:00 to 18:30 Thursday, June 8 - 9:00 to 17:00 A list of exhibitors and the floor plan are included in this publication (see Maps). First Aid The Canadian Red Cross Society is responsible for all first aid services. The infirmary is located on the 3rd Floor of the Palais des Congres in room 314. It is open from Sunday to Friday during Conference hours. First aid personnel on duty will be identified by a red cross on a white background on their fronts and backs. Foreign Exchange and Banking Facilities (Bank of America) Foreign exchange service is available in the Entrance Hall of the Convention Centre. There are several banks located near the Convention Centre. Most have automatic tellers and province interbanking service (Plus System and Interac) including the following: Bank of Commerce Guy-Favreau Complex Bank of Montreal (Cirrus service) 355 Ste-Catherine St. Bank of Nova Scotia 437 St-Jacques St. Caisse Desjardins Complexe Desjardins National Bank of Canada Complexe Desjardins an automatic teller is also situated at the metro entrance to the Palais des Congres Royal Bank Complexe Desjardins Toronto-Dominion Bank 305 Ste-Catherine St. Housing The Housing Desk of the Conference is located in the Main Entrance Hall. Housing is managed by the Greater Montreal Tourist and Convention Bureau. Information Desk Information on the city, restaurants, shopping, churches, public transportation, theatre and sporting activities is available at the information desk situated in the Entrance Hall. 34 [Page 35](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/37) Insurance The V International Conference on AIDS cannot accept liability for injuries arising from accidents which may occur during or arising from the Conference. We recommend that you take out appropriate travel and health insurance. Local Tours Desk Tickets for the various touristic activities, which are still available, can be purchased from the Maestro Plus Tours Desk, located in the Main Entrance Hall. Media Centre The media centre is located at the back of room 100-A. Only accredited media wearing green badges will be admitted. Message Centre (Bell Canada) During the Conference, messages can be telephoned to the Bell Canada Message Centre, located on the 4th floor lobby of the Palais des Congres. Telephone number is (514) 397-0583. Name Badges All Conference registrants are required to wear their name badge in order to gain entry to the scientific sessions, the exhibits and the social functions. Black: Committee members Blue: Delegates Green: Media Orange: Exhibitors Yellow: Staff All those wearing black badges participated in the organization of the Conference; they welcome any questions from delegates. All delegates are required to wear a blue badge which allows them access to sessions, exhibits and social functions. Access to Media Centre, Broadcast Centre and news conferences are limited to accredited media representatives wearing the official green badge. Exhibitors, wearing an orange badge, have access only to plenaries because of the limited number of places in the scientific sessions. It will be possible however to follow the sessions on closed circuit TV in overflow areas located on the first and sixth floors of the Palais des Congrbs. All Conference staff will be identified by a yellow badge. Questions regarding the Conference services should be directed to them. Parking The Palais des Congres has two parking areas, one of which is situated under the Centre. The rate is $8.50 per day. The other parking area is located on Bleury Street between St-Antoine and Viger Streets. The rate is $1.50 per half hour, maximum of $5.00 per day. 35 [Page 36](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/38) Pictograms The nine programme sections, as well as a few conference activities, are illustrated throughout the Palais and in the publications by pictograms. Here is a complete description: Epidemiology and Public Health AIDS and the Individual Clinical Aspects Basic Research (Biomedical) AIDS, Society and Behaviour Ethics and Law International Issues The Economic Impact of AIDS Audiovisual Posters Media Overflow Sli SIDART 36 [Page 37](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/39) Post Conference Enquiries Any post-conference enquiries can be addressed to: International Development Research Centre c/o Conference Section P.O. Box 8500 Ottawa, Ontario CANADA K1G 3H9 Post Office The Convention Centre has a post office situated in the lobby on the 4th floor. Poster Presentation The title and the name of the abstracts accepted for poster display are listed in this programme. The presenting authors are marked with an asterisk* at the upper right corer of the name. Example M. A. P. 18 Immunology monitoring I I t L. Tremblay, R. Smith, L. Caruso Day of Section Poster Presenting author poster Board display Number The poster sessions are held in the Exhibit Hall of the Palais des Congres (see Floor Plan). Each section is identified by a sign post baring the sections's pictogram (as described under Pictograms). Public Telephones Public telephones are located throughout the Palais des Congres. To make a local call deposit 25 cents and dial the desired number. To make a long distance telephone call, it may be simpler to place a collect call. Approved telephone credit cards may also be used to charge calls. For more information, please consult the telephone book. Public Transportation You may purchase a five-day pass at a cost of $10.00 CAN for the subway/bus system in the Main Entrance Hall. Clean, quiet and safe, Montreal's public transit system is operated by S.T.C.U.M. (Societ6 de Transport de la Communaut6 Urbaine de Montr6al). 37 [Page 38](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/40) The subway stations for the Palais des Congres and for most hotels and the residences are as follows: Place d'Armes Place Bonaventure Place des Arts des Congres, M6ridien Hotel Grand Hotel, Queen Elizabeth Hotel and Chateau Champlain Holiday Inn Crowne Plaza Le Baccarat Hotel and McGill University residences Holiday Inn Richelieu Holiday Inn Place Dupuis Concordia University residences Universit6 de Montr6al residences Refreshments/Meals Coffee and other beverages, as well as snacks, are served in snack bars throughout the Palais des Congres. There is also a restaurant and a bar on the 6th floor of the Palais. Registration Desk On Saturday and Sunday, the Registration Desk will be in Room 100-A. For the rest of the week it will be situated in the Entrance Hall of the Palais. Business Hours Saturday, June 3: Sunday, June 4: Monday, June 5: Tuesday, June 6: Wednesday, June 7: Thursday, June 8: 17:00 Rest Areas for People with HIV/AIDS The Welcome Centre for people with AIDS and people with HIV is located in the Anjou meeting room at the Meridien hotel. A rest area is located next door, in the Lorraine room. Both rooms are located at the south end of Basilaire 2 on the west side of Complexe Desjardins. A shuttle service for PWAs and PWHIVs operates during the Conference hours between the Palais des Congres (Viger Street entrance on the lowest level) and the M6ridien Hotel (drive-through entrance on Jeanne Mance Street). The Welcome Centre and the Rest Centre are being operated by the Canadian Red Cross Society with the collaboration of the Comit6 des personnes atteintes du VIH du Comit6 SIDA-Aide Montr6al and the Vancouver People with AIDS Society. Restaurants Restaurants and fast food outlets are situated within short walking distance from the Palais des Congres. Several are located in China Town, Complexe Guy-Favreau, Complexe Desjardins and the M6ridien Hotel, north of the Palais. 38 [Page 39](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/41) Restaurant Reservation Service Montreal is widely known as the gastronomic capital of North America. To assist you in finding a restaurant to suit your tastes and budget, a complimentary restaurant recommendation and reservation service will be offered during the conference. Located on the Conference (4th floor) level of the Palais des Congres, the service will operate during the official Conference hours. The recommendation and reservation service will allow delegates and accompanying persons to study menus from a wide selection of establishments featuring a full variety of cuisines and budget levels available in Montreal. Secretarial Services for Delegates Secretarial services for delegates are provided by Sandoz in the lobby area of the 4th floor at the Palais des Congres and will be available during Conference hours. You are invited to take advantage of their services: * Typing: Manuscript revisions, Conference communications, Posters * Photocopying: Facilities are available for making limited quantities * Slide duplication: Slides returned within 24-hours * Postal Service: Sale of stamps * Interpreters: Assistance available in several languages * Literature Search Shuttle Buses Delegates residing in hotels outside the centre core will be shuttled to/from the Palais des Congres. To obtain a schedule, please consult the Shuttle Desk in the Main Entrance Hall of the Palais. Simultaneous Interpretation All plenary sessions will be interpreted into French, English and Spanish. All specialized sessions will offer simultaneous interpretation in French and English. Receivers for simultaneous interpretation will be distributed on the 4th floor. A valid identification card will be required as deposit: either a credit card, a driver's licence, or a passport will be accepted. Receivers must be returned at the end of each day in order to be recharged overnight. Smoking Policy The V International Conference on AIDS recognizes the probable negative health implications of smoking. Its policy, therefore, is that there will be no smoking inside the Palais des Congres and the Broadcast Centre. 39 [Page 40](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/42) University Accreditation The continuing Medical Education units at McGill University and l'Universite de Montreal grant, for participation at the Conference, a minimum of 24 study credits or the equivalent of 24 credit hours, Category 1 from the Physicians Recognition Award of the American Medical Association. To get your participation certificate enquire at the Information Desk in the Main Entrance Hall. The continuing Medical Education services of McGill University and l'Universit6 de Montreal are fully accredited by La Corporation professionnelle des M6decins du Qu6bec, The Accreditation Committee of the Canadian Association of Medical Colleges and the corresponding accreditation organization from the United States (ACCME). Video Overflow Conference sessions will be taped and retransmitted live in Room 100-A and the two cafeterias on the 6th floor. To know where specific sessions will be shown please consult the daily newspaper \"DIMENSIONS\". Video Tapes Conference sessions in rooms 407A, B and C will be filmed and the videotapes will be on sale on the fourth level, lobby area. 40 [Page 41](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/43) * concert, vous adresser au kiosque d' information situds du (sur invitation seulement). LE MARDI 6 JUIN 7 JUIN 1989 (19h00) Soiree de gala - Palais de la civilisation Spectacle et buffet gastronomique au milieu de scenes reconstitudes de grands films (exposition). 85 inscrits A JUNE 4, 1989 (16:30 hours) Opening Ceremony - Palais des Congrds Opening Ceremonies followed by a reception for all registered participants. Included in the registration fees. MONDAY, JUNE 5 1989 (17:00 hours) Reception - Contemporary Art Museum Reception hosted by the Government of Qu6bec (invitations only). TUESDAY, JUNE 6 1989 (18:30 hours) Concert at Notre-Dame Basilica An evening of classical music performed by I Musici de Montr6al in historic Notre-Dame Basilica in the heart of Old Montreal. Cost: $15.00/person. WEDNESDAY, JUNE 7 1989 (19:00 hours) Gala Evening - Palais de la civilisation Entertainment and gourmet buffet amidst reconstituted film sets (exhibit). Cost: $85.00/person. THURSDAY, JUNE 8 1989 (18:00 hours) Reception at Montreal's Botanical Garden Health and Welfare Canada will host a reception at Montreal's Botanical Garden for all registered participants. Transportation from the Palais will be available for all participants. Included in the registration fees. Social Activities Ask the General Information Desk (Main Entrance Hall) where you can purchase tickets to the gala or concert. 43 [Page 44](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/46) 4M ~ ~~.-.~~. ~ ii _i_.i - I.I. _^-_l. --.~ll^. i-~L-.ll*-..-~.i.l - 111 111 1 I III - I I I I...... [Page 45](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/47) I [Page 46](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/48) HOtels et Centre-Ville Hotels and Downtown 46 [Page 47](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/49) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. Centre Sheraton 17. Chateau Champlain 18. Delta Hotel 19. Grand Hotel 20. Holiday Inn Crowne Plaza 21. Holiday Inn Dupuis 22. Holiday Inn Richelieu 23. H8tel Maritime 24. La Citadelle Le Berri H6tel 47 [Page 48](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/50) Coupe du Palais des Congres Cross-Section of the Palais des Congres L 0 1?Ti1 1 I 1 48 et aires de visionnement (1st Floor) Exhibition Floor, Exhibition Posters & Overfow Areas 3 (4e ~tage) Etage des Congr~s Floor 4 5 Stationnement souterrain Underground Parking 6 Avenue Viger Viger Street 7 Hall d'accueil Main Entrance Hall 8 Toilettes Rest Rooms 9 Cafdt~ria, bar et restaurant, aires de visionnement Cafeteria, Bar & Restaurant, Overfow Areas 10 [ 49 [Page 50](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/52) 1 er 6tage: Inscription (3 et 4 juin) 1st Floor: Registration (June 3 and 4).:...................................................................................... ~............ '.I.'.'..., \" i ii~i~i~i~iiiiiiidiiiiii \" 1a...............,X'l XXXI.... -.. ~X | Xn i / / / / s / i / / CJ i: i~............................................... % ~ ~ ~ ~ ~: J i. %6%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 50 [Page 51](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/53) de diffusion Broadcast Service Centre 2 Hall d'accueil (information) Main Entrance Hall (Information) 3 * Bureau de service pour la navette Shuttle Service Desk * Visites guid6es Tours * Air Canada * Bureau de change Currency Exchange 4 * Guichet h6bergement Housing Desk * Guichet vente de billets Events Ticket Croix-Rouge (urgence) Red-Cross (Emergency) 6 Inscription exposants Exhibitors' m6dias Media Registration 8 Prd-inscription, ddldguds Pre-Registration, delegates 9 Correction des insignes Badge Correction 10 Inscription sur le site, dl66gu6s On-Site Registration, delegates 11 Renseignements Enquiries 12 * Accreditation C.M.E. C.M.E. Accreditation * Soci6t6 internationale sur le SIDA International AIDS Society 13 Distribution des porte-documents Satchel Distribution 14 Centre des m6dias Media Centre 15, 16, 17 Casse-crofite Snack Bar 51 [Page 52](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/54) 1 er 6tage: Affiches, -:: ii'iii i.............. ' de ) S. %./ % / /. / /%......: I// / / / / / / / / /,!1'1\",\" ~ ~: \" / ' # // /,. I. \". \" \"-.\"- - -.\".\" T1- I -- I / / / / / / / / / / /.'1-: --i'--I I i--iiiil~iii;;... w.................... /.. /. /..;..-....:,: -...I % % % %6 6 6 % 6 %6\" - \" - \",, \"', \"', \", \"' - \"', \"'1- ' 6, ' 6, *, %. % '% %6 %6 i X.0 We i / / / / 59 [Page 53](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/55) 1 Centre de diffusion Broadcast Services Centre 2 Hall d'accueil Main Entrance Hall 3 * Bureau de service pour la navette Shuttle Service Desk * Visites guidees Tours * Air Canada * Bureau de change Currency Exchange 4 * Pre-inscription Pre-Registration * Inscription sur le site On-Site Registration * Caisse Cashier * Evenements speciaux, cahiers d'abr6g6s Social Events, Abstract Books 5 Exposition Exhibition 6 Seances d'affiches, module C Poster Sessions, Section C 7 Comptoir de service pour affiches, module C Poster Service Desk, Section C 8 Seances d'affiches, module A Poster Sessions, Section A 9 Comptoir de service pour affiches, module A Poster Service Desk, Section A 10 Croix-Rouge (urgence) Red-Cross (Emergency) 11 pour affiches, modules D-E Poster Service Desk, Sections D-E 13 Comptoir de service pour affiches, module B Poster Service Desk, Section B 14 Comptoir de service pour affiches, modules F-G-H Poster Service Desk, Sections F-G-H 15 Aire visionnement # 1 (retransmission) Overflow Area #1 16 Aire de visionnement # 2 (retransmission) Overflow Area #2 17 Aire de visionnement # 3 (retransmission) Overflow Area #3 18 Aire de visionnement # 4 (retransmission) Overflow Area #4 19 Aire de visionnement # 5 (retransmission) Overflow Area #5 20 Centre des medias Media Centre 21, 22, 23 Casse-croftes Snack Bars 24 Douanes Milgram Milgram Customs Office 53 [Page 54](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/56) 4 119 117 118 115 116 113 114 111 112 110 219 217 218 215 13 214 211 212 210 319 310 POSTER SESSION AREA SEANCE D'AFFICHES 511 510S 510 619 613 POSTER SESSION AREA StANCE D'AFFICHES 044 045 047 049 305 409 407 408 405 401 402 400 507 610 609 608 603 606 604 600 710 701 803 810 ~)/)/////, /////))//, /)//////)i /)/////l))///i ) / / / / / 7fA I 100 LfwlI /I(// IF [Page 55](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/57) 001 005 008 009 011 014 015 016 017 018 019 022 023 024 025 026 027 028 029 030 031 032 034 052 054 056 100 110 111 112 113 114 115 116 117 118 119 200 211 212 213 214 215 217 C.R.D.I./I.D.R.C., CANADA O.M.S./W. H.O, SUISSE MICROGENESYS, U.S.A. INCSTAR, U.S.A. GOV. OF BRITISH COLUMBIA, CANADA GOV. OF ALBERTA, CANADA ASSOCIATION CANADIENNE DE SANTE PUBLIQUE, CANADIAN PUBLIC HEAL TH ASS., CANADA SOCIETE CANADIENNE D'HEMOPHILIE, CANADIAN HEMOPHILIA SOCIETY, CANADA SOCIETi CANADIENNE DU SIDA, CANADIAN AIDS SOCIETY, CANADA HIGHWAY BOOKSHOP, CANADA INSTITUT VIRION, SUISSE MAROUEST MEDICAL PRODUCTS, U.S.A. RAVEN PRESS, U.S.A. PFIZER INTERNATIONAL, U.S.A. AMFAR, U.S.A. MEDICAL PUBLISHING GROUP, U.S.A. RHONE POULENC PHARMA INC., CANADA AMERICAN SOCIAL HEALTH ASS., U.S.A. M.A. LIEBERT PUBLISHING,, U.S.A. AMERICAN ASS. ADV. SCIENCE, U.S.A. BIOSCIENCES INFORMATION SER., U.S.A. CURRENT SCIENCE, U.S.A. FORMA, U.S.A. N.A.B.I., U.S.A. FAMILY HEALTH INTERNATIONAL, U.S.A. FISONS CORPORATION, U.S.A. NEW ZEALAND HEALTH DEPT, NEW ZEALAND PHYSICIANS ASS. FOR AIDS CARE, U.S.A. PANOS INSTITUTE, ENGLAND CALYPTE BIOMEDICAL, U.S.A. BAXTER HEALTHCARE CORP. PANDEX, U.S.A. CAREMARK HOMECARE, U.S.A. DEUTSCH AIDS-HILFE E.V., WEST GERMANY IMRE CORPORATION, U.S.A. CHANNING L.BETE, U.S.A. MARCEL DEKKER, U.S.A. LYPHOMED INC., U.S.A. SANTE ET BIEN-ETRE SOCIAL, CANADA HEALTH & WELFARE CANADA, CANADA IAF BIOCHEM CANADA, CANADA VIRX, U.S.A. CITY OF TORONTO, CANADA ASS. NURSES IN AIDS CARE, U.S.A. LABMEDICA. U.S.A. ACADEMY EDUC. DEVELOPMENT, U.S.A. NATURE, U.S.A. W.G.B.H. BOSTON, U.S.A. MUREX CORPORATION, U.S.A. BECKMAN INSTRUMENTS INC., CANADA BURROUGHS WELCOME, CANADA CELLULAR PRODUCTS, U.S.A. STATE OF HAWAI, U.S.A. MIAMI UNIVERSITY, U.S.A. CANADIAN CABINETS CO., CANADA CAMBRIDGE RESEARCH, U.S.A. GENE TRAK SYSTEMS, U.S.A. 218 219 300 303 305 310 311 312 313 314 316 317 318 319 400 401 402 405 407 408 409 410 500 501 502 503 504 507 510 511 600 601 603 604 606 608 609 610 613 619 700 701 710 800 810 900 901 902 903 CITY OF SAN FRANCISCO, U.S.A. ORTHO BIOTECH, U.S.A. GOUVERNEMENT DU QUEBEC, CANADA AUSTRALIA HEALTH DEPT, AUSTRALIA ORGANON TEKNIKA, BELGIQUE MINISTERIO DE SANIDAD-ESPANA, ESPANA EPITOPE, U.S.A. CAMBRIDGE BIOSCIENCE, U.S.A. TRITON BIOSCIENCES INC., U.S.A. CARTER WALLACE INC., U.S.A. PAN DATA SYSTEMS, U.S.A. BYOSIN, U.S.A. BIO-RAD, CANADA AMGEN, U.S.A. BEHRINGWERKE, WEST GERMANY GAY MEN HEALTH CRISIS, U.S.A. BECTON DICKINSON, CANADA ADVANCED TECHNOLOGIES, U.S.A. PENINSULA LABORATORIES, U.S.A. AM. EUROPEAN CLINICAL LAB., U.S.A. GOV. OF ONTARIO, CANADA COULTER CORPORATION, U.S.A. INSTITUT MERIEUX, FRANCE MARYLAND MEDICAL LAB., U.S.A. N.I.A.I.D., U.S.A. OLYMPUS CORPORATION, U.S.A. ANGEWANDIE COMPUTER SOFTWARE, WEST GERMANY DUPONT COMPANY, U.S.A. SYNTEX INTERNATIONAL, U.S.A. SYVA, U.S.A. JULIUS SCHMID, CANADA IMMUNODIAGNOSTICS INC., U.S.A. GENETIC SYSTEMS, U.S.A. SWETS & ZEITLINGER, HOLLAND PORTON INTERNATIONAL INC., U.S.A. BRITISH HEALTH DEPT, ENGLAND ORTHO DIAGNOSTICS SYSTEMS, U.S.A. ABBOTT LABORATORIES, U.S.A. NAIC, U.S.A. PHARMACIA E.N.I., CANADA FUJIREBIO, U.S.A. ANSELL INTERNATIONAL, FRANCE ICN PHAMACEUTICALS, U.S.A. HOFFMANN LAROCHE, U.S.A. OKAMOTO U.S.A. INC., U.S.A. COMMUNITY RESEARCH INITIATIVE, U.S.A. DISEASE DETECTION INTERNATIONAL, U.S.A. IN TOUCH COMMUNICATIONS, CANADA 55 [Page 56](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/58) 4e 6tage: Etage Signposting screens Ecrans d'assignation des salles Room ~ L 56 [Page 57](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/59) 1 Comptoir de vente des cassettes viddo Video Cassette Sales Counter 2 Comptoir de vente des cassettes audio Audio Cassette Sales Counter 3 Centre de messages Bell Bell Message Centre 4 Reservation de restaurants Restaurant Reservation 5 Sandoz 6 Ecouteurs d'interpretation simultan6e Simultaneous Interpretation Headsets 7 Secretariat Kenness Kenness 8 Salle de visionnement de diapositives pour conf6renciers Speakers' Audiovisual Preview Room 9 #9 2 Aire de visionnement # 8 (retransmission) Overflow Area #8 3 Aire de visionnement # 7 (retransmission) Overflow Area #7 4 Aire de visionnement # 6 (retransmission) Overflow Area #6 5 Bar & Restaurant 6 Caf6teria Cafeteria 7 Aire de visionnement # 12 (retransmission) Overflow Area #12 8 Aire de visionnement # 11 (retransmission) Overflow Area #11 9 Aire de I k 60 [Page 61](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/63) 1 I NFB Cinema Audiovisual Presentation, Section I 4 Centre de ressources audiovisuelles: Salle des drables Audiovisual Centre: * C.R.D.I I.D.R.C. * Sant6 Bien-&tre Social Canada Health and 61 L, L-11-j-D IL-i I 62 [Page 63](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/65) Place des Arts 1 Cafd de la place de theatre Play H~tel 1Mdridien 2 Amphithd~itre Drawings, Paintings, Comics 6 Amphithdatre du Complexe * Animation le midi Complexe Amphitheatre * Noon Hour Shows 7 Plafond * Courtepointe Ceiling * Names Project--Quilt Corridor Posters By Montreal Artists Complexe Guy-Favreau En baslLower Level 9 Exposition d'affiches (art et dducation) Poster Exhibitions (Art and Education) 10 Cindma ONF -Films et viddos NFB Cinema-Films and Videos En hauti Upper Level 11 Exposition de photos Photo Exhibit Palais des Congr~s Foyer/Lobby 12 Exposition du concours international de logotype de l'O.M.S. International Logotype Contest Exhibition by the W. H. 0. 63 [Page 64](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/66) - I\"'-~''~ *~- i'~~l~-;-i~~-- I ~~; ~ ~~~ ----~~i~-slow, ~ ~91111 1 I ii I 1 I plan d'dtage) Chaque temps des disponible en tout temps sur les lieux pout porter assistance en cas de besoin. n'accepte sont pas demont6es h temps. Auteurs de films et de videos Les personnes qui pr6sentent des films ou des vid6os ou dimanche projection des diapositives durant les pr6sentations est prise en charge par les techniciens de la Conference * Retour des carrousels au Centre pour conf6renciers i la fin chaque session 67 Assurez-vous d'enregistrer votre session. 3) Rencontrer le pr~sident de session dams la salle de conf~rence appropri~e 15 minutes avant le d~but de la session. 4) Pour la durde de la presentation, pri~re de se conformer prids de se rendre Zi lear salle 15 minutes avant le d~but de la session afin 69](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/71) Chairpersons All chairpersons are invited to a brief meeting on Sunday evening at the Meridien Hotel (Grand Salon \"A\") at 19:30 hours. Chairpersons for each day's sessions meet on the morning of their session at 07:45 hours in Room 401ABC at the Palais des Congrbs. Chairpersons are requested to meet with their speakers in the session hall 15 minutes before the session starts. Poster Presenters The poster sessions will be on the Exhibit Floor, lower level of the Palais des Congrbs (see Floor Plan). Each section will be identified by a sign post showing the section pictogram such as: General Instructions Epidemiology and Public Health Clinical Aspects Basic Research (Biomedical) ~~ I~I flT AIDS and the AIDS, Society Ethics and Law Individual and Behavior International Issues The Economic Impact of AIDS 69 [Page 70](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/72) In order to provide ample time for all participants to view and discuss poster presentations, each poster will be on display for one day. Authors are requested to adhere to the following schedule in mounting and removing their posters on their assigned boards: Schedule Day Mounting Time Session Time Removal Time June 5 Mon. 07:30 - 08:30 13:00 - 14:00 18:00 - - 08:30 13:00 - 14:00 - - 08:30 13:00 - 14:00 - - 08:30 13:00 - 14:00 18:00 - 18:30 Authors must be present at their poster from 13:00 to 14:00 on the day of presentation. The poster board pictogram identifies the section; posters are numbered consecutively within each section. Each specialty area will be identified by a sign. Conference personnel will be on the floor at all times should assistance be required. The Conference accepts no responsibility for posters not removed on time. Speakers The Speakers Centre situated in Room 402-A is open: Sunday, June 4 through Friday, June 9 08:00 - 19:00. Services provided * Transfer of slides to conference-standard slide trays * Projection equipment for viewing slides * Sealing and identification of slide trays to be stored by conference staff, ready to be taken at the proper time and place to the speaker's presentation. (Projection during the presentation is provided by Conference staff.) Slide trays will be returned to the Speakers' Centre and speakers can collect them at the conclusion of each session. 70 [Page 71](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/73) We kindly ask speakers to observe the following procedures: 1) Report to the Speakers' Centre at least 24S hours prior to the scheduled time of the presentation and drop your slides at that time. No te Speakers scheduled for Monday should report at the Centre on Sunday after registration. M~ake sure that each slide is marked at the bottom left hand corner to ensure proper loading in the slide trays. 2) Sign Discharge forms to allow Conference staff to tape sessions. 3) Meet with the Session Chairperson in the session hall 15 minutes prior to the beginning of the session. 4) During the presentation, please conform. to the instructions regarding the length of the oral presentation. Videotape Presenters All people presenting films or videos as well as speakers for the Audiovisual sections are asked to contact Fran(;ois Lalibertd upon their arrival at the Complexe Pgm [Page b OA Le dimanche 4 juin l0 h 19 h Inscription Palais des Congr~s 100A 16 h30 a 19 h C~r~monie Registration Palais des Congres Saturday June 3 100A 10:00 to 19:00 Registration Palais des Congres 100A 16:30 to 19:00 Opening Ceremonies Palais June 4 20:00 to 21:30 Complexe Nouvelles prespectives ~ --P1~ninre Palais des Congr~s 407 ABC ll 7 h 3O Pr~sentations audiovisuelles Centre de conf~rences Guy-Favreau 11 publique ttudes stro-tpidtmiologiques: 408 A Apects VIH chez les enfants 401 ABC (Table ronde) Coordination des soins le point de vue du personnel 403 ABC (Colloque) Infections g Le SIDA et I'indlvidu Recherches sur le comportement (partie 1) 409 ABC E. Le SIDA, Ia soci&t~ et le comportement (Colloque) Vivre avec le SIDA le atteintes 411 A (Atelier) et ~thique (Colloque) Vue d'ensemble de la lCgislation sur le SIDA 411 C G. Implications Internatlonales Le s~rodiagnostic 406 A (Colloque) Aspects culturels et sociaux de la sexualiul 406 BC H. Repercussions &conomiques du SIDA Aper~u et co~ts de la prevention et de 1'&Iucation 404 AB l3 ha 4 h Presentation MTS Incidence et pr~valence du VIII 407 A 408 A 408 BC 76 [Page 77](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/79) B. Aspects cliniques Manifestations buccales du SIDA 401 ABC Nouvelle technique de diagnostic rapide et amelioree 403 ABC (Colloque) Traitement des infections assocines les r6trovirus 407 C Pathogenese (partie 1) 410 ABC D. Le SIDA et I'individu Les adolescents (partie 1) 409 ABC E. Le SIDA, la soci6td et le comportement Les proches et la pour l'6ducation des minorites sujet 411 B F. Droit et 6thique (Table ronde) Points de controverse dans les rapports sur les politiques relatives au SIDA 411 C G. Implications internationales Information et comportement sexuel 406 A (Colloque) Les nourrissons ' risque: de vue africain 406 BC H. R1percussions 6conomiques du SIDA CoOts en milieu hospitalier 404 AB 16 h 17h30 A. et sant6 publique La transmission sexuelle du VIH (partie 1) 407 A Infection par le VIH chez les d6tenus 408 A Histoire clinique de l'infection au VIH: Cofacteurs et progression 408 BC B. Aspects cliniques Infections concomitantes du SIDA 401 ABC P6diatrie: d6veloppement 407 C 410 ABC D. Le SIDA et 1'individu Travailleurs de la sant6 409 ABC E. Le SIDA, la sociWt6 et le B F. Droit et 6thique (Colloque) tthique et injustice sur le plan international 411 C G. Implications internationales Prevalence (partie 1) 406 A dehors du milieu hospitalier 404 AB 77 [Page 78](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/80) Monday June 5 8:30 - 10:30 \"New Perspectives\" - Plenary session Palais des Congres 407 ABC 11:00- 17:30 Audiovisual Presentations Guy-Favreau Conference Centre 11:00 - 12:30 A. Epidemiology and Public Health Seroepidemiologic studies: United States 407 A AIDS/HIV: Blood and blood products 408 A Other retroviruses: HIV-2 and HTLV-I/Il 408 BC B. Clinical Aspects of AIDS HIV in children 401 ABC (Round table) Coordinating care: A nurse's perspective 403 ABC (Symposium) Natural History and Diagnosis of HIV infection 407 B C. Basic Research Biomedical (Symposium) Mechanisms of pathogenesis of HIV 407 C Molecular Biology (part 1): Genomic diversity and relationship to clinical aspects 410 ABC D. AIDS and the Individual Behavioural research (part 1) 409 ABC E. AIDS, Society and Behaviour (Symposium) Living with AIDS: A person with AIDS perspective 411 A (Workshop) AIDS education: Lessons from developing countries 411 B F. Ethics and Law (Symposium) Global survey of AIDS legislation 411 C G. International Issues Serodiagnosis 406 A (Symposium) Cultural and social perspectives of sexuality 406 BC H. The Economic Impact of AIDS Overview plus costs of prevention and education 404 AB 13:00 - 14:00 Poster Presentations by Authors (Posters on display throughout the day) 14:00- 15:30 A. Epidemiology and Public Health (Round table) Analysis of Public Health Policy 407 A HIV testing in STD clinics 408 A HIV incidence and prevalence 408 BC 78 [Page 79](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/81) B. Clinical Aspects of AIDS Oral manifestations of AIDS 401 ABC New improved rapid diagnosis 403 ABC (Symposium) Management of infections associated with HIV immunodeficiency 407 B C. Basic Research Biomedical (Symposium) Molecular and cellular bases of retrovirus induced immunodeficiencies 407 C Pathogenesis (part 1) 410 ABC D. AIDS and the Individual Adolescents (part 1) 409 ABC E. AIDS, Society and Behaviour Close friends and family 411 A (Symposium) Innovative strategies for AIDS education with minorities 411 B F. Ethics and Law (Round table) Points of controversy between policy reports on AIDS 411 C G. International Issues Knowledge and sexual behaviour 406 A (Symposium) Infants at risk: An African perspective 406 BC H. The Economic Impact of AIDS Hospital-based costs 404 AB 16:00 - 17:30 A. Epidemiology and Public Health Sexual Transmission of HIV (part 1) 407 A HIV infection in prisoners 408 A Natural Histoiy of HIV infection: Co-factors for progression 408 BC B. Clinical Aspects of AIDS Concomitant infections in AIDS 401 ABC Pediatric: Neuro-development in HIV-infected children 403 ABC Therapy: AZT trials 407 B C. Basic Research Biomedical Molecular biology (part 1) 407 C Pathogenesis (part 2) 410 ABC D. AIDS and the Individual Health care workers 409 ABC E. AIDS, Society and Behaviour (Round table) Self-help: A coping strategy 411 A Cultural determinants in responding to AIDS 411 B F. Ethics and Law (Symposium) Ethics and intemnational inequity 411 C G. International Issues Prevalence (part 1) 406 A (Workshop) Regional workshop: East Africa 406 BC H. The Economic Impact of AIDS Out-of-hospital costs 404 AB 79 [Page 80](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/82) Le mardi 6 juin 8 h 30 a 10 h 30 < tat de la question >> -Pleniere Palais des Congres 407 ABC 11 h a 17 h 30 Presentations audiovisuelles Centre de conf6rences Guy-Favreau 11 h a 12 h sant6 publique (Table ronde) L'annonce prevention de l'infection par le VIH 407 A Surveillance du SIDA 408 A Infections par le VIH chez les consommateurs de drogues par voie intraveineuse B. Aspects cliniques (Atelier) Prophilaxie de la PCP 401 ABC Le SIDA dans les pays en voie de developpement 406 A (Colloque) Traitement des infections B (Colloque) et d6fis 409 ABC Recherches sur le comportement (partie 2) 411 A E. Le SIDA, la sociWt6 et le comportement (Table ronde) Services sociaux: 6thique (Colloque) La confidentialite (Colloque) rentables H. R6percussions 6conomiques du SIDA Planification et gestion 404 AB 13 h a 14 h Presentation d'affiches par les auteurs 100A/100B (Affiches exposies loute la journde'e) tpid6mlologie cet sant6 publique Transmission sexuelle du A (Table ronde) Efficacit6 et 6valuation des programmes 408 A (Table ronde) D6claration du VIIH 408 BC 80 [Page (Table ronde) Transmission p6rinatale du 401 ABC (Colloque) Diagnostic et histoire clinique de l'infection B mol6culaire: de r6gulation de type tat des genes viraux 410ABC D. Le SIDA et I'individu Minorites 409 ABC Psychologie et sexologie 411 A E. SIDA, la socitW et le comportement (Atelier) Empowerment: R6appropriation de la B F. Droit et 6thique (Colloque) tthique clinique 411 C G. Implications internationales Risques prevention 406 A (Colloque) Compassion et soins communautaires dans les pays en voie H. R6percussions 6conomiques du SIDA Coits dans les pays en voie de d6veloppement 404 AB 16 h a 17 h 30 A. tpid6miologie et sant6 publique Histoire clinique de l'infection A Modbles math6matiques 408 A (Colloque) tvaluation de l'efficacit6 des programmes de prevention 408 BC B. Aspects cliniques Traitement de la PCP 401 ABC (Colloque) Problmes de laboratoire dans le Virologie (partie mol6culaire: les genes r6gulateurs et leurs produits 410 ABC D. Le SIDA et I'individu Les adolescents (partie 2) 409 ABC Counseling 411 A E. Le SIDA, la sociktd et le comportement Problmes de la communaut6 gaie 411 F. Droit (Colloque) Infection par le VIH, reproduction parentale 411 C G. R6percussions macroeconomique dans les pays en voie de d~veloppement 404 AB 81 [Page 82](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/84) Tuesday June, 6 8:30 - 10:30 \"State-Of-The-Art\" Plenary session Palais des Congnis 407 ABC 11:00- 17:30 Audiovisual Presentations Guy-Favreau Conference Centre 11:00 - 12:30 A. Epidemiology and Public Health (Round table) Partner notification in 11W prevention 407 A AIDS surveillance 408 A HIV infection in IVDUs 408 BEC B. Clinical Aspects of AIDS (Workshop) PCP Prophylaxis 401 ABC AIDS in the developing world 406 A (Symposium) HIV therapy 407 B C. Basic Research Biomedical Virology 403 ABC (Symposium) Mechanisms of pathogenesis of human retroviruses 407 C Molecular biology; different level of expression of HIV-l provirus 4lO ABC D. AIDS and the Individual (Symposium) Prisoners: constraints and challenges 409 ABC Behavioral research (part 2) 411 A E. AIDS, Society and Behaviour (Round table) Social Services: Experiences and evaluations 411 B F. Ethics and Law (Symposium) Confidentiality and its limits 411 C G. International Issues (Symposium) Cost-effective serodiagnosis 406 BC H. The Economic Impact of AIDS Planning/Management 404 AB 13:00 - 14:00 Poster Presentations by Authors (Posters on display throughout the day) 14:00 - 15:30 A. Epidemiology and Public Health Sexual transmission of I-IV (part 2) Programme effectiveness and evaluation (Round table) HIV reporting B. Clinical Aspects of AIDS (Round table) Perinatal transmission of HIV (Symposium) Pneumocystis Carinii infections 407 A 408 A 408 BC 401 ABC 407 B 82 [Page 83](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/85) C. Basic Research Biomedical Pathogenesis (part 3) 403 ABC (Symposium) Origins of human retroviruses and animal models 407 C Molecular biology: TAT-mediated regulation of viral genes 410 ABC D. AIDS and the Individual Minorities 409 ABC Psychology and sexology 411 A E. AIDS, Society and Behaviour (Workshop) Empowerment: Reappropriation of health and experience of persons with AIDS 411 B F. Ethics and Law (Symposium) Clinical ethics 411 C G. International Issues Risks and prevention 406 A (Symposium) Community compassion and care in the developing world 406 BC H. The Economic Impact of AIDS Costs in developing countries 404 AB Tuesday, June, 6 16:00 - 17:30 A. Epidemiology and Public Health Natural history of HIV infection: Early manifestation and progression 407 A Mathematical models 408 A (Symposium) Evaluation of programme effectiveness 408 BC B. Clinical Aspects of AIDS PCP Treatment 401 ABC (Symposium) Laboratory issues in the diagnosis of AIDS 407 B C. Basic Research Biomedical Virology 403 ABC Animal models (part 1) 407 C Molecular biology: Regulatory genes and their products 410 ABC D. AIDS and the Individual Adolescents (part 2) 409 ABC Counselling 411A E. AIDS, Society and Behaviour The gay community issues 411 B F. Ethics and Law (Symposium) HIV infection, reproduction and parenthood 411 C G. International Issues Prevalence (part 2) 406 A (Workshop) Regional workshop: Asia 406 BC H. The Economic Impact of AIDS Macroeconomic impact in developing countries 404 AB 83 [Page 84](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/86) Le mercredi 7juin 8 h 30 a 10 h 30 << tat de la question > -Pl6niere Palais des Congres 407 ABC 11 h 17 h 30 Pr6sentations audiovisuelles Centre de conf6rences Guy-Favreau 11 h A 12 h 30 A. tpid6miologie et sant6 publique Transmission du VIH dans le milieu des soins de la sant6 407 A (Table ronde) Transmission h&t~rosexuelle 408 BC B. Aspects cliniques Pharmacologie et 1) 408 A Biologie molculaire (partie 2) 410 ABC D. Le SIDA et I'individu Les femmes 409 ABC E. Le SIDA, la socilt6 et le comportement R61e des ONG dans la C Implications internationales Le VIH en pediatrie 406 A (Colloque) Infections VIH 406 BC H. R6percussions 6conomiques R61e des assurances 404 AB 13 h a 14 h Presentation d'affiches par les auteurs 100A/100B (Affiches etudes s6ro-6pidemiologiques des femmes enceintes cliniques Hemophilie: histoire clinique et 6tudes par le VIH: atteintes ' certains organes 407 A 408 BC 401 [Page 85](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/87) C. 407 C Mise au point des m6dicaments: nouvelle approche antiviraux 408 A Moddles animaux E. Le SIDA, ia soci6td et le comportement Le SIDA en milieu de travail 411 A Le SIDA dans les m6dias 411 B F. Droit et sant6 publique 411 G. internationales Perspectives mondiales 406 A Transmission h6t6rosexuelle et r6le des MTS 406 BC H. Repercussions 6conomiques du SIDA Financement et assurances 404 AB 16 h \" 17 h 30 A. tpid6miologie et sant6 publique L'annonce aux VIH/Questions en matibre de politiques et de programmes 408 BC B. Aspects cliniques Infections associ6es au SIDA 401 ABC Atteintes neuropsychiatriques 403 (Colloque) Essais cliniques: points de Recherche fondamentale (biom6dicale) Virologie (partie 3) 407 immunologie 408 A Modeles animaux (partie 3) 410 ABC D. Le SIDA et I'individu (Colloque) Les femmes dans les pays industrialis6s: Questions et options 409 ABC E. Le SIDA, la soclit6 et le comportement Services de pastorale 411 Coercition A H. R6percussions 6conomiques du SIDA M&thodologie des analyses de cofits 404 AB 85 [Page 86](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/88) Wednesday June 7 8:30 - 10:30 \"State-Of-The-Art\" Plenary session Palais des Congr~ts 407 ABC 11:00 - 17:30 Audiovisual Presentations Guy-Favreau Conference Centre 11:00 - 12:30 A. Epidemiology and Public Health HJV transmission in the health care setting 407 A (Round table) Heterosexual transmission 408 BC B. Clinical Aspects of AIDS AZT Pharmacology and toxicity 401 ABC Therapy: Thrombocytopenia 403 ABC (Symposium) Quality of care for patients with AIDS 407 B C. Basic Research Biomedical (Symposium) Regulatory genes and viral genomic diversity 407 C Basic immunology 408 A Molecular biology (part 2) 410 ABC D. AIDS and the Individual Women 409 ABC E. AIDS, Society and Behaviour The role of NGO in the global response to AIDS 411 A The community-based response to AIDS into the 1990s 411 B F. Ethics and Law (Symposium) Research for treatments and vaccines 411 C G. International Issues HIV in pediatrics 406 A (Symposium) Tropical diseases: the impact of HIV 406 BC H. The Economic Impact of AIDS The role of insurance 404 AB 13:00 - 14:00 Poster Presentations by Authors (Posters on display throughout the day) 14:00 - 15:30 A. Epidemiology and Public Health Seroepidemiologic studies: Neonatal AIDS incidence and mortality B. Clinical Aspects of AIDS Clinical manifestations Hemophilia: Natural history/cohort studies (Symposium) HIV Infection: Organ specific involvement C. Basic Research Biomedical (Symposium) Vaccine developments in AIDS Drug development: Novel study approach to anti-viral drugs 407 A 408 BC 401 ABC 403 ABC 407 B 407 C 408 A 86 [Page 87](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/89) Animal models (part 2) 410 ABC D. AIDS and the Individual (Symposium) Injection drug users: Changing realities and persisting myths 409 ABC E. AIDS, Society and Behaviour AIDS in the workplace 411 A AIDS in the media 411 B F. Ethics and Law (Symposium) Preventing HIV transmission: Religious conflicts in public health 411 C G. International Issues Global Perspectives 406 A Heterosexual transmission and the role of STDs 406 BC H. The Economic Impact of AIDS Financing and Insurance 404 AB 16:00 - 17:30 A. Epidemiology and Public Health Partner notification 407 A HIV testing/policy and programme issues 408 BC B. Clinical Aspects of AIDS AIDS-related infection 401 ABC Neuropsychiatric involvement 403 ABC (Symposium) Clinical trials: The \"actors\"' perspective 407 B C. Basic Research Biomedical Virology 407 C Basic Immunology 408 A Animal models (part 3) 410 ABC D. AIDS and the Individual (Symposium) Women in developed countries: Issues and options 409 ABC E. AIDS, Society and Behaviour Pastoral care 411 B F. Ethics and Law (Symposium) Coercion or voluntarism: An international critical review 411 C G. International Issues Prevalence (part 3) 406 A (Workshop) Regional workshop: West Africa 406 BC (Symposium) International travel and AIDS: A perspective 411 A H. The Economic Impact of AIDS Methodology of cost studies 404 AB 87 [Page 88](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/90) Le jeudi 8 juin 8 h 30 a 10 h 30 << Synthese des pl6nieres >> Palais des Congres 407 ABC 11 h a 17 h 30 Pr6sentations audiovisuelles Centre de conferences Guy-Favreau 11 h a 12 h 30 A. Ppid6miologie et sant6 publique (Table Modelisation mathematique 408 A Transmission p rinatale 408 BC Aspects cliniques Thdrapie: la ribavirine et les autres mddicaments 401 de ddpistage par r6action en chaime des polymrrases 404 AB les (Colloque) Aspects pathologiques de l'infection par le VIH 407 utilisation des mol6cules CD4 dans le traitement du SIDA ABC D. et I'individu Consommateurs de drogues par voie intraveineuse (partie 1) 409 ABC Prostitution 411 A E. Le SIDA, la sociWt et le comportement (Atelier) Innovations en matiere de prevention et d'6ducation au sujet du SIDA 411 B G. Implications internationales SIDA et tuberculose 406 A (Colloque) Recherches sur la humaine SIDA Affectation des ressources et processus d6cisionnels 411 C 13 h les auteurs 100A/100B (Affiches exposees et santO publique (Table ronde) R8le du d6pistage et counseling la pr6vention SIDA Questions de m6thodologie Transmission sexuelle du VIH (partie 3) 407 A 408 A 408 BC 88 [Page 89](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/91) B. Aspects cliniques Neurologie 401 ABC au 407 C Vaccins 6 tude de 1'immunisation g 1'aide des glycoprot~ines du VIII 410 ABC D. I'individu Consommateurs de drogues par voje intraveineuse (partie Les femmes des pays en voie de d~veloppement 411 A E. Le SIDA, Ia soci~tC et le comportement Politiques sociales exp~riences et critiques G. femmes g risque 406 A (Colloque) la de programmes 406 BC MTS et facteurs de risque 411 C l6 ha 17 A. tpidemiologie et sante publique de le VIII: progression vers 407 A (Colloque) Infection par le VIII et la sant6: questions actuelles 408 BC Autres r~trovirus:le HThV-I 409 ABC B. Aspects cliniques SIDA et nutrition 401 ABC Immunomodulateurs 404 AB (Colloque) des m~dicaments anti-SIDA 1'6tude vaccins anti-VIH ABC E. Le SIDA, Ia soci~tC et le comportement Dimensions sociales du SIDA 411 B F. Droit et 6thique (Colloque) Discrimination et droit de la personne 411 C internationales 1'enfant 411 A 89 [Page 90](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/92) Thursday June 8 8:30 - 10:30 \"Synthesis\" Plenary speakers Palais des Congres 407 ABC 11:00- 17:30 Audiovisual Presentations Guy Favreau Conference Centre 11:00 - 12:30 A. Epidemiology and Public Health (Round table) Monitoring the HIV epidemic 407 A (Symposium) Mathematical modelling 408 A Perinatal transmission 408 BC B. Clinical Aspects of AIDS Therapy: Ribavirin and other anti-HIV drugs 401 ABC PCR diagnostic test 404 AB (Symposium) Respiratory infection in IV drug users 407 B C. Basic Research Biomedical Basic immunology 403 ABC (Symposium) Pathological aspects of HIV infection 407 C Drug development: Use of CD-4 molecules in AIDS therapy 410 ABC D. AIDS and the Individual Injection drug users (part 1) 409 ABC Prostitution 411 A E. AIDS, Society and Behaviour (Workshop) Innovations in AIDS education and prevention 411 B G. International Issues AIDS and tuberculosis 406 A (Symposium) Human sexuality research 406 BC H. The Economic Impact of AIDS Resource allocation and decision-making 411 C 13:00 - 14:00 Poster Presentations by Authors (Posters on display throughout the day) 14:00 - 15:30 A. Epidemiology and Public Health (Round table) The role of HIV testing and counselling in AIDS prevention 407 A Methodologic issues 408 A Sexual transmission of HIV (part 3) 408 BC B. Clinical Aspects of AIDS Neurology 401 ABC Lymphokines 404 AB (Symposium) HIV related issues in hemophilia: today and tomorrow 407 B 90 [Page 91](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/93) C. Basic Research Biomedical Drug development: Use of AZT and other oligonucleotides in AIDS therapy 403 ABC Virology 407 C Vaccines: Immunization study using HIV glycoproteins 410 ABC D. AIDS and the Individual Injection drug users (part 2) 409 ABC (Symposium) Women in developing countries 411 A E. AIDS, Society and Behaviour Public policy: Experiences and critiques 411 B G. International Issues (Symposium) Women at risk 406 A (Symposium) Challenge of programme management 406 BC STD and risk factors 411 C Thursday, June 8 16:00 - 17:30 A. Epidemiology and Public Health Natural history of HIV infection: Progression to disease 407 A (Symposium) HIV infection and the healthcare worker: contemporary issues 408 BC Other retroviruses: HTLV-I 409 ABC B. Clinical Aspects of AIDS Nutrition and AIDS 401 ABC Immunomodulators 404 AB (Symposium) Pharmacology of anti-AIDS drugs 407 B HIV-II and other retroviruses 408 A C. Basic Research Biomedical Oncology 403 ABC (Symposium) Role of macrophages and lymphocytes as reservoirs of HIV-1 407 C Vaccines: Use of animal model to study anti-HIV vaccines 410 ABC E. AIDS, Society and Behaviour Social dimensions of AIDS 411 B F. Ethics and Law (Symposium) Discrimination and human rights 411 C G. International Issues Clinical 406 A (Workshop) Regional workshop: Caribbean 406 B (Workshop) Regional workshop: Latin America 406 C Pediatric AIDS 411 A 91 [Page 92](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/94) Le vendredi 9 juin Friday June 9 8 h 30 \" 12 h o Perspectives d'aveniro -P16niere Palais des Congres 407 ABC C6r6monie de cloture 8:30 - 12:00 \"Future Prospects\" Plenary session Closing Ceremonies Palais des Congres 407 ABC 92 [Page 93](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/95) EEEEEEEEEI Les prdsentations de ce programme sont et par section. La num~rotation des abr~g~s indique le jour et La pr~sentation: P Affiche orale de la Section A The presentations in this program are grouped by day, by section. The numbering system utilized for the abstracts serves to identify the day, type of presentation. These numbers also refer to the abstracts in the Abstract Volume. Key to Numbering System Exarmpke M.A.O.37 M.A. 0. Day of the Section Type pres M: Monday P: P W: Thursday F: Friday 37 e of Presentation number: wentaltion: Refers to the 37th oradl )ral presentation in oster Section A la Conf6rence President, Centre de recherches pour le d6veloppement international Monsieur Robert Bourassa Le Premier Ministre du Qu6bec Dame Nita Barrow Reprdsentante permanente de la Barbade aux Nations Unies Kevin Brown President dm6rite Vancouver Persons with AIDS Society Canada Jonathan Mann Directeur, Programme mondial de lutte Qu6bec Canada Brian Mulroney Premier Ministre du Canada CONFl;RENCIER PRINCIPAL: Son Excellence Kenneth Kaunda la Zambie 94 [Page 95](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/97) Chairman: Ivan Head Conference Chairman Opening President-International Development Ceremony Research Centre Mr. Robert Bourassa Sunday Premier of Quebec June 4 Dame Nita Barrow Permanent Representative of Barbados at the United Nations Kevin Brown Chairman Emeritus Vancouver Persons with AIDS Society Canada Jonathan Mann Director Global Programme on AIDS World Health Organization Armand Frappier Founder, Institut Armand Frappier Montreal, Quebec Canada The Right Honourable Brian Mulroney Prime Minister of Canada KEYNOTE ADDRESS: His Excellency Kenneth Kaunda President of the Republic of 95 et bien-&tre social Canada Donald deGagnR Directeur, Vancouver Persons with AIDS Society Canada Confdrenciers: June Caliwood Joumnaliste Globe & Mail Canada AlIbert Jacquard Professeur a 1 'Universit6 de Gen~ve Chef Institut national d'dtudes ddmographiques France Mechai Viravaidya Fondateur Community ande Stephen Joseph Commissaire de la Etats-Unis David Suszuki Scientifique/Joumlaliste D~partement zoologie University of British Columbia Canada 98 [Page 99](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/101) New Perspectives M na Chairpersons: Maureen Law June 5 Deputy Minister Health and Welfare Canada Donald decagne' Director Vancouver Persons with AIDS Society Canada Plenary speakers: June Caliwood Columnist Globe & Mc~ail Canada AlIbert Jacquard Professor, University of Geneva Chief, Genetic Services Institut national d'6tudes ddmographiques France Mechai Viravaidya Founder Population and Community Development Association Thailand Stephen Joseph Commissioner of Health New York City U.S.A. David Suzuki S cientist/B roadc as ter Department of Zoology University of British Columbia Canada 99 [Page 100](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/102) 11:00 - 12:30 Salleoom 407A Room Chairpersons Etats-Unis Seroepidemiologic Studies: United States J. Borgano (Chile) Gary Noble (U.S.A.) Stan Vermund (U.S.A.) 11:00 M.A.O.1 M.A.O.2 HIV Seroconversion Rate in a Serially-tested Population of Young Adults in the United States (1987-1988). John G. McNeil*, Z. F. Wann**, D. S. Burke*, J. F. Brundage*, *Walter Reed Army Institute of Research, Washington, DC; **SRA Technologies, Alexandria, VA, U.S.A. Sentinel Hospital Surveillance for HIV Infection in the United States: Early Cross-Sectional Findings. Michael E. St. Louis, K. J. Rauch, C. R. White, J. E. Anderson, T. J. Dondero, the Sentinel Hospital Investigation Group, Centers for Disease Control, Atlanta, GA, U.S.A. Epidemiology of HIV Infection in Active Duty Army Men at No Identified Risk (NIR). Philip O. Renzullo*, J. G. McNeil*, J. R. Bunin**, J. F. Brundage*, *Walter Reed Army Institute of Research, Washington, DC; **AIDS Program, NIAID, Rockville, MD, U.S.A. Evaluation of the Estimated Number of HIV Infections Using a Spreadsheet Model and Empirical Data. Timothy J. Dondero, M. St. Louis, J. Anderson, L. Petersen, M. Pappaioanou, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Measuring Levels and Trends of HIV Infection in the General Population by Monitoring HIV Seroprevalence in Primary Care Outpatients. Lyle R. Petersen*, T. J. Dondero*, R. Engel**, N. Herring**, *Centers for Disease Control, Atlanta, GA; **Damon Clinical Laboratories, Needham Heights, MA, U.S.A. Prevalence and Estimated Incidence Rates of HIV Infection among Civilian Applicants for US Military Service: Current Status and Trends. John F. Brundage*, L. Gardner*, D. Burke*, J. McNeil*, R. Visintine**, M. Goldenbaum*, et al., *Walter Reed Army Institute of Research, Washington, DC; **U.S. Military Entrance Processing Command, North Chicago, IL, U.S.A. 100 [Page 101](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/103) 11:00 - 12:30 Salle Room 408A Section A Lundi 5 juin Monday, Specialty Session Chairpersons ~idmiologieet sant~ publique Epidemiology Health SIDAIVIH le sang et les prodults sanguins AIDSIHIV: Blood and Blood Products Pier M. Manucci (Italy) Cladd E. Stevens (U.S.A.) V. I. Pokrovsky (USSR) M.A.O.7 IM.A.O.11 Transfusion-associated Cases in Europe. Angela M. &wn*, R. A. Ancelle-Park*, J. B. Brunet*, and national surveillance correspondents of 31 countries, *WHO Collaborating Centre on AIDS, Paris, France. The Epidemiology of Transfusion-associated (TA) AIDS in the United States. John W. Ward*, R. Reisler**, J. Karon\"\", *JAJDS Program, Centers for Disease Control, Atlanta, GA; **Cotlumia School of Public Health, New York, NY, U.S~A. Blood and Plasma Donations among a Cohort of IV Drug Users. Kenrad E. N~elson. D. Vlahov, J. Margolick, M. Bernal, The ALIVE Study, Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S~A. Prospective Evaluation of Contemporary Screened Blood Donors for Occult HIV Infection. Michael P. Busch*/**, B. Eble*, P. Ulrich*, Z. ElAmad**, H. Perkins*/**, G. Vyas*F, * University of California at San Francisco; **Jpry,,j Memorial Blood Centers, San Francisco, CA, U.S~A. Routine 6-Month Monitoring for Blood Transmitted HIV Infection. Anna Giovanetti, F. Mozzi, A. Bellobuono, L. Vianello, A. at Bonn Hemophiliac Center. Bernd S. Kames*, D. Niese*, H. institutes of Technology, Cambridge, MA, U.SA. - 5 Specialty Session Presidents Chairpersons 12:00 M.A.O.17 12:15 M.A.O.18 Observations on the Natural History of HIV-2. Richard G. Marlink*, I. Thior**, T. Siby**, I. Ndoye**, P. Kanki*, I. Romieu*, et al., *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.; **University of Dakar and the National HTLV-I, HIV-1 and HIV-2 Gerard Agius*, V. Dindinaud*, Universitd Curie, France. Epidemiology of HIV-2 in Female Prostitutes in Senegal. Phyllis J. Kanki*, S. M'Boup**, I. Romieu*, R. Marlink*, T. Siby**, M. Essex*, et al., *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A.; **University of Dakar, 6 pays d'Afrique centrale. Eric Delaporte*, M. P. Peeters*, J. P. Durand**, Cameroon. HIV 1 HTLV-I a U.S. Population Survey: NHANES-II. Carl Saxinger, G. McQuillan, W. Haddon, R. Murphy, A. Bodner, R. Gallo, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. Human Immunodeficiency (HIV) and Human T-Lymphotropic (HTLV-I/l) Viruses in Childbearing Women: Tests of 24,569 Consecutive Newborns. Roy W. Stevens, J. A. Wethers, D. S. Berns, K. G. Pass, New York State Department ofHealth, Albany, NY, U.S.A. 102 [Page 103](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/105) 11:00 - 12:30 Salle Room 401ABC Section B Lundi 5 juin Monday, June 5 S6ance th6matique Specialty Session Presidents Chairpersons Aspects cliniques Clinical Aspects of AIDS Le VIH chez les enfants HIV in Children Claude Griscelli (France) E. Mworosi (Uganda) Gwendolyn Scott (U.S.A.) 12:00 in Born to HIV-positive Mothers: Results from the European Collaborative Study. Catherine Peckham, European Collaborative Study, Department of Paediatric Epidemiology, Institute of Child Health, London, U.K. Natural History of Infants Born to HIV-positive Women. Anne Willoughby*, H. Mendez**, J. Goedert*, M. CRMC, NICHD, Bethesda, MD; **State University of New York at Brooklyn Health Science Center, Brooklyn NY, U.S.A. Prospective Study of Infants Born to Mothers Seropositive to HIV-1: French HIV in Newborn Study Group. S. Blanche*, F. Verber, M. J. Mayaux, C. Rouzioux, A. M. Duliege, M. L. Moscato, et al., France. Prospective Evaluation of Immune Function in Infants Born to HIV-seropositive Mothers. Martha F. Rogers, NYC Perinatal HIV Transmission Collaborative Study Group, Centers for Disease Control, CID/AIDS Program, Atlanta, GA, U.S.A. Predictive Value of Beta 2 Microglobulin Level in Serum from Children Born to HIV Infected Mothers. Hugo Di Maria*, M. E. Toubert****, M. H. HIV-1 DNA Detection by PCR for Studies on Perinatal HIV Transmission in Africa. Patricia Paterlini*, S. Lallemant-Lecoeur**, M. Lallemant***, P. M'Peld*****, B. Larouze**, C. Brdchot*/**** and Research Group Infection in Congo,*INSERM B Lundi 5 juin Monday, 5 Table ronde Round Table Presidents Chairpersons Aspects cliniques Clinical Aspects of AIDS Coordination des soins: le point de vue du personnel infirmier Coordinating Care: Nurses' Perspectives Joan Bennett (U.S.A.) Diane M.B.O.8 11:30 M.B.O.9 St. Paul's Experience. Irene Goldstone, St. Paul's Hospital, Vancouver, BC, Canada. The Impact of AIDS on Families of Hemophiliacs in Wales. JakeBee School of Nursing Studies, Cardilfj; U.K. The Challenge Facing Nursing in Central Mfrica. Qliyve.K Ko~l., University Teaching Hospital, Lusaka, Zambia. A Comparison of the Projected Nursing Care Needs of Hospitalized AID S and Non-AIDS Patients. LidialIvanus, Royal Victoria Hospital, Montreal, Q2C, Canada. Home Needs (Care for AIDS Patients). Pat Maynard, St. Elizabeth Nursing Home, Don Mills, ON, Canada. 104 [Page 105](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/107) 11:00-12:30 Sale Rom 407B Section B June 5 Colloque Symposium Pr6sidents Chairpersons Aspects cliniques Clinical Aspects of AIDS Les infections & Pneumocystis carinil Pneumocystis Carinil Infections John Mill (U.S.A.) Richard 11:00 M.B.O.12 11:15 M.B.O.13 11:30 M.B.O.14 11:45 M.B.O.15 Changing Pattern of Pneumocystis Carinii Infections. PhiL Hopewell. San Francisco GeneralHospital, San Francisco, CA, U.SA. Animal Models of Pneumocystis Carinii Pneumonia. Sherry F Quee rt, Indiana University School of Medicine, IN, U.SA. Treatment Pneumocystis QC, and Prophylaxis of PCP. Julio Montaner., St 12:30 Salle Room 407C Section C 5 Colloque Presidents Chairpersons fondamentale Basic Research de la du VIH Mechanisms of Pathogenesis of HIV Ten Feizi (U.K.) Jay A. Levy (U.S.A.) 11:00 M.C.O.1 11:15 M.C.O.2 11:30 M.C.O.3 11:45 M.C.O.4 Viral and Host Factors Influencing the Progression to AIDS. Jay A. Levy*, C. Cheng-Mayer, C. Walker, J. Homsy, *University of California at San Francisco, Department of Medicine, San Francisco, CA, U.K. Immune Responses to HIV. John Sullivan, University of Massachusetts, Department of Pediatrics, Boston, MA, U.S.A. Role of N-Linked Glycosylations in HIV Infection. Jean-Claude Gluckman*, Paris, France. New Approach to the Study of Oligosaccharides as Determinants of the Tissue Tropisms of HIV-1. Ten Feizi*, *MRC Clinical Research Centre, Harrow, U.K. 106 [Page 107](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/109) 11:00 - 12:30 Salle Room 410ABC Section C Lundi 5 juin Genomic diversity and Relationship to Clinical Aspects M. Hayami (Japan) Louis F. Qualtibre (Canada) Pierre Sonigo (France) 11:00 M.C.O.5 11:15 M.C.O.6 11:30 Fukasawa**, T. Miura*, et al., *Institute for Virus Research, Kyoto University, Kyoto; **Institute of Medical Science, University of Tokyo, Tokyo; J. Miki***, M. Isahakia****, M. Hayami**, et al., *Institute of Medical Science, University of Tokyo, Tokyo; **Institute for Research, Kyoto University, Kyoto; ***Toa Nenryo Kogyo, Japan; ****Institute of Primate Research, National of Kenya, Kenya. Prospective Clinical, Immunological, and Virologic Follow-up of an Infected Lab Worker (LW). Blattner*, Nara*, G. Shaw**, 12:15 Biological Phenotype of Sequential Human Immunodeficiency Virus (HIV) Isolates in Seroconverting Homosexual Men. Matthiis Tersmette*, R. E. Y. De Goede*, F. De Wolf**, J. Goudsmit**, J. G. Huisman*, F. Miedema*, *Central Laboratory Netherlands RedCross Blood Transfusion Service and Laboratory of Experimental and Clinical Immunology, University of Amsterdam; **Academic Medical Centre, Amsterdam, Netherlands. Replicative Capacity of Sequential Virus Isolates from HIV-1 Infected Subjects and Relationship to Clinical Progression. Eva M. Fenv*, J. Albert**, L. Morfeldt-Manson*, B. Asjo*, *Karolinska Institute, Department Virology; **National Bacteriological Laboratory, Stockholm, Sweden. CD4+ T Lymphocytes from the Peripheral Blood Mononuclear Cells (PBMC) of Healthy Seropositive Individuals Harbor Psallidopoulos*, M. H. Lane**, N. P. Salzman*; *School of Medicine, University, Washington, DC; **NIAID, National ofHealth, MD; ***PRI, Frederick, MD, Room 409ABC S6ance th6matique Section Lundi 5 juin Monday, June 5 Le SIDA et I'individu AIDS and the Individual Recherches sur le comportement (partle 1) Specialty Session Behavioural Research Michel Careal (Switzerland) M.D.OA 12:00 M.D.O.5 12:15 M.D.O.6 Population Prevalence of AIDS High Risk Behaviors in France, the United Kingdom and the United States. James A. Wells*, G. R. Wilensky*, A.-J. Valleron**, G. Bond***, R. L. Sell*, P. De Filippes*, *Project HOPE Center for Health Affairs, Washington, DC, U.S.A.; **Universitd Paris, Paris, France; Central Office of Information, London, U.K. Behavioral Determinants of Blood Donations among HIV-Seropositive Persons: A Multi-Center Study. Lynda S.. Doll*, HIV Blood Donor Study Group**, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A.; **Investigators from 20 blood donation sites throughout the U.S.A. Sexual Behavior and Behavior Changes in Kinshasa: Implications for AIDS Counselling. Melinda Moore*/**, A. Doppagne***, S. E. Hassig*/**, L. Piripiri*, W. E. Bertrand*l**, T. of LA, U.S.A.; Kinshasa, Zaire. An Ethnographic Survey of Nonpenetrative Sexual Behaviour. Glen E. Maro*, B. Porter**, C. M. Cassidy**, D. Feldman**, *Academy for Educational Development, AIDSCOM, Washington, DC; Porter Novelli, Washington, DC, U.S.A. Compliance with AIDS Prevention Measures among Intravenous Drug Users: Health Beliefs or Social/Environmental Factors? Karen H. Watters**/***, P. Case***, University, Palo Alto; **University of California at San Francisco; *** Urban Health Study, San Francisco, CA, U.S.A. The National Survey of Health and Sexual Behavior: The Pretest Experience. Marcie L. Cvnamon, National Center for Health Statistics, Department of Health and Human Services, Hyattsville, MD, U.S.A. 109 [Page Chairpersons Section E Lundi 5 juin Monday, June 5 Le SIDA, la socieai et le comporremera AIDS, Society and Behaviour Vivre avec le SiDA: les points de vue de personnes atteintes Living with AiDS: A Person with AIDS Perspective Michel Callen (U.S.A.) U.SA. Women's Hemophilia. Rogerio Fiaro Guimares, Brazilian Interdisciplinary AIDS Association, Brazil. AIDS in the Caribbean. Godfrey Sealy, Community Action Resource, Trinidad and Tobago. Homophobia and Mfrica. Pee k.ebbti4, Uganda. Isolation of PWAslMedi a Relations. Hassan Bangura, National AIDS Committee, Sierra Leone. 110 [Page 111](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/113) 11:00 12:30 Salle Presidents Chairpersons Section E Lundi 5 juin Monday, June 5 Le SIDA, la societ6 et le comportement AIDS, Society and Behaviour Educatlon-SIDA: legons A tirer des pays en vole de d6veloppement AIDS Education: Lessons from Developing Countries Ousmane Diouf (Senegal) Rodrigues pour la santd, Dakar, Senegal. The Role of Health Education in Prevention of AIDS (Uganda's Experience). Jonathan K. Gaifuba, A. B. Amana, Ministry of Health, Uganda. Street Teenagers and an AIDS Prevention Program in Brazil. Flavio Braune Wiik*, A. Filguerias**, ***Street kids' educator, Rio de Janeiro, Brazil. AIDS Education for Young People in a Multilingual Society. Soulemavne M'Boup*, A. Sow**, P. G. Sow**, M. M'Diaye**, M. M'Diaye***, et al., *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A., Universitd the Condom: Folklore and Religion as Adjuncts of AIDS Prevalence among Haitian Migrant Agricultural Workers in the Dominion Republic. Nelson Didiez, M. Arbaje, S. Rosario, E. Guerrero, R. A. De I. Troncoso, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic. Lessons Learned from Family Planning Communication Programs. Phyllis T. Piotrow, P. Coleman, L. Liskin, Centerfor Community Programs, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. 111 [Page 112](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/114) 11:00 - 12:30 Salle Room 411C Section F Lundi 5 juin Monday, June 5 Droit et 6thique Ethics and Law Vue d'ensemble de la 16gislation sur le SIDA Global Survey of AIDS Legislation Colloque Symposium Presidents Chairpersons Sev Fluss Human Rights Context of AIDS Law. Justice Michael Kirby, Court of Appeal, Supreme Court of Australia, Sydney, Australia. Implementing HIV/AIDS Legislative Policy Focusing on Ethical Issues in a National Health Care System. Marvelu R, Peterson, S. H. Mather, E. Shelp, L. N. Stout, S. K. Sverha, R. A. Allen, Department of Veterans Affairs, Washington, DC, U.S A. State AIDS Legislative and Policy Trends: 1983-1988. Mona J. Rowe, D. M. Merritt, C. C. Ryan, B. Bridgeham, I. Bowleg, AIDS Policy Center, Intergovernmental Health Policy Project, Washington, DC, U.S.A. The Limits and Prospects of AIDS Legislation in Anglophone Africa. Akwasi Aidoo, IDRC Fann, Dakar, Senegal. de St-Just, Maison Chaboillez, Longueuil, QC, Canada. A Global Survey of AIDS Legislation. Larry Gostin, Harvard School of Public Health, Boston, MA, U.S.A. A Global Survey of AIDS Legislation. William Curran, Harvard School of Public Health, Boston, MA, U.S.A. 112 [Page 113](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/115) 11:00- 12:30 Salle Room 406A Savigny M.G.O.5 12: 15 1M.G.O.6 Evaluation of the Program of Prevention and Control of Blood Transmission of HIV in Mexico. JgjmegSe4lv4dK, M. L. Garcia*, J. L. Dominguez**, J. L. Valdespino*, *Directorate of Epidemiology, Ministr~y of Health; **National Center of Blood Transfusion, Mexico Cily, Mexico. A Regional Perspective of IIIV Antibody Testing in the Americas. Mi'chael V. OlShaughnessv*, J. A. Meltzer*, *Federal Centre for AIDS; **Health Welfare Canada, Ottawa, ON, Canada. Detennination of LIIV-1 Sero-prevalence in a Cohort of 8000 Individuals in Kinshasa, Zaire Using Pooled Sera Compared to Testing of Individual Sera. rEnd4aj.lledwL, M. Kasai*, Ndilu*, MD, U.S~A. A Simple, Rapid, Practical HIV Screening Assay for Developing Country Manufacturing and Use. BabaaA. Schaeffler. M. Herrick, M. Coulter, F. Spielberg, M. Tam, Program for Appropriate Technology in Health (PATH), Seattle, WA, U.S~A. The Use of Dilution Techniques in Screening for HIV-1 and -2 Antibodies in West Africa. Andrew S. B. Hughes*, R. Njie*, K. Manneh*, B. Oelman**, Department, Banjul, The Gambia; ****Middlesex Hospital, London, U.K. Pooling of Sera to Reduce Costs of HIY-Antibody Screening in Blood Bank Donors from Bogota, Colombia, South America. Joa ohl\" M. Garcia**, L. S. Jaramillo*, M. V. Florez**, Guzman*, * Virds Laboratory, Instituto Nacional de Salud; **Red Cross National Bank, Bogota, Colombia. 113 [Page 114](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/116) 11:00 - 12:30 Salle Room 406BC Section G 5 juin Monday, June 5 Colloque Implications intemationales Intemrnational Issues Aspects culturels et soclaux de la sexualit6 Cultural and Social Perspectives of Sexuality Symposium Presidents Chairpersons Iona Campagnolo Sex and Science: Anthropological Perspectives for AIDS Prevention and Care. Barbara O. de Zalduondo, Harvard School of Public Health. Boston. MA. U.SA. Cultural, Sexual and Social Perspectives of AIDS in Brazil. Arlettv Pinel, Centro de Referdncia e Treinamento AIDS, Sao Paulo, Brazil. Adolescent Sexuality in Europe. L. Slikkerveer, Institute of Culture and Social Studies, University of Leiden, Leiden, The Netherlands. AIDS and the South African Culture. Musa Zazayokwe, South African Institute for Medical Research, Johannesburg, South Africa. Sexuality in Africa: The Role of Cultural Beliefs and Behaviour. V. N. Kimani, Department of Community Health, University of Nairobi, Nairobi, Kenya. Cultural Determinants of Sexuality in the Sudan. L. Asma, University of Khartoum, Faculty of Medicine, Khartoum, Sudan. Summation. Iona Campagnolo, McMaster Centre for International Health, Hamilton, ON, Canada. 114 [Page 115](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/117) 11:00 - 12:30 Salle Room 404AB Section H Lundi 5 juin Speciality Session Pr6sidents Chairpersons R6percussions economiques du SIDA The Economic Impact of AIDS Apergu et coOts de la pr6vention et de I'rducation Overview Plus Costs of Prevention and Education Nick Drager (Switzerland) Margaret Duckett (Canada) 11:00 M.H.O.1 Overview. Margaret Duckett, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. Cost of Medium-Term AIDS Prevention and Control Programmes in Sub-Saharan Africa. Nick Drager*, L. Collis**, D. Tarantola*, J. L. Lamboray**, U. Camen***, Phillips****, et al., *World Health Organization, Geneva, Switzerland; **World Bank, Washington, DC, U.S.A.; ***University of Geneva, Geneva, Switzerland, ****London School of Hygiene and Tropical Medicine, London, U.K. Costs of AIDS Education. Harvey Fineber, Harvard School of Public Health, Boston, MA, U.S.A. HIV Screening among Potential Immigrants: A Cost/Benefit Analysis. Hanna Zowall*, N. Gilmore*, R. D. Fraser**, A. Deutsch*, S. A. Grover*, *Division of Clinical Epidemiology, Montreal General Hospital, Montreal, QC; **Queen's University, Kingston, ON, Canada. Cost-effectiveness of HIV Screening among Pregnant Women in Paris Hospitals. Catherine Le Galds*, J. P. Moatti*, Collectif Paris-Tours d'dtude de la Perinatal Transmission HIV); *INSERM Research U240, Fontenay-aux-Roses, France. The Role of Community Based Organizations in Containing the Costs of the AIDS Epidemic. M. Smith, Hospital of the University of Pennsylvania, Pittsburg, PA, U.S.A. 115 [Page 116](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/118) 11:00 -12:30 uSectionLud5jn C ine a d Sesion by: AIDS 1:33 IM.I.V.2 \"PRE AND POST HIV Viddo de/Video by: Suzan 1Muska Norwegian Red Cross Annie/Year: 1989 est devenu un didment capital dams les traitements l'infection ses modes transmission et ses possibilitds de traitement; ii doit aussi les aider a faire face g leur situation tout en abordant les probl~mes de la confidentialit6, des droits, des du consentement dclair6. Ces deux films viddo destind~s a la formation de consultants (le premier en deuxi~me en fran~ais) Counselling has become a vital element in AIDS-related medical treatment or antibody testing. As well as helping people understand HIV infection, transmission routes and treatment possibilities, the care provider must help people to cope with their situation while addressing issues such as confidentiality, rights, responsibilities and informed consent. These two videos for counsellor training (the first in English, the second in French) were chosen from many submissions on the subject. 116 [Page 117](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/119) 1245-1345 0, Aspects auo-visuels m 409ABC 9M=v% Room Audio-Visual Aspects Sessions du midi L'histoire: Qu'avons-nous appris? Noon Hour History Teaches: What Myron of a year Italy (1630): imaginary and social behaviours. Guila Calvi, Universitd 13:00 L'aspect culturel de la tuberculose et son impact sur les efforts pour contr61er la maladie en Afrique du Sud./Cultural construction of tuberculosis and its impact on efforts to control it within South Africa. Randal M. Packard, Universitd de Tufts, Atats-Unis/Tufts Legons de in the face of the other, condemned and damned: Lessons from history. Mikael Elbaz, Universitd Laval, Quebec, r6flexions./The Europe: Some reflections. Alfred Crosby. Jr., Universitd du Texas, Austin, Texas, Etats-Unis/University of Texas, Austin, Texas, U.S.A. 13:30 Le SIDA comme maladie post-modeme: Entre la biologie et la soci6dt, pass6 et le pr6sent./AIDS as a postmodern illness: Between biology and society, between past and present. Mirko D. Grmek. Ecole Pratique des Hautes Itudes, Paris, France. quelques de leur oeuvres en tirer en relation avec le SIDA. Following dramatic readings from recent works by several internationally-respected authors of medical history, the authors talk about their works, what it has taught us, and applications to our contemporary dilemma around AIDS. 117 [Page 118](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/120) 14:00 - 15:30 Salle 407A Room 407A Lundi 5 juin Monday, June 5 Table ronde Round Table pid~miologie et sant6 publique Epidemiology and Public Health Evolution des O0 allons-nous? Analysis of Public Health Policy for the Prevention of AIDS: Where Have We Gone Wrong? Where Do We Go from Here? Donald P. Francis (U.S.A.) Bertino Somaini (Switzerland) decision-making difficult political Pr6sidents Chairpersons 14:00 M.A.0.19 Program Content: * Public health environment * Are currently HIV prevention policies rational? clear? * Policies that have failed * Policies that have succeeded * Lessons for future policy development Panelists: Randy Shilts, San Francisco, CA, U.S.A. Ronald Bayer, New York, NY, U.S.A. John K. Watters, San Francisco, CA, U.S.A. Additional speaker, to be announced 118 [Page 119](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/121) 14:00-15:30 Roomii~~~~~~iiiii~~~~~ 408A Section June 5 idja~uioogie et sanaipubliqlue Epidemiology and Public Health Tests de deplstage du VIH dans les cliniques de MATS S~ance Session Testing In STD Clinics Pre~sidents N. N. Clients Attending Sexually Transmitted Disease (STD) Clinics in the U. S. Elan crv I. M. Onorato, P. A. Sweeney, AIDS Program, HIV Seroepidemiology Branch (MS-G29), Centers for Disease Control, Atlanta, GA, U.S~A. Surveillance of HIV Infection Using a Network of Sentinel Physicians: A Pilot Project in the Province of Quebec. Midhwl STD Who Decline HIV Counseling and Testing. David W. Fleming*, D. Bennett*, R. Klockner*, County Health Division, Portland, OR, U.S~A. HIV-1 Seroprevalence in Sexually Transmitted Disease (STh) Clinic Patients in Central North Carolina. Suzanne E. Landis*, V. J. Schoenbach*, D. J. Weber*, M. Mittal*, G. G. Koch*, P. H. Levine**\", * University of North Carolina, School of Public Health, Department of Epidemiology, Chapel Hill, NC; \"\"aioa Cancer Institute, Bethesda, MD, U.S~A. Centre de gratuit la collaborateur O.M.S., Europe SIDA, Paris, France. HIV Seroprevalence in Sexually Transmitted Disease (STD) Clinic Patients. Iohn Qyv~, P. Bracci, R. Kappes, L. Kunches, I. Day, R. Timperi, et al., Massachusetts Department of Public Health, Boston, MAi, U.S.A. 119 [Page 120](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/122) 14:00 - 15:30 Salle Room 408BC Chairpersons pidmiologie et sant and Public Health Incidence et pr6valence du VIH HIV Incidence and Prevalence Margareta Bottiger (Sweden) Marc Dionne Risk Factors in a Cohort of Homosexual Men: Results at 6 Years. Phil Sestak*, M. T. Schechter*, B. Willoughby*, K. J. P. Craib*, M. Maynard*, M. V. O'Shaughnessy**, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC; **Federal Centre for AIDS, Ottawa, ON, Canada. Incidence and Prevalence of HIV Infection among Homosexual and Bisexual Men, 1978-1988. Nancy A. Hessol*, A. R. Lifson*, R. Kohn*, J. S. Harrison**, L. S. Doll**, G. W. Rutherford*, et al., *San Francisco Department of Public Health, AIDS Office, San Francisco, CA; **AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. HIV Seropositivity in a Clinic for the Homeless. Pedro Greer, *LL.*, G. Dickinson**, F. Parra***, F. Eqea***, L. of Medicine; **Miami VA Medical Center; ***State of Florida Department of Health and Rehabilitation Service, Miami, FL, U.S.A. Pr6valence de l'infection HIV et de la Patients: United States. Thomas A. Peterman, V. Beral, R. L. Berkelman, S. D. Holmberg, H. W. Jaffe, Centers for Disease Control, Atlanta. GA, U.S.A. Epidemiology of HIV Encephalopathy in the United States. Robert S. Janssen, J. Stehr-Green, T. Starcher, Centers for Disease Control, Atlanta, GA, U.S.A. 120 [Page 121](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/123) 14:00 - 15:30 Sane Room 401ABC Specialty Session Chairpersons Aspeas clnues Clinical Aspects of AIDS Manifestations buccales du SIDA Oral Manifestations of AIDS Silvio Gomez (Canada) J. J. Pindborg Nacional de Medicina, B uenos Aires, Argentina. Oral Manifestations of HIV Infection in African Patients. Joseph H. Perriens*, Z. Mugaruka**, B. Zaire. Demonstration of EBV-DNA Prior to the Occurrence of OHL and Its Correlation with the Clinical Status. Helmut Ndher*, U. K. Freese**, L. Gissmann**, C. Von Knebel Doeberitz**, al., **Deutches Krebsforschungszentrum, Heidelberg, Federal Republic of Germany; ***University of California at San Francisco, San Francisco, CA, U.S.A. Sexual Practices as Risk Factors for Candidiasis and Hairy Leukoplakia: The Oral AIDS Epidemiology Project. David Feial*, D. Greenspan**, G. Overby**, A. Moss*, G. Rutherford***, J. S. Greenspan**, University of California at San Francisco, Schools of *Medicine and **Dentistry, The Oral AIDS Center, ***Department of Public Health, San Francisco, CA, U.S.A. Risk Factors for Rapid Progression from Hairy Leukoplakia (HL) to AIDS. Deborah Greenspan*, J. S. Greenspan*, G. Overby*, C. Borowsky**, H. Hollander**, D. W. Feigal**, University of California at San Francisco, Schools of *Dentistry and **Medicine, Oral AIDS Center, San Francisco, CA, U.S.A. Oral Kaposi's Sarcoma in AIDS: Management with Intralesional Chemotherapy. Joel F. Lozada-Nur**, W. A. McLeod***, J. Spinelli****, *Cancer Control Agency of British Columbia, Vancouver, BC, Canada; **University of California at San Francisco, San Francisco, CA, U.S.A.; ***St. Paul's Hospital; ****Cancer Control Agency of British 121 [Page 122](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/124) 14:00 - 15:30 Salle Roo th~matique Specialty Session Pr~sidents Chairpersons Aspects dliniques Clinical Aspects of AIDS Nouvelle techique de diagnostic rapide New Rapid Diagnosis Approach G. Charlier (Haiti) Thomas Quinn Tames A. Lautenberger*, G. C. Dubois**, K. P. Samuel**, S. D. Showalter**\", M. Zweig**, T. S. Papas*, *Laboratory of Molecular Oncology, National Cancer Institute; * *Program Resources Incorporated, Frederick Research Facility, Frederick, MD, U.S.A. Antibody Responses to Accessory Gene Products in LIlY-i Infection. Toep M. A. L~ange*, P. Reiss*, A. De Ronde*, F. De Wolf*, C. Debouck**, J. Goudsmit1', et al., *Academic Medical Centre, Amsterdam, the Ne therlands; *\"D epartmen tofMo leculZar Smith PA, U.SA. Seroreactivity to HIV-1 vif, and Jassoy*, E. Kuehn*, R. W. Braun*, *Institute for Medical Virology, University of Heidelberg; **MaxPlanck Institute for Medical Research, Heidelberg, Federal Republic of Germany. A Rapid and Simple Procedure for Field Testing of ITI-1 Antibodies. Falk Fish. M. Ritterband, M. Herzberg, ORGENICS Ltd., Yavne, Israel. A Rapid Whole Blood Application for LIlY Antibody Testing Using Liposome-based Technology. Charles F. Hilbegm, D. Duschl, J. Blackwell, J. Huff, J. Britz, J. Smialek, *Becton Dickinson and Company, Sparks; **Office of the Medical Examiner, Baltimore, MD, U.S~A. A Multistate Study of a Particle Agglutination Test for Detection of HIV Antibodies. Robr LSh~ifc, R. Piccirilli**, M. Busch***, F. Company **NE Pennsylvania Region ARC, Wilkes Barre, PA; ***Jpwjn Memorial Blood Bank, San Blood Portland, OR; *****\" \"Commpunity BlIood juin Monday, June 5 Colloque Aspects cliniques Clinical Aspects of AIDS Traitement des infections associbes A I'immunod6ficience causee par le VIH Management of Infections Associated with HIV Immunodeficiency Symposium Pr6sidents Chairpersons S. H6pital Cantonal de Geneve, Geneva, Switzerland. Cryptococcosis. Merle Sande, San Francisco General Hospital, San Francisco, CA, U.S.A. Tuberculosis (TB) and Atypical Mycobacteria in Patients with HIV Infection. Richard Chiasson, John Hopkins Hospital, Division of Infectious Diseases, Los Angeles, CA, U.S.A. Human Cytomegalovirus (HCMV) Infections in AIDS: Diagnosis and Antiviral Treatment. Isosporiasis and Microsporidiosis. Pearl Ma. St. Vincent's Hospital and Medical Center of New York, NY, U.S.A. 123 [Page 124](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/126) 14:00 - 15:30 Salle Room 407C Section des immunod6flclences provoqu6es par les r6trovirus Molecular and Cellular of (MAIDS) is Caused by a Defective Retrovirus. Ming Huan *, Z. Hanna*, D. Azziz*, C. Simard*, Jolicoeur*/**, FeLV and Relevance to SIV- and HIV- Disease. J. Mullins. E. A. Hoover, M. Murphey-Corb, P. R. Donahue, J. Overbaugh, et al., Harvard University of Public Health, Boston, MA, U.S.A. Role of Antibodies, Cytokines, and Virus Variation in SIV/SMM Induced Disease. PatriciaFultz, R. Stricker, L. Montagnier, P. Sonigo, H. McClure, et al., Emory University, Yerkes Regional Primate Research Centre, Atlanta, GA, U.S.A. New Concepts in Human AIDS Pathogenesis. Luc Montagnier. on Infectivity of Six Monocytotropic Strains of HIV Peter John Gomatos*, H. Gendelman**, N. Stamatos*, A. Fowler***, D. Burke*, et al., * ReedArmy Institute of Research; **Henry M. Jackson Foundation; ***5f/Q Tech., Inc., Washington, DC, U.S~A. HIV Persistence in Monocytes Involves Negative Regulation of Viral Replication and Escape from Immune Surveillance.,Judy A. MikQvitiL\", M. Razuiddin*, M. Gonda**, F. NCI-FCRF, Frederick, MD, for ADCC. S~amuel Stanlev*, Medical Center, Durham, NC; **National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S~A. Antiviral Effects of Amino Sugars: Potency of N-Butyldeoxynojirimycin (Bu-DNJ). Abraham Karvas*, R. A. Dwek**, J. Fleet***, G. S. Jacob**, T. W. Rademacher**, *University of Cambridge Clinical School of Medicine, Department of Haematology, Cambridge; **University of Oxford, Glycobiology Unit, Department of Biochemistry; ***Universily of Oxford, Dyson Perrins Lab, Department of Organic Chemistry, Oxfobrd, U.K. Novel Mode of HIV Replication in Persistently Infected Monocytoid Cells: Accumulation of Self-Integrated, Extrachromosomal Provirulsess Leads to the Production of Defective Virions.. DavidPjuzr The Salk Institute for Biological Studies, San Diego, CA, U.S.A. Biologic, Biochemical and Molecular Analyses of Monocytotropic Human Immunodeficiency Virus. Howard E. GCnddlmanL*, L. Baca*, M. Leader*, P. Kr~iebel**, A. Fowler**, et al., * Walter Reed Army Institute of Research, H. M. Jackson Foundation; **5fM Tech, Washington, DC, D Lundi 5 juin Monday, June 5 Le SIDA et l'individu AIDS and the Individual Les adolescents (partie 1) Adolescents (Part 1) Christine Charmasson (France) Angus Adolescents, U.S.A. Helene D. Gayle, S. Manoff, M. Rogers, Centers for Disease Control, Atlanta, GA, U.S.A. Adolescents at Risk of HIV Infection. Jovce L. Radford, W. K. Warren, A. J. C. King, Social Program Evaluation Group, Queen's University, Kingston, ON, Canada. The Significance of the AIDS Pandemic for Homeless Adolescents. Cafetan G. Luna*, R. C. Brown*, E. Eisenstein**, *Mount Zion Hospital and Medical Center, University of California at San Francisco, San Francisco, CA, U.S.A.; **Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil. Infection with HIV and HBV in Adolescents Lodged in Security Institutes of Buenos Aires City: IVDA as a Risk Factor of Infection. Mercedes C. Weissenbacher*, E. Casanueva**, R. Hosokawa***, the Protection Youth and Family; ***National Institute of Microbiology, Buenos Aires, Argentina. Sex, Drugs and AIDS: Two Innovative Approaches to HIV/AIDS Prevention Education and Outreach for Minority Adolescents. Adewale Troutman*, J. Y. Hall**, *Newark Department of Health and Human Services, Newark, NJ; **New York City Health and Hospitals Corporation, New York, NY and Greater Brownsville Youth Council, Inc., Brooklyn, NY, U.S.A. The Development of a Street Based Outreach Programme to Reach Young Male, Female and Transsexual, Street Based Prostitutes in Sydney, Australia. Julian Gold, L. Griggs, M. Toomey, D. L. Alan, P. Turbitt, M. Anns, et al., Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. 126 [Page 127](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/129) 14:00 - 15:30 Salle411A Room 5 S6ance th6matique Specialty Session Prisidents Chairpersons Le SIDA, la soci&6 et le comportement AIDS, Society and Behaviour Les proches et la famille Close Friends and Family the Family. Robert Bor, R. Miller, E. Goldman, M. Johnson, C. Lee, P. Kernoff, AIDS Counselling Unit, Royal Free Hospital and School of Medicine, London, U.K. Gay Men with AIDS: Family of Choice vs. Family of Origin. John T. Parten, G. Walker, New YorkHospital, Cornell Medical School, AIDS Project, Ackerman Institute of Family Therapy, New York, NY, U.S.A. The Developmental and Family Services Unit: A Model AIDS Project Serving Developmentally Disabled Children and Their Families. Karen Hopkins. J. Grosz, Albert Einstein College of Medicine, Rose F. Kennedy Center, Bronx, NY, U.S.A. Effectiveness of a Support Group with Families of HIV-infected Children: A One-year Follow-up. Cancellieri*, *Kings County Hospital Center, AIDS Team; State University of New York, Health Science Center, Brooklyn, NY, U.S.A. Multiprofessional Experience with HIV-infected Patient's Family Members Group in Rio de Janeiro, Brazil. Lahire D. Carvalho Neto, E. M. M. Moura, J. L. L. Hanan, P. H. P. Longo, M. C. Rachid de Lacerda, C. A. Morais de Sd, Gaffrde and Guinle University Hospital,University of Rio de Janeiro (UNI-RIO), Rio de Janeiro, Brazil. Discussant. Steven Scribailo, PWA Coalition, Vancouver, BC, U.S.A. 127 [Page 128](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/130) 14:00 - 15:30 Salle Room 411B Section E Lundi 5 juin Monday, June 5 Colloque Symposium President Chairperson Le SIDA, la soci&6 et le comportement AIDS, Society and Behaviour Strat6gles innovatrices pour I'rducation des minoritbs au sujet du SIDA Innovative Strategies for AIDS Education with Minorities Jean Merveille (Canada) My Mission; A Minority Adolescent AIDS Education. V. A. Cargill, University Hospitals of Cleveland, Cleveland, OH, U.S.A. Triple Jeopardies - Reaching Ethnic and Racial Minority Youth Who are Gay-Identified and/or IV Drug Users. Jacob A. Gayle, Kent State University andAmerican SchoolHealth Association, Kent, OH, U.S.A. AIDS Education in Communities of Color: How to Make a Difference. Rashidah Hassan. BEBASHI, Philadelphia, PA, U.S.A. Integrating HIV/AIDS Information into School Health Education for Minority Students. Rueben C.Warren, Centersfor Disease Control, Bethesda, MD, U.S.A. AIDS and Minorities: Strategies for Prevention. James R. Dumpson, Black Leadership Commission on AIDS, New York, NY, U.S.A. 128 [Page 129](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/131) 14:00- 15:30 1 HI Section Lundi~juin Ethics and Law Table Points de controverse dans les rapports sur les poiltiques relatives au SIDA Round Table Points of Controversy between Policy Reports on AIDS Pr~sident Michel Chrdtien (Canada) Chairperson Thomas Iiemrick (U.S.A.) 406A June IInternational Issues S6ance th6matique Information et comportement sexuel Specialty Session Knowledge and Sexual Behaviour Presidents Chairpersons Laura Caldiz (Argentina) Uganda. Joseph K. Konde-Lule, E. A. Rwakaikara, Makerere University, Institute of Public Health, Kampala, Uganda. An Assessment of AIDS Related Knowledge, Attitudes, and Practices (KAP) in Rakai District, Uganda. David Serwadda*, M. J. Musgrave**, J. Konde-Lule*, J. Naamara****, *Makerere Medicine, Mulago Hospital/AIDS Control Programme, Kampala, Uganda; **Columbia University, New York, U.S.A.; ***Uganda Virus Research Institute; ****AIDS Control Programme, Entebbe, Uganda. Impact of AIDS on Rural and Urban Behaviour in Uganda. E. Maxine Ankrah, S. O. Ouma, Department of Social Work and Social Administration, Makerere University, Kampala, Uganda. Knowledge and Behavior Related to AIDS: A Study of 3500 Zairian Health Workers. Melinda Moore*/**, N. Lusakulira*, S. E. Hassig*/**, W. E. Bertrand*/**, T. Kashala*, *Zaire School of Public Health, Kinshasa, Zaire; **Tulane University, New Orleans, LA, U.S.A. An HIV Serosurvey in the General Population of Kinshasa Appears Feasible. Munkolenkole M. Kamenga*/**, R. W. Ryder**/***, B. T. Ngoy**, Ngandu****, et al., *National **Projet SIDA, United States Embassy, Kinshasa, Zaire; ***Centers for Disease Control, Atlanta, GA, U.S.A.; ****Ministry of Public Health, Kinshasa, Zaire. Knowledge of HIV/AIDS and Sexual Practices in Sri Lanka. L. A. Adeokun*, J. Weeramunda**, M. Carballo*, O. Tawil*, *Social and Behavioral Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland; **Department of Sociology, University of Colombo, 406BC juin Monday, June 5 Implications internationales International Issues Nourrissons A risque: le point de vue africain Infants at Risk: An African Perspective Colloque Symposium Presidents Chairpersons Joan Kreiss in Uganda. E. A. Mworozi, Makerere University, Department of Pediatrics, Kampala, Uganda. Infant Morbidity and Mortality in Nairobi. Pratibha Datta, University of Nairobi, Nairobi, Kenya. Risk Factors for Maternal-Infant Transmission in Zaire. Robert W. Ryder, Projet SIDA, Kinshasa, Zaire. Breast Milk as a Risk Factor for HIV-1 Transmission. Subhash Hira. University Teaching Hospital, Lusaka, Zambia. Safety and Efficacy of Immunizations with Live Vaccines. Joanne Embree, University of Manitoba, Winnipeg, MB, Canada. 131 [Page 132](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/134) 14:00 - 15:30 Salle Room 404AB 5 juin Monday, June 5 S6ance th6matique Specialty Session Presidents Chairpersons Repercussions &xmomiques du SIDA The Economic Impact of AIDS CoOts en milieu hospitalier Hospital-based Costs Dennis P. Andrulis (U.S.A.) Gabriel Bez AIDS Patients: Clinical Problems and Associated Daily Costs. Steven A. Grover*, N. Gilmore**, J. Falutz*, C. Tsoukas*, L. Coupal*, R. *Montreal General Hospital, Division of Clinical Epidemiology; **Royal Victoria Hospital, Montreal, QC, Canada. Pediatric HIV-Related Discharges in a Sample of U.S. Hospitals: Demographics, Diagnoses, and Resource Use. Judy K. Ball, S. J. Thaul, USDHHS, National Center for Health Services Research, Rockville, MD, U.S.A. Longitudinal Hospital Use and Charges of Scatter Bed and AIDS Cluster Unit Inpatients. Marianne Fahs*, J. Strain*, G. Fulop*, *Mount Sinai Medical Center; **Empire Blue Cross and Blue Shield, New York, NY, U.S.A. The $147,000 Misunderstanding: Overstating the Cost of AIDS. Jesse Green*, M. Leigh*, G. Oppenheimer**, *New York University Medical Center, Department of Health Policy Research, New York; **Brooklyn College, Brooklyn, NY, U.S.A. New York Medicaid AIDS Patients: Trends in Hospital Use and Mortality Rates. Barbara J. Turner*, T. Fanning**, M. Keyes***, *Jefferson Medical U.S.A. par le VIH. J. Salin, P. Buchet, F. Petit, H. G. Bez, Direction des Hdpitaux, Ministire de la Solidarite, de la Santd et de sociale, session La Sexualit6, Ia politique et l'histoire Sex, and History le Ce groupe eclectique d'artistes de militants du monde aborde problemes de la sexualite, sexuelle, du racisme, du de sante, de diverses phobies reliees au SIDA, des ste6rotypes et de la consideration du SIDA comme une catastrophe ideologique. Ces films vont comment s'articule le discours sur le SIDA. Video offers the use of a myriad of historical and analytical methods. This diverse grouping of artists and aesthetic activists touches on issues of sexuality, sexual orientation, racism, sexism, politics of health, various AIDS-related phobias, stereotyping and confronting AIDS as an ideological catastrophe. It ranges from visual to textual analysis attempting to understand the construction of AIDS discourse. 134 [Page 135](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/137) Notes [Page 136](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/138) June 5 Specialty Session Presidents Chairpersons ~pidmiologie et sanai and Public Health Transmission sexuelie du ViH (partie 1) Sexual Transmission of HiV (Part 1) Rand L. Stonebumne (U.S.A.) Shu-Tao-Msu (China) a Risk Factor for IIIV Infection in Africa, but not in Europe. &1te&Ql*t, E. Van Dyck*, R. Ryder**, N. Nzila**, M. Belgium; **Projet SIDA, Kinshasa, Zaire. Assessment by PCR of Transmission of ILIV from Infected Hemophiliacs to Their Sex Partners and Children. LIndira..K.. Hevneku*, J. Epstein*, Y. Laurian**, J. P. MD; **JHTC, Bice~tre, France; ***~Abbott Laboratories, North Chicago, IL, U.S.A. A Prospective Cohort Study of HIV-1 Seroconversion in Patients with Genital Ulcer Disease in New York City. Ediard E. Telzak* Sloan-Kettering Cancer Center, New York, NY; ***Centers for Disease Control, Atlanta, GA, U.S.A. Extramarital/Prostitute Sex and Genital Ulcer Disease (GUD) Are Important Risk Factors in 7068 Male Kinshasa Factory Workers and Their 4548 Wives. Robert W. Rvder*/**k, S. Hassig\", Disease GA, Efficacy of Nonoxynol-9 in Preventing I{IV Transmission.,LQ.an.Kteist*, I. Ruminjo\"\", E. Ngugi**, P. Roberts*, J. Ndinya-Achola**, Plummer***, * University of Washington, Seattle, WA, U.S~A.; **University of Nairobi, Nairobi, Kenya; ***University of Manitoba, Winnipeg, MB, Canada. Anti-HIV Efficacy of Barrier Contraceptives in lIY-discordant Couples. Paul J. Feldblum*, S. K. Hira**, J. Kamanga**, G. Tembo**, *Family Health International, Research Triangle Park, NC, U.S.A.; **University Teaching Hospital, Lusaka, Zambia. 136 [Page 137](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/139) Sane 408A Room Chairpersons pmidmiologie et sanmt publque Epidemiology and Public Health Infection par le VIH chez les d6tenus HIV Infection in Prisoners Jane Balthazar (Philippines) Harold W. Jaffe (U.S.A.) Prisons. Diego Serraino*, S. Franceschi*, E. the Short-term Incarcerated: The Philadelphia Prison Seroprevalence Study. Bruce L. Davidson*, A. DeMeis*, D. A. Paul**, R. Kline***, T. C. Quinn***, *Philadelphia Department of Health, Philadelphia, PA; **Abbott Laboratories, North Chicago, IL; ***Johns Hopkins University, School of Medicine and National Institutes of Health, Baltimore and Bethesda, MD, U.S.A. etude des risques de contamination par les virus de l'h6patite B, du VIH1 en milieu carc6ral. Pierre EsDinoza*, P. Balian*, I. Bouchard*, Gdndrale Toxicomanie, *Hdpital de Fresnes (EHPNF), Fresnes, France. Prevalence and Risk Factors for HIV Infection among Adolescent Inmates in Madrid. Concepcion Colomo-Gomez*, M. V. Zunzunegui**, P. Estebanez*, de Centro, Madrid; **EASP, Granada, Spain. Sexual Practices and HIV Infection in Some Zambian Prisons. Mwendaweli N. Maboshe*, O. O. Simooya*, S. K. Hira*, E. P. L. Perine**, M. Sandala**, M. Mukunyandela*, *Tropical Diseases Research Centre, Ndola; **University Teaching Hospital, Lusaka, Zambia. Corrections AIDS Prevention Program (C.A.P.P.) in New York City. Ellen Rautenberg, R. Hayes-Cozier, J. M. Vowels, L. C. Kayser, I. Solis, New York City Department of Health, New York, NY, U.S.A. 137 [Page 138](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/140) 16:00 - 17:30 Salle Room 08BC 5 juin Monday, June 5 Specialty Session Presidents Chairpersons piddmiologie et sant= publique Public Health Histoire clinique de I'infection au VIH: cofacteurs et progression Natural History of HIV Co-Factors for Progression Mads Melbye (Denmark) Khorshed AIDS in Homosexual Men Developing HIV-1 Specific Antibody. John P. Phair, A. Muoz, L. Kingsley, R. Fox, R. Kaslow, B. Visscher, et al., Multicenter AIDS Cohort Study, Chicago, IL, U.S.A. Immunologic Markers Model the Risk of AIDS. Alexander Krdmer*, P. S. Rosenberg*, D. Fuchs**, R. J. Biggar*, W. A. Blattner*, J. Cancer MD, Innsbruck, Innsbruck, Austria. Human Herpes Virus 6 (HHV6) in a Cohort of Homosexual Men. Scott D. Holmberg*, C. A. Lopez**, R. H. Byers*, G. W. Rutherford***, H. W. Jaffe*, *AIDS Program and **Division of Viral Diseases, Centers for Disease Control, Atlanta, GA; ***San Francisco Department of Health, San Francisco, CA, U.S.A. HIV- 1 p24 Antigenaemia and Loss of Anti-Core Antibodies Are Correlates of Rapid Disease Progression and not of Disease Progression Per Se. Frank De Wolf*, J. Lange*, J. Houweling**, R. Coutinho*, J. Van der et al., *University ofAmsterdam, Department of Virology; **Municipal Health Service, Amsterdam, Netherlands. Psychosocial Co-factors in Illness Onset among HIV-positive Men. Ronald C. Kessler*, J. Joseph*, D. Ostrow*, J. Phair*, J. Chmiel**, C. Rusk**, *The University of Michigan, Institute for Social Research, Ann Arbor, MI; **Northwestern University, Chicago, IL, U.S.A. Psychosocial Predictors as Co-Factors for Disease Progression in Men Infected with HIV: The San Francisco Men's Health Study. Thomas J. Coates*, R. D. Stall*, M. Ekstrand*, G. F. Solomon**, * University of California at San Francisco, San Francisco; **University of California at Los Angeles, Los Angeles, CA, U.S.A. 138 [Page 139](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/141) 16:00 - 5 juin Monday, June 5 J Aspects cdlniques Clinical Aspects of AIDS S6ance th6matique Infections concomitantes et SIDA Specialty Session Concomitant Infections in AIDS Pr6sident Chairperson Donald Armstrong (U.S.A.) Pierre HIV-Infected Individuals. Stewart Reid, H. Umedaly, D. Forrest, W. A. McLeod, R. Chan, J. Ruedy, et al., St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Concomitant Syphilitic and HIV Infection. Helene Douville*, W. Mondino-University of Pavia, Pavia, Italy. Effect of Previous Syphilis Infection on CSF Abnormalities in HIV-1 Infected Individuals. Julie H. McArthur, K. Alwood, R. Fox, C. Herman, E. Hook, J. C. McArthur, et al., Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A. Traitement de la toxoplasmose c6r6brale par France. Central Nervous System Toxoplasmosis in AIDS Patients. Efficacy of an Intermittent Maintenance Therapy. JoseL M Gatell. E. Pedrol, J. M. Gonzalez-Clemente, J. Mallolas, M. Miro, E. Soriano, Infectious Disease Unit/Hospital Clinic, Univerity of Barcelona, Barcelona, Spain. Mortality, Treatment Results and Relapse Rates of Pulmonary Tuberculosis in African HIV(+) and HIV(-) Patients. Joseoh H. Perriens*, C. 403ABC Room Lundi 5 juin Monday, June 5 S6ance th6matique Specialty Session Chairpersons Aspects cliniques Clinical Aspects AIDS Pediatric: Neuro-Development in HIV Infected Children Pediatric: Neuro-Development in HIV Infected Children G. Delage (Canada) Sir Mohamed K. Hashim Marc Tardieu*, S. U56, Universit6 de Paris Sud, Le Kremlin-Bicetre, France. A Prospective Study of Neurological Development in Infants at Risk for Human Immunodeficiency Virus (HIV-1) Infection. Gwendolyn B. Scott*, D. Cohen, R. Curless, A. Naguiat, R. Morgan, W. P. Parks,*University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.S.A. The Course of Neurodevelopmental Functioning in the Infants of IVDA and HIV-seropositive Parents. Molly Nozyce*, G. Diamond*, A. Cabot***, H. Cohen*, A. Rubinstein***, et al., *Albert Einstein College of Medicine, Department of Pediatrics, Bronx; **State University of New York at Stony Brook, Stony Brook; ***Rose F. Kennedy Center, Bronx, NY, U.S.A. Prospective Neurodevelopmental Outcome of Infants with Perinatally Acquired HIV Infection and Their Controls. JoLan Hittelman*, A. Willoughby**, H. Mendez*, J. Kehe*, J. Goedert**, S. Landesman*, et al.,*State University of New York at Brooklyn, Health Science Center, Brooklyn, NY; **National Institutes of Health, Bethesda, MD, U.S.A. The Adaptive Behavior of Children with Symptomatic HIV Infection and the Effects of AZT Therapy. Pamela L. Wolters, H. Moss, P. Brouwers, J. Eddy, P. Pizzo, National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A. Neurologic Disease in Pediatric HIV Infection. Ram Kairam. A. Kaul, M. Bamji, A. Gupta, S. Bakshi, J. Pitt, St. Luke's-Roosevelt Hospital Center, Columbia University Presbyterian Medical Center and New York Medical College, New York, NY, U.S.A. 140 [Page 141](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/143) 16:00 -17:30 Salle Roo 5 S~ance th~matique Specialty Session Presidents Chairpersons Aspects cbiniues Clinical Aspects of AIDS Traltement essals Survival Experience among a Large Cohort of AIDS Patients Treated with Zidovudine. TertuilL CrahKr* P. Dci, E. Andrews, H. Tilson, *Burroughs Weilcome Co., Research Triangle Park, NC, U.S~A. Survival Patterns of Zidovudine-Treated AIDS Patients Compared to Untreated Controls. Stefano Vella. F. Menniti Ippolito, M. G. Agresti, P. Pezzotti, D. Greco, National Institute of Health, Rome, Italy. Nature, Time Course and Dose Dependency of Zidovudine Related Side Effects. Results from the Multicentre Canadian Azidothymidine Trial (MCAT).JohnRuedv, J. S. G. Montaner, K. Gelmon, M. Fanning, J. R. M. Smith, J. Falutz, et al., Multicentre Canadian Azidothymidine Trial, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Double-Blind Placebo Controlled Study of Recombinant Human Erythropoietin in AIDS Patients with Anemia Caused by HIV Infection and Zidovudine. Mark U. Rarick, E. Wilson, M. Bernstein-Singer, P. 5. Gill, F. Muggia, A. M. Levine, University of Southern California, Los Angeles, CA, U.S~A. Toxicity of Combined AZT/Ganciclovir (DHIPG) Therapy in AIDS Patients. Ioeg ~psybgm, D. Antoniskis, D. Causey, J. M. Leedom, Los Angeles County/University of Southern California Medical Center, Los Angeles, CA, U.S~A. One Year Follow-up of Zidovudine Plus Barnhart***, A. Lifson***, *AIDS Clinic, University of California at San Francisco, San Francisco, CA; * *Burroughs-Wellcome Company, Research Triangle Park, NC; ***AIDS Ocffice, Department of Public Health, San Francisco, CA, 141 [Page 142](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/144) 16:00 - 17:30 Salle Room 5 juin Monday, Specialty (Biomedical) Biologle mol6culaire (partle 1) Molecular Biology (Part 1) William A. Haseltine (U.S.A.) Yoshiro Ohta Biological and Immunological Significance. David J. Looney. L. Ivanoff, J. R. Rusche, J. Hoxie, R. Redfield, F. Wong-Staal, Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S.A. Molecular Analysis of Single Cell Lysis by HIV-1. Joseph G. Sodroski, M. Kowalski, T. Dorfman, L. Bergeron, M. Wojtkowsky, W. Haseltine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, U.S.A. Three-Dimensional Structure of the HIV-1 Protease and Its Role in Virus Maturation. Manuel A. Navia. P. M. D. Fitzgerald, B. M. McKeever, I. S. Sigal, P. L. Darke, J. P. Springer, et al., Merck, Sharp & Dohme Laboratories, Rahway, NJ, U.S.A. Structural Patterns in Regulatory Sequences of HIV. Gerald Myers, C. S. Tung, C. R. Linder, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, U.S.A. Construction of an Infectious Molecular Clone of SIVagm and Genetic Complementation with a Replication-Defective env Mutant of HIV-1 and Pol Mutant of SIVagm. Hayami, T. Miura, A. Adachi, R. Shibata, M. Fukasawa, Kyoto University, Institute for Virus Research, Kyoto, Japan. Experience with Eight HIV-Vaccine Trials in Chimpanzees. Jorg W. Eichberg. Southwest Foundation for Biomedical Research, San Antonio, TX, U.S.A. 142 [Page 143](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/145) 16:00- 17:30 Salle Room (Part 2) Roberto Cauda (Italy) Francine AIDS and ARC: Correlation with Tissue Content of p24 and of Interleukin-1 Beta. Safak Hospital Center, New York; **Lenox Hill Hospital, New York, NY, U.S.A. Activated Astrocyte-Conditioned Medium Stimulates HIV-1 Expression in a Chronically Infected Promonocyte Liubisa Vitkovic, T. Kalebic, A. S. National Institutes ofHealth, Bethesda, MD, U.S.A. Sperm-Mediated Transfer of HIV into Target Cells: Role in AIDS Transmission. Veronica E. Miller, V. L. Scofield, University of California at Los Angeles, School of Medicine, Deptartment of Microbiology and Immunology, Los Angeles, CA, U.S.A. Investigation of the Susceptibility of Thymic Precursor T Cells to Infection by HIV-1. Rosemarie Pereira*, M. T. Nugeyre*, Barre-Sinoussi*, *Institut Pasteur; **Universit6 Paris, Paris, France. Transient Expression of the HIV-1 Genome during Infection of the Developing Human Nervous System. Charles Kunsch, B. Wigdahl, The Pennsylvania State University College of Medicine, Department of Microbiology and Immunology, Hershey, PA, U.S.A. HIV gp41 Synthetic Peptides Inhibit LAK Activity. Roberto Cauda*, M. Tumbarello*, L. Ortona*, P. Kanda*, R. Kennedy**, T. Chanh*, *Catholic University of Rome, Department of Infectious Diseases, Rome, Italy; **Southwest Foundation, Department of Virology and Immunology, San Antonio, TX, U.S.A. 143 Lundi 5 juin Monday, June 5 SIDA et l'individu DS and the Individual wvalileurs de Ia sant6 of AIDS on Acute Care Hospitals: A Survey of Infectious Disease Teaching Hospitals in the United States. Toseph R. Thurn*/**, S. Campbell*, K. Henry*/**, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul; **\"Universily of Minnesota Medical School, Minneapolis, MN, Intraoperative Blood Exposures. A. Brown, A. Tarkington, W. Schecter, University of California at San Francisco; San Francisco General Hospital, San Francisco, CA, U.S~A. Improving the Care of AIDS Patients: Roles of Provider Gender and Specificity of Training. Tosevh M. Merrill*, L. Laux, S. Wente, I. Thornby, *Baylor College of Medicine, Department of Community Medicine, Houston, TX, U.S~A. AIDS-Related Knowledge, Attitudes, and Behaviour of Nurses and Physicians: A Comparative Analysis. Scott Camvbell*, M. Maki**, K. Henry***, Department of *Medicine and **Infection Control, St. Paul-Ramsey Medical Center, Section of Infectious Diseases; ***University of Minnesota Medical School, St. Paul, MN, U.SA. Sexual Behavior and Perceived AIDS Risk among 3,500 Zairian Health Workers. AfrLind Mo.tP*/Ic\"I, S. E. Hassig*/**, N. Luslakulira*\", W. E. Bertrand*/**, D. Kashala*, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S~A. Preventing HIV Infection in England and Wales: What Has Primary Care to Offer? Ti~mLRJwARod, S. Bond, M. Gallagher, C. Foy, P. Philips, J. Bond, Health Care Research Unit, University of Newcastle upon Tyne, Newcastle upon Tyne, U.K. 144 [Page 145](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/147) 16:00 Salle Room 411A Section E Lundi 5 juin Monday, June 5 Table Ronde Round Table Pr6sidents Chairpersons Le SIDA, la soci~ et le comprtement AIDS, Society and Behaviour L'entraide: une strat6gle d'adaptation Self-Help: A Coping Strategy AIDS Patient. J. Hector Balthazar. Canadian Council on Social Development, Ottawa, ON, Canada. Self-Help: A Personal Perspective. Alex Kowalski. Vancouver Person's with AIDS Society, Vancouver, BC, Canada. The AIDS Prevention Concept of the Deutsche AIDS-Hilfe Co-operative Model. lan Schaffer, N. Specht, Deutsche AIDS-Hilfe, Berlin, Federal Republic of Germany. The Difficulties of PWA Coalitions in Providing Services to Active Drug Misusers. John Mordaunt, London Lighthouse, London, U.K. Physicians Self-Support Group. Michel Chateauvert. Royal Victoria Hospital, Montreal, QC, Canada. Self Help Experience in Africa. Nicolas Anumudu, Ministry of social Development, Youth and Sports, Social Welfare Division, Owerri, Uganda. 145 [Page 146](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/148) 16:00- 17:30 Salle Room Monday, June 5 S6ance th6matique Specialty Session Pr6sident Chairperson Le SIDA, la soci6 et le comportement AIDS, Society and Behaviour Facteurs culturels d6terminants dans les attitudes envers le SIDA Cultural Determinants in Responding to AIDS Carol La Fabor (USA) J. M. Lema Sri Lanka: The Role of Anthropological Approaches in a Global Programme. J. Weeramunda*, M. Carballo**, A. Mehryar**, *Department of Sociology, University of Colombo, Sri Lanka; **Social and Behavioural Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland. Comportements sexuels et contexte culturel. Une approche Training for AIDS Providers Serving Culturally Different Patients. Noel A. Day*, A. Houston-Hamilton*, P. Evans**, *Polaris Research and Development; **Department of Public Health, San Francisco, CA, U.S.A. Is There a Unique Role for Anthropology in the Study of AIDS? Douglas A. Feldman, Department ofEpidemiology, University ofMiami, School ofMedicine, Miami, FL, U.S.A. Les Enquetes CAP sur le SIDA. Exp6rimentation d'une technique d'enquete par discussions de groupe Room Section F juin Monday, June 5 Colloque Symposium Presidents Chairpersons Droit et thique Ethics and Law tthique et injustice sur le plan International Ethics and International Inequity Bernard Kouchner Humanitaire, Paris, France. The Reach of International Codes of Ethics. George Annas, Boston University Schools of Medicine and Public Health, Boston, MA, U.S.A. Limited Resources for AIDS. Bosenge N'Galy, Project SIDA, Kinshasa, Zaire. The Dearth of Therapeutic Agents in Developing Countries. Cicile De Sweemer. International Development Research Centre, Dakar. Overcoming the NIMBY Syndrome for Facilities to Care for HIV Infected People. Robert E. Stein, Washington, DC, U.SA. A Focus on Latin America. Susan S. Connor, Washington, DC, U.S.A. Ethics and Inequity. Reng Sabbatier, London, U.K. 147 [Page 148](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/150) Room 406A International Issues S6ance th6matique Pr6valence (partie 1) Speciality Session Prevalence (Part 1) Pr6sidents Chairpersons C. Bartholomew (Trinidad & Tobago) Jean the Dominican Republic. Ivelisse Garris. E. A. De Moya, E. Guerrero, C. Pena, L. Dominguez, M. Belliard, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic. Trend Analysis of AIDS Cases Reported in Brazil, 1982-1988. Pedro Chequer, L. Rodrigues, E. Castilho, D. Bergamaschi, Ministry Health, National Division of STD/AIDS, Brasilia; Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil. HIV Epidemiological Patterns and Trends in Mexico. An Update. Jose-Luis Valdespino. J. Sepulveda, J. A. Izazola, M. L. Garcia, M. Palacios, E. Bravo, General Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico. HIV Infection in Ecuador. Roy A. Ringenberg*, G. Leoro**, M. L. Merino**, Rumbea*, et al.,*Ministry ofPublicHealth; **Ecuadorian Red Cross, Quito, Ecuador. HIV Infection in Voluntary Blood Donors in Argentina. Oscar E*, G. Muchinik**, J. Rey***, S. Fernandez, Buenos Aires, Argentina. A Critique of the Cumulative Rate of AIDS in the Caribbean. Courtenay Bartholomew*, F. Cleghorn**, P. Imperato***, *Faculty ofMedical Sciences, The University of the West Indies; **The Caribbean Epidemiology Centre, Port of Spain, Trinidad; ***State University of New York, Health Science Centre, Brooklyn, NY, U.S.A. 148 [Page 149](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/151) 16:00 Care System. M.QwOe., World Bank, Washington, DC, U.S~A. Social Economic Impact of AIDS in a Home. Elizabeth N. 1NjgpgL University of Nairobi, Department of Community Health, Nairobi, Kenya. The Impact of HIV on the Laboratory in Developing Countries.,Loh&&bha2, Muhimbili Medical Centre, Dar-es-Salaam, Tanzania. AIDS and Community Based Care. 1ioerin Kakeeba, TASO, Uganda, Kampala, Salle Room 404AB 5 juin Monday, June 5 S6ance th6matique Speciality Session Presidents Chairpersons Repercussions conomiques du SIDA The Economic Impact of AIDS CoOts en dehors du milieu hospitalier Out of Hospital Costs Joel Finlay (Canada) Joao Santos Lucas (Portugal) Paula of HIV Infection of Patients Followed in General Practice in France. VZronique France. Trends in Utilization and Cost of Treating AIDS in an H.M.O. Kathrvn L. Coltin, J. Goldberg, L. Kuvin, Harvard Community Health Plan, Boston, MA, U.S.A. Place of Death Measures Effectiveness of AIDS-Specific Community-Based Services. Sharon G. Hopkins, A. Kruzich, R. Wood, Seattle-King County Department of Public Health, Seattle, WA, U.S.A. Post Discharge Needs of Hospitalized Persons with AIDS and HIV-Related Illnesses in New York City. Nicholas Rango*, E. J. Anderson*, I. Feldman*, B. Collins**, York State Department of HealthlAIDS Institute; **New York State Department of Social Services, Albany; ***New York University Hospital, New York, NY, U.S.A. Resource Use and Costs of Care for AIDS Patients in Los Angeles. Charles L. Bennett, A. Pascal, R. L. Bennett, M. Cvitanic, RAND/UCLA Center for Health Policy Study, Santa Monica, CA, U.S.A. Impact of Degree of Immune Deficiency on Planning of Publicly Funded Outpatient Services for HIV. David E. Dasseyv C. Braithwaite, AIDS Program Office, Department of Health Services, Los Angeles, CA, U.S.A. 150 [Page 151](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/153) Lundi 5 juin Monday, June 5 Sessionviddo Video session Les Femmes et le sida Women and SIDA prisme Ces films s'attaquent la les des femmes face au SIDA et g l'infection par le VII. Mothers, daughters, lovers, workers, lesbians, patients, activists, prostitutes and caregivers: women are depicted in many ways in relationship to AIDS. From various viewpoints, these videos challenge the marginalization of women. Each depicts the special struggles which women face in relation to AIDS and HIV infection. 152 [Page 153](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/155) Notes [Page 154](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/156) Section Lundi 5 June 5 S pid6miologie et sant6 publique Epidemiology and Public Health Session d'affichage Poster Session Etudes s6ro-6pid6mologiques sur la prevalence du VIH Seroepidemiologic HIV Prevalence Studies M.A.P.1 Prevalence of HIV Infection among U.S. Army Reserve Component Personnel. David N. Cowan*, J. F. Brundage, R. N. Miller, M. Goldenbaum, R. Pomerantz, F. Wann, *Walter Reed Army Institute of Research, Washington, DC, U.S.A. M.A.P.2 HIV Prevalence among Military Women: An Examination of Military Applicant, Active Duty, and Reserve Testing Data. Jacqueline A. Horton*, L. Alexander, J. Brundage, *Walter Reed Army Institute of Research, Washington, DC, U.S.A. M.A.P.3 HIV Prevalence Rates and Trends in Endemic and Non-Endemic Metropolitan Areas in the United States, 1985-1988. Lvtt I. Gardner*, J. Brundage, D. Burke, R. Miller, *Walter Reed Army Institute of Research, Washington, DC, U.S.A. M.A.P.4 Surveillance for HIV Infection in the Active Duty U.S. Army: Overall Seropositivity and Trends from 1985 to 1988. Patrick W. Kelley*, R. Pomerantz, F. Wann, J. Brundage, D. Burke, R. Miller, et al., *Walter Reed Army Institute of Research, Washington, DC, U.S.A. M.A.P.5 Prevalence of HIV Infection in Heterosexual Persons in the United States, 1988-89. Ida M. Onorato*, L. Peterson, M. Pappaioanou, T. Dondero, *AIDS Program, Centersfor Disease Control, Atlanta, GA, U.S A. M.A.P.6 Prevalence of HIV Antibodies in Childbearing Women in Florida. Marlene LaLota*, D. G. Withum, D. Holtzman, E. E. Buff, M. S. Chan, S. Lieb, et al., *AIDS Program, Department of Health and Rehabilitative Services, Tallahassee, FL, U.S.A. M.A.P.7 Seroprevalence of Antibodies to the Human Immunodeficiency Virus (HIV) in Applicants for Marriage Licenses in Alabama. Donald E. Williamson*, L. A. Foss, J. B. Parker, W. J. Callan, R. C. Moody, *State of Alabama Public Health Department, Montgomery, AL, U.S.A. M.A.P.8 Anonymous HIV Testing on Newborns in 63 Italian Hospitals: An Estimate of Prevalence of Infection among Women in Reproductive Age. Giuseppe oppolito*, P. Angeloni, M. Stegagno, E. Mannella, U. Angeloni, F. Costa, et al., *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy. M.A.P.9 HIV Seroprevalence on University Campuses, U.S.A. Helene D. Keeling, M. Garcia-Tunon, B. Kilbourne, J. Narkunas, *Centers Disease Atlanta, GA, U.S.A. 154 [Page 155](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/157) M.A.P.10 HIV Seroprevalence at the Bronx Lebanon Hospital Center, CDC Sentinel Hospital. Jerome A. Ernst*, S. Bauer, L. Amaral, M. St. Louis, I. Falco, *Bronx Lebanon Hospital Center, Bronx, NY, U.S.A. M.A.P.11 Incidence of HIV Seroconversion in U.S. Navy Personnel: Results of Total Navy Screening. Frank C. Garland*, D. Mayers, T. Hickey, M. Miller, L. Bigbee, *Navy Retroviral Study Group, Naval Health Research Center and University of California at San Diego, San Diego, CA, U.S.A. M.A.P.12 HIV Seroprevalence among Parturients in Los Angeles County, 1988. Deirdre A. Hill*, P. R. Kerndt, L. M. Frenkel, R. Settlage, M. Lee, M. L. Yonekura, et al., *Los Angeles County Department of Health Services, Los Angeles, CA, U.SA. M.A.P.13 Demographics of HIV Infection in the United States Air Force (USAF) Personnel. Robert A. Zaiac*, D. R. Lucey, G. P. Melcher, D. Weisenfeld, S. Abbadessa, R. N. Boswell, et al., *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A. M.A.P.14 Trends in Newborn HIV Rates Reveal the True Proportion Seen Clinically. Lvnne M. Mofenson*, R. Hoff, G. F. Grady, *Massachusetts Department of Public Health, Boston, MA, U.S.A. M.A.P.15 A Prospective Study of HIV in 30,525 Pregnant Women Screened in the Paris Metropolitan Area Between February 1987 and July 1988. Alain M. Goudeau*, Y. Brossard, M. Larsen, J. Huchet, F. R. Henrion, et al., *CHRU Bretonneau, Tours, France. M.A.P.16 Sentinel Hospital Surveillance for HIV-1 Antibody Versus Clinical Laboratory Submissions in a University Hospital. Joseph M. Lombardo*, P. Kloser, B. Pawel, R. Trost, R. Kapila, M. St. Louis, *University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A. M.A.P.17 Epidemiology of HIV Infection among Young Adults in the US: Regional Variations and Trends. Erica S. Sharp*, D. Cowan, M. Goldenbaum, J. Brundage, J. McNeil, Walter Reed Retroviral Research Group, *Henry M. Jackson Foundation, Rockville, MD, U.S.A. Le VIH chez les d6tenus HIV in Prisoners M.A.P.18 Seroepidemiological Survey of AIDS, Hepatitis and Syphilis in Portuguese Prisoners. Antonio Melico-Silvestre*, V. Pombo, A. Pereira, R. Lopses, R. Cdrte-Real, Infectious Diseases Clinic, University Hospital of Coimbra, Coimbra, Portugal. Prevention for Intravenous Drug Users Paroled from Prison. Stephen Magura*, H. K. Wexler, H. Josepher, R. Bixler, M. Beardsley, *Narcotic and Drug Research Inc., New York, NY, U.S.A. 155 [Page 156](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/158) M.A.P.21 Occurrence of Serological Markers of Different Infections in HIV Seropositive and Seronegative Inmates from a Penitentiary Population. Rdul Ortiz de Leiarazu*, J. M. Eiros, A. Ordua, M. A. Bratos, A. Rodriguez-Torres, *University Hospital, Faculty of Medicine, Department of Microbiology, Valladolid, Spain. M.A.P.22 HIV Seroprevalence and the Efficacy of Voluntary HIV Testing among Male Prison Inmates in Wisconsin. Jeffrey P. Davis*, J. M. Vergeront, H. F. Frisby, N. J. Hoxie, R. Golubjatnikov, J. Pfister, *Wisconsin Division of Health, Section of Acute and Communicable Disease Epidemiology, Madison, WI, U.S.A. M.A.P.23 Risk Factors Associated with HIV Infection among Women Incarcerated in a Medium Security Prison. Catherine A. Hankins*, S. Gendron, S. St-Pierre, C. hospitalibre infection le VIH en milieu carc6ral. Isabelle Bouchard*, P. Espinoza, S. Stein, J. Polo I. Fresnes (EHPNF), Fresnes, France. M.A.P.26 Updated Temporal Trends of HIV-1 Infection among Inmates Entering Maryland Prisons (USA) 1985-88. David Vlahov*, A. Muhioz, C. Taylor, E. Taylor, F. Brewer, B. F. Polk, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. M.A.P.27 Increasing Tuberculosis in Association with AIDS/HIV among New York State Prison Inmates. Dale L. Morse*, B. Truman, M. Braun, G. DiFerdinando, B. Maguire, R. Broaddus, *New York State Department ofHealth, Albany, NY, U.S.A. M.A.P.28 Incidence and Prevalence of HIV Infection during 44 Months of Testing Prostitutes/IVDUs in the Women's Jail, Orange County, California. Peter G. Burrell*, T. J. Prendergast, R. Maxwell, J. R. Greenwood, C. Swatzel, *County of Orange Health Care Agency, Santa Ana, CA, U.S.A. Donneurs et receveurs de sang et de produits sanguins Recipients and Donors of Blood and Blood Products M.A.P.29 Frequency of HIV Seroconversion among Blood Donors: Relationship to Risk of HIV Transmission. Roger Y.Dodd*, J. Nardolillo, *American Red Cross, Jerome Holland Laboratory, Rockville, MD, U.S.A. M.A.P.30 Blood Center, Health Department Collaboration: A Method for Detecting Infected Previous Donors. Susan Samson*, M. Busch, P. Holland, J. Ward, J. Garner, H. Perkins, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A. M.A.P.31 Blood Donations by Individuals Who Later Develop AIDS. David W. Feigal*, H. Hollander, J. Ziegler, M. Clement, P. A. Volberding, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. 156 [Page 157](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/159) M.A.P.32 Surveillance for Unusual Modes of Transmission in the USA: A 5-Year Multicenter Study of Blood Donors. Lvl ILB Centers for Disease Control, Atlanta, GA, U.SA. M.A.P.33 Sdropositivit6 HIV chez les donneurs de sang et estimation du risque r~siduel en transfusion. Anne-Marie Courouc6', Groupe de Travail Rd'trovirus de la S.N.T.S, Fondation nationale de Transfusion sanguine, Paris, France. M.A.P.34 The Risk of LIIV-1 Transmission by Transfusion of Screened Blood. Kenrad E. Nelson*, N. Cohen, A. Muri~oz, 0. Frazier, D. Yawn, B. F. Polk, et al., *Johns Hopkins University, Department of Epidemiology, Baltimore, MD, U.S~A. M.A.P.35 The Epidemiology of Transfusion-associated (TA) AIDS in Children in the United States, 1981 to 1988. Donna S. Jones*, R. Byers, T. Bush, M. Rogers, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S A. M.A.P.36 Seroprevalence of HJV Infection among Blood Donors in Mannella*, G. Ippolito, M. Miceli, P. Angeloni, *National Center for Blood Transfusion, Italian Red Cross, Rome, Italy. M.A.P.37 Thirty-six Post-Transfusional (P-TRF) HIV Infection in a Regional City Hospital Since 1980. Pierre Dellamonica*, I. F. Q~uaranta, E. Cassuto-Viguier, F. Sanderson, M. de l'Archet, France. M.A.P.38 Blood Sale and Donation Behaviour of IVDUs. Dale D. Chitwood* M. Comerford, C. B. McCoy, E. J. Trapido, * University of Miami Medical School, Miami, FL, U.S~A. M.A.P.39 Impact of an Auto-designation Form on Blood Donor Selection. Yve Lan4tv*, C. Hankins, Jean, J. C. Soto, F. *La Socid'tk caznadienne de Ia Croix Rouge, Montreal, QC, Canada. M.A.P.40 Prevalence of HIV-Antibodies in Blood Donors in the ERG. Dorothree G1Iiic*, D. Koerner, B. Kubanek, G. Caspari, G. Elbert, W. Graissmann, et al., * University of Ulm, German Red Cross Blood Bank, Ulm, Federal Republic of Germany. M.A.P.41 A Follow-up Study of Children of Anti-HIY Positive Haemophiliacs. Christine Ann Lee*, P. B. A. Kernoff, E. Goldman, J. Morris-Smith, P. D. Grif~iths, R. S. Trompeter, *Haemophilia Centre, Royal Free Hospital, London, U.K. M.A.P.42 Hemophiliacs Doubly Infected by HIV-1 and IITLV-I. Fujimaki, *Tokyo Medical College, of Clinical Pathology, Shinjuku-ku, Tokyo, Japan. M.A.P.43 Anti-HIV Seroprevalence in Blood Donations from July '85 until December '88 in Switzerland. Tohann J. Burckhardt*, E. Bditler-B runner, L. H. Perrin, P. Bachmann, *Central Laboratory, Blood Transfusion Service, Swiss Red Cross, Bern, Switzerland. 157 [Page 158](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/160) M.A.P.44 Different Epidemiology of HIV Infection in Hemophiliacs (H) from Three European Countries. Pier Mannucci*, A. Gringeri, A. Bianchi, *Bonomi Hemophilia and Thrombosis Center, University of Milan, Milan, Italy. M.A.P.45 Hepatitis B and HIV Coinfection in Hemophiliacs. Paul R. Becherer*, G. White, C. McMillan, S. M. Lemon, * University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, NC, U.SA. Le VIH chez les prostitue(e)s et les sans-abri HIV in Prostitutes and Homeless Populations M.A.P.46 HIV Spread in Prostitute Population in Toulouse (France). Review. Catherine M. Bisset*, A. Kynaston, S. M. Burns, R. P. Brettle, *HIV Counselling Clinic, City Hospital, Edinburgh, U.K. M.A.P.48 Risk Behaviours of Italian U. Tirelli, R. Italy. M.A.P.49 Female in Antwerp: A Risk Group for HIV Infection. Christ' 1 Praats*, M. Laga, P. Van Royen, M. Piot, *Institute of Tropical Medicine, Aniwerp, Belgium. M.A.P.50 Risk of HIV Infection among Homeless IV Drug Users (JYDUs) in Chicago. Wayne W. Wiebel*, T. Lampinen, D. Chene, D. Jimenez, W. Johnson, L. Quellet, et al., * University of Illinois at Chicago, Chicago, IL, U.S~A. M.A.P.51 HTV Infection among Homeless Men in a New York City Shelter. Ramon A. Torres*, S. Mani, J. Altholz, P. W. Brickner, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S~A. M.A.P.52 Prevalence and Risk Factors/or HIV-1 and HTLV-I Infection in Prostitutes in Southern Catalonia. Jordi Casabona*, R. Salinas, E. Sanchez, C. Lacasa, P. Ver~anni, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain. M.A.P.53 Social and Seroepidemiologic Survey for Antibodies to Human Ixnmunodeficiency Virus and Other Sexual Diseases in Prostitutes in Rio de Janeiro. Maria-Josd Andrada-Serva*, C. De Me is, A. C. Vasconcellos, D. Linhares, *Basic Research Centre, National Cancer Institucte, Rio de Jarneiro, Brazil. 158 [Page 159](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/161) Le VIH chez les clients des cliniques de MTS et des centres de d6pistage HIV among Clients of STD Clinics and Testing Centres M.A.P.54 HIV Seroprevalence in Heterosexual Men and Women, Denver Metro STD Clinic, 1985-1988. Franklyn N. Judson*, D. L. Cohn, J. M. Douglas, *Denver Public Health, University of Colorado, Denver, CO, U.S.A. M.A.P.55 Comparison of Race/Ethnicity, Transmission Category in Persons Electing HIV Counselling and Testing Services. Kathv Cahill*, G. S. Bowen, C. Kirby, *Centers for Disease Control, Atlanta, GA, USA. M.A.P.56 HIV Seroprevalence in Patients with PID. Rhoda S. Sperling*, F. Friedman, *Mount Sinai Medical Center, Department of Obstetrics and Gynecology, New York, NY, U.S.A. M.A.P.57 Risk Factors for HIV-1 Infection in a British Population. Colin Kennv*, E. J. Beck, C. Donegan, C. S. Cohen, V. W. Moss, P. Terry, et al., * St. Mary's Hospital Medical School, Virology Division, Paddington, UK. M.A.P.58 Heterosexual Transmission of HIV Is Rare amongst Attenders at an STD Clinic in London. David Barlow*, J. E. Banatvala, C. S. Bradbeer, R. N. Thin, I. Christie, S. Palmer, *St. Thomas' Hospital, London, U.K. M.A.P.59 HIV Prevalence in an AIDS Counselling Center in Israel. Zeev T.Handzel*, R. Burstein, M. Meyer, R. Levinstein, R. Nave, Z. H. Bentwich, *Hebrew University Medical School, Kaplan Hospital, Rehovot, Israel. M.A.P.60 Trends in HIV Seroprevalence among Self-Identified Risk Groups Utilizing Anonymous Test Sites in San Francisco.John B. Greenhal h*, M. J. Wilson, B. H. Nguyen, G. F. Lemp, R. E. Evans, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. M.A.P.61 Trends in HIV Seroprevalence in an Urban Sexually Transmitted Disease Clinic, 1986-1989. H. Hunter Handsfield*, E. Sohlberg, S. Hopkins, P. D. Swenson, N. Harris, *Seattle-King County Department of Public Health, University of Washington, Seattle, WA, U.SA. M.A.P.62 Effectiveness of Voluntary HIV Antibody Testing Provided at a Clinic Treating Sexually Transmitted Diseases. Michele M. Ginsberg, County of San Diego Department of Health Services, San Diego, CA, U.S.A. M.A.P.63 Epidemiological Observations of a Territorial HIV Screening Centre in Milan. Clara Schiantarelli*, M. Rastrelli, M. C. Moioli, M. Meini, M. Orso, R. *Niguarda Ca' Granda Hospital, Milan, Italy. M.A.P.64 HIV Seroprevalence Surveys in the San Francisco Bay Area. Mart J Wilson*, J. B. Greenhalgh, G. F. Lemp, C. I. Perkins, K. W. Kizer, G. W. Rutherford, et al., *California Department of Health Services, San Francisco, CA, U.S.A. 159 [Page 160](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/162) M.A.P.65 Heterosexual Transmission of HIV: Prevalence and Risk Jame Guinan*, C. Stone, A. Morlet, J. Gold, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. M.A.P.66 Prevalence of HIV-infection among STD-Patients in Antwerp, Belgium. Dirk Avonts*, M. Van Den Bruaene, C. Goliav, G. Vercauteren, M. Laga, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium. M.A.P.67 HIV-1 Infection in New York City STD Clinic Patients: Evidence for Stable Seroprevalence, 1987-1988. Isaac B. Weisfuse*, M. A. Chiasson, S. Back, L. Ramirez, B. Greenberg, W. Ewing, et al., *New York City Department of Health, New York, NY, U.S.A. M.A.P.68 Characterization of HIV-infected STD Clinic Clients Identified through Routine Voluntary Screening: Implications for Future Health Care Needs. Beth Erickson*, D. Glasser, J. N. Wasserheit, A. M. Rompalo, W. Brathwaite, E. W. Hook, *Baltimore City Health Department, Baltimore, MD, U.S.A. M.A.P.69 Frequency of HIV Infection among Patients of STD Out-patient Clinic. Lidia Napidrkowska, *Warsaw Medical Academy, Warsaw, Poland. M.A.P.70 Analysis of Trends over Time in Client Characteristics at Minnesota (MN) HIV-1 Antibody Counselling and Testing Sites. Richard N. Danila*, J. Shultz, M. Osterholm, K. Henry, M. Simpson, K. MacDonald, *Minnesota Department of Health, Minneapolis, MN, U.S.A. M.A.P.71 Blind HIV-AB and Syphilis-AB Seroprevalence Survey in New York State STD Clinics. George T. Diferdinando Jr.*, K. Arthur, S. Hipp, D. Murphy, *New York State Department of Health, Albany, NY, U.S.A. M.A.P.72 HIV-1 Infection in Persons Attending Sexually Transmitted Disease (STD) Clinics in Minnesota (MN). Richard N. Danila*, K. Henry, M. Simpson, M. Osterholm, K. MacDonald, *Minnesota Department of Health, Minneapolis, MN, U.S.A. M.A.P.73 HIV Seroprevalence of STD Clinics in Houston, Texas, U.S.A. Robert L. Falletti*, M. Enochs, K. Sullivan, D. Sanchez, D. Penaloza, H. Honeycutt, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A. M.A.P.74 HIV Seroprevalence in Sexually Transmitted Disease Clinics in Los Angeles County. Wesley L. Ford*, T. Rose, P. Kerndt, I. Onorato, S. Waterman, *Los Angeles County Department ofHealth Services, Los Angeles, CA, U.S.A. M.A.P.75 Development and Funding of Public HIV Counselling and Testing Services in the United States. Kathy Cahill*, G. S. Bowen, C. Kirby, *Centersfor Disease Control, Atlanta, GA, U.S.A. M.A.P.76 Incidence of HIV Infection in Gay and Bisexual Men Attending a Counselling and Testing Site or an AIDS Prevention Program. DavidL. Cohn*, J. Koleis, S. Cooper, V. Cole, F. Judson, *Denver Disease Control Service, Denver, CO, Aspects Portugal. Julio Botas*, L. Tavares, C. Carvalho, H. Feliciano, F. Antunes, *Department of Infectious Disease, Hospital Santa Maria, Lisbon, Portugal. M.A.P.78 HIV-2 in Italy: No Evidence, Yet. Giampiero Immunodeficiency Virus Type 2 (HIV-2) Screening of a High Risk Population in Addis Ababa, Ethiopia. Seyoum Ayehunie*, D. Zewdie, J. Woody, N. Constantine, B. Gebrehiwot, T. Messele, et al., *National Research Institute ofHealth, Addis Ababa, Ethiopia. M.A.P.80 Detection of Antibodies against HIV-2 Proteins in HIV-1 Seropositive Subjects from France and Greece. Vassilis Georgoulias*, P. Fountouli, A. Carvela, A. M. Beroli, E. Malliaraki-Pinetidou, A. Ammar, et al., *School of Medicine, University of Crete and AIDS Reference Center of Crete, Iraklion, Greece. M.A.P.81 HIV-2 in Drug Abusers of Spain. Pujol\", Badalona, AIDS in Portugal. Laura Avres*, A. Pista, A. Benito-Garcia, C. Furtado, F. Avillez, *Instituto da Saude, Lisbon, Portugal. M.A.P.83 AIDS Caused by HIV-2 in Southern Africa. Susan F. Lyons*, G. M. McGillivray, B. D. Schoub, A. N. Smith, L. Clausen, *National Institute for Virology, Sandringham, South Africa. M.A.P.84 HIV-2 Infection in Female and Male Brazilian Prostitute Groups. Maria Odette Santos-Ferreira*, C. Mazza, M. H. Lourenco, R. Focaccia, R. Rdtrovirus de la SNTS, Fondation nationale de Transfusion sanguine, Paris, France. M.A.P.86 Prevalence of HIV-1 and HIV-2 Antibodies in Individuals Attending a Clinic for S.T.D. A Two Year Follow-up. Laura Avres*, J. Cardoso, F. Avillez, I. Santo, A. *National of Lisbon, 162](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/164) Progression marqueurs de laboratoire et cofacteurs Cofactors M.A.P.87 The Level of Epstein-Barr Virus Excretion is a Predictor of Disease Progression in HIV Infection. Francisco Dfaz-Mitoma*, A. Ruiz, S. Houston, B. Romanowski, J. Preiksaitis, D. L. J. Tyrrell, * University of Alberta, Edmonton, AB, Canada. M.A.P.88 Prognostic Value of Anemia in Asymptomatic HLIV-Positive B. Ledergerber, J. Briihwiler, W. Siegenthaler, R. Liithy, * University Hospital Zurich, Department of Internal Medicine, Zurich, Switzerland. M.A.P.89 Age at Time of HIV Infection as Cofactor of Progression to Advanced Immune Dysfunction and AIDS. Angelo Hatzakis*, T. Mandalaki, K. Katsouyanni, A. Karafoulidou, H. Polychronaki, A. Gialeraki, et al., *Athens University Medical School, Athens, Greece. M.A.P.90 History of Syphilis as a Cofactor for the Expression of HIV Infection. Tosellh R. Berger*, M. McCarthy, L. Resnick, M. A. Flectcher, N. Klimnas, L. Pall, et a!., * University of Miami School of Medicine, Department of Neurology, Miami, FL, U.S~A. M.A.P.91 Effect of Previous Knowledge of HIV Positivity on Survival of AIDS Patients in Norway. Anae Ls&ikd*, P. Magnus, Nilsen, 'Ntoa Institute of Public Health, Oslo, Norway. M.A.P.92 Continued Injecting Drug Use as a Cofactor for Progression of LILY. Peter J. Flegg*, M. E. Jones, L. R. MacCallum, A. G. Bird, J. M. Whitelaw, R. P. Brettle, *City Hospital, Infectious Diseases Unit, Edinburgh, U.K. M.A.P.93 Co-factors and Cohort Effects in Progression to AIDS among IIIV-1 Infected Homosexual Men. Cladd E. Stevens*, P. E. Taylor, T. R. Holford, P. Rubinstein, *Laboratory of Epidemiology, The New York Blood Center, New York, NY, U.S~A. M.A.P.94 Progression of ARC to AIDS in a Population of Drug Abusers and Correlation with CD4 Decrease and Rise of HIVi Antigenaemia. &izo Ras\" V. S. Sabbatani, Schiattone, L. Pulsatelli, et al., *C~A. Pizzardi Hospital, Department Disease and Immunopathology Unit, Bologna, Italy. M.A.P.95 Predictors of Progression of LILY Arici, M. G. Finazzi, E. Minola, *Ospedali Riluniti di Bergamo, Department of Infectious Diseases, Bergamo, Italy. M.A.P.96 Use of Serial T4 Lymphocyte Counts to Predict Time to Develop AIDS in Anti-HIV Positive Haemophiliacs. Christine Ann Lee*, A. N. Phillips, J. Elford, G. Janossy, P. D. Grq~fiths, P. B. A. Kernoff *Haemophilia Centre, Royal Free Hospital, London, U.K. M.A.P.97 Laboratory Markers of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with LILY Disease. Randall A. Coates*, V. Farewell, J. Raboud, S. E. Read, D. MacFadden, L. Calzavara, et a!., *Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. 162 [Page 163](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/165) M.A.P.98 T Cell Subsets in a Cohort of Intravenous Drug Users (IVDUs): Initial Levels and Stability Over Time. Joseph B. Margolick*, A. Mufioz, S. Cohn, D. Vlahov, *Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, U.S.A. M.A.P.99 Presence of HIV p24 Antigen Strongly Predicts Development of AIDS. William Lang*, R. Anderson, S. Shiboski, H. Sheppard, M. Ascher, W. Winkelstein, *Children's Hospital, San Francisco Men's Health Study, San Francisco, CA, U.S.A. M.A.P.100 A Comparison of the Prognostic Value of B2 Microglobulin, Neopterin, and Soluble CD8 in HIV-2 Infection. Dennis Osmond*, P. Bacchetti, W. Krampf, E. Ross, E. Winger, A. R. Moss, *University of California, San Francisco General Hospital, San Francisco, CA, U.S.A. M.A.P.101 Is HLA Associated with Progression of HIV-1-Induced Immunodeficiency? Richard A. Kaslow*, R. Duquesnoy, M. J. Van M. Marrari, L. Kingsley, R. Detels, et al., *National Institute of Allergy and Infectious Diseases, National Institutes ofHealth, Bethesda, MD, U.S.A. M.A.P.102 Evolutive Process towards AIDS in the Majority of Symptomless HIV-infected Subjects. Jean-Jacques Lefrdre*, P. Lambin, C. Doinel, A. Couroucd, *Institut national de Transfusion sanguine, Paris, France. M.A.P.103 Different Courses of HIV Infection in PGL/ARC Patients of Frankfurt University, Out-patient Clinic, Infectiology. Hans-Reinhard Brodt*, G. Kindervater, S. Helm, *Universitdtsklinik Frankfurt, Zentrum der inneren Medizin/Infektiologie, Frankfurt, Federal Republic of Germany. M.A.P.104 Lack of Antibodies against p17 as Predictive Value for AIDS. Josd Barrera*, C. Sanchez, J. Mallolas, I. Planas, J. M. Miro, J. M. Gatell, et al., *Blood Transmitted Diseases Unit, Barcelona Hospital Clinic, Barcelona, Spain. M.A.P.105 Prospective Evaluation of HIV Progression in Edinburgh Injection Drug Users. Peter J. Flegg*, F. M. Cowan, M. E. Jones, L. R. MacCallum, J. M. Whitelaw, R. P. Brettle, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K. M.A.P.106 Signifiance of Increase of CD8 Lymphocytes in Asymptomatic HIV Christian Doinel*, J. Lefrdre, P. Lambin, P. Rouger, *Institut national de transfusion sanguine, Paris, France. M.A.P.107 Clinical and Laboratory Progression of HIV Infection in Blood Recipients and Their Spouses. Jane Garner*, M. Busch, S. Samson, H. Perkins, J. Ward, *Irwin Memorial Blood Bank, San Francisco, CA, U.S.A. M.A.P.108 Prediction of HIV-related Clinical Outcomes by Using Beta-2 Microglobulin (B2), p24 Antibody (Ab), and Antigen (Ag) in a Cohort of Initially Asymptomatic Gay Men. Kenneth H. Maver*, A. Stoddard, L. Falk, S. Saltzman, G. Dawson, J. McCusker, et al., *Memorial Hospital/Brown University, Pawtucket, RI, U.S.A. 163 [Page 164](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/166) M.A.P.109 Evaluation of Group Specific Component as Determinant of HIV Susceptibility and Progression. Angelos Hatzakis*, T. Mandalaki, R. Butler, R. Pflugshaupt, C. Tsoukala, K. Katsouyanni, et al., *Athens University Medical School, Athens, Greece. M.A.P.110 Factors Associated with HIV Progression in Nairobi Prostitutes. Donna Holton*, D. W. Cameron, J. N. Simonsen, J. O. Ndinya-Achola, E. Ngugi, F. A. Plummer, *University of Manitoba, Winnipeg, MB, Canada. M.A.P.111 The Natural History of HIV Infection in a Cohort of Homosexual and Bisexual Men: Cofactors for Disease Progression 1978-1979. NancA,. Hessol*, A. R. Lifson, S. P. Buchbinder, L. S. Doll, G. W. Rutherford, J. L. Barnhart, *San Francisco Department of Public Health, AIDS Office, San Francisco, CA, U.S.A. M.A.P.112 No Evidence for Risk Factors for Progression of HIV Infection among Homosexual Men. Godfried J. P. Van Griensven*, E. M. M. De Vroome, F. De Wolf, J. Goudsmit, M. Roos, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands. M.A.P.113 Cofactors of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with HIV Disease. RandallA. CoatesV, V. Farewell, S. E. Read, D. MacFadden, L. M. Calzavara, J. K. Johnson, et al., *Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. Prevention: politiques et evaluation des programmes Prevention: Policy issues, Program Evaluation M.A.P.114 Virus Leakage through Natural Membrane Condoms. WiHoward Cxr*, L. E. Bockstahler, C. D. Lytle, P. G. S. Vohra, Division ofLife Sciences, CenterforDevices and RadiologicalHealth, Rockville, MD, U.S.A. M.A.P.115 AIDS Street Nurses. Michael L. Rekart*, M. McCarthy, C. Farrow, *STD Control, Ministry of Health, Vancouver, BC, *Socidt6 France. M.A.P.119 evaluation de l'int6r~t d'un test utilisant des peptides a VIH. Rosenheim*, M. France. M.A.P.120 Safer Sex Behavior Reinforcement in Public Parks. Charles E. Halev*, M. Lerro. A. C. Freeman, J. A. Valentine, *Dallas County Health Department, Dallas, TX, U.S.A. 164 [Page 165](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/167) Notes [Page 166](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/168) Section Lundi 5 juin B Monday, June 5 Clinical Aspects of AIDS Aspects cliniques Session d'affichage Poster Session Grossesse et obst6trique in HIV Pregnant Women. Jean-Francois Delfraissv*, D. Srirni, J. C. Pons, D. Meyer, V. P. Engelman, et al., *Hdpital Antoine-Bfcldre, Clamart, France. M.B.P.3 Disease Progression following Pregnancy in HIV Seropositive Women. Frances M. Cowan*, L. MacCallum, J. Whitelaw, S. M. Burns, R. P. Brettle, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K. M.B.P.4 Pregnancy Arising in HIV Infected Women While Being Repetitively Counselled about \"Safe Sex\". Mark H. Kaplan*, B. F. Farber, W. W. Hall, C. Mallow, C. O'Keefe, R. G. Harper, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S A. M.B.P.5 Failure of Targeted Screening to Identify HIV+ Pregnant Women. Marguerite Barbacci*, T. Quinn, R. Kline, J. Repke, R. Chaisson, *Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A. M.B.P.6 Pregnancy and Acceleration of HIV-related Illness. Marie-Marcelle Deschamps*, J. W. Pape, S. Madhavan, W. D. Johnson, *GHESKIO, Cornell University Medical College, Division of International Medicine, New York, NY, U.S.A. M.B.P.7 Factors Influencing Maternal Decision-making Regarding Pregnancy Outcome in HIV Infected Women. Arve Rubinstein*, A. Wiznia, C. Bueti, C. Douglas, T. Cabat, *Albert Einstein College of Medicine, New York, NY, U.S.A. M.B.P.8 The Effect of Pregnancy on Progression of HIV-related Disease. Katherine Davennv*, E. E. Schoenbaum, P. A. Selwyn, D. Hartel, M. Rogers, *Montefiore Medical Center/Albert Einstein College of Medicine, AIDS Research, Bronx, NY, U.S.A. M.B.P.9 Pharmacokinetics (PK) of Zidovudine (ZDV) K. Coombs, R. Opheim, S. Burchett, *University of Washington, Department of Obstetrics and Gynecology, Seattle, WA, U.SA. 166 [Page 167](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/169) M.B.P.10 Knowledge of HIV Serostatus and Pregnancy Decisions. Marguerite Barbacci*, R. Chaisson, J. Anderson, J. Horn, *Johns Hopkins University, Baltimore, MD, U.S.A. M.B.P.11 Grosch-Worner, et al., *Universitatsklinikum Rudolf Virchow, Charlottenburg Pathologie, Berlin, Federal Republic of Germany. M.B.P.12 HIV Seroprevalence in an Inner City Obstetric Population. L.Alger*, S. Watkins, S. Hines, D. Richardson, J. P. Johnson, *University of Maryland School ofMedicine, Baltimore, MD, U.S.A. M.B.P.13 Transplacental Transfer of Unadkat*, A. A. Schumann, *University of Washington, Department of Pharmaceutics, Seattle, WA, U.S.A. M.B.P.14 A Prospective Study of HIV in Pregnant Women. Carlo Giaquinto*, L. Di Lenardo, D. Truscia, P. V. Grella, Padua, D. Lopez-Anaya, A. Schumann, *University ofWashington, Department ofPharmaceutics, Seattle, WA, U.SA. M.B.P.16 Pregnancy and HIV Infection: An Experience about 15 Cases. Giampiero Carosi*, F. Castelli, A. Chiodera, Brescia, M.B.P.17 Ultrasonic Assessment of Fetal Growth and Morphology in HIV-1 Positive Pregnant Women. Marc Boucher*, J. Samson, G. Delage, C. Be Demonstrated Immunohistochemically in Formalin-Fixed Material from Therapeutic Abortions of HIV-Exposed Pregnancies. Florian Eitelback*, M. Unger, Z. Huang, Schdfer, *Universitdtsklinikum Rudolf Virchow, Charlottenburg Pathologie, Berlin, Federal Republic of Germany. M.B.P.19 Seroprevalence of HIV-1 and HTLV-I among Pregnant Women in Newark, N. J. Thomas N. Denny*, E. Connor, L. Goode, P. Niven, M. Oxtoby, J. Oleske, et al.,* University ofMedicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A. M.B.P.20 Pathology and HIV Expression in Term Placentas from Seropositive Women. Sulachni Borkowsky, *New York University Medical Center and Bellevue Hospital Center, New York, NY, U.S.A. M.B.P.21 Differences in Immunosuppression during Pregnancy in HIV-infected W. Friedmann, B. Schwartldnder, *Free University ofBerlin, Department of Obstetrics and Gynecology, Berlin, Federal Republic of Germany. 167 [Page 168](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/170) M.B.P.22 Effect of Pregnancy on the Pharmacokinetics D. Unadkat*, A. Lopez-Anaya, L. A. Department of Pharmaceutics, Seattle, WA, U.SA. M.B.P.23 Seroprevalence in a Pregnant Multiethnic Population. Mary J. O'Sullivan*, A. Fajardo, P. Ferron, J. Efantis, C. Senk, M. Duthely, *University of Miami, Department of Obstetrics and Gynecology, Miami, FL, U.SA. M.B.P.24 A Prospective Study of the Mental and Motor Development of Infants Born to HIV Infected Intravenous Drug Using Mothers. Ron Kletter*, R. J. Jeremy, C. Rumsey, P. Weintrub, M. Cowan, *BAART/FACET, San Francisco, CA, U.S.A. M.B.P.25 Influence of Gestation on HIV Infection. Alain Berrebi*, J. Puel, J. Tricoire, H. Grave, Service de Gynecologie-Obstitrique, Toulouse, France. M.B.P.26 Effects of HIV Infection on Pregnancy. Alain Berrebi*, W. E. Kobuch, J. Puel, J. Tricoire, Grave, de Gyndcologie-Obstitrique, Toulouse, France. M.B.P.27 Pregnancy Outcome in Women: HIV Infection in Puerto Rico in a Population of Predominant Heterosexual Transmission. J. Romaguera, C. Zorrilla, C. Dfaz, R. Moscoso, A. De La Vega, J. Carrodeguas, San Juan, Puerto Rico. M.B.P.28 Comparison of Lifestyles and High Risk Sexual Behavior between HIV Seropositive and HIV Seronegative Pregnant Women. Carmen D. Zorrilla*, J. Romaguera, J. Torres, L. Morales, K. Adamsons, *University of Puerto Rico School of Medicine, San Juan, Puerto Rico, M.B.P.29 Reproductive History (Hx) of HIV Antibody Positive (HIV AB+) Women Followed in a Prospective Study in Newark, N.J., U.S.A. Mary Shneck*, L. Goode, E. Connor, B. Holland, M. Oxtoby, J. Oleske, *University of Medicine and Dentistry, New Jersey Medical School, Newark, NJ, U.S.A. M.B.P.30 Drug Abuse and Pregnancy: Concomitant Risk Factors for HIV Infection. Susan M. Weiner*, K. A. Kaltenbach, L. P. Finnegan, *Family Center, Thomas Jefferson University Hospital, Philadelphia, PA, U.S.A. M.B.P.31 Equally Poor Response to Tetanus Vaccine in HIV Seropositive and Seronegative Mothers in Zaire. Robert W. Ryder*, E. Baende, N. Halsey, A. Seroprevalence and Risk Beh i vior Are Increased in Pregnant Women Receiving no Prenatal Care. 3onnie J. Dattel*, L. B. Hauer, W. Crombleholme, D. V. Landers, R Edison, R. L. Sweet, et al., * University of California at San Fran:isco, San Francisco General Hospital, San Francisco, CA, U.S.A. 168 [Page 169](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/171) M.B.P.34 Does Pregnancy Influence Disease Progression in HIV Positive Women? Jean-Francois Delfraissv*, J. C. Pons, D. Sdrdni, V. Meyer, P. Engelman, et al., *H6pital Clamart, France. Infections opportunistes diverses Miscellaneous Opportunistic Infections M.B.P.35 Quantification of Glomerular and Tubular Marker Proteins in Urine of Hemophiliacs with Positive HIV Antibody Test. Dirk Schmidt*, H. Pohlmann, W. Hofmann, Manchen-Bogenhausen, Munich, Federal M.B.P.36 Isolation of a Bacterium from Epithelioid Angiomatosis. Alvin E. Friedman-Kien*, C. J. Cockerell, D. Zucker-Franklin, P. M. Tierno, *New York University Medical Center, New York, NY, U.S.A. M.B.P.37 AZT's Effect on Responses to Pneumococcal Hospital, Staten Island, NY, U.S.A. M.B.P.38 Growth of the Cat Scratch Disease Bacillus from Skin Lesions and Blood in Two HIV Positive Men. Pearl Ma*, J. Nord, J. Oliver, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A. M.B.P.39 Empiric Antibiotherapy of Febrile Episodes in Comparative Study of Clinical Laboratory and Pathological Diagnosis in 35 Patients with AIDS. Rosana Del Bianco*, J. Sullemmann, M. F. Araujo, P. S. Prado, D. Carnaadba, R. L. Mecelis, et al., *Centro de Referencia e Treinamento em AIDS, Sao Paulo, Brazil. M.B.P.41 Apport de la tomodensitom6trie au diagnostic des complications pulmonaires du SIDA de l'adulte. Pierre M. Trotot*, C. Marichez, R. *Hdpital Pitid-Salpetridre, Paris, France. M.B.P.43 The Value of Gallium-67 Scan in the Diagnosis of Lymphadenopathy in Symptomatic HIV-infected Patients. Daniel Podzamczer*, I. Spain. M.B.P.44 Lymphadenopathy and Human Immunodeficiency Virus (HIV) Infection in Sao Paulo, Brazil. Ricardo L. Chaves*, M. F. A. Nascimento, L. Batista, M.B.P.45 Disseminated Coccidioidomycosis in Patients with HIV Infection. Diana Antoniskis*, M. U. Rarick, B. Akil, R. A. Larsen, J. M. Leedom, *LosAngeles County, University of Southern California, Pasadena, CA, U.S.A. 169 [Page 170](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/172) M.B.P.46 Coccidioidomycosis among Patients Infected with HIV: A Study. L~J.ilAL.Amoel*, C. L. Dols, J. N. Gagliani, *Tucson Veterans Administration Medical Center, University of Arizona College of Medicine, Tucson, AZ, U.S~A. M.B.P.47 Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus with Foscarnet in a Person with AIDS. Renslow Sherer*, K. Muller, S. Blair, S. Kathpalia, R. Muldoon, E. Hill, et al., *Cook County Hospital, (ACV)-resistant 26 ~hrozL.afri&*, T. Assaykeen, S. Follansbee, J. Mills, *San Francisco General Hospital, Division of infectious Diseases, San Francisco, CA, U.S~A. M.B.P.49 Successful Therapy of Patient. Rkihard L5..riLL, C. L. Kaulffman, C. S. Levy, * Washington Center, Washington, DC, U.S~A. M.B.P.50 Ulcerative Alessi, *1st Clinic of Dermatology, University of Milan, Milan, Italy. M.B.P.51 Successful Treatment of Severe Acyclovir-resistant Herpes Simplex Virus Type 2 Proctitis in Two Patients with AIDS: Use of Continuous Infusion Acyclovir. Jeffrey P. Engel*, J. Englund, C. Fletcher, *East Carolina University School of Medicine, Greenville, MS, U.S~A. M.B.P.52 Acyclovir Therapy of Acute Retinal Necrosis Syndrome (ARN) in AIDS Patients. EvaT-Maria Fabricius, Augenklinik Krankenhaus Misnchen-Harlaching, Munich, Federal Republic of Germany. M.B.P.53 HIV, Human Papillomavirus, and Cervical Dysplasia in Nairobi Prostitutes. Ioa LKIreJ.s. N. Kiviat, F. Plummer, E. Ngugi, P. Waiyaki, K. Holmes, * U/niversity of Washington, Seattle, WA, U.S.A. IM.B.P.54 Prevalence and Risk Factors for HIV- 1 Infection in Patients with Acute Pelvic Inflammatory Disease (PID). 5JhareL StdtL*, B. I. Dattel, L. B. Hauer, R. Edison, W. Crombleholme, R. L. Sweet, et al., * University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. M.B.P.55 Diagnostic et traitement des lCsions cervico-vaginales M.B.P.56 Human Immunodeficiency Virus and Human Papilloma Virus in the Development of Cervical Intraepithelial Neoplasia (CIN) in Past Intravenous Drug Abusers E. Milan, italy. M.B.P.57 Genital Ulcers (GU) and HIV Infection in an Urban Sexually Transmitted Disease (STD) Clinic. Ket hrri\" S. Dillonr, J. Dehovitz, S. H. Landesman, W. McCormack, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A. 170 [Page 171](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/173) M.B.P.58 The Risk of Progression of Cervical Dysplasia in Women with HIV. Caroline S. Bradbeer*, E. Thomas' Hospital, London, UX. M.B.P.59 Infected Women. Diana A. F. Babin, A. Distrito Centro, Madrid Council, Madrid, Spain. M.B.P.60 High Rates of Cervical Dysplasias, Cervical Intraepithelial Neoplasias (CIN) and Human Papilloma Virus Infections in HIV-infected Female Patients. Klaus F. Hille, R. Lutz, S. Baur, M. Stauber, *University of Munich, University Women's Hospital, Munich, Federal Republic of Germany. M.B.P.61 Infection in HIV Seropositive Individuals with the EBNA Eme, Beldjord, M. Andrieu, et al., *Facultd de de Grenoble, La M.B.P.62 Association in AIDS Patients. Jeannette Guarner*, E. R. Unger, *Emory University, Department of Anatomic Pathology, Atlanta, GA, U.S.A. M.B.P.63 Effects of rhG-CSF on Secondary Infections in AIDS. SatoshiKimura*, H. Mohri, H. Sugiyama, A. Nakagawa, K. Mitamura, et *Institute ofMedical Science, the University ofTokyo, Tokyo, Japan. M.B.P.64 Prevalence and Clinical Significance of Coomb's Test and Cold Agglutinins in AIDS Patients. Johannes R. Bogner*, B. Gathof, B. Heinrich, A. F.-D. Goebel, *University of Munich, Medizinische Poliklinik, Munich, Federal Republic of Germany. M.B.P.65 Increase of Factor VII Activity in HIV Infected Patients. Sergio Gafd*, P. Italy. M.B.P.66 Therapy of Salmonella Infections in AIDS Patients. Kenneth V. I. Rolston*, S. J. Rodriguez, P. Mansell, *The University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A. M.B.P.67 Salmonella Bacteremia and HIV Infection. Inmaculada Ocafia*, A. De Luis, A. Planes, A. Pahissa, E. Serra, J. M. Martinez-Vdzquez, *Autonomous University ofBarcelona, Barcelona, Spain. M.B.P.68 Shigella Enteritis among AIDS Cases in Los Angeles. Loren E. Lieb*, M. P. Tormey, D. P. Ewert, P. K. Wakamarsu, G. H. F. Y. Run, P. R. Kerndt, *Los Angeles County Health Services, Los Angeles, CA, U.S.A. M.B.P.69 Clinical Presentation and Quinolone (Q) Therapy of Salmonella in HIV Infection. Nigahus Karabulut*, R. Porwancher, C. Cherney, A. Ricketti, R. Friedland, Trenton, NJ, U.S.A. 171 [Page 172](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/174) M.B.P.70 Nosocomial Infection (NI) in Patients with HIV Infection. Christopher P. Kales*, R. S. Holzman, K. Krasinski, R. LaCouture, *New York Medical Center, New York, NY, U.SA. M.B.P.71 Bacteremic Pneumococcal Disease as the First Manifestation of Human Immunodeficiency Virus (HIV) Infection in Adults. Jav F. Dobkin*, W. Mandell, N. Sethi, *Presbyterian Hospital, Columbia University, New York, NY, U.SA. M.B.P.72 Staphylococcus Aureus Nasal Carriage Rate in Patients with AIDS or ARC. Mario C. Raviglione*, P. Mariuz, A. Pablos-Mendez, P. Ottuso, A. Taranta, S. Scimeca, *Department Medicine, Cabrini Medical Center, New York, NY, U.SA. M.B.P.73 Prevalence of Significant Lower Respiratory Bacterial Infections in HIV Positive Persons Undergoing Bronchoscopy with Semi-Quantitative BAL Culture. Kenneth J. Skahan*, R. P. Baughman, P. T. Frame, *University of Cincinnati Medical Center, Department of Medicine, Cincinnati, OH, U.SA. M.B.P.74 AIDS-Associated Urinary Tract Infection (UTI). Luiz Paulo Josd O. Santos, G. S. Lopes, M. C. De Lacerda, G. B. Teixeira, M. M. Fernandes, *Universidade do Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.75 Severe Bacterial Infections in AIDS Patients. Piero Marone*, P. Sacchi, P. Grossi, Infections in AIDS. Pramod M. Shah*, A. Bolz, E. B. Helm, W. Stille, *University Hospital, Center for Internal Medicine, Frankfurt, Federal Republic of Germany. M.B.P.77 Listeriosis in Patients with HIV Infection. Christopher P. Kales*, R. S. Holzman, *New York University Medical Center, New York, NY, U.SA. M.B.P.78 AIDS Related Histoplasmosis. James M. Parks*, S. D. Nightingale, S. M. Pounders, *University of Texas Southwestern Medical Center, Dallas, TX, U.SA. M.B.P.79 Disseminated Histoplasmosis in a Danish AIDS Patient. Else Smith*, M. Franzman, L. Mathiesen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. M.B.P.80 Chronic Suppression of Disseminated Histoplasmosis in HIV Disease with Oral Ketoconazole. Robert E. Neihart*, J. Brewer, *St. Luke's Hospital, Kansas City, MO, U.SA. M.B.P.81 Histoplasmosis in an AIDS Patient Treated with Itraconazole. Mike Youle*, J. Midgley, D. Shanson, C. U.K. M. J. Sta. Maria, Lisbon, Portugal. M.B.P.83 Rhodotorula Rubrum Septicemia in an AIDS Patient with an Indwelling Hickman Catheter. Dennis M. Causey*, J. M. Leedom, C. Olsen, * University of Southern California, Los Angeles, CA, U.S.A. 172 [Page 173](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/175) M.B.P.84 Sepsis from Implanted Catheters in Patients with AIDS. Jonathan H. Rosenthal*, C. Langley, M. Lederman, *Case Western Reserve University, Cleveland, OH, U.S.A. M.B.P.85 Experience with Central Venous Catheters (CVCs) in Patients with AIDS. Joseh R. Thurn*, C. Miller, S. Johnson, F. Rhame, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A. M.B.P.86 Indwelling Right Atrial Catheter (IAC) Infections in AIDS Patients. Athanasios Skoutelis*, J. Phair, C. Sterkel, J. Von Roenn, R. Murphy, K. MacDonell, *Northwestern University Medical School, Section of Infectious Diseases, Chicago, IL, U.SA. M.B.P.87 Infections and Complications of Indwelling Central Venous Catheters (CVC): Comparisons between Patients (PTS) with AIDS Vs. Other Illnesses (Non-AIDS). Brian R. Saltzman*, D. C. Perlman, D. I. Levey, D. Sturm, L. Kelly, *Beth Israel Medical Center, M.B.P.88 Pharmacocin6tique (sang-liquide rachidien) de HIV+. Pascal Chavanet*, M. Buisson, P. Lokiec, S. Aho, C. R. Rattan, Pablos-Mendez, P. Mullen, A. Taranta, *Department of Medicine, Cabrini Medical Center, New York, NY, U.S.A. M.B.P.90 Invasive Aspergillosis (IA) in AIDS: Clinical Manifestations and Predisposing Factors. David C. Perlman*, N. Salomon, B. R. Saltzman, A. Klapholz, W. Talavera, *Beth Israel Medical Center, New York, NY, U.S.A. M.B.P.91 Cryptococcose, histoplasmose africaine et SIDA au Congo. Bernard Carme*, A. Mbitsi, A. Ngolet, A. Itoua-Ngaporo, B. Ebikili, G. universitaire de Brazzaville, Brazzaville, Congo. M.B.P.92 A Multicenter Trial on the Efficacy and Safety of Fluconazole in the Treatment of Opportunistic Fungal Infections, Sponsored by the Italian Institute of Health. S. Vella*, D. Greco, M. G. Agresti, A. Cassone, G. De Crescenzo, M. P. Ruffilli, *National Institute of Health, Rome, Italy. M.B.P.93 Paracoccidioidomycosis and HIV Infection. Rogerio J. Pedro*, F. H. Aoki, M. L. Branchini, J. N. Lima, W. B. Abreu, M. B. S. Dias, *Hospital de Clinicas, UNICAMP, Grupo de AIDS, Campinas, Brazil. M.B.P.94 Disseminated Infection Due to Penicillium Mameffei in an HIV Positive Patient. Massimo Coen*, M. A. Viviani, G. Infection? Juan Grosse, F. Staib, M. Steibold, W. Heise, *Auguste-Viktoria Hospital, Department of Pathology, Berlin, Federal Republic of Germany. 173 [Page 174](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/176) M.B.P.96 Fluconazole Treatment for Fungal Infection in ARC and AIDS. Francesco M. Griari*, E. Raise, V. Vannini, G. in Inmaculada Ocafla*\", A. De Luis, D. Irreguible, T. Vallespi, M. Torrebadella, J. M. Martfnez-Vdziquez, *Autonomaus University Barcelona, M.B.P.100 Tropical Diseases of HIV Patients in Non-endemic Countries: A Case of Visceral Leishmaniasis and a Case of Tropical Pyomyositis. C.Esi~ J. F. Erckenbrecht, F. Borchard, G. Strohmeyer, *Departpent of Medicine, University of Duisseldorf, Duisseldorf, Federal Republic of Germany. M.B.P.1O1 Detection of HIV-1 in Cerebrospinal Fluid (CSF): Correlation with Presence and Severity of the AIDS Dementia Complex. ALordi Q. id*l, B. J. Brew, R. W. Price, A. Khan, M. Gallardo, *Memarisl Sloan-Kettering Cancer Center, NewY York, Cerebral Abcess Caused by Trypanosoma Cruzi in Patient with AIDS. Kronfeld*, A. Cavalcanti, A. Carneiro, L. Severo, * Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. Function Tests (PFT) and CD4 Lymphocyte Count for Diagnosing Lung Complications in AIDS. Bonaventura Clotet*, 0. Parra, H. Sala, J. Ruis, J. Morera, *Pneumalogy and Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain. M.B.P.104 The Efficacy of Screening Tests for Infectious Diseases in Persons with Symptomatic ARC. &rAL.Q. Grdki*\", P. M. Hartigan, C. Oster, *VA Medical Center, DC, U.S~A. M.B.P.105 Elevation of Lactate Dehycirogenase in Asymptomatic AIDS Patients. Regeniter*, W. H. Siede, H. D. Brede, H. Ruibsamen-Waigmann, U. M. E. Unkelbach, Klinikum der J. W. of Germany. M.B.P.106 67 Gallium Scintigraphy of Chest in AIDS Patients. Analysis of 152 Cases. Giseo pVj1co, P. Narciso, F. M. Pau, F. Rosci, P. Sette, * Hospital \"L. Spallanzani\", Department of infectious Diseases, Rome, italy. M.B.P.107 Adenosine Deaminase (ADA) Levels in Sera of Patients Infection. ~aierE~nW\", V. Valls, V. Roca, R. De Salamanca, *Hospital Clinico San Carlos, Madrid, Spain. M.B.P.108 Clinical Manifestations of AIDS in Women from Sao Paulo, Brazil. Ana-Carolina Ferreira*, J. L. Gracndi, M. E. Fernandes, *Reference and Training Center for AIDS, Sac Paulo, Brazil. 174 [Page 175](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/177) M.B.P.109 Opportunistic Infections in AIDS Patients: A Comparison of Clinical and Postmortem Findings in Rio de Janeiro, Brazil. Carla Ismael*, D. J. H. Signorini, D. P. Oliveira, M. C. R. Lacerda, C. A. Bastlio de Oliveira, C. A. Morals de Sd, *Gaffrde and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.110 A Serologic Study of Cryptosporidium Infection in HIV Positive Men and the Relationship to T-Cell Subsets. Charles T. Leach*, T. Kuhls, D. Mosier, P. English, J. Giorgi, J. Cherry, et al., *University of California at Los Angeles School ofMedicine, Los Angeles, CA, U.SA. M.B.P.111 CD4+ T-Lymphocytes and the Manifestation of Opportunistic Mucocutaneous Infections in HIV Infection. Helmut Schofer*, F. R. Ochsendorf, R. Milbradt, *Klinikum der J. W. Goethe-Universitdt, Department of Dermatology, Frankfurt, Federal Republic of Germany. M.B.P.112 Prevalence of Hepatitis B and Delta Virus Infection in Hemophiliacs with AIDS. Carlos Eduardo Brandao-Mello*, A. L. Gonzaga, J. P. Simonetti, S. *Centro de Hematologia Santa Catarina, Hospital Gaffrde e Guinle, Rio de Janeiro, Brazil. M.B.P.113 Chronic Acute Hepatitis (CAH) in Two Groups of IVDAs (HBcAb Positive) with and without HIV Infection. Franco Fedeli*, G. Gardini, S. Gafa, M. G. Giudici, A. Monitoring Systemic Infections and Ganciclovir Treatment in AIDS Patients. Lorenzo Minoli*, M. G. Revello, E. Percivalle, M. Zavattoni, P. Grossi, Gerna, Infectious Diseases, University of Pavia, Pavia, Italy. M.B.P.115 The Significance of Detecting Cytomegalovirus in Bronchoalveolar Lavage Samples from AIDS Patients with Respiratory Disease. Simon E. Barton*, D. A. Hawkins, B. G. Gazzard, *Kobler Centre, St. Stephen's Hospital, London, U.K. M.B.P.116 Cytomegalovirus Colitis in AIDS: Presentation in 33 Patients. Douglas T. Dieterich*, M. Rahmin, H. Rotterdam, D. Dolitsky, *New York University Medical Center, New York, NY, U.S.A. M.B.P.117 Prophylaxis of CMV Retinitis Relapse: Evaluation of Christine E. Dohin, I. Massin-Cochereau, of Katlama*, E. Dohin, B. Girard, AIDS. G. Grosse, M. L'Age, H. Timm, *Auguste-Viktoria Hospital, II Department Internal Medicine, Berlin, Federal Republic of Germany. M.B.P.121 Ganciclovir Therapy for Cytomegalovirus Related Polyradiculo(myelo)pathy in Patients with AIDS. Jan De Gans*, G. Tiessens, Portegies, Department Amsterdam, M.B.P.122 An Open Comparative Study of Foscarnet and Ganciclovir in the Treatment of CMV Retinitis. Mark E. Newell*, M. Harris, G. J. Clarbour, B. G. Gazzard, *St. Stephen's Hospital, London, UK. M.B.P.123 Tolerance and Efficacy of Daily Intravenous (IV) Maintenance Foscarnet (PFA) Therapy for Cytomegalovirus (CMV) Protocol 015). Mark A. Jacobson*, D. Causey, D. Hardy, B. Polsky, J. Mills, J. Feinberg, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. M.B.P.124 Cytomegalovirus Cultures during Maintenance DHPG Therapy for CMV Retinitis in AIDS. Jennifer F. Hoy*, I. D. Jennens, C. R. Lucas, A. M. Sandland, H. MacLean, K. Hayes, *Fairfield Infectious Diseases Hospital, Fairfield, Australia. M.B.P.125 Pulmonary CMV Infection in AIDS Patients: A Clinicopathologic Study. Pohle, *Rudolf Virchow University Hospital, Freie Universitdt Berlin, Berlin, Federal Republic of Germany. M.B.P.126 Possible Usefulness of High Dose Acyclovir as Prophylaxis for CMV. Craig E. Metroka*, H. Josefberg, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. M.B.P.127 Diagnosis and Grading of CMV Colitis: Comparison of H & E Stains, DNA In-situ Hybridization, and Immunoperoxidase Stains for Early and Late Antigens. Heidrun Rotterdam*, Y. J. She, D. Dieterich, *New York University Medical Center, New York, NY, U.S.A. M.B.P.128 A Randomized Controlled Clinical Trial of Foscamet for the Treatment of Cytomegalovirus Retinitis in Patients with Acquired Immunodeficiency Syndrome. Michael A. Polis*, R. T. Davey, H. Lane, J. Manischewitz, H. Masur, A. Palestine et al., *National Institutes ofHealth, Clinical Center, Bethesda, MD, U.S.A. M.B.P.129 Therapy of Cytomegalovirus (CMV) Infections with Ganciclovir. Kenneth V. 1. Rolston*, S. J. Rodriguez, F. Carvajal, J. Nelson, G. P. Bodey, P. Mansell, et al., *University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.S.A. 176 [Page 177](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/179) M.B.P.130 Treatment with Vitro Secretion of CMV Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. Jean-Pierre Vendrell*, M. Segondy, J. Ducos, Montpellier, France. M.B.P.132 AIDS-related Retinitis. Will infectieuses, Rothschild, Paris, France. M.B.P.133 Foscarnet Continuous Infusion in HSV Infection with AIDS. Alberto YQlQLILerjQ.o, I. Schlacht, F. Genova, R. Villa, I. Cerobrospinal Fluid of Cytomegalovirus Amsterdam, M.B.P.135 Intestinal IIIV Expression in AIDS Patients with Cytomegalovirus Colitis. Donald P. Kotler*, S. Reka, W. Cronin, A. Borcich, A. New M.B.P.136 Electron Microscopy of AIDS Related Cytomegalovirus (CMV) Infection of the Lung. &ierre D. iaert, C. A. Basilio, F. Fialho, H. A. Valle, F. S. Sion, C. A. M. Sd, *Department of Virology, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil. Transfusions Transfusions M.B.P.137 Demographic and Epidemiological Characteristics of HIV Positive Blood Donors in Catalonia. LordiLCasabotia.~ G. Barba, A. Segura, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain. M.B.P.1138 A Safer Test Tube for 11W and Other Viral Marker Tests. Habib j. jitjf\"r, M. S. Jacobson, M. A. Renaud, S. V. Kevy, *Medcon Research and Development Inc., Brookline, MA, U.S~A. M.B.P.139 11W Screening of Commercially Available Blood Products in India. Srikanth Prasad Trivathy*, K. Chaudhuri, Y. N. Singh, P. Seth, T. Varghese, A. N. Malaviya, *All India Institute of Medical Sciences, N~ew Delhi, India. M.B.P.140 Detection of HWV Markers Prior to IgG Antibody Seropositivity in Plasma Donors. Susan L. Stramer*, J. S. Heller, R. W. Coombs, R. V. Party, D. D. Ho, J. L. Stewart, et al., *Abbott Laboratories, Diagnostics Division, Abbott Park, IL, U.S.A. M.B.P.141 Risk Factors for HIV among New York Blood Donors in 1988. Suzanne Ma.ewino\", D. Kessler, P. Berge, S. Andrews, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A. 177 [Page 178](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/180) M.B.P.142 Self-Exclusion by HIV Antibody Positive Blood Donors. Suzanne M. Gaynor*, D. Kessler, S. Andrews, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A. M.B.P.143 Changing Profile of HIV-Seropositive Blood Donors. Penny J. Ballem*, N. A. Buskard, M. Elliot, S. Lord, M. Sinclair, *Canadian Red Cross Blood Transfusion Service, Vancouver, BC, Canada. M.B.P.144 Immunophenotypes of Anti-HTLV-I Positive (+) Blood Donors. Mary A. Fletcher*, Transfusion Safety Study, *University of Miami School of Medicine, Department of Medicine, Miami, FL, U.S.A. M.B.P.145 Clotting Factor Treatment and CD4 Counts in Anti-HIV+ Hemophiliacs. George F. Gierset*, Transfusion Safety Study, *Puget Sound Blood Center, University of Washington, Seattle, WA, U.S.A. M.B.P.146 Serological Evidence of Prior Sexually Transmitted Diseases in HIV-1 Seropositive Blood Donors. Alan E. Williams*, K. W. Creedon, T. Grandinetti, M. T. Sullivan, *American Red Cross, Jerome H. Holland Laboratory, Rockville, MD, U.SA. M.B.P.147 Photoinactivation of HIV-1 with Merocyanine 540. James C. Sunstrum*, R. L. Harvey, L. L. Sensenbrenner, *Wayne State University, Detroit, MI, U.S.A. M.B.P.148 P24 HIV Antigen Screening of Blood Donors. JosefEberle*, B. Gathof, U. Backer, E. Gossrau, R. Stute, K. Baumgarten, et al., *Max von Pettenkofer Institute, University of Munich, Munich, Federal Republic of Germany. M.B.P.149 HIV Seroprevalences amongst Health Blood Donors in 31 Hospitals in Zambia. Nkandu P. Luo*, A. B. C. Dallas, L. Chipuka, R. Nshimbi, R. Tedder, J. Siyambango, *University Teaching Hospital, Lusaka, Zambia. M.B.P.150 Risk of HIV-1 Transmission by Blood Transfusions in San Francisco prior to Anti-HIV-1 Screening. MichaelBusch*, S. Samson, M. Young, J. Ward, H. Perkins, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A. M.B.P.151 Transmission du VIH-1 par transfusion: d6croissance du Girard, M. H. Elghouzzi, B. Habibi, *Fondation Nationale de Transfusion Sanguine, H6pital Saint-Antoine, Paris, France. M.B.P.152 Experience with Notification and Follow-up of Western Blot Indeterminate Donors. Suzanne M. Gavnor*, B. Hosein, C. Del Valle, C. Bianco, *The New York Blood Center, New York, NY, U.S.A. M.B.P.153 Donor Showing only Core Positive HIV Antibody: A 3-Year Follow-up. Prakash C. Das*, of JIIV Counselling Consultation Meetings at the North London Blood Transfusion Centre (1986-1989). RiaMle\" P. Hewitt, C. Moore, J. Barbara, M. Contreras, S. O'Brien, *Hanaphilia Centre, Royal Free Hospital, London, U.K. M.B.P.156 Changes in the Prevalence of lil~s among Nigerian Blood Donors in Ibadan, Nigeria. Etim M. Essien*, I. Saliu, * University College Hospital, Ibadan, Nigeria. M.B.P.157 Anti-lil Screening of Blood Donors in Canada (November 1985 to December 1988). Sdnd akar, A. Adatia, N. B. Whittemore, *The Canadian Red Cross Society, Ottawa, ON, Canada. M.B.P.158 HIV-2 Seroprevalence in Different Groups Tested in University College Hospital, Ibadan, Nigeria. Etim.Essiean*, I. Saliu, *Departmp.nt of Hematology, University College Hospital, Ibadan, Nigeria. M.B.P.159 Transfusion and H1V, Finnish National Look Back Program. Jukka KQLiLL1LeLL Finnish Red Cross Blood Transfusion Service, Helsinki, Finland. M.B.P.160 Absence of HIV Seropositivity in Children with Sickle Cell Anaemia at Kenyatta National Hospital, Nairobi, Kenya. Samuel E. N. Waweru*, J. S. Meme, D. M. W. Kinuthia, G. W. Kitonyi, *Department of Paediatrics, University of Nrairobi, Nairobi, Kenya. M.B.P.161 Risk of Transmission of HTLV-I by Transfusion. James G. Donahue*, N. Cohen, A. Munoz, B. Reitz, 0. Frazier, B. F. Polk, et al., *The Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, U.S~A. M.B.P.162 Prevalence of HTLV-I Antibodies in Blood Donors in the Netherlands. Cees L. van der Poel*F, N. Lelie, H. Reesink, P. Ehlers, E. Netherlands. Transfusions/D~pistage Transfusions/Tests M.B.P.163 Comparison of Immunoassays for Early Detection of HIV-1 Seroconverters. James R. George*, W. Velleca, S. Phillips, G. Schochetman, *Centers for Disease Control, Atlanta, GA, U.S~A. M.B.P.164 Comparison of Nine LIV-1 Seroconversion Donors on Six Antibody Assays. Susan L. Stramer*, J. Gibes, E. Zemel, K. Sachs, M. Mathieu, J. S. Heller, *Abbott Laboratories, HlV Technical Product Development, Chicago, IL, U.S~A. M.B.P.165 Progressive Changes with Time in Expression of Carbohydrates Antigen in PBL of HIV Infected Patients. td ~Q&n Gll*, C. Schiozawua, N. Kaslhiwagi, D. Church, M. Ohnishi, M. C. Poon, et al., * Uni'versity of Calgary, Departments of Microbiology, Infectious Diseases and Medicine, Calgary, AB, Canada. M.B.P.166 Packed Red Blood Cell (PRBC) Transfusion Therapy for Anemia in Patients with AIDS and ARC: Incidence, Associated Factors. Mark AJcbo\" L. Peiperl, P. A. Volberding, D. Porteus, P. T. C. Y. Toy, D. Feigal, *San Francisco General Hospital, University of Caifornia, San Francisco, CA, U.S.A. 179 [Page 180](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/182) M.B.P.167 Screening of Blood Donation with EIA Combined Test (COMBI IgG EIA) by Using Synthetic Peptides to Detect Anti-HIV1/Anti-HIV-2. Nelson Hamerschlak*, M. B. Carvalho, H. Mizawa, K. Cavagnoli, C. C. C. Guerra, L. Szterling, *Hospital Israelita Albert Einstein, Centro de Hematologia de Sao Paulo, Sao Paulo, Brazil. M.B.P.168 Detection of Antibodies to Human Immunodeficiency Virus in Venous and Capillary Whole Blood by Latex Cleste Chenet-Monte*, C. H. Riggin, K. Mayer, *Cambridge Bioscience Corporation, Worcester, MA, U.S.A. M.B.P.169 Impact of Leukocyte Filtration of Donor Blood on Reduction of Human Immunodeficiency Virus-infected Cells. Bhupat Rawal*, M. Busch, R. Endow, H. Perkins, R. Schwadron, G. Vyas, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A. M.B.P.170 The Adaptation and Evaluation of High Performance ELIS A Assays for Detection of HIV Antibodies in Dry Blood Spots. John W. D. Kay*, T. S. Flowers, J. V. Roman, F. V. Crout, *Organon Teknika Corporation, Durham, NC, U.S.A. M.B.P.171 Do Autoantibodies to Red Blood Cells in Patients with Positive Anti-HIV Serology Really Exist? Roberto Luzzati*, G. M. Malena, *Institute of Infectious Diseases, University of Verona, Civil Hospital, Verona, Italy. M.B.P.172 Evaluation of Serodia Particle Agglutination Assay for Antibody to HIV. Michael P. Busch*, C. Bueno, R. Cordell, *Irwin Memorial Blood Centers, San Francisco, CA, U.S.A. M.B.P.173 Sensitivity and Selectivity of HTLV-I Immunoassays. Steven K. H. Foung*,J. Lipka, J. Parker, *Stanford University, Department of Pathology, Palo Alto, CA, U.S.A. M.B.P.174 Use of Three Recombinant Assays to Test Blood Donor Samples with Western Blot (WB) Indeterminate Patterns. Vito Scalia*, B. K. Buchner, J. P. Reeves, L. Sabourin, P. Gill, *Canadian Red Cross Society, Ottawa, ON, Canada. La peau Skin M.B.P.175 Recurrence Rate for Buccal Candidosis and Its Relationship to T4 Count and p24 Antigen. Don E. Smith*, M. Allan, J. Migley, B. G. Gazzard, *St. Stephen's Hospital, London, U.K. M.B.P.176 Probability of Developing AIDS in HIV-Infected Patients with Mucocutaneous Lesions. Daniel Podzamczer*, F. in AIDS. Stylianos Lomvardias*, K. Vaidya, *Woodhull Medical and Mental Health Center, NY, U.S.A. M.B.P.178 Hyperkeratotic Disseminated Herpes Zoster in Preterminal AIDS. B. Hoppenjans, R. Orme, M. Bibler, *University of Cincinnati College of Medicine, Cincinnati, OH, U.S.A. 180 [Page 181](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/183) M.B.P.179 Varicelle et infection i HIV. Christian M. Perrone*, M. Lazanas, C. Leport, D. Salmon, T-Lymphocytes and Stage of Infection. Falk R. Ochsendorf*, H. Sch6fer, R. Milbradt, *Klinikum der J. W. Goethe-Universitdt, Frankfurt, Federal Republic of Germany. M.B.P.181 Manifestations cutan6es et v6n6rologiques chez les malades Infection. P. Ouinhoes*, E. A. V. Abreu, M. C. Rachid de Lacerda, M. S. Serra, F. S. Sion, C. A. Morals de Sd, *Gaffrde & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.183 Manifestations cutan6o-muqueuses du SIDA africain. A.M. Coll*, M. D. Ball, E. Benga, C. Faty-Ndieye, M. A. Infection with Virus Demonstrated in Histocytes of Skin Rash. Joyce 1. Wallace*, J. Oliver, S. Beatrice, *St. Vincent's Hospital and Medical Center, New York, NY, U.S.A. M.B.P.185 Dermatological Manifestations Related to AIDS in Central Africa. M. Dieudonnd Vohito*, R. Koyada, L. Belec, B. Di Costanzo, Georges, J. Testa, *Centre National Hospitalier Universitaire, Bangui, Central African Republic. M.B.P.186 Basal Cell Carcinoma in HIV Disease. lan Gilson*, J. Barnett, S. Snow, *Internal Medicine Specialties, Milwaukee, WI, U.S.A. M.B.P.187 Psoriasis in HIV Infection: Clinic, Histology Frdschl*, M. Landthaler, O. Braun-Falco, *Dermatological Department of Ludwig-Maximilians University, Munich, Federal Republic of Germany. M.B.P.188 Les manifestations cutan6es de l'infection au HIV au Rwanda. in Zidovudine Treated Patients. Frederick P. Duncanson*, P. C. Don, F. Fusco, P. Fried, A. Batterman, T. H. Lenox, et al., *New York Medical College, Metropolitan Hospital, New York, NY, U.SA. 181 [Page 182](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/184) Manifestations cliniques Clinical Manifestations M.B.P.190 Killing Effect of Amikacin on Mycobacterium Avium Complex (MAC) in Beige Mice and Macrophages. Pattisavu R. I. Gangadharam*, L. Kesavalu, J. Goldstein, R. J. Debs, N. Duzgunes, *National Jewish Center for immunology and Respiratory Medicine, Denver, U.S~A. M.B.P.191L Human Papilloma Virus (HPV) in Anal Homosexual Men. Gregory Y. Lauwers*, WV. Cronin, H. L. Joachim, *Department of Pathology, New Y~ork, NY, U.S~A. M.B.P.192 Peripheral CD4 Lymphocyte Counts Are Predictive of CMV, MAI, and Pneumocystis in HIV. Craig E. Metroka*, D. Jacobus, N. Lewis, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.SA. M.B.P.193 A High Incidence of Allergic Disorders in Patients with HIV Infection. David N. Chernoff\", S. Sample, G. Lenahan, M. Serwonska, H. Hollander, E. Goetzl, * University of Calffornia at San Francisco, San Francisco, CA, U.SA. M.B.P.194 Acute HIV Infection: Clinical and Biological Study of Twelve Patients. Alessandro Si'nicco*, G. Palestro, P. Caramello, D. Giacobbi, G. Giuliani, G. Paggi, et al., \"Isitt of infectious Diseases, \"A madeo di Savoia \" Hospital, University of Turin, Turin, Italy. M.B.P.195 Aspects cliniques HIV-1 et HIV-2 et classifications de Bangui. A. M. Coll*, A. Sow, M. A. Faye-Ndao, G. Diouf, E. Feller-Dansokho, A. Cabanis, A. E. Cabde, M. Thibierge, J. M. et al., *Instiptu Pasteur, Paris, France. M.B.P. 197 etude de la cours France. M.B.P.198 The Implications of Human Immunodeficiency Virus (HIV) Infection and Accidental Falls (AF) among Young Patients in a City Hospital. ToyW hu~\" I. Weg, *Qiwens Hospital Center, Long island Jewish Medical Center, Jamaica, NY, U.S~A. M.B.P.199 HIV Infection Natural History: \"Persistent\" and \"Active\" Exist and They Are Distinguishable. Francesco Montella*, F. Di Sora, A. F. Propersi, P. A. Preite, G. Macchia, et per delle Sindromi Correlate, Rome, italy. M.B.P.200 HIV-2 in New England. Richard Marlink*, K. Mayer, M. Essex, J. Ayanian, J. Macguire, P. Kanki, *Depaptpi.nt of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S~A. M.B.P.201 Clinical and Autopsy Findings in HIV-1 Seropositive Patients. Bekele Afets\", W. Green, L. Olopoenia, S. Barnes, C. Saxinger, W. Frederick, *Howard University Hospital, Washington, DC, U.S~A. 182 [Page 183](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/185) M.B.P.202 Pain in Patients with AIDS. Mathew Lefkowitz*, A. H. Lebovits, *State University of New York, Department of Anesthesia, Brooklyn, NY, U.S.A. M.B.P.203 Recurrent Maxillary Sinusitis in AIDS Patients. Roel J. Hadderingh. Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. Manifestations pulmonaires Pulmonary Manifestations M.B.P.204 Nocardia Asteroides Infections in Patients with the Acquired Immunodeficiency Syndrome (AIDS). Lawrence A. Cone*, G. R. Polkinghorn, D. R. Woodard, A. Berk, M. Fiala, J. Lynch, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A. M.B.P.205 Prolonged Healing of Spontaneous Pneumothorax and Sclerotherapy in AIDS Patients. Susan J. Jacobson*, K. McGowan, R. Scheib, S. Schwaitzberg, C. Quinn, *Division of Geographic Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, MA, U.SA. M.B.P.206 Role of HIV Infection in Alteration of Pulmonary Function in Intravenous Heroin Addicts. Valeriano Foresti*, A. Villa, G. Guareschi, E. Parisio, N. M. Pediconi, *Fatebenefratelli Hospital, Milan, Italy. M.B.P.207 Pneumothoraces in Patients with AIDS. Kent Sepkowitz*, E. E. Telzak, M. Carrow, M. Dickmeyer, E. Bernard, J. M. W. Gold, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.SA. M.B.P.208 Spontaneous Pneumothorax in AIDS Patients on Prophylactic Aerosolized Pentamidine. Glenn S. Newsome*, D. J. Ward, P. F. Pierce, *Georgetown University Hospital, Washington, DC, U.SA. M.B.P.209 Fatal Adverse Reaction with Induced Sputum in Patients with Pleural Effusions. Mark R. Nelson*, D. E. Smith, D. Hawkins, B. G. Gazzard, *St. Stephen's Hospital, London, U.K. M.B.P.210 Lavage (BAL) and TransbronchialLung Biopsy (TBLB) from Patients with Advanced HIV Infection and Diffuse Pulmonary Infiltrates. Michael G. Rust*, M. Schneider, H. Kronenberger, S. Falk, E. B. Helm, J. Meier-Sydow, *Frankfurt University Hospital, Division of Pneumology, Department of Internal Medicine, Frankfurt, Federal Republic of Germany. M.B.P.211 Spectrum of Pulmonary Diseases Associated with the Acquired Immunodeficiency Syndrome. Thomas Weinke*, W. Scherer, C. Ortmann, H.-D. Pohle, Federal Republic of Germany. M.B.P.212 Fiberoptic Bronchoscopic Diagnosis of Pulmonary Disease in 171 HIV-infected Patients. Francisco J. Aspa Marco*, M. B. Padilla Ortega, I. Garcia Polo, M. Sanz, N. Baena Mendo, M. L. Jimenez Spain. 183 [Page 184](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/186) M.B.P.213 Early Detection of Pulmonary Complications in AIDS Patients: Value of Lung Function Tests (LFT) and Nuclear Medicine Procedures (NMP). Christine Armbruster*, N. Vetter, Kbhn, *2nd Medical Department, Pulmogisches Zentrum, Vienna, Austria. M.B.P.214 Valuation of the Cellular Populations in the Bronchalveolar Lavage (BAL) from HIV-Infected Patients with Pneumonitis by Various Ethiology. Francisco I. AsPaMarco*, C. Jimenez, C. Lopez Elzaurdia, M. Padilla Ortega, Noguerado, M. L. G.I., Liver/Hepatitis and Other Manifestations Chronic HBsAg Positive Hepatitis in HIV Infection. Antonietta Cargar*, P. Vigan3, Gubertini, P. Meraviglia, M. A. N. Zanchetta, *2nd Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy. M.B.P.216 Chronic Hepatitis in HIV Infected Patients. Francesco Caredda*, A. d'Arminio Monforte, S. Antinori, G. C. Parravicini, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. M.B.P.217 Reactivation of Acute Hepatitis B in AIDS. Roberto Luzzati*, G. Di Perri, M. Malena, E. Rossi, P. of Verona, CivilHospital, Italy. M.B.P.218 HIV Infection and Delta Hepatitis in Intravenous Drug Addicts. G. Lake-Bakaar*, K. Bhat, S. Govindarajan, *SUNY Health Science Center, Brooklyn, NY, U.S.A. M.B.P.219 Correlation between HIV and HBV Infections. Alessandro Sinicco*, M. Valle, A. Santoro, C. Cariti, *Institute Infectious Savoia\" Hospital, University of Turin, Italy. M.B.P.220 Modulation of Viral Hepatitis in HIV-1 Infection. Siegbert Rossol*, R. Voth, K. H. Meyer zum Biischenfelde, G. Hess, *University of Mainz, 1st Medical Clinic, Mainz, Federal Republic of Germany. M.B.P.221 Influence of HIV Infection in Hepatitis Delta Chronic Carriers. Inmaculada Castillo*, J. Bartolomd, M. F. Marttnez, Jimdnez D(az, Madrid, Spain. M.B.P.222 The Effect of HIV on Chronic Hepatitis B: A Study of 150 Homosexual Men. Neil I. Bodsworth*, B. J. Donovan, *Department of Public Health, University of Sydney, Sydney, Australia. M.B.P.223 Liver Disease in Patients with AIDS. Carlos Eduardo Brandao-Mello*, M. A. Silva, M. B. Correa Lima, C. A. Basilio de Oliveira, A. L. Gonzaga, *Hospital Gaffrde e Guinle, Universidade do Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.224 The Interaction of HIV and Hepatitis B Vaccination in a Cohort of Homosexual and Bisexual Men. Susan P. Buchbinder*, N. A. Hessol, A. R. Lifson, P. M. O'Malley, G. W. Rutherford, S. C. Hadler et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A. 184 [Page 185](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/187) M.B.P.225 Toxoplasmose oculaire L. Zazoun, P. Truchis, J. P. Coulaud, A. Paris, Toxoplasmose du SIDA. Mohamed Pelosse, L. Zazoun, B. Leport, *H6pital Claude Bernard, Paris, France. M.B.P.227 Ocular Involvement in Children with HIV Infection. Mirella Blini*, Orsola, in HIV Patients. Andrea Antinori*, A. Minnella, E. Pizzigallo, M.B.P.230 A Study of Retinal Cotton Wool Spots in HIV Patients. Enrica Tamburrini*, A. A Histologic Study. Dirce Bonfim de Lima*, R. Lana Braga Costa, O. Fernandes da Silva, E. Jurado da Silva, P. Moreira, *Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.232 Gastrointestinal Lymphoid Hyperplasia in AIDS. M. Paulli, of Infectious Diseases, Pavia, Italy. M.B.P.233 Pancreatitis Associated with HIV-1 Infection. Scott E. Dowell*, E. A. Holt, F. K. Murphy, *Johns Hopkins University, School of Public Health, Baltimore, MD, U.SA. M.B.P.234 The Value of Gastrointestinal Endoscopy for Strategy and Control of Therapy in Epidemic KS. Andreas Plettenberg*, Republic of Germany. M.B.P.235 Acute Pancreatitis in Patients with AIDS. Antonio Bernal*, G. Del Junco, D. Piot, E. Stool, Lusaka, Zambia: A Clinical, Microbiological, Histological and Functional Study. Christopher P. Conlon*, S. B. Lucas, N. P. Luo, A. H. Moody, A. J. Pinching, *St. Mary's Hospital Medical School, London, U.K. M.B.P.237 Acute Diarrhea in HIV+ Patients Associated with B. Hominis. Scott K. Morris*, S. Shaunak, E. G. Estevez, J. A. Bartlett, H. L. M. Grigsby, S. Barnes, B. Afessa, W. Frederick, *Howard University Hospital, Washington, DC, U.S.A. 185 [Page 186](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/188) M.B.P.239 Zidovudine Myopathy: A Prospective Study. Barry S. Peters*, G. Wilson, A. J. Pinching, *St. Mary's Hospital, London, U.K. M.B.P.240 Candida Esophagitis (CE) by (HIV). Bonaventura Clotet*, G. Sirera, J. Boix, M. Dominguez, A. Jou, J. Tor, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain. M.B.P.241 Gastrointestinal (GI) Structure and Mucosal Function in HIV Positive Patients. M. John Gill*, D. Church, L. Sutherland, W. Huang, J. Kelly, *University of Calgary, Departments of Microbiology, Infectious Diseases and Medicine, Calgary, AB, Canada. M.B.P.242 Relation between HIV Infection and Non-A, Non-B Hepatitis. Inmaculada Castillo*, M. Madrid, Hemophagocytic Histiocytosis in the Liver of an HIV-infected Former Drug User. David M. ovick*, R. Tempesta, R. J. Stenger, *Beth Israel York, NY, U.SA. M.B.P.244 Ulcerating Pharyngo-Oesophageal Leukoplakia in Advanced HIV Disease. Valerie S. Kitchen*, M. Helbert, N. Francis, R. Logan, F. Lewis, A. J. Pinching, et al., *Praed Street Clinic, St. Mary's Hospital, London, U.K. M.B.P.245 Spontaneous Resolution of Candida Esophagitis (CE) in a Seroconverting for Sirera, J. A. Jou, A. Ribera, Tural, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain. M.B.P.246 Detection of Hepatitis B Virus DNA in Peripheral Blood Mononuclear Cells from Asymptomatic Anti-HIV Carriers. Inmaculada Castillo*, J. Bartolomd, of the Gastrointestinal Tract in Patients with AIDS. Michael C. Bach*, D. A. Howell, A. J. Valenti, T. Smith, R. H. Dretler, D. L. Winslow, *Maine Medical Centre, Portland, ME, U.SA. Abnormalities in Sophie Matheron*, M. A. P. Detruchis, E. Oksenhendler, P. Dosquet, J. P. Clauvel, al., *Hdpital Bichat Claude Bernard, Paris, France. M.B.P.250 ftude prospective des anomalies de la coagulation chez 156 patients cons6cutifs s6ropositifs pour le VIH. Bruno C. Pesce, J. Bayle, 1, Nice, France. 186 [Page 187](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/189) M.B.P.251 Bone in AIDS Patients. V. Mondain, Department, Nice, France. M.B.P.253 Lupus-like Anticoagulant and Anticardiolipin Antibodies in Non Hospitalized HIV Infected Patients. Nathan Clumeck*, P. Capel, W. Feremans, M. Girard, A. Janssens, D. Vandevelde, et al., *Division of Infectious Diseases, St-Pierre University Hospital, Belgium. M.B.P.254 M.B.P.255 Abdominal Lymphadenopathy in 200 HIV Positive Patients. Ultrasound and Clinical Study. J.P. Cassuto*, A. Geoffray, P. Dujardin, HIV A Report. P. Baglioni, E. Ricchi, F. Tumietto, P. Costigliola, *Sezione \"L. e A. Seragnoli\", Bologna, Italy. M.B.P.257 Bone Marrow Findings in HIV-Infected Patients at Gaffr6e and Guinle University Hospital - University of Rio de Janeiro (UNI-RIO). Carlos Alberto Morais de Sd*, L. C. Brito Lyra, M. Campos de Magalhaes, C. Bastlio W. Eyer-Silva, F. S. Sion, *Gaffrde & Guinle Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.258 Bone Marrow Findings in 33 Multistaged HIV-Infected Patients. Lorenzo Minoli*, A. Patients. Thyge Lvnghi Nielsen*, R. Videbak, K. Lindvig, C. Pedersen, Department of Infectious Diseases, Hvidovre, Denmark. M.B.P.260 Neuromuscular Involvement in HIV Infection. Inmaculada Ocaiia*, A. De Luis, J. Montalbdn, J. M. Ferndndez, C. Cervera, J. M. Martinez Vdzquez, *Autonomous University Barcelona, Spain. 187 [Page 188](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/190) M.B.P.261 Rheumatic Symptomatology in Patients Infected with the Human Immunodeficiency Virus (HIV): Prevalence and Relationship to Clinical and Laboratory Variables. Leonard H. Calabrese*, A. Myers, D. Kelley, *Cleveland Clinic Foundation, Cleveland, OH, U.S.A. M.B.P.262 Joint, Bone and Muscle Lesions and HIV Infection. Ian F. Rowe*, S. M. Forster, M. S. Youle, D. A. Hawkins, A. G. Lawrence, M. H. Seifert, et al., *Department of Rheumatology, Westminster Hospital, London, U.K. M.B.P.263 Reduced Cortisol Production and Adrenal Necrosis in Patients with AIDS. David Salomao Lewi*, C. A. Accetturi, H. Sader, R. Kater, P. Motta, Paulista de Medicina, Sao Paulo, Brazil. M.B.P.264 Diabetes Insipidus as a Complication of Cerebral Toxoplasmosis in an AIDS Patient. Drago Stambuk*, S. Singh, B. Gazzard, *St. Stephen's Hospital, London, U.K. Deficiency Falkenbach*, S. Michels, E. Schifferdecker, P. H. Althoff, et al., *University Hospital Frankfurt, Department of Internal Medicine, Frankfurt, Federal Republic of Germany. M.B.P.266 Gonadal Hormone Levels and Testicular Histology in AIDS. Conceicao Accetturi*, D. S. Lewi, E. N. Arruda, A. Cedenho, J. G. Vieira, I. T. N. Verreschi, *Escola Paulista de Medicina, Sao Paulo, Brazil. M.B.P.267 HIV Glucocorticoid Resistance in Mononuclear Cells. Claudia Balotta*, M. Norbiato, M. Moroni, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. M.B.P.268 Assessment of Adrenal Function in AIDS Patients with Documented CMV Infection. Mary A. Young*, T. Taylor, P. Pierce, *Georgetown University Hospital, Division of Infectious Diseases, Washington, DC, U.S.A. M.B.P.269 Modifications in Circadian Rhythms of Plasma Levels H6pital Saint-Louis, AIDS. Albrecht Falkenbach*, S. Klauke, U. Unkelbach, W. Marz, H. F6rster, P. H. Althoff, et al., *University Hospital Frankfurt, Department of Internal Medicine, Frankfurt, Federal Republic of Germany. M.B.P.271 Hyporeninemic Hypoaldosteronism Associated with HIV-1 Positivity. Nathan Clumeck*, T. Bril, S. Harnie, S. De Wit, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium. M.B.P.272 Comparison of Thyroid Biochemical Abnormalities (TBA) in Acquired Immunodeficiency Syndrome (AIDS) and Other Illnesses. Nathan Clumeck*, P. Bourdoux, M. Bonnyns, *Division of Infectious Diseases, [Page 189](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/191) M.B.P.273 Myocarditis Intravenous Drug Abusers with and Acquired Immunodeficiency Syndrome: An Autopsy Study. James W. Roberts*, C. Francis, C. Navarro, J. Brown, W. El-Sadr, *Harlem Hospital Center, College ofPhysicians and Surgeons, Columbia University, New York, NY, U.S.A. M.B.P.274 The Pathology of the Male Genital Tract in AIDS. William J. Cronin*, M. Shevchuk, M. Da Silva, N. Armenakas, J. Fracchia, M. Tannenbaum, *Lenox Hill Hospital, Department of Pathology, New York, NY, U.S.A. M.B.P.275 Genitoanal Ulcers in HIV Infection. Falk R. Ochsendorf*, H. Sch6fer, R. Milbradt, *Klinikum der J. W. Goethe-Universitdt, Department of Dermatology, Frankfurt, Federal Republic of Germany. M.B.P.276 Need for Gynecologic Protocols in AIDS Primary Care Clinics. Carola Marte*, D. Ribble, C. Keyes, J. Wolbert, P. Rodgers, J. Kelly, *Bellevue Hospital Center, Community Health Project, New York, NY, U.S.A. M.B.P.277 Outcome of Patients with Human Immunodeficiency Virus (HIV) on Chronic Dialysis (D). M.D. Gurbindo Gutierrez*, R. Perez Garcia, J. Lufo, J. M. Lopez Gomez, A. Franco, F. Valderrabano, *Hospital General Gregorio Maraion, Madrid, Spain. M.B.P.278 Henoch-Schonlein Purpura IgA Glomerulonephritis Associated with HIV Infection. Ian L. Thompson*, D. Cooper, E. Savdie, J. Gold, R. Melville, *St. Vincent's Hospital, Sydney, Australia. M.B.P.279 Outcome of Kidney Transplanted Patients with HIV. Miguel Neto Cendoroglo*, C. A. P. Pereira, C. Stabile, A. C. A. Acetturi, Peixinho, *Escola Paulista de Medicina, Sao Paulo, Brazil. M.B.P.280 Lack of Clinical Evidence for a Glomerulopathy (GP) in 203 Patients with HIV Infection. Ulrike Brunkhorst*, R. Brunkhorst, B. Tschechne, G. Eisenbach, I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany. M.B.P.281 Nephropathy as the Initial Sign of AIDS. Luiz Paolo Jose Marques*, O. Santos, G. S. Lopes, A. V. Oliveira, F. Fialho, E. P. Madeira, *Universidade do Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.282 The Treatment of Infectious Causes of AIDS-associated Heart Disease. Evlin L. Kinne*, Reichert, C. Visser, A. Dunning, *Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. M.B.P.284 Characteristics of Patients with AIDS-associated Heart Disease but no FL, U.S.A. M.B.P.285 Left Ventricular Dysfunction in AIDS Patients with Severe Pneumocystis Carinii Infection. Robert D. Wood*, B. Akil, J. Tuchschmidt, R. S. Swinney, C. T. Boylen, *Los Angeles County, University of Southern California, Medical Center, Pulmonary Medicine, Los Angeles, CA, U.S.A. 189 [Page 190](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/192) M.B.P.286 Electrographic Changes in Patients Receiving Pentamidine for Treatment of Pneumocystosis. Bisher Akil*, A. Gonzalez, A. Bhandari, P. Sager, C. Leon, S. H. Rahimtoola, *University of Southern California, West Hollywood, CA, U.S.A. M.B.P.287 Staphylococcus Aureus Endocarditis in HIV+ and Sone, Fischl, M.B.P.288 Meeker, E. Feigal, B. Herndier, F. Khayam-Bashi, M. S. McGrath, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. M.B.P.289 Kaposi's Sarcoma in Patients with HIV Infection. Ahmed S. Lati*, S. Houston, P. Neill, M. Bassett, C. Thornton, J. Sitima, *Medical School, University ofZimbabwe, Harare, Zimbabwe. M.B.P.290 Lymphomas in Patients with HIV Infection. Carlos Del Rio*, J. Guarner, D. Carr, L. E. Hendrix, *Emory University School of Medicine, Crawford W. Long Hospital, Atlanta, GA, U.S.A. M.B.P.291 Kaposi's Sarcoma, Clinical Distribution, Opportunistic Infections and Survival. Carla Ismael*, R. G. Pacheco, M. G. Dias, W. A. Eyer-Silva, L. A. Miguez, C. A. Morais de Sd, *Gaffrde & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. M.B.P.292 Lower Genital Tract Neoplasia. Its Incidence in HIV Infected Women and the Role of Human Papilloma Virus (HPV) and Other Risk Factors. James R. Smith*, M. Byrne, M. Botcherby, P. Munday, D. Taylor-Robinson, S. M. Forster, *St. Mary's Hospital, The Praed Street Clinic, London, U.K. M.B.P.293 Malignant Neoplasms in Surgical Specimens of Different AIDS Risk Groups. Heidrun Rotterdam*, M. Vasquez, G. Sidhu, *New York University Medical Center, New York, NY, U.S.A. M.B.P.294 B-ALL in HIV-Positive 27 Y.O. Man. Pierluigi Oreste*, Cataldo, L. Gargantini, H. Mura, of Pathology, Cd Granda Hospital, Unusual Presentation and Clinico-pathological Correlations in Non-Hodgkin's Lymphomas (NHL) Association with HIV Infection. Eric Oksenhendler*, J. P. Farcet, G. Gisselbrecht, J. P. Clauvel, A. Thyss, M. Raphael, *H6pital Saint-Louis, France. M.B.P.296 Absence of Sarcoma in Wilson, F. Cleghorn, *Faculty ofMedical Sciences, The University of the West Indies, Port of Spain, Trinidad. M.B.P.297 Kaposi's Sarcoma (KS) in Women with Acquired Immunodeficiency Syndrome (AIDS). Tony W. Cheung*, F. Siegal, *Queens Hospital Center, Long Island Jewish Hospital Affiliation, Jamaica, NY, U.S.A. M.B.P.298 Lymphoblastic Leukemia in HIV-infected Patients. Lorenzo Minoli*, R. Pan, A. Malfitano, Shortened Survival in Patients with Kaposi's Sarcoma and HIV-1 Infection. Barbara Tschechne*, U. Brunkhorst, I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany. M.B.P.300 Treatment of Disseminated Mycobacterium Avium (MAI) J. A. McCutchan, et al., VCIMC, Orange, CA, U.SA. Programmes de soins Infirmiers: education Nursing Health Care Programmes: Education M.B.P.301 Patient Compliance and Termination in Community-based Clinical Trials of AIDS Treatment. Steohen P. Holzemer*, J. D. Seaman, *Community Research Initiative, New York, NY, U.S.A. M.B.P.302 Clinical Impact of Case Management by an Inpatient AIDS Clinical Nurse Specialist on Costs and Quality of Patient Care. Diane E. Schull. Parkland Memorial Hospital, Dallas, TX, U.S.A. M.B.P.303 The Role of Nursing in Managing Community-Based Research. S~l1phen P. Holzemer*, M. Tomita, J. Forrest, J. A. Bennett, P. B. Scherer, *Community Research Initiative, New York, NY, U.S.A. M.B.P.304 Nursing in the Community for People with IIV: Description of a Training/Implementation Programme. Gorm D. Kirsch*, H. Moore, R. Mayon-White, I. Klimes, *Oxford Regional Health Authority, Oxford, U.K. M.B.P.305 Projective Report about Self, Family, Environment and Discomfort Associated with Symptomatic Human Immunodeficiency Virus Infection in Children. Susan R. Carter*, P. Schwartz, T. Raburn, I. Hanson, *Clinical Research Center, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, U.S.A. M.B.P.306 Infection Control Nurse Role: Powerful Change Agent in Psychiatric Systems in the Era of AIDS. Sheila H. Dollard-Pavlis*, J. B. Gordon, *Connecticut Medical Health Center, Yale-New Haven Mental Center, New Haven, CT, U.S.A. M.B.P.307 HIV Self-assessment and Care Program. Tom E. Emanuele. Parkland Memorial Hospital AIDS Clinic, Dallas, TX, U.S.A. M.B.P.308 Outbreak of Norwegian Scabies among Health-Care Workers. Kellv*, C. Fry, *St. Stephen's London, U.K. M.B.P.309 Developing Community Nurses' Skills in HIV/AIDS Programmes. Thomas H. Snee*, B. Robottom, R. Pratt, C. Wills, J. Kuykendall, J. Newbury, *Department of Health, London, UX. M.B.P.310 Total Home Health Care for Patients with HIV Disease. Susan E. Carr*, A. J. Esposito, *Windsor Home Care Inc., New York, NY, U.SA. M.B.P.311 Interdisciplinary HIV Case Management Team. Tom E. Emanuek*, K. Joy, L. McMurtry, *Parkland Memorial Hospital AIDS Clinic, Dallas, TX, U.S.A. 191 [Page 192](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/194) M.B.P.312 A Description of NYC's Gay Population as a Legitimate Community, and Its Response to HIV Disease. Donald G. Smith*, M. Lyden, K. May, *Mount Sinai Medical Center, New York, NY, U.S.A. M.B.P.313 Los Angeles Pediatric AIDS Network (LAPAN): A County-Wide Model to Maximize Service Delivery for Children Diagnosed with HIV and Their Families. Marcy E. Kaplan*, D. C. Garell, *Los Angeles Pediatric AIDS Network, Children's Hospital of Los Angeles, Los Angeles, CA, U.SA. M.B.P.314 The Development of a Prenatal-Pediatric AIDS Liaison Service at a Municipal Hospital. Peter A. Laqueur*, L. Watts, L. Urcuyo, J. Tropnes, P. Grier, B. Abisogun, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.S.A. M.B.P.315 Comprehensive Care Program for Children with HIV-related Problems and Their Care Givers. Stanley E. Read*, S. M. King, C. Arneson, S. Palmer, R. Goldie, L. Szewczyk, et al., *Hospitalfor Sick Children, Toronto, ON, M.B.P.316 M.B.P.317 The Effectiveness and Feasibility of Hospital-based Support Group Intervention for Parents of HIV-Infected Children. Marcy E. Kaplan*, J. A. Church, K. T. Mitsuhata, *Los Angeles Pediatric AIDS Network, Children's Hospital of Los Angeles, Los Angeles, CA, U.S.A. M.B.P.318 HIV and Maternal Child Health: Expanding the Expertise among Providers. Marcia J. Quackenbush*, C. Pies, E. Melia, A. Horton, M. Schuyler, A. Mayes, *University of California AIDS Health Project, San Francisco, CA, U.SA. M.B.P.319 A Comparison of Health Care Delivered to People with AIDS and ARC by a Nurse Practitioner and a Physician: A Case Matched Retrospective Study. Jerry Wolbert*, P. Rodgers, C. Keyes, C. Marte, K. Smothers, *Bellevue Hospital Center, Community Health Project, AIDS Assessment Program, New York, NY, U.S.A. M.B.P.320 Survey of Tennessee Nurses' Attitudes toward AIDS. Regina L. Monnia*, V. Harris, *Meharry Medical College, Nashville, TE, U.SA. M.B.P.321 Gay Grief in the Context of AIDS. Hildur Helgadottir, University of Calgary, Calgary, AB, Canada. M.B.P.322 Provider Education: The Effect of AIDS Inservice Training on Nursing Staff in a Psychiatric Setting. Jonathan Jacobs*, P. Reid, *New York Hospital, Center for Special Studies, New York, NY, U.S.A. 192 [Page 193](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/195) Therapie and Hepatic Disorders. Hdldne Sauvageon-Martre*, F. Bannie, I. Tabah, B. Oksenhendler, et al., *H6tel-Dieu, Pharmacie, Laboratoire de pharmacologie, Paris, France. M.B.P.324 Evaluation of Less Frequent Dosing in Children with Symptomatic HIV Infection. Carlo Giaquinto*, A. Terragna, A. Plebani, P. Tovo, A. De Rossi, P. Dowd, et al., *Department of Pediatrics, University of Padua, Padua, Italy. M.B.P.325 Cyanocobalamin (Vitamin B 12) Supplementation Does not Prevent the Hematologic Toxicity of Azidothymidine (AZT). J. Allen McCutchan*, C. Ballard, B. Freeman, A. Bartok, D. Richman, *University of California, San Diego Medical Center, San Diego, CA, U.S.A. M.B.P.326 Investigation of HIV Positive Patients with Gastrointestinal Symptomatology. Bary S. Peters*, N. Francis, A. W. Boylston, J. R. W. Harris, A. J. Pinching, *St. Mary's Hospital, London, U.K. M.B.P.327 Non Conclusive Results in HIV Western Blot Analysis of Mozambican Sera. Cesar A. D. Palha de Sousa*, J. A. X. Barreto, F. V. De La Cruz, L. Barquet, *Immunology Laboratory, National Health Institute, Maputo, Mozambique. M.B.P.328 A Study of the Safety and Efficacy of Recombinant Human Erythropoietin (r-HuEPO) in AIDS Patients with Anemia Induced by Zidovudine (Retrovir, AZT). Jennifer E. Thompkins*, R. Abels, J. E. Galpin, T. J. Turpen, *Porton Medical Group of Sherman Oaks, Sherman Oaks, CA, U.S.A. M.B.P.329 Myopathy Associated with Long-Term Zidovudine Therapy. Margaret A. Fischl*, Gagnon, R. Uttamchandani, J. Patrone-Reese, L. Dearmas, S. Tarras, et al., * University of Miami School ofMedicine, Miami, FL, U.S.A. M.B.P.330 HIV Associated Myopathy: Features in 21 Patients and Role of AZT. David M. Simpson*, D. Wolfe, J. Farraye, A. Bender, *Mount Sinai Medical Center, New York, NY, U.S.A. M.B.P.331 Serum Level and Serum Kinetic of Zidovudine: Investigation with a Radioimmunoassay (RIA). Stefan K6ppen*, B. Ruf, J. Pannhorst, H.-D. Pohle, *2nd Department of Internal Medicine, Rudolf Virchow University Hospital, Berlin, Federal Republic of Germany. M.B.P.332 Pharmacokinetics (PK) of Zidovudine (ZDV) in Adult Patients with HIV Infection and Hepatic Disease (HD). Teresa Tartaglione*, K. Opheim, C. Van der Horst, R. Raasch, S. Cheeseman, K. High, et al., *Harborview Medical Center, Seattle, WA, U.S.A. M.B.P.333 Assessment by PCR of HIV-1 Activity in AIDS-KS Patients Treated with Recombinant Interferon Alpha (r-IFNa). Jay Epstein*, I. K. Hewlett, J. Metcalfe, C. Hawthorne, H. C. Lane, *Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, U.S.A. 193 [Page 194](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/196) M.B.P.334 Bayesian Estimation of the Pharmacokinetic Parameters of Chronic Zidovudine (ZDV) Therapy in HIV Infected Patients. Janice Y. Ta*, B. J. Guglielmo, H. Hollander, H. K. Mohammad, *University of California at San Francisco, Division of Clinical Pharmacy, San Francisco, CA, U.S.A. M.B.P.335 Effect of Zidovudine with Phase I and II Metabolism in the Liver. N.H. Brockmeyer*, L. Mertins, M. Goos, *Department of Dermatology, University of Essen, Essen, Federal Republic of Germany. M.B.P.336 Zidovudine Levels in AIDS and ARC: Virologic Lazzarin*, M. T. Reale, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. M.B.P.337 A Preliminary Study of Serum AZT Levels in HIV-Infected Individuals. Erika Steff*, N. M. Flynn, J. King, K. Batra, T. Tonjes, A. Winship, et al., *University of California at Davis, Sacramento, CA, U.S.A. M.B.P.338 Interactive Pharmacokinetics of Zidovudine and Acetaminophen. George J. Pazin*, R. J. Ptachcinski, M. Sheehan, M. Ho, *University of Pittsburgh, School of Medicine and Graduate School of Public Health, Pittsburgh, PA, U.S.A. M.B.P.339 A Sensitive and Specific HPLC Method for the Determination of Zidovudine and Zidovudine Glucuronide in Plasma and Urine. Mohsen A. Hedaa*, R. J. Sawchuk, *University of Minnesota, Department of Pharmaceutics, Minneapolis, MN, U.S.A. M.B.P.340 Pharmacokinetics of AZT among HIV-infected Y. Lige, Liege, Belgium. Molecular Interaction of Recombinant 1 Interferon and Zidovudine (AZT): Alterations of AZT Phamacokinetics in HIV-infected Patients. Mostafa A. Nokta*, J. P. Loh, S. M. Douidar, E. A. Ahmed, R. B. Pollard, W. R. Snodgrass, *The University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX, U.S.A. M.B.P.342 Intravenous and Oral Pharmacokinetics of Zidovudine in Hemophilia Patients with Human Immunodeficiency Virus Infection. Gene D. Morse*, J. Olson, A. Portmore, C. Taylor, C. Plank, R. Reichman, *State University of New York at Buffalo, Department of Pharmacy, Buffalo, NY, U.S.A. M.B.P.343 Pharmacokinetics of Zidovudine and p24 Ag Time Course in 48 ARC Patients Under Steady-State Conditions. Bertrand Diquet*, F. Simon, L. Ory-Lavollde, F. Brun-V6zinet, J. N. Colin, Groupe Vigie, et al., *H6pital de la Salpetrigre, Paris, France. M.B.P.344 Pharmacokinetics of Zidovudine (AZT) and Its Glucuronide (G. AZT) in Healthy Subjects and in Uremic Patients: Influence of Hemodialysis. Eric Singlas*, J. C. Pioger, A. M. Taburet, J. N. Colin, J. P. Fillastre, Radioimmunoassay (RIA) High Performance Liquid Chromatography (HPLC) Methods for Serum Zidovudine (AZT) N. Blynn, T. Tonjas, *University of California at Davis Medical Center, Department of Pathology, Sacramento, CA, U.S.A. Th6rapie et evaluation clinique: marqueurs de I'6volution en cours de th6raple Therapy and Clinical Evaluation: Markers of Evolution during Therapy M.B.P.346 The Enumeration of Peripheral Blood HIV-antibody Secreting Cells as a Monitor of the Activity of Antiviral Drugs. Andre J. Nahmias*, F. Lee, S. Nesheim, S. Lowery, A. Smith, S. Thompson, *Emory University School of Medicine, Atlanta, GA, U.S.A. M.B.P.347 evaluation des lymphocytes actives et des Marvse U13, Paris, France. M.B.P.348 Relevance of Antigenemia in AIDS Patients Treated with AZT. Marie-Christine Dazza*, E. Dournon, S. Matheron, et al., *H6pital Bichat Claude Bernard, Paris, France. M.B.P.349 Clinical and Laboratory Effects of AZT in HIV Positive Men Compared to a Concurrent Control Group. Mary M. Fanning*, K. Johnson, J. Osachoff, J. Montaner, R. Coates, J. Ruedy et al., *Toronto General Hospital, Toronto, ON, Canada. M.B.P.350 Chez le patient, une fraction seulement de M.B.P.351 of in Subjects Receiving Zidovudine. Adriano Cinque, O. Varnier, T. Bini, R. Terzi, *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. M.B.P.352 Disease Progression despite Antigen Decline during Zidovudine Treatment of Asymptomatic HIV-infected Subjects: Need for Placebo Controlled Trials. Joep M. A. Lane*, J. Mulder, F. De Wolf, R. Coutinho, J. Goudsmit, *Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. M.B.P.353 Follow-up of In-vitro Immunologic Parameters and Interferon Production during Long-term Zidovudine Treatment in HIV-positive Patients. Alberto Bilino*, A. Pugliese, B. Forno, A. M. M. Busso, M. Sciandra, et al., *University of Turin, Institute of Infectious Diseases, Turin, Italy. M.B.P.354 AZT Treatment Induces a Decrease of Soluble Interleukin 2 Receptor (SIL-2R) but not of Soluble CD8 Antigen (SCD8) Serum Levels in HIV Infected Patients. Massimo C. Italy. 195 [Page 196](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/198) M.B.P.355 AZT Therapy is Associated with an Increased Capacity of PHA-stimulated Cells to Express IL-2 Receptors (IL-2R). Deborah McMahon*, A. Winkelstein, H. Hawk, J. A. Armstrong, G. J. Pazin, M. Ho, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. M.B.P.356 Predictive Value of CD8 Cell Count in Morbidity and Mortality among AIDS and ARC Patients (P) Treated with Zidovudine (AZT). Stp.hane De Wit*, M. G6rard, B. Sommereijns, N. Clumeck, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium. M.B.P.357 Quantitative Dosage of Core Antibodies is a Better Prognostic Marker than HIV Antigen Assay. Corinne A. Magnani, F. Fiaccadori, E. Parma, Parma, Italy. M.B.P.359 Effect of AZT Cessation on Levels of Antibodies Participant in Antibody-Dependent Cell Cytotoxicty (ADCC) Reactions. General Hospital, Montreal, Canada. of Azidothymidine (AZT) on Neopterin, Beta-2-Microglobulin, Soluble CD8, Soluble Interleukin-2 Receptor, Tumor Necrosis Factor and HIV p24 Antigen Levels in Patients with AIDS Related Complex and AIDS. Mohan M. Reddv*, G. McKinley, A. Englard, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. M.B.P.361 Serologic HIV Ag Levels and AZT Therapy inDrug Addicts. Antonietta Caranel*, P. Meraviglia, A. N. Zanchetta, *2nd Department of Infectious Diseases, L. Sacco Hospital, Milan, Italy. M.B.P.362 Effect of Zidovudine on Hepatitis B Virus (HBV) Replication in Patients with Chronic HIV and HBV Infections. Gilles Pialoux*, M. Girard, P. a Woman and Regrowth of Hair after Zidovudine Therapy (A Case Report). Pietro Braun-Falco, *Dermatological Department of Federal Republic of Treatment of Advanced AIDS-Related Kaposi's with 112 Patients from One Institution. Pak5s SjGll*, A. M. Levine, M. Bernstein-Singer, B. Espina, M. Rarick, * University of Southern California at Los Angeles, Los Angeles, U.S~A. M.B.P.367 Bone Marrow Changes in HIV-1 Positive Asymptomatic Patients on Zidovudine. Mar M.gnnin*\", K. Gelmon, J. et a!., *Toronto General Hospital, Toronto, ON, Canada. M.B.P.368 Evaluation of the Association of Zidovudine (Z) and Vinbiastine (V) in the Treatment of infectieuses, Hdpital Rothschild, Paris, France. M.B.P.369 Results after 18 Months of Treatment with Zidovudine. Maria-Jos6 MelladQ.*, M. J. Cilleruelo, Carlos Servicio de Pediatria, Madrid, Spain. M.B.P.370 Viral Antigen (HIV-Ag) Evolution in AIDS and ARC Patients with Zidovudine Treatment. Maria-Eulalia Valencia*, R. M. Zapico, V. Pintado, J. M. L. Dupla, M. P. Lavilla, A. Gil, *Hospital La Paz, Madrid, Spain. Additlonnels Addi ti onal M.B.P.371 Bacteremia in Patients with Human Immunodeficiency Virus. Jean Chw* I. Luten, G. Thomas, N. Garcia, C. Ugokwe, A. Gupta, *Lincoln Hospital, New York Medical College, Department of Pediatrics, Bronx, NY, U.S~A M.B.P.372 Pulmonary Tuberculosis and HlV Disease in Infants and Children. ALde N. A. Male~k*, K. Mukelabai, N. P. Luo, * University Teaching Hospital, Lusaka, Zambia. M.B.P.373 HIV Infection and Tuberculosis in Mozambique. Torge A. X. Barreto*, C. Paiha de Soissa, M. Djedje, L. Parkkali, L. F. De La Cruz, F. Neves, et. a!., *National Health Institute, Immunology Laboratory, Tuberculosis Control Programme, Map uto, Mozambique. M.B.P.374 High Case Rate of Extrapulmonary and Pulmonary Tuberculosis AIDS and Pneumocystis Carinii Pneumonia (PCP). PalM Sla* H. M. Krumholz, I. B. Tager, *VA Medical Center, University of Cal Wornia at San Francisco, San Francisco, CA. U.S~A. M.B.P.376 Results of a Consensus Panel on Process of Care for Patients with Pneumocystis Carinii Pneumonia (PCP). Charles L. Bennett*, W. C. Mathews, J. Kosecoff, D. Kanouse, *RN Corp., University of California at Los Angeles, Center for Health Policy Study, Santa Monica, CA, U.S.A. 197 [Page 198](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/200) M.B.P.377 Splenic Pneumocystosis. Junco, E. W. Stool, J. R. Trujillo, *Park Plaza Hospital, Houston, TX, U.S.A. in a Patient Receiving Aerosolized Pentamidine Prophylaxis. Douglas J. Ward, George Washington University Hospital, Washington, DC, U.S.A. M.B.P.379 Pneumocystis Carinii Choroiditis. Dennis M. Causey*, N. A. Rao, P. L. Zimmerman, *University of Southern California, Los Angeles, CA, U.S.A. M.B.P.380 Incidence of Pneumocystis Carinii Pneumonia (PCP) in Men Infected with Human Immunodeficiency Virus-1 (HIV-1). John P. Phair*, A. Munoz, R. Detels, C. Rinaldo, A. Saah, *Northwestern University Medical School, Chicago, IL, U.S.A. M.B.P.381 Psychiatric Morbidity in HIV Infected Individuals in India. K.S.Jacob*, H. Moses, J. K. John, T. J. John, *Department of Psychiatry, Christian Medical College, Vellore, India. M.B.P.382 Prevalence and Course of Psychiatric Disturbances Associated with HIV Infection (CDC Categories IH-IV). Frans M. van den Boom*, H. Sno, J. Storosum, *Netherlands Institute of Mental Health, Utrecht, Netherlands. M.B.P.383 Diagnosis of Depression in HIV-Infected Individuals. Barry A. Hong*, J. Rice, D. Brookshire, P. Guedet, *Washington University School of Medicine, St. Louis, MO, U.SA. M.B.P.384 Pr6valence des troubles psychiatriques parmi les Zamperetti*, 5 juin C June 5 Recherche fondamentalebiom&dicale) Basic Research (Biomedical) Session d'affichage Poster Session Mise au point de m6dicaments et vaccins Drug Development and Vaccines M.C.P.1 Differential Viral Gene Expressions and Their Effect on the Biological Properties of Clones of an HIV-1 Infected Cell Line. V. S. Kalvanaraman*, V. Rodriguez, S. Joseph, R. C. Gallo, M. G. Sarnagadharan, *Bionetics Research, Inc., Rockville, MD, U.S.A. M.C.P.2 Protective Vaccine against Feline Leukemia Virus Using a Recombinant Antigen. Charlotte R. Kensil*, G. A. Beltz, C.-H. Hung, A. Aubert, D. J. Marciani, *Cambridge Bioscience Corp., Worcester, MA, U.S.A. M.C.P.3 Clinical Evaluation of Experimental AIDS Vaccines. Wayne C. Koff*, S. L. Wescott, J. Novak, D. Stablein, B. Fernie, J. Gerin, *Vaccine Research and Development Branch, National Institutes ofHealth, Rockville, MD, U.SA. M.C.P.4 Humoral and Cellular Immune Response to Recombinant HIV-Hepatitis B Surface Antigen Particles. Maryline Mancini*, M. L. Michel, G. Vogt, Y. Hinin, Y. Rividre, D. Dormont, et al., *UREG, Institut Pasteur, Paris, France. M.C.P.5 Production and Characterization of Human-Mouse Chimeric Monoclonal Antibody (CB1) Against HIV. Shuzo Matsushita*, Y. Maeda, S. Tokiyoshi, Y. Hattori, K. Takatsuki, et al., *Kumamoto University Medical School, Second Division of Internal Medicine, Kumamoto, Japan. M.C.P.6 Mapping the Neutralizing Epitope of HIV-1 Envelope Protein. Kashi Javaherian*, K. Ross, A. Profy, A. Langlois, T. Matthews, S. Putney, et al., *Repligen Corp., Cambridge, MA, U.S.A. M.C.P.7 In Vivo Immunization against HIV Proteins Using gag Synthetic Peptides: Preliminary Results. Bruno Vaslin*, J. M. Claverie, F. Vaccine Demonstrate gpl60-Specific Lymphocyte Proliferation Prior to Western Blot Reactivity. Michael C. Keefer*, W. Bonnez, J. Roberts, R. Dolin, R. C. Reichman, *University of Rochester School of Medicine, Infectious Diseases Unit, Rochester, NY, U.S.A. M.C.P.9 200 [Page 201](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/203) M.C.P.1O B. Morein, *Swedish Universily of Agriculture Science, Department of Microbiology, Section of Virology, Uppsala, Sweden. M.C.P.11 Clinical and Virologic Response to a Recombinant Vaccinia HIV-1 gpl6O Vaccine (HIVAC-le). Ann C. Collier*, S. L. Hu, R. Coombs, D. Arditti, L. Corey, * University of Washington, Harborview Medical Center, Seattle, WA, U.S~A. M.C.P.12 Kinetics, Magnitude and Duration of Antibody Responses in rgp 160 Vaccinees. LULLi Gazzzj*n, K. Midthun, B. Clayman, R. Viscidi, NIAID, AIDS Vaccine Evaluation Group, *Johns Hopkins University, Baltimore, MD, U.S~A. M.C.P.13 Evaluation of a Synthetic mIv-i p17-Based Candidate AIDS Vaccine, HGP-30. Allan L. Goldstein*, P. H. Naylor, J. E. Kirkley, C. W. Naylor, C. J. Gibbs, P. S. Sarin, *George Washington University, DC, Cellular Immunity HLV-1 rgpl6O Vaccinees. Karen MidLtwzL*, L. Garrison, K. Gershman, M. L. Clements, G. Smith, W. Adler, *FJohns Hopkins University, Baltimore, MD, U.S~A. M.C.P.15 Expression of Recombinant Particles which Display to the HBV/HBc Anign f*iS G. B. Thornton, A. M. Moriarty, D. Milich, *R. W. Johnson Pharmaceutical Research Institute, San Diego, CA, U.S~A. M.C.P.1L6 Recombinant Vaccinia Viruses that Coexpress my or gag-Encoded Proteins Produce Retroviral Qenwis Ruthann M. Hesselton*, R. Koup, D. Panicali, G. Mazzara, E. Day, J. Sullivan, * University of Massachusetts Medical School, Department of Pediatrics, Worcester, MA, U.S~A. M.C.P.18 Hypericin: Efficacy of a New Agent against HIV In Vitro. Fred Valentine*, D. Meruelo, V. Itri, G. Lavie, *Department of Medicine, New York University Medical Center, New York, U.S~A. M.C.P.19 Functional Antibody Response in Persons Immunized with B aculovirus-D~erived gpl6O. Barney S. Graham*, J. Rowland, E. Robinson, D. Montefiori, W. Mitchell, P. Wright, et al., *Vanderbilt University, Division of Infectious Diseases, Nashville, TN, U.S~A. M.C.P.20 lILA-DR Peptide Inhibits Ulrich, H. Atassi, M. Medicine, Houston, TX, U.S~A. M.C.P.21 Recombinant Adenovirus Induces Antibody Response to lIly gag in Mice. KYenneth L. Rosenthal*, F. L. G'raham, L. A. Prevec, *McMaster University Health Sciences Centre, Hamilton, ON, Canada. 201 [Page 202](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/204) M.C.P.22 Human T-Cell Clones Define Distinct Epitopes within the V3 Region of HIV-1 gpl20. Kent J. Weinhold*, S. D. Stanley, K. Javaherian, C. Scott, S. Putney, D. P. Bolognesi, *Duke University Medical Center, Durham, NC, U.SA. M.C.P.23 Plaque Reduction Assay to Detect HIV Neutralizing Antibodies in Sera from Human Vaccinees. Terry W. Fenger*, R. Belshe, T. Seaman, *Marshall University School of Medicine, Huntington, OH, U.S.A. M.C.P.24 Quantitative Assessment of Sera Inhibition of HI/Receptor Binding. Janis V. Giorji*, P. G. Nishanin, D. D. Ho, I. Schmid, *University of California at Los Angeles, School of Medicine, Department of Microbiology and Immunology, Los Angeles, CA, U.S.A. M.C.P.25 Cross Reactivity of Goat Sera Generated against Five HIV-Derived Recombinants Synthetic Javaherian, J. Rusche, *E. I. Dupont de Nemours & Co. Inc., Medical Products Department, Wilmington, DE, U.S.A. M.C.P.26 Immunogenicity of HIV-env Glycoproteins Is Dependent on Virology, National Veterinary Institute, Uppsala, Sweden. M.C.P.27 SIV Vaccine Development Surveillance. Alan M. Schultz*, M. Glass, * Vaccine Research and Development Branch, AIDS Program, NIAID, National Institutes of Health, Rockville, MD, U.S.A. M.C.P.28 Zairian HIV-1 Variable and Hypervariable Envelope Fragments. Gdrard Agius*, Snart, V. Kolesnitchenko, Marie Curie, Physiologie cellulaire, Paris, France. M.C.P.29 Comparison of Immune Responses in Mice Immunized with Native HIV-2 Envelope Glycoprotein or Corresponding Immunosome. of the HIV gp 160 Envelope Glycoprotein Recognized by Class I, MHC Immunized Humans. Ammar Achour*, Fossati, R. Gallo, D. Zagury, * Universitd Pierre et Marie Curie, Paris, France. M.C.P.31 Mapping of T- and B-Cell M. Sabatier, B. Guy, M. E. Bahraoui, et al., *H6pital de la Pitid-Salp'triere, CERVI, Paris, France. M.C.P.32 Demographic Characteristics and Frequency of Exclusionary Criteria in a Population Volunteering for HIV Immunization. T. Ulf Westblom*, R. B. Belshe, G. J. Gorse, E. L. Anderson, C. F. Berry, NIAID, AIDS Vaccine Program, *Marshall University School of Medicine, Department of Medicine, Huntington, OH, U.S.A. M.C.P.33 An Automated Microtiter Test System for the Detection of HIV-1 and HIV-2 Neutralizing Antibodies. Germany. 202 [Page 203](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/205) M.C.P.34 Novel Approach to Purification of HIV p24 Protein by Cleavage from Hybrid Ty Virus-like Particles. Jacqueline E. M. Gilmour*, N. R. Burns, S. M. Kingsman, A. J. Kingsman, S. E. Adams, *British Bio-Technology Limited, Oxford, U.K. M.C.P.35 HIV Vaccine Design: Exploitation of Ty Virus-like Particles. Mark Richardson*, S. E. Adams, J. M. Griffiths, N. R. Burns, J. M. Senior, A. J. Kingsman, *British Bio-Technology Limited, Oxford, U.K. M.C.P.36 Rhesus Monkeys Immunized with Recombinant Vaccinia Viruses Containing HIV-1 Envelope Genes Develop Antibodies Reactive with Envelope of Divergent HIV-1 Strains. Alec E. Wittek*, M. A. Wells, R. M. Hendry, E. W. Carrow, B. Moss, G. V. Quinnan, Jr. et al., *Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A. M.C.P.37 Salivary Antibodies to HIV in an AIDS Vaccine Trial. David W.Archibald*, C. Amrheim, D. Sun, C. Tacket, *University of Maryland at Baltimore, Baltimore, MD, U.S.A. M.C.P.38 Retention of Purified HIV-1 gp 120 by Alhydrogel. Julian W. Bess. Jr.*, S. W. Pyle, J. E. Drummond, L. O. Arthur, *NCI, Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A. M.C.P.39 Replication of HIV under Single Growth Cycle Conditions: A Model for Studying the Effect of Antiviral Drugs. Ferdinando Dianzani*, G. Antonelli, M. R. Capobianchi, P. Amicucci, P. Di Marco, O. Turriziani, *La Sapienza University, Institute of Virology, Rome, Italy. M.C.P.40 Induction of Antibody to HIV-1 Envelope Proteins by p24 Core T Epitopes. Anthony R. M. Coates*, D. Y. Sia, P. Mascagni, G. K. Toth, L. R. Haaheim, W. A. Gibbons, *London Hospital Medical College, Department ofMedical Microbiology, London, U.K. M.C.P.41 T Cell Epitopes in a Chemically Synthesized 104-MER Core Protein (p24) of Human Immunodeficiency Virus (HIV-1). Dwo Yuan Sia*, P. Mascagni, G. K. Toth, W. A. Gibbons, A. R. M. Coates, *London Hospital Medical College, Department of Medical Microbiology, London, U.K. M.C.P.42 M.C.P.43 Low Response Rates to Hepatitis B Vaccine in Inactive Drug Addicts. Mariagrazia Rumi*, R. Romeo, S. Sampietro, D. Mari, E. Tanzi, M. Colombo, *Institute of Internal Medicine, Milan, Italy. M.C.P.44 Immune Response of Rabbits and Chimpanzees to Inactivated Whole Virus Concentrates of HIV-1. Jens-Peter Gregersen*, P. N. Fultz, J. F. Lemp, J. Hilfenhaus, *Behringwerke AG, Marburg, Federal Republic of Germany. M.C.P.45 Study Design Issues in SIV Vaccine Trials. Susan S. Ellenberg*, D. R. Spriggs, *Biostatistics Research Branch, AIDS Program, Rockville, MD, U.S.A. M.C.P.46 Plus Primaquine Is Effective for Prophylaxis of Pneumocystis Carinii Pneumonia in Rats. James W. Smith*, M. S. Bartlett, M. M. Durkin, T. P. Glancy, S. F. Queener, *Indiana University, Indianapolis, IN, U.S.A. 203 [Page 204](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/206) M.C.P.47 Generation and Analysis of Recombinant Vaccinia Viruses that Express SIV Polypeptides. Dennis L. Panicali*, V. Stallard, G. P. Mazzara, M. D. Daniel, R. Desrosiers, A. Destree, et al., *Applied bioTechnology Inc., Cambridge, MA, U.SA. M.C.P.48 The Search for a Candidate Vaccine against AIDS: Progress Report II. Daniel Zagurv*, O. Picard, J. Bernard, J. J. Salau~n, Z. Lurhuma, R. C. Gallo, *Universitd Pierre et Marie Curie, Paris, France. M.C.P.49 Inhibition of De Novo HIV Infection in Monocyte/Macrophages by Agents which Block the Binding of HIV-1 gpl20 to CD4. Carlo-Federico Perno*, R. Yarchoan, S. Broder, *National Cancer Institute, Bethesda, MD, U.S.A. M.C.P.50 Use of Nucleic Acid Hybridization for HIV Susceptibility Testing. Stuart H. Cohen*, D. R. Scholl, V. Bolton, M. Loeffelhoelz, M. Jennings, J. R. Carlson, *University of California at Davis, Sacramento, CA, U.S.A. M.C.P.51 HeLa Cells Stably Expressing HIV env and tat as Tools for Studying Structure, Function and Candidate Inhibitors of These Key HIV Gene Products. Ruth M. Ruprecht*, M. A. Gama-Sosa, R. DeGasperi, F. Fazely, *Dana-Farber Cancer Institute, Boston, MA, U.S.A. M.C.P.52 Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythtopoietin (r-HuePO) May Abrogate the Neutropenia and Anemia of AIDS and May Allow for Resumption of Zidovudine (AZT) in Patients with AIDS. Steven A. Miles*, R. T. Mitsuyasu, S. McCarthy, K. Alton, L. Souza, J. Glaspy, et al., *University of California at Los Angeles, AIDS Center, CHS, Los Angeles, CA, U.S.A. M.C.P.53 Use of AZT as a Chemopreventive Agent: Efficacy and Toxicity in Murine Retrovirus Infections. John A. Bilello*, C. MacAuley, R. A. Yetter, J. L. Eiseman, T. Frederickson, S. Shapiro, et al., *VA Medical Center Research Service, Baltimore, MD, U.SA. M.C.P.54 Phosphorylation of 3'-Azido-2'3'-Dideoxyuridine, 3'-Azido-3'-Deoxythymidine, and Thymidine in HIV-1 Infected CEM Cells. Bertil F. H. Eriksson*, B. J. Oswald, J. P. Sommadossi, C. K. Chu, G. Williams, R. F. Schinazi, *Veterans Administration Medical Center, MedicalResearch, Decatur, GA, of Dehydroepiandrosterone (DHEA) in Lymphocytes and Macrophages Infected with HIV-1. Raymond F. Schinazi*, B. F. H. Erikson, B. Arnold, P. Lekas, M. S. McGrath, *Veterans Administration Medical Center, Medical Research, Decatur, GA, U.SA. M.C.P.56 Role of Fc Receptors in the Binding of HIV to Monocytes. Guerrero Loyda Melgndez*, J. Nicholson, S. McDougal, C. Dawson, *Emory University, Pathology Department, Atlanta, GA, U.S.A. M.C.P.57 Ocular Diffusion of DHPG After Systematic Administration: Animal Study and Application to a Clinical Case. H*lene Sauvageon-Martre*, F. Chast, F. Johnston*, N. Sarver, J. McGowen, *MIDS Program, National Institute of Allergy and Infectious Diseases, Rockville, MD, U.SA. M.C.P.59 Impact on AIDS Clinical Trials of the Use of Non Approved Therapies. Bernard Bihari*, *SUNY/Health Science Center at Brooklyn, Kings County Addictive Disease Hospital, Brooklyn, NY, U.SA. M.C.P.60 Preliminary Results from an On-going Prospective Evaluation of the Treatment Gathe, Jr., E. W. Stool, K. L. Redding, *Foscarrnet Research Project, Park Plaza Hospital, Houston, TX, U.S~A. M.C.P.61 Shortening the Research and Development Time for New AIDS Drugs: The Pre-IND Program and Proactive Clinical Guidance at FDA's Division of Antiviral Drugs. Elie &.Co~r, P. C. Hoyle, *U.S~A. Food and Drug Administration, Rockville, MD, U.SA. M.C.P.62 Low Dose Naltrexone in the Treatment of AIDS: Long Term Follow-up Results. Bernard Bihari*, F. Drury, V. Ragone, G. Ottomanelli, G. Cannon, E. Klein, *State University ofNew York, Health Science Center at Brooklyn, King's County Addictive Disease Hospital, Brooklyn, NY, U.SAl. M.C.P.63 Anti-LIlY-i Activity, Toxicity and Pharmacokinetics of Totally Novel Analogs. Mark A. Wainberg*, Stern, R. Zidovudine (IAZT) as a Pro-Drug with Enhanced Efficacy against HIV-1. Krishna C. Agrawal*, S. K. Aggarwal, S. R. Gogu, R. H. Lupia, J. J. L. Lertora, S. R. S. Rangan, *Tulane University School of Medicine, Department of Pharmacology, New Orleans, LA, U.S.A. M.C.P.65 The Carbocyclic Analogue of Oxetanocin G Inhibits the Replication of Cytomegalovirus and Herpes Simplex Viruses In Vitro. Daniel Nobc\" W. Rosenbrook, J. Plattner, J. Erickson, G. Arnett, W. Shannon, *Abbott Laboratories, Abbott Park, IL, U.S~A. M.C.P.66 P. L. Nara, H.-S. *NCI, Frederick Cancer Research Facility, Frederick, MD, U.S~A. M.C.P.67 Neutralization of HIV-1 by Anti-Idiotypic Antibodies. Didier J. Leturcq*, B. J. Winslow, P. Johnson, G. B. Thornton, *R. W. Johnson Pharmaceutical Research Institute, San Diego, CA, U.S.A. M.C.P.68 Phosphonoformate Inhibits Feline Retrovirus Infection in Cats. ClweryL L. ~jenszi*, S. E. Weisbrode, R. Sams, L. Nagode, K. Hayes, L. E. Mat hes, et al., *The Ohio State University, Columbus, OH, U.S~A. M.C.P.69 Pharmacoskinetics, Toxicity and Prophylactic Antiviral Activity of Pmea in Feline Retrovirus Infected Cats. Lawrence E. Mathes*, C. L. Swenson, P. A. Polas, R. Samns, K. Hayes, G. Kociba, *The Ohio State Columbus, OH, U.S~A. 205 [Page 206](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/208) M.C.P.70 Phosphate Triester Derivatives of AZT as Inhibitors of HIV. Chris Mc GCuiian*, K. Devine, T. O'Connor, S. Galpin, J. D. Williamson, D. J. Jeffries, *University College, London, U.K. M.C.P.71 Fluconazole Treatment of Esophageal Candidiasis in AIDS Patients. Antonio Gil Aguado*, P. Lavilla, A. Gonzalez, M. E. Valencia, J. M. L. Dupla, J. J. Vasquez, *Hospital La Paz, Madrid, Spain. M.C.P.72 Recombinant Soluble CD4 as a Vehicle to Deliver Ricin to HIV-Envelope Expressing Cells. Nancy A. Cochran*, A. R. Collinson, T. Liu, W. Meier, M. D. Rosa, V. S. Goldmacher, *ImmunoGen Inc., Cambridge, MA, U.S.A. M.C.P.73 Effects of Dideoxynucleosides on the Cell Cycle. Camilla M. Smith*, J. F. Henderson, *Cancer Research Group, University of Alberta, Edmonton, AB, Canada. M.C.P.74 In Vivo Anti-Retrovirus J.Bronson*, I. Ghazzouli, M. J. M. Hitchcock, E. R. Kern, J. C. Martin, *Bristol-Meyers Company, Wallingford, CO, U.S.A. M.C.P.75 Comparative Inhibitory Effects of Sulfated Polysaccharides on Giant Cell Formation Induced by Co-Cultivation of CD4-Positive Cells with Persistently HIV-1 Infected Cells. Masanori Baba*, D. Schols, R. Pauwels, H. Nakashima, J. Institute Medical Research, Leuven, Institute for Medical Research, Leuven, Belgium. M.C.P.77 Inhibition of HIV Replication in Cell Culture by Anti-Sense RNA Expressed from Recombinant Murine Retroviruses. William S. James*, A. R. Rhodes, *University of Oxford, Sir William Dunn School of Pathology, Oxford, U.K. M.C.P.78 Megakaryocytes of HIV-Seropositive Individuals Express Viral RNA. Dorothea Zucker-Franklin*, Y. Z. Cao, Y. Z. Kouri, *New York University Medical Center, New York, NY, U.S.A. M.C.P.79 Inhibitory Effect of Sulfated Amphotericin B on the Proliferation of HIV In Vitro. Toru Otake*, K. Miyano, H. Shimonaka, M. Kanai, N. Ueba, N. Kunita, et al., *Osaka Prefectural Institute of Public Health, Osaka, Japan. M.C.P.80 Inhibition of Human Immunodeficiency Virus (HIV-1) Replication by Synthetic Oligo-DNA Derivatives. Sudhir Agrawal*, D. K. Sun, P. S. Sarin, P. C. Zamecnik, *Worcester Foundation for Experimental Biology, Shrewsbury, MA, U.S.A. M.C.P.81 Assessment of the Therapeutic Activity of Phosphonylmethoxyethyl Adenine (PMEA) Azidothymidine (AZT) in a Murine Model of Acquired Immunodeficiency Disease. J. David Gangemi*, R. M. Cozens, A. Matter, H. Hochkeppel, *University of South Carolina, School of Medicine, Department of Microbiology and Immunology, Columbia, SC, U.S.A. 206 [Page 207](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/209) M.C.P.82 Inhibition of HIV Replication by Alpha Interferon. Marilyn S. Smith*, E. L. Brian, R. Thresher, J. S. Pagano, *University of North Carolina, Chapel Hill, NC, U.SA. M.C.P.83 Experimental Azidothymidine (AZT) Pulse Therapy Leads to Adequate and Prolonged Levels of Intracellular AZT-Triphosphate (AZT-TP). Markus W. Vogt*, W. Nadai, B. Joos, R. Liithy, *University Hospital, Division of Infectious Diseases, Zurich, Switzerland. M.C.P.84 Expression of Authentic and Enzymatically Active HIV-1 and HIV-2 Proteases in Saccharomyces L. Babe, P. Barr, C. Craik, *University of California at San Francisco, Department of Pharmaceutical Chemistry, San Francisco, CA, U.SA. M.C.P.85 Immunologic Effect After Single Dose Atvogen (Ampligen) in Healthy Volunteers. Craig W. Hendrix*, P. S. Lietman, P. O. P. TSo, J. B. Margolick, H. Farzadegan, B. G. Petty, *Johns Hopkins University, Division of Clinical Pharmacology, Baltimore, MD, U.SA. M.C.P.86 Studies of E. Busso, M. A. Mian, *Mount Sinai Medical Center of Greater Miami, Miami Beach, FL, U.SA. M.C.P.87 The Antiviral Effect of Dextran Dependent. Lionel Resnick*, M. E. Busso, *Mount Sinai Medical Center of Greater Miami, Miami Beach, FL, U.SA. M.C.P.88 In Vitro Activity of Ribavirin in Acute and Cocultivated HIV Infection of Human Peripheral Blood Mononuclear Cells. Richard B. Roberts*, *Cornell University Medical College, New York, NY, U.SA. M.C.P.89 Expression and Characterization of Chimeric Proteins Containing Human CD4 Linked to Human Immunoglobulin Heavy Chain Constant Regions. Tamio Mizukami*, C. D. Smith, E. A. Berger, B. Moss, *LVD, NIAID, National Institutes of Health, Bethesda, MD, U.SA. M.C.P.90 Analogs of 3'Amino-3'-Deoxyadenosine Inhibit Myra 0. McClure*, D. Whitby, R. Chensong-Popov, J. Weber, D. Davies, R. A. Weiss, *Chester Beatty Laboratories, Institute for Cancer Research, London, U.K. M.C.P.92 CSF from Patients with Early HIV Infection Produces Neuronal Cell Killing In Vitro: Prevention by Peptide T. Candace B. Pert*, J. M. Buzy, D. E. Brenneman, A. Salazar, A. Martin, M. R. Ruff, *National Institute of Mental Health, Bethesda, MD, U.SA. M.C.P.93 Synthesis of New Sugar-Fluorinated Guanosine Analogues Roger Gued*, Gosselin, J. L. E. France. M.C.P.94 Population Phamacokinetic Behavior of Zidovudine (AZT) in Patients with ARC. George L. Drusano*, S. R. Gitterman, M. J. Egorin, H. C. Standiford, *University of Maryland, Division of Infectious Diseases, Baltimore, MD, U.SA. 207 [Page 208](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/210) M.C.P.95 Anti-Retroviral M. D. Hoggan, *NIAID, National Institutes ofHealth, the Anti-HIV Agent '-Didehydrothymidine (D4T) (PBMC) in Culture. Hsu-Tso Ho*, H. Yang, M. J. M. Hitchcock, *Bristol-Meyers Pharmaceutical Research and Development Division, Wallingford, CO, U.S.A. M.C.P.97 Three Drug Synergistic Inhibition of HIV-1 Replication by Recombinant Soluble CD4 (rsT4), Zidovudine (AZT), and Recombinant Interferon-Alpha-A (rlFN-A) Victoria Anne Johnson*, M. A. Barlow, T. C. Chou, D. P. Merrill, M. S. Hirsch, *Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A. M.C.P.98 Comparative Pharmacokinetics of 3'-Azido-2', 3'-Dideoxyuridine (AZddU) and 3'-Azido-3'-Deoxythymidine (AZT) in Monkeys. Douglas F. Boudinot*, R. F. Schinazi, J. M. Gallo, H. McClure, D. Anderson, C. K. Chu, *University of Georgia, College of Pharmacy, Athens, GA, U.S.A. M.C.P.99 Differential Sensitivity of Bone Marrow DNA Polymerases Alpha and Delta to Inhibition by Dideoxynucleotides. John J. Bvrnes University of Miami, Miami, FL, U.S.A. M.C.P.100 Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) Increases Neutrophil Number and Function but Does not Alter HIV Expression in Patients with AIDS. Steven A. Miles*, J. Glaspy, Y. Chung, K. Lee, L. Souza, G. Baldwin, * University of California, Los Angeles, AIDS Center, Los Angeles, CA, U.S.A. M.C.P.1O1 Randomized Phase II Trial of Recombinant Tumor Necrosis Factor (rTNF) and Recombinant Interferon-Gamma (rIFN-Gamma) in Patients with ARC. Jan M. Aqosti*, R. Coombs, P. G. Kidd, M. Paradise, S. Sherwin, L. Corey, *University of Washington, Harborview Medical Center, Seattle, WA, U.S.A. M.C.P.102 A Long-Lived CD4 Carrier in Circulation: Red Blood Cells with CD4 Receptors Inserted in Their Membrane. Cla ude icolau*, T. Arvinte, A. Cudd, B. Schulz, *Biophor Corporation and Baylor College of Medicine, College Station, TX, U.S.A. M.C.P.103 Treatment of AIDS Associated Tumors with Recombinant DNA Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF). Umberto Tirelli*, RNA in HIV Replication. Maurizio Federico*, F. Carlini, B. M. R. Taddeo, I. Saggio, A. M. di Rienzo, G. B. Rossi, Superiore di Sanitd, Rome, Italy. 208 [Page 209](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/211) M.C.P.106 Organic Gold Compounds Are Effective against HIV-1 Reverse Transcriptase. Herbert Blough*, M. Ricchetti, the Potential for Improved Anti-AIDS Activity in the Central Nervous System. John S. Driscoll*, V. E. Marquez, J. J. Barchi, H. Ford, D. A. Cooney, H. Mitsuya, et al., *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. M.C.P.108 A Novel Compound that Inhibits Reverse Transcriptase. Hideki Ohnota*, S. Morikawa, D. Momose, H. T. Kitamura, *Creative Products Research Laboratories, Kissei Pharmaceutical Co. Ltd., Matsumoto, Japan. M.C.P.109 Chronically Infected Monocyte-Macrophages (M) Are Markedly Less Sensitive to Zidovudine (AZT), Foscamet (FOS) and Alpha Interferon (IFN) When Compared to Acutely Affected M. Suzanne M. Crowe*, M. S. McGrath, T. Elbeik, J. Kirihara, N. McManus, J. Mills, *Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Fairfield, Australia. M.C.P.110 Computerized Quantification of Synergism/Antagonism of Anti-HIV Agents. Ting-Chao Chou*, J. Chou, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. M.C.P.111 Possible Protective Effect of Dehydroepiandrosterone (DHEA) and/or DHEA-Sulfate (DHEA-S) in HIV Infection. Mark A. Jacobson*, P. Lekas, M. S. McGrath, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.SA. M.C.P.112 A Very Effective Anti-Diarrhea Agent Inhibits HIV-1 Replication in a HumanMonocytic Cell Line. Louis Mercure*, D. Phaneuf, R. Morisset, M. A. Wainberg, *Universitd de Montrial, Lady Davis Medical Research Institute, Montreal, QC, Canada. M.C.P.113 Analysis of the Effect of Acetaminophen on Zidovudine Pharmacokinetics in HIV Infected Patients. Erika M. Steffe*, J. Inciardi, J. King, N. Flynn, E. Goldstein, T. Tanjes, *University of California, Davis School of Medicine, U.C. Davis Medical Center, Sacramento, CA, U.S.A. M.C.P.114 Comparative Evaluation of Three Thymidine Analogs (D4T, FDDT and AZT) Active against HIV.Roman Z. Sterzvcki, Bristol-Myers Company, Pharmaceutical Research Development Division, Wallingford, CO, U.S A. M.C.P.115 Anti-HIV Activities of Anthraquinone Derivatives In Vitro. C. K. Chu*, R. F. Schinazi, M. Nasr, *University of Georgia, Athens, GA, U.S.A. M.C.P.116 Azidothymidine (AZT)-Alpha-Interferon (IFN) Combination Therapy Reduces p24 Antigenemia. Brian R. Edlin*, S. M. Whaling, R. A. Weinstein, J. D. Bitran, *Michael Reese Hospital, Division of Infectious Diseases, Chicago, IL, U.S.A. M.C.P.117 Castanospermine Analogs as Potent Inhibitors of Human Immunodeficiency Virus (HIV). Prasad S. Sunkara*, P. Taylor, M. Kang, P. Liu, T. Bowlin, A. Tyms, et al., *Merrell Dow Research Institute, [Page Anti-HIV PC6. Patrick K. Lai*, H. Takayama, Y. T. Wu, M. Nonoyama, *Showa University Research Institute, St. Petersburg, FL, U.SA. M.C.P.119 Effect of Chloroquine on HIV-1 Infection of Desportes*, M. Fouchard, C. K. Pyne, B. Rdveil, Paris Paris, France. M.C.P.120 Agents Azidothymidine (AZT) and 2', (D4T) Fridland*, M. R. Ashmun, *St. Jude Children's Research Hospital, M.C.P.121 Anti-HIV Activities of a Novel Nucleoside Seki*, Takahashi, T. Hoshino, *Department Hygiene, Gunma University School ofMedecine, Gunma, Japan. M.C.P.122 Computer-Assisted Structure Activity Correlations of Anti-HIV Drugs. Charles Litterst*, M. Nasr, P. Johnston, J. McGowan, *AIDS Program, National Institutes of Health, Bethesda, MD, U.SA. M.C.P.123 Discovery and Development of Therapies for AIDS and Its Sequela. Margaret I. Johnston*, C. Litterst, J. McGowan, M.C.P.124 Inhibitory Effects of Unsaturated Phospholipids on HIV Production In Vitro. Doroth E. Lewis*, A. J. Baran, V. Knight, M. Jett, *Baylor College of Medicine, Houston, TX, U.SA. M.C.P.125 Further Studies on the Potent Antiviral Synergism of Carbovir and AZT against Human Immunodeficiency Virus (HIV) In Vitro. William M. Shannon*, G. C. Lavelle, K. J. Qualls, E. L. White, J. M. Johnson, R. Vince, *Southern Research Institute, Birmingham, AL, U.SA. M.C.P.126 Quantitative Analysis of HIV-1 Expression Using Magnetic Particle RNA-RNA Hybridization: Application to Anti-HIV Drug Screening. Scott R. Decker*, K. A. Logan, J. M. Lawrie, M. G. Pelligrino, G. Li, D. J. Volsky, *Gene-Trak Systems, Framingham, MA, U.S.A. M.C.P.127 Pharmacokinetics of Recombinant Soluble CD4 (sT4) in Cynomolgus Monkeys Following Intravenous Administration. Carl Crysler*, K. L. L. Fong, K. E. Boyle, *Smith Kline & French Laboratories, King of Prussia, PA, U.S.A. M.C.P.128 Strong Synergistic Anti-HIV Activity of a T. C. Chou, *Oncogen, Seattle, WA, U.S.A. M.C.P.129 The Construction and Characterization of Immunotoxins Specific for HIV-Infected Cells. Victor Ghetie*, M. A. Till, D. Capon, E. Patzer, J. W. Uhr, E. S. Vitetta, *University of Texas Southern Medical Center, Department ofMicrobiology, Dallas, TX, U.S.A. M.C.P.130 Phase I Study of 2'3' Dideoxyinosine (ddl) Administered Twice Daily to Patients with AIDS/AIDS-Related Complex. John S. Lambert*, R. Dolin, M. Seidlin, C. Knupp, C. McLaren, R. C. Reichman, * University of Rochester, School of Medicine, Rochester, NY, U.S.A. 210 [Page 211](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/213) M.C.P.131 Development of an In Vitro Human Monocyte-Derived Macrophage (MDM)-Based System for Drug Screening against HIV-1. Bru Polsky*, P. A. Baron, H. E. Gendelman, J. W. M. Gold, T. C. Chou, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.SA. M.C.P.132 Polyvinyl Alcohol Membrane Permeability Characteristics of Zidovudine. Andrew P. Pearson*, D. L. Blandford, M. L. Maliszewski, T. J. Smith, *University of Kentucky, Department of Ophthalmology, Lexington, KY, U.SA. M.C.P.133 Effect of Organic Arsenicals on Productive Infection of HIV. Phalguni Gupta*, S. O'Marro, C. R. Rinaldo, M. Ho, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. M.C.P.134 Novel Glucosidase Inhibitors as Anti-HIV Agents. Hirovuki Shimizu*, S. Morikawa, H. Yamamoto, H. Ushijima, T. Kitamura, Institute of Health, Tokyo, Japan. M.C.P.135 Carbocyclic Oxetanocin Analogues that Inhibit De Novo Replication of Human Immunodeficiency Virus in T-Cells and Monocytes/Macrophages In Vitro. Hiroaki Mitsuva*, Hayashi, Norbeck, J. Plattner, S. Broder, *The Clinical Oncology Program, NCI, National Institutes of Health, Bethesda, MD, U.S.A. M.C.P.136 New Analogues of 2', 5'-Oligoadenylate with Improved Anti-HIV-1 Activity In Vitro. David C. Montefiori*, R. J. Suhadolnik, R. W. Sobol, Jr., N. L. Reichenbach, R. Charubala, W. Pfleiderer, et al., *Vanderbilt University, Department of Pathology, Nashville, TN, U.SA. M.C.P.137 Phase I Study of the Administration of Recombinant Soluble CD4 (rCD4) by Continuous Infusion to Patients with AIDS or ARC. Robert Yarchoan*, R. V. Thomas, J. M. Pluda, C. F. Perno, S. A. Sherwin, S.y Broder, et al., *National Cancer Institute, Bethesda, MD, U.SA. M.C.P.138 Metronidazole (M) Trichomoniasis (T) Eradication as Possible Procedure in AIDS. Sukrija Krvavac*, A. Rustembegovic, *University and Medical Center, Women's Health Institute, Sarajevo, Yugoslavia. M.C.P.139 A Useful Immunotherapy in AIDS. BernardJ. Marichal*, M. C.Jenaer, Brussels, Belgium. Additionnels of AIDS-Virus Disinfection. Luben G. Angeloff*, *Angel's Biomedical Laboratories, Ltd., Montreal, QC, Canada. M.C.P.141 Concentration Dependent Dual Effects of the Monolauryl Ester of Sucrose (L.S.) on the Antifungal Activity and Absorption Spectra of Amphotericin B (AmB). Janina M. Braitburg*, I. Gruda, G. Medoff, *Washington University, School of Medicine, St. Louis, MO, U.S.A. M.C.P.142 Serologic and Immunologic Parameters in a Randomized, Double-Blind, Placebo-Controlled Trial of Ampligen Administered to Subjects with HIV Infection. Kenneth R. Ong*, G. F. McKinley, M. M. Reddy, Y. Inada, J. I. O'Connor, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, Columbia University, New York, NY, U.S.A. 211 [Page 212](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/214) M.C.P.143 Treatment of J. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany. M.C.P.144 Inhibition of HIV Reverse Transcriptase by Center Research Institute, M.C.P.145 Viral Inhibition Therapy against AIDS (VITA). Sadhna Joshi*,A. Van Brunschot, I. Robson, A. Bernstein, *University of Toronto, Faculty of Medicine, Department of Microbiology, Toronto, ON, Canada. M.C.P.146 Effect of Pepsin Treatment on the HIV Envelope and Core Antigens. Eszter Uihelyi*, G. Fuist, R. Holldn, Institute ofHematology and Blood Transfusion, Budapest, Hungary. M.C.P.147 Menaquinone (Bacterial Vitamin K) Inhibits HIV-1 Induced Syncytia Formation but not HIV-1 Replication. Louis F. Oualtiere*, A. Zbitnew, J. M. Heise-Qualtiere, J. Conly, *University of Saskatchewan, Department of Microbiology, Saskatoon, SK, Canada. M.C.P.148 The Effects of Traditional Medicine (Sho-Saiko-To: SST) on Peripheral Mononuclear Cell (PMC) from AIDS and ARC Patients. Kazuhito Watanabe*, Y. Inada, H. Ikegami, M. Lange, W. Clark, Luke's-Roosevelt Hospital Center, New York, NY, U.SA. M.C.P.149 AIDS: Is a Safe Vaccine Readily Available? Norman J. Godin, Geneva University Hospital, Geneva, Switzerland. M.C.P.150 African Traditional Medicine and AIDS. Chief S. O. Ajisefinni. Ijero-Ekiti, Nigeria. 212 5 Le SIDA et l'individu ________ ATIDS and the Individual Session d'affichage Poster Session Adolescents (partle 1) Adolescents (Part 1) M.D.P.1 HIV Infection in Disadvantaged Adolescents in the U.S.: Findings from the Job Corps Screening Program. Michael E. St-Louis*, C. L. Hayman, C. Miller, J. E. Anderson, L. R. Petersen, T. J. Dondero, *Centers for Disease Control, Atlanta, GA, U.S.A. M.D.P.2 Young People's Lay Beliefs about HIV Infection and AIDS. L'an Waruicyk1, P. J. Aggleton, *Bristol Polytechnic, Department of Education, Bristol, U.K. M.D.P.3 AIDS Risk Behavior among Sexually Active Hispanic and Caucasian Adolescent Females. Susan M. Ke geles*, R. Greenblatt, J. Catania, C. Cardenas, J. Gottlieb, T. Coates, et al., * University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.SA. M.D.P.4 Predictors of Condom Use and Multiple Partnered Sex among Highly Sexually Active Adolescent Women. Josevh A. Catania*, T. Coates, R. Greenblatt, P. Dolcini, S. Kegeles, M. Corman, et al., * University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. M.D.P.5 Behavioral Survey among High Risk Adolescents. 5.u sin HsrfV% R. Morris, J. Roseman, E. Aslanivatan, C. Baker, 0. Rt', *L4C, University of Southern California, Medical Center, Clinical Instructor of Pediatrics, Los Angeles, CA, U.S.A. M.D.P.6 AIDS Prevention in Junior High School Students in an AIDS Epicenter: Results of a Baseline Survey. Meg A. Durbin*, D. Siegel, L. Lazarus, F. Krasnovsky, M. Chesney, D. Kakimoto, * University of California at San Francisco, San Francisco, CA, U.S.A. M.D.P.7 Sexual Abuse in Children and HIV Infection. Patricia Estela Uribe*, H. G. Ornelas, G. J. L. Valdespino, M. M. *Palacios, AIDS Information Center of Mexico City, D.G.E Ministry of Health, Mexico City, Mexico. M.D.P.8 Influence of Percieved Referent-Group Normative Behavior on Adolescents' Use of Condoms. Ralv~h J. Diclemente*, R. DuNah, * University of California at San Francisco, San Francisco, CA, U.S.A. M.D.P.9 Differential Effects of AIDS Knowledge and Perceived Susceptibility on the Reduction of High-Risk Sexual Behaviors among College Adolescents. RaiohiJ. Diclemente*, K. Forrest, S. Mickler, * University of California at San Francisco, San Francisco, CA, U.S.A. 214 [Page 215](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/217) M.D.P.10 HIV Infection in Adolescents: Can We Predict Who Is at Risk. Lawrence J. D'Angelo. P. Getson, N. Luban, E. Stallings, H. Gayle, Children's Hospital National Medical Center, Washington, DC, U.SA. Comportement (partle 1) Behaviour (Part du Saint-Sacrement, Canada. M.D.P.12 Knowledge of Risk Factors and the Avoidance of AIDS in the Gambia, West Africa. Bruce J. Oelman, K. O. Jaiteh, M. K. Cham, A. B. H. Njie, H. A. Wilkins, S. Baldeh, Epidemology and Statistics Unit, Medical and Health Department, Banjul, Gambia. M.D.P.13 Knowledge Regarding AIDS among Employees and Spouses at a Bank in Kinshasa, Zaire. Melinda Moore, A. Doppagne, S. E. Hassig, N. Lusakulira, T. D. Kashala, Zaire School of Public Health/Tulane University, New Orleans, LA, U.SA. M.D.P.14 AIDS-Related Knowledge, Attitudes and Behaviors among a Population-Based Sample of California Residents. Melinda K. Moore*, M. Jang, N. Day, *URSA Institute, San Francisco, CA, U.SA. M.D.P.15 High Risk Sexual Behaviour and Condom Use in a Sample of Homosexual Men in England. Mary Boulton*, R. Fitzpatrick, G. Hart, J. Dawson, J. McClean, *St. Mary's Hospital Medical School, London, UX. M.D.P.16 Appropriate AIDS Knowledge but Negative Attitudes of College Students. Harold P. Katner*, M. V. Smith, K. W. Couch, J. N. Tripp, E. H. Young, *Mercer University School of Medicine, Macon, GA, U.SA. M.D.P.17 HIV Associated Health Beliefs of Army Basic Trainees. Linda L. Alexander*, H. Overton, *Division of Preventitive moeurs sexuelles au S6n6gal (contribution la conaissance M.D.P.19 Demographic and Practices of Male Bar Workers in Bangkok. Werasit Sittitrai*, P. Phanupahak, N. Satirakorn, E. Wee Ekweera, R. E. Roddy, *Institute of Population Studies, Chulalongkorn University, Bangkok, Thailand. M.D.P.20 Peer and Partner Influence and Self-Confidence as Correlates of AIDS Preventive Behavior (APB) in a Low Prevalence State. Suzanne E. Landis*, J. A. Earp, University of North Georgia, School of Public Health, Department of Epidemiology, Chapel Hill, NC, U.SA. M.D.P.21 The Impact of Community-Based Behavioral Group Intervention to Help Persons Reduce High-Risk Sexual Behaviors. Kelly A. Jeffrey*, J. S. St. Lawrence, T. L. Brasfield, M. V. Hood, R. Betts, *University of Mississippi Medical Center, Jackson, MS, U.SA. 215 [Page 216](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/218) M.D.P.22 Psychological and Demographic Characteristics of Gay Men Who Do or Do Not Engage in Unsafe Sex. Jeffrey A. Kell*, J. S. St. Lawrence, T. L. Brasfield, J. E. Smith, H. V. Hood, A. L. Lemke, et al., * University of Mississippi Medical Center, Jackson, MS, U.S.A. M.D.P.23 Persistence of High-Risk Sexual Behavior in Homosexual/Bisexual Men: A Multi-Center Study. Lvnda Doll*, R. J. Douglas, P. Moss, P. Weller, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. M.D.P.24 Condom Use Can Occur Despite Use of Alcohol and Drugs. Janet S. Harrison*, L. S. Doll, P. Weller, B. Bartholow, D. Joy, P. Moss, *The U.S. Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. M.D.P.25 Casual Sexual Contacts of Swiss Tourists in Tropical Africa, the Far East, and Latin America. Robert Steffen*, M. Stricker, A. Eichmann, F. Gutzwiller, *Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland. M.D.P.26 Changes in AIDS Knowledge, Attitudes, and Behaviors in San Francisco's Latino Communities: 1987 to 1988. Susan F. Pavne*, G. F. Lemp, G. Bregman, G. Sandlin, F. Sabogal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, U.S.A M.D.P.27 Cognitive Differences between Boys and Girls Relating to the Use of Condoms. Joanne Otis*, G. Godin, J. Lambert, R. Pronovost, *DSC de l'H6pital Charles LeMoyne, Greenfield Park, Canada. M.D.P.28 Predictors of Higher Risk Sexual Behaviors among Gay and Bisexual Men Attending an STD Clinic. Dan M. Joy*, G. Bolan, J. Harrison, L. Doll, C. Goeghegan, V. Lore, *Division of STD Control, Department of Public Health, San Francisco, CA, U.S.A. M.D.P.29 Factors Affecting Retention in a Longitudinal AIDS Risk Reduction Study of Gay Men. Charles E. Hale*, A. Freeman, B. A. Petty, D. W. Diehl, *Dallas County Health Department, Dallas, TX, U.S.A. M.D.P.30 AIDS knowledge and Unsafe Sexual Practices at an STD Clinic. Robert Kohn*, P. M. Gibson, G. Bolan, *Division of STD Control, Department of Public Health, San Francisco, U.SA M.D.P.31 Prevalence and Change of AIDS High Risk Sexual Behavior among Bisexual Men in San Francisco The San Francisco Men's Health Study. Maria L. Ekstrand*, T. J. Coates, S. Lang, J. Guydish, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. M.D.P.32 Intentions to Change Behavior, Perceived Change and Reported Change: Do they Correlate? Donna L. Higgins*, C. Galavotti, K. R. O'Reilly, J. Sheridan, *AIDS Community Demonstration Projects, Centers for Disease Control, Atlanta, GA, U.S.A. M.D.P.33 Changes in Hatian Immigrants' Knowledge, Attitudes and Practices about AIDS in Montreal, Canada. Alix Adrien*, Y. Tousignant, C. A. Canada M.D.P.34 Safe and Unsafe Sex among Homosexual Men in the Netherlands. Roberta A.P. Tielman*, S. Polter, *University of Utrecht, Utrecht, The Netherlands. 216 [Page 217](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/219) M.D.P.35 Predicting HIV Risk Behaviors among Gay Men. Robert W. Wood, L. Krueger, P. Diehr, K. O'Reilly, Seattle-King County Department of Public Health AIDS Prevention Project, Seattle, WA, U.SA. M.D.P.36 Knowledge, Beliefs, Attitudes and Behaviour about AIDS in the 14 to 20 Age Group. Evaluation of an Educational Program. Yann Sevrer*, W. Bohm, W. Heckmann, S. Michel, *World Health Organization-Centre Paris, H6pital Claude Bernard, Paris, France M.D.P.37 Sexual Behaviour and HIV Related Knowledge among a Random Sample of Young Population of Italy. Giuseppe Marasca*, E. D'Arcangelo, D. De P. Pezzotti, *Instituto Superiore di Santi, Rome, Italy M.D.P.38 Peer Norms for Safer Sex as a Predictor of Sexual Risk Behaviours in a Cohort of Gay Men. Theresa M. Exner*, H. F. L. Meyer-Bahlburg, R. S. Gruen, A. A. Ehrhardt, J. M. Gorman, *New York State Psychiatric Institute and Columbia University, New York, NY, U.SA. M.D.P.39 Gay Identification Influences the Effects of Alcohol Use on AIDS Risk Behavior. Peggy L. Peterson*, D J. Mckirnan, *University ofAlabama, School of Public Health, Department of Health Behavior, NY, U.S.A. M.D.P.40 Knowledge, Attitude and Practice Relating to AIDS among a Random Sample of Students at a Paris University. JuanMenares*, P. Echevarria, V. Massari, F. Lepont, J. Biostatistique INSERM U263, Paris, France. Travailleurs de la sante Health Care Workers M.D.P.41 Decentralized Services: Global Network Type Approach. Andre Bouchard*, M. R. Morissette, *tquipe de prevention et CHUL), Ste-Foy, Canada. M.D.P.42 Overestimations of Risk for Occupational HIV Transmission as a Factor within AIDS-HIV Education and Care. Margaret M. Grade*, H. S. Bartnof, T. J. Ficarrotto,J. S. Mandel, L. S. Zegans,J. L. Ziegler, *AIDS Professional Education Project, School of Medicine, University of California at San Francisco, San Francisco, CA, U.S.A. M.D.P.43 Job-Related Stress among HIV-Antibody Test Counsellors. Susan Lloyd Schulz*, D. Rugg, R. Fagan, F. Rhodes, *Centersfor Disease Control, Altlanta, GA, U.S.A. M.D.P.44 Primary Care Physicians' Knowledge, Attitudes, and Willingness to Treat AIDS Patients. James E. Fordvce*, R. Stoneburner, D. Gemson, J. Colombotos, J. Elinson, *New York City Department ofHealth, AIDS Research Unit, New York, NY, U.S.A. M.D.P.45 Collaborative Evaluation Study of AIDS Training Programs for Women's Health Providers. Sharen I. Duke*, E. Drucker, P. Gillette, H. Sacks, *New York City Department of Health, AIDS Program Services, New York, NY, U.S.A. M.D.P.46 The Needs of Persons Living with AIDS. Nena M.Nera*, Degner L., *Federal Centre for AIDS, Ottawa, Canada. 217 [Page 218](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/220) M.D.P.47 The Knowledge and Understanding of Human linmunodeficiency Viral (HIV) Infection among Health Care Workers in Teaching and Non-Teaching Hospitals in Jaac.izo,Ort\" P. Prabhakar, * University of the West Indies, Department of Microbiology, Kingston, Jamaica. M.D.P.48 Impact of AIDS Workshop of Knowledge and Attitudes in Health Care Workers. Grania M. Christie*, Zazayokwe M., R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa. M.D.P.49 Experience with AIDS among 3,500 Zairian Health Workers, 19871-1988. Mdtinda Moote\", E. E. Hassig, N. Lusakulira, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Tulane University, New Orleans, LA, U.S~A. M.D.P.50 A KAP Survey of Healthcare Workers is AIDS. Pravhan ~Phajgha, V. Sittitrai, B. Veerasukont, *Chulalongkrn University Hospital, Bangkok, Thailand. M.D.P.51 General Practitioners and Management of lIlY Infection. Y~oiqu. Massd*, Landman, F. Fagnani, Universit6 Paris, Paris, France. M.D.P.52 Would Patients Switch Physicians if Their Doctor Were J{IV Positive? Barbara Gerbert*, B. Maguire, S. Hulley, T. Coates, * University of California at San Francisco, San Francisco, CA, U.S~A. M.D.P.53 Access to Dental Care in the San Francisco AIDS Behavioral Research Cohort. Barbara Gerbert*, B. Maguire, J. Sumser, T. Coates, * University of California at San Francisco, San Francisco, CA, U.S~A. M.D.P.54 Fear of Contagion in Home Health Aides: A Community Survey. Latiie Bell Meisenhelder. New England Deaconess Hospital, Boston, MA, U.SA. M.D.P.55 Health Workers and AIDS: Knowledge, Attitudes and Experiences as Determinants of Anxiety. LE1Fochr4.\", A. Krasnik, T. Bayer, N. Keiding, * University of Copenhagen, Institute of Social Medicine, Copenhagen North, Denmark. M.D.P.56 Knowledge of HIV Transmission and Attitudes about AIDS among 629 Registered Nurses at a Minnesota Hospital. 5cot Lai~pIll*, M. Maki, K. Willenbring, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S~A. M.D.P.57 The AIDS-Related Knowledge, Attitudes and Behaviour of Internists and Surgeons: A Comparative Analysis. Keith Henrv*, S. Campbell, S. Eyer, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S~A. M.D.P.58 Knowledge, Attitude and Concerns of Hospital Staff about AIDS. &ath Maclloo\"', G. Taerk, W. J. Lancee, R. Coates, M. Fanning, M. Keatings, * University of Toronto, Toronto, ON, Canada. M.D.P.59 Knowledge and Attitudes of Rural Georgia Physicians Concerning AIDS. Harold P. Katner*, M. U. Smith, R. E. Godeau, *Mercer University School of Medicine, Macon, GA, U.S~A. 218 [Page 219](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/221) M.D.P.60 Staff Discomfort in Working with H1V Spectrum Patients. Micbael.Q. Kn~~ M. G;. Dow, * University of South Florida, Tampa, FL, U.S~A. M.D.P.61 Analysis of Nurse-AIDS Patient Verbal Interaction by SAVI. Elucir Gjirf, T. M. Moriya, E. C. Carvaiho, * University of Sao Paulo, School of Nursing of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil. M.D.P.62 Needle Stick Injuries. Pasca i.Dk Cao~rarii?\", S. Dansky, G. Rodriguez, L. Laviena, I. Madera, E. Visconti, et al., *Luthreran Medical Center, Brooklyn, NY, U.S~A. M.D.P.63 Assessment of Nursing Home Preparation for Long-Term Care of Persons with HIV Infection. Nathan L. Linsk*, E. J. Wright, G. Youngman, R. Miller, P. Hefron, L. Chen, * University of Illinois at Chicago, Chicago, IL, U.S~A. M.D.P.64 AIDS Mini-Survey on Attitudes, Beliefs and Knowledge among Dental Professionals in Metropolitan Montreal. Julio C. Soto*, M. Levy, R. M.D.P.65 Measuring Attitudes about AIDS among Public Health Personnel Using the Semantic Differential Technique. Yves J.Q ~ignaz, A. Adrien, Canada. M.D.P.66 HIV Patients' Perceptions of their General Practitioners. Michael M. Kpchet\"~, J. Hasford, *Biometric Center for Theraputic Studies, Munich, Federal Republic of Germany. M.D.P.67 HIV-Related Problems Facing General Practitioners (G.P.) in Belgium. D irk Avonts*, F. Buntinx, P. Sweetlove, \"lsitt of Tropical Medicine, Antwerp, de dispositifs de r~cuperation des aiguilles la pr~vention de l'infection HIV chez les Personnels de Sante et Proposition de CritP~res de Choix. ALai St. Georges, France. M.D.P.69 Myths and S tigmas about AIDS in Health Personnel in a Latin Americ an Country. Lore jGaIci, J. A. Izazola, J. L. Valdespino, L. Alan (s, M. L. Cravioto, J. Sepulveda, *Gnea Directorate of Epidemiology, Mexico, Mexico. M.D.P.70 HIV-1 Knowledge, Attitudes and Risk Perception in Biomedical Research Facility Employees. Robyn R. M. Gersho n*, B. A. Curbow, D. Vlahov, Johns Hopkins University School of Health, Department of Environmental Health Sciences, Kellogg Program, Baltimore, MD, U.SA. M.D.P.71 Medical Students' Knowledge and Concerns about HIV Infection. 6L~e SLnminii', A. Culbert, *Boston University School of Public Health, Boston, MA, U.S~A. 219 [Page 220](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/222) M.D.P.72 Risk of Occupational Exposure to HIV Infected Dody Fluids and Transmission of HIV I among Health Care Workers:A Multicentre Study. Giuseppe Ipoolito*, *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy. M.D.P.73 Adverse Exposures to Blood and Body Fluids among Practicing Midwives in the United States. David K. Henderson*, M. Willy, G. Dhillon, N. Loewen, R. Wesley, National *Institutes of Health, The Clinical Center, Office of the Director, Bethesda, MD, U.S.A. M.D.P.74 The Impact of AIDS on Health Care Providers: An Annotated Bibliography and International Survey. Merriioy Kelner*, K. M. Taylor, J. M. Eakin, *University of Toronto, Department of Behavioural Science, Toronto, ON, Canada. M.D.P.75 The Role of the Homemaker/Home Support Services in AIDS Care in Canada. Kathleen L. Jacobson*, Fietz M., *Canadian Counsil on Homaker Services, Toronto, ON, Canada. M.D.P.76 The Doctor-Patient Relationship: Is It Working for People with HIV Infection? Michelle E. Roland*, L. Temoshok, * University of California at San Francisco, San Francisco, CA, U.S.A. M.D.P.77 AIDS/HIV Infection: Knowledge, Attitudes and Beliefs of Dental health Faculty and Students. Diana M. Shin*, A. Y. Wong, *Center for Interdisciplinary Research in Immunology and Disease (CIRIC) at UCLA, Los Angeles, CA, U.S.A. M.D.P.78 Physician perception of Personal Risk from AIDS (HIV Virus). Kathrvn M. Taylor*, H. A. Skinner, J. E. Eakin, M. J. Kelner, M. Shapiro, *University of Toronto, Department of Behavioural Science, Toronto, ON, Canada. M.D.P.79 Practices and Attitudes of Health Care Workers (HCW) towards HIV-Infected Patients in a Large Acute Care Hospital. Walter F. Schlech*, S. Mac Donald, C. Fanning, S. *Lefort-Jost, Dalhousie University and Victoria General Hospital, Halifax, Canada. M.D.P.80 AIDS and Dental Health Professionals: Knowledge, Attitudes and Infection Control Practices. Francisco S. S*, N. Steplight, J. Kronenfeld, J. Daniel, K. Jackson, *University of South Carolina, School of Public Health, Columbia, SC, U.S.A. M.D.P.81 A Method for Implementation of Universal Precautions. Christopher LaCharite*, S. Marino, S. Nottebart-Finn, J. Sniffen, R. Platt, *Brigham and Women's Hospital, Boston, MA, U.S.A. M.D.P.82 A Survey of Knowledge and Attitudes Concerning HIV Infection and AIDS among Faculty and Students at 3 U.S. Dental Schools. James A. Cottone*, S. B. Dove, R. Bebermeyer, J. A. Molinari, *University of Texas Dental School at San Antonio, San Antonio, TX, U.S.A. M.D.P.83 HIV-Related Risk, Worry, and Behaviour Changes among Emergency Medical Workers: Personal and Job-Related Factors. Rick S. Zimmerman*, T. Bolon, M. Rodriguez, J. Patrone-Reese, *University of Miami Coral Gables, FL, U.SA. 220 [Page 221](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/223) M.D.P.84 Attitudes and Practices of General Internists Regarding Care of People with HIV Infection. Harvey J. Makadon*, R. S. Phillips, Beth Israel Hospital, Harvard University, Boston, MA, U.S.A. M.D.P.85 Evidence for the Benefits and Need for Ongoing AIDS/HIV Curiculum Revision for Medical, Nursing, Pharmacy and Dentistry Students at the University of California at San Francisco, School of Medicine. Harvey S. Barntof, M. A. Papadakis, M. M. Grade, B. A. Koenig, L. S. Zegans, J. L. Ziegler, *University of California at San Francisco, AIDS Professional Education Project, School of Medicine, San Francisco, CA, U.SA. M.D.P.86 The Attitudes of PWAs to Their Primary Care Physician. Surinder Singh*, S. J. Mansfield, *St. Stephen's Hospital, London, U.K. M.D.P.87 Verbal Interaction between the Nursing Team and the AIDS Patients. ElucirGir*, T. M. for Occupational/Nosocomial Transmission of Human Immunodeficiency Virus-1 in Health Care Workers. David K. Henderson*, B. J. Fahey, J. M. Schmitt, A. J. Saah, H. C. Lane, *National Institute of Health, The Clinical Center, Bethesda, MD, U.S.A. M.D.P.89 The AIDS-Related Knowledge, Attitudes, and Behavior of Internists and Family Physicians: A Comparative Analysis. Keith Henry*, S. Campbell, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A. 221 [Page 222](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/224) \" -':.l Section June 5 ll4l4 LeSIDA, la societ6etlecomportannent AIDS, Society and Behaviour Session d'affichage Poster Session Information Information M.E.P.1 A Structured Educational Support Group for HIV Infected Individuals. Nancy L. Van Devanter*, C. Tendler, R. Shipton-Levy, M. Steilen, A. Stuart, *Columbia University School of Public Health, New York, NY, U.S.A. M.E.P.2 Report From a Public Health Psychosocial Clinic for Gay and Bisexual Men with HIV-Related Problems. M. G. Claes Von Anti-Gay Prejudice: Public Reactions to AIDS-Related Policies to Gay Men in the U.S.A. Gregory M. Herek*, E.K. Glunt, Graduate Center, *City University of New York, New York, NY, U.S.A. M.E.P.4 Communicating AIDS Information to Hispanics: The Importance of Language and Media Preference. Dale J. Hu*, R. Keller, D. Fleming, *Johns Hopkins University Preventive Medicine Residency, Baltimore, MD, U.S.A. M.E.P.5 AIDS: A Proactive Approach to Mental Handicap. Gillian James, Royal College of Nursing, London, U.K. M.E.P.6 Evaluation of Aids Education Programs for Offenders. Jan. Godes*, K.J. Bell, V.M. Thelen, R.D. Miller, R. E. Sherman, J.L. Craig, *Hennepin County Community Health Department, Minneapolis, MN, U.S.A. M.E.P.7 An Application of Social Marketing to the Development of AIDS Educational Materials. Peter G. California, Santa Ana, CA, U.S.A. M.E.P.8 Using National and Regional Minority Organizations to Provide Culturally Relevant HIV Information and Education in the the United States. M. Isabel Fernandez*, W. Duncan, B. Lindsey, A. Kwarmoogi, *Centers for Disease Control, National AIDS Information and Education Program, Atlanta, GA, U.S.A. M.E.P.9 AIDS in the Inner City: How a Black Community Organization Has Responded to the AIDS Epidemic. Mindy Fullilove*, M. Weinstein, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. 222 [Page 223](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/225) M.E.P.1O AIDS Education Program for Haitian Immigrants in Montreal. Ali~ Addri*n, J. Merveille, A. Alcindor, M. L. Partnership Model. Catlin P. Fullwood*, K. Har~field, *People of Color against AIDS Network, Seattle, WA, U.S~A. M.E.P.12 Implementing a Culturally Sensitive AIDS Prevention Program for Haitian Immigrants in New York City. A rzB *,f~~ P. Freedman, Y. Norat, J. DeHovitz, *State University of New York- Health Science Center at Brooklyn, Brooklyn, NY, U.S.A. M.E.P.13 AIDS Knowledge, Language Use and Response to Spanish and Englsih Radio Messages of Low-Income Mexican-American Women in South Texas~Marc iWeitler*, C., Jr. Martinez, T. Pri hoda,A. Rogan, M. Reyes, * University of Texas Health Science Center, Department of Medicine, San Antonio, TX, U.S.A. M~dfas Media M.E.P.14 Aids: The Language, Media, and Public Response. I&se CyDffliy.s, Waterloo Regional Health Unit, AIDS Program Supervisor, Kitchener, ON, Canada. M.E.P.15 Utilizing the Mass Media to Provide Culturally Relevant HlVEducation to Hispanic Americans. M. Isabel Fernandez*, R. L~epicier, L. Montealegre, *Centers for Diseases Control, National AIDS Information and Education Program, Atlanta, GA, U.S.A. M.E.P.16 The Development of a Large Scale AIDS Media Campaign by Combining Public and Private Sector Resources. Claudia L. Webster*, D. Fleming, R. McAlister, G. Tycer, R. Schmidt, *Oregon Health Division, Portland, OR, U.S.A. M.E.P.17 The Impact of Media Events on Public Interest in AIDS. RQLerLW. Wod\" K. A. Hartfield, L. Ray-Keil, *Seattle..King County Department of PublicHealth, Seattle, WA, U.S.A. M.E.P.18 Perceived Risk of HIV Transmission from a Promiscuous Bisexual Patient with AIDS among Lay People and Public Health Specialists. GeiCzi.Qj, Teikyo University, School of Medicine, Tokyo, Japan. M.E.P.19 The Metaphors of AIDS: Reporting of an Epidemic in Puerto Rico. Ineke Cunnna* E. L. Cunningham, * University of Puerto Rico, Department of Sociology, Rio Piedras, PR, U.S.A. M.E.P.20 AIDS Information Center in Lima, Peru. Mae L. Lujia*, P. G. Goicochea, L. R. Varela, P. Coleman, *Ministry of Health/AIDS Project, Lima, Peru. M.E.P.21 AID S Medi a and Anti -Discrimina ti on: A Critical Presentation. Catherine G. Saalfieldl*, R. Narvarro, * Whitney Museum Independent Study Program, New York, NY, U.S.A. M.E.P.22 AIDS Makes Newspapers Sell. *amnreod iur, F. Conde, A. Coronado, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spain. 223 [Page 224](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/226) Milieu de travail Workplace M.E.P.23 Employment and the Social Challenges of AIDS. LindaJ. Laubenstein*, J. B. Greene, J. R. Campbell, M. S. Weisberg, *New York University Medical Center, New York, NY, U.S.A. M.E.P.24 Healthcare Workers and AIDS: Risk Prevention and Education. Genevieve M. Clavreul, World Immunological Network Project Foundation, Los Angles, CA, U.S.A. M.E.P.25 The Metro Toronto AIDS Education Program: A Model for Low-Budget Municipal Training. Diane M. Riley*, W. A. Davey, S. Varley, J. Sloggett, *Municipality of Metropolitan Toronto, Toronto, ON, Canada. M.E.P.26 Effecting Behavior Change through Policy and Training. Julie Louise Gerberding, San Francisco General Hospital, San Francisco, CA, U.SA. M.E.P.27 An Employer-based Approach to AIDS Prevention, Education and Management. William L. Beery*, R. D. Vance, N. S. Sofian, E. S. Anderson, *Centerfor Health Promotion, Group Health Cooperative of Puget Sound, Seattle, Washington, DC, U.S.A. M.E.P.28 An AIDS Education Intervention in a Multinational Hotel Industry. Grania M. Christie*, M. Zazayokwe, R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa. M.E.P.29 Responding to AIDS: Ten Principles for the Workplace. Carol Levine. Executive Director, Citizens Commission on AIDS for N.Y. City and Northern NJ., New York, NY, U.S.A. M.E.P.30 Workplace AIDS Education: An Evaluation of Centers for Disease control Employees. Deborah L. Rug *, S. Kidd, D. Brownell, D. Schnell, *Centers for Disease Control, Atlanta, GA, U.S.A. M.E.P.31 Educational Strategies on AIDS at Workplaces. Joao Luis e Treinamento AIDS, Sao Paulo, Brazil. M.E.P.32 Rules for Adequate Care after Accidental Skin Lesions with Risk of Exposure for Blood-borne Infection. Lars Hambraeus*, Y. Greitz, *National Bacteriological Laboratory, Department of Epidemiology, Stockholm, Sweden. M.E.P.33 Results on the Effectiveness of an AIDS in the Workplace Education Pilot Program. Susan M. Blake*, D. Najjar, A. George, R. Makinodan, *American Red Cross, National Headquarters, Washington, DC, U.S.A. 224 [Page 225](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/227) Famille Family M.E.P.34 Family Treatment Approach for HIV Infected Children. Anita Se ptimus*, A. Rubinstein, *Albert Einstein College of Medicine, D.S.S., Bronx, NY, U.S.A. M.E.P.35 Multi-Family Support Group for Transfusion Related HIV Infection. Ann Stuart*, M. Steinlen, S. Campbell, *Columbia University, New York, NY, U.S.A. M.E.P.36 Bisexual Men and their Partners Workshop Session. William A. Palmer*, *Gay and Married Men's Association / Dental Hospital, Melbourne, North Balwyn, Victoria, Australia M.E.P.37 AIDS and Hemophilia: A Coordinated Education, Support and Personal Care Program. Evaluative Report From a Two-Year Pilot Project. John R. McDonald*, G. Dowdle, *Faculty of Social Welfare, University of Calgary and Calgary Region Canadian Hemophilia Society, Calgary, AB, Canada. M.E.P.38 The HIV-Endangered/Infected Child Frankfurt, Federal Republic of Germany. M.E.P.39 Who Speaks for the Abandoned Child Born with HIV? A Foster Parent and Adoptive Parent Respond. Barbara A. Chamness*, T. McCarroll, *Childkind, Inc., Norcross, U.S.A. M.E.P.40 AIDS Orphans in New York City: Projected Numbers and Policy Demands. Chris Norwood, Women and AIDS Studies, New York, NY, U.SA. M.E.P.41 Exp6rience Qu6b6coise Quebec, Services sociaux hospitaliers, Quebec, Canada. M.E.P.42 Providing Comprehensive Services for Developmentally Disabled Children with AIDS: Services and Issues. PhvllisL. Susser*, T. Anthony, *The Herbert G. Birch Community Services, Inc., Springfield Gardens, U.S.A. M.E.P.43 Accessing, Educating and Researching Married Homosexual and Bisexual Men. William A. Palmer Gay and Married Men's Association/ Dental Hospital, Melbourne, North Balwyn, Victoria, Australia 225 [Page 226](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/228) La communaut6 (partie 1) Community (Part 1) M.E.P.44 The Genesis and the Rapid Development of the AIDS Activist Movement. Henry J. Yeager. The Dwight Foundation, New York, NY, U.S A. M.E.P.45 Des professionnels de la sant6 communautaire, Quebec, QC, Canada. M.E.P.46 A Comparative Study of Local AIDS Programmes in the United Kingdom. Mukesh Kapila*, M. Pye, G. Buckley, D. Cuningham, *Health Education Authority, London, U.K. M.E.P.47 The Establishment and Administration of Casey House Hospice, Toronto. Miriam Mayhew*, D. Ley, *Casey House Hospice, Toronto, ON, Canada. M.E.P.48 Homelessness and AIDS: Video. Barbara Blakenev*,J.R.McMahon, *Long Island Shelter: Department ofHealth andHospitals, Boston, MA, U.S.A. M.E.P.49 Community Coalition Building As a Means of Improving Service Systems for People with HIV Infection. C. Hostetter*, S. Matheny, D. McMenamin, *Department of Health and Human Services, Rockville, MD, U.S.A. M.E.P.50 A Community-Based AIDS Education, Counselling and Information Service in Zimbabwe: A Model for Africa? Geoff Foster. Mutare Provincial Hospital, Mutare, Zimbabwe. Services sociaux Social Services M.E.P.51 An Assessment of the Psychosocial Needs of the HIV Antibody Positive Population Using the Montreal Health and Social Service Network. Elizabeth Clark*, V. Atkinson, N. Grayson, *Comitd SIDA AIDE Montreal, Montrdal, QC, Canada. M.E.P.52 Hospitalized AIDS/ARC Patients Presenting Disposition Problems: No Simple Solutions. Rachel A. Pousson, King's County Hospital Aids Team, Brooklyn, NY, U.S.A. M.E.P.53 Developing the Skills of Home Care Staff in Caring for People Living with AIDS. Terry M. Cotton*, D. Platt, *London Borough of Hammersmith and Fulham, Social Services Department, London, U.K. M.E.P.54 Estimating Numbers of People Living with AIDS/HIV Infection in a Small Urban Area for Social Services Planning Purposes. Nicholas P. Manning, London Borough ofHammersmith andFulham,London, U.K. M.E.P.55 Establishing Quality Control Targets for the Provision of Personal Social Services to People Living with AIDS and HIV Infection. Nicholas P. Manning, London Borough of Hammersmith and Fulham, London, U.K. 226 [Page 227](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/229) M.E.P.56 Local Government Provision of Social Care to People Living with AIDS/HIY Infection. Deis l.aW'\" T.M. Cotton, *London Borough of Hammersmith and Fuiham, Social Services, London, U.K. M.E.P.57 Political Attack, Medical Comfort, Psychological Deficiencies: Facets and Effects of AIDS policies in Bavaria, West Germany. Walter Satzinger*, H. Jaeger, G. Hammel, U, Weber, *GSFjlnstitute for Medical Informatics (MED IS), Neuhe rberg, Bavaria, Federal Republic of Germany. M.E.P.58 HIV Infection, Aids and Mental Health: The Canadian National Working Group's Experience. Stevhen Woo*, J. De Montigny, *Department of Psychiatry, Mount Sinai Hospital, Toronto, ON, Canada. M.E.P.59 \"We Haven't Dealt with Much of That Here\": Helping Mental Health Providers Prepare to Work with HIV Related Clients. Marcia J. Qtiadc.kinili*, D. Deitch, R. Martin, M. Schuyler, * University of California at San Francisco, AIDS Health Project, San Francisco, CA, US A. M.E.P.60 Sources of Delayed Hospital Discharge for AIDS Patients. Mki4,v WjdmatL*, D.W. Light, JJ. Platt, * University of Medicine and dentistry of New-Jersey, School of Osteopathic Medicine, Camdem, NJ, U.S~A. M.E.P.61 Post-Discharge Housing of HIV Patients Armignacco, Italy. Developing Comprehensive Services for HIV Infected Intravenous Drug Users: A Guide for Case Managers. Diane Pincus Strom. Bronx-Lebanon Hospital, Bronx, NY, U.S~A. M.E.P.63 Needs, Assessment of Persons with AIDS and HIV illness: Implications for Community-Based Service Planning in a Low Incidence Community. Richard V. Carrick*, D. A. Coleman, D. Zelinski, * United Way of Frankli'n County, Columbus, U.S~A. M.E.P.64 Comprehensive Volunteer Program for People with AIDS. Linathan Jjgc.Qbt, S. Miller, N. Streeter, *Center for Special Studies, New York Hospital- Cornell Medical Center, New York, NY, U.S~A. M.E.P.65 Hospital Liaison and Visitation Programs Provide Emotional Support, Advocacy and Linkage to Community Based Organizations for Hospitalized PWA/PWARCs. Michael Hedderman*, S. Jue, D Bergman, S. Stroup, *AJDS Project Los Angeles, Los Angeles, CA, U.SA. M.E.P.66 The Importance of the Social Service Experience at a University Hospital in Rio de Janeiro, Brazil. Eleono ra P.Hanan, E. M. M. Moura, E. R. Oliveira, C. A. Morais de Sd, *Gaffrde and Guinle University Hospital/University of Rio de Janeiro (UNI-RIO), Rio de Janeiro, Brazil. 227 [Page 228](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/230) M.E.P.67 Northern Manhattan Women and Children HIV Demonstration Project: Social Service Issues. Ester Chachkes*, R. Andrew, C. Healton, V. Walter, J. Johnson, *Presbyterian Hospital, New York, NY, U.S.A. M.E.P.68 Group Residence and Scattered Site Apartments as Housing for Homeless Persons with AIDS. Douglas H. Dornan*, K. Wampler, G. Hough, *AIDS Resource Center, New York, NY, U.S.A. M.E.P.69 Social Service Needs for People with AIDS: Perceptions of Need and Unmet Need. John A. Fleishman*, J. Piette, V. Mor, *Center for Gerontology and Health Care Research, Brown University, Providence, U.S.A. M.E.P.70 Step Down Care Acceptability in Hospitalized AIDS Patients. Wayne C. McCormick*, T. S. Inui, R. A. Deyo, C. DeGroff, R. Wood, *University of Washington, Robert Wood Johnson Clinical Scholars Program, Seattle, WA, U.S.A. M.E.P.71 A Multi-Disciplinary Model for Decision-Making and Case Planning for HIV-Infected Children and Youth in Child Welfare and Child Protective Services Systems. Burt J. Annin*, L. J. Emery, K. Ponts, *Child Welfare League ofAmerica, DC, U.SA. M.E.P.72 Community-Based Care for People with FIV Disease. Howard C. Rubin*, H. S. Sacks, *Mount Sinai School ofMedicine, New York, NY, U.S.A. M.E.P.73 The Challenge of AIDS in an Area of Scattered Population and Low Prevalence. Pat Tyson, Regional Joint AIDS Community Support Center, Newcastle-Upon-Tyne, U.K. M.E.P.74 Comprehensive Social Service HIV Retrovirus Program at Walter Reed Army Medical Center. Robert H. Gemmill, Walter Reed Army Medical Center, Washington, DC, U.S.A. 228 [Page 229](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/231) Notes [Page 230](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/232) Section Lundi 5 juin F Monday, June 5 Droit et thique Ethics and Law Session d'affichage Poster Session Vue d'ensemble de la I'6gislation Global Survey of AIDS Legislation M.F.P.1 Legal Protections against HIV-Related Discrimination in the U.S.A.: A Fifty-State Analysis. Benjamin H. Schatz, AIDS Civil Rights Project, National Gay Rights Advocates, San Francisco, CA, U.S.A. M.F.P.2 Legal Authority for HIV Testing of Adolescents. Richard L. North, University of Maryland School ofLaw, Baltimore, MD, U.S.A. M.F.P.3 Impact of the Sanitary Legislation on HIV Transmission in Blood Donations in Guadalajara, Mexico. Eduardo Vdzquez-Valls*, B. Torres-Mendoza, M. L. Jauregui-Rtos, E. Patologra Infecciosa y Experimental de la Universidad de Guadalajara, Guadalajara, Mexico. M.F.P. AIDS in U.S. and Canadian Correctional Facilities: Epidemiology and Policy Responses. Theodore M. Hammett*, S. Moini, L. Harrold, M. Weissberg, *Abt Associates Inc., Cambridge, MA, U.S.A. M.F.P.5 Current Issues in Drug Regulation in the U.S.A. Stephen C. Smith, Human Rights Campaign Fund, Washington, DC, U.S.A. M.F.P.6 Trends in AIDS Litigation in the United States--1983 to 1988. Gene W. Matthews*, V. S. Neslund, *Office of the General Counsel, Centers for Disease Control, Atlanta, GA, U.S.A. M.F.P.7 AIDS and the Courts: Compelling and Protecting the Disclosure of AIDS Status. H. Patrick Glenn*, Y.-M. Morissette, N. Gilmore, M. Somerville, *McGill Center for Medicine, Ethics and Law, Montreal, Canada. M.F.P.8 The Consequences of the Legislation of Prostitution in Victoria. Cheryl M. Overs, Prostitutes Collective of Victoria, Melbourne, Australia. M.F.P.9 SIDA: Problbmes 6thiques pos6s par la protection des dons de sang. Catherine Manuel*, D. Reviron, M. P. Larher, J. Charrel, P. Promote or Inhibit Public Health? Julie C. Hamblin, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. 230 [Page 231](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/233) Notes [Page 232](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/234) Section Lundi 5 juin G Monday, June 5 Implications intemationales International Issues Session d'affichage Poster Session E~pidemiologie Epidemiology M.G.P.1 Patterns and Trends of Heterosexual Transmission of HIV among Brazilian AIDS Cases. Euclides Castilho*, P. Chequer, D. Bergamaschi, L. Rodrigues, *Oswal&o Cruz Foundation, Ministry of Health, Rio de Janeiro, Brazil. M.G.P.2 HIV-1 and HIV-2 Serological Survey in Lunda Norte, Northeastern Province of Republica Popular de Angola. Manuel Jos~ M. Almeida*, M. 0. Santos-Ferreira, M. H. Lourenco, T. Cohen, J. M. Azevedo Pereira, *5. Dermatologia, Hospital Santa Maria, Lisbon, Portugal. M.G.P.3 The Seroprevalence of HThV-I and HIV-1 Co-Infection in Haiti. Michael Giordano*, J. Pape, W. Blattner, W. D. Johnson, Jr., *Cornell University Medical College, Division of International Medicine, New York, NY, U.S~A. M.G.P.4 Estirnate of HII Infection Prevalence in Brazil. Claudio Struchiner*, E. A. Castilho, M. D. C. Guimaraes, *Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. M.G.P.5 HJV and Hepatitis B. Transmission in Sudan. Michael C. McCarthv*, K. C. Hyams, M. El-Dabi, J. Woody, *United States Naval Medical Research Unit No. 3, New York, NY, U.S~A. M.G.P.6 Ernpirical Extrapolation Projections of AIDS Incidence in Brazil. A. Castilho*, C. Struchiner, M. D. C. Guimaraes, *Qsya4do Cruz Foundation, Rio de Janeiro, Brazil. M.G.P.7 Prdvalence des infections par les virus HIV-1, HIV-2I et HTLV-I dans la region de Tananarive Nlso Me..nd.s*, P. Giraldes, I. Longo, Souza, *Escola Paulista de Medicina, Sao Paulo, Brazil. M.G.P.9 HIV Infection in Sorne Urban and Rural Areas of Cameroon. Gise~ ID~itS V. Angeloni, F. Costa, M. L. Spedini, M. C. Martorana, et al., *L. Spallanzam Hospital for Infectious Diseases, Rome, Italy. M.G.P.1O Prevalence of Anti-HIV Antibodies in a Sample of the General Population. Blanca Torres-Mendoza*, E. Vazquez-Valls, M. L. Jauregui-Rios, *Institato de Patolog(Infecciosa y Experimental tie la Universidad de Guadalajara, Guadalajara, Mexico. 232 [Page 233](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/235) M.G.P.11 Geographic and Risk-Group Patterns of HIV Infection in Africa. Peter 0. Way*, V.-P. Sneller, W. H. Lyerly, *Center for International Research, Washington, DC, U.S.A. M.G.P.12 Study of HIV-1, HIV-2, and HTLV-I in Homosexuals in Brazil. Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, Medicina, UFRJ, Departamento de Clinica Medica, Hospital Brazil. M.G.P.13 Study of HIV-1, HIV-2, and HTLV-I in Female Prostitutes in Brazil. Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, X. L. Li, Medicina, UFRJ, Departamento de Seroprevalence HIV-1, HIV-2, and HTLV-I in Brazilian J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, L. UFRJ, Departamento de de Janeiro, Brazil. M.G.P.15 Seroprevalence of HIV-1 in Emergency Room Patients in Brazil. Eduardo J. B. Cortes*, R. Lourenco, M. Lima, L. Huang, UFRJ, Departamento de HIV-2 in Prenatal Women in Guinea-Bissau. in Rural Zaire. lain R. Hardy*, S. R. Green, W. A. M. Cutting, M. Cranefield, *University ofEdinburgh, Edinburgh, U.K. M.G.P.19 Anti-HIV Testing in Blood Banks in Ecuador. Galo Leoro-Monroy*, M. L. Merino, M. Sanchez, C. Herrera, R. Chiribosa, F. Weilbauer,*Ecuadorian Red Cross, Quito, Ecuador. M.G.P.20 Seroprevalence of HIV-1, HIV-2, and HTLV-I in Male Prostitutes in Rio de Janeiro, Brazil. Eduardo J. B. Cortes*, R. Detels, D. Slamon, D. Aboulafia, L. de Medicina- UFRJ/ de l'infection VIH-1 en Guyane Frangaise J. A. Fleury*, R. Pradinaud, M. Levadoux, *Universite de II, Bordeaux, France. M.G.P.22 HIV Seroprevalance in Egypt: A-Two-and-a-Half-Year Surveillance. Douglas M. Watts*, N. Constantine, F. Sheba, H. Amer, S. Khashaba, R. Danahy, et al, *United States Naval Medical Research Unit No. 3, New York, NY, U.S.A. M.G.P.23 An Epidemiological Review of HIV in Zambia. George S. Tembo*, S. Hira, *University Teaching Hospital, Department of Community [Page 234](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/236) Prevalence:VIH et HIV-2 Tuberculosis (TB) in Abidjan, C8te d'Ivoire. Cock,J. Krebs, R. Bretton, et al., *Centers for Disease Control, Atlanta, GA, U.S.A. M.G.P.25 HIV-1 et HIV-2 parmi les tuberculeux du Centre antituberculeux du C.H.U. de Cocody. Guy-Michel Gershy-Damet*, M. Bobo-Dioulasso Measles: Association with Maternal HIV Infection. Joanne E. Embree*, P. Datta, L. Sekla, M. Braddick, J. Kreiss, F. Plummer, * University of Washington, Department oflnfectious Diseases, Seattle, WA, U.S.A. M.G.P.28 Specific Antibody Response to Plasmodium Falciparum Schizonts in Zambian Children with HIV-1 Infection and Their Hospital Controls. Rosemary M. Mwendavole, Tropical Diseases Research Centre, Ndola, Copperbelt, Zambia. Notes [Page juin H Monday, June 5 R6pecussions economiques du SIDA The Economic Impact of AIDS Session d'affichage Poster Session CoOts des traitements m6dicaux Medical Treatment Costs M.H.P.1 The Impact of Zidovudine on AIDS-Related Hospital Admissions: How Long Does the Honeymoon Last? Timothy Ng*, J. S. G. Montaner, M. Schechter, A. McLeod, B. Willoughby, J. Beardsell, et al., *University of British Columbia, St-Paul's Hospital, AIDS Research Programs, Vancouver, BC, Canada. M.H.P.2 Effects of the Use of AZT on the Medical Care Costs of Persons with AIDS in the First 12Months.AnneA. Scitovsky*,M. Cline,D.I. Abrams, *Palo Alto Medical Foundation, Research Institute, Palo Alto, CA, U.SA. M.H.P.3 Role of a Dedicated HIV/AIDS Ward in a Central London Teaching Hospital. SurinderSingh*, G. M. Connolly, D. A. Hawkins, B. Gazzard, *Kobler Centre, St. Stephen's Hospital AIDS Unit, London, U.K. M.H.P.4 Digestive Infections during AIDS, Diagnostic Strategy and Cost. E. Ren6*, A. Durrbach, R. Bouali, T. Chevalier, L. et *H6pital Bichat, Paris, France. M.H.P.5 Hospital Use by PWA's in New York, Los Angeles and San Francisco. Jesse Green*, M. Leigh, N. Wintfeld, *New York University Medical Center, Department of Health Policy Research, New York, U.S.A. M.H.P.6 Costs and Characteristics of Out-of-Hospital Programs for Persons with AIDS in San Francisco, 1985-1988. Adam C. Stern*,J. Amory,M. Bala, S. Hernandez, G. Rutherford, *Department of Public Health, San Francisco, CA, U.S.A. M.H.P.7 The Contribution of PCP to Trends in AIDS Hospital Discharges and Average Lengths of Stay. Sandra R. Hernandez*, F. Strachaz, G. Rutherford, L. Baskett, A. Stern, *AIDS Office, San Francisco Department of Public Health, San Francisco, U.S.A. M.H.P.8 Costs of Hospital Care for Patients with HIV Infections. Jan C. C. Borleffs*,J. C. Jager, R. M. A. Geels, J. T. L. Jong, C. K. Musch, M. J. J. C. Poos, et al., * University Hospital Utrecht, Department ofInternal Medicine, Utrecht, Netherlands. M.H.P.9 Hospital Use by a Population-Based Cohort of AIDS Patients. David W. Fleming*, S. Modesitt, R. Klockner, D. Bennett, S. Hulman, *Oregon Health Division, Portland, OR, U.SA. M.H.P.10 Outpatient Treatment of AIDS: A Viable Alternative that Demonstrates Significant Cost Savings. Richard J. Liekweg*, P. Dideriksen, T. Adinolfi, J. A. Bartlett, de la Santd, Protection Sociale, Paris, France. M.H.P.12 Medical Charges and Health Care Utilization for Privately Insured Patients with HIV Disease in California. Meg A. Durbin*, B. Bowen, S. Maerki, E. Hudes, *University of California at San Francisco, San Francisco, CA, U.S.A. M.H.P.13 Implications of Prophylactic Aerolsolized Pentamidine for the Direct Medical Care Costs of AIDS. Michael E. Gluck*, R. Chaisson, *School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD, U.S.A. M.H.P.14 The Costs of Treating AIDS in a Rural Setting. Leo E. Waivers*, J. T. Busher, R. L. Rumley, H. G. Adams, *East Carolina University School of Medicine, Section of General Internal Medicine, Greenville, NC, U.S.A. M.H.P.15 L'H6pital et la consommation m6dicale des patients infect6s par VIH. Gabriel Bez*, F. Petit, *Ministdre de la Santg- Direction des H6pitaux, Paris, France. M.H.P.16 Health Care Costs for AIDS Patients in Saskatchewan. John M. Conly*, S. Shafran, K. Browne, *University Hospital, University of Saskatchewan, Saskatoon, SK, Canada. M.H.P.17 Resource Use, Charges, and Mortality for AIDS Patients with PCP. Charles L. Bennett*, J. Garfinkle, S. Greenfield, D. Draper, W. Rogers, W. C. Mathews,*RAND/UCLA Center for Health Policy Study, Santa Monica, CA, U.S.A. M.H.P.18 AIDS Health Care in the United States: Characteristics of the Patients and the Hospitals Who Treat Them. Dennis P. Andrulis*, V. Weslowski, E. Hintz, *National Public Health and Hospital Institute, Washington, DC, U.S.A. M.H.P.19 Cotit par pathologies dues Boulay*, G. J. Salin, *Ministdre de la Solidaritd, de la Santd et de la Protection Sociale, Paris, France. Prevention Prevention M.H.P.20 Potential Impact of HIV in the Labor Force of the Future. Antonia Novella*, A. Wright, *National Institute of Child Health and Human Development, Bethesda, MD, U.S.A. 237 [Page 238](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/240) I._ _ J I II I I I I I I I __ [Page 239](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/241) ~iiiiiiiiiiiiiii:i'`:'..t~ i i iiiiiiiiiii:-i---:- Etats-Unis Conf6renciers: Progres en du & Middlesex School of Medicine Angleterre Difficultis et obstacles Ai la gestion optimale du SIDA et de l'infection par contre au Za're La perspective communautaire - questions auxquelles font face les ayant France HumanitY: les mesures pour une 6thique sur le SIDA David J. Roy Directeur, Centre de biodthique Institut de recherche clinique de Montr6al, Qu6bec Canada La dynamique de l'interprbtation, des parambtres Roy M. Anderson Professeur Imperial College of and Technology Angleterre 240 [Page 241](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/243) State-of-the ArtTuesday Chairperson: James O. Mason June 6 Assistant Secretary for Health of the United States Plenary speakers: Advances in Clinical Management in AIDS and HIV Infection in the Developed World lan Weller Reader in Genito-Urinary Medicine Academic Department of Genito-Urinary Medicine University College & Middlesex School of Medicine England Difficulties and obstacles for optimal management of AIDS and HIV infection in the developing world N'Galy Bosenge Director National AIDS Control Programme in Zaire The community perspective - issues confronting persons with AIDS and HIV infection and the community Daniel Defert Pr6sident AIDES F6d6ration nationale France Humanity: the measure of an ethics for AIDS David J. Roy Director Centre for Bioethics Clinical Research Institute of Montreal, Quebec Canada The transmission dynamics of HIV: the role of models in interpretation, prediction and parameter estimation Roy M. Anderson Professor Imperial College of Science and Technology England 241 [Page 242](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/244) 11:00 - 12:30 Salle Room 407A Section A Mardi 6 juin Tuesday, June 6 Round Table Pr6sidents Chairpersons et la pr6vention de 'infection par le VIH Partner Notification in HIV Prevention Nathan Clumeck (Belgium) Robert Remis (Canada) 11:00 T.A.O.1 Program Content: * Rationale for partner notification * Overviews of policies and programs in different countries * Legal and ethical issues * Operation of a partner notification program * Evaluation of efficacy and cost-effectiveness Panelists: John Gallwey, Oxford, U.K. Jan Amil Kristoffersen, Skarer, Norway. Kathleen Toomey, Atlanta, GA, U.S.A. Fred Wolf, Denver, CO, U.S.A. 242 [Page 243](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/245) 11:00 - 12:30 Sale Rom 408A Section A 6 juin Tuesday, June 6 kl&miologie et sant publique and Public Health S6ance th6matique Specialty Session Pr6sidents Chairpersons Surveillance du SIDA Jean-Baptiste Brunet (France) Pinel (Brazil) 11:45 T.A.O.5 12:00 T.A.O.6 12:15 T.A.O.7 The Impact of the Revised Definition on AIDS Cases Diagnosed in Massachusetts: A Preliminary Analysis. Beverly Heinze-Lace*, J. Day**, G. Seage*, S. Oddleifson*, L. Makarewicz**, *Boston **Massachusetts AIDS Surveillance Programs (BMASP), Boston, MA, U.S.A. L'impact de la nouvelle d6fminition de SIDA A Barcelone: le role de la tuberculose. Joan-Arthur Cavld, A. Plasencia, J. Batalla, J. M. Jansd, N. Parellada, Instituto Municipal de la Salud, Barcelona, Spain. Impact of the 1987 Revision of the AIDS Case Definition in the United States. Richard M. Selik, J. W. Buehler, J. M. Karon, R. L. Berkelman, AIDS Program, Surveillance Branch, Centers for Disease Control, Atlanta, GA, U.S.A. Marked Underreporting of CDC Defined AIDS Due to Poor Utilization of the HIV Antibody Test. Andrew Masterson, A. Oppermann, S. Landesman, Kings County Hospital Center, Brooklyn, NY, U.S.A. Evaluation of AIDS Surveillance in Switzerland: Estimation of Underreporting and Impact of Active Surveillance. Robert R. Enag*, C. Minder*, T. Spuhler**, H. Paradis*, M. Samuel*, B. Somaini*, et al., Federal Offices *of Public Health, **of Statistics, Medical Division, Bern, Switzerland. Underreporting of Minority AIDS Deaths in the San Francisco Bay Area, 1985-1986. Norman G. Hearst*, G. Chu*, A. I. Trachtenberg**, N. Riordan*, J. Creeger**, J. Sorensen*, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco; **California Department of Health Services, Office of AIDS, Sacramento, CA, U.S.A. 243 [Page 244](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/246) 11:00 - 12:30 Salle Room 408BC Section A 6 juin Tuesday, June 6 pid&nmiologie et sant publique Epidemiology and Public Health Infections par le VIH chez les consommateurs de drogues par vole Intravelneuse S6ance th6matique Specialty Session HIV Infection in IVDUs Presidents Chairpersons Graham Hart (U.K.) Harry Haverkos (U.S.A.) J. L. Valdespino (Mexico) 11:00 T.A.O.8 T.A.O.10 T.A.O.12 12:15 T.A.O.13 Trends in HIV Seroprevalence and Risk Behavior among Drug Treatment Program Entrants. James L. Hadler*, T. Farley**, L. Peterson**, M. Cartter*, *Connecticut Department of Health Services, Harcford, CT; **CDC, Atlanta, GA, U.S.A. Needle Exchange in Central London: One Year Follow-up. Graham J. 'Hart*, A. Carvell*, N. A. M. ***PHLS, London, Seroprevalence of Human Immunodeficiency Virus (HIV) Infection among Intravenous Drug Users (IVDUs) in the U.S. David M. Allen, I. Onorato, P. Sweeney, T. Jones, *enters for Disease Control, Atlanta, GA, U.S.A. Seroconversion for HIV in Intravenous Drug Users in San Francisco. Andrew R. Moss. P. Bacchetti, D. Osmond, R. Meakin, A. Keffelew, R. Gorter, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. Risk Factors for HIV-1 Infection among Street-Recruited Intravenous Drug Users in New York City. Samuel R. Friedman*, A. Rosenblum*, D. Goldsmith*, D. C. Des Jarlais**, M. Sufian*, et al., *Narcotic and Drug Research, Inc.; **New York State Division of Substance Abuse Services, New York, NY, U.S.A. Heterosexual Behavior of Intravenous Drug Users. Anneke Van den Hoek, H. J. A. Van Haastrecht, R. A. Coutinho, Amsterdam Municipal Health Service, Amsterdam, Netherlands. 244 [Page 245](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/247) 11:00 - 12:30 Salle401ABC Room 4O1ABC Section Atelier Pr6sidents Chairpersons Frangoise Camus Michael Oncologic Institute; **Chief, Pulmonary Medicine, St. Vincent Medical Center, Los Angeles, CA, U.S.A. Effets des aerosols prophylactiques de B. D. I. Abrams*, L. Wardlaw*, K. Corkery*, D. Busch***, D. W. Feigal*, S. Gordon****, the San Francisco County Community Consortium, *San Francisco General Hospital, Department of Medicine, AIDS Activities, University of California at San Francisco, San Francisco, CA; **State University of New York, Stony Brook, NY; ***Childrens' Hospital; ****Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A. Successful Chemoprophylaxis for Pneumocystis with Dapsone or Luke's-Roosevelt Hospital Center, New York, NY; **Jacobus Pharmaceutical, Princeton, NJ, U.S.A. Low Dose Dapsone (D) Prophylaxis (PX) of Pneumocystis carinii Pneumonia (PCP). Onnie S. Lang, J. M. Kessinger, R. M. Tucker, S. I. Greene, S. C. Deresinski, D. A. Stevens, Santa Clara Valley Medical Center, San Jose, CA, U.S.A. Trimethoprim-Sulfamethoxazole for Secondary Prophylaxis of Pneumocystis carinii Pneumonia in AIDS. Gerald Pierone. J. Masci, P. Nicholas, Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.S.A. 245 [Page 246](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/248) 11:00- 12:30 Salle Room 406A Tuesday, June 6 Aspects clinques Implications intenationales Clinical Aspects of Aids International Issues S6ance th6matique Specialty Session Presidents Chairpersons Le SIDA dans les pays en vole de developpement AIDS in the Developing World Raphael Bittera (Burundi) Richard McLean (Canada) Diana Menwa T.B.O.11 12:15 T.B.O.12 Evaluation of Definitions for AIDS Case Surveillance. Cels F. Ramos Filho*, L. G. M. Rodrigues**, C. A. Morais de Sd***, B. G. Weniger****, A. Sereno*, J. W. Krebs****, et al., *Hospital Universitdrio, Universidade ***Hospital Gaffrie e Guinle, Rio de Janeiro, Rio de Janeiro, Brazil; ****Centers for Disease Control, Atlanta, GA, U.S.A. HIV-1 and HIV-2 Infection Prevalence in the Mortuary-Abidjan. Emmanuel Gnaore*, K. L. Lafontant**, et al., *Projet RETRO-CI, Abidjan, Ivory Coast/Centers for Disease Control, Atlanta, GA, U.S.A.; ** University ofAbidjan, Abidjan, Ivory Coast. etude comparde des pr6valences HIV-1, Congo, du Sdndgal et du Yemen. Clinical Manifestations of HIV-1 and HIV-2 Infections in Abidjan, C6te d'Ivoire. Koudou *Projet RETRO-CI, Abidjan, Ivory Coast; **AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. 2 Years Experience from an AIDS Clinic in Uganda. E, T. Katabira, Department of Medicine, Makerere University, Kampala, Uganda. Epidemiological Approach of Tuberculosis in AIDS Patients: Brazil, 1982-1988. Pedro **Oswaldo of Health, Rio 246 [Page 247](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/249) 11:00 - 12:30 SaRle Room 407B Section 6 Colloque Symposium Prisidents Chairpersons Aspects cniques Clinical Aspects of AIDS Traltement des Infections par le VIH Management of Infections Associated with HIV Immunodeficiency Michel G. Bergeron (Canada) Martin S. Hirsch (U.S.A.) 11:00 T.B.O.13 11:20 T.B.O.14 11:40 T.B.O.15 12:00 T.B.O.16 AZT Update. Margaret A. Fischl. University of Miami School of Medicine, Miami, FL, U.SA. New Anti-HIV Drugs: Hope for the Future. Tom Merigan, Stanford University School of Medicine, Stanford, CA, U.SA. Les Immunomodulateurs: therapeutique alternative Richman, University of California, CA, U.SA. 247 [Page 248](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/250) 11:00 - 12:30 Salle Room 403ABC C Mardi 6 juin Vlrologle (partle 1) Virology (Part 1) Donald Jeffries (U.K.) A. G. B. R. Sourde (Africa) Michael D. Weaver (Canada) 11:00 T.C.O.1 11:15 T.C.O.2 11:30 T.C.O.3 11:45 T.C.O.4 12:00 T.C.O.5 12:15 T.C.O.6 Design and Activity of a Novel Class of Nucleoside Analogs Effective against HIV-1. Bernard Belleau*, D. Dixit*, N. BioChem International Inc., Laval, QC, Canada. Differential Sensitivity of Wild Type and Recombinant HIV-Reverse Transcriptase to Inhibition by Foscarnet. Marilyn M. Lightfoote. J. M. Bailey, Biochemistry Department, Washington University Medical School, Washington, DC, U.S.A. Inhibition of HIV-1 Induced Syncytia Formation by Monoclonal Antibodies to the Membrane Adhesion. Antonio Valentin*, M. Patarroyo**, Asjeo*, *Department of Virology and **Department of Immunology, Karolinska Institute, Stockholm, Sweden. Structure and Function of HIV-1 Reverse Transcriptase (RT). Dorothy J. Purifov, D. Lowe, D. Stammers, B. A. Larder, G. K. Darby, M. Tisdale, et al., Wellcome Research Laboratories, Beckenham, U.K. Identification of Several Species of HIV-1 Major Core Protein: Production and Cell-Surface Expression. Ara G. Hovanessian, A. G. Laurent, B. Krust, M. A. Rey, L. Montagnier, Institut Pasteur, Units d'Oncologie virale, Paris, France. GAG and GAG-POL Protein Precursors Made from a SV40 Late Replacement Vector Are Properly Processed and Assembled into Particles. Alan Smith*, M. L. Hammarskj6ld**, D. Rekosh***, State University of New York at Buffalo, Departments of *Microbiology, **Biochemistry and ***Oral Biology, Buffalo, NY, U.S.A. 248 12:30 Sale Room 407C Section Mechanisms of Pathogenesis of Human Retroviruses Robert C. Gallo (U.S.A.) David T.C.O.8 to (AZT). Brendan A. Larder, G. Darby, D. D. Richman, Wellcome Research Laboratories, Beckenham, U.K. Surface Structures Involved in HIV Recognition. PaulMadden, Columbia University, New York, NY, U.S.A. Trans-Regulation of HIV-1 Gene Expression. Bryan R. Cullen. Duke University Medical Centre, Durham, NC, U.SA. Current Developments in Pathogenesis. Robert C. Gallo, Laboratory of Tumour Cell Biology, National Cancer Institute, National Institutes ofHealth, Bethesda, MD, U.SA. 249 [Page 250](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/252) 11:00 - 12:30 Salle ABC Room 41OABC Section C Mardi 6 juin provirus Level of HIV-1 Provirus Christine C. Debouck (U.S.A.) Freidrich Deinhardt (Federal Republic of Germany) Serge T.C.O.12 11:30 T.C.O.13 11:45 T.C.O.14 12:00 T.C.O.15 12:15 T.C.O.16 Expression, Purification, Structure, Activity and Substrate Specifity of the HIV-1 Retroviral Protease. Christine M. Debouck. I. Deckman, J. Malinowski, T. Meek, M. Moore, J. Strickler, et al., Smith Kline & French Laboratories, King of Prussia, PA, U.S.A. Tumor Necrosis Factor- Activates HIV Expression in a Chronically Infected T Cell Clone through Induction of Nuclear Factor Binding to NF-KB Sequences. Arnold B. Rabson*, E. Duh*, W. J. Maury*, T. Folks**, A. S. Fausi*, *NIAID, National Institutes of Health, Bethesda, MD; **Centers for Disease Control, Atlanta, GA, U.S.A. RNA Splicing Events Detected in Early In Vitro HIV Infection Using Polymerase Chain Reaction (PCR). Mary E. Klotman, A. DeRossi, A. Buchbinder, F. Wong-Staal, Laboratory of Tumor Cell Biology, NCI, National Institutes of Health, Bethesda, MD, U.S.A. Potential Biological Signifiance of a Secondary RNA Start Site within the HIV-LTR. Josejh D. Mosca*, D. P. Bednarik**, *Henry M. Jackson Foundation for Advancement of Military Medicine, Rockville; **The Johns Hopkins Oncology Center and Department of Immunology and Infectious Diseases, Baltimore, MD, U.S.A. Regulatory Elements in the LTR (HIV-1) Responsive to Glucocorticoid Stimulation. Ronald S. Snart*, V. Heisig**, J. F. Physiologie cellulaire, Paris, France; **University of Hamburg, Hamburg, Federal Republic of Germany. Mechanism of HIV-1 Infection of Mononuclear Phagocytes. William A. O'Brien, Y. Koyanagi, I. S. Y. Chen, University of California at LosAngeles, School ofMedicine, LosAngeles, CA, 6 juin Tuesday, June 6 Le SIDA et l'individu AIDS and the Individual DMtenus: contraintes et d6fis Prisoners: Constraints and Challenges Michel R. Morissette (Canada) Kathleen Kay (Switzerland) 11:00 T.D.O.1 11:15 T.D.O.2 11:30 T.D.O.3 11:45 T.D.O.4 12:00 T.D.O.5 HIV in Prison: A Test Case for Human Rights. Timothy Harding, University Institute of Legal Medicine, Geneva, Switzerland. Risk Behaviour in Prison: Sexual Activity. Bruno Gravier, Service Mddico-psychologique rdgional, Paris, France. AIDS and Intravenous Drug Users: The Challenge for the Jail Administrator. Steven Thomas., Department of Correction, New York, NY, U.S.A. Constraints to the Implementation of Preventive Measures in Prison. Patrick Hynes. Prison Medical Services, London, U.K. Approaches to the Seropositive Prisoner. Elizabeth Kantor, San Francisco County Jails; University of California, San Francisco, CA, U.S.A. 251 [Page 252](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/254) 11:00- 12:30 0 Salle ll Room 411A Section D Mardi 6 juin Tuesday, June 6 Le SIDA et I'individu AIDS and the Individual S6ance th6matique Recherches sur le comportement (partle 2) Research (Part 2) Pr6sidents Chairpersons L. Adeorin (Nigeria) Jean Barry (Thailand) Pierre Dionne (Canada) 11:00 T.D.O.6 11:15 T.D.O.7 11:30 T.D.O.8 11:45 Perceived Need for Behavioural Change: Distinguishing between Groups at Risk of HIV Infection in a Longitudinal Cohort of Gay and Bisexual Men. David L. Cohn*, B. Bartholow*, K. O'Reilly**, F. Judson*, *Denver Disease Control Service, Denver, CO; **Centers for Disease Control, Atlanta, GA, U.S.A. Situational Factors Associated with, and Rationalizations Employed to Justify Unprotected Intercourse in Gay Men. Peter J. Grant*, R. Gold**, M. Skinner*, Victoria; ***Monash University, Melbourne, Australia. Risky Sex Relapse, the Next Challenge for AIDS Prevention Programs: The AIDS Behavioral Research Project. MariaL Ekstrand, R. D. Stall, T. J. Coates, L. McKusick, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. Psychological Status and Risk Behavior in Men Seeking HIV Testing. John W. Bobo, B. Fishman, S. Perry, L. Jacobsberg, J. Ryan, Cornell University Medical College, New York, NY, U.S.A. Tension Reduction Expectancies Underlie the Effects of Alcohol Use on AIDS: Risk Behavior among Homosexual Males. David J. McKirnan*, P. L. Peterson**, *University of Illinois at Chicago, Chicago, IL; **University of Alabama at Birmingham, AL, U.S.A. HIV Risk Behavior Screening: Concordance between Assessments through Interviews and Questionnaires. Sevgi O.Aral. L. S. Magder, G. S. Bowen, Centers for Disease Control, Atlanta, GA, U.S.A. 252 [Page 253](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/255) 11:00 - 12:30 Sane 411 Room 411B Section E Mardi 6 juin Tuesday, June 6 Le SIDA, la societ6 et le compotement AIDS, Society and Behaviour Les services soclaux: exp6riences et 6valuations Table ronde Round Table Social Services: Experiences and Evaluations Pr6sidents Chairpersons Marie Berlinguet (Canada) Ralph Garber (Canada) Gayle Chris James (Canada) 11:00 T.E.O.1 11:15 T.E.O.2 11:30 T.E.O.3 11:45 T.E.O.4 New York State's Response to AIDS: A Road Map for Human Services. Cesar A. Perales. B. J. Sabol, J. L. Carples, N. A. Rango, D. P. Whalen, New York State Department of Social Services, Albany, NY, U.S.A. Compte rendu et 6valuation d'une exp6rience de formation le J. Bonneau, Direction de l'Action sociale (Ministkre de la Santd), Paris, France. Evaluation of the Social Service Needs of HIV+ Women Enrolled in a Cohort Study in Kigali, Rwanda. Pauline M. Keogh, C. Almedal, S. Allen, C. Muhawenimana, J. Tice, S. Hulley, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. Obstacles to Use of Public Social Services and Workers in AIDS Prevention and Control Programmes. Gary A. Lloyd, Tulane University School of Social Work, New Orleans, LA, U.S.A. The Social Impact of AIDS in Brazil. Daniel Herbert, Associacao Braseleira Interdisciplinas de AIDS, Rio di Janeiro, Brazil. Social Services Response to AIDS in Quebec. Miriam Green, Ville Marie Social Services, Montreal, QC, Canada. 253 [Page 254](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/256) 11:00 - 12:30 Salle Room 411C Section F Droit et hique Ethics and Law Mardi 6 juin Tuesday, June 6 Colloque Symposium Pr6sidents Chairpersons La confidentialitb et ses limites Confidentiality and Its Limits Michael L. Closen (U.S.A.) Justice T. David Marshall (Canada) of the IssuesMichael L. Closen, Chicago, IL, U.S.A. X v. Y (1988); When is Confidentiality a Legal Right? Dai Harris. The Terrence Higgins Trust Legal Centre, London, U.K. The Stigma of AIDS on the Death Certificate. Michael B. King, Institute ofPsychiatry, London, U.K. AIDS and Privacy: Retaining, Restructuring or Abandoning Medical Confidentiality? H. Patrick Glenn. Y.-M. Morissette, N. Gilmore, M. Somerville, McGill University, Centre fOR Medicine, Ethics and Law, Montreal, QC, Canada. AIDS and the Canadian Privacy Act. John W. Grace, Office of the Privacy Commissioner of Canada, Ottawa, ON, Canada. Medical Privacy for the HIV -- Infected Individual. Clint Hockenberrv AIDS Legal Referral Panel, San Francisco, CA, U.S A. SIDA: Le secret m6dical bouscul6. Patricia Enel, M. P. Larher, J. Charrel, C. J. L. Marco, Laboratoire Santd Montreal, QC, Canada. Commentary. David T. Marshall. University ofOttawa, Ottawa, ON, Canada. 254 [Page 255](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/257) 11:00 - 12:30 Salle R 406BC Section G Mardi 6 juin Tuesday, June 6 International Laboratoire de virologie, Tours, France. Evaluation of HIV Testing. Peter Piot Ddpartement de microbiologie, WHO Collaborating Centre on AIDS, Institut de mddecine tropicale, Belgium. Considerations for Retroviral Serodiagnosis. Phyllis Kanki, Harvard School of Public Health, Boston, MA, U.SA. HIV Testing in Africa. J.-L. Sankale, Universitd de Senegal. HIV Testing Criteria for Africa. Hartmut Hampl, Federal Republic of West Germany. 255 [Page 256](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/258) 11:00 - 12:30 Salle 404AB Room Section H Mardi 6 juin Tuesday, June 6 S6ance th6matique Specialty Session Repercussions &conomiques du SIDA The Economic Impact of AIDS Planification et gestion Planning/Management Anne M. Johnson (U.K.) T.H.O.5 12:15 T.H.O.6 Work Disability among AIDS Clinic Patients. Edward Yelin, R. M. Greenblatt, H. Hollander, J. McMaster, S. Kidd, M. Filson, University of California at San Francisco, San Francisco, CA, U.S.A. Five -- Year AIDS Planning Process at a Health Maintenance Organization. Elizabeth S. Anderson, R. L. Thompson, W. L. Beery, Group Health Cooperative of Puget Sound, Center for Health Promotion, Seattle, WA, U.S.A. Utilization of Community-Based and Hospital Care for Persons with AIDS in San Francisco, 1988-89. Adam C. Stern, R. Chen, L. Udall, Y. Frazier, A. Lifson, G. Rutherford, et al., Department of Public Health, San Francisco, CA, U.S.A. Patient Preference and Satisfaction with AIDS Services. Mary A. Pittman-Lindeman, D. Miller, S. Hernandez, A. Moss, San Francisco Department of Public Health, San Francisco, CA, U.S.A. Publicly-Funded Costs of Community-Based Education Programs by Risk Category in San Francisco. Patricia E. Evans, M. Herring, G. W. Rutherford, J. W. Amory, D. Werdegar, B. Nguyen, San Francisco Department of Public Health-AIDS Office, San Francisco, CA, U.S.A. Community-Based Research in AIDS: CRI as Model. Tom Hannen, New York Community Research Initiative, New York, NY, U.S.A. 256 [Page 257](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/259) 11:00 - Personne est essentielle pour vivre avec le SIDA. Ces films scrutent la vie d'hommes de femmes porteurs l'affaiblissement du systeme immunitaire et k une soci6t6 hostile. Films des Etats-Unis, de Suede, de Grande-Bretagne et du Canada. Self empowerment has become the key to living with AIDS. These videos investigate the lives of those affected by HIV infection and examine alternative means of coping with the hazards of a weakened immune system and a hostile society. Presentations from the United States, Sweden, Britain and Canada. 258 [Page 259](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/261) , Sci Mardi 6 juin 12:45 - 13:45:t& a Section Mrdijui 5 1 4 Tuesday, June 6 Sae 409ABCauio-viswls Room 409ABCAudio-Visual Aspects Sessions du midi VIH et les Noon Hour HIV and Ideas--Theatre and Sessions Transmission: International Examples of Theatre as an Educational Tool Pr6sidents Len Hilgernmann Chairpersons (Etats-Unis/U.S.A.) Herbert Daniel (Br6sil/Brazil) 12:45 Living, New York. (anglais/English).Ane Downer, consultante en dducation de la santd/Health Team, Qudbec, QC, Canada. 13:05 Face to Face, Trinity Theatre, Toronto. (anglais/English). Alan Richardson. directeur/director, Trinity Theatre, Toronto, ON, Canada. 13:15 Puppets against AIDS, AREPP. Gary Friedman and Mike Myvelase, Recherche Africaine et Programme Educatif de marionnettes/African Research and Education Puppetry Programme, de SIDART lors de la Ve Conf6rence internationale sur le sur leurs 6checs. This dynamic session will combine performance of extracts of plays being presented in the SIDART portion of the V International Conference on AIDS along with a short presentation on it's reception in various circumstances and discussion of the successes and failures of it's production. 259 [Page 260](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/262) 14:00 - 15:30 Salle Room 407A Chairpersons et Public Health Transmission sexuelle du VIH (partle 2) Sexual Transmission of HIV (Part 2) King K. Holmes (U.S.A.) A. S. Latif (Zimbabwe) in Edinburgh amongst Heterosexual Injection Drug Users (IDU). Susan J. Davidson*/**, J. R. Robertson**, R. P. Brettle*, *Department of Infectious Diseases, City Hospital; **Muirhouse Surgery, Edinburgh, UX. Co-Factors in the Heterosexual Transmission of HIV in West Germany. Schlomo Staszewski, S. Rehmet, E. B. Zentrum der Inneren Medizin, Infektiologie, Frankfurt, Federal Republic of Germany. Heterogeneous Male-to-Female Transmission of Human Immunodeficiency Virus. Nancy S. Padian, S. Shiboski, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. Risk Factors for HIV Transmission in Steady Heterosexual Couples. Mindell Seidlin, T. Dugan, M. Vogler, D. Krasinski, R. Holzman, New York University Medical School/Bellevue Hospital, New York, NY, U.S.A. Smoking as a Risk Factor for Heterosexual Transmission of HIV-1 in Haitian Women. Neal A. Halsev*, R. Boulos**, E. Holt*, T. C. Quinn*, J. R. Brutus**, A. Rujff, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.; **Centers for Health and Development, Port-au-Prince, Haiti. Risk Factors in Heterosexual Transmission. Paolo Costigliola*, E. Ricchi*, G. Tuesday, June 6 tpid6miologie et sant publique Epidemiology and Public Health Table ronde Round Table Pr6sidents Chairpersons Efficacitd et 6valuation des programmes Programme Effectiveness and Evaluation Richard Lessard (Canada) Patricia O'Connor (Costa Rica) Participants in the First North American Syringe Exchange Program. Don C. Des Jarlais*, H. Hagan**, D. Purchase***, T. Reid**, S. R. Friedman****, *New York State Division of Substance Abuse Services, New York, NY; **Tacoma-Pierce City Health Department, Tacoma, WA; ***Point Defiance AIDS Project, Tacoma, WA; ****Narcotic and Drug Research Inc., New York, NY, U.S.A. Evaluation of the Needle Exchange Program in Amsterdam. Christina Hartaers. E. C. Buning, R. A. Coutinho, *Municipal Health Service of Amsterdam, Amsterdam, Netherlands. Brief Counseling to Reduce AIDS Risk in IV Drug Users: Update. David R. Gibson, J. Lovelle-Drache, S. Derby, M. Garcia-Soto, J. Sorenson, I. Melese-d'Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. Plan for the Prevention and Control of AIDS In Basque Country. D. Zulacia, B. Elizalde, A. Garcia Vasco de Salud, Osakidetza, San Sebastian, Spain. Increasing Condom Sales Following AIDS Education, USA. John S. Moran*, H. R. Janes**, T. A. Peterman*, K. M. Stone*, *Center for Prevention Services, Division of Sexual Transmissions, Centers for Disease Control, Atlanta, GA; **Nielson Marketing Research, Northbrook, IL, U.S.A. Effectiveness of Condom Promotion in a Nairobi Community of Prostitutes. Francis A. Plummer*/***, J. Scarth***, E. N. Ngugi*, P. Waiyaki**, J. O. A. R. Ronald***, et al., *University of Nairobi; **Kenya Medical Research Institute, Nairobi, Kenya; L0pv 6 juin Tuesday, June 6 Table ronde Round Table Presidents Chairpersons tpid&miologie et sant publique Epidemiology and Public Health Signalement du VIH HIV Reporting Ruth L. T.A.O.26 Surveillance for HIV Infection in Minnesota: Results from the First Three Years of Operation. Kristine L. MacDonald, R. Danila, D. Reir, J. Heier, D. Stiepan, M. Osterholm, Minnesota Department of Health, Minneapolis, MN, U.S.A. HIV Infection Reporting in the United States. Jeanette K. Stehr-Green, R. Berkelman, H. Van Patten, J. Curran, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. The Role of HIV Infection Reporting in Public Health. Ruth Berkelman, Centersfor Disease Control, Bethesda, MD, U.S.A. Program Content: * Objectives/rationale of HIV reporting * Does HIV notifiability discourage testing? * Nominal versus non-nominal reporting * Confidentiality issues * Review of HIV reporting in different countries * Mechanisms for reporting Panelists: Molly Coye, Trenton, NJ, U.S.A. O. Noel Gill, London, U.K. Fred Wolf, Denver, CO, U.S.A. 262 [Page 263](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/265) 14:00 - 15:30 Salle oom 401 ABC Section B Mardi 6 juin Tuesday, June 6 Aspects clinques Clinical Aspects of AIDS Table ronde Transmission p6rinatale du VIH Round Table Perinatal Transmission of Catherine Peckham, Institute of Child Health, University of London, London, U.K. Estimates and Projections of Perinatal Transmission of HIV. James Chin, World Health Organization, Global Program on AIDS, Geneva, Switzerland. Modes, Rate, and Risk Factors for Perinatal Transmission of HIV. Martha RogersCentersfor Disease Control, Atlanta, GA, U.S.A. Diagnosis of HIV in Infants. Claude Griscelli, Hdpital des enfants malades, Paris, France. Natural History of HIV Infections in Children. Gwendolvn Scot, University of Miami, School of Medicine, Department of Pediatrics, Miami, FL, U.S.A. 263 [Page 264](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/266) 14:00 - 15:30 Salle Room Section B 6 juin Tuesday, June 6 Colloque Symposium Presidents Chairpersons Aspects cliniques Clinical Aspects of AIDS Diagnostic et histoire clinique de I'infection par le VIH Natural History and Staging of HIV Infection J. P. Coulaud (France) Natural History and Staging of HIV Infection. Robert Redfield. Walter Reed Army Institute of Research, Bethesda, MD U.S.A. Clinical Diagnosis of AIDS and Related Disorders. Henry Masur, Clinical Center, National Institutes of Health, Bethesda, MD, U.S.A. Clinical Diagnosis of HIV Infection in the Developing World. Fernando Zacharias, Pan-American Health Organization, U.S.A. Prognosis Factor. Willy Rozenbaum, Unitd des maladies infectieuses, Salle Rom 403ABC Genes in Simian Immunodeficiency Virus Life Cycle. Xiao-Fang Yu, M. Essex, T. H. Lee, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. Effect of Recombinant Soluble CD4 (rCD4) on Infection of Non-Lymphoid Cells by HIV-1. Kenji Ikeuchi, R. A. Byrn, D. Scadden, S. Goldring, J. E. Groopman, New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. Genetic Analysis of Sequential HIV-1 Isolates from an Infected Lab Worker. Lilly I. Kong*, M. E. Taylor*, D. Waters**, W. A. Blattner***, B. H. Hahn*, G. M. Shaw*, *University of Alabama at Birmingham, Birmingham, AL; **Program Resources Inc., Frederick; ***National Cancer Institute, Bethesda, MD, U.S.A. Molecular Characterization and Complete Nucleotide Sequence Analysis of an Attenuated Isolate of HIV-2. Beatrice H. Hahn*, P. Kumar*, H. Hui*, J. C. Kappes*, J. A. Hoxie**, G. M. Shaw*, *University of Alabama at Birmingham, Birmingham, AL; **University of Pennsylvania, Philadelphia, PA, U.S.A. Antibody Mediated Enhancement of HIV Infectivity: Mechanisms and Significance. Jacques Homsv*, M. Meyer*, M. Tateno*, S. Clarkson**, J. A. Levy*, *University of California at San Francisco, School of Medicine, Cancer Research Institute; **San Francisco General Hospital, Rosalind Russell Rheumatology Laboratory, San Francisco, CA, U.S.A. Serological and Molecular Analysis of the Immunodominant Loop (IL) (296-331 a.a.) from Neutralization Resistant Variants Derived from HIV-I Inoculated Peter L. Nara*, **Program Resources Inc., Frederick, MD, U.S.A.; Medical Centre, Netherlands. 265 [Page 266](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/268) Salle Room 407C Section C 6 Colloque Presidents modbles animaux Origins of Human Retroviruses and Animal Models Myron Essex (U.S.A.) Kenneth Rosenthal (Canada) 14:00 T.C.O.23 14:15 T.C.O.24 The Origins of Human Retroviruses. Myron Essex, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. Transgenic Constructs Involving HIV-1 Genes. Malcolm Martin, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, U.S.A. Relationship Among Primate Retroviruses. Masanori Havami, Institute for Virus Research, Kyoto University, Japan. Primates for the Study of AIDS-Related Disorders. Jorg W. Eichberg, Southwest Foundation for Biomedical Research, Specialty tat des g6nes Molecular Biology: tat-mediated Regulation of Viral Genes Paul Maddon (U.S.A.) Nahum Activates. Sophie Roy*, I. Edery*, N. New York, Syracuse, NY, U.S.A.; ***Washington University, Seattle, WA, U.S.A. Progressive Genetic Changes in HIV-1 tat Gene Coincident with Disease. Andreas Meyerhans*, R. Cheynier*, S. Kwok**, J. Sninsky**, Eqreryville, U.S.A.; ***Karolinska Institute, Stockholm, Sweden. Binding of the HIV-1 tat Protein to tar Sequences In Vitro. Michael A. Skinner. C. Dingwall, I. Ernberg, S. Heaphy, M. J. Gait, J. Karn, MRC Laboratory of Molecular Biology, Cambridge, U.K. SIVmac (BK28) Has the Capacity to Encode Isoforms of the TAT and REV Proteins through Alternative mRNA Splicing. Gregory A. Viglianti. J. I. Mullins, Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. Binding of HIV-1 tat to the 5'Region of mRNA. JayF. Ravaport. S. Josephs, C. Y. Kang, S. Daefler, J. Rusche, F. Wong-Staal, National Cancer Institute, Laboratory of Tumor Cell Biology, Bethesda, MD, U.S.A. CD8+ Lymphocytes Can Control Acute HIV Infection of CD4+ T Cells. Christopher M. Walker. University of California, School of Medicine, Cancer Research Insititute, San Francisco, CA, U.S.A. 267 [Page 268](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/270) 14:00- Chairpersons Section Mardi 6 juin D Tuesday, June 6 Le SIDA et I'individu AIDS and the Individual Les minorit6s Minorities Martha Grieg (Canada) Nzilambi and Retention of Black and Latin Community Leaders in AIDS Prevention Research. Edward S. Morales*, M. Fullilove**, *Center for AIDS Prevention Studies; **Multicultural Inquiry and Research on AIDS, Bayview Hunters Point Foundation, University of California at San Francisco, San Francisco, CA, U.S.A. American Indians/Alaska Natives: Are They at Higher Risk of HIV Infection? Ronald M. Rowell. T. Tafoya, L. Beaulieu, A. Green Rush, National Native American AIDS Prevention Centre, Oakland, CA, U.S.A. Involvement of Native Health Care Providers in Developing an AIDS Prevention Strategy for Native Peoples. Jay Wortman*, M. Rekart**, D. Mearns**, *Division of STD Control, Province of British Columbia; **Vancouver Indian Center Society, Vancouver, BC, Canada. A Video AIDS Prevention Training Program for People Who Are Mentally Retarded/Developmentally Disabled. Raymond M. Jacobs. P. Samowitz, P. Levy, J. Levy, R. Jacobs, Young Adults Institute, New York, N.Y., U.S.A. Deaf Outreach Project on AIDS. Kim Upton*, G. Kerr**, Y. Perreault***, *Ontario Association of the Deaf; **Canadian Hearing Society;***AIDS Committee of Toronto, Toronto, ON, Canada. An AIDS Education Program for Black and Latina Women. Jacquelyn H. Flaskerud, A. M. Nyamathi, University of California at Los Angeles, Los Angeles, CA, U.S.A. 268 [Page 269](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/271) 14:00- 15:30 I Pr6sidents Chairpersons Section D Mardi 6 juin Tuesday, June 6 Le SIDA et l'individu AIDS and the Individual Psychologie et sexologle Psychology and Sexology Ramon Bayes (Spain) Joseph A. Catania Acton**, Hospital, Department of Psychology; **Middlesex Hospital, London, U.K. Social Support, HIV Symptoms and Depression among Gay Men. RobertHays, H. Turner, J. Catania, J. Mandel, T. Coates, CenterforAIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. Modifications of Sexual Behavior Due to AIDS in French Heterosexual \"At Risk\" The Prevalence of AIDS-Risk-Related Sexual Behaviours among White, Middle-Class, Urban American Adults: A Survey of Research from Kinsey to the Present. Stephanie A. Sanders. J. M. Reinisch, M. Ziemba-Davis, The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A. HIV-Positve Gay Men: Sexual Dysfunctions. Heino F. L. Meyer-Bahlburg, A. A. Ehrhardt, J. M. Gorman, R. R. Goetz Jr., New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A. Changes in Lymphocyte Phenotype and Function in HIV Seropositive Homosexual Men Following the Death of a Partner. Margaret E. Kemeny*, R. Durran**, H. Weiner*, S. E. Taylor**, B. Visscher*, J. L. Fahey*, *University of California at Los Angeles, School of Medicine, Department of Microbiology and Immunology; **University of California at Los Angeles, Los Angeles, CA, U.S.A. 269 [Page 270](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/272) 14:00 - juin Tuesday, June 6 Atelier Workshop Pr6sidents Chairpersons Le SIDA, la soci et le corrortent AIDS, Society and Behaviour Empowerment:la rdapproprlation de la sante, les experiences des personnes atteintes Empowerment: Reappropriation of Health and Experience of Persons with AIDS Bernard Lapointe (Canada) Dame Nita PLUSS, an Organization of Body Positives in Norway Encompassing All Groups. Arne N. Husdal, S. Kalbakk, HIV+ leader of the organization Pluss, Oslo, Norway. La place, les responsabilit6s, l'implication dans les maladie. Michiel Garto, AIDES, Fdddration Nationale, Paris, France. The Role of AIDS Service Organizations in Developing Public Health Policy and Services for HIV Disease. James P. Hymes. Philadelphia Department of Public Health, AIDS Activities Office, Philadelphia, PA, U.S.A. Martin Delaney, Project Inform, San Francisco, CA, U.S.A. The Learning about AIDS Project: A Participatory Approach to Health Education about HIV Infection and AIDS. Peter J. Aggleton, Bristol Polytechnic, Department of Education, Bristol, U.K. 270 [Page 271](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/273) 14:00 - 15:30 Sane Room 411C Section F Droit et 4hique Ethics and Law Ethique clinique Clinical Ethics Mardi 6 juin Tuesday, June 6 Colloque Symposium Pr6sidents Chairpersons David J. de recherches cliniques de Montreal, Montrdal, Quebec, Canada. \"Physicians, Ethics and AIDS\": A Framework for Ethical Analysis of HIV/AIDS. MargaretA. Somerville*, N. Gilmore*, **Canadian Medical Association, *McGill University, Centre for Medicine, Ethics and Law, Montreal, QC; **Ottawa, ON, Canada. The Ethical Duty of Health Professionals to Care for Persons with AIDS and HIV Infections. Albert Jonsen. University of Washington, Department of Medical History and Ethics, Washington, DC, U.S.A. HIV Screening for Early Therapeutic Intervention: An Ethical Analysis. Carol Levine*, R. Bayer**, *Citizens Commission on AIDSfor New York City and Northern New Jersey; **Columbia University, School of Public Health, New York, NY, U.S.A. Le M6dicin difficile. G Mardi June 6 Implications intemationales International Issues S6ance th6matique Risques et prevention Specialty Session Risks and Prevention Prisidents Chairpersons Paul Cappon (Canada) Oscar Fay of Perceived Vulnerability to HIV Infection in Sri Lanka. A. H. Mehryar*, M. Carballo*, O. Tawil*, J. Weeramunda**, *Social and Behavioural Research Unit, Global Programme on AIDS, World Health Organization, Geneva, Switzerland; **University of Colombo, Department of Sociology, Colombo, Sri Lanka. The Challenge of Modifying Risky Practices in Well-informed Gay Men. Jose-Antonio Izazola*, J. L. Valdespino*, M. Ramah**, M. Ramos*, *Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico, **AIDSCOM, Washington, DC, U.S.A. Massive Campaign for AIDS Education, Achievements and Problems. Jaime Sepulveda*, J. A. Izazola*, J. L. Valdespino*, M. Mondragon*, J. Townsend**, *Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico, **Population Council. An Internationally Adaptable AIDS Prevention Program for Youth. Wendy Arnold*, S. Mantion**, R. Velly**, L. (JCS); ***Association des Artistes contre le SIDA, Paris, France. Adoption of Safer Sexual Behaviour by an HIV High Risk Group of Bar and Restaurant Workers in Dar es Salaam, Tanzania. Fred S. Mhalu*, C. Akim**, P. Senge**, J. Shao*, U. Bredberg Medical Centre, University ofDar es Salaam; **Dar es Salaam City Council, Dar es Salaam, Tanzania; ***National Bacteriology Laboratory, Stockholm, Sweden. Theory and Practice in Procurement of Safe Blood in Kampala, Uganda. E. J. Watson-Williams, P. Dataaha, S. Coutinho, P. Ssenyonga, E. D. F. Nakasero Blood Bank Project, Ministry of Health, Kampala, Uganda. 272 [Page 273](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/275) 14:00 - 15:30 Sale Room 406BC Section G Mardi 6 juin Tuesday, June 6 Implications intemationales International Issues Colloque Symposium Presidents Chairpersons Compassion et soins communautaires dans les pays en vole de d6veloppement Community Compassion and Care in the Developing World Gloria Ornelas Hall (Mexico) Stephen Uganda. Counselling and Education in the Townships. Alfred Machela, Township AIDS Project, Soweto, South Africa. AIDS Messages and Help to Women in the Thai Sex Industry. Chantawipa Apisook. EMPOWER, Bangkok, Thailand. Counselling in Mexico City. Rosalina Plascencia., CONASIDA, Mexico City, Mexico. Counselling in Bogota. Insitute, London, [Page Room 404AB Tuesday, 6 S6ance th6matique Specialty Session Pr6sidents Chairpersons Repercussions coomiques du SIDA The Economic Impact of AIDS Les coOts dans les pays en vole de d6veloppement Costs in Developing Countries Yamil H. Kouri (U.S.A.) N. Screening Tests. Holly Yona, M. Makinen, ABT Associates Inc., Washington, DC, U.S.A. Prospective Quantification of the Economic and Morbid Impact of Perinatal HIV Infection (PI) in a Cohort of 245 Zairian Infants Born to HIV(+) Mothers. Ntumbanzondo Mposo, B. Bertozzi, S. Hassig, R. Ryder, Projet SIDA, Kinshasa, Zaire. The Economic Impact of HIV Infection in Adult Admissions to Internal Medicine (IM) at Mama Yemo Hospital. Susan E. Hassig*/**, J. Perriens*, E. Baende*, University, New Orleans, LA; Disease AIDS Program, Atlanta, GA, U.S.A.; ****Mama Yemo Hospital, Kinshasa, Zaire. Comparative Study of a Comprehensive Versus a Traditional System of AIDS Health Care in San Juan, Puerto Rico. Yamil Kouri*, J. D. Balling*, J. Garib**, F. Borras***, J. *Harvard Institute for Development, Cambridge, MA, **San Juan AIDS Institute; ***San Juan Department ofHealth; ****Department of Health of the Commonwealth of Puerto Rico, San Juan, Puerto Rico, U.S.A. An Analysis of Direct and Indirect Costs of AIDS and ARC in Mexico. Roberto C. Tapia, A. Martin, J. Lipscomb, J. Bratt, Ministry of Health, Col. Del Valle, Mexico City, Mexico. Costs of AIDS in a Developing Area: Indirect and Direct Costs of AIDS in San Juan, Puerto Rico. Donald S. Shepard*, Y. Kouri*, S. Borras**, J. Garib***, J. Balling*, *Harvard Institute for International Development, Cambridge, MA; **City of San Juan Health Department; ***San Juan AIDS Institute, San Juan, Puerto Rico, U.S.A. situations, trois techniques visuelles: illustration du SIDA au travail et des dilemmes qui en d6coulent, un regard personnel sur une famille aux prises avec une infection par le VIH analyse documentaire des effets n6gatifs de la r6action de la soci6t6 au SIDA. Ces documents offrent une vision 6clairante des problbmes inh6rents a un face a ces difficult6s. Three videos, three situations and three visual techniques: 2 dramatizations of AIDS in the workplace and resulting dilemmas, a personal look at a family dealing with HIV infection, and a documentary analysis of the negative effects of society's response to AIDS. Each gives an insightful look at the problems inherent in a world of fear and prejudice and the various ways by which PWAs cope with these difficulties. 275 [Page 276](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/278) 16:00 - 17:30 Salle Room 407A Section juin Tuesday, June 6 pidniologie et sant publique Health Histoire clinique de i'infection a VIH: manifestations pr6coces et progression Natural History of HIV Infection: Early Manifestation and Progression Randall A. Coates (Canada) Bila M. Kapita (U.S.A.)RI. B. Kemp AIDS within 24 Months. Alfred J. Saah, A. Munoz, R. Fox, R. A. Kaslow, C. Rinaldo, R. Detels, et al., Johns Hopkins School of Hygiene and Public Health and the Multicenter AIDS Cohort Study (MACS), Baltimore, MD, U.S.A. Clinical Course of Primary HIV Infection: Consequences for the Subsequent Course of the Infection. Court Pedersen. B. Lindhardt, B. L. Jensen, E. Lauritzen, J. Gerstoft, E. Dickmeiss, et al., University of Copenhagen, Copenhagen, Denmark. Progression to AIDS in the San Francisco General Hospital Cohort Study. Andrew R. Moss. P. Bacchetti, D. Osmond, B. Brodie, E. Ross, W. Krampf, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. The Natural History of HIV Infection in a Cohort of Homosexual and Bisexual Men: Clinical Manifestations, 1978-1989. George W. Rutherford*, A. R. Lifson*, N. A. Hessol*, S. P. Buchbinder*, L. S. Doll**, H. W. Jaffe**, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA; **AIDS Program, Center for Disease Control, Atlanta, GA, U.S.A. The Probability of Progression to AIDS in a Cohort of Male Sexual Contacts of Men with HIV Disease. Vernon Farewell*, C. Struthers*, R. A. Coates**, *University of Waterloo, Department of Health Studies, Waterloo; **University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. Risk of AIDS Progression Appears Early in HIV Infection. Bruce Douglas, M. T. Schechter, B. Willoughby, W. A. McLeod, P. Constance, M. S. Weaver, et al., The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada. 276 [Page 277](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/279) 16:00- AIDS Epidemic. Philip S.& Rosenberg. M. H. Gail, R. J. Biggar, J. J. Goedert, National Cancer Institute, Bethesda, MD, U.S.A. Statistical Analysis of the Stages of HIV Infection Using a Markov Model. Ira M. Jr Longini*, W. S. Clark*, C. R. Horsburgh**, G. F. Lemp***, R. H. Byers**, W. Darrow**, et al., *Emory University, Altanta, GA; **AIDS Program, Center for Disease Control, Atlanta, GA; ***AIDS Office, Department of Health, San Francisco, CA, U.S.A. Extrapolating Recent Trends to Make AIDS Case Projections. John M. Karon. O. J. Devine, *Centers for Disease Control, Atlanta, GA, U.S.A. Model-Based Optimization of Infectivity Parameters. David J. ghlgren*, M. K. Gorny**, A. C. Stein*, *Trinity College, Department of Engineering and Computer Science, Hartford, CT; **New York University Medical Center, New York, NY, U.S.A. A Risk Behavior Based Model of the Cubic Growth of AIDS in the United States. Stirling A. Colgate*. E. A. Stanley**, J. M. Hyman*, S. P. Layne*, C. Qualls**, *Los Alamos National Laboratory, Los Alamos; ** University ofNew Mexico, Albaquerque, NM, U.S.A. Drugs, Sex and HIV: A Mathematical Model for New York City. Sally M. Blower*, J. M. Courval**, Z. A. Stein**, R. M. May***, R. M. Anderson*, *London University, Imperial College of Science and Technology, London, UX.; **Columbia University and Columbia Presbyterian Medical Center, HIV Center for Clinical and Behavioural Studies, New York State Psychiatric Institute, New York, U.S.A.;***Oxford University, Oxford, U.K. 277 [Page 278](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/280) 16:00 - 17:30 Salle Room 408BC Section A Mardi 6 juin Tuesday, June 6 Table ronde Round Table Pr6sidents Chairperson pidnmiologie et santA publique Epidemiology and Public Health Evaluation de I'efficacitd des programmes de pr6vention Evaluation of Preventive Programme Effectiveness Richard Biritwum (Switzerland) David Heymann (Switzerland) 16:00 T.A.O.41 Program Content: * Surveillance * Serosurveillance * Indicators of process and programme effectiveness * Methods of collecting indicator information * Evaluation in the development of programme interventions Panelists: Richard Biritwum, Geneva, Switzerland. Jean-Baptiste Brunet, Paris, France. Therese Mulandi, Nairobi, Kenya. Ron Waldman, Atlanta, GA, U.S.A. 278 [Page 279](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/281) 16:00 - 17:30 Salle Room 401ABC Tuesday, 6 S6ance th6matique Specialty Session Pr6sidents Chairpersons Aspects ciniques Clinical Aspects of AIDS Traltement de la PCP PCP Treatment John R. Black (U.S.A.) Michael J. Davis Double Trial. A. Bruce Montgomerv*, R. J. Edison**, P. Hopewell**, F. R. Sattler***, J. Feinberg****, D. W. Feigal**, et al., *Department of Pulmonary Medicine, State University of New York, Stony Brook, NY; **University of California at San Francisco, San Francisco; ***\"\"\"University of Southern California, Los Angeles, CA; ****NIAID, Rockville, MD, U.S.A. The Improving Survival Rate after Intensive Care for P. carinii Pneumonia and Respiratory Failure. Robert M. Wachter*, M. B. Russi**, P. C. Hopewell**, J. M. Luce**, *Robert Wood Johnson Clinical Scholars Program, Stanford University, Stanford; **San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.SA. Trimetrexate (TMTX) Salvage Therapy of PCP in AIDS Patients without any Therapeutic Options: Interim Results of the 1st AIDS \"Treatment IND\" Protocol. Judith Feinberg, D. Katz, C. McDermott, M. Myers, D. Hoth, AIDS Program, NIAID, Rockville, MD, U.S.A. Oral Corticosteroids Prevent Respiratory Failure in AIDS-Related Pneumocystis carinii Pneumonia. Julio SG.Montaner. L. Lawson, N. Levitt, A. Belzberg, M. Schechter, J. Ruedy, AIDS Research Program, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Eflornithine in PCP Cases Resistant to Conventional Therapy. Don E. Smith. S. Owen, M. Nelson, B. G. Gazzard, St. Stephen's Hospital, London, U.K. Clindamycin/Primaquine for P. carinii Pneumonia in AIDS. Emil Toma. S. Fournier, M. Poisson, R. Morisset, D. Tuesday, June 6 Colloque Symposium Pr6sidents Chairpersons cliniques Clinical Aspects of AIDS Problimes de laboratoire dans le diagnostic du SIDA Laboratory Issues in the Diagnosis of AIDS Frangoise malades, Paris, France. Serology Tests for the Diagnosis of AIDS. Michael O'Shaughnessv. Federal Centre for AIDS, Ottawa, ON, Canada. Immunological Markers. Jeffrev Lawrence, Cornell University Medical School, New York, NY, U.S.A. Viral Culture as an Adjunct to Clinical Trials: Isolation of AZT-Resistant Variants of HIV-1. Mark A. Wainbergp Jewish General Hospital and McGill University, Montreal, QC, Canada. New Technologies of the Diagnosis of AIDS. Gerald Schochetman., AIDS Program, Centers for Disease Control, Bethesda, MD, U.S.A. 280 [Page 281](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/283) 16:00 - 17:30 Room 403ABC (Biomedical) Virologle (partle 2) Virology (Part 2) Gregory Hammond (Canada) Francisco A. Machado Ramirez (Cuba) G. M. Which Serve as Targets for ADCC Using Human Monoclonal Antibodies. Douglas S. TyLer*, S. Zolla-Pazner**/***, M. Gorny**, S. D. Stanley*, D. P. Bolognesi*, K. J. Weinhold*, *Duke University Medical Center, Department of Surgery, Durham, NC; **New York University Medical Center; New York VA Medical Center, New York, NY, U.S.A. Functional Domains on the HIV-1 Envelope Protein. Patricia L. Earl, B. Moss, National Institutes of Health, Bethesda, MD, U.S.A. Putative Interaction Site between HIV gpl20 and gp41: Antiviral Action of Synthetic Peptides. Dale A. McPhee*. N. Pavuk*, S. Cumming*, of The Transmembrane Glycoprotein is a Hovanessian, Institut Pasteur, Unitd d' virale, Paris, France. Definition of Epitopes Along an Immuno-Dominant Region of the HIV-1 gp41 and the Effect of Conservative and Non-Conservative Amino Acid Substitutions Corresponding to Various HIV-1 Isolates. Peter Horal*, B. Svennerholm*, S. Jeansson*, L. Rymo**, A. Vahlne*, Is in a Containing Compartment of the Golgi Complex. Barry S. Stein*, K. S. Steimer**, E. G. Engleman*, *Stanford University School of Medicine, Blood Center, Palo Alto; **Chiron Corporation, Emeryville, CA, U.S.A. 281 [Page 282](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/284) Salle Room 407C Modbles animaux 1) Animal Models (Part 1) Patricia Fultz (U.S.A.) Alain J. Georges (South Passive Protection. Malcom R. MacKenzie, C. Zaiss, P. Marx, D. Maul, N. Lerche, University of California at Davis, Sacramento, CA, U.S.A. Genetic Characterization of an Acutely Lethal Variant of SIV/SMN. Pierre Soni o*, F. Laure***, Center, Atlanta, GA, U.S.A.; U.75, CHU Necker, Paris, France. Characteristics of SIV AGM Isolated from Wild Caught Animals in Central African Republic (CAR). Francoise Barrd-Sinoussi*, M. C. Georges-Courbot**, M. C. Lang*, P. of California at Davis, Davis, CA, U.S.A. Prophylactic Effects of AZT Following Exposure of Macaques to an Acutely Lethal Variant of SIV (SIV/SMM/PBj-14). Harold M. McClure*, D. C. Lehrman**, *Emory University, Atlanta, GA; **Burroughs Wellcome Company, Department of Virology, Research Triangle Park, NC, U.S.A. SIV from Sooty Mangabey Monkeys: An African Primate M. Hirsch*, M. Murphey-Corb**, P. R. - National Institute ofHealthlTwinbrook II, Rockville; **Delta Regional Primate Research Center, Covington, LA, U.S.A. HIV-1 Infection of Human PBL-Reconstituted SCID Mice. Donald E. Mosier*, R. J. Gulizia*, S. A. Spector**, D. H. Spector**, S. M. Baird**, D. B. Wilson*, *Medical Biology Institute, La Jolla; **University of California at San Diego, San Diego, CA, U.S.A. 282 [Page 283](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/285) 16:00 - 17:30 Salle Room 41OABC leurs produits Molecular Biology: Genes and Their Products Bryan Cullen (U.S.A.) John Product in SIVmac Infected Cells. Sabine Lang, G. Jaenel, M. Weeger, molekulare Erlangen, Federal Republic of Germany. Viral Protein R (CPR) of HIV-1 and HIV-2 Is Dispensable for Replication and Cytopathicity. Douglas Dedera, W. Hu, N. Vander Heyden, L. Ratner, Washington University, Departments of Medicine and Microbiology and Immunology, St-Louis, MO, U.S.A. Functional Characterization of the HIV-1 vpu Gene Product: Not Just Another Protein. Klaus Strebel, T. Klimkait, F. Maldarelli, M. A. Martin, NIAID, National Institutes of Health, Laboratory of Microbiology, Bethesda, MD, U.S.A. Analysis of a Functional HIV-2 REV Gene. Sylvie Paulous, M. Emermen, A. Cordonnier, Institut Pasteur, Paris, France. Analysis of a Potential HIV-1 Coding Sequence. Eric A. Cohen, Y. Jalinoos, E. Terwilliger, Y. C. Lu, W. Haseltine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, U.SA. Identification of Novel HIV- 1 mRNAs by S 1 Nuclease Analysis and PCR Amplification. Barbara K. Felber*, S. Schwartz**, M. Fenyo**, G. Cancer Institute-FCRF, BRI-Basic Program, Room Presidents Chairpersons Section D Mardi 6 juin Tuesday, June 6 Le SIDA et I'individu AIDS and the Individual Les adolescents (partle 2) Adolescents (Part 2) Anna Giovanetti (Italy) Alan J. C. King (Canada) M. Models about HIV and Condoms Predict Condom Use? Ralph W. Hingson, L. Strunin, Boston University School of Public Health, Boston, MA, U.S.A. Predictors of Condom Use and STDs in a Group of Sexually Active Adolescent Women. Ruth M. Greenblatt*, J. Catania*, S. Kegeles*, J. Schachter*, J. Miller**, T. Coates*, et al., *University of California at San Francisco, San Francisco; **Planned Parenthood of Santa Cruz, Santa Cruz, CA, U.S.A. Peer Education Program Reaches High Risk Adolescents with AIDS Information and Prevention. Wendv Arnold, F. Barnes, Adolescent Alliance, Los Angeles, CA, U.S.A. An Evaluation of an AIDS Risk Reduction Education and Skills Training (ARREST) Program for Adolescents. Michele D. Kipk., C. Boyer, K. Hein, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, U.S.A. Steps in Developing a Sex Education, STD and AIDS Program for Adolescents in Brasil. L. G. M. Rodrigues, R. Cavalcante, Brasilia, Brazil. Youth at High Risk for HIV: Knowledge, Sexual Practices and Intentions to Inform Sexual Partners of HIV Status. [ydij Temoshok*, R. M. Ellmer*, J. M. Moulton*, M. Baxter**, J. Shalwitz**, *University of California at San Francisco, School of Medicine; **San Francisco Department of Public Health, San Francisco, CA, U.S.A. 284 [Page 285](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/287) 16:00 - 17:30 Pr6sidents Chairpersons Section D Mardi 6 juin Tuesday, June 6 Le SIDA et I'individu AIDS and the Individual Counseling Counselling Daniel Defert (France) Maria Eugene Fernandez (Brazil) Counsellors in Gaol. Kim Begley*, S. Lyons**, L. McCallum**, L. Sydney Hospital, Sydney; **Bathurst Gaol; ***NSW Department of Corrective Services, Australia. Optimizing Inner City Prenatal AIDS Counselling. Theresa C. Mendez*, H. W. Lischner*, S. A. Raphael*, M. M. Olson*, A. W. Cohen**, Steinberg*** for Children; **University of ***Episcopal Hospital, Philadelphia, PA, U.S.A. Problems Counselling Undereducated People Regarding HIV-1 Serologic Results. Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A. Are Patients Getting the AIDS Education They Want from Their Physicians? Barbara Gerbert, B. Maguire, T. Coates, University of California at San Francisco, San Francisco, CA, U.S.A. Special Problems Involved in Counselling of HIV-Infected Homosexuals and Hemophiliacs. Giinter Reisbeck., M. Ermann, G. Hutner, M. M. Schneider, O. Seidl, W. Schramm, University of Munich, Department of Psychotherapy and Psychosomatics of the Psychiatric Clinic, Federal Republic of Germany. Condom Use and Associated HIV Seroconversion Following Intensive HIV Counselling of 122 Married Couples in Zaire with Discordant HIV Serology. Munkolenkole Kamenga*, K. of Health, Bethesda, MD, U.S.A.; ***Centers for Disease Control, Atlanta, GA, U.S.A. Chairpersons Section E Mardi 6 juin Tuesday, June 6 Le SIDA, la soci6t6 et le comportement AIDS, Society and Behaviour Problmes de la communaut6 gale The Gay Community Issues J. K. Gaifuba (Uganda) Michael Pollak SIDA. Michael Pollak, Author, Paris, France. Coverage of Selected Drugs Under State Medical Assistance (Medicaid) Programs in the U.S.A.. Benjamin H. Schatz, AIDS Civil Rights Project, National Gay Rights Advocates, San Francisco, CA, U.S.A. Networking: A Prevention and Care Strategy for the Gay Minority in South Africa. John V. Pegge, G. Isaacs, S. D. Miller, Gasa/6010 Counselling Service, Woodstock, Cape Town, South Africa. Homophobia in the Development of Public Policy on AIDS in the United States of America. Eric Rosenthal, A. Ziegler, Human Rights Campaign Fund, Washington, DC, U.S.A. Organizational Preconditions for Community Action. Melinda A. Cuthbert, Yale University, New Haven, CT, U.S.A. 286 [Page 287](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/289) 16:00 - 17:30 Sae Room Section 6 Colloque Symposium Pr6sidents Chairpersons Droit et 6thique Ethics and Law Infection par le VIH, reproduction et fonction parentale HIV Infection, Reproduction and Parenthood Bernard Dickens the Issues. Bernard Dickens, Faculty of Law, University of Toronto, ON, Canada, Ethical Dilemmas in Pediatric and Maternal AIDS. Anne D. Willoughby, A. Wright, A. Novello, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, U.S.A. Should HIV Positive Women Have Children? An Ethical Perspective. John D. Arras, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A. Uninfected Children of Infected Women: The Hidden Pediatric Epidemic. Sheldon Landesman. State University of New York, Health Science Centre, New York, NY, U.S.A. Ethical Implications of HIV/AIDS Among Mothers and Children in Kenya. Philista Onyango, Nairobi, Kenya. AIDS and Reproductive Health in the African Setting. Dorothy Temu. Tanzania. Commentary. Ruth Macklin, Albert Einstein College of Medicine, New York, NY, U.S.A. 287 [Page 288](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/290) 16:00 - 17:30 Salle 406A Room 6 juin S6ance th6matique Specialty Session Presidents Chairpersons Iplications intemationales International Issues 2) Prevalence (Part Alix Adrien (Canada) in Pregnant Haitian Women: 1986 through 1988. Reginald Boulos*, N. Halsey**, E. Holt**, T. Quinn**, A. Ruff**, J. R. Brutus*, al., *Centers for Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A. HIV-1 in Hospitalized Haitian Pediatric and Adult Patients. Mario Adrien*, R. Boulos*, A. Louis*, F. Joseph*, P. Kissinger*, N. *Centers for Health and Development, Port-au-Prince, Haiti; **Johns Hopkins University, Baltimore, MD, U.S.A. Prevalence of HIV-l1 and HTLV-I in Gonaives, Haiti. Judith A. Fortney*, M. G. Bonhomme*, T. C. Quinn***, F. Lebrun**, N. Halsey***, et al., *Family Health International, Research Triangle Park, NC, U.S.A.; **Centre pour le Ddveloppement et la Santd, Port-au-Prince, Haiti; ***Johns Hopkins University, Baltimore, MD, U.S.A. Rising Prevalence of Antibodies against Human Immunodeficiency Virus (HIV-1) in Western Maharashtra, India. Kaylan Baneriee, National Institute of Virology, Pune, Maharashtra, Choopanya*, *Bangkok Metropolitan Administration; **Division of Epidemiology, Ministry of Public Health, Bangkok, Thailand. AIDS in Papua New Guinea: Heterosexual Transmission and Some Important Local Considerations. Clement Malau. B. Currie, P. Mondia, T. Pyakalyia, Department of Health, Papua, New Guinea. 288 [Page 289](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/291) 16:00 - 17:30 Salle Room 406BC Section G 6 juin Tuesday, June 6 Atelier Presidents T. Un-eklabh, W. Rojanapithayakorn, Chulalongkorn University, Department of Medicine, Bangkok, Thailand. HIV Transmission Through Blood/Blood Products in India: Difficulties in Control and Suggested Strategies. Khorshed M. Pavri. ICMR Centre for AIDS Research and Control, Pune, India. Health Education Strategies in Control. Shankar Choudhuryv Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India. Strategies for Regional and International Cooperation. S. Pattanavak, World Health Organization, New Delhi, India. 289 [Page 290](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/292) 16:00 - 17:30 Salle Room Tuesday, 6 S6ance th6matique Specialty Session Pr6sidents Chairpersons Repercussions conomiques du SIDA The Economic Impact of AIDS Impact macroeconomique dans les pays en vole de d6veloppement Macroeconomic Impact in Developing Countries Gerald M. Desmond (U.S.A.) N. Hiza (Tanzania) A. Impacts of the AIDS Pandemic: A Co-Ordinated Response by the United Nations System. Gerald M. Desmond, Department of International Economic and Social Affairs, United Nations, New York, NY, U.S.A. The Migrant labour System and its Implications for HIV Transmission. Eddie Webster, National Union of Mineworkers, South Africa. A Production Function Approach to Estimating the Aggregate Macroeconomic Impact of AIDS on Central African Economies. Mead Over, The World Bank, New York, NY, U.S.A. Some Economic Implications of Introducing Control Measures to Reduce the Spread of HIV Infection in Sub-Saharan Africa. Jane T, F. Rowley, T. W. Ng, R. M. Anderson, Imperial College, Pure and Applied Biology, London, U.K. A Medium-Run Model for the Analysis of the Economic Impact of AIDS in Sub-Saharan Africa.Gerard Kambou, Ivory Coast. 290 [Page 291 [Page 292](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/294) Les films de France, de Belgique, de Suisse et du Qu6bec traitent de multiples aspects du SIDA, des campagnes d'information pour les jeunes au contexte international du SIDA, avec des reportages tres personnels. Presentations from France, Belgium, Switzerland and Quebec, these videos address many aspects of AIDS ranging from general information for youth, the international context of AIDS, to very personal accounts. 292 [Page 293](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/295) Notes [Page 294](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/296) Section Mardi June 6 1pid6miologie et sant6 publique Epidemiology and Public Health Session d'affichage Poster Session Prevalence rdgionale du VIH Regional HIV Prevalence T.A.P.1 Virus santd, Yaounde, Cameroon. T.A.P.2 Epidemiology of HIV Infection in Greater Tel Aviv. Michael Burke*, N. Vardinon, A. Hasner, M. Hoffman, I. Yust, *Tel Aviv Medical Center, Tel Aviv, Israel. T.A.P.3 Prevalence of STD and HIV-1 in Risk Groups and Control Populations in Various Regions in Senegal. Fred Van der Veen*, I. Ndoye, S. M'Boup, N. Extent of Heterosexual HIV Transmission in England and Wales: Evidence from Surveillance Data. O Noel Gill*, J. D. H. Porter, G. A. Ellam, S. E. Clarke, K. Porter, E. Miller, et al., *PHLS Communicable Disease Surveillance Centre, Colindale, U.K. T.A.P.5 Temporal Trends of HIV Infection by Risk Indicator in the Latium Region, Italy. Carlo A. Perucci*, M. Arch, D. Abeni, P. Chierchini, N. Orchi, T. Spadea, *Regional Epidemiology Unit of Latium Region, Rome, Italy. T.A.P.6 HIV Serology in Ontario, 1985-1988. Bernadette McLaughlin*, C. J. Major, V. Bond, B. Gregory, G. Strunc, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada. T.A.P.7 HIV Infection Surveillance in Poland. Jacek R. Juszczvk*, D. Naruszewicz-Lesiuk, A. Stapinski, H. Seyfried, B. *Medical Academy, Clinic of Infectious Diseases, Poznan, Poland. T.A.P.8 Apparent High HIV Seroprevalence among Heterosexual Men of Mexico City. Carlos L. Magis*, M. L. Garcia, E. Bravo, E. Uribe, J. L. Valdespino, G. Ornelas, et al., *Direccidn General de Epidemiologia, Secretarta de Salud, Mexico City, Mexico. T.A.P.9 The Epidemiological Situation of HIV in the Federal Republic of Germany. Results Based on Mandatory Reports of Laboratories. Horst-G inter Maxeiner*, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany. 294 [Page 295](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/297) T.A.P.10 Seroepidemiology of Enzensberger, S. Staszewski, *Department of Medical Virology, University Clinic of Frankfurt, Frankfurt, Federal Republic of Germany. T.A.P.11 Anti-HIV Seroprevalence in Adult Rural Populations of Uganda and Its Implications for Preventive Strategies. Jane Frances Kengeya-Kayondo*, A. Amaana, J. R. Ndumu, W. Naamara, *Uganda Virus Research Institute, Entebbe, Uganda. T.A.P.12 4 Year Follow-up Study of the HIV Infection in High Risk and Control Groups in Martinique (FWI). Roger Chout*, D. Cales-Quist, M. at Risk of AIDS? W. Robert Lange*, E. M. Dax, R. Kovacs, D. Kreider, J. D. Frame, *Johns Hopkins Medical Institutions, Medical Advisors Office, Baltimore, MD, U.S.A. T.A.P.14 High-Risk Heterosexuals: Differences between Private and Commerical Partners in Sexual Behavior and Condom Use. Christa Hooykaas*, J. Van der Pligt, G. J. J. Van Doornum, M. M. D. Van der Linden, R. A. Coutinho, *Municipal Health Service ofAmsterdam, Amsterdam, Netherlands. T.A.P.15 Seroprevalence of HIV Infection among Migrant Farmworkers. John P. Narkunas*, K. L. Castro, S. Reig, *Centersfor Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. T.A.P.16 Prevalence of HIV-1 Infection among College Students. Kren L. Kotloff*, C. Tacket, M. Bridwell, J. Cowan, S. Wasserman, T. Quinn, *University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, U.S.A. T.A.P.17 HIV Seroprevalence in Transvestites of the City of Sao Paulo. Galvao Ayroza*, J. Suleiman, G. Suleiman, *Faculdade de Ciencias Mddicas, Hospital Emilio Ribas, Sao Paulo, Testing? Sirkka-Liisa Valle*, S. *University Central pr6cautions P. Boisson, *CNRS-GSPM, Paris, France. T.A.P.20 Changes in Sexual Behavior Connected to Strong Decline in HIV Incidence among Homosexual Men. Godfried J. P. Van Griensven*. E. M. M. De Vroome, J. Goudsmit, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands. T.A.P.21 Incidence of HIV-1 Infections among Homosexual Men in Dallas, Texas, 1987-88. Charles E. Hale*, A. Freeman, P. Anderson, A. Petty, K. O'Reilly, *Dallas County Health Department, Dallas, TX, U.S.A. 295 [Page 296](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/298) T.A.P.22 Prevalence and Seroconversion for HIV Infection in Homosexual and Bisexual Men in Madrid. Francisco Bru*, F. Babin, C. Colomo, I. Pascual, M. Rua-Figueroa, *Ayuntamiento de Madrid, CPS Centro, Madrid, Spain. T.A.P.23 Trends in HIV Antibody Positive Admissions to a Connecticut Community Hospital. Gayle M. Madden*, C. A. Smith, *St. Francis Hospital and Medical Center, Hartford, CT, U.SA. T.A.P.24 HIV Screening in an Urban Hospital Outpatient Population. Michael Marmor*, K. Krasinski, M. Sanchez, H. Cohen, N. Dubin, L. Weiss, et al., *New York University Medical Center, New York, NY, U.SA. T.A.P.25 Surveillance hospitalibre de Clinique des Maladies Infectieuses, CHRU Bordeaux, T.A.P.26 Increase in the Reported Number of HIV-infected Patients in U.S. Dialysis Centers from 1985-1987. Martin S. Favero*, M. J. Alter, *Centers for Disease Control, Hospital Infections Program, Atlanta, GA, U.S.A. T.A.P.27 HIV Antibody in Chronic Hemodialysis Patients, United States. Ruthanne Marcus, Cooperative Dialysis Study Group, Centers for Disease Control, Atlanta, GA, U.S.A. Le VIH chez les consommateurs de drogues par vole intraveineuse HIV in Intravenous Drug T.A.P.28 Prevention of HIV-Infection in Parenteral Drug Abusers (PDAs): About Evaluation and Efficacy of Opiate-Substitution Treatment. Reinhard Bornemann*, G. Grimm, B. Wolf, F. Bschor, *Institut far Rechtsmedizin, Freie Universitdt Berlin, Berlin, Federal Republic of Germany. T.A.P.29 HIV and Hepatitis B Infection Associated with Different Risk Behaviors. Berl A. Koblin*, J. McCusker, B. Lewis, J. Sullivan, B. Patashnik, F. Birch, *University of Massachusetts at Amherst, Amherst, MA, U.S.A. T.A.P.30 Report on an Extremely Low Rate of Seropositivity among I.V. Drug Users (IVDU) in a Local Health District of (LHD) North East Italy. Paolo Mezzelani*, F. of Human Immunodeficiency Serostatus and Risk-Taking in a Cohort of 203 Intravenous Drug Users. Carol A. Skidmore*, J. R. Robertson, *Edinburgh Drug Addiction Study, Muirhouse Medical Group, Edinburgh, U.K. T.A.P.32 Prevalence of Syphilis (S), HTLV-I (I), HTLV-II (II) and HIV-1 among Crack (C) and Other Drug Users (DUs). Jordan B. Glaser*, J. Monnier, K. D'Angelo, A. Drakatos, B. Poiesz, G. Ehrlich, et NY, T.A.P.33 Needle Sharing Practices among Intravenous Drug Users in a State Allowing the Purchase of Injection Equipment. William L. Atkinson*, D. Lawrence, A. Lauro, *Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, U.S.A. T.A.P.34 The AIDS Problem and Drug-Rehabilitation in Therapeutic Communities (TC). Marco Olgiati. Zurich University Hospital, Department of Social Psychiatry, Zirich, Switzerland. T.A.P.35 Coordinated Community Program for HIV Surveillance among IVDU. Beniamin F. Lewis*, J. Sullivan, F. Birch, J. McCusker, B. Koblin, S. Noone, et al., *Spectrum House Inc., Westboro, MA, U.S.A. T.A.P.36 No Trend in Yearly HIV-seroprevalence Rates among IVDU in Amsterdam: 1986-1988.Harr. A. Van Haastrecht*, J. A. R. Van Den Hoek, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands. T.A.P.37 Epidemiology of AIDS Associated with Intravenous Drug Use, United States, 1979-1988. Nicholas Crofts*, L. Petersen, R. Selik, J. Buehler, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. T.A.P.38 Second National Survey on HIV Infection, At-Risk Behaviours and Behavioural Change among Italian Drug Users. H. Sasse, S. Conti, *Istituto Superiore di c.' HIV Infection among Intravenous Drug Abusers (IVDAs) in Low Prevalence Cities. Robert J. Battes*, R. W. Pickens, *National Institute on Drug Abuse, Rockville, MD, U.S.A. T.A.P.40 Heterosexual Transmission of HIV among Intravenous Drug Abusers (IVDAs). Robert J. Battes*, Z. Amsel, R. W. Pickens, P. Sholinsky, L. Ritz, L. S. Brown, *National Institute on Drug Abuse, Rockville, MD, U.S.A. T.A.P.41 Incidence and Risk Factors of HIV Infection in a Cohort of Italian Drug Addicts (NISDA Study). Alfredo Nicolosi. NISDA, National Research Council, Department of Epidemiology, ITBA, Milan, Italy. T.A.P.42 HIV Serostatus and Risk Behaviors of Street IVDUs. Nancy H. Corby*, F. Rhodes, R. J. Wolitski, *Long Beach Health Department, Long Beach, CA, U.S.A. T.A.P.43 A Comparison of HIV-1 Infection Rates in Minnesota (MN) IV Drug Users between 1987 and 1988. Kristine L. MacDonald*, J. Thomas, R. Danila, M. Osterholm, J. Shultz, C. Falkowski, et al., *Minnesota Department of Health, Minneapolis, MN, U.S.A. T.A.P.44 Is Condom Use an Independent Risk for HIV in IV Drug Users? David D. Celentano*, D. Vlahov, J. C. Anthony, M. Bernal, *Johns Hopkins University School ofHygiene and Public Health, Baltimore, MD, U.S.A. T.A.P.45 Risk Factors for HIV-1 Infection among Intravenous Drug Users (IVDU) (1978-1987). David Vlahov*, A. Mufioz, D. D. Celentano, S. Cohn, M. Shapiro, J. C. Anthony, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. 297 [Page 298](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/300) T.A.P.46 Association between Former Place of Residence and Serostatus of IVDUs in South Florida. Mary Comerford*, D. D. Chitwood, C. B. McCoy, E. J. Trapido, *University of Miami Medical School, Miami, FL, U.S.A. T.A.P.47 HIV Infection in Female Intravenous Drug Users in San Francisco. Andrew R. Moss*, A. Keffelew, P. Bacchetti, R. Meakin, B. Brodie, A. R. Moss, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. T.A.P.48 Drug Abuse Patterns and Ethnicity in IVDA during the Early Years of the HIV Epidemic. David M. Novick*, H. L. Trigg, D. C. Des Jarlais, S. R. Friedman, D. Vlahov, M. J. Kreek, et al., *Beth Israel Medical Center, New York, NY, U.S.A. T.A.P.49 Demographic and Behavioral Features of HIV Infection in Intravenous Drug Users (IVDUs) in New York City Drug Treatment Programs: 1985-1988. Lawrence S. Brown*, R. Phillips, D. Ajuluchukwu, R. Battjes, B. J. Primm, T. Nemoto, *Addiction Research and Treatment Corporation, Brooklyn, NY, U.S.A. T.A.P.50 Intravenous Drug Use as a Risk Factor for AIDS and HIV Infection in Louisiana, 1981-1988. William Atkinson*, S. Troxler, M. Dal Corso, L. McFarland, *Louisiana Department of Health and Hospitals, New Orleans, LA, U.S.A. T.A.P.51 Transmission of HIV by Mobility in Injection Drug Users (IDU). Raymond P. Brettle*, G. Jones, J. Davidson, C. Bisset, S. M. Burns, J. M. Inglis, *Department of Infectious Diseases, City Hospital, Edinburgh, U.K. T.A.P.52 Comparative HIV Seroprevalence in IV Drug Users (IVDU) from Four Different Testing and Treatment Programs. David L. Cohn*, J. Douglas, J. Koleis, F. Feeney, F. Judson, *Denver Disease Control Service, Denver, CO, U.S.A. T.A.P.53 Human Immunodeficiency (HIV) and Human T-lymphotropic (HTLV-I/I) Virus Infections Associated with Intravenous Drug Abuse (IVDA). Roy W. Stevens*, J. A. Wethers, C. Samsonoff, D. Berns, *New York State Department of Health, Albany, NY, U.S.A. T.A.P.54 HIV Infection among Intravenous Drug Users (IVDUs) in NYC. Benedict I. Truman*, J. S. Lehman, L. S. Brown, N. Peyser, N. Peters, D. Des Jarlais, et al., *New York State Department of Health, Albany, NY, U.S.A. T.A.P.55 HIV Seroprevalence in Injecting Drug Users in South London, 1985-88. Sheena Sutherland*, T. J. McManus, *Dulwich Hospital, London, U.K. T.A.P.56 HIV Seroconversion in a Group of IVDAs (1985-1988). Giorgio Barbarini*, S. Edo, T. Gola, Matteo, HIV Prevalence among Different Groups of Intravenous Drug Users in Seattle, Washington. Robert W. Wood*, J. P. McGough, N. Harris, J. Kleyn, M. Carlisle, *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A. 298 [Page 299](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/301) T.A.P.58 Sexually Transmitted Diseases (STDs) and HIV Seroprevalence in a Cohort of IV Drug Users. Kenrad E. Nelson*, D. Vlahov, L. Solomon, N. Chowdhury, *Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A. T.A.P.59 Sero-Epidemiology of HIV-1 Infection among Drug Users Seeking Medical Help in Montreal: 1985-1988. Julie Bruneau*, F. Comparative Monitoring of HIV-Spread in the IVDU Population of Berlin and Hamburg. Friedrich Bschor. R. Bornemann, K. Pueschel, R. Rex, W. Platz, R. Lueth, Freie Universitit Berlin, Berlin, Federal Republic of Germany. Surveillance du SIDA et marqueurs de I'infection Surveillance of AIDS and Marker Infections T.A.P.61 Underreporting of AIDS Cases, South Carolina, 1986-1987. George A. Conwa*, B. L. Niemeyer, P. Rion, C. Pursley, C. Cruz, C. W. Heath, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. T.A.P.62 Using Death Certificates to Estimate the Completeness of AIDS Case Reporting in Ontario. B. Lily Montano*, R. J. Johnson, E. M. Wallace, *Public Health Branch, Ontario Ministry of Health, Toronto, ON, Canada. T.A.P.63 Risk Group Differences in Reporting Deaths in AIDS Patients. Owen J. Devine*, R. L. Berkelman, J. M. Karon, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. T.A.P.64 High Percentage of Non-Reported Cases of AIDS in Hemophiliacs of the Federal Republic of Germany. Gert G. Frosner, Max von Pettenkofer-Institut, University of Munich, Munich, Federal Republic of Germany. T.A.P.65 Active Surveillance for Pediatric HIV Infection in Los Angeles County. Laurene Mascola*, M. Evans, T. Frederick, J. Church, Y. Bryson, A. Kovacs, et al., *County of Los Angeles, Department of Health Services, Los Angeles, CA, U.S.A. T.A.P.66 Medical School Subcontract Ensures State-wide Active AIDS Surveillance in New Jersey. D. Jean Schneider*, M. A. Lavenhar, *University of Dentistry and Medicine of New Jersey, New Jersey Medical School, Newark, NJ, U.S.A. T.A.P.67 Evaluating Racial Classification among Native American Indians with AIDS in Los Angeles County, California. Loren E. Lieb*, P. R. Kerndt, M. Hedderman, E. Chase, J. S. Yao, G. A. Conway, *Los Angeles County Health Services, Los Angeles, CA, U.S.A. T.A.P.68 Use of Automated Secondary Data Sets for AIDS Surveillance. Cyrus Hamidi*, J. Hidalgo, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A. 299 [Page 300](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/302) T.A.P.69 A Record Linkage Study to Determine the Degree of Under-Reporting of AIDS Cases in Canada. Liviana Calzavara*, K. Craib, R. A. Coates, M. T. Schechter, K. Elmslie, University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. T.A.P.70 Evaluating Completeness of New York's Case Registry. Rita H. Hindin*, P. Thomas, A. Nicholas, N. Miller, S. Schultz, New York City Department of Health, AIDS Surveillance Unit, *New York City Department ofHealth, AIDS Surveillance Unit, Englewood, NJ, U.S.A. T.A.P.71 Linkage of Records of Persons in the New York City (NYC) AIDS Case Registry with Death Certificates Filed in NYC. Rita H. Hindin*, T. P. Singh, P. Thomas, S. Blum, E. Rautenberg, New York City Department of Health, AIDS Surveillance Unit, New York City Department of Health, AIDS Surveillance Unit, Englewood, NJ, U.S.A. T.A.P.72 Trends in the Outpatient Diagnosis of AIDS: Implications for Epidemiologic Analysis and Surveillance. Sharon G. Hopkins*, W. Lafferty, J. Honey, M. Hurlich, *Seattle-King County Department of Public Health, Seattle, WA, U.S.A. T.A.P.73 Hospital-based AIDS Reporting in a High Incidence Area, Houston, Texas, U.S.A. Robert L. Falletti*, N. Cole, A. Phelps, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A. T.A.P.74 Evaluation of AIDS Case Reporting in Massachusetts. Stephanie Oddleifson*, B. Heinze-Lacey, L. Makarewicz, J. Day, G. Seage, *Boston Department of Health and Hospitals, Boston, MA, U.S.A. T.A.P.75 DMAC: A Software for Cooperative Epidemiology of HIV Infection. Valleron*, O. Retel, Paris 7, Paris, France. T.A.P.76 Temporal Trends for Past Sexually Transmitted Disease in Men with AIDS and ARC In San Francisco. David W. Feigal*, H. Hollander, J. Ziegler, M. Clement, P. A. Volberding, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.SA. T.A.P.77 Impact of the Revision of the CDC AIDS Case Definition on Case Reporting. Cyrus amidi*, J. Hidalgo, A. Rogers, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A. T.A.P.78 Effect of the CDC Revised Definition on AIDS Case Reports in New Jersey. Christine M. Grant*, S. Costa, J. Beil, J. Massey, J. Ryan, L. Robeson, *New Jersey State Department of Health, Trenton, NJ, U.S A. T.A.P.79 Retrospective Review of Non-AIDS Reports in New Jersey Based on CDC Revised Surveillance Definition of 1987. Molly J. Cove*, S. Costa, D. Yeager, J. Ryan, J. Massey, J. Beil, *New Jersey State Department of Health, Trenton, NJ, U.S.A. 300 [Page 301](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/303) T.A.P.80 The Effect of the Revised AIDS 1987 Case Definition on the Characteristics of Cases Reported in Upstate New York. Perry F. Smith*, F. Coles, J. Caouette, D. Putnam, L. Chiarello, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.S.A. T.A.P.81 Can the Infection Rate of HBV Serve as a Predictor of HIV Infection? Edna Ben-Porath*, A. Etzioni, Y. Satinger, N. Rimon, S. Pollack, *Rambam Medical Center, Virology Unit, Haifa, Israel. T.A.P.82 Declining Incidence of Acute Hepatitis B among Drug Users in Amsterdam may Indicate a Change in Risk Behavior. Ernst C.Buning*, C. Bardoux, A. Leentvaar-Kuijpers, A. Verster, R. A. Coutinho, *Municipal Health Service, Amsterdam, Netherlands. T.A.P.83 Fear of AIDS and Incidences of Gonorrhea, Syphilis, and Hepatitis B, 1982-88. Franklvn N. Judson*, D. L. Cohn, J. M. Douglas, *Denver Public Health, Denver, CO, U.S.A. T.A.P.84 Changing Sexual Behavior in the 1980's. Michael L. Rekart. STD Control, Ministry of Health, Vancouver, BC, Canada. Transmission h6t6rosexuelle (partle 1) Heterosexual Transmission (Part 1) T.A.P.85 AIDS Patients with No Identified Risk: Lack of Evidence for New Modes of Transmission. Lois J. Conlev*, T. J. Bush, M. E. Chamberland, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.SA. T.A.P.86 The Relationship Between Male Circumcision and HIV Infection in African Populations. Priscilla Reining*, J. Bongaarts, P. Way, F. P. Conant, *American Association for the Advancement of Science, Washington, DC, U.S.A. T.A.P.87 HIV-1 Infection in Sexually Exposed Women: Risk Factors for Prevalent and Incident Infections. Francis A. Plummer*, J. Pepin, G. Maitha, G. Moss, J. O. Ndinya-Achola, L. D'Costa, *University of Nairobi, Nairobi, Kenya. T.A.P.88 HIV Transmission in Stable Sexual Partnerships in Kenya. Gregory B.Moss*, L. J. D'Costa, J. O. Ndinya-Achola, F. A. Plummer, J. K. Kreiss, D. W. Cameron, *University of Washington, Department of Medicine, Seattle, WA, U.S.A. T.A.P.89 HIV Infection and Circumcision Status. Ilona W. Surick*, M. McLaughlin, M. Chiasson, *New York City Department of Health, New York, NY, U.S.A. T.A.P.90 HIV Risk Factors in Steady Male Sex Partners of Kinshasa Prostitutes. Nzilambi Nzila*, M. Laga, M. Kivuvu, SIDA, Kinshasa, Zaire. T.A.P.91 Serologic Concordance and Incidence of HIV in Regular Sexual Partners in Nairobi, Kenya. D. William Cameron*, M. L. Kosseim, D. Oduor, L. J. D'Costa, G. M. Maitha, G. M. Irungu, et al., *Ottawa General Hospital, Ottawa, ON, Canada. 301 [Page 302](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/304) T.A.P.92 Potential Role of Spermatozoa in the Transmission of HIV. Elisabeth Dussaix*, D. Gudtard, A. Ellrodt, M. De Almeida, M. Auroux, *H6pital de Bicitre, Le Kremlin-Bicetre, France. T.A.P.93 Ethnic Differences in the Heterosexual Transmission of HIV in California. Nancy S. Padian*, A. Moreno, S. Glass, S. Shiboski, G. Maisonet, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. T.A.P.94 Heterosexual Transmission of HIV from Intravenous Drug Users to Their Sexual Partners. Nancy S. Padian*, H. Petersen, R. Meakin, B. Brodie, C. Wofsy, A. Moss, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. T.A.P.95 Statistical Analysis of Infectivity Based on Partner Studies. Stephen C. Shiboski*, N. Jewell, *University of California at Berkeley, Berkeley, CA, U.S.A. T.A.P.96 Comparison of Risk for HIV Infection among Self-Referred and Provider-Referred Heterosexuals in a Study of HIV Transmission. Kenneth H. Maver*, D. Laufer, L. Feingold, S. Zierler, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A. T.A.P.97 Heterosexual Behavior and HIV Status in a Cohort of Persons at Increased Risk for HIV Infection. Kenneth H. Mayer*, S. Zierler, L. Feingold, D. Laufer, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A. T.A.P.98 Heterosexual Transmission of HIV: A European IMET, Paris, France. T.A.P.99 Risk Factors for Heterosexual Transmission of HIV Infection. Alberto Saracco, University of Milan, Infectious Diseases Clinic, Milan, Italy. T.A.P.100 Behavior Modification in Couples Enrolled in a Study of Heterosexual Transmission. Heidi M. Petersen*, N. Padian, S. Glass, A. Moreno, I. Ajaniku, C. Wofsy, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. T.A.P.101 Changes in Sexual and Reproductive Behavior in Heterosexual Couples after HIV Testing. Mary A. Vogler*, T. Dugan, M. Seidlin, *New York University School ofMedicine, New York, NY, U.S.A. T.A.P.102 High Prevalence of HIV-1 Antibodies in STD Patients with Genital Ulcers. Debrework Zewdie*, M. Abdurahman, S. G. Adal, M. Tadesse, T. Yemaneberhan, et al., *National Research Institute of Health, Addis Ababa, Ethiopia. 302 [Page 303](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/305) Transmission h6t6rosexuelle (partie 2) Heterosexual Transmission Transmission Heterosexual Couples. Giuseppe Luzi*, C. Papetti, A. M. Pesce, I. Mezzaroma, E. Pinter, G. D'Offizi, et al., *Department of Allergy and Clinical Immunology, University of Rome \"La Sapienza\", Rome, Italy. T.A.P.104 Preliminary Analysis of Factors Associated with Seroconversion in a Study of Heterosexual Sexual Transmission of HIV in Monogamous Couples. Margaret Nichols*, P. Paroski, G. Sampson, J. Leibel, M. J. Kennedy, *Woodhull Medical and Mental Health Center, Department of Ambulatory Care, Brooklyn, NY, U.SA. T.A.P.105 The Risks for Heterosexual Transmission from Infected Blood Transfusion Recipients. John W. Ward*, H. Perkins, E. Donegan, C.-Y. Ou, S. Laussecq, S. Gaynor, et al., *Centersfor Disease Control, AIDS Program, Atlanta, GA, U.S.A. T.A.P.106 Risk of Heterosexual Transmission of HIV-1 from Recipients of Blood and Blood Products. Elizabeth A. Donegan*, Transfusion Safety Study Group, *University of California at San Francisco, San Francisco, CA, U.S.A. T.A.P.107 No More Seroconversions among Spouses of Patients of the Bonn Hemophiliac Cohort Study. Bernd S. Kamps*, D. Niese, H. H. P. Euler, B. Van Loo, T. Kamradt, *Medizinische Universitdtsklinik, Bonn, Federal Republic of Germany. T.A.P.108 Real Value of Seronegativity in Long-term Exposed Sexual Partners HIV-Infected Buenos Aires, Argentina. T.A.P.109 Results of HIV Antibody Testing in Sexual Partners of Seropositive Hemophiliacs over a 5-Year Period. Ann D. Forsber*, J. L. Sullivan, D. L. Willitts, E. Kraus, D. B. Brettler, *Worcester Memorial Hospital, Hematology Clinic, Worcester, MA, U.S.A. T.A.P.110 Heterosexual Transmission of HIV Infection from Hemophiliacs to Their Spouses. Detlef Niese*, T. G. A. Kamradt, B. S. Kamps, K. E. Schneweis, P. Euler, H. H. Brackmann, *Department of Internal Medicine, University of Bonn, Bonn, Federal Republic of Germany. T.A.P.111 Transmission h6t6rosexuelle de l'infection Factors Infection in STD Clinic Patients: Evidence for Crack-related Heterosexual Transmission. Mary Ann Chiasson*, R. L. Stoneburner, E. Telzak, D. Hildebrandt, S. Schultz, H. Jaffe, *New York City Department of Health, New York, NY, U.S.A. T.A.P.113 Transmission of HIV Infection in Heterosexual Partners of HIV+ Drug Addicts. Luigi Perroni*, L. Le Foche, G. P. F. Albertoni, F. Goretti, 303 [Page 304](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/306) T.A.P.114 Increasing Importance of Heterosexual Transmission of HIV Due to IVDU in Catalonia. Jordi Casabona*, R. Salinas, J. Tor, T. Garcia, M. Campillo, *Epidemiology Section, AIDS Program, Generalitat de Catalunya, Barcelona, Spain. T.A.P.115 Transmission of HIV Infection in Heterosexual Partners of HIV Infected Drug Abusers. Pietro M. Piazza, *University of Naples, Clinic of Infectious Diseases, Naples, Italy. T.A.P.116 Absence of HIV Transmission Through Casual Contacts in Former Drug Users. Alessandro Zanetti*, A. Gringeri, G. Zehender, F. Tradati, A. Boschini, M. Colombo, *University Milan, Institute of Virology, Milan, Italy. T.A.P.117 Anal Intercourse: A Risk Factor for HIV Infection in Female Partners of Bisexual Men, Rio de Janeiro, Brazil. Fernando S. Sion*, C. A. Morais de Sd, M. C. Rachid de Lacerda, N. P. M. Rubini, E. P. Quinhoes, E. A. Castilho, *Gaffrie & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. T.A.P.118 HIV-1 in Patients with Genital Lesions Attending a North American STD Clinic: Assessment of Risk Factors. W. L. Whittington*, B. Jacobs, J. Lewis, F. Lee, T. Edwards, A. J. Nahmias, *Centers for Disease Control, Atlanta, GA, U.SA. T.A.P.119 Gential Herpes as a Possible Risk Factor for HIV Transmission. Andrd J. Nahmias*, L. Corey, F. Lee, N. Clumeck, R. Cannon, S. Holmberg, et al., *Emory University School of Medicine, Atlanta, GA, U.S.A. T.A.P.120 Epidemiology of HIV Infection in Hong Kong. E.K. Yeoh*, P. C. K. Li, W. L. Lim, Y. Y. Chan, S. H. Lee, *Queen Elizabeth Hospital, Medical and Health Department, Hong Kong. 304 [Page 305](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/307) Notes [Page 306](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/308) Section Mardi 6 juin Tuesday, June 6 Aspects cliniques Clinical Aspects of AIDS Session d'affichage Poster Session Traltement de la (diagnostic Treatment: Pentamidine Other Drugs (Clinical Diagnosis) T.B.P.1 evaluation quantitative du parasitisme au cours de la pneumocystose (PNC.P) chez les patients de ou d'autres immunod6pressions. Patricia Roux*, A. F. Lancastre, *Hdpital Tenon, Paris, France. T.B.P.2 Final Diagnosis Patients with Negative Bronchoalveolar Lavage for Pneumocystis. Jihad Slim*, G. Perez, C. Forrester, A. Shafii, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.S.A. T.B.P.3 for Bronchoalveolar Lavage Neutrophilia Foutty, P. Dickman, *Harbor-UCLA Medical expectorations induites le pneumocystose du SIDA. Patricia Roux*, T. Delacour, F. Camus, M. Fay, M. Denis, P. M. Girard, *Hdpital Tenon, Paris, France. T.B.P.5 Antibodies to Pneumocystis Carinii. Reduced Levels in HIV Infected Patients during Pneumocystis Infection and Evaluation of Passive Immunisation. Sheila M. Burns*, J. A. Read, P. L. Yap, R. P. Brettle, *Regional Virus Laboratory, City Hospital, Edinburgh, U.K. T.B.P.6 Purification and Characterization of a Major Human Pneumocystis Carinii Surface Antigen. Bettina Lundgren*, G. Lipschik, J. A. Kovacs, *National Institutes of Health, Critical Care Department, Clinical Center, Bethesda, MD, U.SA. T.B.P.7 The Diagnosis of Pneumocystis Carinii Pneumonia in High Risk Patients by Induced Sputum Using a Direct Immunofluorescent Antibody Test. Margo E. Heath-Chiozzi*, M. Mitchell, J. Rosol-Donoghue, D. Cotton, P. Holme, P. Hanff, *Beth Israel Hospital, Harvard Medical School, Bronchoalveolar Lavage (BAL) CMV Culture with Better Outcome of Pneumocystis Carinii Pneumonia in Men with AIDS. Samuel A. Bozzette*, J. Arcia, A. Bartok, J. A. McCutchan, D. Richman, S. Spector, et al., *University of California at San Diego Medical Center, San Diego, CA, U.S.A. T.B.P.9 A Measure of Pneumocystis Carinii Pulmonary Burden. Robert P. Baughman*, P. T. Frame, * University of Cincinnati Medical Center, Cincinnati, OH, U.SA. 306 [Page 307](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/309) T.B.P.10 Defective Peripheral Oxygen Utilization in AIDS Patients with Respiratory Failure Due to Pneumocystis Carinii. Robert D. Wood*, B. Akil, J. Tuchschmidt, R. Swinney, C. T. Boylen, *LAC-USC Medical Center, Department ofPulmonary Medicine, Los Angeles, CA, U.SA. T.B.P.11 Rapid Diagnosis of Pneumocystis Carinii Pneumonia (PCP) in Patients with AIDS Using Fluorescent Monoclonal Antibody (DFA) Assay. Nzeera A. E. Chaisson, W. K. Hadley, D. Yajko, P. C. Hopewell, et al., *Johns Hopkins Hospital, AIDS Service, Baltimore, MD, U.S.A. T.B.P.12 Frequent Inability to Confirm the Diagnosis of Presumptive Pneumocystis Carinii Pneumonia (PPCP). Samuel A. Bozzette*, D. Gluckstein, J. Coffman, C. Newlett, et al., *University of California at San Diego, San Diego Medical Center, San Diego, CA, U.S.A. T.B.P.13 A New Method for the Diagnosis of Pneumocystis H. Deicher, et al., *Public Health Laboratories, Hannover, Federal Republic of Germany. T.B.P.15 Predictive Data for Positive Bronchoalveolar Lavage Results in Pneumocystis Pneumonia. Jihad Slim*, A. DeLuca, G. Perez, C. Forrester, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.SA. T.B.P.16 Unusual Pathologic Manifestations of Pneumocystis Carinii Pneumonia (PCP) AIDS. William D. Travis*, S. Pittaluga, G. Y. Lipschik, F. P. Ognibene, A. F. Suffredini, H. Masur, et al., *Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.SA. T.B.P.17 How Predictive Are LDH-Elevations for the Severity of Pneumocystis Carinii Pneumonia in AIDS Patients? Chistoph Elsing*, Worth, G. of Diusseldorf Diisseldorf, Federal Republic of Germany. T.B.P.18 Comparison of First Episode of PCP in Community Patients and Inmates. Victoria L. Sharp*, A. Andrews, R. Heyman, R. Weiss, *Albany Medical Center, AIDS Treatment Center, Albany, NY, U.SA. T.B.P.19 Pneumocystose et SIDA a Brazzaville, Congo. P. Mpeld, P. T.B.P.21 Primary against of Internal Medicine, Rudolf Virchow University Hospital, Freie Universitdt Berlin, Berlin, Federal Republic of Germany. T.B.P.22 A Quantitative Scoring System for Evaluating the Response to Therapy of Pneumocystis Carinii Pneumonia (PCP). Larry C. Nichols*, J. Black, F. Sattler, J. Feinberg, *Research Triangle Institute, Research Triangle Park, NC, U.SA. T.B.P.23 Aerosolized Pentamidine (AP) in the Treatment of PCP Episodes: An Open Multinational Trial, Preliminary Results on 70 Patients. Pierre-Marie Girard*, T. Lecompte, A. Lazzarin, *H6pital Bichat-Claude Bernard, Paris, France. T.B.P.24 Survival Rate and Prognosis for AIDS Patients with Severe Pneumocystis Carinii Pneumonia (PCP) Requiring Mechanical Ventilation. Thyge Lvnghi Nielsen*, Guldager, C. Pedersen, L. Mathiesen, J. O. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. T.B.P.25 Reduced Dose of Aerosolized (PCP): 3-6 Month John E. Conte*, D. Chernoff, H. Hollander, D. Feigal, J. Golden, *University of California at San Francisco, San Francisco, CA, U.S.A. T.B.P.26 Penetration of Trimethoprim (TMP) Compared with That M. D. Kitzis, J. Mohler, A. Hirsch, *Saint-Louis Hospital, Paris, France. T.B.P.27 Traitement de la pneumocystose du SIDA par le P. M. Wolff, France. T.B.P.28 Aerosol Therapy with Pentamidine Carinii Pneumonia (PCP). Keikawus Arastdh*, C. *Auguste- Viktoria-Krankenhaus,,Berlin, Carinii S. Hammer*, E. P. Neibart, F. Dembitzer, R. Dembitzer, H. S. Sacks, S. Z. Hirschman, *Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY, U.S.A. T.B.P.30 Clindamycin Plus Primaquine as Primary Therapy for Pneumocystis Carinii Pneumonia in AIDS Patients. John R. Black*, J. Feinberg, R. J. Fass, J. F. Plouffe, R. Murphy, G. Leoung, et al., *Indiana University Medical Center, Indianapolis, IN, U.S.A. T.B.P.31 Correlation between ICU Survival and Required CPAP/PEEP in AIDS Patients with Pneumocystis Carinii Pneumonia. Athanasios Skoutelis*, W. Peruzzi, D. Currie, R. Murphy, R. Cane, B. Shapiro, *Northwestern University Medical School, Chicago, IL, U.S.A. 308 [Page 309](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/311) T.B.P.32 Treatment and Outcome of Pneumocystis Carinii Pneumonia in AIDS Patients. Jens D. Lundgren*, C. Pedersen, T. Nielsen, *National Institutes ofHealth, Bethesda, MD, U.S.A. T.B.P.33 Prospective Randomized Pierre Dellamonica*, J. Durant, P. M. Roger, E. Bernard, V. Mondain, Y. Le Fichoux, *Archet Hospital, Infectious Diseases Department, Nice, France. T.B.P.34 The Bioavailability of Co-Trimoxazole in Patients with AIDS Receiving Treatment for Pneumocystis Carinii Pneumonia. Carole J. Wells*, M. Kapembwa, L. O. White, C. J. Cairns, M. H. Wansbrough-Jones, *Clinical Pharmacy Practice Unit, St. George's Hospital, London, U.K. T.B.P.35 The Use of Steroids in the Therapy of Respiratory Failure Complicating Pneumocystis (PCP). Mark H. Kaplan*, M. J. Schiff, B. F. F. Farber, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A. T.B.P.36 Diagnosis and Treatment of Pneumocystis Pneumonia: A Survey of Oregon and Vancouver, Washington Physicians. James M. Sampson*, C. J. Spence, *Good Samaritan Hospital and Medical Center, Portland, OR, U.S.A. T.B.P.37 Prospective Randomized Treatment for Pneumocystis Carinii Pneumonia (PCP) in AIDS Patients. Frederick P. Duncanson*, N. C. Klein, T. H. Lenox, O. Kawwaff, A. Pitta-Alvarez, G. P. Wormser, et al., *New York Medical College, Metropolitan Hospital, New York, NY, U.S.A. T.B.P.38 Pentamidine Use in a Tertiary Care Hospital: 1984-1988. Lilly J. Miedzinski*, G. Taylor, S. Nazarali, *University of Alberta Hospitals, Edmonton, AB, Canada. T.B.P.39 Erythromycin in the Treatment of PCP in AIDS Patients. Alois Dorlemann*, E. Reisinger, S. Schwander, A. Meyer, M. Dietrich, *Bernhard-Nocht Institutefor Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany. T.B.P.40 Treatment of AIDS-related PCP by Pentamidine Inhalation. Andreas Meyer*, M. Dietrich, *Bernhard-Nocht Institutefor Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany. T.B.P.41 Traitement de la pneumocystose par le Acquired Immune Deficiency Syndrome (AIDS). DavidA. Haase*, W. Ghesquiere, B. L. Johnston, W. F. Schlech, T. J. Marrie, J. Whelan, *Victoria General Hospital, Halifax, NS, Canada. T.B.P.43 High Rates of Recurrence of Pneumocvstis Pneumonia and Toxicity in AIDS Patients Taking Pyrimethamine-Sulfadoxine Prophylaxis. Laurel A. Miller*, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A. 309 [Page 310](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/312) T.B.P.44 Primary Versus Secondary PCP Prophylaxis. Anne M. Miich*, M. Slavin, J. Hoy, C. R. Lucas, *Fairfield Infectious Diseases Hospital, Fairfield, Australia. T.B.P.45 Secondary Prophylaxis of Pneumocystis Carinii Pneumonia with Systemic Pentamidine. Dean L. Winslow*, A. Bincsik, P. Lincoln, H. Smolka, W. Holloway, *Medical Center of Delaware, Infectious Disease Research Laboratory, Wilmington, DE, U.S.A. T.B.P.46 Clinical and Pharmacokinetic Interactions of Combined Zidovudine (ZDV) Sulfadoxine-Pyrimethamine (FANSIDAR) in Post-PCP 021). Hardy*, R. S. Holzman, V. Avramis, R. Bawdon, H. Fall, J. Feinberg, *University of California at Los Angeles, AIDS Clinical Research Center, Los Angeles, CA, U.S.A. T.B.P.47 Utilisation du Fansidar pour la prophylaxie de la Jean-Michel Livrozet*, Mounilaila, J. Pneumonia in AIDS Patients with Cerebral Toxoplasmosis. Gerald Pierone*, G. Turett, J. Masci, P. Nicholas, *Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.S.A. Prophylaxie par la pentamidine Prophylaxis with etude prospective chez patients Girard*, R. Landman, Bichat-Claude Paris, France. T.B.P.50 Data Predict Relapse Rate of Pneumocystis Pneumonia (PCP) During Ledergerber, W. Siegenthaler, R. Liithy, R. Speich, * University Hospital, Department of Internal Medicine, Medical Polyclinic, Zurich, Switzerland. T.B.P.51 Successful Chemoprophylaxis of PCP by and Low Aerosolized Craig W. Keyes*, P. Rodgers, C. Marte, J. Wolbert, J. Kelly, D. Ribble, *Bellevue Hospital Center, Community Health Project, New York, NY, U.S.A. T.B.P.52 Home Aerosolized Pentamidine Prophylaxis in an Inner City Population. Jonathan E. Samuels*, M. Hilton, J. Hendrix, C. B. Small, *North Central Bronx Hospital, Bronx, NY, U.S.A. T.B.P.53 Long Term Safety and Effectiveness of Aerosol Pentamidine for Prevention of Pneumocystis Carinii Pneumonia. Edward M. Bernard*, M. Dickmeyer, H. J. Schmitt, M. Seltzer, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. 310 [Page Aerosolized Pentamidine Carinii Pneumonia in AIDS: A Progress Report from the Canadian Cooperative Trial. Julio S.G. Montaner*, L. Lawson, J. Falutz, R. Hyland, A. Rachlis, A. Gervais, et al., *St. Paul'sHospital, University of British Columbia, Vancouver, BC, Canada. T.B.P.55 Prophylactic Inhalation Pentamidine in Patients with HIV Disease. Jerome Ernst*, L. DiPasquale, E. R. Sy, D. Rubinstein, *Bronx Lebanon Hospital Center, Bronx, NY, U.S.A. T.B.P.56 A Clinical Experience with Aerosolized Pentamidine (AP). StepLIW D. Niahtinaale*, R. S. Ferguson, S. M. Pounders, J. D. Jockusch, K. J. Robertson, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A. T.B.P.57 Absolute Pulmonary Deposition of Nebulized Pentamidine Isethionate. Simon H. L. Thomas*, M. O'Doherty, C. Page, T. Nunan, N. T. Bateman, *St. Thomas' Hospital, London, UX. T.B.P.58 Aerosol Prophylaxis FlamLolc*, S. Haidl, E. Westin, T. Prellner, *Malma General Hospital, Department of Infectious Diseases, University of Lund, Sweden. T.B.P.59 Prophylactic Treatment with Nvbo V. Backer, L. Mathiesen, P. Skinhoj, *Department of Infectious Diseases, State University Hospital, Copenhagen, Denmark. T.B.P.60 Efficacy of Monthly Intramuscular Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia. Steven D. Miller*, D. Sifris, *Johannesburg Hospital, Clinic, Johannesburg, South Africa. T.B.P.61 Pharmacokinetics of Aerosolized Pentamidine in AIDS Patients Being Treated for Acute Pneumocystis Carinii Pneumonia. Yana J. Paulson*, R. J. Ko, R. T. Koda, C. T. Boylen, T. M. Gilman, *University of Southern Calhfornia at Los Angeles, School of Pharmacy, Los Angeles, CA, U.S.A. T.B.P.62 Community Study of the Efficacy of Inhaled Pentamidine on the Prevention of Pneumocystis Carinii Pneumonia: Continuing Experience. Joel D. Weisman*, T. M. Gilman, P. Rothman, A. Scarsella, L. Eppolito, E. Rogolsky, et al., *Sherman Oaks Community Hospital, Sherman Oaks, CA, U.S.A. T.B.P.63 Inhaled Pentamidine as Primary Prophylaxis in a High Risk Group: Continuing Experience. Joel D. Weisman*, T. T. Gilman, E. Rogolsky, P. Rothman, A. Scarsella, L. Eppolito, et al., *Sherman Oaks Community Hospital, Sherman Oaks, CA, U.S.A. T.B.P.64 Comparison of Nebuliser Efficiency for Aerosolising Pentamidine. DQg Smith*, D. G. Gazzard, *St. Stephen's Hospital, London, U.K. T.B.P.65 Effect of Aerosol Characteristics on Pulmonary Deposition of Pentamidine. AnitSitdnds*, S. Newman, M. Johnson, N. Talaee, C. Lee, S. Clarke, *Royal Free Hospital, London, UK. 311 [Page 312](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/314) T.B.P.66 Nebulized Pentamidine Prophylaxis but Poor Long Term Survival. Don E. Smith*, D. Herd, D. Hawkins, B. G. Gazzard, *St. Stephens Hospital, London, UK. T.B.P.67 The Effect of Initial Pentamidine Solution Volume on Total Pulmonary Deposition. Michael O'Doherty*, S. Thomas, C. Page, T. Nunan, N. Bateman, *St. Thomas' Hospital, London, A Cost-Effectiveness Analysis. Kenneth A. Freedberg*, C. J. Cohen, D. J. Cotton, A. N. A. Tosteson, *Harvard Medical School, Beth Israel Hospital, Boston, MA, U.S.A. T.B.P.69 Aerosolized Pentamidine as Chronic Suppressive Therapy for Pneumocystis Carinii in a Heterogeneous AIDS Population. Kassandra Rodriguez*, M. Fischl, P. Deziel, *University of Pentamidine (AP) Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in a Boston Community Health Center. Martha W. Moon*, S. Harris, R. Feldman, K. H. Mayer, *Fenway Community Health Center, Boston, MA, U.S.A. T.B.P.71 Prophylaxie secondaire Picard, *H6pital Paris, France. T.B.P.72 Single and Multiple Dose Pharmacokinetics (PK) of Reduced Dose (3MG/KG) Intravenous Pentamidine. John E. Conte, University of California at San Francisco, San Francisco, CA, U.S.A. T.B.P.73 Nebulized Pentamidine in the Primary R. W. Stille, et al., *Klinikum der J.W.-Goethe-Universitdt, Frankfurt, Federal Republic of Germany. T.B.P.74 Efficacit6 s6curit6 or Oral Dapsone (OD) in Patients with AIDS or with Severe ARC. Ramon A. Torres*, S. Palermo, G. Gregory, S. Carlo, M. Harismides, E. Chanin, et al., *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S.A. T.B.P.76 Pneumothorax in Patients Receiving Aerosol Pentamidine Prophylaxis. Gifford S. Leoung*, L. Wardlaw, A. B. Montgomery, D. I. Abrams, D. W. Feigal, San Francisco County Community Consortium, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A. 312 [Page 313](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/315) T.B.P.77 AZT-Aerosol Pentamidine vs. AZT Alone in Long Term AIDS Survivors: A Retrospective Case-Control Survival Analysis. S&eM.gt D. aightingale\", S. M. Pounders, R. S. Ferguson, J. D. Jockusch, * University of Texas Southwestern Medical Center, Dallas, TX, U.S.A. T.B.P.78 Double-Blinded Randomized Pneumocystis Carinii Pneumonia. Gifford S. Leoung*, A. B. Montgomery, E. McGinty, D. W. Feigal, LyphoMed Consortium Investigation, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A. T.B.P.79 Is Upper Lung Deposition of Nebulized Pentamidine Improved by Inhalation Lying Down? Michael J. O'Doherty*, S. Thomas, C. Page, C. Bradbeer, T. Nunan, N. Bateman, *St. Thomas' Hospital, London, U.K. Analyse de PCR Products by Solution Hybridization with 125I-DNA Probes. Matthew J. Bankowski*, M. Kuhns, A. McNamara, H. Kessler, A. Landay, L. Falk, et al., *Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, U.S.A. T.B.P.81 Detection of HIV-1 by Polymerase Chain Reaction in Relation to Results of Virus Culture. Anders B. S6nnerborg*, B. Johansson, 0. Strannegard, *Central Microbiological Laboratory, Department of Virology, Stockholm, Sweden. T.B.P.82 Failure of the Polymerase Chain Reaction (PCR) to Detect Viral HIV-1 DNA by Amplification of a gag Segment in Hemophiliacs with HIV Antibodies. Elaine M. Evster*, J. Goedert, R. Kumar, *Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, U.S.A. T.B.P.83 Multiparametric Flow Cytometric Analysis (Lymphocyte p24-FCA) Allows Rapid Quantitation of Active HIV-1 Infection in Peripheral Blood Cells. Betsy M. Ohlsson-Wilhelm*, J. M. Cory, H. A. Kessler, M. E. Eyster, F. Rapp, A. Landay, et al., *The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A. T.B.P.84 Use of Flow Cytometric Analysis (Lymphocyte p24-FCA) to Evaluate Active Infection in Female Sexual Partners at High Risk for HIV-1 Infection. Joan M. Corv*, B. M. Ohlsson-Wilhelm, F. Rapp, E. M. Eyster, *Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A. T.B.P.85 Monitoring the Accuracy of the Total Lymphocyte Count to Improve the Absolute CD-4 Count. Robert E. Anderson*, D. Hirschkorn, S. Edmondson, *ViRx, Inc., San Francisco, CA, U.S.A. T.B.P.86 Where Lies the Truth? Methodological Influence on the Zurich, Switzerland. 313 [Page 314](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/316) T.B.P.87 Flow Cytometric Methods for HIV Serology and Antigen Quantitation Using Recombinant HIV Envelope (eNv-9) Protein. Jon R. Gentsch*, D. Campbell, T. Papadopoulos, K. Janney, S. Rifat, S. D. Douglas, *E. I. Du Pont de Nemours & Company, Medical Products Department, Wilmington, DE, U.SA. T.B.P.88 Identification and Quantitation of HIV Infected Cells in Peripheral Blood from AIDS Patients by Flow Cytometry. James J. McSharry*, R. Echols, R. Stevens, J. Lehman, *Albany Medical Center, Albany, NY, U.SA. T.B.P.89 Statistical Analysis of Flow Cytometric Data: Yves Lacouture*, T. Montreal, Human Immunodeficiency Virus Antigenic Determinants and their Use in Diagnostics of AIDS. Serey G.Arsenian*, O. N. Voloshin, A. F. Shevalier, M. V. Michailov, I. A. Nikolaeva, V. M. Rostapshov, et al., *Shemyakin Institute of Bioorganic Chemistry, USSR Academy of Sciences, Moscow, U.S.S.R. T.B.P.92 Sensitivity of Five Commercial HIV-Antigen Detection Methods. Concepcion Casado*, J. M. Varela, Garcia Saiz, Najera, *Instituto de Salud Carlos III, Madrid, Spain. T.B.P.93 Use of Triton-X in the HIV Antigen Assay to Assess the Presence of Infective HIV. James L. Stewart*, S. Ketchum, R. W. Coombs, J.-P. Allain, *Abbott Laboratories, Abbott Park, IL, of Two HIV Antigen Enzyme Immuno Assays on European and African Van der Groen, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium. T.B.P.95 Lack of Correlation of p24 Antigenemia with Clinical Status or Peripheral Blood T4 Lymphocytes (PBT4) in Women with HIV Infection. Charles C. J. Carventer*, K. H. Mayer, L. McCrow, S. Danforth, *Brown University, The Miriam Hospital, Providence, RI, U.SA. T.B.P.96 Correlation of HIV Core Antigen, Antibody and Immune Complex Levels in Sera of HIV-Infected Individuals. Eszter Uihelvi*, J. R. Holldn, et al., *National Institute ofHaematology and Blood Transfusion, Budapest, Hungary. T.B.P.97 Detection of HIV-1 p24 Antigen in Serum with a New Monoclonal EIA. Mendelson, M. Wainberg, et al., *McGill University, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada. 314 [Page 315](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/317) T.B.P.98 Specificity of HIV-1 p24 Antigen Capture Assay as Viral Growth Determinant in Tissue Culture Fluids (TCF). Homavoon Farzadegan*, K. Qatsha, P. Gupta, C. Grovit, C. Rinaldo, A. Saah, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. T.B.P.99 Specificity of HIV Antigen Capture Assays. Jairo Ivo-Dos-Santos*, J. C. Couto-Fernandez, B. Galvao-Castro, *WHO Collaborating Centre on AIDS, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil. T.B.P.100 HIV-Antigens: Prevalence and Correlation with Clinical Evolution in an HIV-Infected Florentine Group. Massimo Di Pietro*, P. Comparison for Detection of HIV-I Antigen. Amy R. Atkinson*, W. A. Meyer, L. Kahl, D. E. Senn, *Maryland Medical Laboratory, Baltimore, MD, U.S.A. T.B.P.102 Comparison of the Organon Teknika Corporation HIV Antigen Assay with Six Commercially Available HIV Antigen Test Kits. Don E. Lockwood*, P. Youngbar, J. Hyman, T. Holody, B. T.B.P.103 Significance of HIV-Antigenaemia in AIDS. Lars L. S. Teglbicerg*, C. Pedersen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. Diagnostic: Infection par le VIH-2 Diagnosis: HIV-2 Infection T.B.P.104 Evaluation of a Synthetic Peptide EIA for Detection of Antibodies to HIV-1 and HIV-2. Rigmor Thorstensson*, F. Mhalu, P. A. Andreasson, T. Buck, S. Brust, G. Biberfeld, et al., *National Bacteriological Laboratory, Department of Immunology, Stockholm, Sweden. T.B.P.105 Aptitude d'un test rapide pour HIV et de tests P. Neumann, D. Lepine, I. D'Souza, C. Major, B. McLaughlin, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, QC, Canada. T.B.P.107 HTLV-I Antibody Prevalence in Patient Populations in Zaire: Analysis of Western Blot (WB) Patterns. Christopher Brown*, N. Nzila, L. Atikala, F. Behets, R. Ryder, T. C. Quinn, et al., *Projet SIDA, Kinshasa, Zaire. T.B.P.108 HIV-1 and HTLV-I Prevalence in African and European Populations: A Comparison of 3 HTLV-I Antibody Assays. Gaby Vercauteren*, R. Colebunders, R. P. Piot, G. Van der Groen, *Institute of Tropical Medicine, Antwerp, Belgium. T.B.P.109 HIV-2 Infection in 2 European Hemophiliac Patients. Francois Simon*, Puel, R. Hammek, France. 315 [Page 316](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/318) T.B.P.110 Detection of HIV-1 in Cultured Peripheral Blood Lymphocytes from HIV-Seropositive Hemophiliacs. Susan Knight*, E. E. Sheid, K. E. Laurie, K. L. Rosenthal, D. G. Harnish, *McMaster University, Department of Pathology, Hamilton, ON, Canada. T.B.P.111 The Effects of Phorbol Ester (TPA) and Iodo-Deoxyuridine (IUDR) on the Isolation and Detection of HIV from Seropositive Individuals. Louis F. Qualtiere*, A. Zbitnew, J. Conly, *University of Saskatchewan, Department of Microbiology, Saskatoon, SK, Canada. T.B.P.112 T-Cells Versus Macrophage for Isolation of HIV from Blood. Arnold K. Fowler*, R. R. Redfield, H. Gendelman, M. Meltzer, C. Oster, D. S. Burke, et al., *SRA Technologies Inc., Rockville, MD, U.SA. T.B.P.113 Fr6quence d'isolement vaginales de femmes s6ropositives. D. Lv*, J. Coulaud, F. Catalan, *Institut Alfred Fournier, Paris, France. T.B.P.114 Development of a Sensitive Microassay for the Measurement of Relative Number of Lymphocytes Infected with HIV. Phalguni Gupta*, M. Ho, A. Enrico, M. Doerr, C. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. T.B.P.115 R6flexions sur Bordeaux II, Bordeaux, France. T.B.P.116 Dual Serologic Reactivity for HIV-1 and HIV-2 in Abidjan. Stephanie L. Lee*, A. Porter, K. De Cock, R. Colebunders, G. Damet, M. Rayfield, et al., *Centers for Disease Control, AIDS Program, International Activity, Atlanta, GA, U.S.A. T.B.P.117 Standardization of HIV Coculture Isolation Techniques in Multicenter Clinical Trials. F. Blaine Hollinger*, J. W. Bremer, S. M. Rao, *Baylor College of Medicine, Houston, TX, U.S.A. T.B.P.118 Tissue Culture and p24 Methods of HIV Detection Compared and Correlated with Demographic Data in Symptomatic ARC Patients. John Hamilton*, C. Compton, K. Weinhold, M. Simberkoff, P. Hartigan, *Veterans Administration Medical Center, Durham, NC, U.S.A. T.B.P.119 Sensitivity of U.S. FDA Licensed HIV-1 Enzyme Immunoassays for Detection of HIV-2 Antibodies. James R. George*, Rayfield, G. Schochetman, W. Heyward, K. Odehouri, R. *Centersfor Disease Control, Atlanta, GA, U.SA. Diagnostic: Contr6le de la qualitY et techniques rapides Diagnosis: Quality Control and Rapid Techniques T.B.P.120 evaluation d'un test de d6tection rapide T. D. Ly, *Institut Alfred Fournier, Paris, France. T.B.P.121 Proficiency in Performing HIV p24 Antigen EIAs and Comparability of Results in a Multicenter Quality Assurance Program. James W. Bremer*, F. B. Hollinger, M. D. Haywood, L. E. Myers, *Baylor College of Medicine, Houston, TX, U.S.A. 316 [Page 317](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/319) T.B.P.122 Is a Virology Quality Assurance (QA) Program Essential for Multicenter Clinical Trials? F. Blaine Hollinger*, J. W. Bremer, *Baylor College of Medicine, Houston, TX, U.S.A. T.B.P.123 Western Blots: Indeterminate Results and Lot-to-Lot Variability in Adults at Low Risk for HIV-1 Infection. Leslie Garrison*, K. Midthun, B. Fernie, H. Farzadegan, Clements, NIAID AIDS Vaccine Evaluation Group, *Johns Hopkins University, Baltimore, MD, U.S.A. T.B.P.124 Detection of Antibodies to HIV-1 by a Rapid, Peptide-Based Immunoassay. Larry H. Gosting*, J. P. Montana, N. Monji, C. A. Cole, P. Coleman, *Genetic Systems Corporation, Seattle, WA, U.S.A. T.B.P.125 A Simplified 5-Minute Staining Procedure for HIV Western Blots Using Protein-A Colloidal Gold. Peter K. Chun*, A. E. Chu, *E-Y Laboratories, Inc., San Mateo, CA. U.S.A. T.B.P.126 Utility of a Rapid Antibody Assay for Detection of HIV-1 Infection in Patients Attending an Emergency Department. Richard L. Kline*, G. D. Kelen, T. A. Brothers, T. C. Quinn, *National Institutes ofHealth, Johns Hopkins Hospital, Baltimore, MD, U.S.A. T.B.P.127 Evaluation of a Recombinant HIV-1 Enzyme Immunoassay (EIA) in Patients Attending an Emergency Room and a Sexually Transmitted Disease Clinic. Richard L. Kline*, G. D. Kelen, E. W. Hook, T. A. Brothers, S. M. O'Sullivan, T. C. Quinn, *National Institutes of Health, Johns Hopkins Hospital, Baltimore, MD, U.S.A. T.B.P.128 Detection of Anti-HIV Antibodies with Synthetic Peptides Using a 3-Minute Rapid Test. Stdphane Bettinger*, J. Martin, A. Herranen, P. K. Tsai, C. Richardson, G. Sommd, *CLONATEC, Paris, France. T.B.P.129 Use of a Peptide-Based, Rapid Immunoassay for the Detection of Antibody to HIV-1. Monica S. Krieger*, R. L. Stout, S. S. Fotopoulos, B. Kyle, M. Hosseini, C. Ferrera, *Genetic Systems Corp., Seattle, WA, U.S.A. T.B.P.130 Comparison of Serum and Paper-Absorbed Fingerstick Blood Samples for Diagnosis of HIV Infection in Intravenous Drug Users. Rodney Hoff*, K. Steger, G. Deutsch, B. Weiblen, B. Comella, D. Craven, *Massachusetts Department of Public Health, Center for Disease Control, Jamaica Plain, MA, U.S.A. T.B.P.131 Anti-HIV Testing by Quick Tests and a Comparison with a Standard Enzyme Method. Prakash C. Das*, A. H. De Vries, R. L. McShine, C. T. Smit Sibinga, *Red Cross Blood Bank Groningen-Drenthe, Groningen, Netherlands. T.B.P.132 A Simultaneous Unidot Quick Test for Detection of HIV-Antibody and HBs Ag for Blood Screening. Augusta K. Takeda*, J. Hardy, A. J. Wilson, M. R. Schmal, F. T. Yamada, M. M. Provesana, *Akita Co., Emilio Ribas Hospital, Sao Paulo, Brazil. T.B.P.133 Field Evaluation for Immunobinding and Agglutination Tests for HIV. Sheila W. Mitchell*, P. M. Tukei, S. M'Boup, J. Mingle, P. R. Lamptey, *Family Health AIDSTECH Division, Durham, 318](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/320) T.B.P.134 Use of Agglutination Assays as Supplemental Tests for Antibody to HIV. Peter M. Tukei*, S. Mitchell, J. Nyamongo, *Virus Research Center, Nairobi, Kenya. T.B.P.135 Confirmation ofHIV Infection with a Line Immune Assay (INNO-LIA) Using Whole Blood Impregnated Filter Paper Discs. Luc Kestens*, D. E. Poller, P. L. Gigase, M. Vandenbruaene, D. Peeters, G. Van Der Groen, *Institute of Tropical Medicine, Department of Immunopathology, Antwerp, Belgium. T.B.P.136 A Rapid Colorimetric EIA for Detection of Antibody to HIV-1. Robert K. Shocklev*, T. Maitski, M. White, B. Davis, C. Abel, *Murex Corporation, Norcross, GA, U.S.A. T.B.P.137 Rapid, Manual Screening Test (HIV/CHEK (TM)) for Antibodies against HIV-1 and HIV-2. William R. Pagels*, J. P. Galvin, J. Tirado, D. Reed, P. K. Chun, A. E. Chu, *E. I. du Pont de Nemours & Co., Inc., Wilmington, DE, U.S.A. T.B.P.138 Multiple Use of Single HIV/CHEK (TM) Device for Screening for HIV-1 Antibodies. William R. Pagels*, J. P. Galvin, J. Tirado, C. M. Mitten, P. K. Chun, A. E. Chu, *E. I. du Pont de Nemours and Co, Inc., Wilmington, DE, U.S.A. T.B.P.139 A Particle-Agglutination Assay for Anti-HIV-1 in Developing Pdrez Buenos Aires, Argentina. T.B.P.140 Evaluation of a New Rapid Screening Assay for HIV Antibodies. Guillermo Muchinik*, E. Rickard, G. Picchio, Manca, P. Cahn, de Medicina, Buenos Argentina. T.B.P.141 Evaluation of Laboratory Performance of Enzyme Immunoassay Tests for HIV-1 Antibody. Thomas L. Hearn*, W. Schalla, R. Taylor, H. Muir, C. Griffin, R. Wood, et al., *Centers for Disease Control, Atlanta, GA, U.S.A. T.B.P.142 Results of CDC's Model Performance Evaluation Program for HIV-1 Antibody Testing. Roger N. Taylor*, T. L. Hearn, C. W. Griffin, W. O. Schalla, H. Muir, *Centers for Disease Control, Atlanta, GA, U.S.A. T.B.P.143 Centers for Disease Control Model Performance Evaluation Program: Results of the Western Blot and Indirect Immunofluorescnece Tests for Detection of HIV-1 Antibodies. William O. Schalla*, T. L. Hearn, R. N. Taylor, C. W. Griffin, H. W. Muir, R. O. Valdiserri, *Centersfor Disease Control, Atlanta, GA, U.S.A. T.B.P.144 Quality Control in Anti-HIV Testing. The Experience of Zambia. Evelyn C. Chimfwembe*, C. Stahli, M. Mukunyandela, *Tropical Diseases Research Centre, Ndola, Zambia. T.B.P.145 Problems Encountered in HIV Serology. Carol J. Major*, B. McLaughlin, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada. 318 [Page 319](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/321) P6diatrie: VIH Pediatrics: HIV T.B.P.146 Enhanced Cardiac Function in Pediatric HIV Infection. Steven E. Lipshultz*, P. Sanders, D. Colan, K. Mclntosh, *Department of Cardiology, The Children's Hospital, Boston, MA, U.SA. T.B.P.147 Mortality in Children with AIDS: Age at Diagnosis as Risk Factor. Silvia losub*, M. Bamji, R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.SA. T.B.P.148 Isolation of Human Immunodeficiency Virus (HIV) from Cerebral Tissue and Characterization of Its Biological Properties. F. Blaine Hollinger*, D. H. Dimitrov, F. Gyorkey, I. Hanson, J. L. Melnick, W. Shearer, *Baylor College of Medicine, Houston, TX, U.SA. T.B.P.149 Cutaneous Manifestations of Pediatric Human Immunodeficiency Virus Infection. Neil S. Prose. State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.SA. T.B.P.150 Clinical Spectrum of Human Immunodeficiency Infection in Children Less than 4 Months of Age. Ellen R. Cooper*, M. D. LeMay, T. Schwartz, S. I. Pelton, A. Fine, *Boston University School of Medicine, Boston City Hospital, Boston, MA, U.SA. T.B.P.151 HIV Activation by Cofactors: p24 Antigenemia after Injections of Soluble Antigens in Children Lymphoid Interstitial Pneumonia in Perinatal HIV-1 Infection. Graciela Gray*, G. Scott, A. Castro, B. B. Bradford, M. T. Mastrucci, W. P. Parks, *University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.SA. T.B.P.153 Pneumocystis Carinii Pneumonitis Infection. Gwendolyn B. Scott*, J. Reyes, M. Mastrucci, L. Smith, W. P. Parks, *University of Miami School of Medicine, Department of Pediatrics, Miami, FL, U.S.A. T.B.P.154 Adrenal Dysfunction in Perinatal HIV Infection. Eileen Sacharski*, S. losub, M. Bamji, R. Stone, D. Pincus, R. Noto, *New York Medical College, Valhalla, NY, U.S.A. T.B.P.155 Broncho-Alveolar Lavage to Evaluate Pulmonary Status in the HIV Infected Child. Liliane A. Boccon-Gibod*, A. Sardet, A. Grimfeld, J. Costil, C. Primary, Not Reactivation of Infection? Jean Chow*, K. Shah, K. Li, A. Gupta, V. Chablani, A. Kaul, et al., *Lincoln Hospital, New York Medical College, Department ofPediatrics, Bronx, NY, U.SA. T.B.P.157 Seroprevalence of HIV Infection in an Urban Pediatric Population. Naomi L. C. Luban*, S. J. Josephs, P. Getson, H. Gayle, *Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC, U.S.A. 319 [Page 320](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/322) T.B.P.158 11W Infection and Pediatric AIDS in Semi-Rural Dabou Protestant Hospital (Ivory Coast). Gui deJTcM.\". L. Schuerman, V. Seynhaeve, A. Quattara, *CNRS Laboratory of Epidemiology and Immunovirology of Tumors, Alexis Carrel Faculty of Medicine, Lyon, France. Maternal Perinatal 11W Seropositivity. Anidiiw Wizni'a*, T. Checola, L. Hand, M. Kim, L. M. Noble, J. J. Yoon, \"BoxLeao Hospital Center, Bronx, NY, U.S~A. T.B.P.160 Difficulties Encountered in Informing the Parents of Newborns of IJIV Testing Results in an Urban Community. Andrew Wiznia*, B. Caif'rey, R. Checola, A. Thorpe, T. Daley, W. Caspe, *Bronx-Lebanon Hospital Center, Albert Einstein College of Medicine, Bronx, NY U.S~A. Pbdiatrle Histoire cilnique Pediatrics: Natural History T.B.P.161 Clinical and Immunologic Features Associated with Pediatric LILY Infection in Los Angeles County, California. TonL.&ede!ick*, L. Mascola, M. Evans, J. Church, Y. B ryson, A. Kovacs, et al., *County CA, U.S~A. T.B.P.162 Newark Perinatal Cohort Natural History Progress Report. Edward M. Qtm&r, M. Schneck, T. Denny, M. Oxtoby, C. Y. Ou, J. Oleske, et al., *Children's Hospital of New Jersey, Newark, R. Lutz, B. H. Belohradsky, *Jmmunodeficieptcy Clinic, University Hospitals for Sick Children, Munich, Federal Republic of Germany. T.B.P.164 Evolution of a Series of 23 Children Who Are Seropositive to LHlY. PWblo.neIQo2\", M. J. Cillerurelo, M. (a, *Instiwuto Carlos III, Servicio de Pediatrria, Madrid, Spain. T.B.P.165 Natural History of Pediatric 11W Infection. Carlo Giaguinto*, A. De Rossi, S. Girotto, S. Cozzani, R. D'Elia, L. Chieco Bianchi, et al., *Department of University of Padua, Padua, Italy. T.B.P.166 Human Immunodeficiency Virus-i (HIV-1) Infected Infants: Association of Laboratory Parameters and Clinical Outcome. Gwendolvn B. Scott*, C. Hutto, S. Lal, M. T. Mastrucci, W. P. Parks, * University of Miami School of Medicine, Deparment of Pediatrics, Miami, FL, U.S~A. T.B.P.167 Seven Year Follow-up of 11W Infection in Neonatal Transfusion Recipients. Thomas LALMun4,*, L. Lieb, J. Ward, F. Allen, M. Oxtoby, J. Faust, et al., *Cedars-Sinai Medical Center, Department of Pediatrics, Los Angeles, CA, U.S~A. T.B.P.168 Clinical Characteristics of Pediatric AIDS below and above One Year of Age. SilyiaJljsk2\", M. Bamji, R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.S~A. T.B.P.169 Natural History of Pediatric AIDS, 1988. Lawrence D. Frenkel*, S. Gaur, H. Kesaiwala, R. Scudder, * University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, U.S~A. 320 [Page 321](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/323) T.B.P.170 HIV Infection in Children: Prognostic Factors for the Progression of the Disease. Anne-Marie S. Dulidge*, S. Blanche, M. Tardieu, C. Kremlin-Bicdtre, France. T.B.P.171 T.B.P.172 Longitudinal Evaluation of Immunologic and Viral Markers of HIV Infection in Children: Clinical Correlation. Teresa Hernandez-Sampelayo*, L. Perez Alvarez, M. D. Gurbindo Gutierrez, L. Mufoz, J. Fermosel, C. Casado, et al., General Gregorio Maranon, Madrid, Spain. T.B.P.173 Long Term Follow-up of Infants Born to Intravenous Drug Users of Known HIV Serostatus in the Bronx, N.Y.: Clinical and Lab Parameters. Marguerite M. Mavers*, K. Davenny, E. E. Schoenbaum, A. Feingold, P. Selwyn, M. Rogers, et al., *Montefiore Medical Center, North Central Bronx Hospital, Bronx, NY, U.S.A. P6diatrie: DDveloppement neurologique Pediatrics: Neuro-Development T.B.P.174 Early CNS with Perinatally-acquired HIV Infection. Anita L. Belman*, Y. Park, G. Diamond, M. Notcze, C. Douglas, T. Cabot, et al., *State University of New York at Stony Brook, Stony Brook, NY, U.S.A. T.B.P.175 Behavioral Changes in Children with Human Immunodeficiency Virus (HIV) Infection. Marta Lifschitz*, C. Hanson, G. Wilson, W. T. Shearer, *Baylor College of Medicine, Houston, TX. U.S.A. T.B.P.176 Neurologic Symptoms as the Initial Presentation of HIV Infection in Pediatric Patients. Judy Vincent*, M. Bash, D. Shanks, D. Daigh, R. Moriarty, G. Fischer, *Walter Reed Army Medical Center, Department of Pediatrics, Washington, DC, U.S.A. T.B.P.177 AIDS-Related Peripheral Neuropathy in Children and Young Adult Hemophiliacs. Thomas K. Koch*, A. Wesley, E. Lewis, D. Bredesen, M. Koerper, P. Weintraub, et al., *University of California at San Francisco, San Francisco, CA, U.S.A. T.B.P.178 Psychic Development of Children Born to HIV-Infected Italian Mothers.A. M. Laverda*, A. of Pediatrics, Padua, Italy. T.B.P.179 Neuropsychological Profile of Children with Symptomatic HIV Infection Prior to Anti-Retroviral Treatment. Pim Brouwers*, H. Moss, P. Wolters, J. Eddy, P. Pizzo, *National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A. T.B.P.180 Neurodevelopmental Assessment of Children with Symptomatic HIV Infection. Joan Hittelman*, S. Fikrig, H. Mendez, F. Skovera, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.SA. 321 [Page 322](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/324) T.B.P.181 Developmental Abnormalities May Occur Before Other Clinical Manifestations of Perinatally-acquired HIV Infection: A Cohort Study of 119 Zairian Children Born to Seropositive Mothers. Robert Ryder*, K. T.B.P.182 Neurocognitive Functioning among Infants Exposed Perinatally to HIV. Thomas P. Swales*, G. B. Scott, D. S. Cohen, R. G. Curless, A. D. Falk, W. P. Parks, *Division of Behavioural Sciences, Department of Pediatrics, University of Miami, Miami, FL, U.S.A. T.B.P.183 Neurodevelopment in Children with HIV Infection Acquired from Neonatal Blood Transfusion. Sarale Cohen*, T. Mundy, B. Karassik, J. Ward, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A. T.B.P.184 Divergence of Onset of Neurologic and Immunologic Impairment in Infants Born to HIV Seropositive Mothers. Theresa A. Calvelli*, A. Belman, C. Bueti, M. Golodner, A. Rubinstein, *Albert Einstein College ofMedicine, Bronx, NY, U.S.A. T.B.P.185 Pattern of Neurological Abnormalities in Infants at Risk of Developing AIDS. JToseh C. Marcus*, C. A. Butler, H. Mendez, J. J. Goedert, A. Willoughby, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A. T.B.P.186 Neurological Manifestations in Perinatally HIV-Infected Children. A Prospective Study. Anna Maria Laverda*, P. Cogo, A. Del Mistro, M. Pampazzo, E. Ruga, F. Zacchello, et al., *Department Pediatrics, University of Padua, Padua, Italy. T.B.P.187 Expression neurologique grave et dans les pays en vole de d6veloppement Pediatrics: Vertical Transmission and HIV Infection in Developing Countries T.B.P.188 Incidence of Opportunistic Infections in 196 Children with Symptomatic AIDS in Kinshasa. Farzin Davachi*, Yemo Hospital, Kinshasa, Zaire. T.B.P.189 Perinatal Transmission of HIV Infection in Uganda: 0 to 34 Months Follow-up. Edison A. Mworozi*, C. M. Ndugwa, P. K. Kataaha, S. Kiguli, *Makerere University, Kampala, Uganda. T.B.P.190 Pediatric HIV Infection at Gaffr6e & Guinle University Hospital. Epidemiologic, Clinical and Survival Characteristics. Norma P. M. Rubini*, D. J. H. P. Signorini, M. H. P. Graga, F. S. Sion, C. A. Morais de Sd, M. D. C. Guimaraes, *Gaffrde & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. T.B.P.191 Kaposi's Sarcoma in 4 African Pediatric Cases. Alain J. Geores*, J. C. Bouquety, M. 323](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/325) T.B.P.192 Standardized Assessment of Psychopathology in an HIV Sample. Robert H. Remien*, J. B. W. Williams, J. G. Rabkin, R. L. Spitzer, J. Gorman, A. A. Ehrhardt, *HW Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A. T.B.P.193 Clinical Behaviour of 13 Mexican Pediatric Patients Infected by the Human Immunodeficiency Virus. Gustavo Perez Rguez*, H. L. Alvarez, R. M. C. Gorbea, G. F. Torres, L. V. M. Peredo, *Hospital de Infectologia, Centro Mddico La Raza, Mexico City, Pediatric AIDS: Risk Factor Distribution at Hospital Emilio Ribas, Sao Paulo, Brazil. Marinella Della Negra de Paula*, C. Rodriguez, M. Janini, G. Suleiman, W. Queiroz, C. Soraggi, et al., *Emilio Ribas Hospital, 3rd Sao Brazil. Balloul, France. T.B.P.196 Cryptosporidium SP and Isospora Belli Infections in Pediatric Patients. Marinella Della Negra de Paula*, W. Queiroz, M. Janini, C. V. C. Rodriguez, et al., *Hospital Emilio Ribas, 3rd Inpatient Unit, Sao Paulo, Brazil. T.B.P.197 Diseases Indicative of AIDS in Children of African Origin Seen in Belgium: Evidence for Two Patterns. Till Jonckheer*, J. Levy, J. Ninane, *Institute for Tropical Medicine, Antwerp, Belgium. T.B.P.198 Perinatal Transmission of HIV-1: Is a Decreased CD4 Cell Count Predictive? Bonnie J. Dattel*, L. B. Hauer, C. B. Wofsy, W. Crombleholme, P. Weintrub, R. L. Sweet, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. T.B.P.199 Pulmonary Infectious Complications in Pediatric AIDS Patients. Marinella Della Negra de Paula*, M. Janini, W. Queiroz, V. C. R. Lorengo, et al., *Hospital Emilio Ribas, 3rd Inpatient Unit, Germany. T.B.P.201 Immunological, Serological and Clinical Evaluation of H1V Positive Pregnant Women in Relation to Vertical Transmission of HIV. Maria-Luisa Muggiasca*, M. Conti, N. Clinical and Serologic Prospective Study in Infants Born from HIV Seropositive Mothers. Claudia Fortunv*, C. Sanchez, J. M. Barrera, M. G. Ercilla, D. Navio, R. Jimenez, et al., *Department of Pediatrics, Hospital Clinic, Universidad de Barcelona, Barcelona, Spain. 323 [Page 324](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/326) T.B.P.203 Ophthalmic Manifestations of HIV Infection in an African Pediatric Population. Philippe G. Kestelyn*, P. Lepage, A. M. Stevens, P. Van de Perre, *Department of Ophthalmology, Centre hospitalier de Kigali, Kigali, Rwanda. T.B.P.204 Anthropometric Measures in a Cohort of Children Born to HIV+ Women in Kinshasa, Zaire. Susan E. Hassig*, T. Manzila, W. Nsa, M. Kashamuka, R. Ryder, *Projet SIDA, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A. T.B.P.205 High HIV-Associated Infant Mortality Correlates with Poor Post-Partum Maternal Health: 18 Months Follow-Up of 477 Children (CH) Born to HIV (+) Mothers (MO) in Zaire. Nsanga Badi*, R. Ryder, M. Nsuami, B. Function in Offspring of HIV Seronegative Women at Risk for AIDS. Kenneth C. Rich*, A. Landay, I. Chasnoff, *University ofIllinois at Chicago, College of Medicine, Department of Pediatrics, Chicago, IL, U.S.A. T.B.P.207 ADCC in HIV-1 Infected Children. Emmanuel B. Walter*, R. E. McKinney, C. Wilfert, D. S. Tyler, D. P. Bolognesi, K. J. Weinhold, *Duke University Medical Center, Durham, NC, U.S.A. T.B.P.208 Long Term Follow-up of Immunologic Parameters in HIV-Exposed Infants. Uwe Wintergest*, C. Rosendahl, R. Lutz, E. Fahrenheim, B. H. Belohradsky, *Immundefekt-Ambulanz der Universitdts-Kinderkliniken, Munich, Federal Republic of Germany. T.B.P.209 HIV-Specific Immune Response in Congenital HIV Infection. Katherine F. Luzuriaga*, R. A. Koup, D. Panicali, J. L. Sullivan, *University ofMassachusetts Medical School, Worcester, MA, U.S.A. T.B.P.210 HIV Infection in Infants: Natural History and Outcome. John P.Johnson*, P. Nair, M. Advani, K. O'Neil, S. Seiden, S. Hines, *University of Maryland School ofMedicine, Baltimore, MD, U.S.A. T.B.P.211 Perinatal Transmission of HIV: Indicators of Infection. Jacqueline Y. Q. Mok*, R. A. Hague, F. D. Hargreaves, J. Whitelaw, P. L. Yap, *Infectious Diseases Unit, City Hospital, Edinburgh, U.K. T.B.P.212 SerumInterleukin-2 Receptor (SIL-2R) Levels inNeonates Born of HIV Infected Preliminary Results. Galli*, L. R. Novati, et al., *L. Sacco Hospital, Infectious Diseases Clinic, University of Milan, Milan, Italy. T.B.P.213 Serum Neutrophil Antibodies in Children with HIV Infection. Joseph A. Church*, L. Beyer, T. Coates, *Children's Hospital of Los Angeles, Division of Allergy and Clinical Immunology, Los Angeles, CA, U.S.A. T.B.P.214 Immunological Abnormalities in HIV Infection by Vertical Transmission. Teresa Espaiol*, N. Curell, T. Figuera, J. Quer, X. Garcia, I. Caragol, *Immunology and Pediatric Infectious Disease Units, R. S. Valle Hebrdn, Barcelona, Spain. 324 [Page 325](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/327) T.B.P.215 Immunoglobulin E (IgE) in Children with Syndrome (AIDS). M. D. Gurbindo Gutierrez*, P. Tornero, A. Del Moral, J. Fermosel, Marqueurs Pediatrics: Early of HIV Infection Childhood. Inmaculada Castillo*, M. Ruiz-Moreno, Unit, Detection of Specific IgM Antibody by Radioimmunoprecipitation Assay for Early Diagnosis of HIV Infection in Infants. Micheline Fauvel*, J. Lecomte, C. Claessens, Concentration and Antibody Levels to Bacterial Toxids in Children with Human Immune Deficiency Virus (HIV). W. Kreuz*, S. Enenkel, S. Zielen, T. Gaingo-r, S. et al., Klinikum derJ. W. HIV Infection in Infants. John P. Johnson*, E. Davis, R. Shinaberry, P. Nair, *University of Maryland School of Medicine, Baltimore, MD, U.S.A. T.B.P.221 The Use of Anti-HIV IgM Immunoblot in the Diagnosis of Neonatal HIV Infection: A Report of 5 Cases. Wattana Sirivichayakul, S. Chumdermpadetsuk, S. Likitnukul, P. Phanuphak, *Chulalongkorn University Hospital, Department of Microbiology, Bangkok, Thailand. T.B.P.222 Is the IgM Antibodies Status a Useful Marker to Assess the Neonates Contamination by HIV-I? Jacqueline M. L. of Peripheral Blood Antibody-Secreting Cells as a Diagnostic Aid for HIV Infection in Children. Andrd J. Nahmias*, F. Lee, S. Nesheim, C. O'Neill, J. Muther, B. Slade, *Emory University School of Medicine, Atlanta, GA, U.S.A. T.B.P.224 Recovery of HIV from Lymphocytes and Monocytes of Symptomatic HIV-Infected Children. Alan L. Landay*, E. G. Chadwick, S. Kucik, R. Yogev, *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A. T.B.P.225 Neopterin: Potential Early Marker of Perinatal HIV Infection. Harold W. Lischne*, O. Bagasra, S. A. Raphael, C. S. Treston, L. Shandilya, *Temple University School of Medicine, St. Christopher's Hospitalfor Children, Philadelphia, PA, U.S.A. 325 [Page 326](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/328) T.B.P.226 High Prevalence of HIV-specific IgA and in Neonates of HIV-Positive Mothers. J6rg Schupbach*, Baumgartner, Z. Tomasik, *Swiss National Center of Retroviruses, University of Zurich, Zurich, Switzerland. T.B.P.227 Prospective Study of Polymerase Chain Reaction for Early Detection of HIV Infection in Infants Born to HIV Antibody Positive Women. Morton J. Cowan*, P. Weintrub, P. Ulrich, J. Edwards, C. Rumsey, G. Vyas, et al., *University of California at San Francisco, San Francisco, CA, U.S.A. T.B.P.228 The HIV p24 Antigen Assay as a Diagnostic/Prognostic Test in Pediatric HIV Infection. Warren A. Andiman*, T. J. Silva, B. Olson, B. J. Simpson, *Yale University School of Medicine, Department of Pediatrics, New Haven, CT, U.S.A. T.B.P.229 Sequential in Parallel Study of HIV Infected Mothers and Their Children since the Neonatal Period Age. Alvarez Lucia Perez*, M. D. Gurbindo Gutierrez, L. Muioz, T. Hernandez-Sampelayo, A. Garcia Saiz, J. M. Varela, et al., *Instituto de Salud Carlos III, Unidad de SIDA, Madrid, Spain. T.B.P.230 Comparison of the Ortho HIV Recombinant Antigen Neutralization Assay and Dupont Western Blot for Confirmation of ELISA Reactive Sera from Children. Andra R. Frost*, C. Mohla, N. Luban, J. Campos, *George Washington University Hospital, Department of Pathology, Washington, DC, U.S.A. T.B.P.231 A Novel HIV-1 EIA Detects IgG and IgM Antibodies in Adults and Neonates. Sylvie Blanc*, *Wellcome Laboratoires, France. T.B.P.232 IgM May Be Directed to Conformational Epitopes Early in Seroconversion to HIV. Robert A. Gregg*, G. Smith, R. Mayner, L. Pollock, J. S. Epstein, *Federal Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A. T.B.P.233 Hypergammaglobulinemia and Hypogammaglobulinemia as Manifestations of HIV Disease in Perinatally Infected Children. Theresa A. Calvelli*, E. Steinhauer, R. Pathak, V. Davydov, L. Bernstein, A. Rubinstein, *Albert Einstein College of Medicine, Bronx, NY, U.SA. T.B.P.234 Association between Plasma Human Immunodeficiency Virus Type-1 (HIV) Viremia and Clinical Class of Pediatric HIV Infection. Sandra K. Burchett*, R. Coombs, K. Chaloupka, J. Stamateou, C. Wilson, L. Corey, et al., *University of Washington, Children's Hospital and Medical Center, Seattle, WA, U.S.A. T.B.P.235 Detection of HIV Sequences in Children Born to Seropositive Mothers. Vanni Borghi*, L. De Torelli, Diseases, of Modena, Modena, Italy. T.B.P.236 Lymphokine Production and Immunoglobulin Production In Vitro in Neonates and Infants with Human Immunodeficiency Virus (HIV) Infection. Cecilia Prieto*, I. C. Hanson, T. N. Hansen, W. T. Shearer, *Baylor College of Medicine, Texas Children's Hospital, Houston, TX, U.SA. 326 [Page 327](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/329) T.B.P.237 Early Detection of HIV-1 Seroconversion in Infants of Seropositive Mothers Using Serial Dilutions in Western Blotting. Sandra E. Barnes*, S. Alexander, M. Young, L. Olopoenia, M. Manak, W. Frederick, *Howard University Hospital, Washington, DC, U.S.A. T.B.P.238 Detection of Secretory Antibodies to HIV in Neonates. David W. Archibald*, P. Nair, S. Hines, E. Davis, J. Johnson, *University of Maryland at Baltimore, Baltimore, MD, U.S.A. T.B.P.239 Anemia and Hypergammaglobulinemia in Infants with Perinatal HIV Infection. Greor M. Welsh*, N. Hutton, J. F. Modlin, *Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A. T.B.P.240 ELISA (E) and Western Blot (WB) Patterns and a Possible Marker of Seroreversion (SR) in Infants Born to Seropositive (SP) Women. Hermann Mendez*, S. Holman, R. Stevens, J. Wethers, H. Minkoff, S. Landesman, et al., *State University of New York, Department of Pediatrics, Brooklyn, NY, U.S.A. T.B.P.241 Sequential Western Blot Patterns in Confirmed HIV Seropositive Infants. Naomi L. C. Luban*, V. C. Criss, S. Josephs, C. Mohla, J. M. Campos, *Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC, U.S.A. T.B.P.242 Evaluation of the Western-Blot IgM Technique Specificity. Jacqueline M. of HIV Antibody Profiles by RIPA as a Means of Diagnosing Infection in Infants. Micheline Fauvel*, J. Samson, G. Delage, M. Canada. T.B.P.244 Early Diagnosis of HIV Infection in Children Born to Seropositive Mothers: Critical Evaluation of New Diagnostic Approaches. Anita De Rossi*, A. Amadori, C. Giaquinto, A. Del Mistro, F. Mammano, enfants *Universitd de Bordeaux, France. Pddiatrie: Traitement du SIDA chez les enfants Pediatrics: AIDS Treatment in Children T.B.P.246 Infusion of Anti p24 Antibody Rich Plasma in Two Children with Persistent HIV Antigenaemia: A Pilot Study. Rosemary A. Hague*, P. L. Yap, J. Y. Q. Mok, G. G. Jackson, F. D. Hargreaves, N. A. Coutts, *City Hospital, Infectious Diseases Unit, Edinburgh, U. K. T.B.P.247 Dideoxycytidine (ddC) Alone and in Combination with AZT for Children with Symptomatic HIV Infection. A Phase IEvaluation. Philip A. Pizzo*, M. Einloth, K. Butler, J. Eddy, J. Meer, J. Falloon, *Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. 327 [Page 328](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/330) T.B.P.248 The Effects of Encephalopathy and AZT Treatment on the Social and Emotional Behavior of Pediatric AIDS Patients. Howard A. Moss*, P. Wolters, P. Brouwers, J. Eddy, L. Weiner, P. Pizzo, *Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. T.B.P.249 Elevated Hepatic Transaminases Are not Associated with Increased Zidovudine Toxicity in Children with Congenitally Acquired HIV-1 Infection. Steven R. Martin*, M. D. LeMay, K. Mclntosh, H. S. Winter, *Children's Hospital, Harvard Medical School, Boston, MA, U.S.A. T.B.P.250 Long-term Treatment of Symptomatic HIV Infection in Children with Zidovudine. Mechthild Vocks-Hauck*, U. Wintergerst, S. Rosendahl, et al., *Free University Berlin, Kinderklinik, Berlin, Federal Republic of Germany. T.B.P.251 Chorioretinitis Responding to AZT Therapy in an Infant with AIDS. TIi Jonkheer*, C. Pierre, A. De Selijs, E. Moens, H. Taelman, P. Piot, *Institute of Tropical Medicine, Antwerp, Belgium. T.B.P.252 AZT Therapy in HIV-Infected Children. Andrea De Maria*, A. Terragna, B. Ciravegna, A. Loy, F. Forni, A. Ferrazin, *University of Genoa, Ist Clinic of Infectious Diseases, G. Gaslini Institute, Genoa, Italy. T.B.P.253 Zidovudine Treatment in Adolescent Hemophiliac Children with HIV Infection. Alan P. Knutsen*, J. D. Bouhasin, K. Gioia, K. B. Mueller, *St. Louis University Medical Center, St. Louis, MO, U.S.A. T.B.P.254 Disease Progression and Effect of Zidovudine (AZT) in Pediatric AIDS. Anil Gupta*, M. Ravipati, H. Slade, C. Leombruno, M. Marecki, Pahwa, *North Shore University Hospital, Manhasset, NY, U.SA. T.B.P.255 Our Experience in Treatment with Zidovudine in Children. Maria Josd Mellado*, M. J. Cilleruelo, Madrid, Spain. T.B.P.256 Selenium Deficiency and Cardiomyopathy in Malnourished Pediatric AIDS Patients. Andrea J. Ruff*, A. Kavanaugh-McHugh, S. Rowe, Y. Benjamin, N. Hutton, J. Modlin, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A. T.B.P.257 Clinical and Immunological Course of HIV Infection in Hemophiliac and Perinatally Infected Children Prophylactically Treated with Immunoglobulines Containing High Titers of Anti-CMV, Anti-EBV and Anti-HIV and Timing of Azidothymidine Indication. A Prospective Longitudinal Study of 61 Children. Wolfhart Kreuz*, U. Ebener, B. Wegerich, T. Guing6r, S. Enekel, et al., *Universitdtsklinik Frankfurt, Zentrum der Kinderheitkunde, Frankfurt, Pediatrics: Infection/Neoplasia T.B.P.258 Donna Futterman*, E. Connor, M. Boland, J. Oleske, *Children's Hospital AIDS Program, University of Medicine and Dentistry of New Jersey, Newark, NJ, U.S.A. T.B.P.259 Neoplastic Diseases in Children with AIDS. Viiav V. Joshi*, E. M. Connor, F. DiCarlo, L. Epstein, J. M. Oleske, *East Carolina University School of Medicine, Greenville, NC, U.S.A. T.B.P.260 Safety and Efficacy of Central Venous Catheters in Pediatric AIDS Patients. Deborah Gleason-Morgan*, J. Church, H. Bagnall, J. Atkinson, *Childrens Hospital of Los Angeles, AIDS Program, Los Angeles, CA, U.S.A. T.B.P.261 HIV Infection (HIV) in Patients (PTS) Treated for Leukemia or Solid Tumor, a Pediatric Oncology Group (POG) Study. Svlvain S. Baruchel*, L. Montreal Children's Hospital, Montreal, QC, Canada. T.B.P.262 Very Late Onset of Group B Streptococcal Sepsis in Infants with HIV Infection. David pi John*,J. P. Johnson, R. Lawrence, L. S. Schieken, M. B. Rennels, *New York University Medical Center, New York, NY, U.SA. T.B.P.263 Diarrhea and Its Consequences in HIV-Infected Children. Karen L. Kotloff*, J. P. Johnson, P. Nair, G. A. Losonsky, A. Young, J. G. Morris, *University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD, U.S.A. T.B.P.264 Burkitt Lymphoma in an Candidiasis in Pediatric AIDS. losub*, M. R. K. Stone, D. S. Gromisch, E. Wasserman, *New York Medical College, New York, NY, U.S.A. T.B.P.266 Opportunistic Infections and Mortality in an Urban Pediatric Population Infected with Human Immunodeficiency Virus (HIV). I. Celine Hanson*, H. M. Rosenblatt, W. T. Shearer, *Texas Children's Hospital, Baylor College of Medicine, Houston, TX, U.S.A. T.B.P.267 Spectrum of Infections Identified at Autopsy in Pediatric AIDS. Lawrence A. Ross*, V. K. Wong, E. D. Gomperts, A. L. Ricalde, J. A. Church, *Childrens Hospital ofLos Angeles, Division of nfectious Diseases, Los Angeles, CA, U.S.A. 329 [Page 332](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/332) T.B.P.289 Doses of Interferon Alfa-2b in Kaposi's LInmarudada Qcafja*, A. De Luis, I. E. Bejarano, L. De Buen, J. M. Martinez-Vdzquez, *Autonomous University of Barcelona, Barcelona, Spain. T.B.P.290 Intralesional Vinbiastine (VELB AN) Treatment of Lesions of Marcus A. Conant*, G. Gaizagorry, M. L. Illeman, * University of California at San Francisco, San Francisco, CA, U.S~A. T.B.P.291 Remission of Kaposi-Sarcoma by a Combined Therapy with Interferon-Beta + AZT in an AIDS Patient. Heribert Knechten*, F. Braeck, *Heatology-Oncology Institute, Aachen, Federal Republic of Germany. T.B.P.292 Interferon Administered Intralesionally in Skin, Conjunctiva and Oral Cavity Lesions in Patients with AIDS-Related Kaposi's Efisio of of Kaposi's Sarcoma (KS) in AIDS Patients. Iluminada Garcfa-Polo*, I. Santos Gil, C. Del Arco Galan, J. Fraga, J. Ferndfndez, A. Noguerado Asensio, *Medicina Interna-Infecciosas, de et autres and Other Drugs T.B.P.294 Comparison of Ribavirin versus Placebo for Preventing the Progression of HIV Infected Subjects from CDC Stage II to Stage IV. LALM.Gat11*, E. Bouza, X. Came, R. Cisterna, B. Clotet, J. Cosin, et al., *Spanish Ribavirin Study Group, Barcelona, Spain. T.B.P.295 Dextran Sulfate Is Poorly Absorbed after Oral Administration. Kevin JLzranzer, C. W. Hendrix, I. M. Collins, R. H. Eckel, B. G. Petty, P. 5. Lietman, et al., *Johns Hopkins University School of Medicine, Baltimore, MD, U.S~A. T.B.P.296 Ribavirin Dose Escalating Phase I Trial in Patients with AIDS and ARC. Clyde S. Crumvacker*, D. Cotton, G. Pearlstein, F. Valentine, J. Mills, S. Spector, *Beth Israel Hospital, Harvard University School of Medicine, Boston, MA, U.S~A. T.B.P.297 Phase I Study of 2', 3' Dideoxyinosine (ddl) Given Once Daily to Patients with AIDS or ARC. Timothy P. Coolev*, C. A. Saunders, C. J. Perki'ns, R. P. McCaffr~ey, C. McLaren, H. A. Liebman, *Boston University School of Medicine, Boston, MA, U.S~A. T.B.P.298 Evaluation of Megestrol Acetate Treatment in AIDS. ~~Jul..Q Gd*, C. Oliver, *Albion Street (AIDS) Centre, Sydney A ustralia. T.B.P.299 Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Lack of Neurological Toxicity. Bruce J. Brew\"' J. G. Keilp, A. E. Sadler, S. E. Krown, J. Sidtis, R. W P~rice, et al., *Menwrial York, NY, U.S~A. 332 [Page 333](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/333) T.B.P.300 Operational Therapy for People with AIDS. Jonathan Jacobs*, V. Lebowitz, *Center for Special Studies, New York, NY, U.S.A. T.B.P.301 Supervised Physical Exercise Leads to Psychological and Immunological Improvement in Pre-AIDS Patients. Celia A. Schlenzig*, H. Jdger, M. Popesco, *AIDS Group, Schwabinger Krankenhaus, Munich, Federal of T.B.P.302 Long Term Treatment. Ddnes Bdnhegyi*, J. F. Vdrnai, *Institutefor Infectious and Tropical Diseases, Postgraduate Medical School, Budapest, Hungary. T.B.P.303 A Phase I Study of the Safety and Pharmacokinetics of the Soluble Recombinant CD4 (rCD4) in Patients with AIDS or ARC. J. Davis Allan*, J. Kahn, T. Hodges, S. Sherwin, P. Volberding, J. Groopman, *New England Deaconess Hospital, HIV+. Pascal Chavanet*, Aho, J. Mallet, A. Waldner, medicaments Sarrazin, *H6pital Cizanne, Aix en Provence, France. T.B.P.306 Effective Doses in HIV-ITP Is Associated with Erythroid Hypoplasia. Lothar Huebsch*, G. Garber, D. W. Cameron, M. T. Aye, *Ottawa General Hospital, Ottawa, ON, Canada. T.B.P.307 Vitamin B12 Supplements in Patients Treated with Paris, France. T.B.P.308 of Zidovudine (AZT) in Patients with AIDS. Bonaventura Clotet*, J. M. Gimeno, A. Jou, G. Sirera, J. Tor, M. Dominguez, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, after an Allergic Cutaneous Reaction to AZT. Anne Mathieu-Boug*, P. Malfon, P. Caquet, Kremlin-Bicitre, France. T.B.P.311 Role of p24 AG Testing in Patients on Zidovudine. Jennifer F. Hoy*, J. Chua, A. M. Mijch, M. Dimitrikakis, I. D. Gust, C. R. Lucas, *Fairfield Infectious Diseases Hospital, Fairfield, Australia. 333 [Page A. Jacobson*, D. Abrams, P. Bacchetti, K. Kocurek, J. Wilber, A. R. Moss, et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. T.B.P.313 Use of Multiparametric Flow Cytometry (Lymphocyte p24-FCA) to Evaluate Azidothymidine Therapy. Betsy M. Ohlsson-Wilhelm*, J. M. Cory, H. A. Kessler, M. E. Eyster, F. Rapp,A. Landay, et al., *The Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA, U.S.A. T.B.P.314 The Inhibitory Effects of AZT on HIV Replication as Determined by p24 Antigen Capture Assays. Michael V. O'Shaughnessy*, D. Lepine, J. Wainberg, J. Ruedy, C. Tsoukas, M. Fanning, et al., *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. T.B.P.315 The Effect of Treatment with Zidovudine on Immune System Defects Early in the Course of HIV Infection. William M. Reiter*, P. J. Cimoch, *Centerfor Special Immunology, Inc., U.S.A. T.B.P.316 to (TMP-SMZ) Carinii Pneumonia (PCP). Helmut Schifer*, F. R. Ochsendorf, H. R. Milbradt, W. Stille, *Klinikum der J. W. Goethe-Universitat, Department of Dermatology, Frankfurt, Federal Republic of Germany. T.B.P.317 Preliminary Observations about the Adverse Effects of Pefloxacin in the Treatment of Salmonella Bacteremia in. Guido Carlos Levi*, E. A. S. Meideros, J. S. De Mendonga, M. C. S. De Carvalho, H. A. V. Stefani, H. Pinczowski, *Hospital do Servidor Acute Trimethroprim- Sulfamethoxazole (T-S) Reaction Mimics Sepsis in AIDS Patients. Michael P. Johnson*, S. D. Goodwin, Jr., J. W. Shands, *University of Florida School of Medicine, Gainesville, FL, et diabete dfls au SIDA. M. Perronne*, F. Bricaire, Leport, Trimethoprim-Sulfamethoxazole (TMP-SMZ) in 4 Patients with Acquired Immunodeficiency Syndrome. Jose N. Moreno*, C. M. Maggio, *University of Miami School of Medicine, Miami, FL, U.S.A. T.B.P.321 A Method for Rapid Oral Desensitization of Patients Allergic to AZT. Douglas K. MacFadden. Department of Medicine, University of Toronto, Toronto, ON, Canada. T.B.P.322 Recombinant Interferon Bser Protects against Zidovudine-Induced Genetic Damage in AIDS Patients. Hasnaa M. Shafik*, M. A. Nokta, R. B. Pollard, *University of Ain Shams, Faculty of Medicine, Department of Community Medicine, Cairo, Egypt. 334 [Page 335](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/335) T.B.P.323 Megaloblastic Changes in the Bone Marrow of AZT Treated AIDS Patients as a Prognostic Marker for Need of Blood Transfusion. L. jL&eein&*, L. Buys, M. Van den Berg-Wolf, R. Pietersz, J. Ten Veen, *Red Cross Blood Bank, Amsterdam, Netherlands. T.B.P.324 The Effects of PCP Prophylactic Agents on Zidovudine-Induced Anemias. Craig W. Keves*, P. Rodgers, C. Marte, J. Kelly, J. Wo~lbert, D. Ribble, *Communily Health Project, New York, NY, U.S~A. T.B.P.325 Home Transfusion for AIDS Patients on Zidovudine. Miaty luslaccdi*, K. Ivantic, I. Allis, WI, U.SA. T.B.P.326 The Toxicity of Zidovudine in the Treatment of Patients with AIDS-related Complex (ARC) and AIDS. Dra tmu\" N. Mir, D. Hawkins, C. Costello, B. Gazzard, *PSt. U.S~A. T.B.P.328 Eosinophilia in 11W Infected Patients under Zidovudine Therapy. Pierre M. J. T. Deiace*, J. E. Morgan, C. E. O'Neil, G. Valainis, N. E. Hyslop, *Tulane University Medical School, New Orleans, LA, US A. AZT: Double-Edged Sword. Ilona L. Pivar*F, L. Medical Center, Berkeley, CA, U.S.A. T.B.P.330 Psoriasis in HIV AB Positive Drug Abusers. Mqzc Mafin.w.', A. Patrizi, A. M. and in Margaret A. Fischl*, R. Uttamchandani, L. Thompson, S. Santiago, S. Gagnon, * University of Miami School ofMedicine,Miami, FL, U.SA. T.B.P.332 A New, More Sensitive and Highly Specific Anti HIV-1 Assay Based on Recombinant Proteins. Urzsula Beckford*, C. Berrisford, R. J. S. Duncan, L. Mackinlay, P. Weston, R. S. Tedder, *Wellcome Diagnostics, Beckenham, U.K. Diagnostic Diagnosis T.B.P.333 Update on Program Standardization among Public Health Laboratories in the U.S.A. Performing Tests for Human Retroviruses. William LLIHaysLet\", A. F. DiSalvo, J. M. Joseph, J. P. Getchell, *State Hygienic Laboratory, University of Iowa, Iowa City, IA, U.S.A. T.B.P.334 T4A-\"Internal Image\"-Bearing Antibodies in Sera of Patients with HIV-1 Infection. In golf Schedel*, P. Winkelmann, U. Dreikhausen, J. Flik, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany. T.B.P.335 Evaluation of Different Anti-HIV Reagents that Are Available in Mexico.!os6-Luis Dominguez*, C. Morales, M. Romero, M. Moreno, M. Orozco, *Centro Nacional de la Transfusidn Sangur'nea, Mexico City, Mexico. 335 [Page 336](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/336) T.B.P.336 Which Is the Best Laboratory Marker when HIV-Positive Persons? Myriamreis*, E. Sprinz, M. Porto Alegre, Brazil. T.B.P.337 Comparison of Commercially Available for HIV Antibodies Using Zambian Sera. Nkandu P. Macwacwa, *University Teaching Hospital, Lusaka, Zambia. T.B.P.338 Comparison of Two HIV-1 Immunoblot Techniques. Peter Wanzala*, G. Maitha, *Kenya Medical Research Institute, Nairobi, Kenya. T.B.P.339 Laboratory Testing for HIV-1 Antibody Testing in California: Analysis of Current Practices and Improvement Efforts. K. Michael Peddecord*, A. S. Benenson, L. K. Hofherr, M. S. Ascher, *San Diego State University, San Diego, CA, U.SA. T.B.P.340 Cross-Reactivity between ELISAs for Detection of Maria Belen Bouzas*, G. Muchinik, de Medicina, Buenos Aires, Argentina. T.B.P.341 Failure of ELISA and WB Testing to Detect HIV Infected Subjects. Emilio Mannella*, G. Ippolito, M. Miceli, M. Mirolo, *Italian Red Cross, Rome, Italy. T.B.P.342 Correction of False-Positive Results of ELISA of Immunodeficient State. V.Svirska*, Denisova, *August Kirchenstein Institute of Microbiology, Latvian SSR Academy of Sciences, Riga, U.S.S.R. T.B.P.343 Serosurvey of Women in a Maternity Ward. A. Santos-Pinto*, W. Canas Ferreira, E. Prieto, R. Sousa, *Instituto e Medicina Tropical, Lisbon, Donneurs et receveurs de sang et de produits sanguins Recipients and Donors of Blood and Blood Products T.B.P.344 Lookback: An Update on the New York Experience. Suzanne M. Gavnor*, D. Kessler, S. Andrews, P. Berge, C. Del Valle, *The New York Blood Center, New York, NY, U.S.A. T.B.P.345 The Italian Hemophilic Register and Natural History of HIV Infection. Nicola Schinaia*, A. Ghirardini, C. Valdarchi, Italy. Nicola Schinaia*, C. *National Institute of Health, Rome, Italy. T.B.P.347 HIV-1 p24 Antigen Screening of Male Blood Donors in Localities with High HIV-1 Antibody Prevalence. Michael P. Busch, Irwin Memorial Blood Center, San Francisco, CA, U.S.A. T.B.P.348 HIV Infection in Western Blot Indeterminate Blood Donors. J. Brooks Jackson*, M. Hanson, S. Kwok, S. Stramer, H. H. Balfour, Jr., K. MacDonald, et al., *University of Minnesota, Minneapolis, MN, U.SA. 336 [Page 337](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/337) T.B.P.349 Immunoassay. Hugo Troonen*, H. Hampl, B. L. Avilez, S. Ranger, et al., *Abbott Laboratories, Wiesbaden-Delkenheim, Federal Republic of Germany. T.B.P.350 Human Immunodeficiency Virus Antibody Screening of Blood Donors: An International Survey. Roger A. Perrault*, S. Mankikar, A. Adatia, *The Canadian Red Cross Society, Ottawa, ON, Canada. T.B.P.351 Use of Rapid Assays for Antibody to HIV in Blood Donors, Persons Practicing High Risk Behaviors and Suspected AIDS Cases in Ghana. Julius Mingle*, S. Mitchell, O. Osei-Kwasi, *Noguchi Memorial Institutefor Medical Research, Accra, Ghana. T.B.P.352 The Gift Relationship Revisited: HIV Seroprevalence of Blood Donors and Other Low-Risk Groups in Africa. Barbara B. Torrey*, M. Mulligan, P. Way, *Center for International Research, U.S. Census Bureau, Washington, DC, U.S.A. T.B.P.353 The Impact of AIDS on Blood Transfusion Services at the University Teaching Hospital, Lusaka. Abraham Mwile, University Teaching Hospital, Lusaka, Zambia. T.B.P.354 HIV Antigen Tests among New Blood Donors. Prakash C. Das*, A. H. de Vries, R. L. McShine, C. T. Smit Sibinga, *Groningen-Drenthe Red Cross Blood Bank, Groningen, Netherlands. T.B.P.355 Indeterminate HTLV-I Western Blot Results in Blood Donors: Absence of Infectivity to Recipients of Blood. Cees L. Van der Poel*, N. Leslie, H. Reesink, P. Ehlers, E. Bakker, H. Huisman, *Amsterdam, Red Cross Blood Bank, Amsterdam, Netherlands. T.B.P.356 Case Control Study in HIV Seropositivity in Hemodialysis Patients. Conceicao A. Accetturi*, R. Salomao, R. J. I. Longo, N. F. Mendes, *Escola Paulista de Medicina, Sao Paulo, Brazil. T.B.P.357 A and Serological Follow-up of HIV-2: Positive Patients from Guinea-Bissau (West Africa). Wanda Canas-Ferreira*, C. Costa, J. Champalimaud, K. Mansinho, A. Santos Pinto, E. Prieto, Instituto de Higiene e Medicina Tropical, Lisbon, Portugal. T.B.P.358 Latex Agglutination Testing of Whole Blood for HIV-1 in the Field. B. Biryahwaho*, S. Musgrave, J. Ndumu, R. Downing, A. Ojiwya, Research Institute, Entebbe, Uganda. T.B.P.359 Anti-HIV Lookback Programme of the Canadian Red Cross Society. Sadanand Mankikar*, V. Hogan, A. Adatia, N. B. Whittemore, *The Canadian Red Cross Society, Ottawa, ON, Canada. T.B.P.360 Retrospective Study of Post-Transfusion HIV Infection. Birit E. Gathof, U. Backer, G. Gathof, L. Gurtler, J. Eberle, F. Deinhardt, *Bavarian Red Cross Blood Transfusion Service, Munich, Federal Republic of Germany. T.B.P.361 Determination of Erythrocyte Adenosine Deaminase Activity in Anti-HIV Seronegative Homosexual Men with Latent HIV Infection. Mario Ferrazzi*, M. L. De Rinaldis, M. Pezzella, F. Caprilli, A. Bozzi, R. Strom, *Institute Infectious Diseases, University of Rome \"La Sapienza\", I, Manifestations T.B.P.362 Clinical Disease in West Africa. L.Cowrah*, A. Egboga, A. Wilkins, I. Gaye, H. Whittle, B. Greenwood, *Medical Research Council, Fajara, Gambia. T.B.P.363 Clinical Evolution of Cases of LAS/ARC (Follow-up Since 6-48 Months). Sergic Ranieri*, F. Italy. T.B.P.364 Clinical and Epidemiological Spectrum of AIDS Disease in Rio de Janeiro, Brazil. Eleonora P. Quinhoes*, A. B. Sereno, C. Ismael, C. F. Ramos Filho, M. A. Perez, B. G. Weniger, et al. *Hospital Universitario Gaffr~e e Guinle, Universidade do Rio de razil. T.B.P.365 AIDS-Associated Glomerulopathy. Luiz Paulo C. A. Brasilio de Oliveira, A. V. Oliveira, L. S. Riodja, *Universidade dio Rio de Janeiro, Rio de Janeiro, Brazil. T.B.P.366 Cervical Lesions and HIV Infections in a Cohort of Prostitutes in Kinshasa, Zaire. Ann Marie Nelson*, Z. Nsiangana, HIV Infection. Eleonora P. Quinhoes*, C. A. Basilio, H. A. Valle, F. Fialh~o, F. S. Sion, C. A. Morais de Sdf, *Gaffre6 & Guinle University Hospital, University of Rio de Janeiro, Rio de.Janeiro, Brazil. T.B.P.370 Thymic Pathology in Pediatric AIDS. M. Alba Greco*, P. Thomas, V. Mahnovski, M. Magid, E. Kahn, V. Anderson, *New York University, Department of Pediatric Pathology, New York, NY, U.S~A. T.B.P.371 Delayed Healing of Infectious Syphilitic Lesions in HIV-Infected Zambian Men Receiving Appropriate Penicillin Treatment. Suhs K. Hira*, D. Mwendasilumba, R. Macauca, P. L. Perine, * University Teaching Hospital, Lusaka, Zambia. T.B.P.372 Dermatitis of the Face and Yellow Toe Nail Changes Indicate Progression to AIDS/Ol in Patients with HIV Infection. Ldinda Morfeldt-Monson*, I. Julander, Nilsson, *Karolinska Institute, Manifestations in African Children Perinatally Infected by HIV and Aged 5 Years Old or More. Philippe Lepage*, P. Van de Perre, D. G. Hitimana, C. Van Goethem, P. Kestelyn, F. Nsengumuremyi, *Department of G. Grosse, M. L'Age, *Auguste-Viktoria Hospital, 2nd Internal Department, Berlin, Federal Republic of Germany. T.B.P.376 Severe Reversible Gastrointestinal Dilatation Associated with HIV-1 Infection. Rui M. M. Victorino*, M. Lucas, F. Neto, M. C. Moura, *Faculty ofMedicine ofLisbon, Lisbon, Portugal. T.B.P.377 The Spectrum of Clinical Disease among Filipino AIDS Cases. Ofelia T. Monzon*, V. Basaca-Sevilla, C. Hayes, J. Capellan, C. Manaloto, M. C. Saniel, *Research Institute for Tropical Medicine, Manila, Philippines. T.B.P.378 Intrauterine HIV Exposed Children: Results of a Four-Year Prospective Investigation. Ilse Grosch-W6rner*, M. Carinii Pneumonia (PCP) Presenting Aerosolized Pentamidine Prophylaxis. Bary N. Flynn, W. Martin, M. Soehn, S. Pomerantz, *University of California at Davis, Medical Center, Division of General Medicine, Sacramento, CA, U.SA. T.B.P.380 Occurrence of Kaposi's Sarcoma (KS) in Patients Treated of Kaposi's Sarcoma and Improvement of Performance Status by a Combined Interferon-beta 1 and Zidovudine Therapy in AIDS Patients. N.H. Brockmeyer*, Mertins, R. Biniek, M. Goos, CHG, Elbeuf, France. T.B.P.383 T.B.P.384 Physician Experience with HIV Infection in a Low Prevalence Area. Barry A. Hong*, J. Rice, S. Wightman, W. Seyfried, W. Powderly, L. Ratner, *Washington University School of Medicine, St. Louis, U.SA. 339 [Page 340](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/340) Basic Research (Biomedical) d'affichage Poster Session Immunologle de base Basic Immunology T.C.P.1 Measurement of Affinity Maturation in HIV-1 Infected Chimpanzees. Richard T. Coughlin*, P. Bulger, V. G. Masison, D. J. Marciani, Corp., U.S.A. T.C.P.2 Type-specific CTL Response to the HHIV-1 Envelope Gene Product. Karen A. Birch-Limberger*, B. D. Walker, C. Flexner, R. T. Moss, T. J. Schooley, T. J. Paradis, *Massachusetts General Hospital, Boston, MA, U.S.A. T.C.P.3 AZT Inhibits LPS-Induced Secretion of IL-1 by Cultured Normal Human Monocytes. Cellular Cytotoxicity Immune Response. Tsugiva Murayama*, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. T.C.P.5 CD4+ and CD8+ Cytotoxic T Antigens. Torvey*, T. Murayama, P. Gupta, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. T.C.P.6 Differential Kinetics of HIV Infection of Blood Monocytes and Macrophages In Vitro and Effects of Subsequent Functions. Farhad Kazazi*, J. M. Mathijs, P. Foley, T. C. Sorrell, A. L. Cunningham, *Westmead Hospital, Virology Unit, ICPMR, Westmead, Australia. T.C.P.7 Immunotoxins Prepared from Human Monoclonal Antibodies Coupled to Deglycosylated Ricin A Chain Kill HIV-Infected Lines of T Cells and Monocytes. Susan Zolla-Pazner*, M. A. Till, M. K. Gorny, J. S. Patton, J. W. Uhr, E. S. Vitetta, *New York University Medical Center, Department of Pathology, New York, NY, U.S.A. T.C.P.8 Selective Infection of Macrophage Subsets in the Lung by HIV. Margaret A. Johnson*, L. W. Poulter, *Department of Thoracic Medicine, Royal Free Hospital, London, U.K. T.C.P.9 Normal Capacity of Monocytes from AIDS Patients for Uptake and Growth Inhibition of Mycobacterium Avium-Intracellulare. John LzJohnson*, H. Shiratsuchi, H. Toba, J. J. Ellner, *Case Western Reserve University, Cleveland VA Medical Center, Cleveland, OH, U.S.A. 340 [Page 341](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/341) T.C.P.1O Definition of a Subset SIV/Mne using and PCR. Edward A.LClar&*, I. Gibbon, D. Wiliford, M. J. Gale, P. Hoffman, W. M. Gallatin, * Universily of Washington, Regional Primate Research Center, Department of Microbiology, Seattle, WA, U.SA. T.C.P.11 Pilot Study of Anti-LEU3a in HIV-1 Seropositives. David Wilks*, L. C. Walker, J. A. Habershaw, A. G. Dalgleish, *Clinical Research Centre, Division of Immunological Medicine, Harrow, U.K. T.C.P.12 CD8+ Lymphocytes Can Control Acute HIV Infection of CD4+ T Cells. Christoolher M. Walker*, G. Thomson-Honnebier, F. Hsieh, J. A. Levy, * University of California at San Francisco, SchoolI of Medicine, Cancer Research Institute, San Francisco, CA, U.S~A. T.C.P.13 Antibody-Binding Epitopes of HIV-1 Envelope Glycoproteins. John &. roka.\", D. P. Stites, B. Singh, * University of California at San Francisco, Department of Laboratory Medicine, San Francisco, CA, U.SA. T.C.P.14 Mechanisms of Lymphocyte Dysfunction in IIIV-Infected 'nm, P. Stanley, P. L. Beverley, *Academic Department of Genito-Ur~inary Medicine, James Pringle House, London, U.K. T.C.P.15 Inhibition of CD3 Signalling by gpl2O Is Associated with Modulation and Altered G Protein-Regulated Calcium Gating. Hardy Klrfeld2\", W. W. Cruikshank, S. W. Pyle, D. M. Center, *Boston University School of Medicine, Pulmonary Center, Boston, MA, U.SA. T.C.P.16 Identification of a Potent Synthetic HIV-1 Immunogen Comprising of gag-p24 Tandem-T and B-Cell Epitopes. &1i..Chi.ng*, Sia, M. Sydov, Klein, *Connaught Laboratories Ltd., Willowdale, ON, Canada. T.C.P.17 IIIV Infection of Bone Marrow Stromal Macrophages. Florence t~LHofmatY, J. Zheng, M. Rarrick, P. Gill, A. Mazumder, *University of Southern California, Los Angeles, CA, U.S~A. of Epitopes Recognized by THY-Specific CTL. LLot Koinig*, P. Earl, L. Wood, B. Powell Moss, A. S. Fauci, \"Ntoa Institutes of Health, Bethesda, MD, U.S~A. T.C.P.19 The Role of L{IV-Induced 1L 6 Production in B Cell Activation in AIDS. Elizabeth C. Breen*, J. F. Salazar-Gonzalez, T. Hirano, T. Kishimoto, 0. Martinez-Maza, * University of California, Department of Microbiology and Immunology, Los Angeles School of Medicine, Los Angeles, CA, U.S~A. T.C.P.20 CD8+ T Cells Can Suppress lIlY Replication Via a Soluble Factor. Jan ~.Brnhmgatm., G. Gaudernack, E. Thorsby, F. Vartdal, *lrtitute of Transplantation The Hospital, Oslo, Norway. T.C.P.21 Monocytes and Neutrophils from IIIV-Infected Individuals Contain Very Low or Undetectable Levels of Provirus as Determined by PCR Analysis. Gr~egory T. Svear*, J. L. Moore, A. L. Landay, H. A. Kessler, G. Schochetman, C.-Y. Ou, of M. Martin*, L. Belec, G. Steenman, M. C. Georges-Courbot, A. J. Bangui, African Republic. T.C.P.23 A Cross-Reactive Cytotoxic Cell Epitope Between HIV-1 and Douglas Nixon*, C. Rizza, Howland, A. J. McMichael, *John Radcliffe Hospital, Institute of Molecular Medicine, Molecular Immunology Group, Oxford, U.K. T.C.P.24 Antibodies Which Recognize both Conserved and Variable Regions of HIV-1 gpl20 Are Responsible for HIV-Specific ADCC. Richard A. Koup*, C. Pikora, S. McKenzie, G. Mazzara, D. Panicali, J. Sullivan, *University of Massachusetts Medical Center, Department of Pediatrics, Worcester, MA, U.S.A. T.C.P.25 CD8+HNK1+ Cells Suppress the HIV-Specific T Cell Activities. Brigitte P. Joly, J. M. al., *Hdpital Pitid-Salpetriere, Paris, France. T.C.P.26 An HLA-DR+, Light Density, Peripheral Blood Mononuclear Cell Produces Alpha Interferon in Response to HIV. Charles R. Rinaldo*, J. Toso, G. Rappocciolo, P. Gupta, J. Ferbas, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. T.C.P.27 Antigen-Reactive T Lymphocytes are Present in HIV-Infected in Lymphocyte Fass, C. Whitacre, *Ohio State University, Department of Medical Microbiology and Immunology, Columbus, OH, U.S.A. T.C.P.28 The Immunoregulation of Human Immunodeficiency Virus in Human Semen. Joanne Rhoads*, V. Polonis, D. L. Birx, R. Hendricks, D. S. Burke, R. R. Redfield, et al., *Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S.A. T.C.P.29 Relationship between Antibody against the C-Terminal Region of gpl20 and Markers of HIV-Specific Immunoregulation. Victoria Polonis*, H. Husayni, T. H. Lee, M. Essex, D. S. Burke, R. R. Redfield, * Walter Reed Army Institute ofResearch, Department ofRetrovirology, Rockville, MD, U.S.A. T.C.P.30 Cytokines Alter Susceptibility of Human Monocytes to Infection by HIV-1. Donald R. Skillman*, H. E. Gendelman, M. S. Meltzer, *Walter Reed Army Medical Center, Washington, DC, U.S.A. T.C.P.31 Function of CD8 Cell Subsets in HIV Infection. Susan F. Plaeger-Marshall*, M. A. Hausner, V. Gudeman, D. Smith, J. V. Giorgi, *University of California, Los Angeles School of Medicine, Department of Pediatrics, Los Angeles, CA, U.S.A. T.C.P.32 Anti-HIV Antibody Directed Cytotoxicity: Cellular and Humoral Defects. Douglas S. Tvler*, S. D. Stanley, C. L. Nastala, K. C. Stine, D. P. Bolognesi, K. J. Weinhold, *Duke University Medical Center, Department of Surgery, Durham, NC, U.S.A. 342 [Page 343](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/343) T.C.P.33 Characterization of p 17 Protein on Plasma Membrane of HIV-Infected Cells by Monoclonal Antibodies and Epitope Mapping. Francis W. J. Mikovits, M. Baseler, M. Sheu, L. Papsidero, *Frederick Cancer Research Facility, Laboratory of Molecular Immunoregulation, Frederick, MD, U.S.A. T.C.P.34 HIV-1 Stimulates Tumor Necrosis Factor-Alpha Release from Human Monocyte/Macrophages (MI). Eric S. Daar*, J. K. S. Chia, D. Yim, D. D. Ho, *Cedars-Sinai Medical Center and University of California, Los Angeles School of Medicine, Los Angeles, CA, U.SA. T.C.P.35 Comparative Study of NK and ADCC Activity of CD3-,CD2+,CD16+ Cell Lines Obtained from Normal Seronegative and HIV Seropositive Subjects. Daniel Scott*, Paris, France. T.C.P.36 Role of FC Receptors in the Binding of HIV to Monocytes. Lovda Melndez-Guerrero*, J. K. A. Nicholson, J. S. McDougal, C. D. Dawson, *Emory University, Department of Pathology, Atlanta, GA, U.S.A. T.C.P.37 Identification of Common Epitopes of HIV-1 Antibodies. Bernd Zorr*, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany. T.C.P.38 Effect of HIV on Antigen-Induced T Cell Proliferation. Zaruhi Kiipci*, N. Barrett, F. Dorner, R. C. Gallo, M. M. Eibl, J. W. Mannhalter, *Immuno A.G., Department of Immunological Research, Orth/Donau, Austria. T.C.P.39 HIV Induced, HIV-Specific In Vitro Response. Delfraissv*, France. T.C.P.40 Tumor Necrosis Factor Inhibits Activation of B Cells by Human Immunodeficiency Virus (HIV).Jean-Francois Delfraissy*, Cell Lines. C. Carini*, M. Chierchi, F. Aiuti, *Allergology and Clinical Immunology, University Italy. T.C.P.42 Prevalence of Anti-nef Postive Sera in HIV Infected Patients: Mapping of the Major Epitopes of nef Protein Using Synthetic Peptides. Elmostafa Bahraoui*, J. Van Rietschoten, C. Granier, Levels of Soluble 1L-2 Receptors (sIL-2R) in HIV Infection. Correlation Studies and Clinical Significance. Jean-Marie Lang*, G. Coumaros, S. Levy, A. Aleksijevic, Koehl, *H6pital de Hautepierre, Strasbourg, France. T.C.P.44 Low Levels of LFA1+ Cells in HIV Infection. Corinne Amil*, B. Gobert, T. May, M. C. Bene, G. Faure, P. Canton, *Department of Infectious Diseases, Nancy, France. 343 [Page 344](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/344) T.C.P.45 Expression of the T-Cell Receptor Molecule in HIV Infection. Corikme Amil\", M. C. Bene, T. May, G. Faure, P. Canton, *Department of Infectious Diseases, Nancy, France. T.C.P.46 Most Sera from HIV Infected Individuals Contain HIV Antigen as Immune Complexes. Parunag G. Nishanian*F, K. Huskins, S. Stehn, R. Detels, J. L. Fahey, *University of California, Los Angeles School of Medicine, CHS, Department of Microbiology and Immunology, Los Angeles, CA, U.SA. T.C.P.47 Productive In Vitro lIlY Infection of Normal CD8+ Lymphocytes. Richrard W. Bailev*, D. E. TX, U.SA. T.C.P.48 CD4-Derived Golding, K. L. Vujcic, A. F. Robey, *National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S~A. T.C.P.49 HIV- 1 Disease Status and Seroreactivity to gag, pol and env Gene Products. Philliv P. Shadduck*, T. J. Matthews, T. Grove, C. S. Chiang, C. W. McMillan, G. C. White, *Duke University Medical Center, Durham, NC, U.SA. T.C.P.50 Phenotypic Characterization of the Expanded CD8Leu-7+ Cell Population in Patients with HIV Infection. Ces.S~n\" J. A. McCutchan, D. D. Richman, * University of California at San Diego, School of Medicine and the VA Medical Center, San Diego, CA, U/S A. T.C.P.51 Immunodominant Epitopes of gpl12O: A Potential Obstacle for Vaccine Development. T A-1.Q Le\" W. J. Syu, B. Du, W. R. Lee, R. D. Chang, M. Huang, et al., *Hatrvard School of Medicine, Department of Cancer Biology, Boston, MA, U.S.A. T.C.P.52 Differences among Lymphocyte Subpopulations in H~IV Positive or Negative Homosexual and Heterosexual Males as Determined by Multiparameter Flow Cytometry. Carol T. Schnizlein-Bick*, M. R. Magier, R. B. Jones, K. H. Fife, E. B. Walker, *Indiana University School of Medicine, Departments of Medicine and Infectious Diseases, Indianapolis, IN, U.S~A. T.C.P.53 Envelope Glycoproteins of HILV- 1 Inhibit Expression of mRNA for IL-2 but not for IL2R in Tetanus-Specific T Cell Cones. Nak ~az\" N. Chirmule, W. Hall, V. S. Kalyanaraman, H. Slade, S. Pahwa, *North Shrore University Hospital, Manhasset, NY, U.SA. T.C.P.54 Interferon Beta and Interleukin-2 but not Interferon Alpha Augment Natural Killing of lIY-Infected Targets among HIY (+) Subjects. Keiiti M.Rme\" G. J. Stanton, M. W. Cloyd, * University of Texas Medical Branch, Galveston, TX, U.SA. T.C.P.55 Correlation of ADCC and Neutralization with a Better Clinical Stage in Children Born to HIV-l Infected Mothers. Kristina Liunggren*, V. Moschese, P. A. Broliden, B. Wahren, P. Rossi, M. Jondal, *Karolinska Institute, Department of Immunology, Stockholm, Sweden. 344 [Page 345](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/345) T.C.P.56 An Analysis of the Expression of CD4 Receptors by Blood Monocytes and T Cells from Normal and HIV-1+ Individuals. Lionel G. Filion*, C. A. Izaguirre, G. E. Garber, L. Huebsch, *University of Ottawa, Ottawa, ON, Canada. T.C.P.57 Augmentation of Direct Cytotoxicity and Jewett, P. Nishanian, R. Mitsuyasu, *University of California, Los Angeles School of Medicine, Los Angeles, CA, U.S.A. T.C.P.58 Monocytes/Macrophages Infected with HIV-1 Produce Acid-Labile Interferon-a.dnos Szebeni*, R. M. Friedman, S. M. Wahl, L. M. Wahl, J. N. Weinstein, *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. T.C.P.59 Characterization of Human Monoclonal Antibodies against HIV-1 with Group Specific Neutralizing Activities. Veronique against Collagen in AIDS: Correlation with Risk Factors and Disease Progression. Michael D. Grant*, M. S. Weaver, G. W. Hoffmann, *University of British Columbia, Department of Microbiology, Vancouver, BC, Canada. T.C.P.61 Potential Extracorporeal Treatments Using a CD8 T-Activator for Patients with AIDS. Dewey J. Moody*, A. Mizerek-Erhart, L. A. Feeney, S. Finch-Manzagol, H. Hollander, T. B. Okarma, *Applied Immune Sciences, Menlo Park, CA, U.S.A. T.C.P.62 Anti-Lymphocyte Antibodies Associated with HIV Infection. William J. Cronin*, B. D. Dorsett, H. L. loachim, *Lenox Hill Hospital, Department of Pathology, New York, NY, U.S.A. T.C.P.63 Preferential Loss of LEU 8-, CD45R-, HLA-DR+ CD8 Cells during Culture of Mononuclear Cells from Former Blood Donors Seropositive for HIV-1. Harry E. Prince, American Red Cross Blood Services, Los Angeles, CA, U.S.A. T.C.P.64 Inverse Aberrancies of the Mucosal and Systemic IGA Systems in AIDS. Susan Jackson*, D. Kotler, *The University of Alabama at Birmingham, Department of Microbiology, Birmingham, AL, U.SA. T.C.P.65 Heightened Complement Sensitivity of AIDS/ARC Lymphocytes Related to Diminished Expression of Decay Accelerating Factor (DAF). Michael M. Lederman*, S. F. Purvis, E. I. Walter, J. T. Carey, M. E. Medof, *University Hospitals of Cleveland, Cleveland, OH, U.SA. T.C.P.66 Evaluation of Mononuclear Cell Associated HIV Antigens in Infants and Children. Merlin L. Robb*, J. Baker, L. Toro, J. Vincent, G. Pettett, G. Fischer, et al., *Walter Reed Army Medical Center, Department of Pediatrics, Washington, DC, U.SA. T.C.P.67 Sequential Analysis of HIV-Specific CTL Function in HIV-Infected Patients during AZT Therapy. Agnes Hoffenbach*, G. Dadaglio, F. Michel, N. Chenciner, P. Paris, France. Complement Deposition on the Surface ofHIV-Infected Cells Mediates Binding to Cells Carrying Complement Receptors. Briitte Solder*, T. Schulz, P. Hengster, G. Dierich, *Institute for Hygiene, Innsbruck, Austria. T.C.P.69 Functional and Envelope Binding Antibodies to HIV-1 in Seropositive Subjects from Africa and the Americas. Emily W. Carrow*, D. A. Katzenstein, L. A. Sawyer, R. M. Hendry, E. J. Boone, G. V. Quinnan, et al., *Centerfor Biologics Evaluation Research, Food and Drug Administration, Laboratory of Retrovirus Research, Division of Virology, Bethesda, MD, U.S.A. T.C.P.70 The Transmembrane Protein of HIV-1, gp41, Exists in Virions in the Form of Tetrameric Structures Which Possess Enhanced Immunoreactivities. Abraham Pinter*, W. J. Honnen, S. A. Tilley, C. Bona, M. K. Gorny, S. Zolla-Pazner, *Public Health Research Institute, New York, NY, U.S.A. T.C.P.71 In Vitro Activation of Natural Killer (NK) Cells by Interleukin-2 (IL-2) or Interferon-B (IFN-B) Induces Loss of Cytotoxic Capacity. Gregory T. Spear*, B. N. Dittel, A. L. Landay, R. A. Bray, *Rush Presbyterian-St. Luke's Medical Center, Department Immunology/Microbiology, Chicago, IL, U.S.A. T.C.P.72 Unique and Cross-Reactive Antigenic Regions within the Transmembrane Proteins of HIV-1/HIV-2 and Their Utility in Diagnosis of Viral Infections. Sushil G. Devare*, J. Hunt, K. Boardway, R. Gutierrez, G. Dawson, V. Sarin, *Abbott Laboratories, Abbott Park, IL, U.S.A. T.C.P.73 Human Antibody Response to HIV-1 Protease According to Disease Stage. Charles A. B. Boucher*, M. H. De Jager, C. Debouck, F. De Wolf, T. F. W. Wolfs, J. Goudsmit, *Academic Medical Center, Human Retroviral Laboratory, Amsterdam, Netherlands. T.C.P.74 Quantitative, not Qualitative, Defects Characterize Responses of Cells from HIV+ Subjects to B Cell Mitogens. Andrew S. Edelman*, S. Zolla-Pazner, *New York University Medical Center, Department of Pathology, New York, NY, U.S.A. T.C.P.75 Human Monoclonal Antibodies (HuMAb) to HIV-1. Douglas Lake*, T. Kawamura, A. Morice, Y. Masuho, E. Petersen, E. Hersh, *University ofArizona Cancer Center, Tucson, AZ, U.S.A. T.C.P.76 Fine Specificity Cytotoxic T Lymphocytes in Humans. Pierre R. Fisher, F. Plata, *Institut Pasteur, Paris, France. T.C.P.77 HIV Recombinant p 18 Core Protein Inhibits Proliferative Responses by Normal Lymphocytes in Humans and Mice. Freddrique Michel*, R. Cheynier, G. Lacaud, M. Plata, et al., *Institut Pasteur, Paris, France. T.C.P.78 Localization within the HIV-1 LTR of Nucleotides Responsive to CMV-Mediated Transactivation. Paul A. Luciw*, P. Barry, E. Pratt-Lowe, M. Marthas, N. Duchange, K. Jones, *University of California at Davis, Department of Pathology, Davis, CA, U.S.A. 346 [Page 347](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/347) T.C.P.79 Lymphokine-Activated Killer Cell Activity in Patients B. Brenner, R. Margolese, M. Gornitsky, M. Wainberg, *Sir Mortimer Davis Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada. Biologie molbculaire Molecular Biology T.C.P.80 Analysis of the Mechanism Underlying rev Regulation of HIV Structural Protein Gene Expression. Marie-Louise Hammarskiald*, J. Heimer, A. Smith, N. Lewis, W. Andrews, D. Rekosh, *State University of New York at Buffalo, Departments of Microbiology and Oral Biology, Buffalo, NY, U.S.A. T.C.P.81 Assay Systems for HIV rev Function Using Chimeric Gene X iaobin Lu*, Rekosh, *State University of New York at Buffalo, Department of Biological Sciences, Buffalo, NY, U.S.A. T.C.P.82 Direct Analysis of Genetic Diversity and Evolution of HIV in Infected Persons Using Polymerase Chain Reaction (PCR). Chin-Yih Ou*, K. Robbins, J. Jason, C. R. Horsburgh, B. Evatt, G. Schochetman, et al., *Centersfor Disease Control, AIDS Program, Atlanta, GA, U.S.A. T.C.P.83 Human Chromosome-12 Is Required to Support an Elevated Level of HIV Gene Expression in Human-Hamster Hybrid Cells. Clyde E. Hart*, J. Galphin, C.-Y. Ou, L. T. Bacheler, J. Wasmuth, S. R. Petteway, et al., *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. T.C.P.84 Epitope Mapping of the HIV-1 gag Region by Analysis of gag Gene Deletion Fragments Expressed in E. ~1j Defines Eight Antigenic Determinants. Carol J. Marcus-Sekura*, A. Woerner, Zhang, M. Klutch, *Division of Virology, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A. T.C.P.85 Active HIV Protease Purified in a Single Step from Escherichia Coli Inclusion Bodies. Alfredo G. Tomasselli*, J. O. Hui, D. J. Staples, T. K. Sawyer, C.-S. C. Tomich, R. L. Heinrikson, *The Upjohn Company, Kalamazoo, MI, U.S.A. T.C.P.86 Analysis of the Expression of HIV-1 Antigens in the Baculovirus System. David Parker*, R. Weller, S. Ahern, B. Rodgers, *Wellcome Diagnostics, Beckenham, U.K. T.C.P.87 Translated Effects of the 5' Untranslated Region of HIV-1 In Vivo: Regulation by tat. Neil T. Parkin*, C. Rosen, N. Sonenberg, *McGill University, Department of Biochemistry, Montreal, QC, Canada. T.C.P.88 Failure of Interferon- and messenger RNA Synthesis in PBMC of HIV-1 Infected Patients at Late Stages. Rila Voth*, S. Rossol, K. Klein, W. E. G. Muller, S. Brunner, K. H. Meyer zum Biischenfelde, et al., * University of Mainz, First Medical Clinic, Mainz, Federal Republic of Germany. T.C.P.89 Acidic Residues within the Amino Terminal Region of HIV-1 tat is Critical for Transactivation. Ja, F. Rappa5ort*, S. J. Lee, K. Khalili, F. Wong-Staal, *Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A. 347 [Page 348](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/348) T.C.P.90 Post-Infection Viral Transmission In Vitro, at Micromolar Concentrations. Dianne M. Rausch*, L. Eiden, K. Hwang, P. Nara, M. Padgett, J. Lifson, *National Institute of Mental Health, Bethesda, MD, U.S.A. T.C.P.91 Promotor Activity of 5' LTR Region of a Highly Cytopathic Strain of HIV-1.Josephine Sire*, I. Hirsch, V. Zachar, J. *INSERM U322, Marseille, France. T.C.P.92 Detection and Sequencing of Individual Molecules of HIV DNA Amplified by a Modified PCR. Peter Simmonds*, P. B. Balfe, A. J. Leigh-Brown, J. O. Bishop, *University of Edinburgh, Department of Genetics, Edinburgh, U.K. T.C.P.93 Binding of the HIV-1 tat Protein to tar Sequences in Vitro. Michael A. Skinner*, C. Dingwall, I. Ernsberg, S. Haephy, M. J. Gait, J. Karn, *MRC Laboratory of Molecular Biology, Cambridge, U.K. T.C.P.94 Characterization of the Infectivity of HIV Proviruses Containing Mutations in LTR Regulatory Sequences. Arnold B. Rabson*, J. M. Leonard, C. M. Parrott, A. Buckler-White, M. A. Martin, *NIAID, National Institutes ofHealth, Bethesda, MD, U.S.A. T.C.P.95 Analysis of VPX Function in HIV-2 Infected Cells. Lee Ratner*, W. Hu, N. Vander Heyden, *Washington University, St. Louis, MO, U.SA. T.C.P.96 Highly Efficient Neutralization of HIV with Recombinant CD4-Immunoglobulin Molecules. Klaus E. Karialainen*, A. Traunecker, J. Schneider, H. Kiefer, *Basel Institute for Immunology, Basel, Switzerland. T.C.P.97 Packaging and Transfer of a Marker Gene by HIV Vector Particles. Francois Clavel*, O. Danos, M. Alizon, *LMN, NIAID, National Institutes ofHealth, Bethesda, MD, U.S.A. T.C.P.98 Interaction of HIV with Interferon Regulated, Antiviral Enzymes. Bryan Williams*, R. H. Silverman, D. N. Sengupta, M. Dion, *Toronto Hospital for Sick Children, Toronto, ON, Canada. T.C.P.99 HIV-1 Replicates in Human Sperm Mitochondria ofHIV-1 Lischner, G. Haligen, B. Hains, M. Freund, *University of Medicine and Dentistry of New Jersey, Camden, NJ, U.S.A. T.C.P.100 Transmission of SIVmnd in a Semi-Free Range Breeding Colony of Mandrills in Gabon. Martine Peeters*, E. Delaporte, C. Honord, R. W. Cooper, P. the HIV-1 LTR. Edward D.QBlair*, M. G. Davis, C. R. Roberts, *The Wellcome Research Laboratories, Beckenham, U.K. T.C.P.102 HIV-1 rev Induced Modulation of nef Protein Underlies Regulation of Viral Replication. R. K. Maitra, S. Venkatesan, MD, U.S.A. 349](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/349) T.C.P.103 HIV-1 tat Functions in Xenopus Oocytes in the Presence of Transcription Inhibitors. Martin Braddock*, A. Chambers, W. Wilson, A. J. Kingsman, S. M. Kingsman, *Department of Biochemistry, University of Oxford, Oxford, U.K. T.C.P.104 Genes in the 3'End of HIV Control HIV Replication and Cytopathology. Cecilia Cheng-Maver*, M. Quiroga, D. Dina, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. T.C.P.105 Molecular Cloning and Sequencing of a New HIV-2 Isolate (HIV2CAM2). Michael Tristem*, A. Karpas, F. Hill, *University of Cambridge Clinical School of Medicine, Department ofHaematology, Cambridge, U.K. T.C.P.106 Stable Expression and Secretion of Recombinant HIV-1 Envelope Protein in Drosophila Schneider Cells. Hanne R. Johansen*, J. Culp, S. Mai, B. Vickroy, M. Chaiken, S. Comer, et al., *Smith Kline & French Laboratories, Swedeland, PA, U.SA. T.C.P.107 Possible Mode of Insertion into a Lipid Bilayer of N-Terminal Fusogenic Segment of Viral Envelope Proteins. Recombinant HIV Reverse Transcriptase: Purification of Homogeneous, Stable P66 by Nature/Denaturation Protocols. Gary Tarpley*, T. J. McQuade, D. P. Brunner, M. R. Deibel, *The Upjohn Company, Kalamazoo, MI, U.S.A. T.C.P.109 An HIV 1 Peptide Library Expressed in Yeast Reveals New Continuous Epitopes. Pascal Madaule*, J. E. T.C.P.110 Effect of Hydrocortisone on the Replication of HIV-1 in Different Cell Types. Hugo Soudevns*, R. Geleziunas, G. Shyamala, M. A. Wainberg, W. Schneider, *Lady Davis Institute for Medical Research, Montreal, QC, Canada. T.C.P.111 Characterization of HIV-1 Clinical Isolates Resistant to Zidovudine. Ronald Rooke*, M. Tremblay, M. A. Wainberg, *McGill University, Montreal, QC, Canada. T.C.P.112 The Effect of HIV Infection on Monocyte Differentiation. Romas Geleziunas*, F. Boulerice, S. Bour, Montreal, QC, Canada. T.C.P.113 Chromosomal Localization tat-Interacting Cellular Factors. Peter R. Shank*, M. Newstein, *Division of Biology and Medicine, Brown University, Providence, RI, U.S.A. T.C.P.114 The rev Gene Product of the Human Immunodeficiency Virus Affects RNA Localization. Keith Peden*, M. Emerman, R. Vazeux, *Johns Hopkins University, School ofMedicine, Baltimore, MD, U.S.A. T.C.P.115 Effect of Mutations in vpx on the Infectivity of Viral Particles of HIV-2. Keith Peden*, M. Guyader, M. Emerman, L. Montagnier, *Johns Hopkins University, School of Medicine, Baltimore, MD, U.S.A. 349 [Page 350](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/350) T.C.P.116 Expression inE. coli and Purification in One Step of a Functional Hybrid Protein between a Bacterial Periplasmic Protein (Male) and the T Lymphocyte-Helper Inducer CD-4 Protein (Soluble Part). Jean-Marie Clement*, Y. Henin, L. Montagnier, et al., *PMTG, Institut Pasteur, Paris, France. T.C.P.117 Constitutive Synthesis of NF-xB-like Nuclear Proteins in Monocytes: An Explanation for HIV Latency? Nancy L. McCartney-Francis*, M. Norcross, *NIDR/National Institutes of Health, Bethesda, MD, U.SA. T.C.P.118 Activation of HIV and Interferon Regulatory Elements in Hematopoietic and Epithelial Cells. Lucie Cohen*, J. F. Leblanc, L. Sportaza, S. Xanthoudakis, J. Hiscott, *Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. T.C.P.119 Detection of a Novel DNA Topoisomerase I Activity Associated with a Human Immunodeficiency Virus (HIV) and Other Retrovirus Particles. Esther Priel*, O. Yosef, S. Segal, M. Aboud, S. D. Showalter, M. Roberts, et al., *National Cancer Institute, Frederick, MD, U.S.A. T.C.P.120 Nef Responsive Sequences (NRS) of the HIV-1 LTR Suppression. Lee Ratner*, T. M. J. Niederman, *Washington University, St. Louis, MO, U.SA. T.C.P.121 Myristoylation-Dependent Assembly of Infectious HIV-1. Lee Ratner*, M. L. Bryant, *Washington University, St. Louis, MO, U.SA. T.C.P.122 Biological Significance of HIV-1 Envelope Heterogeneity. Terry McNearnev*, P. Westervelt, B. J. Thielan, D. Trowbridge, J. Garcia, L. Ratner, *Washington University, St. Louis, MO, U.S.A. T.C.P.123 HIV Infection of Colonic Mucosa Associated with Colitis. J. M. Mathis*, M. Hing, C. Goldschmidt, D. A. Cooper, A. L. Cunningham, *Westmead Hospital, Virology Unit, Westmead, Australia. T.C.P.124 Analysis of HIV Sequence Change During Infection. Andrew J. Leigh Brown*, P. Balfe, *University of Edinburgh, Department of Genetics, Edinburgh, U.K. T.C.P.125 Localization of a Domain of Human CD4 Required for HIV-Mediated Syncytium Formation by Comparison with CD4 cDNAs Isolated from the Chimpanzee and Rhesus Monkey. David Camerini*, B. Seed, *Massachusetts General Hospital and Harvard Medical School, Boston, MA, U.S.A. T.C.P.126 Studies of the Function of vpx in HIV-2. John C. Kappes*, W. D. Decker, S. W. Lee, C. D. Morrow, G. M. Shaw, B. H. Hahn, *University of Alabama at Birmingham, Birmingham, AL, U.S.A. T.C.P.127 Comparative Analysis of HIV-1 and HIV-2 Gene Expression. Suresh K.Arya*, R. C. Gallo, *National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. T.C.P.128 Restriction Map Patterns in Selected Clinical Pairs of HIV Isolates. Mary Anne T. Vahey*, F. McCutchan, J. Mosca, R. Redfield, D. Burke, *Walter Reed Army Institute of Research, Department of Retroviral Research, Rockville, MD, U.S.A. 350 [Page 351](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/351) T.C.P.129 A Strategy for the Detection of Specifically Spliced mRNAs Encoding HIV-1 Regulatory Genes. John C. Guatelli*, D. Richman, T. Gingeras, *University of California at San Diego Medical Center, Division of Infectious Diseases, San Diego, CA, U.SA. T.C.P.130 Processing of the gag Polyprotein by Human Immunodeficiency Virus Protease Occurs in a Sequential Manner. Susan K. Erickson-Viitanen*, J. Manfredi, P. Viitanen, D. Tribe, R. Tritch, R. Swanstrom, et al., *E. I. Dupont de Nemours & Co. Inc., Medical Products Department, Wilmington, DE, U.S.A. T.C.P.131 Polymerase Chain Reaction in HIV Infection. Jean-Jacques Lefrdre*, M. Mariotti, S. Berriche, D. Vittecoq, B. Noel, *Institut National de transfusion sanguine, Paris, France. T.C.P.132 In Vitro Expression of a Functional HIV-nef Gene Product. Louise Poulin*, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.SA. T.C.P.133 Two Epstein-Barr Virus Latent Marie-Louise Hammarskoild*, M. C. Simurda, *State University of New York at Buffalo, Departments of Microbiology and Oral Biology, Buffalo, NY, U.S.A. T.C.P.134 Infection of Rhesus Macaques with a Molecularly Cloned Simian Immunodeficiency Virus. Paul A. Luciw*, M. Marthas, B. Banapour, T. McGraw, P. Marx, N. Pedersen, *University of California at Davis, Department of Pathology, Davis, CA, U.S.A. Additionnels Additional T.C.P.135 T.C.P.136 T.C.P.137 HIV-1 pol Expression Is Dependent on a General \"Shifty\" Sequence. Wilma Wilson*, M. Braddock, S. M. Kingsman, A. J. Kingsman, *University of Oxford, Department of Biochemistry, Oxford, U.K. T.C.P.138 Molecular Characterization of the Human CD4 Gene. Zaher Hanna*, E. Cheung, P. Jolicoeur, *Clinical Research Institute of Montreal, Montreal, QC, Canada. T.C.P.139 Regulation of HIV-1 Gene Expression by tat, rev and nef. Geore N.Pavlakis*, B. K. Felber, C. M. Drysdale, A. Athanassopoulos, S. Schwartz, *National Cancer Institute, Frederick Cancer Research Facility, BRI, Basic Research Program, Frederick, MD, U.S.A. T.C.P.140 HIV Infection through Endocytosis Mediated by Szegedi, *Institute of Isotopes of the Hungarian Academy of Sciences, Budapest, Hungary. 351 [Page 352](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/352) T.C.P.141 Study of the CD45R and UCHLi Positive Lymphocyte Subsets in the Blood NEG) and Blood Transifusion, Budapest, Hungary. T.C.P.142 The Immunomodulating and Antiviral Effects of AS 101, an Organotellurium Compound. Ami Vonsover*, Y. Kalechman, M. Oron, F. Shalit, Albeck, *Bar-llan University, Ramat Gan, Israel. T.C.P.143 A Nucleotide Sequence of Unknown Function Amplified from DNA Polymerase Chain Reaction (PCR) in THY-IVnfected Cells. Wu-Tse Liu*, S.-T. Hu, S.-R. Republic of China. T.C.P.144 Inhibition of lIlY-i Reproduction by Synthetic Peptides from Region of Proteins Similar to Cell Receptors CD-4 and liLA-DR. Andrev G.Pokrovskv*, A. Kozhich, et al., *A~llUnion Research Institute of Molecular Biology, Novosibirsk, U.S.S.R. T.C.P.145 5'-Phosphonate Derivatives of 3'-Azido-2', 3'-Dideoxynucleosides: A. Kornilova, et al., *Institute of Mlolecular Biology USSR Academy of Sciences, Moscow, U.S.S.R. T.C.P.146 Reduced In Yitro Growth and Differentiation of Monocytes from Patients with liY Infection. Fredrik Mailler*, H. Rollag, G. Gaudernack, S. Frland, * University of Oslo, The National Hosp ital, Oslo, Norway. T.C.P.147 The Role of Interleukin-4 (IL-4) in AIDS. Khtorshed M. Pavri, Centre for AIDS Research and Control, Indian Council of Medical Research, Pune, India. T.C.P.14~ Further Investigations on a Laboratory Model Based on HIY-1 Specific Cytotoxic T Lymphocytes. Elie N. Arida, National Research Centre, Research Group of Viruses and Tissue Culture, Cairo, Egypt. T.C.P.149 Monoclonal Antibodies Raised to Recombinant HIY-1 gag-Proteins Can Identify Immuno-Dominant B Cell Epitopes in AIDS Patients. Etk~ Saa\" P. De Baetselier, R. J. De Leys, C. Van Heuverswyn, *Innogenetics N.y., Antwerp, Belgium. liuman Monoclonal Antibodies to lilY. Dirk Berzow*, M. Boegel, C. G. Meyer, R. Grunow, R. Von Baehr, H. Schmitz, *Bernijard..Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany. 352 [Page 353](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/353) Notes [Page 354](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/354) m Section Mardi 6 juin D O Tuesday, June 6 Le SIDA et l'individu AIDS and the Individual Session d'affichage Poster Session Adolescents (partie 2) Adolescents (Part 2) T.D.P.1 Modifications of Sexual Activities in the Era of AIDS: A Trend Analysis. Eleanor Tyndale, Vanier College, University of Calgary, Calgary, AB, Canada. T.D.P.2 Sexual Behaviour, Contraceptive Use and STD History among Heterosexual College Students. June M. Reinisch*, S. A. Sanders, M. Ziemba-Davis, C. A. Hill, *The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A. T.D.P.3 Short-term Impact of an AIDS Education Curriculum for Adolescents. Susan M. Blake*, E. Tishman, R. Makinodan, *American Red Cross National Headquarters, Washington, DC, U.S.A. T.D.P.4 Sexual Behaviour in High-Risk Adolescents. Heino F. L. Mever-Bahlburg*, M. J. Rotheram-Borus, C. Koopman, T. M. Exner, A. A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A. T.D.P.5 Condom Behavior in 17, 18 and 19-Year Old Norwegians. Bente Trcen*, J. Rise, P. Kraft, *National Institute of Public Health, Oslo, Norway. T.D.P.6 The Impact of Teenagers' Knowledge and Concern of AIDS on Sexual Behavior and Prevention Strategies. Timothy M. Sankary, AIDS Prevention Center, San Francisco, CA, U.S.A. T.D.P.7 Demographic and High Risk Behavior Study of Incarcerated Adolescents. RobertMorris*, S. Huscroft, J. Roseman, O. Rd, C. Baker, K. Iwakoshi, *University of California at Los Angeles Department of Pediatrics, Los Angeles, CA, U.S.A. T.D.P.8 Knowledge, Attitudes and Behaviour of Street-Involved People in Vancouver. Michael L. Rekart*, L. Manzou, P. Loftus, *STD Control, Ministry ofHealth, Vancouver, BC, Canada. T.D.P.9 HIV-Related Knowledge, Beliefs, and Behaviors among High School Students in the United States. Laura Kann*, G. Nelson, J. Jones, L. Klobe, * Centers for Disease Control, Division of Adolescent and School Health, Atlanta, GA, U.S.A. T.D.P.10 ftudiants et SIDA: Lazartigues, H. L. Pailleux, 355](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/355) T.D.P.11 Adolescent Runaways' Behavioral Risk Factors, Knowledge about AIDS and Attitudes about Condom Use. Chre~ae\" R. A. Hudson, B. A. Petty, A. C. Freeman, M. A. Krepcho, *Dallas County Health Department, Dallas, TX, U.S~A. T.D.P.~12 The Relationship of Knowledge and Attitudes towards AIDS to Safe Sex Practices among Runaway and Gay Adolescents. Mary Jane Rohrz-ou\" C. Selfridge, C. Koopman, C. Haignere, H. Meyer-B ahl burg, A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S~A. T.D.P.13 Youth in Detention at High Risk for HJV: Knowledge, Attitudes and Behaviours Regarding Condom Usage. Lydia Temoshok*, J. M. Moulton, R. M. Ellmer, D. M. Sweet, M. Baxter, J. Shalwitz, * University of California at San Francisco, School of Medicine, San Francisco, CA, U.S~A. Comportement (partie 2) Behaviour (Part 2) T.D.P.14 The National Study of Health and Sexual Behaviour. VignaS.Ci\" W. Baldwin, *NICHD/Nationcd Institutes of Health, Bethesda, MD, US A. T.D.P.15 HIV Status Related to Knowledge and Behavioural Change. K.net P Millep4, Patient Managers, * University of California at San Francisco, Department of Physiological Nursing, San Francisco, CA, U.SA. T.D.P.16 Self Perception of the Risk of Contracting AIDS among University Students. Francisco H. Aoki*, M. M. Diaz, P. Goodson, S. Vera, J. Diaz, J. L. Pinto e Silva, *State University of Campinas, Campinas, Brazil. T.D.P.17 Prevalence of Genital Lesions in an STI) Clinic: Sexual Behavior Characteristics. W. L. Whittington*, B. Jacobs, T. Edward, R. Moxey, N. P. Whittington, A. Nahmias, *Centers for Disease Control, Atlanta, GA, U.S~A. T.D.P.18 Behavioral Patterns of Bisexual Males in the U.S., 1982. David L.Kanoise2, J. Lever, W. H. Rogers, S. Carson, R. Hertz, *The RAND Corporati'on, Santa Monica, CA, U.S~A. T.D.P.19 Patterning in the Sequences of Sexual Activity between Men and Its Implications for HIV-1 Transmission. Peter M. Davies*, A. P. M. Coxon, *Project SIGMA, South Bank Polytechnic, London, U~K. T.D.P.20 Factors Associated with Seropositivity to HIV-1 among a Non-Clinic Sample of Gay and Bisexual Men in London. Peter M. Davies*, A. J. Hunt, A. P. M. Coxon, T. J. McManus, S. Sutherland, *Project SIGMA, South Bank Polytechnic, London, U.K. T.D.P.21 Trends in AIDS Knowledge, Attitudes and Behaviours (KAB) in Heterogeneous, High-Risk Groups, Florida. 5nec.r LL.Le*, R. S. Zimmerman, M. Kuechler, L. M. Langer, J. Sims, J. J. Witte, *Florida Department of Health Rehabilitative Services, [Page 356](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/356) Psychosocial Predictors of Compliance in HIV Asymptomatic and Symptomatic Patients in Clinical Trials. Janie Patrone-Reese*, M. McCann, J. Chidekel, T. Fayne, B. * University ofMiami School of Medicine,Miami, FL, U.S.A. T.D.P.23 Male Homosexual Behaviour in the U. K.: 1985-1988. Thomas J. McManus*, P. Davies, A. M. P. Coxon, *King's College Hospital, London, U.K. T.D.P.24 A Review of Studies of Behavioural Response to HIV-Antibody Testing among Gay Men. Robert R. Stempel*, A. R. Moss, *San Francisco General Hospital, AIDS Activities, San Francisco, CA, U.S.A. T.D.P.25 Attitudes of Dentists and Graduation Students towards AIDS in Belo Horizonte, Brazil. Dirceu B. Greco*, E. I. Oliveira, M. R. Oliveira, U. H. M. Paulino, M. A. A. Vitoria, I. Adams, *Federal University of Minas Gerais, Immunodeficiency Clinic, Belo Horizonte, Brazil. T.D.P.26 A Study to Investigate the Effectiveness of Role Play in HIV Health Education Groups for Drug Abusers. Mary P. J. Burgess, King's College Hospital, London, U.K. T.D.P.27 Perceived Community Norms and Risk Reduction: Behavior Change in a Cohort of Gay Men. Kevin R. O'Reilly*, D. L. Higgins, C. Galavotti, J. Sheridan, R. Wood, D. Cohn, *Centersfor Disease Control, Atlanta, GA, U.S.A. T.D.P.28 Hypermasculinity as a Predictor of Sexual Risk Behaviours in a Cohort of Gay Men. Theresa M. Exner*, H. F. L. Meyer-Bahlburg, R. S. Gruen, A. A. Ehrhardt, J. M. Gorman, *New York State Psychiatric Institute, Columbia University, New York, NY, U.S.A. T.D.P.29 Behavioral Targets for Possible Immunomodulation Therapy in AIDS Patients. Robert M. Schmidt*, V. I. Kvitash, *Center for Preventive Medicine and Health Research, Pacific Presbyterian Medical Center and San Francisco University, San Francisco, CA, U.S.A. T.D.P.30 Willpower Assessment: A Decision-Making Model for Designing Tailored Targetted and Positive Promotion. Carol L. Pass*, B. J. Lapointe, *McGill University, Department of Epidemiology, Montreal, QC, Canada. T.D.P.31 Factors Associated with Recurrence of Unsafe Sexual Practices in a Cohort of Gay Men Previously Engaging in \"Safer\" Sexual Practices. Scott P. Saltzman*, A. M. Stoddard, J. McCusker, K. H. Mayer, *Fenway Community Health Center, Boston, U.S.A. T.D.P.32 The Role of Penitentiary Reform and Solidarity Enhancement among Jail Inmates in the Prevention of AIDS in the Dominican Republic. E. Antonio De Mova*, S. Car(as, S. Rosario, E. Guerrero, L. of Public Health, Santo Domingo, Dominican Republic. T.D.P.33 Implications of Health Beliefs for AIDS Prevention Programs: The San Francisco Men's Health Study. Maria L. Ekstrand*, T. J. Coates, G. Stone, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. 356 [Page 357](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/357) T.D.P.34 Sexual Behaviour of Expatriates in Africa. Hans Houweling*, P. W. Kok, A. De Grave, S. P. Smits, R. J. Ligthelm, A. Leentvaar, et al., *National Institute of Public Health, Department of Epidemiology, Bilthoven, Netherlands. T.D.P.35 Changes in Sexual Practices in the Sydney AIDS Project: 1984-1989. Brett D. Tindall*, T. Nicholas, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology, Surry Hills, Australia. T.D.P.36 Change in Sexual Behavior in Homosexuals at Risk for AIDS. S. Maurice Adib*, M. Tal, J. G. Joseph, *University of Michigan, Ann Arbor, MI, U.SA. la Health Promotion Messages. lain McLellan*, A. Richardson, *World Health Organization, Global Programme on AIDS, Health Promotion Unit, Geneva, Switzerland. T.D.P.39 Behavioral Intentions and Other Factors Influencing Behaviour Change in a Cohort of Gay Men: A Prospective Study. Christine Galavotti*, K. R. O'Reilly, D. L. Higgins, J. Sheridan, D. L. Cohn, *Centers for Disease Control, Department of Sexually Transmitted Diseases, Atlanta, GA, U.S.A. T.D.P.40 AIDS-Related Behavior Change of Gay Men in Richmond, VA, 1985-1988. Judith B. Bradford*, M. Johnson, *Virginia Commonwealth University, Survey Research Laboratory, Richmond, VA, U.S.A. T.D.P.41 Sexual Behaviour Changes among Male Sexual Contacts of Men with HIV Disease: A 3 Year Overview. Liviana Calzavara*, R. Coates, S. E. Read, J. K. Johnson, V. Farewell, M. Fanning, *University of Toronto, Department ofPreventive Medicine and Biostatistics, Toronto, ON, Canada. T.D.P.42 Psychological and Behavioural Components of Belief of Anti-HIV-1 Status in Healthy Gay Males. Sharon M. August*, M. H. Antoni, G. Ironson, A. Laperriere, N. Schneiderman, M. A. Fletcher, *University of Miami, Department of Psychology, Coral Gables, FL, U.SA. T.D.P.43 Safe and Unsafe Sexual Practices by Heterosexuals and Homosexual Men: Predicting Intentions and Behaviour. Malcolm McCamish*, C. Gallois, Y. Kashima, A. Ede, A. Chauvin, *University of Queensland, Queensland AIDS Council, St. Lucia, Australia. T.D.P.44 Psychoneuroimmunologic Relationships in Men with ARC. Lydia Temoshok*, G. F. Solomon, S. Jenkins, D. P. Stites, D. M. Sweet, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A. T.D.P.45 Changes in Condom Use among Gay Men: Predictors and Methodological Issues. Joseph A. Catania*, T. Coates, R. Stall, L. Bye, F. Capell, H. Turner, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.SA. 357 [Page 358](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/358) T.D.P.46 Coping of HIV-Infected Men and Patients. P. Leiberich, M. Engeter, T. Harrer, E. Olbrich, Kalden J. R., *AIDS-Center of Federal Health Administration, Berlin, Federal Republic of Germany. T.D.P.47 De nouveaux comportements parmi les homosexuels en Europe: les cas de Paris et d'Amsterdam. Michael Pollak*, Y. Algra, O. Berges, W. A. M. Droge, H. I. Hannema, G. Pele, *Centre National de la Recherche Scientifique France. Psychologie et sexologie Psychology and Sexology T.D.P.48 Psychological Factors Associated with Prognosis in AIDS. Michelle R. Reillo*, R. M. Brownell, *University of Maryland Medical Systems, State of MarylandAIDS Administration, Baltimore, MD, U.S.A. T.D.P.49 Psychosocial Reactions of Men Who Are Carers for HIV-Infected Peers and Men Who Are HIV-Antibody Positive. Crooks*, Viney, M. Walker, *University of Wollongong, Wollongong, Australia. T.D.P.50 Psychological Interventions in the Treatment of Persons with AIDS, ARC and Asymptomatic HIV Infection. Anne K. Enthus. Metaformation Inc., Montreal, QC, Canada. T.D.P.51 Defense Mechanisms and HIV Risk Related Behaviors in Substance Abusers. Bernard Bihari*, G. Ottomanelli, *SUNY Health Science Center at Brooklyn, King's County Addictive Disease Hospital, Brooklyn, NY, U.S.A. T.D.P.52 Processus d'adaptation g la maladie de personnes CSW*, l'infection France. T.D.P.54 Difficulties in the Management of AIDS Patients and Infected People in Brazil. L. Rodrigues*, L. Ervolino, A. Silva, Saade, Brasilia, Brazil. T.D.P.55 Psychological Correlates of the Transmission and Acceptance of Rumors about AIDS. Allan J. Kimmel, Fitchburg State College, Behavioral Sciences Department, Fitchburg, MA, U.S.A. T.D.P.56 The Stress of Caring: Dimensions of Strain among Informal AIDS Caregivers. Heather A. Turner, University of California at San Francisco, San Francisco, CA, U.S.A. T.D.P.57 Help-Seeking for AIDS-Related Concerns: A Comparison of Gay Men with Various HIV Diagnoses. Robert B. Ha.s*, J. Catania, L. McKusick, T. Coates, *Center for AIDS Prevention Studies, University of Calhfornia at San Francisco, San Francisco, CA, U.S.A. T.D.P.58 Short Term Memory (STM) Capacity Declines as a Function of AIDS Dementia Complex Severity. LQhn LJ.Sidis*, J. G. Keilp, A. E. Sadler, D. Dorfman, L. Wolf, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. 358 [Page 359](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/359) T.D.P.59 Evidence of Frank Cognitive Impairment and Depression Appearing Independently of Walter Reed Stage. William C. Grace*, E. C. Tramont, C. N. Oster, *Walter Reed Army Medical Center, Washington, DC, U.S.A. T.D.P.60 Attributional Style and Depression in HIV-Related Illness. David B. Freeman*, G. Evans, W. Van Gorp, J. Rosenbaum, L. George, J. Hamil, *West Los Angeles VA Medical Center, Psychology Service, Los Angeles, CA, U.S.A. T.D.P.61 HIV-1 Patients' Self-Reported Complaints of Memory Failure and Their Relationship to Actual Memory Performance. John G. Keilp*, A. E. Sadler, A. Wolf, D. Dorfman, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer Center, Department ofNeuropsychology, New York, NY, U.S.A. T.D.P.62 Quality of Life of Persons with AIDS/ARC. Donald Ellerman*, M. D. Smith, *University of Pennsylvania, Philadelphia, PA, U.S.A. T.D.P.63 Emotional States in Relation to Immune Function in a Cohort of Male Sexual Contacts of Men with HIV Disease. Rosemary Barnes*, L. Calzavara, R. Coates, S. Read, D. MacFadden, K. Johnson, *Women's College Hospital, Toronto, ON, Canada. T.D.P.64 Personality Disorders and HIV Infection in Heroine Abusers. Roberto Muga Bustanante*, C. Jacas, J. Tor, R. Trias Autonoma Spain. Neuropsychological Status in Heroin Tor Aguilera*, Autonoma de Barcelona, Badalona, Barcelona, Spain. T.D.P.66 Psychological Factors Predicting Distress after HIV Testing. Baruch Fishman*, S. Perry, L. Jacobsberg, A. Frances, *Cornell University Medical College, Department of Psychiatry, New York, NY, U.S.A. T.D.P.67 Psychological and Social Functioning in a Cohort of Homosexual Men at Risk for AIDS. Susan Caumartin*, M. Tal, J. C. Joseph, R. Kessler, *University of Michigan, Ann Arbor, MI, U.S.A. T.D.P.68 The Psychological Management of a Care Support Unit for Male Prisoners with HIV in England and Wales. Kay Nooney*, L. Curran, *H.M. Prison Wandsworth, London, U.K. T.D.P.69 Beyond Information-Provision as a Technique for HIV Education: A Study of the Psychological Determinants of Young Offenders' Beliefs about HIV. David Thornton*, L. Curran, *Young Offender Psychology Unit, Prison Department, London, U.K. T.D.P.70 Psychosocial Adaptation among HIV Positive Patients. Denise M. Korniewicz.Johns Hopkins University School of Nursing, Baltimore, MD, U.S.A. T.D.P.71 Risk of Adult HIV Infection and Childhood Sexual Abuse. Kenneth H. Mayer*, S. Zierler, L. Feingold, D. Laufer, *Memorial Van Dis*, M. Beuzekom, F. De Wolf, R. A. Coutinho, *University ofAmsterdam, Department of Psychology, Amsterdam, Netherlands. T.D.P.73 Psychosexual Assessment in AIDS Research: Interviewer Selection, Training and Monitoring. Rhoda S. Gruen*, M. Calderwood, H. F. L. Meyer-Bahlburg, A. A. Ehrhardt, *New York State Psychiatric Institute, Columbia University HIV Center, New York, NY, U.S.A. T.D.P.74 SIDA, sexologie et culture en Afrique Projet CONNAISSIDA, Kinshasa, Zaire. T.D.P.75 Self-Labeled Sexual Orientation and Sexual Behaviour among Women. Stephanie A. Sanders*, J. M Reinisch, M. Ziemba-Davis, *The Kinsey Institute for Research in Sex, Gender and Reproduction, Bloomington, IN, U.S.A. T.D.P.76 Safer Sex Practices amongst Homosexual Men: Meaning and Motivation.Jane Chewyvnd*, J. Horn, J. Kelleher, *Christchurch School of Medicine, University of Otago, Christchurch, New Zealand. T.D.P.77 Variables Influencing Condom Use among Intravenous Drug Users. Stephen Magura*, J. L. Shapiro, Q. Siddiqi, D. S. Lipton, *Narcotic and Drug Research, Inc., New York, NY, U.S.A. T.D.P.78 Sexual Behaviour Survey of Brazilian Men that Are Clients of Transvestite Prostitutes. Arletty Pinel, Centro de Referencia e Treinamento-AIDS, Brazil. T.D.P.79 Childhood Gender Nonconformity Predicts HIV-1 Seropositivity in Homosexual Men. James D. Weinrich*, I. Grant, J. H. Atkinson, D. Richman, S. Spector, J. A. McCutchan, *University of California, at San Diego, Treatment Center, San Diego, CA, U.S.A. T.D.P.80 Sex and Drug Practices in the Illicit Sex Industry as Related to the Spread of AIDS. Joyce I. Wallace*, S. Beatrice, *Foundation for Research on Sexually Transmitted Diseases, Inc., New York, NY, U.S.A. T.D.P.81 Condom Use among Heterosexual Male IV Drug Users Is Affected by the Nature of Social Relationships. J. L. Sotheran*, S. R. Friedman, D. C. Des Jarlais, S. D. Engel, J. Weber, R. Rockwell, et al., *Narcotic and Drug Research, Inc., New York, NY, U.S.A. T.D.P.82 HIV Seroprevalence and Its Implications for a Transsexual Population. Diana Lnne Alan*, J. J. Guinan, L. Mc Callum, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. T.D.P.83 Evaluation of Sexuality in HIV-Infected Patients by the Wartegg Test. Paulo H. P. Lon*, L. D. Carvalho, C. A. Morais de Sd, *Gaffrde & Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. T.D.P.84 AIDS Phobia: A Clinico-Psychoanalytical Study. Ishwarprasad S. Gilada,*, G. V. Bhimani, B. Shah, V. Thakur, *Indian Health Organisation, Bombay, India. 360 [Page 361](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/361) T.D.P.85 Attitudes and Behavioural Research for AIDS. Antonio Leon*, L. Guerra, V. Cazco, E. Noboa, O. Cruz, E. Sanchez, *Central University, Ministry of Health, School of Professional Psychology, Quito, Ecuador. Les adolescents (partie 3) Adolescents (Part 3) T.D.P.86 Le risque de contamination par le VIH dans une de jeunes en psychiatrie. Alain France, Targeting AIDS Information at Sexually Active 15-17 Year-Olds. Barbara J. Jones*, M. Liepold, S. Lunney, *Federal Center for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. T.D.P.88 Peer Education in Adolescent AIDS Prevention: Experimental Phase. A. Bunde-Birouste*, D. Jayle, D. Guillemot, *Association pour la prevention du SIDA, Paris, France. T.D.P.89 Impact of Adolescent Health Messengers' AIDS Prevention Program on Peers and Adult Relatives in the Dominican Republic. E. Antonio De MoAy*, M. Brea de Cabral, E. Guerrero, L. Dominguez, M. Buttler, *PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic. T.D.P.90 General and Personalized Knowledge of AIDS among Adolescents. Cheryl Koopman*, J. Hunter, R. Henderson, M. J. Rotheram-Borus, *New York State Psychiatric Institute, Columbia University, New York, NY, U.S.A. T.D.P.91 Influence of Perceived Referent-Group Normative Behavior on Adolescents' Use of Condoms. Ralph J. Diclemente*, R. DuNah, *University of California at San Francisco, San Francisco, CA, U.S.A. T.D.P.92 Differential Effects of AIDS Knowledge and Perceived Susceptibility on the Reduction of High-Risk Sexual Behaviors among College Adolescents. Ralph J. Diclemente*, K. Forrest, S. Mickler, *University of California at San Francisco, CA, San Francisco, 361 [Page 362](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/362) S1:. Section Mardi 6 juin mires- Section P. \" E Tuesday, June 6 (g g (44 Iz SIDA, la soci&t6 et le comportement AIDS, Society and Behaviour Session d'affichage Poster Session Education (partie 1) Education (Part 1) T.E.P.1 Reported Likelihood of Sexual Activities with a New Partner in a Survey of Bar Patrons in a Local Gay Community. David J. Martin*, C.W. Edwards, W. Geiger, *University of California at Los Angeles, School of Medicine, Harbor-UCLA, Los Angeles, Medical Center, Department of Psychiatry, Torrance, CA, U.S.A. T.E.P.2 AIDS-Prevention Activities Targeting Homo- and Bisexual Men. Michael Von Brdckel, Deutsche AIDS-Hilfe, Berlin, Federal Republic of Germany. T.E.P.3 Adaptation of Safer-Sex Workshop for Gay and Bisexual Men in Barcelona, Spain. Daniel A. Wohlfeiler*, C. Frutchey, R. De Blai, A. Procupet, *University of California at Berkeley, School of Public Health, Berkeley, CA, U.S.A. T.E.P.4 Sources of Information on AIDS in Zaire and Implications for Program Planning. Melinda Moore*, N. Lusakulira, S. E. Hassig, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A. T.E.P.5 AIDS Education: Using Community Television to Reach Gay Men and Bisexuals. Michael Sobotq, AIDS Committee of Thunder Bay, Thunder Bay, ON, Canada. T.E.P.6 Les effets d'une campagne grand P. Bocsson, *CNRS-GSPM, Paris, France. T.E.P.7 Tracking Survey of AIDS Knowledge, Attitudes and Behaviors in San Francisco's Black Communities. Noel A. Da*, A. Houston-Hamilton, D. Taylor, G. Lemp, G. Rutherford, *Polaris Research and Development, San Francisco, CA, U.S.A. T.E.P.8 Effective Safe Sex Discussion Groups. Bill Rowe*, C. Crossman, W. Fisher, *King's College, University of Western Ontario, London, ON, Canada. T.E.P.9 R6action de la soci6t6 Zairoise envers le SIDA. Wa Nkera Rukarangira, Harvard Schook of Public Health, Boston, MA, U.S.A. T.E.P.10 Community Based AIDS Prevention and Education: Linking Research, Resources and Community. Debbie Indyk*, P. Lefkowitz, E. Barrett, R. Belville, D. Rose, *Mount Sinai School of Medicine, New York, NY, U.SA. 362 [Page 363](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/363) T.E.P.11 Development of a Unique AIDS Consortium Center to Address HIV/AIDS in the Minority Community in theU.S.Rudolph E. Jackson*, M. Haynes, P. Griffith, *Morehouse School of Medicine, Atlanta, GA, U.SA. T.E.P.12 Local Action and Research. Paul Christian Madsen*, for ArmyUnits. Inon Schenker. School of Public Health and Community Medicine, Hebrew University Medical Faculty, Jerusalem, Israel. T.E.P.14 An Assessment of Knowledge, Perceived Risk and Beliefs about Prevention Strategies among New York State Residents. Carolyn G. Beeker*, M. Zielinski, J. Holmes, *New York State Department of Health AIDS Institute, Albany, NY, U.SA. T.E.P.15 Effectiveness of Fear Appeals in AIDS-Education Posters: Comparison by Race/Ethnicity, Age, and Gender in Three Populations. Fen Rhodes*, R. J. Wolitski, L. Arguelles, *AIDS Research and Education Project, Long Beach, CA, U.S.A. T.E.P.16 Computer-Assisted HIV Education for IVDUs. Beniamin F.Lewis*, D. J. G. Grace, *Spectrum House, Inc., Westboro, MA, U.SA. T.E.P.17 Promotion of HIV Prevention Outreach Activities Targeting Intravenous Drug Users in the United States. Imani P. Thompson*, T. S. Jones, K. O'Reilly, *Centers for Disease Control, Atlanta, GA, U.S.A. T.E.P.18 Married Homosexual and Bisexual Men: The Development of AIDS Education Strategies and Resources for Healthcare Professionals. John W. Molenaar, Gay and Married Men's Association, Ministry of Education, Victoria, North Balwyn, Australia. T.E.P.19 Direct Approach with Information to Blood Donors at Risk of AIDS Increases the Safety of the Blood Supply. C. Van der Poel*, H. Reesink, *Red Cross Bloodbank Amsterdam, Amsterdam, Netherlands. T.E.P.20 Evaluation of the AIDS Education Programme in N.S.W. Prisons, Australia. Lisa Conolly*, F. Potter, *N.S.W. Department of Corrective Services, Sydney, Australia. T.E.P.21 Knowledge, Attitude and Practice (KAP) of Selected Population Groups towards the Disease AIDS. Zenaw E. Adam*, A. Yeneabat, D. Fekadu, E. Yacob, A. Helina, T. Mulai, *Department of Community Health, Faculty of Medicine, Addis Ababa University, Addis Ababa, Ethiopia. T.E.P.22 CIS-AIDS Zagreb: Telephone Enquiry Service: Two M. Stritof, Z. Baklaic, M. Vodopija, et al., *Institute of Public Health, Zagreb, Yugoslavia. T.E.P.23 pr6vention Montreal, QC, Canada. Beyond Your Limits. LQui Naaney*, G. R. Kolb, *Lousise L. Hay Educational Institute, Santa Monica, CA, U.SA. T.E.P.26 Evaluation of the Italian National AIDS Information Campaign. ~isoe Maac\" V. Bonvini, T.E.P.27 Those Mffected by AIDS Treated as Outsiders: Consequence of Misinformation. Alonso Coronado Luengo*, F. Conde, C. Arredondo, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spai'n. T.E.P.28 Needs of Family Caregivers of Persons with AIDS. NancL & Cobv?, G. Wilson, *Long Beach Health Department, Long Beach, CA, U.SA. T.E.P.29 The Male Couple: A Case Study. Judy G. Krueckl. St.Paul's Hospital, Vancouver, BC, Canada. T.E.P.30 AIDS Prevention as Community Intervention. Viveka Urwitz*, T. Juvall, M. Ojhgren, P. Sennerfedlt, * Youth Project Stockholm AIDS Prevention Programme, Stockholm, Sweden. T.E.P.31 The HIV Epidemic: Attitudes towards Public Preventive Measures in the Norwegian Population. L~L~j&R Ri e, P. Kraft, *National Institute of Pubic Health, AIDS Information Centre, Oslo, Norway. T.E.P.32 AIDS in Barbados. Errol R. Walrond*, M. Hoyos, * University of the West Indies, St. Michael's, Barbados. Politiques soclales Social Policy T.E.P.33 Community Participation in the Development of a Five- Year Plan on AIDS: New York State's Process and Significant Findings. ~ae~ &.AnwreIla*, C. Bergmtann, *AIDS Institute, New York State Department of Health, Albany, NY, U.S~A. T.E.P.34 Patients' Preferences for Locus of Care and for Active Treatment: Preliminary Results of a Multi-site Study. Yincn o' I. A. Fleishman, J. D. Piette, *Brown University, Center for Gerontology and Health Care Research, Providence, RI, U.S~A. T.E.P.35 A Feminist View of AIDS: Policy Implications of the Social Construction of a Disease. Barbara L. A. Herbert, Fenway Community Health Center, Cambridge, MA, U.S~A. T.E.P.36 The Social Correlates of AIDS Bigotry: Causes for Concern. Earr1ll L1YWebb New York University, Department of Sociology, New York, NY, U.SAl. T.E.P.37 L'infection par le VII: analyse de sant6 des publics (pp) en Pissarro, *Facult6 Xavier Bichat, Paris, France. T.E.P.38 Sexual and Injecting Risk Behavior amongst Drug Users in Birmingham, England. Hilarv R. Kinnell*, R. K. G. Grifflths, *kCommunity Medicine Department, Central Birmingham Health Authority, District Offices, Birmingham, U.K. 364 [Page 365](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/365) T.E.P.39 AIDS-related Knowledge, Attitudes, and Behavior of Hospital Administrators and Physicians: A Comparative Analysis. Scott Campbell*, K. Willenbrig, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.SA. T.E.P.40 HIV Counselling for Women Policies and Programs. Helen Rodriguez-Trias*, A. Dumois, V. Alexander, W. Chavkin, S. Kohn, *New York State Department of Health, AIDS Institute, New York, NY, U.S.A. T.E.P.41 Developing Long-Range AIDS Plans in New York City and San Francisco. Linda L. Udall*, E. L. Rautenberg, G. W. Rutherford, M. Baker, J. W. Amory, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. T.E.P.42 Factors Associated with Willingness to Enter Drug Treatment. Jeanne E. Klen*, R. Fiser, E. Lake, *University of Washington, Seattle, WA, U.S.A. T.E.P.43 Current Utilization of Inpatient Alcohol and Drug Treatment Services in a Cohort of IV Drug Users. Liza Solomon*, R. Frank, D. Vlahov, D. Celentano, S. Cohn, *The ALIVE Study, Johns Hopkins University, Baltimore, MD, U.S.A. T.E.P.44 The Soft Underbelly of Research: Administrative and Cost Challenges in a Study of Heterosexual HIV Transmission. Kenneth H. Maver*, D. Laufer, L. Feingold, S. Zierler, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A. T.E.P.45 New Jersey's Emergency Retrovir Reimbursement Program: Evaluation of Its Effect on Survival Time. Robert F. Hummel*, R. Conviser, S. Young, E. Bishberg, S. Costa, *New Jersey State Department ofHealth, Trenton, NJ, T.E.P.46 Politique d'intervention municipale de la ville de Montr6al la probl6matique du SIDA. Lda Cousineau*, L. Dord, R. Blain, *Ville de Montrdal, Montreal, QC, Canada. T.E.P.47 Recent Changes in Sexual Behavior among Men in Los Angeles. Kathleen Montgomery*, H. Freeman, C. Lewis, C. Corey, *University of California at Los Angeles, Los Angeles, U.S.A. T.E.P.48 Science as a Political Force: The Case of the AIDS Epidemic. Stephen C. Smith, Human Rights Campaign Fund, Washington, DC, U.S.A. T.E.P.49 The Reference and Training Center on AIDS, Sao Paulo, Brazil. Maria Eugenia Fernandes*, P. R. Texeira, R. Del Veda, *Centro de Referencia e Treinamento AIDS, Sao Paulo, Brazil. T.E.P.50 A Study of National AIDS/HIV Policies and Programmes in the 32 Countries for the European Region. Brigitte Gredler*, S. Wayling, *World Health Organization, Regional Office for Europe, Copenhagen, Denmark. T.E.P.51 Providing Access to Promising Investigational Drugs for AIDS: A Management Model for \"Treatment IND\". Deborah G. Katz*, J. Feinberg, M. Myers, E. Gubish, D. Hoth, *AIDS Program, National Institute of Allergy and Infectious Diseases, Rockville, MD, U.S.A. 365 [Page 366](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/366) T.E.P.52 The Extent and Impact of HIV-related Discrimination in New York City: A Survey of PWAs and Service Providers. Mitchell Karp, New York City Commission on Human Rights/AIDS Discrimination, New York, NY, U.S.A. T.E.P.53 Psychosocial Adaptation and Economic Circumstances of Persons with AIDS or ARC. Stephen Crystal*, M. Jackson, *Rutgers University, Institute for Health, New Brunswick, NJ, U.S.A. ROle des organismes non-gouvernementaux The Role of Non-Governmental Organizations T.E.P.54 Canadian Hemophilia Society: A Planned Response to HIV and AIDS. Nena M. era*, R. O'Neill, *Federal Centre for AIDS, Ottawa, ON, Canada. T.E.P.55 Canadian Hemophilia Society: A Collaborative Model Approach with a Non-Governmental Organization (NGO). Nena M. Nera*, R. J. Shearer, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. T.E.P.56 Role of the University: Education, Research, Policy and Service. Caryn Berman*, J. A. Cooksey, *University of Illinois at Chicago, Chicago, IL, U.S.A. T.E.P.57 Primary Care at a Residence for Persons with AIDS (PWAs): Bailey House, New York City, New York. Ramon A. Torres*, J. Staats, *St. Vincent's Hospital and Medical Center of New York, New York, NY, U.S A. T.E.P.58 AIDS Coalition for Education (ACE): A Broad Organization for the Coordination of AIDS Education, Information and Prevention Efforts. Peter L. Ralin*, D. Holbrook, M. Peterson, *Denver Disease Control Service, Denver, CO, U.S.A. T.E.P.59 Un exemple de collaboration entre une ONG et le programme mondial de lutte contre le SIDA de l'OMS: la formulation clinique dans les pays africains. Jean E. Malkin*, L. J. Lebas, D. T. Tarantola, L. A. Landi, *Organisation Mondiale de la Santd, Geneva, Switzerland. T.E.P.60 A Proposal for a Permanent International Forum of NGOs Working with AIDS. Walter Almeida*, H. Daniel, S. Ramos, C. D. Guimaraes, R. Cardoso, F. Braune Wiik, *Brazilian Interdisciplinary AIDS Association, Rio de Janeiro, Brazil. T.E.P.61 Social Marketing of Condoms and Spermicides in Kinshasa, Zaire. Tibo Van der Does*, Services International, Kinshasa, Zaire. T.E.P.62 Obtaining Multi-Sectorial Commitments to AIDS Prevention through Leadership Workshops in Developing Countries. John D. Dupree*, M. Lioy, B. Nirigara, *Academy for Educational Development, Washington, DC, U.S.A. T.E.P.63 Role of Voluntary Organizations in Developing Countries in the Battle against AIDS. Audrey V. Courtneay, Belize Red Cross, Belize, Belize. 366 [Page 367](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/367) T.E.P.64 ABIA: A Brazilian Strategy for AIDS Prevention Based on Action and Solidarity. Carmen D. Guimaraes*, W. Almeida, R. Cardoso, H. Daniel, S. Ramos, *Brazilian Interdisciplinary AIDS Association, Rio de Janeiro, Brazil. T.E.P.65 Out-Patient Clinic for Social Outcasts in Rio de Janeiro, Brazil. Maria Inez Linhares Carvalho*, I. M. Tame, L. R. Castello-Branco, N. Feijd, *Banco da Providencia da Arquidiocese do Rio de Janeiro, Rio de Janeiro, Brazil. T.E.P.66 Prise en charge des patients infectts par le VII au sein d'une Baudry, G. Gonzalez, J. C. Imbert, *H~pital St-Antoine, Paris, France. T.E.P.67 Survey of the Client Structure of the Austrian AIDS Foundation's Counselling Centre in Vienna, July 1987-December 1988. A 40-Hour Training Program on AIDS for Public High School Teachers. Maria Eugaenia Fernandes*, A. Pinel, M. A. Nardi, E. Inglese, *Centro e Treinamento AIDS, Sac Paulo, Brazil. T.E.P.70 AIDS: New Types of Public Health Programs in West Berlin. Monika H1IttiatLni, P. C. Bargstedt, *Landesinstitut fuir Tropenmedizin, Arbeitsgruppe AIDS, Berlin, Federal Republic of Germany. T.E.P.71 AIDS Service Organization: Lessons for Strategic Planning and Organizational Design. Richard Rector*, S. Wayling, R. Grose, *AIDS Health Consultant, Copenhagen, Denmark. T.E.P.72 Placing Educ ational Interventions within the Context of Comprehensive Social Policies to Reduce the Spread of HIV Infection. Ronnv A htrAshxill, The Hebrew University, Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel. T.E.P.73 AIDS and the Role of Civic Movements: A Communication Bridge in Both Directions. H~ctor Anabitarte*, J. R. Usieto, Successful Community-Based HIV/AIDS Education and Information Programs Targeting Racial and Ethnic Minority Communities in the United States. Stevhen E. Schindler*, M. Murgia, A. E. Gambrell, C. Nowicki, R. D. Johnson, G. S. Bowen, et al., *Centers for Disease Control, Atlanta, GA, U.S.A. T.E.P.76 The Stockholm Model: Community Intervention as a Means to Reach 1.6 Million People with AIDS Prevention. Anna-Karin Asv*, B. Gustafsson, L. Abascal, V. Urwitz, Sweden. 367 [Page 368](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/368) Section Mardi 6 juin Tuesday, June 6 Droit et 6thique Ethics and Law Session d'affichage Poster Session La confidentialit6 et ses Ilimites Confidentiality and Its Limits T.F.P.1 Trial Chemo-Prophylaxis and the Health-Care Worker's Right-to-know Vis-4-vis the Patient's Right to Confidentiality. Stanley Bauer, The Bronx-Lebanon Hospital Center, Department of Pathology, Bronx, NY, U.S.A. T.F.P.2 Confidentiality and AIDS: A Canadian Perspective. Robert M. MacMillan*, M. E. Barnes, *Assistant Deputy Minister, Community Health, Toronto, Canada. Santd Publique, Facultd de Mddecine, Marseille, France. Confidentiality in HIV+ Males. Dena J. Seiden*, *Union Theological Seminary, New York, NY, U.S.A. Ethique clinique Clinical Ethics T.F.P.5 Perceptions and Attitude of Health Care Workers on Ethical and Social Aspects of AIDS in a Developing Country. Prabhakar Parimi*, F. A. Orrett, *University of the West Indies, Kingston, Jamaica. T.F.P.6 A Model for Facilitating Physicians' Acceptance of Risk when Treating Patients with AIDS. Walter V. Flegenheimer*, J. Wallack, P. Bialer, *Beth Israel Medical Center, New York, NY, U.S.A. T.F.P.7 CHUL Bioethics Committee and the Anti-HIV Screening Test. A Legal or Ethical Duty to Warn: One Last Time. Richard L. North*, K. Rothenberg, * University ofMaryland School ofLaw, Baltimore, MD, U.S.A. T.F.P.9 Ethical Standards in the Context of HIV Infection. Norbert S Iecht*, lan Schifer, *Deutsche AIDS-Hilfe, Berlin, Federal Republic des malades. Catherine Manuel*, Y. Charrel, P. Larher, France. T.F.P.12 Influence of HIV Status on Decision Making for Newborns. Kathieen E. Powderlv*, J. D. Moreno, B. W. Levin, *Columbia University School ofNursing, New York, NY, U.SA. 369 [Page 370](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/370) Section Mardi 6 juin G Tuesday, June 6 Implications intemationales International Issues Session d'affichage Poster Session Strategies et programmes Strategies and Programmes T.G.P.1 The International AIDS Activities of the U.S.A. Government. Kathrvn S. Aultman*, J. R. Harris, J. D. Wells, *United States Agency for International Development, Washington, DC, U.S.A. T.G.P.2 The Epidemiology of AIDS in the Americas. Ronald K. St-John*, M. Clifford, F. R. K. Zacarias, *Pan American Health Organization, Washington, DC, U.S.A. T.G.P.3 Priorities for HIV Epidemiological Research. Marc Karam*, B. Nkowane, R. Biritwum, P. Bres, E. Beausoleil, J. Mann, *The World Health Organization, Geneva, Switzerland. T.G.P.4 Impact of the HIV Epidemic: Emergency Department Resource Utilization by Patients with Known HIV-1 Infection. Gabor D. Kelen*, G. Johnson, T. DiGiovanna, K. Loring, K. Sivertson, *The Johns Hopkins Hospital, Baltimore, MD, U.S.A. T.G.P.5 The International Working Group on AIDS and IV Drug Use. Joycelyn Sue Woods*, D. C. Des Jarlais, S. R. Friedman, *Narcotic and Drug Research, Inc., New York, NY, U.S.A. T.G.P.6 Serosurveillance of Human Immunodeficiency Virus (HIV) Infection in Tribal Population of Andaman-Nicobar Islands, India. Pradeep SeLth*, M. Mukherjee, I. C. Verma, R. Elango, S. Mathew, *All India Institute of Medical Sciences, New Delhi, India. T.G.P.7 Detailed Estimates of the Current and Future Extent of the HIV/AIDS Pandemic in Sub-Saharan Africa. Paul Sato*, J. Chin, S. Lwanga, E. G. Beausoleil, J. Mann, *World Health Organization, Geneva, Switzerland. T.G.P.8 Control of Tranfusion Related Transmission of HIV Infection, Strategies of the EEC's AIDS Programme for Developing Countries. Johannes C. Van Dam*, T. Amat Cortadillas, L. Fransen, *AIDS Task Force, Brussels, Belgium. T.G.P.9 Planning a National Strategy on AIDS and Injection Drug Use: Lessons from the Literature. Betsy Mackenzie*, K. Elmslie, *Federal Centre for AIDS, Ottawa, ON, Canada. T.G.P.10 Medium Term Plan for the Control of AIDS in Cameroon, Africa: October 1988-September 1993. Roger de organis6e Mons, Belgium. T.G.P.12 The Importance of Qualitative Research in Developing Operations Research Protocols: Strategies for Gay and Bi-Sexual Men in the Dominican Republic. Michael L. E. Ramah*, R. Pareja, *Porter/Novelli, AIDSCOM, Washington, DC, U.S.A. T.G.P.13 Contraceptive Social Marketing Principles: Promoting Condom Use in Uganda and Tanzania for AIDS Prevention. Dace Stone*, D. Levy, S. Saunders, *Academy for Educational Development/Johns Hopkins University, Washington, DC, U.S.A. T.G.P.14 Follow-up of Groups at Risk for HIV Infection. M. Beatriz S. Dias*, J. N. Lima, W. B. Abreu, F. H. Aoki, N. Gongales, R. J. Pedro, *Hospital de Clinicas, University of Campinas, Grupo de AIDS, Campinas, Brazil. T.G.P.15 Education and Law: The Control of Transmissible Diseases through the Control of Gossip, Ignorance, andDiscrimination. Kit Traub. University of Georgia School of Law, Athens, GA, U.SA. T.G.P.16 Training Health Workers in Zambia for HIV Infection. A. Haworth* K. Kalumba, M. Kelly, A. Chingono, *University of Zambia School of Medicine, Lusaka, Zambia. T.G.P.17 International AIDS Programs at the National Institutes of Health. Kenneth Bridbord*, M. Hamburg, P. E. Schambra, J. Whitescarver, A. S. Fauci, *Fogarty International Center, National Institutes of Health, Bethesda, MD, U.S.A. T.G.P.18 Development of the AIDS Epidemic in South Africa. Sylia S. Johnson*, B. D. Schoub, D. Martin, S. F. Lyons, G. N. Padayachee, S. Naidoo, *National Institute for Virology, University of the Witwatersrand, Transvaal, South Africa. T.G.P.19 Small Particle Permeability of Used Versus Unused Surgical Rubber Gloves. Andrew S. Goldstein*, K. Stokes, P. Yoshihara, S. C. Arya, *Epitope, Inc., Beaverton, OR, U.S.A. T.G.P.20 A Study on HIV-1 Infection amongst Haemophiliacs in Iran. HIkwi Rezvan*, S. Taroyan, S. Jalali, M. Kayhani, *Iranian Blood Transfusion Service, Tehran, Iran. T.G.P.21 Adapting Western Experiential Exercises into AIDS Prevention Counselling Training in Developing Countries. John D. Dupree*, A. Demby, R. Chingono, *Academy for Educational Development, Johns Hopkins University, Washington, DC, U.S.A. T.G.P.22 Prevention Counselling: Integrating Concepts and Techniques in all AIDS Prevention Strategies. pace Stone*, N. Kaleeba, V. Orias, *Academy for Educational Development, Johns Hopkins University, Washington, DC, U.S.A. T.G.P.23 AIDS and Adolescents: A Preliminary Study of Youths' Perception of AIDS as a Disease: Nigerian Experience. Lola Vivian Adekunle, Department of Preventive Nigeria. 371 [Page 372](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/372) T.G.P.24 Margaret Duckett*, A. Orkin, *McGill Centre for Medicine, Ethics Epid6mlologle: VIH.2 Epidemiology: HIV-2 T.G.P.25 Detection of HIV-2 Infection and Ratio to HIV-1 among Hospitalized Patients in Rio de Janeiro, Brazil. John W. Krebs*, F. S. Sion, A. B. Sereno, R. S. Goncalves, E. P. Quinhoes, B. G. Weniger, et al., *Centers for Disease Control, AIDS Program, AIDS Laboratory Branch, Atlanta, GA, U.S.A. T.G.P.26 Probl6matique Marlink, S. M'Boup, P. J. Kanki, M. Hernandez, M. Essex, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. T.G.P.28 Double HIV-1 and HIV-2 Seropositivity in Guinea. Catherine Foucault-Fretz*, J. C. Gluckman, Fournel, K. Kourouma, P. K. Diallo, Ricard*, S. de Dakar, Dakar, Senegal. T.G.P.30 The Epidemiology of HIV-1 and HIV-2 in the Gambia, West Africa. Bruce J. Oelman*, H. A. Wilkins, A. Hughes, H. Whittle, K. O. Jaiteh, M. K. Cham, *Epidemiology and Statistics Unit, Banjul, Gambia. T.G.P.31 No Evidence of Vertical Transmission of HIV-2 in Bissau. Anne-Grethe Poulsen*, B. Copenhagen, Denmark. T.G.P.32 Prevalence and Correlates of Retroviral Infections among Prostitutes Working in the Gambia. Jacques PdPin*, A. Egboga, P. Alonso, I. Gaye, H. Whittle, H. A. Wilkins, et al., *The MRC Laboratories, Banjul, Gambia. juin H Tuesday, June 6 Reprcussions economiques du SIDA The Economic Impact of AIDS Session d'affichage Poster Session Planification/Gestion Planning/Management T.H.P.1 The Impact of Caring for AIDS Patients on the Workload of Primary Care Physicians in a Health Maintenance Organization. Kathryn L. Coltin*, J. Goldberg, *Harvard Community Health Plan, Brookline, NY, U.SA. T.H.P.2 Hospital-Based AIDS Volunteer Program in Health Maintenance Organization (HMO). Deborah Casdo*, J. Stone, *Kaiser Permanente (Department of Social Work Services), San Francisco, CA, U.SA. T.H.P.3 Demographic, Utilization and Reimbursement Data for AIDS Patients in 21 U.S. Cities. S.Mathenv*, C. Hostetter, N. Paquin, D. McMenamin, *Department of Health and Human Services, Rockville, MD, U.SA. T.H.P.4 Development of a Severity Index for Use with Statewide Medicaid AIDS Patient Files. Barbara J. Turner*, F. Alemi, L. Markson, *Jefferson Medical College, Philadelphia, PA, U.SA. T.H.P.5 Specific and Sensitive Estimates of Acute Care Hospital Stays Associated with HIV in New York. George T. DiFerdinando*, G. Kaufman, *New York State Department of Health, Albany, NY, U.SA. T.H.P.6 The C-100 Clinic: The Establishment of a Primary Care Program at Charity Hospital at New Orleans, Louisiana. Ted L. Wisniewski, Louisiana State University Medical Center, New Orleans, LA, U.S.A. T.H.P.7 Scatter Bed Versus Cluster Unit Treatment of AIDS Inpatients. George Fulop*, J. J. Strain, M. C. Fahs, H. S. Sacks, *The Mount Sinai School of Medicine, New York, NY, U.S.A. T.H.P.8 The Economic Impact of Early Intervention in HIV Disease. Peter S. Arno*, D. Shenson, N. F. Siegel, P. Franks, P. R. Lee, *Montefiore Medical Center, Bronx, NY, U.S.A. T.H.P.9 Assessing the Cost of AIDS to Both Patients and the Health Care Institution. Mary A. Pittman-Lindeman*, D. Miller, P. E. Sowa, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. T.H.P.10 Hospital Costs and DRG Reimbursements for HIV Admissions. Jihad Slim*, D. Heldge, G. Perez, E. S. Johnson, E. Perez, *Saint-Michael's Medical Center, Newark, NJ, U.S.A. 374 [Page 375](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/375) T.H.P.11 Shifting towards Ambulatory Care of AIDS Patients: Lessons from the PCP Epidemic. Nirvair Levitt*, J. S. G. Montaner, L. Lawson, R. Sigurnjak, L. Malysh, J. Ruedy, *University of British Columbia, St. Paul's Hospital, Vancouver, BC, Canada. T.H.P.12 Health Care Costs of Class 4 HIV Care in an HMO Setting. Elizabeth S.Anderson*, A. Shields, T. Revis, M. Mehring, Y. Chi, R. L. Thompson, *Group Health Cooperative of Puget Sound, Center for Health Promotion, Seattle, WA, U.S.A. T.H.P.13 An Interdisciplinary Model of AIDS Care in a Teaching Hospital. Irene L. Goldstone*, J. Ruedy, A. McLeod, *St. Paul's Hospital, T.H.P.15 Community-based Pneumo-Clinics as a Model for Cost-effective Lowered Morbidity and Mortality in HIV Disease. Mark Harrington*, D. Z. Kirschenbaum, *ACT-UP/NY, New York, NY, U.S.A. Financement et assurances Financing and Insurance T.H.P.16 The \"Medicaidization\" of AIDS. Jesse Green*, P. Arno, *New York University Medical Center, Department ofHealth Policy Research, New York, NY, U.S.A. T.H.P.17 Lifetime Patterns of Medicaid Expenditures for Persons with AIDS in California. Roxanne M. Andrews*, M. Keyes, P. Pine, *Systemetrics/McGraw Hill, Washington, DC, U.S.A. T.H.P.18 Consumption of Mental Health and Social Services by PWAs. Marilyn Cvitanic*, C. L. Bennett, R. L. Bennett, A. Pascal, *RAND/UCLA, Center for Health Policy Study, Santa Monica, CA, U.S.A. T.H.P.19 Meeting the Needs? Jonanthan P. Cooper, The Haemophilia Society, London, U.K. T.H.P.20 Access to Insurance and Perceived Discrimination by Homosexual Men. Nancy E.Kass, Johns Hopkins University, School ofHygiene and Public Health, Baltimore, MD, U.S.A. T.H.P.21 Costs of Hospitalization for AIDS Patients at a Community Hospital in Connecticut. Robert W. Lyons*, G. M. Madden, R. M. Costanzo, *St. Francis Hospital and Medical Center, University of Connecticut, Hartford, CT, U.S.A. T.H.P.22 How Do Persons with Symptomatic HIV Disease Finance Their Care in Texas? Martin M. Crane*, S. Tortolero, A. Hines, L. Jardine, C. Johnson, *University of Texas, Department of Health Science, Houston, TX, U.S.A. T.H.P.23 Health Insurance Status and the Utilization of Health Services in a Cohort of IV Drug Users. Liza Solomon*, R. Frank, D. Celentano, D. Vlahov, S. Cohn, *The ALIVE Study, Johns Hopkins University, Baltimore, MD, U.SA. 375 [Page 376](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/376) T.H.P.24 The Share of AIDS Medical Care Costs Paid by Private Insurance in the U.S.A. Charles L. Eby, Health Insurance Association ofAmerica, Inc., Washington, DC, U.S.A. T.H.P.25 The Global Philanthropic Response to AIDS. Michael S. Seltzer*, S. Moskie, *Executive Director, Funders Concerned About AIDS, New York, NY, U.S.A. Additionnels Additional T.H.P.27 AIDS Case Management: What Insurance Companies Are Doing. Charles L. Eby*, C. Jajich-Toth, *Health Insurance Association of America, Inc., Washington, DC, U.S.A. T.H.P.28 Statistical Methodology for Study of the AIDS Epidemic. Donald L. Thomsen, Societal Institute of the Mathematical Sciences, New Canaan, CT, U.S.A. T.H.P.29 AIDS in the Workplace: A Worldwide Health Concern Becomes a Business Concern. Paul A. Ross, Digital Equipment Corporation, Concord, MA, U.S.A. 376 [Page 377](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/377) Mercredi Wednesday [Page du Canada Conf6renciers: Les femmes, les enfants et le SIDA - questions touchant les femmes, les enfants et le chez les enfants en Afrique: perspectives et defis Angela A. de et I'avenir Directeur, National Cancer Institute Etats-Unis Pour Chairpersons pid6miologie et and Public Health Transmission du VIH dans le milieu des soins de la sant6 HIV Transmission in the Health Care Setting James Curran (U.S.A.) Julian Gold (Australia) Catherine Peckman (U.K.) 11:00 W.A.O.2 11:30 W.A.O.3 11:45 W.A.O.4 12:00 W.A.O.5 Health-Care Workers Exposed to Patients Infected with Human Immunodeficiency Virus (HIV), United States. Ruthanne Marcus and the Cooperative Needlestick Surveillance Group, Centers for Disease Control, Atlanta, GA, U.S.A. Surveillance Update: Health-Care Workers with AIDS. Mary E. Chamberland, L. Conley, T. Bush, H. Jaffe, Centers for Disease Control, CID, AIDS, Atlanta, GA, U.S.A. Prevalence of HIV Infection among Persons Employed in Medicine and Health Occupations. David N. Cowan, Walter Reed Army Institute of Research, Washington, DC, U.S.A. Adherence to Universal Precautions by HCWs in an Inner-City Emergency Department with High HIV-1 Prevalence among Patients. Gabor D. Kelen, T. DiGiovanna, D. Kalainov, L. Bisson, C. Scott, The Johns Hopkins Hospital, Baltimore, MD, U.S.A. Nosocomial Outbreak of HIV Infection in Elista, USSR. V. V. Pokrovsky, E. U. Eramova, Laboratory of Immunodeficiency, Central Institute U.S.S.R. Room 408BC A Mercredi 7 June 7 Table ronde Round Table Presidents Chairpersons tpidmiologie et sant6 publique Epidemiology and Public Health Transmission h6t6rosexuelle Heterosexual Transmission Frank Plummer (Canada) Martin Schechter (Canada) 11:00 W.A.O.6 Program Content: * Efficiency of transmission: male-to-female, female-to-male * STDs as cofactors for index and secondary partner * Other possible co-factors, including circumcision, menstrual cycle * Viral factors, e.g. strain virulence, size of inoculum * Efficacy of condoms, spermicides, other barrier contraceptives * Methodologic issues in designing and interpreting transmission studies Panelists: Marie Laga, Antwerp, Belgium. Nancy Padian, San Francisco, CA, U.S.A. Nzilambi Nzila, Zaire. 381 [Page 382](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/382) 11:00 - 12:30 Salle Room 401ABC Section B Mercredi 7 juin Wednesday, 7 S6ance th6matique Specialty Session Pr6sidents Chairpersons Aspects cliniques Clinical AIDS Pharmacologle et toxicit6 de I'AZT AZT Pharmacology and Toxicity Robert E. Allen (USA) Fred Aoki (Canada) David Cooper (Australia) 11:00 W.B.O.1 11:15 W.B.O.2 11:30 HIV-Infected Homosexual Males. John Ruedy, J. S. G. Montaner, T. Le, K. Gelmon, M. Fanning, J. Smith, et al., St. Paul's Hospital, University of British Columbia, Multicentre Canadian AZT Trial (MCAT), Vancouver, BC, Canada. A Phase One Study of Zidovudine (AZT) in Infants, Less than Three Months Old, at Risk for HIV Infection. Francois D. Boucher*, C. G. Prober*, A. M. Arvin*, J. F. Modlin**, M. Maha***, S. Lafon***, et al., *Stanford University Medical Center, Division of Pediatric I. D., Stanford, CA; **Johns Hopkins University, Baltimore, MD; ***Burroughs-Wellcome Co., Research Triangle Park, NC, U.S.A. Pharmacokinetics of Zidovudine in IDU Related HIV Infection. Raymond P. Brettle*, G. A. Jones*, J. Bingham*, B. E. M. Spacey**, Laboratories, Beckenham, U.K. Probenecid Inhibits the Metabolic and Renal Clearance of Zidovudine in Human Volunteers. Mohsen A. Hedaya, W. F. Elmquist, R. J. Sawchuk, University of Minnesota, Department of Pharmaceutics, Minneapolis, MN, U.S.A. Effect of Acetaminophen (ACET) on the Pharmacokinetics of Zidovudine (AZT). Richard J. R. I. Koda*, D. Antoniskis*, M. Shields*, H. Malancon*, J. L. Cohen**, J. M. Leedom*, F. R. Sattler*, et al., *University of Southern California, School ofPharmacy, Los Angeles, CA; ** University of Kentucky, Lexington, KY, U.S.A. Long-term Non-Hematological Adverse Effects of AZT and Its Effect on Pre-Treatment Symptomatology. Mary M. Fanning*, J. Osachoff*, J. S. G. C. Tsoukas***, K. Gelmon****, J. Ruedy*, et al., *University of Toronto, Toronto, ON; **University of ***McGill University, ****St. 12:30 Room 403ABC Section B Mercredi 7 juin Wednesday, June 7 S6ance th6matique Specialty Session cliniques Clinical Aspects of AIDS Traltement: thrombocytop6nie Therapy: Thrombocytopenia Penny Ballem Zidovudine as a Possible Treatment for Thrombocytopenia Associated with AIDS and ARC. Stephen T. Green, W. C. Love, D. Nathwani, D. J. Goldberg, R. J. Fallon, D. H. Kennedy, Clinical Department of Infectious Diseases, Ruchill Hospital, Glasgow, U.K. The Effect of Zidovudine on Platelet Count in HIV-Associated Thrombocytopenia. Columbia; **Multicentre Canadian Azidothymidine Trial (MCAT), Vancouver, BC, Canada. Zidovudine HIV-Associated Thrombopenia. Matei A. AIDS Study Group, Schwabinger Krankenhaus, Munich, Federal Republic of Germany. The Epidemiology of Immune Thrombocytopenia (ITP): Are Increases in ITP in the Population a Manifestation of the HIV Epidemic? Walter F. Schlech, C. Nesdoly, N. Meagher, J. Turner, D. Dickey, et al., Dalhousie University and Victoria General Hospital, Halifax, NS, Canada. Treatment of Severe HIV-Related Thrombocytopenia in Drug Users. Massimo Galli*, G. Landonio**, F. De Cataldo**, *L. Sacco Hospital, University of Milan, Infectious Diseases Clinic; **Niguarda Hospital, Department ofHematology, Milan, Italy. HIV-1 Associated Thrombocytopenia: Disappointing Long Term Results of Splenectomy. Sunil Shaunak, D. S. Tyler, J. A. Bartlett, J. D. Iglehart, Duke University Medical Center, Durham, NC, U.S.A. 383 [Page 384](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/384) 11:00-12:30 Salle Room 407B Section B Mercredi 7 juin Wednesday, June 7 Aspects cliniques Clinical Aspects de SIDA Quality of Care for Patients with AIDS Norbert Gilmore (Canada) Paul A. Volberding (U.S.A.) 11:00 W.B.O.13 11:15 W.B.O.14 11:30 W.B.O.15 11:45 W.B.O.16 12:00 W.B.O.16a Quality of Care for Patients with AIDS: Role of Community Physician. B. Willoughby. Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada. Hospital Care of AIDS Patients. Nathan Clumeck, Free University ofBrussels, St-Pierre University Hospital, Brussels, Belgium. Outpatient Clinics. Paul Volberding, San Francisco General Hospital, San Francisco, CA, U.S.A. Home Care Therapy. Jeannie Parker-Martin, Visiting Nurses and Hospice of San Francisco, San Francisco, CA, U.S.A. AIDS and US Veterans: A Comprehensive Care Approach in a National Health Care System. Robert Allan, AIDS Program Office, Department of Veterans Affairs, Washington, DC, U.S.A. 384 [Page 385](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/385) 11:00- 12:30 Salle Room Flossie Wong-Staal W.C.O.4 of HIV-1 Expression. Flossie Wong-Staal, Laboratory of Tumour Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A. Feline Immunodeficiency Virus: Genetic Organization and Regulation. Paul Luciw*, J. Elder**, R. Talbott**, E. Sparger*, N. Pedersen*, *University California, Davis, CA; **Research Foundation of Scripps Clinic, LaJolla, CA, U.S.A. Viral Mutogenesis. William Haseltine, Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, MA, U.S A. The HIV-Quasispecies: A Necessary Description. S. Wain-Hobson, Unitd de recombinaison et expression gedntique, Institut Pasteur, Paris, 385 [Page 386](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/386) 11:00 - 12:30 Salle Room 08A Section 7 juin Wednesday, June 7 Recherche fondamentale (biomdlicale) Basic Research (Biomedical) Elements de base en immunologie Basic Immunology (Part 1) S6ance th6matique Specialty Are Critical Cells Mediating Suppression of HIV Release by CD4+ Cells. Lory D. Wiviott, C. M. Walker, J. A. Levy, University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. Infection by HIV-1 of Purified NK Cells with a CD3-, CD2+, CD8+, CD et Immunohimatologie, Institut Pasteur, Paris, France. Activation and Infection of T Cells by HIV-1 Infected Antigen Presenting Monocyte/Macrophages. Dean L. Mann, S. Gartner, M. Popovic, National Cancer Institute-FCRF Laboratory of Viral Carcinogenesis, Frederick, MD, U.S.A. Macrophage-Activating-Factors (MAFs) Alter HIV-1 Production from Primary Mononuclear Phagocytes. John W. Mellors, M. Ortiz, N. Asato, B. Griffith, M. Landry, J. Ryan, Yale University School of Medicine and Veterans Administration Medical Center, West Haven, CT, U.S.A. Pattern of HIV Replication during In Vitro Maturation of Monocytes into Macrophages. Ren6 Olivier*. F. Activity HIV-infected Monocytes. Melder*/**, P. Gupta*, R. B. Herberman*/**, *University of Pittsburgh; **Pittsburgh Cancer Institute, Pittsburgh, PA, U.S.A. 386 [Page 387](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/387) 11:00 - 12:30 Sane Room 41OABC Section C Mercredi 7 juin Wednesday, Specialty (Biomedical) Biologie mol6culaire (partie 2) Molecular Biology (Part 2) Jesus V. Benitez Fuentes (Cuba) M. P. Kieny (France) Paul Luciw (U.S.A.) W.C.O.11 Inhibitors of HIV- Protease Inhibit the Processing of GAG and GAG/POL Polyproteins in Infected T-Cells. Stephen R. Pettewav. D. M. Lambert, T. Meek, G. Dreyer, J. J. Leary, B. Metcalf, Smith Kline & French Laboratories, Departments of Antiinfectives and Chemical Sciences, King of Prussia, PA, U.S.A. Interaction of CD4 with gpl20 of the HIV Viruses. Raymond W. Sweet*,, J. Arthos*/**, K. C. Deen*, R. Axel***, J. Hoxie**, et al., *Smith Kline & French Laboratories, King of Prussia; **University of Pennsylvannia, Philadelphia, PA; Columbia University, New York, NY, U.S.A. Identification of an Attenuated AIDS-Inducing FeLV that Has a Defect in Envelope Protein Processing. Julie Overbaugh*, E. A. Hoover**, J. I. Mullins***, M. Poss**, *University of Washington, Seattle, WA; Colorado State University, Fort Collins, CO; ***Harvard School of Public Health, Boston, MA, U.S.A. Single Point Mutations in the HIV Envelope Gene Encoding Extracellular Glycoprotein Affect Viral Tropism and Receptor Binding. Agnds Y. Rividre, M. Emerman, Institut Pasteur, Units d' Oncologie virale, Paris, France. The Effect of HIV Infection on Monocyte Differentiation. Romas Geleziunas, F. Boulerice, S. Bour, M.A. Wainberg, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada. Evidence that CD4(81-92) May Constitute a Unique Binding Epitope for HIV Envelope Glycoprotein/CD4 Interaction. Lee E. Eiden*, V. J. Lifson**, City, MD, 11:00- 12:30 Presidents Chairpersons Section D Mercredi 7 juin Wednesday, June 7 Le SIDA et l'individu AIDS and the Individual Les femmes Women Kimberly Elmslie (Canada) Helga Rubsamen-Waigmann (Federal Republic of Germany) J. K. W. Mati (Kenya) 11:00 W.D.O.1 11:15 W.D.O.2 11:30 W.D.O.3 11:45 W.D.O.4 12:00 W.D.O.5 12:15 W.D.O.6 HIV Infection among Women Attending Women's Health Clinics in the United States, 1988-89. Patricia A. Sweeney, D. Allen, I. Onorato, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Relationship between HIV Awareness, Partner Selection Criteria and Early Relationship Formation in Two Groups of San Francisco Bar Patrons. Leon McKusick, C. C. Hoff, University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. AIDS-Related Knowledge, Attitudes, Behaviors and Practices in HIV+ and HIV- Urban Women in Kigali, Rwanda. Susan Allen*/**, F. Nsengumuremyi**, P. Vandeperre***, A. Serufilira**, M. Carael****, S. Hulley*, et al., *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A.; **Projet San Francisco, Kigali; ***National AIDS Prevention Program of Rwanda, Kigali, Rwanda; ****World Health Organization Global Programme on AIDS, Geneva, Switzerland. Gender Rules as Barriers to Risk Reduction for Black Women. Mindy T. Fullilove, R. Fullilove, K. Haynes, S. A. Gross, University of California at San Francisco, Center for AIDS Prevention Studies and the Bayview-Hunter's Point Foundation, San Francisco, CA, U.S.A. Barriers to AIDS Interventions among Sexual Partners of IV Drug Users. Claire E. Sterk*, S. R. Friedman*, M. Sufian*, D. C. Des Jarlais**, B. Stepherson*, *Narcotic and Drug Research Inc.; **New York State Division of Substance Abuse Services, New York, NY, U.S.A. Contraceptive Utilization and Reproductive Desires in a Group of HIV-Positive Women in Kinshasa. Susan E. Hassig*/**, L. Piripiri*, A. Doppagne***, M. Moore*/**, E. Bertrand*/**, T. D. Kashala*, R. Ryder****, *Zaire School of Public Health, Kinshasa, Zaire; **Tulane LA, U.S.A.; juin Wednesday, June 7 S6ance th6matique Specialty Session Le SIDA, la societet le compotement AIDS, Society and Behaviour R61e des ONG dans la lutte mondiale contre le SIDA The Role of NGOs in the Global Response to AIDS Pr6sidents Chairpersons Walter Almeida (Brazil) Henri Maurel W.E.O.7 The Key Role of a National Non-Governmental AIDS Education Program in Canada. David J. Walters, K. Wardrop, R. Burr, I. Gemmill, Canadian Public Health Association, Ottawa, ON, Canada. Significance of the American Red Cross Role in HIV/AIDS Education. Carole K. Kauffman, M. Cotton, American Red Cross, National Headquarters, Washington, DC, U.S.A. Swift...and Sure? The U.K. Voluntary Response to AIDS. Stephanie Grimshaw**, S. Mansfield*, U. O'Brien*, *London Lighthouse; **Landmark, London, U.K. Role of Non-Governmental Organisations and NGO Networks in the Control of HIV Infection. Susan E. Lucas, P. Poore, U.K. NGO AIDS Consortium for the Third World, London, U.K. Role of Non-Governmental Organizations in the Struggle against AIDS. Case Study: Uganda Red Cross Society. Juliet *Lubea*, O. Mueller**, J. Senoga*, R. Sebbowa*, *Uganda Red Cross Society, Kampala, Uganda; **League of Red Cross and Red Crescent Societies, Geneva, Switzerland. Developing a Programme of World Health Organization Support for Non-Governmental Organizations in the Framework of National AIDS Control Programmes. Robert N. Grose, J. M. Mann, World Health Organization, Geneva, Switzerland. Community Organization for HIV Prevention: Programs and Priorities of the Centers for Disease Control. Gary R. West*, R. N. Kohmescher*, S. E. Schindler*, K. Cahill*, G. S. Bowen*, R. Johnson**, et al., *Centers for Disease Control, Atlanta, GA; **United States Conference of Mayors, District of Columbia, Washington, DC, U.S.A. 389 [Page 390](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/390) 11:00- 12:30 Salle Room 411B Wednesday, June 7 S6ance th6matique Specialty Session Presidents Chairpersons Le SIDA, la soci6t6 et le comportement AIDS, Society and Behaviour La lutte communautaire contre le SIDA dans les annbes 1990 The Community-Based Response to AIDS into the 1990s Richard Burzynski (Canada) Peter Wood (Canada) 11:00 W.E.O.8 11:15 W.E.O.9 11:30 W.E.O.10 11:45 W.E.O.11 12:00 W.E.O.12 12:15 W.E.O.13 Role of Community Based Organisations in the Australian AIDS Response. Bill H. Whittaker, Australian Federation of AIDS Organisations, Surry Hills, Australia. The Community Based AIDS Response in the 1990's. Jim Holm, The National AIDS Network, Washington, DC, U.S.A. Innovations in Health Care Delivery for HIV-infected Individuals. Judith B. Braslow, C. Hostetter, M. Homer, G. Dolecek, J. Hutchings, Health Resources and Services Administration, Public Health Service, Department of Health and Human Services, Rockville, MD, U.S.A. Community Groups into the 1990s. Mary Mantell Network of Voluntary Organisations in AIDS and HIV (NOVOAH), Reading, U.K. Comparative Study of AIDS Service Organizations. Ken A. Morrison, The Canadian AIDS Society, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. Discussant. Freda Paltiel. Health and Welfare Canada, Ottawa, ON, Canada. 390 [Page 391](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/391) 11:00 - 12:30 S41Salle1C Room 411C Section et &dhiqe Ethics and Law Mercredi 7 juin Wednesday, June 7 Colloque Symposium Presidents Chairpersons Recherche de traltements et de vaccins Research for Treatments and Vaccines Robert J. Levine (U.S.A.) C. Zavariz (Brazil) 11:00 W.F.O.1 Issues. RobertLevine, Yale School ofMedicine, New Haven, CT, U.S.A. Ethical Aspects of the International AIDS Research Agenda, Nicholas A. Christakis. Cambridge, MA, U.S.A. Vaccine Testing: An Important Legal Question. Wendy Mariner, Boston University Schools of Public Health and Medicine, Boston, MA, U.S.A. Ethical Points on Placebo and Treatment Controls in HIV Drug Trials. Beniamin Freedan. McGill CentreforMedicine, Ethics and Law, Montreal, QC, Canada. The Ethics of Placebo-Controlled Trials of Therapy for HIV Infection. Kathleen Nolan, The Hastings Center, Briarclff, NY, U.S.A. Special Problems in IRB Review of Community-Based AIDS Research. Vanessa Merton*/**, C. Levine**/***, *City University ofNew York Law School; \"Citizens Commission on AIDS for New York City and Northern New Jersey; ***Community Research Initiative, New York, NY, U.S.A. Commentary. Carole Levinew New York, NY, U.S.A. 391 [Page 392](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/392) 11:00 - 12:30 Salle Room 406A Section G Mercredi 7 juin Wednesday, June 7 Implications intemationales International Issues S6ance th6matique Le VIH en pediatrie 11:15 W.G.O.2 11:30 W.G.O.3 Inability to Demonstrate a Dose-response Effect between Receipt of Mother's Milk and Perinatally-acquired Infection (PI) in a Cohort of 114 Infants Born to HIV(+) Mothers. Tarande Manzila*, E. Control, Atlanta, GA, U.S.A. Symptomatic Children with Perinatally Acquired HIV Infection in Puerto Rico: The San Juan City Hospital and University Pediatric Hospital. Clemente Diaz, E. Jimenez, L. Ldpez, R. Ldpez-Correa, M. Carrer, J. M. Garcda, et al., University of Puerto Rico School ofMedicine, San Juan, Puerto Rico, U.S.A. Complications loco-r6gionales de la vaccination par le BCG chez des enfants France. Cause-Specific Morbidity in the First 18 Months of Life in 477 Infants Born to Seropositive Mothers in Zaire. Wato Nsa*, T. Kinshara, Zaire; **Centersfor Disease Control, Atlanta, GA, U.S.A. HIV Disease in Infants and Children: 22-Month Prospective Study. Adel N. A. Malek, K. Mukelabai, N. P. Luo, University Teaching Hospital, Lusaka, Zambia. Clinical Manifestations in African Children Perinatally Infected by HIV and Aged 5 Years Old or More. Phillipe Levage*, P. Van de Perre**, C. Van 392 [Page Salle Room 406BC Section G Mercredi 7 juin Wednesday, June 7 Implications internationales International Issues Colloque Symposium Presidents Chairpersons Infections parasitaires tropicales: Impact du VIH Tropical Diseases: The Impact of HIV Hunnington Pamba (Kenya) W.G.O.9 11:45 W.G.O.10 12:00 W.G.O.11 Studies of the Relationship Between Plasmodium Falciparum Malaria and HIV Infection in Africa. Alan E. Greenberm, AIDS Program and Malaria Branch, Centers for Disease Control, Bethesda, MD, U.S.A. Leishmaniasis and Leprosy. Warren D. Johnson, Department of Medicine, Cornell University Medical Center, Ithica, NY, U.S.A. Isopora Belli and Other Sporozoa. Jean Pape, Cornell University Medical Center, Ithaca, NY, U.S.A. Microsporidiosis and ARC. Ann Cali*, Robert L. Owen**, *Rutgers University, Department of Biological Science, Newark, NJ; **VA Medical Center, San Francisco, CA, U.S.A. HIV: Its Potential to Alter the Epidemiology of Parasitic Diseases. Warren Johnson, Cornell University Medical Center, Ithica, NY, U.S.A. 393 [Page 394](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/394) 11:00- 12:30 Salle Room Specialty Session Pr6sidents Chairpersons Rpercussions &aonomiques du SIDA The Economic Impact of AIDS R61e des assurances The Role of Insurance Jacques Ross (Canada) W. Whittaker (Australia) 11:00 W.H.O.1 11:15 11:30 11:45 W.H.O.2 W.H.O.3 Kourouma Hamadou, Togo. Carl Schramm, U.S.A. Who Pays for AIDS in the U.K. Life Insurance Industry? Dai Harris, The Terrence Higgins Trust Legal Centre, London, U.K. Bernard Pottier, U.S.A. 12:00 W.H.O.5 394 Mercredi 7 juin Wednesday, June 7 Sessionvideo Video session La Perte et le deuil Loss 11:00 Introduction: Andy 11:11 Ann6e/Year: qui le sont momins. Dealing with the loss of a loved one. These tapes range from tributes to elegies, from collective to individual grief and from alternative family to traditional family grieving. 396 [Page 397](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/397) SMercredi 7 juin 12:45 - 13:45 Wednesday, June 7 e 409ABC Aspects auo-visuels RoOmAudio-Visual Aspects Sessions du midi L'6rotisme, la sexualit6 s6curitaire et les changements de comportement Noon Hour Erotica, Safer Sex, and Behavior Sessions Change Pr6sidents Kevin Orr (Canada) Chairpersons Alfred Machela (South des produits sexuels-s6curitaires/Pomo or Pablum? - Reading Your Audience in Preparing Safer Sex Material. Cindy Patton, Directrice de l'dducation communautaire/Manager of Community Education, AIDS Action Committee, Boston, MA, U.S.A. 13:05 Serre-le ou perds-le: la censure de l'ttat, la censure de l'institution ou l'auto-censure/Lace Up or Lose It: State Censorship, Institutional Censorship, Self-censorship. Simon Watner, Prdsident du Comitd politique/Chairperson of Policy Sexe s6curitaire explicite et Bordowitz, Section de production audio-visuelle, Ddpartement d' dducation/Audio-visual production unit, Education Department, GMHC, New York, NY, U.S A. 13:25 Travailler avec le langage cin6matographique des films porno: Une vision allemande du sexe s6curitaire/Working with the Film Language of Porn: A German View of Safer Sex. Wieland Speck, Producteur/Filmmaker, Berlin, Federal Republic Cette session regroupe diff6rentes perceptions de la contexte de sexualit6 s6curitaire. Des exemples recentes de New York et Berlin sont pr6sent6s. Porn has created enormous controversy. Few remain indifferent to its existence or availability. This session combines several views of the contemporary construction of porn within the context of Safer Sex education. Examples of recent works from New York and Berlin are included 398 [Page 399](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/399) Notes 7 S6ance th6matique Specialty Session et Itudes femmes enceintes Seroepidemiological Studies in Childbearing Women Alastair J. Clayton (Canada) George F. Grady of Newborns with Resultant Changes in Screening and Delivery System Policy. Christine M. Grant, R. Altman, D. Brandon, S. Shahied, E. Rappaport, S. Costa, et al., New Jersey State Department of Health, Trenton, NJ, U.S.A. HIV Infection in Adolescent Childbearing Women. Lloyd F. Novick*, D. Glebatis*, R. Stricof*, D. Berns**, *New York State Department of Health, Center for Community Health; **New York State Department ofHealth, Wadsworth Centerfor Laboratories and Research, Albany, NY, U.S.A. Measurement of HIV Seroprevalence in Childbearing Women in London. Richard S. Tedder*, M. Briggs*, N. Parra*, A. Ades**, M. **Institute of Child Health; ***The Hospitalfor Sick Children, London, U.K. HIV Infection in Pregnant Women and Perinatal Transmission in Sweden. Ann-Britt Bohlin**, B. Anzdn***, M. Bottiger*, M. *Department of Epidemiology, National Bacteriology Laboratory, Stockholm; **Huddinge Hospital, Department of Pediatrics, Huddinge; ***Departments of Obstetrics and Infectious Diseases, Danderyds Hospital, Danderyds; ****Central Microbiology Laboratory, Stockholm, Sweden. HIV-Screening Program at a Los Angeles Prenatal/Family Planning Center. Laura J. Fehrs, D. Hill, P. Kerndt, T. Rose, C. Henneman, New Mexico Health and Environment Department, Santa Fe, NM, U.S.A. National Surveys of HIV Seroprevalence in Women Delivering Live Children in the United States. Marguerite Pappaioanou*, R. George*, H. Hannon**, R. Hoff***, A. Willoughby\"**** A. et al., *AIDS Program, Centers for Disease Control; **CEHIC, Centers for Disease Control, Atlanta, GA; ***Massachusetts Department of Health, Boston, MA; ****NICHD, Bethesda, MD, 400 [Page 401](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/401) 14:00 Salle Room 408BC juin Wednesday, 7 S6ance th6matique Specialty Session pidemiologie et sant publique Epidemiology and Public Health Incidence et mortalitb du SIDA AIDS Incidence and Mortality Dale N. Laurence (U.S.A.) Jaime Sepulveda (Mexico) Ruth L. Berkelman*, J. Karon*, P. Thomas**, P. Kerndt***, G. Rutherford****, J. *Centers for Disease Control, AIDS Program, Atlanta, GA; **New York City Department ofHealth, New York, NY; ***Los Angeles County Health Department, Los Angeles; ****San Francisco Department of Public Health, San Francisco, CA, U.S.A. Heterosexual AIDS in the Province of Qu6bec. Robert S. Remis, L. Bidard, R. W. H. Palmer, Bureau rdgional des maladies infectieuses, Montreal, QC, Canada. Surveillance of Heterosexually Acquired AIDS, U.S.A. Mary E. Chamberland, L. Conley, J. Buehler, *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. Impact of the HIV Epidemic on Mortality Trends in Men 25-44 Years of Age, United States. James W. Buehler, R. L. Berkelman, O. J. Devine, F. M. Chevarley, Centers for Disease Control, Centerfor Infectious Diseases, AIDS, Atlanta, GA, U.S.A. National Surveillance of Perinatally-Acquired AIDS, U.S.A. MargaretJ. Oxtoby, M. Rogers, T. Bush, R. Berkelman, Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. The Relative Importance of AIDS as a Cause of Death in Pediatric and Young Adult Populations in the U.S. 1980-1987. Barbara W. Kilbourne, M. F. Rogers, T. J. Bush, Centers for Disease Control, Atlanta, GA, U.S.A. 401 [Page 402](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/402) 14:00 - 15:30 Salle 401AB Room S6ance th6matique Specialty Session Pr6sidents Chairpersons Aspects cliniques Clinical Aspects of AIDS Manifestations cliniques Clinical Manifestations Katabira (South Africa) Yves Mouton Syndrome and Psoriasiform Manifestations Associated with HIV Infection. Lenore J. Brancato, S. Itescu, M. L. Skovron, C. Navarrete, G. Solomon, R. Winchester, Hospital for Joint Diseases, New York University Medical Center, New York, NY, U.S.A. Clinicopathologic and Immunocytochemical Study of the Eye in AIDS: Observations in 25 Cases. Dominique Hfnin*, U. De Girolami*, B. Girard*, R. Vazeux**, *H6pital de la Salpitridre; **lnstitut Pasteur, Paris, France. Changing Prevalence of Malignancies in Men at San Francisco General Hospital during the HIV Epidemic. David M. Hever*, S. Desmond**, P. Volberding*, J. Kahn*, *San Francisco General Hospital; ** University of California at San Francisco, San Francisco, CA, U.S.A. Malignant Lymphomas in HIV-infected Patients: Clinical and Pathological Features. Department for Pathology, Steglitz; ***Freie Universitdt, Clinic for Oral Surgery, Berlin, Federal Republic of Germany. The Value of Lymph Node Biopsy in HIV Infection. Maria Jose' Foriaz Lacerda, L. Tavares, R. Madureira, Faculty of Medicine/Santa Maria Hospital, Departments of Pathology and Infectious Diseases, Lisbon, Portugal. Increased Capillary Pulmonary Volume during AIDS-related Kaposi Wednesday, June 7 S6ance th6matique Specialty Session Aspects cliniques Clinical Aspects of AIDS histoire clinique et 6tudes cohortes Hemophilia: Hemophilia-Associated AIDS in the United States. Jeanette K. Stehr-Green, R. C. Holman, M. A. Mahoney, AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Cumulative Risk for AIDS and Other HIV-outcomes in a Cohort of Hemophiliacs in Western Pennsylvania. Margaret V. Ragni*, L. A. Kingsley**, * University of Pittsburgh School of Medicine, Hemophilia Center of Western Pennsylvania; **Graduate School of Public Health, Pittsburgh, PA, U.S.A. Natural History and Pathogenesis of HIV Infection in Patients with Hemophilia. John L. Sullivan*, R. Koup*, D. Brettler**, P. Levine**, *University of Massachusetts Medical Center, Department of Pediatrics; Worcester Memorial Hospital, Worcester, MA, U.S.A. Natural History of HIV in Patients of the Bonn Haemophiliac Cohort Study. Bernd S. Kamps*, D. Niese*, H. Republic of Germany; ***Massachusetts Institute of Technology, Cambridge, MA, U.S.A. Canadian National Hemophilia Study (CNHS): HIV Infection in Hemophilia (HEM) and Other Bleeding Disorders (1985-1989). Man-Chiu Poon*, S. K. Ali, R. Card, B. Garvey, G. Growe, N. Kobrinsky, et al., *University of Calgary, Foothills Hospital, Calgary, AB; Memorial University, St. John's NF; University of Saskatchewan, Saskatoon, SK; University of Toronto, Toronto, ON; University of British Columbia, Vancouver, BC; University of Manitoba, Winnipeg, MB; Universitd de Montrdal; McGill University, Montreal, QC, Canada. Follow-up of a Cohort of 112 Anti-HIV Seropositive Haemophiliacs. Christine Ann Lee, A. N. Phillips, J. Elford, G. Janossy, P. D. Griffiths, P. B. A. Kernoff, Haemophilia Centre, Royal Free Hospital, London, U.K. 403 [Page 404](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/404) 14:00 - 15:30 Salle Room 407B Section B Mercredi 7 juin Wednesday, June 7 Aspects cliniques Clinical Aspects of AIDS Colloque Symposium Pr6sidents Chairpersons le VIH: Infection: Organ Specific AIDS. Donald P. Kotler, St. Luke's Hospital Center, New York, NY, U.S.A. Clinical Bone Marrow Involvement. Karen Gelmon, St Paul's Hospital, London, U.K. Clinical Central Nervous System Involvement. CourtPederson, Hvidovre Hospital, Hvidovre, Denmark. Pathology of the Central Nervous System in AIDS. Jean Michaud, H6pital Ste-Justine, Ddpartement de pathologie, Montrial, QC, U.S.A. The Lungs, The Cause of Death and Bacterial Infections in AIDS: What Autopsy Studies Show. Larry Nichols, currently at Research Triangle Institute, Research Triangle Park, NC, U.SA. 404 [Page 405](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/405) 14:00- 15:30 Salle Room au point de vaccins contre le SIDA Vaccine Developments in AIDS Stanley E. Read (Canada) Geoffrey C. Marc Girard. Pasteur Vaccins and Institut Pasteur, Paris, France. Development of an HIV Subunit Vaccine. Scott Putney, Repligen Corporation, Cambridge, MA, U.S.A. Immunisation experimentale anti HIV chez l'homme. Daniel Zagury, Universitd Pierre et Marie Curie, Paris, France. Evaluation of a Recombinant HIV-1 Envelope Protein (gp 160) as an Immunogen in Humans. Clifford Lane. NIAID, National Institutes of Health, Bethesda, MD, U.S.A. 405 [Page 406](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/406) 14:00 - 15:30 Salle Room 408A 7 juin Wednesday, Specialty Chairpersons Recherche fondamentale (biom6dicale) Mise approche pour I'6tude des mbdicaments antiviraux Drug Development: Novel Study Approach to Anti-Viral Drugs Louis S. Kucera (U.S.A.) Brendan a Novel Class of Membrane-Active Ether Lipid Analogs. Louis S. Kucera*, Modest*, *Bowman Gray School of Medicine, Winston-Salem; **University of North Carolina, Chapel Hill, NC, U.S.A. Generation of Indicator Cell Lines for Fast Assay of HIV-1 and for the Study of Antiviral Drugs. George N. Pavlakis, B. K. Felber, National Cancer Institute-FCRF, BRI-Basic Research Program, Frederick, MD, U.S.A. Mechanism of Action of Sulphated Polyanions as Inhibitors in HIV Infection In Vitro. L. Low. A. L. Cunningham, C. Parish, H. Warren, J. M. Mathys, F. Kazazi, Westmead Hospital, Virology Unit, Westmead, Australia. Colchicine Inhibits HIV-1 In Vitro. Stanley E. Read*, M. Lyons**, H. Li*, J. Zabriskie**, *Toronto Hospital for Sick Children, Toronto, ON, Canada; **Rockefeller University, New York, NY, U.S.A. Structures Necessary for HIV-2 Entry. David B. Weiner*, W. V. Williams*, J. A. Hoxie*, K. Hubner**, J. A. Berzofsky***, M. I. Greene*, *University Pennsylvania, Department of Pathology; **Wistar Institute, Philadelphia, PA; ***National Institutes of Health, Bethesda, MD, U.S.A. Identification and Characterization of Complement-Mediated Enhancement of HIV-1 Infection by Mannosidase I and II Inhibitors. David C.,Montefiori, W. E. Robinson, Jr., A. Modliszewski, W. M. Mitchell, Vanderbilt University, Department of Pathology, Nashville, U.S.A. 7 juin Wednesday, Specialty (Biomedical) Modbles animaux (partie 2) Animal Models (Part 2) Zvi Bentuich (Israel) Ming Huang (Canada) James I. Mullins (U.S.A.) 14:00 W.C.O.27 Evaluation by PCR of HIV-1 Status of Chimpanzees Challenged with HIV after Receiving Human HIVIG. Indira K. Hewlett*, J. Epstein*, C. A. Hawthorne*, J. Eichberg***, A. M. Prince**, *Food and Drug on AIDS (MAIDS). Zvi H. Bentwich*, Z. Weisman*, A. Meshorer**, J. Rubinstein**, E. Mozes***, *R. Ben Ari Institute of Clinical Immunology, Kaplan Hospital, Hebrew University Medical School; **Experimental Animal Unit; ***Department of Chemical Immunology, Immunodeficiency Virus (FIV). Robert A. Olmsted*, A. K. Barnes**, J. K. Yamamoto***, V. M. Hirsch*, R. H. Purcell**, P. R. Johnson*, *Georgetown University, National Institute ofHealth/Twinbrook II, Rockville; **NIAID, National Institutes of Health, Bethesda, MD; ***University of California at Davis, Davis, CA, U.S.A. T-Cell Killing by the FeLV-FAIDS Immunodeficiency Virus. Peter R. Donahue*, E. A. Hoover**, C. M. C. De Noronha*, S. L. Quackenbush**, J. Overbaugh*, J. I. Mullins*, *Harvard University School of Public Health, Department of Cancer Biology, Boston, MA; **Colorado State University, Fort Collins, CO, U.S.A. Infection of the New Zealand White Laboratory Rabbit (Oryctolagus Cuniculus) with HIV-1. Phillip D. Markham*, S. Reina**/***, E. A. Gard*, G. Ford*, A. Buchbinder***, R. C. et al., *Bionetics Research Inc., Rockville, U.S.A.; **Visiting from Institute of Microbiology, Genova, Italy; ***National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A. 408 [Page 409](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/409) 14:00 - 15:30 0 Chairpersons Section Mercredi 7 juin Wednesday, June 7 Le SIDA et l'individu AIDS and the Individual Consommateurs de drogues par vole r alites changeantes et mythes persistants Injection Drug Users: Changing Realities and Persisting Myths System. Robert Olin. National Health and Welfare, Stockholm, Sweden. Drug Injecting and Sexual Behaviour. Giovanni Rezza, Italian Ministry of Health, and WHO Consultant, SBR/GPA, Geneva, Switzerland. Impact of Improved Needle Accessibility on Drug Use Patterns and Demand for Treatment. Roel A. Coutinho, MunicipalHealth Service, Amsterdam, The Netherlands. The Prevention Message: AIDS and Initiation into Drug Injection. Don C. Des Jarlais. Beth Israel Medical Center, New York, NY, U.S.A. AIDS Among Drug Users in Developing Countries: The Thai Experience. Pratlom Sakuntanaga, Bangkok, June 7 S6ance th6matique Specialty Session Pr6sidents Chairpersons Le SIDA, la soci6t et le corportement AIDS, Society and Behaviour Le SIDA en milieu de travail AIDS In the Workplace Philippe Engelhard (Senegal) Louise Lamothe (Canada) Workplace: United States Policy and Education Initiatives. John F. Bunker, The Circle, Inc., McLean, VA, U.S.A. HIV/AIDS: A Psychosocial Task for Managers. Anita Sandblom, I. Osterberg, G. Ramstedt, J. A. Gunnarsson, Personnel and Organisation Department, Stockholm, Sweden. An AIDS Prevention Program Designed for Civil Construction Workers in Rio de Janeiro. Silvia Ramos*, C. Afonso**, C. **Audiovisual Training Center; ***Social Workers of Civil Construction Companies, Rio de Janeiro, Brazil. AIDS in the Workplace: An African Model from Uganda. Dace Stone*, J. Kasswara**, D. Weeks***, P. Uganda. Neuropsychological HIV-Infected Persons: Legal Implications for the Workplace. Mark Barnes. I. John, C. Berti, AIDS Law Clinic, Columbia University School ofLaw, New York, NY, U.SJA. Regional and Time Differences in the Effects of AIDS-HIV (A-H) Education on Changes in Knowledge and Fears among Worksite Employees. Harvey Bartnoa*/***, D. Verolini**, D. Roth***, *University of California at San Francisco, School of Medicine and AIDS Virus Education Research Institute; **California School of Professional Psychology; ***AIDS Virus Education and Research Institute (AVERI), San Francisco, 7 S6ance th6matique Specialty Session Le SIDA, la soci&~ et le comportement AIDS, Society and Behaviour Le SIDA dans les m6dias AIDS in the Media John F. James (U.S.A.) Teresa Gonzales Kury (Mexico) P. Bagaley, Concordia University, Department of Education, Montreal, QC, Canada. A l'6preuve du SIDA: et americaine. G. Pial, Journal \"Libdration\", Paris, France. Correlation between Large Scale Mass Media Campaigns on AIDS Prevention, and Homosexual and IVDUs Giving Up Risk Practices in Madrid. P. Estebdfiez*, A. Martinez**, C. Manzano**, Department; **Journalist, Universidad Complutense, Madrid, Spain. The U.K. National AIDS Health Promotion Programme: Recent Developments. Mukesh Kapila, K. Wellings, S. Perl, S. Hagard, Health Education Authority, London, UX. Flagrant Bias and Lack of Representation of Women's Groups and Experts in Media Coverage of Major AIDS Issues. Chris Norwood, Women and AIDS Studies, New York, NY, U.S.A. Evaluation of the National AIDS Multi-Media Public Information Campaign. Kenneth R., Williams*, D. D. Dawson**, P. Murdock***, *Centers for Disease Control, Atlanta, GA; **National for Health Statistics, Hyattsville,MD; ***Ogilvy GA, Salle Room 411C juin Wednesday, June 7 Colloque Droit et 6thique Ethics and Law Prbvenir la les religieux en matiere de sant6 publique Preventing HIV Transmission: Religious Conflicts in Public Health Earl Shelp (U.S.A.) For Interfaith Research and Ministry, Houston, TX, U.S.A. A Roman Catholic Perspective. Gregory Baum. Montreal, QC, Canada. A View From Scotland. Archie McLullich, Glasgow, U.K. AIDS and Indian Ethical Values. D. V. P. Raja, Madurai Institute of Social Work, Madurai, India. Saving Life As An Overriding Demand: A Jewish Perspective. W. Gunther Plaut, Toronto, ON, Canada. Commentary. David Hallman, The United Church of Canada, Toronto, ON, Canada. Commentary. De Sweemer, G Mercredi 7 juin Wednesday, June 7 I f m | Implcaions intana s SIInternational Issues S6ance th6matique Perspectives mondlales Specialty Global Perspectives Pr6sidents Chairpersons Manuel Carballo (Switzerland) on Immigration and Travel: U.S. Policy and Its Ramifications. Richard K. Edwards*, R. E. D. Whitaker**, *Northeastern University and Pine Manor College; **Boston University and Tufts New England Medical Center, Boston, MA, U.S.A. Comparison of National AIDS Strategies in Australia and Canada. Margaret Duckett. McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. The Epidemiological Surveillance System for AIDS in Brazil: Critical Assessment. Lair Rodrigues*, P. Chequer*, D. Bergamaschi*, E. Castilho**, L. De National Division of STD/AIDS, Brasilia; **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil. Functional and Dysfunctional AIDS Prevention Programs in Latin America and the Caribbean. Fernando R. K. Zacarias, L. Zessler, G. Mongalo, S. Luelmo, R. St. John, Pan American Health Organization, Washington, DC, U.S.A.; Global Programme on AIDS, World Health Organization, Geneva, Switzerland. Strategies of the EEC's AIDS Programme for Developing Countries to Control Sexually Transmitted HIV Infections. Discussion of Programme Implementation and Main Issues. Lieve Fransen, C. J. Van Dam, AIDS Task Force, Brussels, Belgium. National AIDS Programmes. Progress Achieved and Opportunities for Further Development. Daniel J. M. Tarantola. J. M. Mann, World Health Organization, Geneva, Switzerland. 413 [Page 414](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/414) 14:00 - 15:30 Salle Room 406BC Mercredi 7 juin Wednesday, June 7 Implications intemationales International Issues Colloque Symposium Presidents Chairpersons Transmission h6tbrosexuelle et r61e des MTS Heterosexual Transmission among Commercial Sex Workers in Zimbabwe. David J. Wilson, S. Sibanda, L. Mboyi, S. Msimanga, G. Dube, University ofZimbabwe, Department Dakar, Prostitutes as Health Educators for Their Peers in Yaounde: Changes in Knowledge, Attitudes and Practices. Marcel Monny-Lobe*, D. Nichols**, L. Zekeng***, R. Salla*, ***University Teaching Hospital, Yaounde, Cameroon. Social Characteristics and Sexual Behaviour of Women in the High Risk Behaviour Category. M. N. Katsivo, L. N. Muthami, Kenya Medical Research Institute, Nairobi, Kenya. AIDS Prevention among Brazilian Prostitutes: A Pilot Project. Lair G. M. Rodrigues*, T. Mathias**, F. Borges**, F. Delgrange***, ***Inter AIDE, France. Sexual Practices and HIV Infection of Female Prostitutes in Nigeria. Ekanem E. Williams*, Nigeria; **Centre for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. 414 [Page 415](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/415) 14:00 - 15:30 Sae Room 404AB 7 juin Wednesday, 7 S6ance th6matique Specialty Session Presidents Chairpersons R6percussions monomiques du SIDA The Economic Impact of AIDS Financement et assurances Financing and Insurance Geoffrey Carliner (U.S.A.) Rod Blue Shield: The First 7,500 AIDS Cases. Jon Eisenhandler, A. Padgug, Empire Blue Cross and Blue Shield, New York, NY, U.S.A. Health Insurance Industry Modeling of the HIV Epidemic in the United States. Charles L. Eb*, J. Dinius**, *Health Insurance Association of America, Inc.; **Aetna Life and Casualty, Washington, DC, U.S.A. Coverage of Selected Drugs Under State Medical Assistance (Medicaid) Programs in the U.S.A. Benjamin Schatz, National Gay Rights Advocates, San Francisco, CA, U.S.A. Analysis of AZT Assistance Provided by a Private Hospital. Mark A. Benge, M. Cintron, R. Muniz, T. Watson, St. Clare's Hospital and Health Center, New York, NY, U.S.A. National Survey of State Spending for AIDS Program Activities. Mona J. Rowe*, C. C. Ryan*, R. M. Keintz*, D. M. Merritt*, J. Richland**, S. Madden**, K. Farrell***, et al., *George Washington University, Health Policy Project-AIDS Policy Center; **Public Health Foundation; ***National Association of State Budget Officers, Washington, DC, U.S.A. Financing the Medical Cost of the HIV Epidemic in the United States: A Policy Review. Harvey J. Makadon*, G. R. Seage**, K. E. Thorpe*, H. V. Fineberg*, *Center for Policy and Education, Harvard AIDS Institute, Harvard School of Public Health; **Department of Health and Hospitals, Boston, MA, U.S.A. 415 [Page 416](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/416) 14:00 - June 7 Session viddeo Video session Le Militantisme et la r6sistance culturelle Activism and Cultural Testing the militantisme artistique et la r6sistance culturelle face au SIDA ont une prolif6ration de SIDA mais aussi le langage du SIDA. Aesthetic activism and cultural resistance in response to AIDS has meant a proliferation of videos. This session is a sampling of some of the best. From guerrilla fashion shows to subversive music videos, from civil disobedience to media deconstruction, the aesthetic strategies illustrated show that not just the politics of AIDS but the politics of language related to AIDS needs to be reinvented. 417 [Page 418](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/418) 16:00 - 17:30 Salle 407A Room Heterosexuals in Brussels. Nathan Clumeck, V. Arendt, P. Hermans, M. Schoumacher, Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium. Partner Acceptability of Health Department Notification of HIV Exposure, South Carolina. Jeffrey L. Jones*, R. F. Wykoff**, W. B. Gamble**, S. L. Hollis**, S. T. Longshore**, R. A. Gumm*, *Centers for Disease Control, Division of Field Services, Atlanta, GA; **South Carolina Department ofHealth and Environmental Control, Columbia and Greenwood, SC, U.S.A. Result and Benefit: Cost Analysis of Provider-Assisted HIV Partner Notification and Referral. Nancy E. Spencer, C. Raevsky, F. Wolf, Colorado Department of Health, STD/AIDS Section, Denver, CO, U.S.A. Partner Notification for HIV Prevention: Current State Policy in the United States. Kathleen E. Toomey, K. Cahill, W. Cates, Centers for Disease Control, Division of STDs, Atlanta, GA, U.S.A. Assessment of the Development and Implementation of State AIDS/HIV Partner Notification Programs: Five Case Studies. Lorraine M. Fishback*, J. W. Flynt**, J. Focht**, L. Baughman**, C. Morgan**, *Office of the Assistant Secretary for Health, Public Health Service, Washington, DC; Macro Systems Inc., Silver Spring, MD, U.S.A. Combatting AIDS with Contact Tracing. J. Giesecke, Swedish Study Group on Contact Tracing, Environmental Health and Disease Control, Karolinska Hospital, Stockholm, Sweden. 418 [Page th6matique Specialty Session lpid&miologie et sant6 publique Epidemiology and Public Health Test de d6pistage du VIH/Questions en matibre de politiques et de programmes HIV Testing/Policy and Programme Issues Presidents Chairpersons Shankar Choudhury (India) A TwelveMonth Experience. Chester J. Kelly, B. J. Turnock, Illinois Department of Public Health/AIDS Activity Section, Springfield, IL, U.S.A. HIV Antibody Testing among Adults in the United States. Ann M. Hardy, D. Dawson, National Center for Health Statistics, Hyattsville, MD, U.S.A. HIV Antibody Status and Behavior Change in Two Cohorts of Gay Men in San Francisco: The San Francisco Men's Health Study (SFMHS) and the AIDS Behavioral Research Project (ABRP). Thomas J. Coates, M. Ekstrand, S. M. Kegeles, R. D. Stall, University of California at San Francisco, San Francisco, CA, U.S.A. Targeting AIDS Prevention towards HIV-Infected Persons. Do Prevention/Treatment Programs Reduce Transmission and Improve the Quality of Life? Donald P. Francis*, M. Gorman**, M. Fenstersheib***, A. Esposito***, N. Padian****, et Disease Control, Berkeley; **Rand Corporation, Santa Monica; ***Santa Clara County Health Department, San Josd; ****Long Beach Department of Public Health, Long Beach; ******University of California at San Francisco, San Francisco, CA, U.S.A. HIV Epidemiology in Sweden. Margareta B6ttiger, National Bacteriological Laboratory, Stockholm, Sweden. Risk Factors and HIV Seroprevalence in Screening U.S. Immigration Applicants: 1988. Timothy M. Sankary, AIDS Prevention Center, San Francisco, CA, U.S.A. 419 [Page 420](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/420) 16:00- 17:30 Salle Room 4ABC Wednesday, June 7 S6ance th6matique Specialty Session Aspects cliniques Clinical Aspects of AIDS Infections associbes au SIDA AIDS Related Infections Donald Armstrong (U.S.A.) Jean R. **Ophthalmology Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. Monitoring of Cytomegalovirus (CMV) Antigenemia during Treatment of Serious CMV Infection in AIDS Patients. Herman G. Sprenger, J. Weits, J. T. Anema, J. Schirm, T. H., The Groningen University Hospital, Groningen, Netherlands. Foscarnet Treatment of Cytomegalovirus Retinitis in AIDS. Mary M. Fanning, S. E. Read, M. F. Benson, A. Rachlis, S. Vas, V. Kouzesek, et al., Toronto General Hospital, Toronto, ON, Canada. Differences among Pulmonary (PT), Extrapulmonary (ET) and Disseminated Tuberculosis (DT) in HIV-Infected Patients. V. Cdrcaba, J. A. Carton, Z. Garcta, J. J. Palacio, J. A. Maradona, J. A. Mufioz, et al., Hospital Universitario de Oviedo, Oviedo, Spain. Intestinal Microsporidiosis as a Cause of Diarrhea in AIDS. Jan Marc Orenstein*, W. Steinberg*, J. Chiang*, P. Smith**, H. Rotterdam***, *George Washington University Medical Center, Washington, DC; **NIDR, National Institutes of Health, Bethesda, MD; ***New York University Medical Center; ****St. Luke's-Roosevelt Hospital, New York, NY, U.S.A. Improved Survival in AIDS Patients with Opportunistic Infections. Jonathan W. M. Gold. S. W. Campbell, M. Carrow, D. Niedzwiecki, D. Armstrong, Memorial Sloan-Kettering Cancer Institute, New York, NY, U.S.A. 420 [Page 421](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/421) 16:00 - 17:30 Salle Rm 403ABC Wednesday, 7 S6ance th6matique Specialty Session clines Clinical AIDS Atteintes neuropsychiatriques Neuropsychiatric Involvement M. I. Botez (Canada) P. Bridges (U.S.A.) Rolf R. Riedel (Federal in Gay and Bisexual Men during the AIDS Epidemic: The San Francisco Men's Health Study. Thomas J. Coates*, F. Castro**, M. Ekstrand*, *University of California at San Francisco, San Francisco; **Stanford University, Stanford, CA, U.S.A. Is There Adaptive \"Habituation\" to Loss in the AIDS Epidemic? Robert H. Remien. R. Neugebauer, J. Williams, J. Rabkin, J. Gorman, Columbia University, New York State Psychiatric Institute, HIV Centerfor Clinical and Behavioral Studies, New York, NY, U.S.A. Neurological and Neuropsychological Deficits in 240 HIV-Seropositive Hemophiliacs in WR 2-6. ilau**, C. Helmstadter**, C. Bruzki*, K. Wirtz, et al., University Clinic, Department of Neurology, Bonn, Federal Republic of Germany. Slowed Cognitive Processing in HIV+ Patients in Comparison to Psychiatric Controls. Alex Martin, D. Kampen, A. M. Salazar, J. Williams, W. Law, T. Roller, et al., Walter Reed Army Medical Center, Washington, DC, Prevalence and Pattern in HIV Spectrum Disorders. Lydia Temoshok, M. Drexler, J. P. Canick, D. M. Sweet, H. Hollander, University of California at San Francisco, School of Medicine, San Francisco, CA, U.S.A. Further Evidence of Lack of HIV-1 Related Cognitive Impairment during the Asymptomatic Stages: The Multicenter AIDS Cohort Study. Ola A. Selnes*, J. C. McArthur*, E. N. Miller**, K. Sheridan***, J. T. Becker****, B. Gordon*, et al., *Johns Hopkins Medical Institutions, Baltimore, MD; **University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA; ***Northwestern University, Chicago, IL; ****University of Pittsburgh, Pittsburgh, PA, U.S.A. Peptide T Phase I Study: Neuropsychiatric Results. Peter T. Bridee*, F. K. Goodwin*, P. N. R. Heseltine**, E. Eaton**, E. S. Parker**, *National Institute of Mental Health, Bethesda, MD; ** University of Southern California, Lo. Angeles, CA, U.S.A. 422 [Page 423](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/423) 16:00 - 17:30 Sane Room 407B Mercredi 7 juin Wednesday, June 7 Aspects cliniques Clinical Aspects of AIDS Colloque Symposium Presidents Chairpersons Essais points de vue des \"acteurs\" Clinical Trials: W.B.O.46 16:15 W.B.O.47 16:30 W.B.O.48 Investigators Perspective. Allan R. Ronald, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. Clinical Trials in AIDS: The Regulatory Perspective. Ellen C. Cooper, U.S. Food and Drug Administration, Rockville, MD, U.SA. The Role of the Pharmaceutical Industry in Drug and Vaccine Development. John C. Petricciani, Pharmaceutical Manufacturers Association, Washington, DC, U.SA. Patient's Perspective. Claude Leblanc, Montreal, QC, Canada. The Challenge of Testing Therapies for HIV Infection. Daniel Hoth, NIAID, National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.SA. Ethicists and Clinical Trials. Robert J. Levine, Yale University School of Medicine, New Haven, CT, juin Wednesday, 7 Recherche fondamentale (biom&dicale) Basic (Biomedical) Virologle (partle 3) Virology 3) S6ance th6matique Specialty Session Presidents Chairpersons S. T Cell Nuclear Factors Which Bind to the Negative Regulatory Elements (NRE) of the HIV LTR. Bruno Guy, B. Acres, M. P. Kieny, Transgine S.A., Strasbourg, France. Functional Role of HIV-1 VPU. Eric Cohen, E. Terwilliger, J. Sodroski, W. Haseltine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, U.S.A. Effects of Mutations in the nef Gene on the Growth of HIV. Sunyoung Kim*, K. Ikeuchi**, R. Byrn**, J. Groopman**, D. Baltimore*, *Whitehead Institute and Department of Biology, Massachusetts Institute of Technology, Cambridge; **New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. VPU: A Protein Unique for HIV-1 Is Required for Efficient Virion Maturation and Release. Thomas Klimkait*, K. Strebel*, J. Orenstein**\", M. A. Martin*, *NIAID, National Institutes of Health, Bethesda, MD; **George Washington University Medical School, Washington, DC, U.S.A. Effects of nef Expression on HIV Replication and Cellular Functions. Cecilia Cheng-Maver*, P. Iannello*, P. A. Luciw**, J. A. Levy*, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco; **University of California at Davis, Department of Medical Pathology, Davis, CA, U.S.A. In Vitro Generation of Neutralization-Resistant Human Immunodeficiency Virus (HIV). Shinii S. University, Institute for Virus Research, Kyoto; University School, Kumamoto, Japan 424 [Page 17:30 Sale Room 7 juin Wednesday, Specialty Chairpersons Recherche fondamentale illments de base en immunologle (partle 2) Basic Immunology (Part 2) G. L. in HIV-Infected Patients. Giuseppe Pantaleo, S. Koenig, M. Baseler, H. C. Lane, A. S. Fauci, National Institutes of Health, Bethesda, MD, U.S.A. In Vitro Lymphocyte Proliferative Responses to Recombinant and Synthetic Peptide Antigens of HIV-1. John F. Krowka*, D. P. Stites*, K. S. Steimer**, N. Duzgunes*, et al., * University of California at San Francisco, Department of Laboratory Medicine, San Francisco; **Chiron Corporation, Emeryville, CA, U.S.A. Determination of Epitopes Recognized by HIV-Specific CTL. Scott Koenig, P. Earl, L. Wood, D. Powell, B. Moss, A. S. Fauci, et al., LIR, LVD, NIAID, and National Institutes of Health, Bethesda, MD, U.SA. A Cytotoxic T Lymphocyte Inhibits AIDS Virus Replication in Peripheral Blood Lymphocytes. Hiroshi Tsubota, C. I. Lord, N. L. Letvin, Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A. Long-Term Culture and Fine Antigen Specificity of HIV-1 Reverse Transcriptase-Specific Cytotoxic T-Lymphocyte (CTL) Clones. Bruce D. Walker*, K. L. L. Ficher*, R. A. Young**, B. Moss***, R. T. Schooley*, *Harvard Medical School and Massachusetts General Hospital, Boston; **Massachusetts Institute of Technology, Whitehead Institute, Cambridge, MA; ***NIAID, National Institutes of Health, Bethesda, MD, U.S.A. Analysis of the Structural and Non-Structural Proteins of HIV-1 Recognized by Primary Cytotoxic T Lymphocytes. Rividre*, 16:00 - 17:30 Salle Room 41OABC Animal Models (Part 3) Muthiah Daniel (U.S.A.) Vanessa M. Hirsch Ansari*, P. Fultz*, S. University, Yerkes Primate Research Center, Atlanta, GA; **Armed Forces Institute of Pathology and Walter Reed Army Institute of Research, Washington, DC; VA Medical Center, Atlanta, GA, U.S.A. Clinical, Immunological and Virological Follow-Up of l' de santd armies, Fontenay-aux-Roses; **Institut Pasteur, Paris, France. Monkeys with Simian AIDS Produce an Antibody Directed against a Histone-like Protein on CD4+ T-Cells. Raphael B. Stricker*, P. N. Fultz**, A. M. Haislip*, *University of California at San Francisco, San Francisco, CA; **Emory University, Yerkes Regional Primate Research Center, Atlanta, GA, U.S.A. Vaccine Protection against Simian Immunodeficiency Virus Infection. Muthiah Daniel, P. Sehgal, M. Wyand, D. Ringler, N. King, R. Desrosiers, New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, U.S.A. Evidence for Progression to Disease in Chimpanzees Chronically Infected with HIV-1? Patricia N. Fultz*, R. Siegel*, H. McClure*, K. Steimer**, et al., *Emory University, Atlanta, GA; **Chiron Corp., Emeryville, CA, U.S.A. Genetic Variation of SIV in Experimentally Infected Macaques: Tissue Versus Tissue Culture. Philip R. Johnson*, R. A. Olmsted*, R. H. Purcell**, V. M. Hirsch*, *Georgetown University, National Institutes of Health/Twinbrook II, Rockville; **NIAID, National Institutes of Health, Bethesda, MD, U.S.A. 426 [Page 427](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/427) 16:00 - 17:30 P Sale Presidents Chairpersons Section Mercredi 7 juin Wednesday, June 7 Le SIDA et l'individu AIDS and the Individual Les femmes dans les pays industrialls6s: questions et options Women in Developed Countries: Issues and Options Marjo Meijer (The Netherlands) Janet Mitchell and Strategies. Yolande Serrano, Association for Drug Abuse Prevention and Treatment, (ADAPT), Inc., New York, NY, U.S.A. Community Development Model for Interventions with Prostitutes. Julie Bates, Australian Prostitutes' Collective Inc., Canberra, Australia. On Being HIV-Positive, European, Female, and \"Non-Existent\". Amanda Heggs, Copenhagen, Denmark. Psychosocial Factors that Hinder Health in HIV-Infected Women. Denise Ribble, Bellevue Hospital/Community Health Project; New York, NY, USA. Access to Services for Women with AIDS in Poor Minority Communities. Melinda Cuthbert, Yale University, New Haven, CT, U.S.A. 427 [Page 428](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/428) 17:30 Salle Room 411B Section E Mercredi 7 juin Wednesday, June 7 it lt ti Le SIDA, la soci6dt et le compoteint AIDS, Society and Behaviour Sdance th6matique Services de pastorale Specialty Session Pastoral Care Presidents Chairpersons Santo Dharan Management. Alison D. Rader. M. Malama, I. D. Campbell, T. Chaava, The Salvation Army Chikankata Hospital, Mazabuka, Zambia. An Evangelical Denomination Responds to AIDS. Reginald F. Einger*, M. Malloy**, *Nazarene Health Care Fellowship Compassionate Ministries/Church of the Nazarene, Kansas City, MO; **Christian Counseling Services, Nashville, TN, U.S.A. Jewish Law, Values and the Social Issues Arising from HIV Disease. Beniamin Freedman, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada Religious Leaders in Sao Paulo, Brazil Join the AIDS Prevention and Control. Elisabeth Inglesi. M. E. Fernandes, Centro de Referencia e Treinamento AIDS, Sao Paulo, Brazil. Baha'i Concepts towards AIDS Patients and Society. Farin Davachi*, M. Wingi***, of Kinshasa, Kinshasa, Zaire. Discussant. Stephen A. Pieters, Universal Fellowship of Metropolitan Community Churches, Los Angeles, CA, U.S.A. 428 [Page 429](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/429) 16:00- 17:30 Salle Room 411C Section ~hique Ethics and Law Mercredi juin Symposium Pr6sidents ou volontarisme? Analyse critique internationale Coercion or Voluntarism: An International Critical Review Ronald Bayer (U.S.A.) O. Gostin, Harvard University, School of Public Health, Boston, MA, U.S.A. Cuba: A Review. Hector Terry-Molinert, Ministry of Public Health, Havana, Cuba. Bavaria: Coercion or Voluntarism; An International Critical Review. Hans JdLger, Stadtkrankenhaus, Minich, Federal Republic of Germany. Sweden: A Review on Compulsive Treatment. Gunnar Agren, County Council of Stockholm, Stockholm, Sweden. Ethical and Legal Issues of AIDS in South Africa. Gideon L Knobel, University of Cape Town, Cape Town, South Africa. A Human Rights Perspective. Justice Michael Kirby, Court of Appeal, Supreme Court ofAustralia, Sydney, Australia. Ethical and Policy Issues Posed by the Use of Coercion to Combat the Spread of HIV Infection. Ronald Baver, Columbia University School of Public Health, Division of Sociomedical Sciences, New York, NY, U.S.A. 429 [Page 430](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/430) 16:00 - 17:30 Salle Room 406A Section G Mercredi 7 juin Wednesday, June 7 L Implicationsiemraonales SI International Issues S6ance th6matique Pr6valence (partie 3) Specialty Session Prevalence (Part 3) Pr6sidents Chairpersons Lutz Guertler (Federal Republic of Germany) Pierre of HIV Surveillance Data for Guiding National AIDS Programme Decisions. Gary Slutkin, J. Chin, D. Tarantola, J. Mann, World Health Organization, Geneva, Switzerland. Suggestion of a Stabilization of HIV Infection in Selected Populations in Zaire between 1986 and 1989. Bosenge N' Galy*, R. Ryder**/***, M. Kamenga**, Bureau; **Projet SIDA, Disease Control, Atlanta, GA, U.S.A.; ****Mama Yemo Hospital, Kinshasa, Zaire. Sentinel Site Surveillance for AIDS in Abidjan, C6te d'Ivoire. Kevin M. De Cock*, A. Porter*, J. K. *Projet RETRO-CI, Abidjan, Ivory Coast; **Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. Les aspects 6pid6miologiques des affections li6es au HIV-1 et 2 en R6publique Centrale Africaine. Alain J. Georges*, P. Somse**, M. R. Siopathis***, J. publique, Bangui, Central African Republic. Comparison of the Age Distribution of Anti-HIV-1 and Anti-HBc in an Urban Population from Malawi. Lutz Guertler*, N. G. Liomba**, J. Eberle*, H. M. Ntaba**, F. Deinhardt*, T. Rehle***, *University of Munich, Max von Pettenkofer Institute, Munich, Federal Republic of Germany; HIV, HTLV-1 and HBV Infection in Pregnant Women from an Urban Population in Zaire. Oscar Kashala*, L. Lomami**, K. Ngalula**, P. Kanki*, M. Kalengayi**, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.SA.; ** University of Kinshasa, Kinshasa, Zaire. 430 [Page 406BC Section G Mercredi 7 juin Wednesday, June 7 Implications Chairpersons Femi Soyinka, Obafemi Awolowo University, Ile-Ife, Nigeria. Poverty, Women and AIDS. Patrick A. Twumasi, University of Ghana, Department of Sociology, Legon, Ghana. Pediatric AIDS. JanetNeeguavee, University ofGhana Medical School, Department of Child Health, Accra, Ghana. AIDS and other AIDS. Dakar, Senegal. Blood Bank Service and AIDS. Lamina Mercredi 7 juin Wednesday, June 7 International Issues Colloque Symposium Pr6sidents Chairpersons DUplacements Internationaux et SIDA International Travel and AIDS: A Perspective Allan S. Meltzer (Canada) Taitt, Ministry of Health, St. Michael, Barbados. Freedom of International Travel. Terry Mooney, WHO Global Programme on AIDS, World Health Organization, Geneva, Switzerland. Le SIDA et les voyageurs: Perspectives en sante publique. Michel June 7 S6ance th6matique Specialty Session R6percussions 6conomiques du SIDA The Economic Impact of AIDS M6thodologle des analyses de coots Methodology of Cost Studies Andr6-Pierre Contandriopoulos (Canada) Hans Jaiger (Federal Republic of Germany) Paris, France. Use and Costs of Health Care Services of Persons with AIDS in Three Practice Settings in San Francisco, 1986-87. Anne A. SQcitovsky. M. Cline, Palo Alto Medical Foundation/Research Institute, Palo Alto, CA, U.S.A. Forecasting the Medical Care Costs of AIDS in the United States: 1989-1993. Fred J. Hellinger, National Center for Health Services Research, United States Department ofHealth and Human Services, Rockville, MD, U.S.A. Scenarios Linking Epidemiology and Economics: Possible Impacts of Drug Treatment of HIV-Infected in the FRG. Reiner Leidl, Institute for Medical Info rmatics/GSF, Munich-Neuherberg, Federal Republic of Germany Development and Application of a Model HIV Information System. Julia Hidalgo, C. Hamidi, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A. Labour Market Productivity. Sherry Glied, Harvard University, Department of Economics, Cambridge, MA, U.S.A. 433 [Page 434](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/434) 16:00 - 17:30: Section Mercredi 7 juin a Wednesday, June 7 Cinema deNsessionviso I'ONF, Video session Complexe Guy Les de ou la peur et la prise en charge de soi. Prevention campaigns remain the primary means of getting information to the general public. Many organizations, both government and community-based, have tried to intervene using existing media techniques such as Television Public Service Announcements (PSA's) or community-specific shorts intended for use in public venues. These clips vary from coy to conservative, explicit to hilarious, reactionary to riveting. They are purposefully juxtaposed to force the audience to actively participate in choosing between promotion of fear or of empowerment. 434 [Page 435](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/435) Notes [Page 436](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/436) Section June 7 pidc~miologie et sant6 publique Epidemiology and Public Health Session d'affichage Poster Session Pr6valence du VIH chez les femmes et les enfants HIV Prevalence in Women and Children W.A.P.1 Seroprevalence of HIV Antibodies in Neonates and Children. Shannon C. Fenn*, W. Bigler, M. Wilder, S. Manoff, J. Patti, J. Witte, et al., *Health and Rehabilitative Services ofFlorida, Tallahassee, FL, U.S.A. W.A.P.2 Routine HIV Antibody Screening in Los Angeles County Prenatal Clinics: A Demonstration Project. Wendv Cozen*, L. Mascola, S. Bauch, M. Finn, C. Heneman, *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A. W.A.P.3 Epidemiology of HIV Infection in Women from Frankfurt Area. Schlomo Staszewski*, E. Schieck, S. Rehmet, J. Odewald, R. Goethe Universitat, Zentrum der immeren Medizim, Frankfurt, Federal Republic of Germany. W.A.P.4 Epidemiology and Outcome of HIV Seropositive Children in Madrid Community. M. D. Gurbindo Gutierrez*, R. Bueno, J. Herrera, M. Moro, F. Omehiaca, J. Ruiz, et al., *Hospital General Gregorio Maraiion, Madrid, Spain. W.A.P.5 Newborn Screening for HIV Antibody Seropositivity in the South Bronx. Andrew Wiznia*, I. L. Hand, R. T. Checola, M. H. Kim, L. M. Noble, J. J. Yoon, *Bronx-Lebanon Hospital Center, Albert Einstein College ofMedicine, Bronx, NY, U.S.A. W.A.P.6 HIV Risk Factor Prevalence among Young Women of Child-Bearing Age Attending Women's Primary Care Clinics. Robert W. Wood*, N. V. Harris, S. G. Hopkins, E. H. Sohlberg, T. J. Kimball, H. Watts, et al., *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A. W.A.P.7 Herpes Simplex, Syphilis and Hep. B: Association Pregnant Haitian Women. Re~inald Boulos*, N. Halsey, A. Ruff, M. Adrien, T. C. W. Quinn, A. Nahmius, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A. W.A.P.8 HIV Infection in Pregnant Women at a Public Hospital in New Orleans, Louisiana. Louise McFarland*, H. Dean, B. Trahan, L. Muirhead, *Louisiana Department of Health and Hospitals, New Orleans, LA, U.S.A. W.A.P.9 The Seroprevalence of HIV Infection in New York City Children. Isac B. Weisfuse*, P. Thomas, M. Oxtoby, S. Back, R. Stevens, D. Berns, et al., *New York City Department ofHealth, New York, NY, U.S.A. 436 [Page 437](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/437) W.A.P.10 HIV Infection in Lesbians. Denise J. Ribble*, C. Marte, J. Kelly, C. Keyes, P. Rodgers, J. Wolbert, *Bellevue Hospital, Community Health Project, New York, NY, U.S.A. W.A.P.11 No Change in HIV Seroprevalence among Parturients and Women Having Induced Abortions in New York City, 1987-1988. Maria Rosario G. Araneta*, P. A. Thomas, L. L. Ramirez, I. B. Weisfuse, S. Schultz, *New York City Department ofHealth, AIDS Research Unit, New York, NY, U.S.A. Incidence du SIDA AIDS Incidence W.A.P.12 The Evolving Epidemiology of AIDS in New York City: Trends in AIDS Case Surveillance Data. Alan E. Greenberg*, P. A. Thomas, R. H. Hindin, A. W. Greene, E. L. Rautenberg, S. J. Schultz, *AIDS Surveillance Unit, New York City Department of Health; AIDS Center for Disease Control, New York, NY, U.SA W.A.P.13 The Epidemiology of AIDS in San Francisco's Elderly Population. Susan F. Payne*, C. Wilson, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.A.P.14 The Epidemiology of AIDS-related Non-Hodgkin's Lymphoma in San Francisco. George F. Lemp*, S. F. Payne, D. P. Neal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.A.P.15 Changing Trends in the AIDS Epidemic in Europe.Angela M. Downs*, R. A. Ancelle-Park, J. B. Brunet, *World Health Organization Collaborating Centre on AIDS, IMET, Paris, France. W.A.P.16 Four-fold Increase in Tuberculosis/AIDS Patients in New York City, 1985-1988. Eddy Laroche*, M. R. G. Araneta, R. L. Stoneburner, J. J. Adler, *New York City Department ofHealth, New York, NY, U.SA. W.A.P.17 Epidemiology of AIDS-associated Lymphomas: United States. Thomas A. Peterman*, V. Beral, R. L. Berkelman, *Centersfor Disease Control, Atlanta, GA, U.S.A. W.A.P.18 Changing Patterns of Heterosexually-acquired AIDS in Florida. Deborah Holtzman*, N. A. Brandenburg, J. Sims, J. J. Witte, *Department of Health and Rehabilitative Services, AIDS Program, Tallahassee, FL, U.S.A. W.A.P.19 The Relative Risk of AIDS for the Black and Hispanic Communities in New Jersey. Molly J. Cove*, N. Williams, J. Ryan, *New Jersey State Department ofHealth, Trenton, NJ, U.S.A. W.A.P.20 Changes in Mode of Transmission among AIDS Cases in Houston, Texas, U.S.A. Robert L. Falletti*, A. Phelps, *Bureau of Epidemiology, Houston Department of Health and Human Services, Houston, TX, U.S.A. W.A.P.21 Heterosexually Transmitted AIDS in New York State. J.Stan Lehman*, P. Smith, J. Mikl, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.SA. 437 [Page 438](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/438) W.A.P.22 Hepatitis Delta (HDV) and AIDS in Risk Communities in Argentina. Oscar Fay*, G. R. Muchinik, J. Biglione, M. B. Bouzas, E. Fernandez, J. Galindez, Publica, Rosario, Argentina. W.A.P.23 Risk of AIDS and HIV Infection in American Indians and Alaska Natives. George A. Conwav*, E. Y. Hooper, M. E. St. Louis, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. W.A.P.24 Decline in Rate of New AIDS Cases among Homosexual and Bisexual Men in San Francisco. Christina P. Lindan*, G. W. Rutherford, S. F. Payne, N. Hearst, G. F. Lemp, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. W.A.P.25 Analyse des tendances des caract6ristiques socio-d6mographiques des cas de SIDA rapport6s en France. Anne Laporte*, B. H. Hubert, A. M. Marciniack, S. C. Cluzan, J. B. Brunet, *Ministere de la Santd, Direction gdndrale, Paris, France. W.A.P.26 AIDS in the Department of Veterans' Affairs: Demographics and Epidemiology. Robert E. Allen*, S. H. Mather, M. R. Peterson, *AIDS Program Office, Veterans Administration, Washington, DC, U.SA. MortalitY lide au SIDA/VIH AIDS/HIV Related Mortality W.A.P.27 Impact of AIDS on Mortality in San Francisco: 1979-1986. George W. Rutherford*, L. D. Saunders, G. F. Lemp, L. Barnhart, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.A.P.28 HIV-associated Mortality in England and Wales Is Greater than that Identified by AIDS Surveillance. Anna McCormick*, *PHLS Communicable Disease Surveillance Centre, London, U.K. W.A.P.29 Estimate of HIV-related Deaths in Young Adult Men, United States, 1986. James W. Buehler*, R. L. Berkelman, O. J. Devine, *Centersfor Disease Control, Centre for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. W.A.P.30 Causes of Death in a Large Cohort of I.V. Drug Users (IVDUs) inMilan: An Update. L. Ciacci, et al., *Infectious Diseases Clinic, L. Sacco Hospital, University of Milan, Milan, Italy. W.A.P.31 Mortality among 1,862 HIV-Infected Persons in a Geographically Dispersed U.S. Population: Preliminary Results. Andrew L. Dannenberg*, J. McNeil, J. Brundage, *National Heart, Lung, and Blood Institute, Bethesda, MD, U.S.A. W.A.P.32 AIDS Mortality among Puerto Rican-bom Residents of New York City: 1981-1987. Ernest Drucker*, B. Menendez-Bergad, S. Blum, S. H. Vermund, *Montefiore Medical Center/Albert Einstein College ofMedicine, Bronx, NY, U.S.A. W.A.P.33 The Impact of Non-Opportunistic Infections on Mortality in a National Sample of AIDS Hospitalizations. Barbara J. Turner*, J. K. Ball, *Jefferson Medical College, Philadelphia, PA, U.SA. 438 [Page 439](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/439) W.A.P.34 Stabilization of AIDS Mortality in Non-Drug Using Men in New York City (NYC). Rand L. Stoneburner*, C. Stevens, M. Chiasson, J. Morrison, W. E. Ewing, T. Singh, et al., *New York City Department ofHealth, New York, NY, U.S.A. W.A.P.35 Comparison of U.S. HIV Mortality Trends from Vital Statistics and AIDS Surveillance. Frances M. Chevarley*, K. D. Kochanek, J. W. Buehler, *National Center for Health Statistics, Hyattsville, MD, U.S A. Transmission homosexuelle Homosexual Transmission W.A.P.36 Risk Factors for Transmission and Impact of Knowledge of HIV-AB Seroconversion on Sexual Behavior among Homosexual Men. Godfried J. P. Van Griensven*, C. Kuiken, E. M. M. De Vroome, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands. W.A.P.37 Retrospective Study of Factors Responsible for HIV Transmission in Male Homosexuals. Anastasia Roumeliotou*, G. Kallinikos, M. Kotsianopoulou, A. Nestoridou, E. Trichopoulou, G. Papaevangelou, *National Center for AIDS, Athens School of Hygiene, Athens, Greece. W.A.P.38 Risk Factors for HIV Infection among Male Prostitutes in Atlanta. Kirk Elifson*, J. Boles, M. Sweat, W. Darrow, *Georgia State University, Department of Sociology, Atlanta, GA, U.S.A. W.A.P.39 Relationship of STD History to HIV Seropositivity in a Cohort of Homosexual Men in Dallas, Texas. Charles E. Haley*, P. Anderson, A. Freeman, A. Petty, *Dallas County Health Department, Dallas, TX, U.SA. W.A.P.40 HIV-1 Discordant Couples in the Baltimore MACS Study. John G. Palenicek*, R. Fox, N. Odaka, H. Armenian, J. Harris, W. Hardy, et al., *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. W.A.P.41 Failure to Confirm Herpes Simplex Virus Type 2 (HSV-2) Infection as a Risk Factor for HIV-1 Seroconversion among Homosexual Men. Lawrence A. Kingslev*, J. Armstrong, A. Rahman, M. Ho, C. R. Rinaldo, *University of Pittsburgh, Infectious Diseases and Microbiology, Pittsburgh, PA, U.S.A. W.A.P.42 Seroepidemiologic Study of HIV Infection among Homosexual Men Attending a Medical Practice in Montreal. Robert S. Remis*, M. Najjar, C. Pass, G. infectieuses, Montreal, QC, Canada. in Homosexual Transmission of HIV. Ennio Ricchi*, P. Costigliola, M. Borderi, N. in a Cohort of Homosexual Men: Sequential Changes Over Six Years. Brian P. Mulhall*, L. Carter, I. H. Frazer, *Royal Melbourne Hospital, Melbourne, Australia. 439 [Page 440](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/440) W.A.P.45 The Incidence of Human Immunodeficiency Virus (AIDS) Infection among the Cohorts of Sexually Transmitted (STD) Patients with Different Veneral Disease Histories. Wayne X. Shandera. Baylor College of Medicine, Ben Taub Hospital, Houston, TX, U.S.A. W.A.P.46 Recent HIV Seroconverters (SC) in a San Francisco Cohort of Homosexual/Bisexual Men: Risk Factors for New Infection. Alan R. Lifson*, P. M. O'Malley, N. A. Hessol, L. S. Doll, L. Cannon, G. W. Rutherford, *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A. Transmission verticale Vertical Transmission W.A.P.47 Maternal Factors and Neonatal Characteristics Associated with HIV Infection in Infants of Seropositive Women. Prasanna Nair*, J. Johnson, S. Hines, L. Alger, S. Seiden, *University of Maryland School of Medicine, Baltimore, MD, U.S.A. W.A.P.48 Risk Factors (RF) in Symptomatic HIV Seropositive (SP) Children in the San Juan City Hospital (SJCH), Puerto Rico. Eleanor Jimenez*, M. T. Carrer, L. A. Lopez, I. Perez, C. N. Reyes, *San Juan City Hospital, Rio Piedras, Puerto Rico W.A.P.49 Prospective Study of the Vertical Transmission of HIV. Jack Lev*, S. Sprecher, J. Duchateau, N. Clumeck, Subhash K. Hira*, G. Bhat, J. Kamanga, C. Mwale, N. Luo, P. Perine, et al., *University Teaching Hospital, Lusaka, Zambia. W.A.P.51 Perinatally Acquired HIV Infection and the Risk of Vertical Transmission in Rio de Janeiro, Brazil. Dario J. H. P. Signorini*, N. P. M. Rubini, R. Rocco, W. A. Eyer-Silva, F. S. Sion, C. A. Morais de Sd, *Gaffrde and Guinle University Hospital/University of Rio de Janeiro, Rio de Janeiro, Brazil. W.A.P.52 HIV-Isolations in Pregnant Women and Their Offspring. Anneka C.Ehrnst*, S. Lindgren, A. B. Bohlin, A. Sonnerborg, et al., *Central Laboratory, Stockholm, Sweden. Progression de I'infection vers la maladle Progression from Infection to Disease W.A.P.53 Follow-up of HIV-Infected Homosexuals with Lymphadenopathy Syndrome (LAS). Thomas Harrer*, K. Messing, E. Meyer, U. J. R. Kalden, *Medizinische Klinik III Universitdt Erlangen-Niirnberg Erlangen, Federal Republic of Germany. W.A.P.54 Risk of AIDS in Patients Presenting with Herpes Zoster, PGL or \"Other\" Features of J. Kamanga, R. Hospital, Lusaka, Zambia. 440 [Page 441](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/441) W.A.P.55 Incidence of AIDS in Spanish HIV Infected Patients. Josd M. Gatell*, D. Podzamczer, B. Clotet, I. Ocafia, C. Estany, J. M. Miro, et al., *Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain. W.A.P.56 Natural History of HIV Infection in Women of Child-Rearing Age in Uganda. E. Mworozi*, S. Kiguli, *Makerere University, Kampala, Uganda. W.A.P.57 Deflection of an AIDS Progression Curve in a Gay Cohort. Martin T. Schecter*, K. J. P. Craib, T. N. Le, B. Willoughby, J. S. G. Montaner, *Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada. W.A.P.58 Progression to AIDS in Cohorts of Seroprevalent and Seroincident Gay Men: Results at 6 Years. Kevin J. P. Craib*, M. T. Schechter, W. A. McLeod, M. S. Weaver, B. Willoughby, B. Douglas, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Canada. W.A.P.59 Progression of HIV Disease among Intravenous Drug Abusers (IVDA): A Three-Year Prospective Study. L. Pellegrin, A. Schmitt, Groupe d'4piddmiologie clinique du on Aquitaine Universitd Bordeaux 2, Ddpartment d'Informatique mddicale, Bordeaux, France. W.A.P.61 Risk Estimates of AIDS in Hemophiliacs. Joyce F. Killinger*, P. S. Rosenberg, J. J. Goedert, L. M. Aledort, C. M. Kessler, M. H. Gail, et al., *Research Triangle Institute, Research Triangle Park, NC, U.S.A. W.A.P.62 Enhancement Prediction of AIDS in HIV Seropositive Asymptomatic Men: Relative Value of 8 Cellular and Serologic Markers Singly and in Combination. J. L. Fahey*, J. M. G. Taylor, R. Detels, B. Hofmann, R. Melmed, P. Nishanian, et al., *University of California at Los Angeles, Schools of Medicine and Public Health, Los Angeles, CA, U.S.A. W.A.P.63 Follow-up of a Cohort of Ex-IVDAs Resident in Therapeutical Communities in Italy. Giuseppe Marasca*, C. *Istituto Superiore di Sanitd, Rome, Italy. W.A.P.64 AIDS Yearly Incidence in 1984 HIV Seroprevalent Cohort: No Definite Trend 1985-1988. Barbara R. Visscher*, L. Jacobson, R. Detels, J. Dudley, P. English, J. Chmiel, et al., *University of California at Los Angeles School of Public Health, Los Angeles, CA, U.S.A. W.A.P.65 Natural History of HIV-1 Infection Following Pregnancy. Pratibha Datta*, J. E. Embree, M. Braddick, J. Kreiss, J. Ndinya-Achola, F. A. Plummer, *University of Nairobi, Nairobi, Kenya. 441 [Page 442](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/442) W.A.P.66 The Prognosis of Asymptomatic HIV Infection: The United States Army Three-Year Experience. Robert R. Redfield*, J. Brundage, C. Oster, E. Tramont, D. Burke, U.S. Army Retroviral Research Group, *Walter Reed Army Institute of Research, Department of Retroviral Research, Rockville, MD, U.S.A. W.A.P.67 Estimation of Maturity of HIV-1 Infection in Subgroups of Seroprevalent Cohort of Homosexual Men. Alvaro Munoz*, V. Carey, A. Saah, J. Chmiel, R. Detels, L. Kingsley, et al., *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A. W.A.P.68 AIDS-Free Time After HIV-1 Seroconversion in Homosexual Men According to Demographic Subgroups. Alvaro Munoz*, S. Bass, A. Saah, J. Chmiel, J. Taylor, L. Kingsley, *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A. W.A.P.69 Statistical Models for Assessing Feedback: An Analysis of Immune Function and Social Behaviors in the Multicenter AIDS Cohort Study. Scott L. Zeger*, K. Y. Liang, L. Park, R. Fox, L. Kingsley, J. Chmiel, et al., *Johns Hopkins School of Public Health, Baltimore, MD, U.S.A. W.A.P.70 Survival and Time of Progression to AIDS among Patients at Gaffr6e and Guinle University Hospital, Rio de Janeiro, Brazil. Fernando S. Sion*, W. Eyer-Silva, M. C. Rachid de Lacerda, C. A. Morais de Sd, E. A. Castilho, M. D. C. Guimaraes, *Gaffrde and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. W.A.P.71 Natural History of HIV Infection in a Cohort of Intravenous Drug Users (IVDUs): A Five-Year Prospective Study. Roberto Muga Bustamante*, J. Spain. W.A.P.72 Problem-Oriented Data Collection for Natural History Studies of HIV-Infected Patients. Frank W. Stitt*, G. Dickinson, N. G. Klimas, G. Laperriere, *University of Miami, School of Medicine, Miami, FL, U.SA. W.A.P.73 Progression of HIV-1 Disease in a Population of Seropositive Navy and Marine Corps Personnel. Douglas L. Mayers*, D. B. Wilson, K. F. Wagner, *Infectious Diseases Division, National Naval Medical Center, Bethesda, MD, U.S.A. W.A.P.74 Prospective Multicenter Cohort Study in Homosexual Men in the FRG. A 4-Year Follow-up: Epidemiological Results. Bernhard Schwartlander, AIDS Center, Federal Health Office, Berlin, Federal Republic of Germany. W.A.P.75 Natural History of HIV Infection among IV Drug Abusers in Basque Country. J. Arrizabalaga*, J. A. Iribarren, C. G. des personnes atteintes du SIDA the AIDS Patient W.A.P.76 Degree of HIV-Related CNS Involvement and Long-Term Survival: Preliminary Results. Frank T. Kennv*, D. K. MacFadden, *Toronto Western Hospital, Toronto, ON, Canada. W.A.P.77 Immunologic and Determinants of CD4+ and CD8+ Lymphocytes. Fiala Milan*, L. A. Cone, L. Schwartz, V. Kermani, W. W. Tourtellotte, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A. W.A.P.78 Predictors of Survival for AIDS in Barcelona (Spain). Juan Batalla*, J. M. Gatell, J. A. Cayld, J. M. Jansd, A. Plasencia, N. Parellada, *Institut Municipal de la Salut, Barcelona, Spain. W.A.P.79 Predicting In-Hospital Mortality for AIDS Patients: A Validated Model. Steven A. Grover*, N. Gilmore, J. Falutz, C. Tsoukas, L. Coupal, R. Fakhry, *Montreal General Hospital, Division of Clinical Epidemiology, Montreal, QC, Canada. W.A.P.80 Effect of Multiple Disease Manifestations on Length of Survival for AIDS Patients in San Francisco. Susan F. Pavne*, G. F. Lemp, G. W. Rutherford, D. P. Neal, T. Temelso, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.A.P.81 Improved Survival of AIDS Patients in Dallas, Texas After 1986. Charles E. Hale*, V. Reff, A. Freeman, I. Haslund, M. Bierman, *Dallas County Health Department, Dallas, TX, U.S.A. W.A.P.82 Increased Survival for PWA. William E. Lafferty*, D. Glidden, S. Hopkins, J. Harwell, J. Honey, M. Fields, *Washington State Office on HIV/AIDS, Epidemiology Section, Seattle, WA, U.S.A. W.A.P.83 Surveillance-based Survival Analysis of Quebec AIDS Patients. Denis Roy*, R. W. H. Palmer, R. S. Remis, *Bureau through Partner Notification W.A.P.84 Syphilis Contact Tracing in a New York City STD Clinic: Implications for HIV Partner Notification. Suzanne Laussucq*, M. A. Chiasson, W. E. Ewing, S. Schultz, R. L. Stoneburner, *New York City Department Health, AIDS Research Unit, New York, NY, U.S.A. W.A.P.85 Sexually Transmitted Disease (STD) Clinic Client Opinions on HIV Partner Notification. Catherine Raevsky*, N. Spencer, F. Wolf, C. Simms, *Colorado Department of Health, STD/AIDS Section, Denver, CO, U.S.A. W.A.P.86 Study of Sexual Contacts of the HIV Seropositive Persons. Enrique Galbdn*, J. Mendndez, R. Gil, H. Terry, *Ministerio de Salud Piblica, Havana, Cuba. W.A.P.87 Epidemiologic Benefits of Health Department Notification of HIV Exposure. Randolph F. Wykoff*, J. L. Jones, S. L. Longshore, S. L. Hollis, C. B. Quiller, W. B. Gamble, *South Carolina Department of Health and Environmental Control, Greenwood, SC, U.S.A. 443 [Page 444](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/444) Prevention de la transmission par contact sexuel et par consommation de drogues Preventing Transmission by Sexual Contact and Drug Use W.A.P.88 Ineffectiveness of Education in Intravenous Drug Users to Prevent HIV Sexual Transmission. Jean-Francois Delfraissv*, A. Levy, A. Abelhauser, D. Penso, France. W.A.P.89 Risk Behaviours of IV Cocaine Users: Implications for Intervention. Dale D. Chitwood*, C. B. McCoy, M. Comerford, E. J. Trapido, *University of Miami Medical School, Miami, FL, U.S.A. W.A.P.90 Trends of Risk Reduction among Initiates into Intravenous Drug Use 1982-1987. David Vlahov*, J. C. Anthony, D. D. Celentano, L. Solomon, N. Choudhury, W. Mandell, *Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. W.A.P.91 Self-Efficacy and Community Norms Predict AIDS Risk Reduction among Gay and Bisexual Men in San Francisco: The AIDS Behavioural Research Project. Leon McKusick*, T. J. Coates, S. Morin, *University of California at San Francisco, Department of Medicine, Division of Internal Medicine, San Francisco, CA, U.S.A. W.A.P.92 Sexual Behaviours and Characteristics of 627 Gay and Bisexual Male Participants of the Talking Sex Project: Small Group Educational Interventions for the Prevention of AIDS. Fred G. Tudiver*, T. Myers, R. Kurtz, E. Jackson, K. Orr, C. Rowe, *Sunnybrook Medical Centre, Toronto, ON, Canada. W.A.P.93 Preliminary Analysis of Factors Associated with Compliance and Guidelines for Prevention of Sexual Transmission of HIV in Heterosexual Couples. Margaret Nichols*, P. Paroski, G. Sampson, J. Leibel, M. J. Kennedy, *Woodhull Medical and Mental Health Center, Department ofAmbulatory Care, Brooklyn, NY, U.S.A. W.A.P.94 Ongoing Impact Evaluation of the Condom Use Promotion/Desensitization Program for Preventing AIDS in the Dominican Republic. Ernesto Guerrero*, E. De Moya, S. Rosario, PROCETS, *Ministry of Public Health, Santo Domingo, Dominican Republic. W.A.P.95 An Evaluation of the Effects of Various Lubricants on Latex Condoms. Bradley L. Pugh*, M. D. Englert, *Ansell Incorporated, Dothan, AL, U.SA. W.A.P.96 Evaluation of Condom Utilization and Acceptability of Spermicides among Prostitutes in Kinshasa, Zaire. Nzilambi Nzila*, M. Laga, Kivuvu, R. Ryder, *Projet SIDA, Kinshasa, Zaire. W.A.P.97 AIDS and Condom Use in the Netherlands. Ernest De Vroome*, T. G. M. Sandfort, M. Paalman, R. A. P. Tielman, *University of Utrecht, Department of Studies on Homosexuality, Utrecht, Netherlands. 444 [Page 445](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/445) W.A.P.98 The Supply of, and Demand for, Condoms to Prevent HIV Transmission in Developing Countries. Lenni W. Kangas*, J. R. Harris, J. D. Shelton, *Office of Health, Agencyfor International Development, Washington, DC, U.S.A. W.A.P.99 Persistent Condom Breakage. Bruce Voeller, Mariposa Foundation, Topanga, CA, U.S.A. W.A.P.100 Increasing Condom Accessibility: What Are the France. W.A.P.101 A Simulated Physiologic Test of Latex Condoms. Bruce A. Herman*, W. A. Herman, S. M. Retta, J. E. Rinaldi, R. F. Carey, T. W. Athey, *U.S. Food and Drug Administration, Rockville, MD, U.S.A. W.A.P.102 Inactivation of HIV-1 in Vaginal and Seminal Secretions by the Spermicide Benzalkonium Chloride. Mark *McGill University, Montreal, QC, Canada. W.A.P.103 The Relationship between Condom Use and Sex Behavior. Jon Martin Sundet*, I. K. Kvalem, P. Magnus, J. K. Grnnesby, H. Stigum, L. S. Bakketeig, *National Institute of Public Health, Oslo, Norway. W.A.P.104 Needle-Sharing and Bleach Use among Intravenous Drug Users (IVDUs) Seeking to Enter an Acute Detoxification Program. Sharon G. Hopkins*, M. Carlisle, J. Honey, N. Harris, J. McGough, *Seattle-King County Department of Public Health, Seattle, WA, U.S.A. W.A.P.105 Outcomes of an AIDS Prevention Program for Methadone Maintenance Patients. Stephen Magura*, Q. Siddiqi, J. L. Shapiro, J. I. Grossman, D. S. Lipton, *Narcotic and Drug Research, Inc., New York, NY, U.S.A. W.A.P.106 Anthropological and Epidemiological Observations of Changes in Needle Use and Needle Sharing Practices Following Twelve Months of Bleach Distribution. Margaret M. Connors*, B. F. Lewis, *Spectrum House, Inc., Westboro, MA, U.SA. W.A.P.107 Evidence for Risk Reduction among IVDU in Amsterdam. Anneke van den Hoek*, H. J. A. Van Haastrecht, R. A. Coutinho, *Amsterdam Municipal Health Service, Amsterdam, Netherlands. W.A.P.108 Changes in HIV Risk Behaviour in Drug Injectors Attending Syringe-Exchange Projects in England and Scotland. Gerry V. Stimson*, M. C. Donoghoe, K. Dolan, *Monitoring Research Group, Goldsmiths' College, London, U.K. W.A.P.109 Drug Treatment Centers as the Nucleus for a Prevention-based Case Management System for Intravenous Drug Users. Jessica Gardom*, T. S. Jones, C. H. Hayden, H. A. Stern, P. O. Poppe, G. S. Bowen, *Centers for Disease Control, Atlanta, GA, U.S.A. 445 [Page 446](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/446) Pr6vention: politiques et 6valuation des programmes Prevention: Policy Issues, Program Evaluation W.A.P.110 CARA: A Tool for AIDS Prevention. Wilfried Belschner, University of Oldenburg, Department ofPsychology and Health, Oldenburg, Federal Republic of Germany. W.A.P.111 Short and Long Term Results of an AIDS Prevention Program. Timothy E. Miller*, C. D. Booraem, J. V. Flowers, A. E. Iversen, *AIDS Response Program, Garden Grove, CA, U.S.A. W.A.P.112 Training the Health Care Professional: The AIDS Regional Education and Training Centers Program of the Health Resources and Service Administration (HRSA). Phyllis B. Heffron*, M. J. Horner, A. Macher, D. Moore, B. Martell, *U.S. Public Health Service, Rockville, MD, U.SA. W.A.P.113 Outcome of HIV Prevention and Counseling at Cook County Hospital, Chicago: A Two-Year Follow-up. Renslow Holder, *Cook County Hospital, Chicago, IL, U.S.A. W.A.P.114 Applications of Methods and Results from Family Planning Operations Research to AIDS Prevention in Africa. Maria J. Wawer, Center for Population and Family Health, Columbia University, New York, NY, U.SA. W.A.P.115 Determinants of AIDS Policy Preference of the General Public. David G. Ostrow*, M. Traugott, *University of Michigan Institute for Social Research, Ann Arbor, MI, U.S.A. W.A.P.116 Sexual Behaviour of Young Adults and the Effects of AIDS-Prevention Campaigns in Switzerland. Francoise H. Dubois-Arber*, P. prdventive, Lausanne, Switzerland. W.A.P.117 Effectiveness of the Swiss AIDS Prevention Campaigns in 1988. Dominique Hausser*, F. sociale et preventive, Lausanne, Switzerland. W.A.P.118 More than One Type of Education and Testing Program Is Necessary to Reach Selected Target Population in Large Numbers. Neil Flvnn*, A. Sweha, S. Jain, N. Nassar, D. Webb, G. Acuna, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A. W.A.P.119 How Can Seroprevalence Survey Data Be Used to Manage HIV Prevention Programs? Ida M. Onorato*, T. S. Jones, W. R. Forrester, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. W.A.P.120 A Program to Encourage AIDS Prevention Counselling by Primary Care Physicians. Jav Wortman*, M. Rekart, M. Gelfer, *College of Family Physicians of Canada, B.C. Chapter, Vancouver, BC, Canada. 446 [Page 447](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/447) Notes [Page 448](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/448) Section Mercredi 7 juin SWednesday, 7 Clinical Aspects of AIDS Aspects cliniques Session d'affichage Poster Session Cryptococcose Cryptococcus Infection W.B.P.1 Fluconazole Therapy of Patients with AIDS and Cryptococcal Meningitis and Failed Conventional Antifungal Therapy. Robert H.Rubin*, P. A. Robinson, A. K. Knirsch, J. A. Joseph, *Massachusetts General Hospital, Boston, MA, U.S.A. W.B.P.2 Itraconazole in the Treatment of Cryptococcal Meningitis in Patients with AIDS. Jan De ans*, P. Portegies, G. Tiessens, J. K. Medisch Centrum, Neurology, Amsterdam, Netherlands. W.B.P.3 Pulmonary Involvement in Cryptococcosis in Patients with AIDS. Miriam L. Cameron*, J. Bartlett, H. Waskin, H. of Cryptococcal Meningitis. Veeraf Sanjana*, M. Davidson, M. Mullen, D. Boyle, M. Raviglione, H. Cortes, *Cabrini Medical Center, New York, NY, U.SA. W.B.P.6 Serum Cryptococcal Antigen Screening in the Early Diagnosis of Cryptococcal Infection in Patients with HIV Infection. Joseph R. Masci*, G. Pierone, P. Nicholas, *Mount Sinai Services, Elmhurst Hospital Center, Elmhurst, IL, U.SA. W.B.P.7 Response of Cryptococcal Meningitis to Anti-Fungal Therapy in Patients with AIDS. Kenrad E. Nelson*, G. K. Thager, W. Merz, J. G. Bartlett, *Department of Epidemiology, Johns Hopkins University, Baltimore, MD, U.S.A. W.B.P.8 Spectrum of Cryptococcus Neoformans Infection in 68 HIV-Infected Patients. Rebecca A. Clark*, D. Greer, W. Atkinson, G. Valainis, H. Hyslop, *Tulane/Louisiana State University ACTU, New Orleans, Cryptococcal Meningitis (CM). Samuel A. Bozzette*, R. Larsen, J. Chiu, M. Leal, K. Large, J. A. McCutchan, et al., * University of California at San Diego, San Diego Medical Center, San Diego, CA, U.SA. 448 [Page (C) in AIDS with Oral Itraconazole. David W. Denning*, R. M. Tucker, J. R. Hamilton, L. H. Hanson, D. A. Stevens, *Santa Clara Valley Medical Center and Stanford University, San Jos6, CA, U.S.A. W.B.P.11 Persistent Cryptococcus Neoformans Prostatic Infection After Successful Treatment of Meningitis. Robert A. Larsen*, S. Bozzette, J. A. McCutchan, J. Chiu, M. A. Leal, D. D. Richman, *Los Angeles County, University of Southern California, Medical Center, Los Angeles, CA, U.S.A. W.B.P.12 Efficacit6 du fluconazole Burundi. Cryptococcal and HIV Infection in North Carolina. Hett Anne Waskin*, J. A. Bartlett, H. A. Gallis, *Duke University Medical Center, Durham, NC, U.S.A. W.B.P.16 Cryptococcal Meningitis in Patients with AIDS. Diagnostic Features and Outcome in 8 Cases. Giuseppe Ippolito*, G. Antonucci, O. R. Grillo, *Lazzaro Spallanzani Hospital for Infectious Diseases, Rome, Italy. W.B.P.17 The Limited Value of Routine Serum Antigen Screening for Cryptococcal Infection. Mark R. Nelson*, D. E. Smith, D. Hawkins, D. Shanson, C. Reed, B. G. Gazzard, *St. Stephen's Hospital, London, UK. W.B.P.18 Cryptococcus Neoformans Pulmonary Infection in 17 HIV-Infected Patients. Rebecca A. Clark*, D. Greer, G. Valainis, N. Hyslop, *Tulane/Louisiana State University ACTU, New Orleans, LA, U.S.A. W.B.P.19 Cryptococcosis in AIDS Patients: Clinical and Therapeutic Aspects. Thomas Weinke*, G. Rogler, C. Ortmann, H. D. Pohle, *Universitdtsklinikum Berlin, Republic of Germany. W.B.P.20 Cryptococcal Meningitis in AIDS Patients: Incidence in Sul (Brasil). Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio de Clinicas de Porto Alegre, Porto Alegre, Brazil. W.B.P.21 Therapeutic Study in 35 Patients with AIDS and Cryptococcal Meningitis. R. Del Bianco*, R. Scapini, P. S. S. Leme, M. Mendonga, *Centro de Referencia 449 [Page 450](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/450) W.B.P.22 Maintenance Therapy with Cryptococcal Meningitis. Bonaventura Clotet*, R. Villegas, G. Sirera, Jou, J. M. Gimeno, et al., *Infectious Diseases Unit, Hospital de Badalona, Barcelona, Spain. Infections D. Matthiessen, *H6pital Bichat Claude Bernard, Bretigny/Orge, France. W.B.P.24 Long-term Survival of AIDS Patients Successfully Treated for Toxoplasmic Encephalitis. Diana Antoniskis*, J. M. Nussbaum, B. R. Dannemann, J. A. McCutchan, J. Chiu, J. M. Leedom, et al., *Los Angeles County, University of Southern California, Pasadena, CA, U.SA. W.B.P.25 Toxoplasma Gondii Pneumonia (TGP) C. Marche, C. Vedrenne, *H6pital Bichat Claude Bernard, Paris, France. W.B.P.27 Cerebral Toxoplasmosis in Danish AIDS Patients. Else Smith*, C. Pers, L. Matthiesen, *Hvidovre Hospital, Department of Infectious c6rebrale et SIDA en Espagne. Inmaculada Ocania*, A. De Luis, I. Ruiz, A. Castro, J. Romero, J. M. Martinez, *Autonomous University of Barcelona, Barcelona, Spain. W.B.P.29 Failure of High Doses of Roxithromycin (R) in AIDS Patients with Central Nervous System Toxoplasmosis (CNST). Jean M. Decazes*, T. France. W.B.P.30 Vesical Toxoplasmosis: A New Sign of Parasitic Dissemination in AIDS. Gregoire No,l*, R. Morriset, M. Gregoire, L. Lamarre, S. Lapointe, *Universitd de Montreal and H6tel-Dieu de Montreal, Montreal, QC, Canada. W.B.P.31 Therapeutic of Toxoplasmic Encephalitis in AIDS Patients. Joao S. Mendonca*, I. M. F. Lobo, H. N. Stefani, M. L. N. Biancalana, G. A. Rodrigues, G. C. Levi, *Hospital do Servidor Ptlblico Estadual de Sao Paulo, Sao Paulo, Brazil. W.B.P.32 In Vitro Secretion of Toxoplasma Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. Jacques Reynes*, J.-P. (FANSIDAR) in the Prevention of CNS-Toxoplasmosis in AIDS Patients. Thomas Balzer*, A. Rolfs, G. Hoffken, K. M. Deppermann, Berlin, Klinikum W.B.P.34 Treatment of CNS Toxoplasmosis in AIDS Patients: Prospective Studies Using Pyrimethamine and Macrolide Antibiotics. Bernhard Ruf*, H. D. Pohle, J. R. Iglesias, *Second Department of Internal Medicine, Rudolf Virchow University Hospital, Berlin, Federal Republic of Germany. W.B.P.35 Localisations la W.B.P.36 Ad6novirus clinique? Dominique Paris, W.B.P.37 Blastocystis Hominis Infection in AIDS Patients. Kenneth V.I.Rolston*, S. J. Rodriguez, *The University of Texas, M. D. Anderson Cancer Center, Houston, TX, U.S.A. W.B.P.38 Variable Localization of Intestinal Cryptosporidiosis in AIDS. Todd D. Heller*, A. R. Tierney, D. P. Kotler, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. W.B.P.39 Colonoscopic Etiological Diagnosis of Diarrhea in AIDS. Dirce Lima*, E. Jurado da Silva, S. Treistman, R. H. Passos, *Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. W.B.P.40 Incidence of Infectious Gastroenteritis in Spanish AIDS Patients. Joseg Mallolas*,A. Moreno, J. M. Miro, J. M. Gatell, X. Latorre, E. Soriano, *University of Barcelona, Infectious Diseases Unit, Hospital Clinic, Barcelona, Spain. W.B.P.41 Gastrointestinal Multiinfection in AIDS Patient: A Case Report. Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio Grande de Porto Alegre, Porto Alegre, Brazil. W.B.P.42 Rotavirus in Adult AIDS Patients. Jihad Slim*, P. DeLuca, G. Perez, J. Shah, A. DeLuca, *Saint Michael's Medical Center, Newark, NJ, U.S.A. longue J. de Montreal, Montreal, Qc, an AIDS Patient. Alain Pesce*, H. Vinti, B. Taillan, M. C. Saint-Paul, P. Y. Le Fichoux, et al., *Service de midecine interne II, H6pital de Nice, France. Successful Use of Hyperimmune Bovine Colostrum to Treat Cryptosporidium Infection in an AIDS Patient. Beth L. P. Ungar*, D. Ward, R. Fayer, C. Quinn, *Uniformed Services University of the Health Sciences, Bethesda, MD, U.SA. 451 [Page 452](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/452) W.B.P.46 Microscopy (L/M) in the Diagnosis of Cryptosporidial and Blastocystis Infection. M. Connolly*, G. Tovey, B. G. Gazzard, *St. Stephen's Hospital, London, U.K. W.B.P.47 Treatment of Cryptosporidial Infection with Recombinant Interleukin-2 (rIL-2). Gerard M. Connolly*, S. L. Owen, D. A. Hawkins, B. G. Gazzard, *St. Stephen's Hospital, London, U.K. W.B.P.48 Gastrointestinal Cryptosporidiosis in Grande do Sul State: The Highest Incidence. Eduardo Sprinz*, M. Kronfeld, K. M. N. Brockmeyer, R. Schwendemann, *Aachen University Clinic, Aachen, W.B.P.51 Syphilitic Myelopathy with Human Immunodeficiency Virus: A Treatable Cause of Spinal Cord Disease. Joseph R. Berger*, G. Hensley, L. Moskowitz, *University of Miami, School of Medicine, Department of Neurology, Miami, FL, U.S.A. W.B.P.52 History of and Conventional Tests for Syphilis in HIV-1 Seropositive Homosexual Men in the Baltimore MACS. Karla Alwood*, R. Fox, E. Hook, J. H. McArthur, D. Starkey, A. Saah, *Johns Hopkins School ofHygiene and Public Health, Baltimore, MD, U.S.A. W.B.P.53 An Association of Syphilis Episodes and Human Immunodeficiency Virus (HIV) Infection in Sexually Transmitted Disease (STD) Patients in Los Angeles County. Thanne P. Rose*, W. Ford, P. Kerndt, E. Mohilef, I. Onorato, *Los Angeles Department of Health Services, Los Angeles, CA, U.S.A. W.B.P.54 \"Seroreversion\" of Treponemal Tests during HIV Infection. Jennifer S. Haas*, G. Bolan, S. A. Larsen, M. J. Clement, A. R. Moss, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. W.B.P.55 Meningovascular Syphilis in AIDS. Thierrv Saint-Marc*, J. Syphilis in HIV Asymptomatic Seropositives. Joseph R. Berger*, M. McCarthy, M. A. Fletcher, N. Klimas, L. Pall, E. Lo, *University of Miami, School of Medicine, Department of Neurology, Miami, FL, U.S.A. 452 [Page 453](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/453) W.B.P.57 Syphilis Treatment Response in HIV Infected Persons. Michele S. Zweig*, E. E. Telzak, J. Harrison, R. L. Stoneburner, S. Schultz, *New York City Department ofHealth, New York, NY, U.SA. W.B.P.58 Retreatment of Syphilis in HIV Positive Patients. Phillip E. Hay*, J. R. W. Harris, D. Goldmeier, *St. Mary's Hospital Medical School, The Praed Street Clinic, London, U.K. W.B.P.59 Failure of Benzathine Penicillin to Eradicate Syphilis in HIV Positive Patients. Phillip E. Hay*, V. Kitchen, J. R. W. Harris, D. Goldmeier, *St. Mary's Hospital Medical School, alternatifs, soins traditionnels Alternative Traditional Care Primary Medical Care for Intravenous Drug Users (IVDU) in a Methadone Maintenance Treatment Program (MMTP). Peter A. Selwvn*, A. R. Feingold, A. lezza, M. Satyadeo, J. F. Shaw, R. Torres, *Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.SA. W.B.P.61 Report on a Statewide Survey to Determine Levels of Outpatient Clinic/Ambulatory Care Services for Persons with HIV Infection. Christine M. Grant*, S. R. Young, *New Jersey State Department of Health, Trenton, NJ, U.S.A. W.B.P.62 A Collaborative Approach to Primary Outpatient-oriented Care of Patients with HIV Infection. Peter C. Jensen*, K. Bartlett, D. Hadley, *University of California at San Francisco, VA Medical Center, San Francisco, CA, U.S.A. W.B.P.63 Comprehensive HIV Case Management Protocols for 26 Northern California Counties. Patty S. Blomberg*, N. Flynn, *Sacramento AIDS Foundation, University of California at Davis Medical School, Sacramento, CA, U.S.A. W.B.P.64 Visiting Physician Service for AIDS Patients in Nassau County. Bruce D. Agins*, G. Feleke, S. Forlenza, *Nassau County Medical Center, East Meadow, NY, U.SA. W.B.P.65 Home Transfusion: A Safe, Effective Alternative to Traditional Care. Rende L. Peugeot, Atlanta Home Care, Atlanta, GA, U.S.A. W.B.P.66 At-Home Care of Terminal AIDS Patients. C. Garde*, C. Arrizabalaga, de San Sebastian, Spain. W.B.P.67 A Survey of Complementary AIDS/HIV Therapies and Services. David G. Ostrow*, M. Heirich, A. Shefner, *University of Michigan, Institute for Social Research, Ann Arbor, MI, U.S.A. W.B.P.68 Effect of Cardiovascular Conditioning in HIV Infection. Craig W. Keyes*, P. Rodgers, J. Wolbert, C. Marte, J. Kelly, D. Ribble, *Bellevue Hospital Center, Community Health Project, New York, NY, U.SA. 453 [Page 454](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/454) Diagnostic: Marqueurs et progression de I'infection par le VIH Diagnosis: Markers of HIV Infection and Progression W.B.P.69 Clinical Value of a tac-Inhibitory Activity Produced Spontaneously by Adherent Cells of HIV-Infected Subjects. Vassilis Georgoulias*, A. Ammar, C. Antigen and Decline of T4 Cell Counts as Predictive Markers in AIDS. M. Elaine Eyster*, J. Goedert, *Pennsylvania State University, College of Medicine, Milton S. Hershey Medical Center, Hershey, PA, U.S.A. W.B.P.71 Chicago/Boston Cohorts Study: dp24/gp41 Antibody Response at HIV Seroconversion. Bernard B. Blaauw*, L. Falk, R. Allen, K. Mayer, G. Dawson, S. Saltzman, et al., *Rush Presbyterian-St. Luke'sHospital, Chicago, IL, U.S A. W.B.P.72 Predictive Value of CD4+ Numbers, Levels of Neopterin and Beta-2 Microglobulin and Risk of Developing Pneumocystis Brihwiler, ofMedicine, University Hospital, Zurich, Switzerland. W.B.P.73 Human Immunodeficiency Virus (HIV) IgA Serum Antibodies in a Longitudinal Study of HIV Infection and Subsequent Progression of the Disease in Homosexual Men. Miriam Margalith*, B. Sarov, I. Sarov, C. Rinaldo, A. Saah, E. Levy, et al., *Virology Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. W.B.P.74 T-Cell Subset, B2 Microglobulin, and Neopterin Levels in Edinburgh Haemophiliacs. Christopher A. Ludlam*, C. M. Steel, R. F. G. Cuthbert, D. Beatson, *Department of Haematology, Royal Infirmary of Edinburgh, Production, Correlation with Circulating IFN-alpha Antigenemia P24 and Serological Profile in HIV-1 Infected Patients at Different Clinical Stages. Annick Ruffault*, N. Genetet, C. Pontchaillou, Rennes, France. W.B.P.76 Comparison of Activation Markers for Progression to AIDS. Matthew J. Di Franco*, C. Berger, A. Friedman-Kien, R. Edelson, M. McLane, R. Marlink, *Harvard School of Public Health, Boston, MA, U.S.A. W.B.P.77 Forecasting Individual Rates of Progression from ARC to AIDS Using Routine Clinical Laboratory Tests. Robert M. Schmidt*, V. I. Kvitash, *San Francisco University, Centerfor Preventive Medicine and Health Research, Pacific Presbyterian Medical Center, San Francisco, CA, U.SA. W.B.P.78 Increased Beta 2-Microglobulin Concentrations in Children with AIDS. Maria Chan*, S. Josephs, J. M. Campos, A. Morales, N. Rifai, *Department of Laboratory Medicine, Children's Hospital, National Medical Center, Washington, DC, U.S.A. 454 [Page 455](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/455) W.B.P.79 Neopterin as Predictive Marker Human Immunodeficiency Virus-1 Infection. Dietmar Fuchs*, T. J. Spira, H. Wachter, of Innsbruck, Innsbruck, Austria. W.B.P.80 Persistence of Good E-CR1 Activity Relates to Non-Progression of Immune Dysfunction in HIV Positive Individuals. Michael Lange*, Y. Inada, E. Buimovici-Klein, W. Ramey, L. Z. Cooper, M. H. Grieco, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. W.B.P.81 Serum B2M in Intravenous Drug Abusers with HIV Infection. Edward H. Cooper*, M. A. Forbes, S. Sutherland, *University of Leeds, Leeds, UK. W.B.P.82 [ 1-14c] Arachidonic Monocytic U 937 and CD4+ T-Lymphocytic CEM Cell Lines in the Early Stage of HIV Infection. Fernand Dray*, C. A. Renard, D. of Beta-2-Microglobulin and Neopterin as Prognostic Markers in HIV Disease. Eric Sandstrrm*, A. Carlsson, V. Holmberg, *The Gay Men's Health Clinic, Stockholm, Sweden. W.B.P.84 Increased Proliferation of Oral Epithelial Cells in HIV-Infected Patients. Angelika Langford*, R. O. F. Pohle, P. A. Reichart, *Freie Universitdt Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany. W.B.P.85 Measurement of Beta-2-Microglobulin (Beta-2M) by Rate Immunonephelometric Assay in Blood from AIDS Patients. Hassan Khayam-Bashi*, N. Johnson, K. Chen, J. Wilber, *Clinical Laboratories, San Francisco General Hospital and Department of Laboratory Medicine, University of California at San Francisco, San Francisco, CA, U.S.A. W.B.P.86 The Classification of HIV Disease: Correlation Saravolatz, Ford Hospital, Detroit, MI, U.S.A. W.B.P.87 Quest for Prognostic Markers in HIV-Infected Haemophiliac Children. Susan J. Skidmore*, M. D. Williams, S. J. Mawson, F. G. H. Hill, *Regional Virus Laboratory, East Birmingham Hospital, Birmingham, U.K. W.B.P.88 Routine Laboratory Tests Which Correlate with HIV-1 Infection Prior to Onset of AIDS. Joyce I. Wallace*, S. Beatrice, H. S. Sacks, *Foundation for Research on Sexually Transmitted Diseases Inc., New York, NY, U.S.A. W.B.P.89 Neopterin Is a Relevant Diagnostic Marker in HIV Infection. Emil C. Reisinger*, P. Kern, S. Schwander, A. Ddrlemann, A. Plettenberg, M. Dietrich, *Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany; University of Innsbruck, Institute for Hygiene, Innsbruck, Austria. 456](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/456) W.B.P.90 The Use of Serum Oligoclonal Immunoglobulins to Monitor the Course of HIV Infection. Nicholas Papadopoulos*, R. Costello, *National Institutes ofHealth, Bethesda, MD, U.S.A. W.B.P.91 CSF Neopterin in HIV-1 Infection and as a Function of AIDS Dementia Complex (ADC) Severity. Bruce J. Brew*, R. Bhalla, M. Schwartz, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.92 Predictive Value of Neopterin, B-2-Microglobulin and Thymidinkinase in HIV Infection. Frank D. Goebel*, A. Matuschke, B. Heinrich, H. S. Fiiessl, J. R. Bogner, *Medizimische Poliklinik, Universitit Le VIH Diagnosis: HIV W.B.P.93 Efficient Screening for HIV-1 and HIV-2 Antibodies with a 3rd Generation Assay. Udo Krupka*, S. Brust, T. Julien, *Behringwerke AG, Marburg, Federal Republic of Germany. W.B.P.94 The Use of the N-Terminal Portion of the Transmembrane Proteins for the Early Detection and Discrimination of HIV-1 and HIV-2 Infection. RolfVornhagen*. W. Hinderer, M. Motz, E. Soutschek-Bauer, H. H.-H. Sonneborn, et al., *BIOTEST AG, Research Department, Offenbach, Federal Republic of Germany. W.B.P.95 A Semiautomated Dot Blot Immunoassay for the Confirmation of HIV Seropositivity. Kevin M. Knigge*, B. Braun, E. Chan, A. Kapsalis, W. Schulze, J. Stephens, et al., *Abbott Laboratories, Diagnostics Division, Abbott Park, IL, U.S.A. W.B.P.96 Improvement of Anti-HIV-2 Reactivity of Vironostika Anti-HTLV-II. Erik D. P. J. A. Hellings, H. J. Theunissen, J. Ariens, R. Van Sprang, *Organon International BV, Oss, Netherlands. W.B.P.97 Development of Two Diagnostic Systems for HIV-1 Seroconversion Using Recombinant Antigens. Jesu4 V. Benitez Fuentes*, J. A. J. Garc(a, G. Padrdn, L. Herrera, et al., *Center of Genetic Engineering and Biotechnology, Havana, Cuba. W.B.P.98 Cross Reaction between HIV-1 and HIV-2 or Double Infection? Felix Mayer*, L. Schmidt, F. Gschnait, J. Hutterer, M. Dierich, F. Banekowich, et al., *Lainz Hospital, Department of Dermatology, Vienna, Austria. W.B.P.99 Evaluation of HIV-1 and HIV-2 ELISA Based on Synthetic Peptides of gp41. Christian Kunz*, F. X. Heinz, U. Parkhede, *University of Vienna, Institute of Virology, Vienna, Austria. W.B.P.100 Aptitude d'un test rapide pour HIV-1 et de anti-HIV-2 Serologic Diagnosis of HIV-1 and HIV-2 Reactivity. Guadalupe Ercilla*, J. M. Barrera, M. P. Gil, A. Baylo, J. M. Gatell, R. Castillo, *Blood Bank Hospital Clinic, Barcelona, Spain. W.B.P.102 Diagnostic Specificity of the Highly Immunoreactive Epitopes *Labsystems Research Laboratories, Evaluation of a New Combined HIV-1/HIV-2 IgG EIA-Based Roten Kreuzes, Frankfurt, Federal Germany. W.B.P.104 Reliable Differentiation between Anti-HIV-1 and Anti-HIV-2 Antibodies Using a Competitive Assay. Christian G. Mever*, D. Berzow, H. Schmitz, *Bernhard Nocht Institute for Tropical Medicine, Hamburg, Federal Republic of Germany. W.B.P.105 Line Immunoassay for the Simultaneous Detection of Antibodies to HIV-1 and HIV-2 in Human Sera. EricSaman*, D. E. Pollet, B. van der Broght, G. Vercauteren, P. Biischer, G. van der Groen, et al., *Innogenetics NV, Antwerp, Belgium. W.B.P.106 Efficacy of Abbott Recombinant HIV- 1/HIV-2 EIA for Early Detection of HIV-2 and/or HIV-1 Seroconversions. F. Ferchal*, F. A. Agbalika, P. Honderlick, V. Barateau, Y. P. Perol, *H6pital St-Louis, Paris, France. W.B.P.107 Detection of HIV-1 and HIV-2 Antibodies in African Sera by the env-9 (gp 120-HIV-1) Recombinant Protein. Martine Peeters*, G. M. Gershy-Damet, A. Sangare, M. Ranger, Denis, *Laboratoire de virologie, CHU Dupuytren, Limoges, France. W.B.P.109 Sensitivity and Discriminatory Value of Synthetic Peptide Assays for HIV-1 and 2 Infections. Joep M. A. Lange*, A. Vahlne, C. Boucher, F. Barin, U. Parkhede, J. Goudsmit, *University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands. W.B.P.110 Comparative Performance of Cyclic Versus Linear Peptides in an ELISA for HIV-1- and HIV-2- Specific Antibodies. Martial Lacroix*, R. Chalifour, M. D. Stern, G. Dionne, *IAF Inc., Laval, QC, Canada. W.B.P.111 A Peptide-Based Microtiter ELISA Kit for the Detection of Antibodies to HIV-1 and HIV-2. Martial Lacroix*, C. L. Penney, R. J. Dwyer, M. D. Stern, F. Bellini, G. Dionne, et al., *IAF BioChem International Inc., Laval, S. Wolinsky, G. Schochetman, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. 457 [Page 458](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/458) W.B.P.113 Evaluation of HIV-1 and HIV-2 Peptide ELISA in Sera from Abidjan, C6te d'Ivoire. L. Hevward*, M. Krebs, Cock, K. Odehouri, Schochetman, et al., *CentersforDisease Control, Atlanta, GA, U.SA. W.B.P.114 Evaluation of Pharmacia HIV-1 and -2 Combi a Synthetic Peptide P. O. Persson, E. Sandstrom, *Karolinska Hospital, Department of Clinical Microbiology, Stockholm, Sweden. Techniques nouvelles et am6lior6es New and Improved Techniques W.B.P.115 Detection of HIV-1 Antibodies Using Synthetic Peptides. Zulma Peixinho*, N. Mendes, H. Hernandez, I. Longo, C. Nakaie, Paiva, *Escola Paulista de Medicina, Sao Paulo, Brazil. Detection of Anti-HIV, Core and Envelope IgG, in HIV-Infected and Tropical Diseased Patients from Brazil. Arthur Timmerman*, N. Hammerschlak, *Hospital Albert Einstein, Sao Paulo, Brazil. W.B.P.117 Comparison of Cambridge Biosciences Recombigen HIV Latex Agglutination Assay with Three Commercial ELISA Assays. Mario Tamburini*, R. G. Downing, B. Biryahwaho, *World Health Organization, AIDS Control Program, Entebbe, Uganda. W.B.P.118 The Determination of Additional Serological Markers Concerning HIV Infection Using Recombinant Viral Antigens of All HIV-1 Reading Frames. Rolf Vornhagen*, M. Motz, E. Soutschek-Bauer, W. Pichler, H. Wolf,H.-H. Sonneborn, et al., Research Department, Offenbach, Federal Republic of Germany. W.B.P.119 Anti-HTLV-I TAX ELISA for Detection of Infection in Standard HTLV-I ELISA Negative Intravenous Drug Users (IVDUs). Jordan B. Glaser*, B. J. Poiesz, M. Sliwkowski, H. Simpkins, J. J. Sninsky, G. D. Ehrlich, et al., *The Staten Island Hospital, Staten Island, NY, U.SA. W.B.P.120 Clinical Evaluation of Testpack HIV-1/HIV-2 Rapid Assay for the Detection of Antibody to HIV-1 and HIV-2 Using Recombinant DNA Derived HIV-1 and HIV-2 Proteins. Rachelle A. Weiss*, X. Alcalde, J. M. Staller, A. Prozorovsky, K. M. Knigge, R. M. IL, U.SA. W.B.P.121 Testpack HIV: Rapid Assays Capable of Detecting Antibodies to HIV Present in Serum, Plasma and Whole Blood. Rachelle A. Weiss*, R. M. Pennington, K. M. Knigge, J. M. Staller, L. A. Prozorovsky, A. Martorano, *Abbott Laboratories, North Chicago, IL, U.SA. W.B.P.122 Unique Immunoreactivity of a Normal Human Serum with Recombinant HTLV-I env Gene Products. James W. Shih*, J. Genesca, T. Frenkl, R. Terry, D. Buonagurio, M. Longiaru, et al., *National Institutes of Health, Department of Transfusion Medicine, Bethesda, MD, U.SA. 458 [Page 459](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/459) W.B.P.123 Improved In Situ Detection of HIV Nucleic Acid with Fluorescent Probes and Laser Excitation. Richard M. Donovan*, L. Hart, P. F. Bradey, W. R. Peterson, E. Goldstein, *University of California at Davis, Department of Medical Microbiology, Davis, CA, U.S.A. W.B.P.124 Detection of HIV in Hematopoietic Cells from Patients with AIDS and AIDS-Related Complex (ARC). Nora C. J. Sun*, M.-Y. Hsu, A. Conrad, P. Shapshak, G. Beall, D. Imagawa, *Harbor-University of California at Los Angeles Medical Center, Torrance, CA, U.S.A. W.B.P.125 Seroconversion Followed by Recombinant and Synthetic Peptide Based Anti-HIV Analysis. Edgar Lauritzen*, C. Petersen, G. L. Laboratory, Denmark. W.B.P.126 Synthetic Peptides. Erik D. Sprengers*, J. J. Schalken, J. A. Hellings, R. Van Sprang, *Organon International BV, Oss, Netherlands. W.B.P.127 Investigation of Recombigen (TM) HIV EIA (Cambridge BioScience Corp.). Carol J. Major*, B. McLaughlin, M. V. O'Shaughnessy, *Ontario Ministry of Health, Laboratory Services Branch, Toronto, ON, Canada. W.B.P.128 Production and Characterization of Monoclonal Antibodies against HTLV-I Core Proteins. Paul H. Yoshihara*, S. Williams, M. Benelli, S. Majewski, A. S. Goldstein, D. Logan, *Epitope Inc., Beaverton, OR, U.S.A. W.B.P.129 Early Seroconversion Detected by Anti-HIV Recombinant ELISA. Agneta B. M. Forsgren, O. Strannegard, *Central Microbiological Laboratory of Stockholm County Council, Stockholm, Sweden. W.B.P.130 Detection of Anti-tax Antibody in HTLV-I Western Blots. Mark C. Connelly*, M. B. Tadler, C. A. O'Connell, *E. I. DuPont de Nemours Co., Medical Products Department, Glasgow, DE, U.S.A. W.B.P.131 Detection of HIV-1 Antibodies in Immunometric ELISA Based on Labeled Synthetic Peptide. Alexander T. Kozhich*, V. S. Ivanov, Z. K. Suvorova, *Shemyakin Institute of Bioorganic Chemistry, USSR Academy of Sciences, Moscow, U.S.S.R. W.B.P.132 Vironostika HIV Core Assay: An Anti-p24/p55 Specific Test Using Viral Antigen and Monoclonal Antibodies. John J. Schaiken*, W. Keur, A. Jacobs, P. Vodegel, J. A. Hellings, *Organon International BV, Oss, Netherlands. W.B.P.133 A Screening Assay for Antibodies for HIV-1 Using Recombinant Antigens. Ping Wu*, D. R. Keehn, D. J. Liu, J. M. Pawlowski, M. A. Roser, J. A. Staser, *Abbott Laboratories, North Chicago, IL, U.S.A. W.B.P.134 Characterization of Full-Length Recombinant HIV-1 p41 and p24 for Use in the Improved Abbott HIV-1 Enzyme Immunoassay. Kevin V. Rote*, R. Holzman, G. Robey, B. Braun, S. Knicker, J. North Chicago, IL, U.SA. 459 [Page 460](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/460) W.B.P.135 Detection of North Chicago, IL, U.S~A. W.B.P.136 Detection of 1gM and IgA Antibodies to lIlY-i after Removal of IgG by Protein G. Barbara Weiblen*, R. Schumacher, R. Hoff, *Massachusetts Department of Public Health, Jamaica Plain, MA, U.SA. W.B.P.137 Structural Characterization of Recombinant HIV-1 Proteins p24 and p41 by HPLC Protease V8 Mapping and Rote, S. Dorwin, Robey, *FAbbott North Chicago, IL, U.S~A. W.B.P.138 A Filter Immunoplaque Assay for the Detection and Enumeration of Human HIV-1 Cells. Jean-Pierre Vendrell*, HIV p2~4 Antibody. &riati ~LIM.RQe.\",R. Thys, R. Fico, L. *Abbott North Chicago, IL, Recombinant Center for Immunology, Sydney, Australia. W.B.P.141 HIV-1 Seropositive Individuals Recognize Different Epitopes of p17: Potential for Staging Disease Progression. PalH ~vo\" A. L. Goldstein, G. Sinnadorai, P. H. Sarin, S. S. Wang, *The George Washington University, Washington, DC, U.S~A. W.B.P.142 Detection of HIV-1 Antibodies in Urines of Asymptomatic and ARC/AIDS Patients. Tob.LEfie.d*, A. G. Govindarajan, J. Kung, A. Friedman-Kien, Y. Cao, H. Urnovitz, et al., *Calypte Biomedical Company, Berkeley, CA, U.S~A. W.B.P.143 Simple, Easy to Use HIV-1 Recombinant Antigen Based Blood Antibody Test. floward B. Urnovitz*, I. Mitra, A. G. G~ovindarajan, T. Got~fried, V. Haight, Weiss, *Calypte Biomedical Company, Berkeley, CA, U.S~A. W.B.P.144 Proliferative Response to Soluble and Microplate-Adsorbed gp4l Synthetic in HIV+ Versus Normal Subjects. Clara A. Biglino, E. Palomba, Peripheral Blood Mononuclear Cells from Asymptomatic Patients: Comparison of Three Different Probes. Inmaculada Castillo*, J. Bartolome, M. G. Martinez, *Hepatology Fundacidn Jimbiez Detection Antibodies Sera of at Risk Individuals. &j.ola YV.t.ni*, F. Titti, S. G. Sanitd, Rome, Italy. 460 [Page 461](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/461) W.B.P.147 Clinical and Theoretical Applications of New Procedures for HIV Reverse Transcriptase and HIV Reverse Transcriptase Antibody Quantitation. J. Simon Gronowitz*, M. Neumaller, C. F. R. Kallander, R. Bhikhabhai, J. Albert, E.-M. Fenyo, et al., *Department of Medical Virology, University of Uppsala, Uppsala, Sweden. W.B.P.148 Passive Agglutination with Recombinant env Antigen to Detect Antibodies to Human Immunodeficiency Virus. Andrie L. Proulx*, C. R. Riggin, *Cambridge Bioscience Worcester, MA, U.S Cells E. G. Jablonski, *Quest Systems Inc., Bedford, MA, U.SA. Tests diagnostiques Diagnostic W.B.P.150 Indirect Immunofluorescence to Detect Anti-HIV Antibody. T.Scott Croxson*, V. J. Shah, C. L. Strand, H. Polensky, P. Holland, R. Randell, *Beth Israel Medical Center, New York, NY, U.S.A. W.B.P.151 S6rologie VIII et infection A plasmodium falciparum. Copin, M. Rosenheim, P. Mpel, Removed Sera with High Antibody Titers to Malaria by Adsorption with Plasmodium fFalciparum Infected Red Blood Cells. Curtis G. Haves*, J. Burans, R. Oberst, *U.S. Naval Medical Research Unit No. 2, San Francisco, CA, U.S.A. W.B.P.153 Evaluation of HIV-1 Antibody Testing Strategy in a Mixed Low Risk/High Risk Population. Jean C. Downie*, R. Howard, B. Bowcock, A. Cunningham, *ICPMR Westmead Hospital, Westmead, Australia. W.B.P.154 Significance of an Indeterminate HIV Western Blot (WBi). Juan Genesca*, J. Shih, B. Jett, I. Hewlett, J. Epstein, H. Alter, *Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, U.S A. W.B.P.155 Western-blot quantitatif: Int6r8t dans Detection of HIV-1 Specific IgG Antibodies (HIV-AB) in Saliva: A Cost-Effective and Accurate Alternative to Blood Testing. Frieda Behets*, B. Edidi, L. Atikala, T. C. Quinn, C. Brown, *Projet SIDA, Kinshasa, Zaire. W.B.P.157 Application of Virus Culture and PCR for HIV Detection in Blood Donors with Persistent Anti-p24 Reactivity in Western Blot. Cees L. van der Poel*, J. Huisman, M. Wester, H. W. Reesnick, M. Tersmette, Bruisten, *Red Cross Blood Bank, Amsterdam, Netherlands. W.B.P.158 Anti-nef Antibodies in Blood Donors with Persistent Anti-p24 Reactivity in HIV Western Blot and Characterization with Recombinant p24 in Bidimensional Blot and ELISA. Cees L. van der Poel*, S. Gadelle, H. Reesnick, Blood Bank, Amsterdam, Netherlands. 461 [Page 462](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/462) W.B.P.159 Detection of HIV-1 Specific Antibodies and Neutralizing Activity (NT Act.) in the Urine of Seropositive Persons. Yunzhen Cao*, M. Mirabile, X. L. Li, D. D. Ho, D. Dietrich, A. E. Friedman-Kien, *New York University Medical Center, New York, NY, U.SA W.B.P.160 Comparison of Western Blot (WB) Interpretive Criteria for HIV-1 Antibody. Charles A. Schable*, J. George, S. Phillips, G. Schochetman, *Centers for Disease Control, AIDS Program, Atlanta, GA, U.S.A. W.B.P.161 The Use of Recombinant HIV ELISA Kits as a Secondary Supplemental Test for Confirmation of HIV Infection. Michael V. O'Shaughnessv*, D. Lepine, S. Frenette, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. W.B.P.162 Laboratory Identification of Recent HIV Seroconversion: The Utility of Early Repeat Specimens and Coordination with the Counselling Team. Judith C. Wilber*, B. Louie, E. Soncuya, A. Back, A. Brickman, A. Lifson, et al., *San Francisco Department of Public Health Laboratory, San Francisco, CA, U.S.A. W.B.P.163 The D-Mannose-Specific Lectin from Gerardia savaglia Blocks Binding of HIV-1 to H9 Cells In Vitro. Werner E. G. Muller*, P. Reuter, K. Renneisen, H. C. Schroder, *Institut fur Chemie, Federal Republic of Serologic Evidence of Infection with Human Immunodeficiency Virus-Type 1 (HIV-1). John P. Phair*, J. Crisler, J. Huprikar, L. Tsung, D. Hart, J. Chmiel, *Northwestern University Medical School, Chicago, IL, U.S.A. W.B.P.165 Is there a Long \"Silent\" Period before Anti-HIV-1 Serum Antibodies, Appearance in HIV-1 Infection? Juan A. Pineda*, M. Leal, I. Aguado, C. Rey, Y. Torres, E. Lissen, *Virgen del Rocto Hospital, University of Seville, Seville, Spain. W.B.P.166 Comparison of False Positive Reactions in Direct Binding Anti-HIV ELISA Using Cell Lysate or Recombinant Antigens. John Craske*, R. Abbott, M. Collier, V. Martlew, E. Love, D. Lee, *Public Health Laboratory, Withington Hospital, Manchester, U.K. W.B.P.167 Negative Results of In Vitro Tests for HIV-1 Antibody Production by Peripheral Blood Cells in 12 Cases of Isolated gag-Encoded Protein Positivity. Comparison of Indirect Immunofluorescence and Western Blot Tests for Detection of Antibody to Human Immunodeficiency Virus. Angulo G. Barria*, L. V. M. Peredo, T. N. Castillo, L. R. Herrera, *Hospital de Infectologia, Centro Medico La Raza, Mexico City, Mexico. W.B.P.169 Resolution of Indeterminate HIV Western Blot Results by Additional Testing. James R. Carlson*, J. L. Yee, *University of California at Davis, Davis, CA, U.S.A. W.B.P.170 Prognostic Value of Repeated Western Blot Analysis. Bernd S. Kamps*, D. Niese, H. H. Brackmann, T. Kamradt, P. Euler, B. Van Loo, *Medizinische Universitdtsklinik, Bonn, Federal Republic of Germany. 462 [Page 463](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/463) W.B.P.171 Sensitivity of a New Recombinant Inhibition Type ELISA System for the Detection of HIV-1 Antibodies. Cees L. van der Poel*, N. Lelie, H. Reesink, A. Plaisier, E. Bakker, T. Moshe-Sterk, *Red Cross Blood Bank, Amsterdam, Netherlands. W.B.P.172 Performance of a Dot Immunoblot Kit for HIV Antibody Testing. Christopher H. Sherlock*, D. Cook, M. O'Shaughnessy, P. Gill, *University of British Columbia and Provincial Laboratory, Vancouver, BC, Canada. W.B.P.173 Use of Agglutination Assays as Supplemental Tests for Antibody to HIV. Jackton A. Nyamongo*, P. Tukei, S. Mitchell, E. Muniu, *National Public Health Laboratory Services, Nairobi, Kenya. W.B.P.174 Performance Appraisal of Laboratories Testing Dried Blood Spot Specimens for Blinded HIV Seroprevalence Surveys in the United States. Harry W, Hannon*, S. Lewis, S. McGee, R. George, M. Pappaioanou, *Center for Environmental Health and Injury Control, Centers for Disease Control, Atlanta, GA. U.S.A. W.B.P.175 Assessment of Dried Blood Spot Quality Control and Performance Evaluation Materials for National HIV Seroprevalence Surveys. Susan A. McGee*, H. Hannon, S. Lewis, *Center for Environmental Health and Injury Control, Centers for Disease Control, Atlanta, GA, U.S.A. W.B.P.176 Chronic HIV Infection with Delayed Appearance of Antibodies by Usual Techniques and a Case of Seroreversion. Bernadette J. McLaughlin*, C. Major, C. Swantee, J. Brunton, S. Read, *Ontario Ministry ofHealth, Laboratory Services Branch, Toronto, ON, Canada. W.B.P.177 Reducing False Reactive Results When Testing for Antibodies to HIV-1. Wolf Prenskv*, M. E. Ganguly, M. Lifshitz, J. H. Brassel, D. Solanki, Y. Li, *St. Clare's Hospital and Health Center, New York, NY, U.S.A. W.B.P.178 Interpretation and Follow-up of Indeterminate Western Blot (WB) Test Results. Radka Argirova*, E. Bodjeva, V. Ivanova, D. Beshkov, O. Troshev, *Bulgaria Medical Academy, Central AIDS Laboratory, Institute for Infectious and Parasitic Diseases, Sofia, Bulgaria. W.B.P.179 Evaluation of Twelve Commercial Kits for Screening of HIV-1 Antibodies in Mexico. Carmen Soler*, C. Mosqueira, C. Morales, J. L. Valdespino, J. Septrlveda, *Instituto de Investigaciones Biomedicas Function in Men. Samuel R. Swanda, W. Barr, L. Jacobsberg, *Cornell University Medical Center, New York, NY, U.S.A. W.B.P.181 Immunological and Psychological Predictors of Disease Progression in Gay Males at Risk for AIDS. Mary A. Fletcher*, G. Ironson, A. Laperriere, J. Simoneau, N. Klimas, N. Schneiderman, *University Miami, U.S.A. 463 [Page 464](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/464) W.B.P.182 A Comparison of Neuropsychological Testing and Mental Status Exam in AIDS Patients. Joyce S. Kobayashi*, R. Heaton, L. Thompson, I. Norton, D. Cohn, *University of Colorado Health Sciences Center, Denver, CO, U.SA. W.B.P.183 Neuropsychological Impact of AIDS on the Developing Brain. Hugh L. Coffman*,B. L. Kammerer, G.A. Gioia, *Harvard Medical School, The Children's Boston, MA, U.S.A. W.B.P.184 Neuropsychological Change on Longitudinal Assessment: Prevalence and Pattern in HIV Spectrum Disorders. Lydia Temoshok*, M. Drexler, J. P. Canick, D. M. Sweet, H. Hollander, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.SA. W.B.P.185 Mood State, Neuropsychology, and Self-Reported Cognitive Deficits in HIV Infection. Mary V. Herns*, S. Newman, R. McAllister, I. Weller, M. Harrison, *University College and Middlesex School of Medicine, London, U.K. W.B.P.186 Neuropsychiatric Disturbances in HIV-Infected Patients. Silvano in Zidovudine-Treated Patients: Standardized Demonstrate Measurable Psychosocial Improvement. Hans Jdger*, G. Franke, *AIDS Study Group, Schwabinger Krankenhaus, Munich, Federal of Germany. W.B.P.188 Peptide T Phase I Study: Neuropsychiatric Results. T. Peter Bridge*, F. K. Goodwin, P. N. R. Heseltine, E. Eaton, E. S. Parker, *National Institute of Mental Health, Intramural Research Program, National Institutes of Health, Rockville, MD, U.SA. W.B.P.189 The Use of Medroxyprogesterone as Pharmacologic Treatment of Hypersexuality in Male Patients with HIV-1 Infection. Frederick W. Schaerf, T. Koenig, B. Wisner-Carlson, F. Berlin, *Johns Hopkins Hospital, Baltimore, MD, U.S.A. W.B.P.190 Norepinephrine Response and Immune Functioning in HIV+ Subjects. Mahendra Kumar*, R. Morgan, M. A. Fletcher, A. M. Kumar, J. Szapocznik, C. Eisdorfer, * University of Miami, School of Medicine, Department of Psychiatry, Miami, FL, U.S.A. W.B.P.191 Response to Antidepressant Therapy in Depressed Persons with Advanced HIV Infection. Francisco Fernandez*, J. K. Levy, P. W. A. Mansell, *St. Luke's Episcopal Hospital TX, U.SA. W.B.P.192 Neuropsychological Manifestations of HIV Infection in Gay Men. Yaakov Stern*, M. Sano, S. Goldstein, D. Mindry, M. Richards, G. Todak, et al., *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A. W.B.P.193 The Use of the Mini Mental Status Exam as a Cognitive Screen in Patients with AIDS. James W. Dillev*, A. Boccellari, A. Davis, *San Francisco General Hospital, University of California at San Francisco, School of Medicine, Department of Psychiatry, San Francisco, CA, U.S.A. 464 [Page 465](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/465) W.B.P.194 Trytophan Levels Are Unrelated to Disturbances of Mood in HIV-1 Infected Patients. John G. Keilp*, B. J. Brew, M. Heyes, A. E. Sadler, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer (Neuropsychology), New York, NY, U.SA. W.B.P.195 Neuropsychological and Immunological Abnormalities in Advanced HIV Infection. Francisco Fernandez*, J. K. Levy, F. P. Pirozzolo, *St. Luke's Episcopal and Baylor College of Medicine, Houston, TX, U.SA. W.B.P.196 A Brief Screening Test Battery for Cognitive Deficits in HIV Infection. Stephen K. C. Woo*, J. Hunter, P. Wang, A. Simor, G. Wortzman, A. Bury, et al., *Mount Sinai Hospital, Department of Psychiatry, Toronto, ON, Canada. W.B.P.197 Drug Use History in Gay Men with AIDS and Its Relation to Neuropsychological Findings. James W. Dillev*, D. San Giovanni, A. Boccellari, A. Davis, *San Francisco General Hospital, University of California at San Francisco, School ofMedicine, San Francisco, CA, U.SA. W.B.P.198 Relationship between Neuropsychological and Immune Variables in HIV-Positive Asymptomatic Men. James W. Dille*, A. Boccellari, A. Davis, A. Moss, P. Bacchetti, M. Young, *San Francisco General Hospital, University ofCalifornia atSan Francisco, School ofMedicine, Department of Psychiatry, San Francisco, CA, U.SA. W.B.P.199 Cognitive Dysfunction and Psychosocial Factors in Symptomatic Seropositive Men. Jonathan P. Canick*, L. Temoshok, D. M. Sweet, *University of California at San Francisco, School of Medicine, San Francisco, CA, U.SA. W.B.P.200 Early Diagnosis of HIV Infection in Infants. Antonella Monforte*, R. Novati, P. Tornaghi, et al., *L. Sacco Hospital, Infectious Diseases Clinic, University of Milan, Milan, Italy. Enqu6tes Surveys W.B.P.201 Impact of HIV Diagnosis on Mood: St. Stephen's Cohort Study. Danitza Jadresic*, M. Riccio, D. Hawkins, B. Wilson, C. Thompson, *John Hunter Clinic, St. Stephen's Hospital, London, UK. W.B.P.202 A VA Hospital Specialized Psychiatry Program for Patients with HIV Disease: A Review of the First 50 Referrals. Douglas G. Vanderburg. San Francisco Veterans Administration Hospital, University of California at San Francisco, San Francisco, CA, U.SA. W.B.P.203 Request of Mental Health-Care Worker Intervention by Physicians Attending HIV+ or AIDS Patients: The Importance of an Integrated and Multidisciplinary Approach. Gisela M. Tostes, A. Queiroz, A. Navarro, University of Rio de Janeiro, Hospital Universitario C.F.F., Rio de Janeiro, Brazil. 465 [Page 466](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/466) W.B.P.204 Personality, Behaviour and Cognitive Changes in AIDS as Rated by Patients and Their Carers and as Related to Neuropychological Test Results. Anes E. Kocsis*, J. A. Church, S. F. Vearnals, J. Green, *St. Mary's Hospital, Paterson Wing, Psychology Department, London, UK. W.B.P.205 Competency Consultation to HIV Patients: A Liaison Psychiatry Perspective. Henry W. Weisman*, L. Perton, P. Agnelli, *Queen's Hospital Affiliation, Long Island Jewish Medical Center, New York, NY, U.SA. W.B.P.206 Positivite6 l'HIV en psychiatrie: Observation sur 18 mois. Zamperetti*, G. F. Goldwurm, I. Fernandez, *Ospedale psychoth6rapeutique 100 patients atteints SIDA. Yves Edel*, F. Rognier-Aeberhard, J. Rodriguez, troubles psychiatriques selon le DSM m-r en cours de SIDA. I. Cd Granda Niguarda, Milan, Italy. W.B.P.209 HIV Seroprevalence Study of Involuntarily Hospitalized Mentally Ill Homeless from the Streets of Manhattan, New York. Maureen Empfield*, A. Weinstock, F. Cournos, H. Schrage, I. Meyer, E. Schoenbaum, et al., *Creedmoor Psychiatric Center, Queens Village, NY, U.S.A. W.B.P.210 Psychiatric Diagnoses among Volunteers for HIV Testing. Lawrence B. Jacobsberg*, S. Perry, B. Fishman, A. Frances, J. Ryan, K. Fogel, *Cornell University Medical College, New York, NY, U.S.A. W.B.P.211 Psychiatric Diagnoses and Treatment Outcome in an AIDS Specialty Center. Jennifer F. Havens*, E. Finkelstein, M. Viederman, J. Jacobs, *New York Hospital, Cornell Medical Center, New York, NY, U.S.A. W.B.P.212 Psychosocial Status of 192 Patients with HIV Infection and AIDS. Michael B. King, Institute of Psychiatry, London, U.K. W.B.P.213 Analysis of Initial Psychiatric Referrals from a Hospital HIV Service. Cleto Di Giovanni*, P. F. Goyer, *National Naval Medical Center, Reston, VA; Johns Hopkins Hospital, Baltimore, MD, U.SA. W.B.P.214 A Comparison of Suicidal Behaviors in Patients in an AIDS-Related Psychiatric Clinic and in a General Psychiatry Clinic. Mary Alice O'Dowd*, F. P. McKegney, C. Natali, J. Harkavy, G. Asnis, *Montefiore Medical Center, Bronx, NY, U.S.A. W.B.-P.215 Psychiatric History among Homosexuals and Drug Addicts Infected with Human Immunodeficiency Virus. Costanzo Gala*, S. Martini, A. Pergami, M. Rossini, R. Russo, A. Lazzarin, *University of Milan Medical School, Department of Psychiatry, Milan, Italy. W.B.P.216 A Comparison of Psychiatric Consultations in AIDS and Non-AIDS Patients. Mary Alice O'Dowd*, F. P. McKegney, *Montefiore Medical Center, Bronx, NY, U.SA. 466 [Page 467](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/467) W.B.P.217 Establishment of an HIV-Related Psychiatric Clinic in an Area of High Substance Abuse. Mary Alice O'Dowd*, C. Natali, F. P. McKegney, *Montefiore Medical Center, Bronx, NY, U.S.A. W.B.P.218 Effect of Neuropsychiatric Signs and Symptoms on Homeless Persons with AIDS in a Group Residence. Joanne Staats*, G. Hough, D. Dornan, *AIDS Resource Center, New York, NY, U.S.A. W.B.P.219 Locus of Control, Social Supports and Depression among HIV-Infected Subjects. Costanzo Gala*, S. Martini, A. Pergami, M. Rossini, R. Russo, F. Durbano, *University of Milan Medical School, Department of Psychiatry, Milan, Italy. W.B.P.220 Frequency of Psychiatric Disorders in Hospitalized AIDS Patients: Comparison to a General Hospital Population. Frederick W. Schaerf*, T. Koenig, B. Wisner-Carlson, *Johns Hopkins Hospital, Baltimore, MD, U.S.A. Psychiatrie/Etudes de prevalence Psychiatry Prevalence Studies W.B.P.221 Handedness and Immune System Function in Gay/Bisexual Men. James T. Becker* L. Kingsley, S. Bass, P. Satz, M. A. Dew, L. Penkower, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. W.B.P.222 Psychoneuroimmunologic Studies of Gay Men withHIV Infection. Jack M. Gorman*. Williams, Y. Stern, R. Mayeux, R. Goetz, R. Kertzner, et al., *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A. W.B.P.223 Psychiatric Disorder and HIV Infection: A Controlled, Longitudinal Study. J Hampton Atkinson*, I. Grant, R. K. Heaton, J. Weinrich, J. A. McCutchan, *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A. W.B.P.224 Neuropsychological and Psychosocial Function in Two Cohorts of Gay Men: Relation to Stage of HIV-1 Infection. Andrew J. Savkin*, R. S. Janssen, G. C. Sprehn, T. J. Spira, L. Cannon, J. E. Kaplan, et al., *University of Pennsylvania, Philadelphia, PA, U.S.A. W.B.P.225 The Effect of HIV Antibody Status on U.S. Military Applicant Aptitude Test Scores. David R. Ardav*, J. F. Brundage, L. I. Gardner, M. Goldenbaum, F. Wann, S. Wright, *HQ U.S. Army Forces Command, Fort McPherson, GA, U.S.A. W.B.P.226 A Longitudinal Analysis of Perception of Physical Health and Symptoms of Depression in Gay/Bisexual Men. James T. Becker*, S. Zeger, M. A. Dew, R. Karim, L. Kingsley, P. Satz, et al., *University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. W.B.P.227 Neuropsychiatric Features of AIDS: A Comparison with Multiple Sclerosis. Frederick W. Schaerf*, R. Morriss, J. Brandt, J. McArthur, M. Folstein, *Johns Hopkins Hospital, Baltimore, MD, U.S.A. W.B.P.228 Psychiatric Findings in HIV-Seropositive Persons in a Mandatory HIV Screening Program. James R. Rundell*, G. R. Brown, S. L. Paolucci, *Uniformed Services University of the Health Sciences, School of Medicine, Bethseda, MD, U.S.A. 467 [Page 468](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/468) W.B.P.229 Auditory Event Related Potentials (ERPs) in the Clinical Examination of HIV-Infected Drug Users. Ann Chiswick*, V. Egan, G. Goodwin, R. St. Clair, R. Brettle, *Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, U.K. W.B.P.230 Discriminating Depression from Cognitive Impairment in HIV Illness. Igor Grant*, R. Olshen, J. H. Atkinson, R. K. Heaton, J. Weinrich, J. A. McCutchan, et al., *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A. W.B.P.231 Preliminary Findings on a Screening Symptom Checklist for HIV Dementia. James W. Dilley*, A. Boccellari, A. Davis, A. Moss, P. Bachetti, B. Wagner, *University of California at San Francisco, AIDS Health Project, San Francisco, CA, U.S.A. W.B.P.232 Correlation of P300 Auditory Evoked Potentials (AEPs) and Tests of Cognitive Function in HIV-Positive Drug Users. Vincent G. Egan*, A. Chiswick, G. Goodwin, D. St. Clair, R. Brettle, *Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, U.K. W.B.P.233 Relating Depression to Neuropsychological Impairment. J. Hampton Atkinson*, R. K. Heaton, I. Grant, J. Weinrich, J. A. McCutchan, *University of California at San Diego, Department of Psychiatry, La Jolla, CA, U.S.A. W.B.P.234 The Development of a Brief Screening Battery to Detect Cognitive Defects in Patients with AIDS. James W. Dilley*, A. Boccellari, A. Davis, *University of California at San Francisco, AIDS Health Project, San Francisco, CA, U.S.A. W.B.P.235 Neuropsychological Functioning in HIV Infection. Uta Schick*, C. F. D. Goebel, *Psychiatrische Universitdt Minchen, Munich, Federal Republic of Germany. W.B.P.236 Qualitative Aspects of Depressed Mood and Neuropsychological Function in HIV-1+/- Gay and Bisexual Men. James T. Becker*, F. W. Schaerf, L. Kingsley, R. Fox, M. A. Dew, *University of Pittsburgh, School of Medicine, Pittsburgh, PA, U.S.A. Soins Care W.B.P.237 Evaluation of Training for Physicians at the National Reference Centers in Brazil. Jos F. Rodrigues*, L. Rodrigues, *University of Brasilia, Brasilia, Brazil. W.B.P.238 A Comprehensive Approach to Community Hospital Care of AIDS Patients. Laurie Andrews*, J. Klimek, *Hartford Hospital, Hartford, CT, U.S.A. W.B.P.239 Inverse Correlation of Complement-Mediated, Antibody-Dependent Enhancing Titers with Stage of Disease in Individuals Infected with HIV-1. William M. Mitchell*, D. C. Montefiori, W. E. Robinson, A. Modliszewski, L. B. Lefkowitz, *Department of Pathology, Vanderbilt University, U.S.A. 469](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/469) W.B.P.240 Impediments to IVDA Trials. Patrick G. Fairchild*, C. Jaffarian, S. Cheeseman, C. Bova, K. Tolson, N. Blacklow, et al., *University of Massachusetts Medical School, Worcester, MA, U.S.A. W.B.P.241 The Role of the Government of Canada in the Nature and Direction of Clinical Research in the Management of HIV Disease in Canada. Sabih R. Khan*, N. N. Joshi, *Drugs Directorate, Health Protection Branch, Health and Welfare Canada, Vanier, ON, Canada. W.B.P.242 Thermographic Imaging of HIV Patients. Ray P. Clark*, M. R. Goff, M. Youle, B. Gazzard, *Clinical Research Center, Harrow, U.K. W.B.P.243 Art Therapy with People with AIDS. Eva I. Sansom, Casey House Hospice, Toronto, ON, Canada. W.B.P.244 Maintenance of Hope in an HIV Sample. Robert H. Remien*, J. G. Rabkin, J. B. W. Williams, R. Neugebauer, *New York State Psychiatric Institute, New York, NY, U.S.A. W.B.P.245 A Rehabilitation Program for Clients with HIV Associated Conditions. Patricia Gentile*, K. Marshall, M. Bennett, P. Laqueur, H. Alexander, I. Davis, *Department of Ambulatory Care, Woodhull Medical and Mental Health Center, Brooklyn, NY, U.S.A. W.B.P.246 Compliance of HIV-Infected Intravenous Drug Users in Clinical Trials. Sarah H. Cheeseman*, P. Fairchild, M. Glode, K. Tolson, C. Jaffarian, N. Blacklow, et al., *University of Massachusetts Medical School, Worcester, MA, U.S.A. W.B.P.247 Insuring Quality of Data in Community-Based Clinical Trials. Donald I. Abrams*, T. F. Mitchell, C. C. Child, Z. Weingart, *San Francisco County Community Consortium, San Francisco, CA, U.S.A. W.B.P.248 tvaluation de la charge de travail infirmier: Comparaison entre patients hospitalis6s infect6s et non VIH. Christian Chidiac*, D. Chaussoy, G. Beaucaire, Leroy, Centre Tourcoing, France. AIDS Registry (ATR) of New York. Iris Lon*, M. Cowing, J. Eigo, R. Huff, *AIDS Treatment Registry Inc., Brooklyn, NY, U.S.A. W.B.P.250 ATR: A Regional Model for Establishing a Community-Based, Computerized Registry of AIDS/HIV Clinical Drug Trials. James Eigo*, M. Cowing, I. Long, *AIDS Treatment Registry, Inc., New York, NY, U.S.A. W.B.P.251 Program Directors' Attitudes towards Residents' Care of Persons with AIDS. Rodney A. Hayward*, R. K. Kravitz, M. K. Shapiro, *University of Michigan Hospitals, Ann Arbor, MI, U.S.A. W.B.P.252 Impact of Serum p24 HIV Antigen Screening on Patient Eligibility for Antiviral Clinical Trials. Margo E. Heath-Chiozzi*, G. Pearlstein, H. Eigenrauch, C. Crumpacker, D. Cotton, *Beth Israel Hospital, Harvard AIDS Clinical Trials Unit, Boston, MA, U.S.A. W.B.P.253 New Developments in a Model Program of AIDS Hospice Care. Bruce A. Priebe. Visiting Nurses and Hospice of San Francisco, San Francisco, CA, U.S.A. 469 [Page 470](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/470) W.B.P.254 A Brief Health Status Instrument for Use in AIDS Clinical Trials. Albert W. Wu*, H. R. Rubin, W. C. Mathews, W. D. Hardy, I. Grant, D. D. Richman, et al., *University of California at San Francisco, San Francisco, CA, U.S.A. W.B.P.255 Neuropsychological Test Performance in HIV-1 Seropositive Patients On and Off Azidothymidine (AZT). John J. Sidtis*, A. E. Sadler, J. G. Keilp, B. J. Brew, H. A. Aronow, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.256 Test-Re-Test Performance on Neuropsychological Tests in a Group of HIV-1 Seropositive Patients. Abigail E. Sadler*, J. G. Keilp, H. Thaler, B. J. Brew, R. W. Price, J. J. Sidtis, et al., *Memorial Sloan-Kettering Cancer Center, Department ofNeurology, New York, NY, U.S.A. W.B.P.257 New Modalities for Clinical Trials: A Synthesis of Pharmacology and Health Care. Mark Harrington*, J. Eigo, D. Z. Kirschenbaum, I. Long, *ACT-UP/NY, New York, NY, U.S.A. W.B.P.258 Co-Morbid Events in First HIV Identified Hospitalizations, New York State (NYS), 1984-86. George T. DiFerdinando*, K. Arthur, G. Kaufman, *New York State Department of Health, Albany, NY, U.SA. W.B.P.259 Neuropsychological Performance as a Function of AIDS Dementia Complex (ADC) Severity. Abigail E. Sadler*, J. G. Keilp, D. Dorfman, B. J. Brew, R. W. Price, J. J. Sidtis, et al., *Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY, U.S.A. W.B.P.260 The Organization of AIDS Services at Cook County Hospital, Chicago. Renslow Sherer*, S. Kathpalia, R. Sable, M. Cohen, L. Gath, A. Hamb, et al., *Cook County Hospital, Chicago, IL, U.SA. W.B.P.261 Clinic for HIV-Related Concerns: One Model of Outpatient Psychiatric Care. Stephen K. C. Woo. Mount Sinai Hospital, Department of Psychiatry, University of Toronto, Toronto, ON, Canada. W.B.P.262 Principles of Rehabilitation of Patients with Immunodeficiencies. R. I. Sepiashvili, Immunological Center, Kutaisi, U.S.S.R. W.B.P.263 Sacramento Cares: One Community's Response to Providing Comprehensive Medical Care to People with HIV-Related Disorders. Neil M. Flynn*, J. Riley, S. Pomerantz, S. Grant, M. Wolf, L. McCandless, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A. W.B.P.264 Referral Patterns in a Comprehensive AIDS Clinic. Shirley J. Lee. The New York Hospital, Cornell Medical Center, New York, NY, U.SA. W.B.P.265 Clinical Care as Part of Integrated AIDS Management in a Zambian Rural Community. Clement M. Chela*, I. D. Campbell, Z. Siankanga, *The Salvation Army Chikankata Hospital, Mazabuka, Zambia. W.B.P.266 Study of a Series of 121 Consecutive AIDS Patients. Mdrio B. Correa-Lima*, M. A. Silva, C. E. Brandao-Mello, C. T. C. Leite, L. R. Haddad, M. A. Fonseca, *Hospital Universitdrio Gaffrde e Guinle, Universidade do Rio Rio de Janeiro, Brazil. 470 [Page 471](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/471) W.B.P.267 AIDS Issues for Rural Hospitals in U.S. Frontier Areas. Vicky L. Carwein*, D. Berry, *University ofNevada at Las Vegas, Las Vegas, NV, U.S.A. W.B.P.268 Seroprevalence of HIV, Herpes Viruses and Immunologic Abnormalities in a Group of IVDrug Abusers. Constance T. Pachucki*, D. Schaaff, J. Lentino, M. Schaefer, W. Dorus, *Edward Hines Jr. Veterans Administration Hospital, School oflnfectious Diseases, Hines, IL, U.S.A. W.B.P.269 Psychosocial Issues Associated with Human Immunodeficiency Virus (HIV) Infection in a City Hospital: Experience of the Multidisciplinary Patient Care Meeting. Tony W. Cheung*, H. Weissman, A. Montreuil, *Queens Hospital Center, Long Island Jewish Medical Center, Jamaica, NY, U.S.A. W.B.P.270 Triage System for Potential Research Subjects into Active AIDS Clinical Trials. Paul A. Volberding*, V. DeGenova, J. Mills, R. Holland, D. Feigal, M. Nash, *University of California at San Francisco, San Francisco, CA, U.S.A. W.B.P.271 Assessment of the Needs of an HIV Acute/Chronic Level Care Unit. Rochelle Scheib*, S. Marks, O. Bradley, B. Morgan, A. Desroches, J. Baer, et al., *Tufts University, Lemuel Shattuck Hospital, Department of Public Health, Boston, MA, U.S.A. W.B.P.272 The Role of the Pharmacist in the HIV Team. Sarah Fitt*, R. J. Bunn, T. J. McManus, J. Moxuam, *Dulwich Hospital, London, U.K. W.B.P.273 Causes of Hospitalizations Following AIDS Diagnosis in a Population-Based Cohort. David W. Fleming*, S. Modesitt, R. Klockner, D. Bennett, S. Hulman, *Oregon Health Division, Portland, OR, U.S.A. W.B.P.274 Tuberculin Skin Testing in HIV-Infected Persons. Gale G. Cromwell, University of Maryland Medical System, Baltimore, MD, U.S.A. Immunomodulateurs Immunomodulators W.B.P.275 Cellular Hartman*, R. Yarchoan, G. S. Ahluwalia, J. A. Kelley, S. Broder, D. G. Johns, *National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A. W.B.P.276 Immunostimulation comme un support chez Diethyldithiocarbamate Inhibits the Progression of HIV Infection: Results of a Prospective Randomized Clinical Study. Manfred Dietrich, Bernhard Nocht Institute for Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany. W.B.P.278 Treatment of HIV-Infected Patients with D-Penicillamin: Tentative 472](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/472) W.B.P.279 Recovery of Delayed-Type Hypersensitivity (DTH) in Patients with AIDS Related Complex (ARC) in Randomized Trial of IMREG-1. Milan Fiala*, L. A. Cone, J. Sayre, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A. W.B.P.280 Effect of Isoprinosine on HIV-Antigenaemia. Lars Teglbiaerg*, S. Moestrup, B. G. Hansson, B. F. Vestergaard, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. W.B.P.281 Induction of T Lymphocyte-related Functions by Imuthiol Down Regulation of Prostaglandin Secretion by Monocytes/Macrophages. Diavad A. H. D. Dormon, H. Fleury, J. Lang, Y. Mouton, al., *Hdpital militaire Bggin, Saint-Mandd, France. W.B.P.283 AS 101: A in the Treatment of AIDS. Jean-Philippe Laporte*, J. Lebas, M. C. Meyohas, G. Gonzales, B. A. Najman, et al., *H6pital St-Antoine, Paris, France. W.B.P.284 Enhancement of T-Cell Growth in HIV+ Patients Treated with (IMUTHIOL): Monocyte *CHU Pitid-Salpe'triere, Paris, France. W.B.P.285 Survival Rate in AIDS Patients Following Transfusion Therapy with CR1 Enriched Erythrocytes. Judith Sulzberger*, Y. Inada, G. McKinley, A. Senderowicz, M. Lange, et al., *St. Luke'sRoosevelt Hospital Center, New York, NY, U.S.A. W.B.P.286 Peptide T Phase I Study: Immuno/Virologic Results. Peter Heseltine*, F. K. Goodwin, T. P. Bridge, J. Martin, J. M. Leedom, *University of Southern California Medical Center, General Hospital, Los Angeles, CA, U.S.A. W.B.P.287 Dose Response Study of Daily Diethyldithiocarbamate (DTC) in Patients with ARC/AIDS. Eskild A. Peterson*, E. Hersh, D. Fish, C. Kaplan, R. Gorman, M. Darragh, *University of Arizona, College of Medicine, Tucson, AZ, U.S.A. W.B.P.288 The Effect of Isoprinosine R (Inosine Pranobex) in Patients with Low Risk for Developing AIDS. Mark O. Loveless*, D. S. Robins, *Oregon Health HIV Sciences University, Portland, OR, U.S.A. W.B.P.289 Effect of Oral Dextran Sulfate on the Mouse Intestine. Frank S. Rhame*, C. L. Wells, S. L. Erlandsen, *University of Minnesota, Minneapolis, MN, U.S.A. W.B.P.290 Immunological Data an Isoprinosine (Imunovir) Seberg*, E. Dickmeiss, P. Skinhj, *University Hospital, Rigshospitalet, Department of Infectious Diseases and Tissue Laboratory, Copenhagen, Denmark. 472 [Page 473](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/473) W.B.P.291 Intravenous Immunoglobulins in Adults ARC Double-Blind Longitudinal Trial. Matthias Schrappe-Bdcher*, H. Rasokat, B. Salzberger, ARC-IVIG Study Group Cologne/Berne, *University of Cologne, Department of Internal Medicine II, Cologne, Federal Republic of Germany. W.B.P.292 Clinical Efficacy of Two Kinds of Kampo Medicine on HIV- Infected Patients. Michio Fulimaki*, S. Ikematsu, M. Hada, K. Mori, H. Takahashi, M. Inagaki, *Tokyo Medical College, Department of Clinical Pathology, Tokyo, Japan. W.B.P.293 The Effect of the Polyene Macrolide Antibiotic Amphotericin B and Its Methylated Derivative (AME) on Human Immunodeficiency Virus and Phagocytosis in Macrophage Cultures. Molly J. Coye*, D. Pontani, D. Sun, B. Wolf, P. Bryant, S. Shahied, et al., *New Jersey State Department of Health, Trenton, NJ, U.SA. W.B.P.294 Activation of Methionine-Enkephalin (MEK): Enhancement of Cytotoxic T-Cells in HIV+ Patients. Nicholas P. Plotnikoff*, G. C. Miller, J. Wybran, *University of Illinois at Chicago, Chicago, IL, U.S.A. W.B.P.295 Therapeutic Effect of Intravenous Immunoglobulines (IVIG) in HIV Infected Hemophiliac Children and Adolescents. Norbert Wagner*, R. Bialek, H. Radinger, M. Becker, *University of Bonn, Department of Pediatrics, Bonn, Federal Republic of Germany. W.B.P.296 Long-term Administration of Dithiocarb in HIV-Seropositive Subjects. Jean-Marie Touraine, Effects of Imuthiol (Dithiocarb, DTC, Diethyldithiocarbamate) in the Therapy of Early Stage HIV-1 Infection. Emil C. Reisinger*, A. Gottesleben, G. Gotze, S. Schwander, A. Dorlemann, M. Dietrich, *Hamburg Tropical Institute, Hamburg, Federal Republic of Germany; and University of Innsbruck Institute for Hygiene, Innsbruck, Austria. W.B.P.298 Clinical Evaluation of on Yoshioka, K. Akatani, *Osaka National Hospital, Clinical Research Institute, Osaka, Japan. W.B.P.299 Intravenous Versus Oral Application of Ruf, H.-D. Pohle, *RudolfVirchow University Hospital, Freie Universitdt Berlin, Berlin, Federal Republic of Germany. W.B.P.300 Two-Year Clinical Trial with Pentosan-Polysulfate (HOE/BAY 946) in Virchow University Hospital, Freie Universitdt Berlin, Berlin, Federal Republic of Germany. W.B.P.301 Clinical Influence of Imuthiol (Sodium Dithiocarb) in HV-Infected Patients: A Review of 4 Controlled Studies and Long-term Influence. Jean Caraux*, International AIDS Imuthiol Study Debrd, B. Milpied-Homsi, *Institut de France. W.B.P.303 Acute HIV-Infected People. George J. Pazin*, X.-L. Huang, D. K. McMahon, J. A. Armstrong, C. R. Rinaldo, M. Ho, et al., *University of Pittsburgh, School of Medicine and Graduate School ofPublic Health, Pittsburgh, PA, U.S.A. W.B.P.304 Failure of Isoprinosine in Prevention of ARC to AIDS. Daniel Barbaro*, H. Fragua, *University of Texas Southwestern Medical School, Dallas, TX, U.S.A. W.B.P.305 Neopterin and T-Helper/Neopterin Ratio in the Monitoring of Long-term Treatment of HIV-Infected Patients by ImuthiolR (sodium Timomoduline and Lithium Carbonate for HIV Patients. Gregorio Buchovsky*, B. Popescu, C. Levin, J. Corrales, *Hospital Escuela General, San Martin, Corrientes, Argentina. W.B.P.307 Case Report of Disulfiram as First Line Therapy in Seropositive Patients Attending a Community Clinic. Iris L. Davis*, J. Leibel, P. Paroski, A. Morgan, B. Norris, *Woodhull Medical and Mental Health Center, Department ofAmbulatory Care, Brooklyn, NY, U.S.A. W.B.P.308 Immunologic and Virologic Parameters in 100 HIV-Infected Patients (PTS) Treated with Isoprinosine (ISO) or Placebo (PLB) as Part of a Multicenter Phase III Clinical Trial. Marcelo B. Sztein*, R. S. Schulof, D. Mai, G. L. Simon, D. M. Parenti, J. Courtless, et al., *The George Washington University Medical Center, Washington, DC, U.S.A. W.B.P.309 Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): A Phase-I Trial in Neutropenic AIDS Patients. Susan E. Krown*, K. O'Boyle, J. W. M. Gold, N. Flomenberg, W. Anselmo, E. Bonnem, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.310 Reestablishment of a Normal Immunoregulatory Mechanism in HIV-Infected Patients with Immune Thrombocytopenic Purpura (ITP). Harry W. Snvder*, F. R. Jones, *IMRE U.S.A. W.B.P.311 of Deteriorated Polymorphonuclear Leukocyte (PMN) Phagocytic Function of Polysaccharide Immunopotentiator Juzo Matsuda*, University School ofMedicine, Department of Medicine, Tokyo, Japan. W.B.P.312 An Open Label Dose-Ranging Trial of AL 721 in PGL and ARC. Donna Mildvan*, D. Armstrong, D. Antoniskis, H. Sacks, H. Balfour, J. Buzas, et al., *Beth Israel Medical Center, New York, NY, U.S.A. W.B.P.313 Inosine Pranobex Therapy in HIV Seropositive Patients at Risk of Developing AIDS. Robert Murphy*, J. Von Roenn, J. Pottage, L. Williams, C. Benson, H. Kessler, et al., *Northwestern University Medical School, Section of Infectious Diseases, Chicago, IL, U.S.A. 474 [Page 475](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/475) W.B.P.314 Effect of Passive Immunization in Patients with ARC and AIDS. Abraham Karpas*, F. Hill, M. Youle, J. Gray, J. K. Oates, B. G. Gazzard, *University of Cambridge Clinical School of Medicine, Department ofHaematology, Cambridge, U.K. W.B.P.315 A Phase /II Dose Ranging Trial of Oral Dextran Sulfate in HIV p24 Antigen Positive Individuals (ACTG 060): Results of a Safety and Efficacy Trial. Donald I. Abrams*, C. Petinelli, M. Power, V. B. Kubacki, M. H. Grieco, W. K. Henry, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. W.B.P.316 Effet du MMI sur les malades atteints du SIDA. Z. Lurhuma*, A. Shafik, M. Wane, K. Tshiamala, *Kinshasa, Zaire. Th6rapie et evaluation clinique: Tests control6s Therapy and Clinical Evaluation: Controlled Trials W.B.P.317 Use of Zidovudine in Injection Drug Use (IDU) Related HIV Infection: Drug Compliance and Clinical Attendance. Frances M. Cowan*, M. E. Jones, P. J. Flegg, L. R. MacCallum, R. P. Brettle, J. A. Gray, et al., *City Hospital, Department of nfectious Diseases, Edinburgh, U.K. W.B.P.318 Effectiveness of Low-Dose Combination Therapy with Azidothymidine (Zidovudine) and Acyclovir in AIDS and ARC Patients. Peter Walger*, P. Baumgart, G. Wilke, Bone Marrow Transplantation (BMT) Plus Azidothymidine (AZT) in an AIDS Patient with Non-Hodgkin's Lymphoma (NHL). Albert D. Donnenberg*, H. K. Holland, J. J. Rossi, J. A. Zaia, G. W. Santos, R. Saral, *The Johns Hopkins University Oncology Center, Baltimore, MD, U.SA. W.B.P.320 AS 101 in Association with AZT in AIDS Patients: A Phase I Pilot Study. Jean-Philippe Laporte*, France. W.B.P.321 Effect of Combination of Zidovudine and Interferon-Alpha Compared with Zidovudine and Acyclovir on Spacey, W. Siegenthaler, et al., *Medical Polyclinic, Department of Medicine, University Hospital, Zurich, Switzerland. W.B.P.322 Zidovudine vs. Alpha Interferon vs. the Combination in Patients with Early HIV Infection. Kathryn M. Zunich*, V. Davey, J. A. Metcalf, H. Masur, A. S. Fauci, H. C. Lane, et al., *National Institutes ofHealth, Rockville, MD, U.S.A. W.B.P.323 An Open-Label Study of the Safety and Efficacy of Co-Administration of Zidovudine and Recombinant-IFN-Beta. Michael J. Borucki*, R. B. Pollard, *University of Texas, Medical Branch, Virology Research, Galveston, TX, U.S.A. W.B.P.324 Effect of a Combined Dextran Sulfate/Zidovudine Therapy Compared to Zidovudine Monotherapy in AIDS. Brockmever*, L. Mertins, M. Goos, *Department of Dermatology, University of Essen, Essen, Federal Republic of Germany. 475 [Page 476](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/476) W.B.P.325 The Safety of Zidovudine and Interleukin-2 in Asymptomatic HIV Infected Patients. John A. Bartlett*, K. D. Blankenship, M. Greenberg, D. S. Tyler, K. J. Weinhold, *Duke University Medical Center, Durham, NC, U.S.A. W.B.P.326 Combined Treatment with Zidovudine and Lymphoblast Alpha in Patients with HIV-Related Kaposi's Sarcoma. Reinhard Baumann*, Swiss Clinical Task *University Hospital, Zarich, Switzerland. W.B.P.327 Long-term (18-Month) Treatment of Severe HIV Infection with an Alternating Regimen of AZT and 2',3'-Dideoxycytidine (ddC). Robert Yarchoan*, J. M. Pluda, R. V. Thomas, C. F. Perno, N. McAtee, S. Broder, *National Cancer Institute, Bethesda, MD, U.S.A. W.B.P.328 Daily Subcutaneous Recombinant Granulocyte-Macrophage Colony Stimulating Factor Improves the Neutropenia Induced by Azidothymidine in Patients with AIDS/ARC: Follow-up. James D. Levine*, J. D. Allan, J. H. Tessitore, N. Falcone, R. Israel, J. E. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. W.B.P.329 The Use of an Alternating Regimen of AZT and Subcutaneous (SC) GM-CSF in Patients with Severe HIV Infection and Leukopenia. James M. Pluda*, R. Yarchoan, N. McAtee, R. Thomas, D. Oette, S. Broder, *National Institutes of Health, National Cancer Institute, Bethesda, MD, U.S.A. W.B.P.330 Augmentation of Non-MHC Restricted Cellular Cytotoxicities in Patients Receiving Zidovudine Plus Interleukin-2. Kent J. Weinhold*, D. S. Tyler, A. A. Austin, H. K. Lyerly, D. P. Bolognesi, J. A. Bartlett, et al., *Duke University Medical Center, Durham, NC, U.S.A. W.B.P.331 Zidovudine (AZT) Treatment of the AIDS Dementia Complex (ADC): Results of a Placebo-Controlled, Multicentered Therapeutic Trial. Richard W. Price*, M. A. Koch, J. J. Sidtis, J. Feinberg, A. Collier, C. Kennedy, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.332 Study Compliance among Asymptomatic HIV Seropositives (ASX HIV+) Being Treated with Azidothymidine (AZT). Paul B. Jacobsen*, C. Vassalos, D. Brown, K. Gorfinkle, G. Philogene, B. Polsky, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.333 Survival of Patients with HIV Disease Treated with Zidovudine (AZT). David H. Shepp*, M. Kaplan, C. Muggeo, M. Smith, M. Lesser, *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A. W.B.P.334 Reduction of Zidovudine Side Effects by an Intermittent Therapy Scheme. Schlomo Staszewski*, J. Odewald, A. Gottstein, E. B. Helm, W. Stille, *Klinikum der J.W.-Goethe-Universitat, Frankfurt, Federal Republic of Germany. W.B.P.335 A Phase I/II Trial of the Contamination of Zidovudine and Interleukin-2 in the Treatment of HIV-RelatedKaposi's Sarcoma.Joseph A. Kovacs*, R. Davey, M. Polis, K. Zunich, A. S. Fauci, H. C. Lane, et al., *National Institutes of Health, Bethesda, MD, U.S.A. 476 [Page 477](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/477) W.B.P.336 Zidovudine Use in Intravenous Drug Users. Jihad Slit*, G. Perez, C. Forrester, G. Tonnesen, E. S. Johnson, *Saint Michael's Medical Center, Newark, NJ, U.S.A. W.B.P.337 Outcomes of Treatment with AZT of Patients with AIDS and Symptomatic HIV Infection (ARC). Patricia Cox\", G. N. Beall, C. Styer, M. Martin, *Harbor-UCLA Medical Center, Torrance, CA, U.S.A. W.B.P.338 AZT Therapy in Infected People: Efficacy and Side Effects. Francesco Ghijd4*, P. Costigliola, E. Clinical and Immunological Evaluation. M. Eulalia Valencia*, M. C. G. Rodriguez, P. Lavilla, V. Pintado, A. Gil, J. J. Vazquez, *Hospital Servicio de Medicina Interna, Madrid, Spain. Zidovudine (AZT) Treatment in AIDS and ARC. Enzo Raise*, V. Vannini, M. L. Schiattone, A. Cicognani, et al., *C.A. Pizzardi Hospital, Department of Infectious Diseases and Immunopathology Unit, CA. Pizzardi Hospital, Bologna, Italy. W.B.P.341 Neurological and Immunological Evaluation of a Patient Treated with AZT with Acute HIV Infection and Encephalopathy. Robert Zangerle*, P. Pohl, of 58 HIV-Infected Patients in Greece. Antonios I. Paoadopoulos*, G. D. Stergiou, G. M. Ploumidis, A. N. Roumeliotou, S. A. Georgopolou, G. I. Papaevangelou, *First IKA Hospital Athens, Melissia, Greece. W.B.P.343 Update on AZT Therapy in an Inner-City Population. I[t1anJ E. Samuels*, J. Hendrix, M. Hilton, V. Sloan, C. B. Small, *North Central Bronx Hospital, Bronx, NY, U.S.A. W.B.P.344 Devenir de 365 malades atteints d'ARC ou de SIDA et traitgs par AZT pendant 4 k 18 mois. Eric Dournon*, W.B.P.345 Experience with Zidovudine in a City Hospital AIDS Clinic. Laurel A..Mil.*, K. Peterson, A. Davidson, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A. W.B.P.346 Effects of Zidovudine Different Dose Regimens on Clinical, Immunological and Virological Indices of ARC Patients for One Year. Piera Cuneo-Crovari*, G. Cassola, P. Crovari, N. Piersantelli, *University of Genoa, Institute of Hygiene and Preventive Medicine, Genoa, Italy. W.B.P.347 Benefits of AZT when Started at Increasing Times after AIDS/PCP Diagnosis. Steven M. Pounders*, S. D. Nightingale, V. Orcutt, S. Collins, J. D. Jockusch, *University of Texas Southwestern Medical Center, Dallas, TX, U.S.A. 477 [Page 478](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/478) W.B.P.348 Progression of et Athens, W.B.P.349 Zidovudine (AZT) in HIV-Positive Haemophiliacs. Seng Gee Lim*, C. A. Lee, M. Hales, P. L. F. Giangrande, P. B. A. Kernoff, *Haemophilia Centre and Haemostasis Unit, Academic Department of Haematology, Royal Free Hospital, London, U.K. W.B.P.350 Zidovudine Therapy in Homosexual/Bisexual Patients with AIDS-Related Complex (ARC) in Australia. Cheryl Elaine Swanson*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, Sydney, Australia. W.B.P.351 Cessation of Zidovudine (AZT) Therapy Leads to Increased Frequency of Viral Isolation. Mark A. Wainberg*, M. Fanning, J. Gill, K. Gelmon, J. S. G. Montaner, M. O'Shaughnessy, et al., *McGill University, Montreal, QC, Canada. W.B.P.352 Improvement of Survival in AIDS Patients with Zidovudine Therapy. Claudio Arici*, M. Rizzi, M. G. Finazzi, E. Minola, *Ospedali Riuniti di Bergamo, Department of Infectious Diseases, Bergamo, Italy. W.B.P.353 Efficacy of AZT at a Municipal Hospital Clinic. Jonathan Cohn*, A. McMeeking, H. Schlamm, M. Vogler, S. Allen, R. Holzman, *New York University, Bellevue Hospital, New York, NY, U.S.A. W.B.P.354 The Effect of Zidovudine (AZT) on Survival of AIDS Patients in San Francisco. George F. Lemp*, S. F. Payne, D. P. Neal, G. W. Rutherford, *San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.B.P.355 Zidovudine (AZT), Preventive Treatment of AIDS in HIV Seropositive Patients? Jean-Marc Tourani*, M. Stern, M. Volstein, W. Lowenstein, J. M. Andrieu, *Laennec Hospital, Paris, France. W.B.P.356 Open Trial of the Long-term Safety of Zidovudine: Interim Analysis. Linda Houle*, J. D. Peake, M. J. F. Fletcher, Canadian Zidovudine Collaboration Group, *Burroughs Wellcome Inc., Kirkland, QC, Canada. W.B.P.357 Disease Status and HIV Isolate Replication in 31 Haemophiliacs Including 11 AZT Treated Patients. Elio Boeri*, P. G. Mori, E. Franchini, T. Lanza, and Oncology, Genoa, Italy. W.B.P.358 Major Opportunistic Infections in AIDS Patients after Eight to One Hundred Fifty Weeks of Zidovudine Therapy. Dennis M. Causey*, J. M. Leedom, H. Melancon, *University of Southern California, Los Angeles, CA, U.S.A. W.B.P.359 Essai clinique du traitement des patients SIDA par la zidovudine. Bila Kapita*, M. Yemo, Kinshasa, Zaire. W.B.P.360 Zidovudine Delays Development of AIDS for Patients with 4C-2, 3 and 4A HIV Disease. Anita R. Rachlis*, M. Bonner, M. Fletcher, L. Houle, *Sunnybrook Medical Centre, University of Toronto, Toronto, ON, Canada. 478 [Page 479](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/479) W.B.P.361 Treatment with Retrovir in Different Stages of the HIV Infection. Elio Manzillo*, G. Maio, C. M. Izzo, S. Buonocore, G. Manzillo, *D. Cotugno Hospital, Naples, Italy. W.B.P.362 Efficacy and Tolerance of Zidovudine in Patients with Asymptomatic HIV Infection or with PGL. Tullio-Cataldo*, M. Piazza, *University of Naples, Clinic of Infectious Diseases, Naples, Italy. W.B.P.363 Long-term Assessment of Toxicity and Clinical Outcome in Treatment of HIV Infection with Zidovudine. Toby S. Dyner*, W. Lang, J. Geaga, J. Bender, *AIDS Clinical Research Project, Children's Hospital of San Francisco, San Francisco, CA, U.SA. W.B.P.364 Zidovudine Treatment in 100 Consecutive Patients with AIDS or AIDS-Related Complex. Alain T. Sobel*, F. Roudot, M. L. C. Filippi, I. Arcidiacono, M. Maggiore, Diseases Department, Lodi, W.B.P.366 et biologique de 108 malades traites par zidovudine sur une p6riode de 12 a 18 mois. J. P. Cassuto*, C. Boillot, A. Pesce, Service de interne II, Nice, France. W.B.P.367 AZT Therapy in Intravenous Drug Users (IVDUs) and Their Sexual Partners. Alice Spears*, S. Landesman, R. Shafer, K. Chirgwin, J. De Hovitz, *Kings County Hospital, Brooklyn, NY, U.SA. W.B.P.368 Treatment of Symptomless HIV Seropositive Subjects by Azidothymidine (AZT). A Control Study in 56 Patients. Daniel Vittecog*, J. J. Lefrdre, P. Lambin, J. F. France. W.B.P.369 Intermittent Zidovudine Regimen: Toxicity and Efficacy. Neil J. Bodsworth*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, University of New South Wales, Surry Hills, Australia. W.B.P.370 Long-term Safety and Efficacy of Zidovudine in Large Cohorts of IV Drug Abusers: 20-Month Experience with 200 Asymptomatic, 500 ARC and 400 AIDS Patients. Stefano Vella*, F. Menniti Ippolito, M. G. Agresti, P. Pezzotti, Institute of Health, Rome, Italy. W.B.P.371 Use of Zidovudine (AZT) in Injection Drug Use (IDU) Related HIV Infection: Clinical Outcome. Frances M. Cowan*, M. E. Jones, P. J. Flegg, L. R. MacCallum, R. P. Brettle, J. A. Gray, et al., *City Hospital, Department of Infectious Diseases, Edinburgh, U.K. W.B.P.372 Zidovudine in ARC and AIDS Patients: Clinical, Immunological and Virological Efficacy. Gerd Hiffken*, M. Petri, M. Deppermann, W. Ludwig, Universitdt Berlin, Klinikum Steglitz, Federal Germany. 479 [Page 480](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/480) W.B.P.373 Compliance with Zidovudine Therapy Y. Williams*, J. Noel-Connor, W. El-Sadr, *Harlem Hospital Center, Infectious Disease Section, New York, NY, U.S.A. W.B.P.374 Interferon (IFN) Alpha+ AZT in AIDS-Associated Kaposi's Sarcoma (KS): Final Results of a Phase I Trial. Susan E. Krown*, D. Bundow, B. Gansbacher, J. Gold, N. Flomenberg, D. Armstrong, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.B.P.375 Outpatient Transfusion Therapy for Retrovir-Associated Anemia. Susan Weiss*, E. Visser, P. Rodgers, A. McMeeking, H. Schlamm, *AIDS Program, Bellevue Hospital Center, New York, NY, U.S.A. W.B.P.376 Self Care Nursing for AIDS/ARC Via Computer Networks. Stefan J. Ripich*, P. F. Brennan, *Case Western Reserve University, Cleveland, OH, U.S.A. W.B.P.377 Complementary Therapies at Casey House Hospice: A Model for Traditional/Alternative Interaction. William E. Berinati*, *Casey House Hospice Inc., Toronto, ON, Canada. W.B.P.378 Problems an AIDS Hospice Setting. JeffA. Bloom*, J. Flannery, *Casey House Hospice Inc., Toronto, ON, Canada. W.B.P.379 Development of a Day Facility for People with AIDS/HIV Infections. Ann Kelly St. Stephen's Hospital, London, U.K. W.B.P.380 Fonctions du psychiatre dans un U158, Hdpital Claude Bernard, Paris, France. W.B.P.381 Implantable Infusion Ports in Patients with AIDS. B. Lynn Johnston*, Y. Lynch, T. Marrie, *Dalhousie University, Halifax, NS, Canada. W.B.P.382 Follow-up of Infants Born to HIV-Infected Mothers in Argentina. Mercedes C. Weissenbacher*, B. Massa, M. Gomez Carrillo, N. Fernandez, M. Balbaryski, M. Boxaca, et The Impact of AIDS on Families of Haemophiliacs in Wales. Jacqueline Y. Beese, University of Wales, College of Medicine, Cardif, U.K. 480 481](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/481) Notes Poster animaux Animal Models W.C.P.1 Aerosol Delivery of Pentamidine to the Deep Lung: A Model of Isotopic Quantitation in Baboons. P. Choutet*, C. Jubault, J. L. Lemarie, A. S. Honjo, M. Hayami, et al., * University of Tokyo, Institute of Medical Science, Tokyo, Japan. W.C.P.3 Persistent HIV-2 Infections of Rhesus, Macaques, Baboons Nicol*, Flamminio-Zola, I. Desportes, D. * UniversitJ Paris VI, Physiologie cellulaire, Paris, France. W.C.P.4 A Rabbit Model of HTLV-I Infection: Seroconversion Patterns and Detection of Virus by PCR. Michael D. Lairmore*, G. C. Cockerell, T. M. Hartley, B. K. De, J. Rovnak, I. Miyoshi, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. W.C.P.5 CD8+ and CD4+ Responses to HIV-1 Pasteur, Infected Murine AIDS. Lazdins*, R. M. Cozens, J. D. *CIBA-GEIGY Ltd., Basel, Switzerland. W.C.P.7 Rhesus and Kitchin*, Cranage, E. J. Stott, A. Baskerville, * WorldHealth Organization AIDS Collaborating Centre, NIBSC, South Mimms, U.K. W.C.P.8 Strain Specificity of Lymphocyte Proliferative Responses in Experimental Animals Immunized with Recombinant HIV-1 gpl20 Antigens. Peggy A. Wentworth*, B. Doe, N. Haigwood, J. Shuster, C. Scandella, K. Steimer, *Chiron Corp., Emeryville, CA, U.S.A. W.C.P.9 The Significance of Premature Stop Codons in env of SIV. Dawn P. WooleV*, T. Naidu, H. Kestler, Y. Li, R. Desrosiers, *Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A. 482 [Page 483](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/483) W.C.P.10 Construction and Characterization of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of SIVmne. Shiu-Lok Hu*, B. M. Travis, K. Abrams, J. Chinn, W. R. Morton, R. Benveniste, *Oncogen, Seattle, WA, U.S.A. W.C.P.11 FIV-AIDS Model for Testing Novel Vaccine Approaches for Human AIDS.JanetK. Yamamoto*, T. Okuda, *School of Veterinary Medicine, Department of Medicine, Davis, CA, U.S.A. W.C.P.12 Evolution of the Envelope Gene of SIVmac-BK28. Paul F. Edmonson*, M. Murphey-Corb, V. Hirsch, J. I. Mullins, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A. W.C.P.13 Isolation and Preliminary Characterization of a Neurotropic Strain of Feline Leukemia Virus. Peter W. Gasper*, L. R. Whalen, J. Overbaugh, D. W. Wheeler, S. W. Dow, M. L. Poss, *Pathology Department, Colorado State University, Fort Collins, CO, U.S.A. W.C.P.14 In Situ Immunoassaying Suggests Central Neuroendocrine Involvement in Infant Feline AIDS (FAIDS). Manuel J. Torres-Anjel*, B. Ray, J. C. Elliott, J. G. Tshikuka, *University of Missouri at Columbia, Columbia, MO, U.S.A. W.C.P.15 In Vivo Analysis of the Minimal Infectious Dose of an Acutely Lethal Pool of SIV (SIV/SMM/PBj-14). Harold M. McClure*, D. C. Anderson, A. Ansari, P. Fultz, *Emory University, Atlanta, GA, U.SA. W.C.P.16 HIV-1 Infection in a Continuous Rabbit Macrophage Line. Kuluga*, D. Recker, E. Gugel, T. *NIHM, St. Elizabeth's Hospital, Washington, DC, U.S.A. W.C.P.17 Regulation of the Visna Virus LTR in Macrophages Involves Cellular Factors Which Bind Sequences Containing AP-1 Sites. Dana H. Gabuzda*, J. Hess, A. Dela Torre, J. Small, J. Clements, *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A. W.C.P.18 Infection with Simian Immunodeficiency Virus (SIV) Via Conjunctival and Mucosae Newborn Rhesus Macaque. Myra B. Jennings*, N. Lerche, S. Tillery, J. Yee, L. Antipa, P. Chesney, *University of California at Davis, Davis, CA, U.S.A. W.C.P.19 Therapy of MAIDS (LP-BM5 Infection of C57BL-6 Mice) with Diethyldithiocarbamate (DTC). Carole Funk*, D. Mosier, E. Petersen, E. Hersh, *University of Arizona, Tucson, AZ, U.S.A. W.C.P.20 et *Institut Paris, Japan. W.C.P.22 Un modele exp6rimental du SIDA chez la souris, qui elicite des infections et des angiosarcomes (AS). Manon F. Dubd*, Serologic the Simian Immunodeficiency Virus Model. ToAnn L. Yee*, M. B. Jennings, N. W. Lerche, J. R. Carlson, * University of California at Davis, Davis, CA, U.SA. W.C.P.24 Enhancement of Antiviral Therapy in HIV Infection Using Blood-Brain Barrier (BBB) Modification with Insulin: Animal Data and Clinical Considerations. Steven G. Avre*, B. Skaletski, A. D. Mosnaim, *Chicago Medical School, Antioch, IL, U.SA. W.C.P.25 Lack of Vertical Transmission of SIVagm in a Breeding Colony of Cercopithecus Aethiops. Birgit Bak V Laboratory, Copenhagen, Denmark. W.C.P.26 Infection of Old World Monkeys. Blesila A. Cato\" J. W. Eichtberg, N. W Lerche, J. A. Levy, * University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.SA. W.C.P.27 Mechanism of Downregulation of CD4 Expression by Plastic Adherent Human Macrophages In Vitro. L. MJ Lathijs*, F. Kazazi, P. Malafiej, P. Foley, A. L. Cunningham, * Virology Unit, Westmead Hospital, Westmead, Australia. W.C.P.28 Culture Requirements for H1V-1 Isolation from Infected Chimpanzees. Paolo A. Piazza*, K. E. Kobb, J. W. Eichberg, *Souttnest Foundation for Biomedical Research, San Antonio, TX, U.S~A. W.C.P.29 Primary Retroviral Infection Versus Chronic Viremia: Differential Response to Therapy. Ruth M. Ruvrecht\"', S. Mullaney, J. Andersen, *Dana-Farber Cancer Institute, Boston, MA, U.S~A. W.C.P.30 Pathology of Early Lesions in SWV Encephalitis. L~eroy R. Sharer*, L. G. Epstein, J. Michaels, M. Murphey-Corb, L. N. Martin, G. B. Baskin, *New Jersey Medical School Department of Pathology, Newark, NJ, U.S~A. W7.C.P.31 HIV-1 Antigenemia in Athymic 'Nude\" Mice. Neal T. Wetherall*, A. Erling, * Vanderbilt University, Medical Center, Department of Pathology, Nashville, TN, U.S~A. W.C.P.32 Langerhans Cells in Rhesus M. Wirthlin, J. Greenspan, et al., *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.S~A. W.C.P.33 Inoculation of Baboons and Macaques with Virus Produced from SIVfMne Molecular Clone. William R. Morton*, L. Kuller, E. A. Clark, M. J. Gale, K. Foy, J. Overbaugh, et al., *Regiop.al Primate Research Center, University of Washington, Seattle, WA, U.S~A. W.C.P.34 Mutational Analysis of the Cytoplasmic Domain of SlY Protein. Lisa A. Chakrabarti*, P. Tiollais, P. Fargnoli, Inc., Rockville, MD, U.SA. W.C.P.36 Clinical and Infection. Takuo Taniguchi, and Zootechnical College, Musashino, Japan. W.C.P.37 Establishment FIV-Producing Cell Lines FIV Seropositive Cats. Joe Chiba*, S. Ishida, National Institute ofHealth, Diagnosis with Kaposi's Sarcoma (KS) Predictors of Shortened Survival. Paul A. Volberding*, A. Moss, P. Bacchetti, E. Winger, R. Edison, P. Cusik, et al., *AIDS Activities Division, San Francisco General Hospital, San Francisco, CA, U.S.A. W.C.P.39 Human Recombinant IL-2 Induces Cytotoxic Tompkins, Tompkins, *North Carolina State University, College of Veterinary Medecine, Raleigh, NC, U.S.A. W.C.P.40 Isolation and Partial Characterization of an HIV-1 Related Virus Occurring Naturally in Chimpanzees in Gabon. Martine Peeters*, R. W. Cooper, C. Honord, T. Huet, Franceville, W.C.P.41 Infection in the Rabbit. Thomas J. Kindt*, H. Kulaga, M. E. Truckenmiller, D. Recker, T. M. Folks, *NIAID, Laboratory of Immunogenetics, National Institutes of Health, Bethesda, MD, U.S.A. W.C.P.42 P24 Antigen in the CSF and Serum of Patients with Non-Hodgkin's Lymphoma Treated with Standard Chemotherapy with or without GM-CSF. James O. Kahn*, L. A. Kaplan, S. Crowe, P. Volberding, *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. W.C.P.43 HIV-1 Infection of Human Fetal Central Nervous System Tissue. Ruy Soeiro*, K. Tanaka, W. Cihak, S. Udem, A. Rubinstein, W. D. Lyman, *Albert Einstein College of Medicine, Bronx, NY, U.SA. W.C.P.44 Natural Antibody Perception of Amino Acid Divergence within an HIV-1 Neutralization Epitope. Jaap Goudsmit*, G. Zwart, M. Bakker, L. Epstein, C. Kuiken, F. De Wolf, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands. W.C.P.45 HIV- 1 Brain Infection: Distribution of Infection and Clinical Correlates. Richard W. Price*, K. C. Cronin, M. Rosenblum, B. J. Brew, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.SA. W.C.P.46 Differences in Risk for AIDS and AIDS Mortality in 49 Individuals Infected with Low- and High-Virulent HIV Variants. Matthijs Tersmette*, J. M. A. Lange, R. E. Y. Goede, J. G. Huisman, J. Goudsmit, F. Miedema, *Central Laboratory Blood Transfusion Service, (KS) Derived Cells Express Cytokines with a Potential Role in the Pathogenesis of KS Lesions. Barbara Ensoli*, S. Nakamura, S. Z. Salahuddin, F. Wong-Staal, R. C. Gallo, *Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A. W.C.P.49 Miscellaneous Carcinomas Developing in Patients with HIV Infection. Mark U. Rarick*, D. Sharma, P. S. Gill, L. Bernstein, M. Bernstein-Singer, A. M. Levine, *University of Southern California, Los Angeles, CA, U.S.A. W.C.P.50 49 Unusual HIV-Related Malignant Tumors. Umberto Tirelli*, HIV-HPV and Penile Carcinomas (PC) Uganda. Franco M. Buonaguro*, E. Beth-Giraldo, M. L. Tornesello, E. Katongole-Mbidde, M. Monaco, G. Giraldo, G. Naples, Italy. Simian AIDS with Retroperitoneal Fibromatosis Associated with Type D Retrovirus (SRV-2) Infection. Cheng C. Tsai*, J. Sligh, M. D. Woon, S. T. Roodman, *St. Louis University School of Medicine, St. Louis, MO, U.SA. W.C.P.53 Cervical Neoplasia in HIV-Infected Women. Wolfgang B. Schwartldnder, *Free University of Berlin, Deparment of Obstetrics and Gynecology, Berlin, Federal Republic of Germany. W.C.P.54 Characteristics of In Vitro Culture of KS-Derived Cells. Peter Biberfeld*, S. Nakamura, Z. S. Salahuddin, B. Ensoli, R. C. Gallo, *Immunopathology Laboratory, Department Stockholm, Sweden. Pathogenbse Pathogenesis W.C.P.55 Vacuolar Myelopathy: HIV-1 Expression Correlates with Extent of Clinical and Pathologic Disease. Barbara Weiser*, N. Peress, D. Eilbott, D. LaNeve, R. Seidman, H. Burger, *State University of New York at Stony Brook, Division of Infectious Diseases, Stony Brook, NY, U.SA. W.C.P.56 HIV-1 Antigenic Variants with Distinct Biological Properties Emerge at the Decline of the Homologous Antibody. Jean-Jacques De Jong*, M. Tersmette, W. Krone, R. Meloen, J. Goudsmit, *AMC, Department of Human Retrovirus Laboratory, Amsterdam, Netherlands. 486 [Page 487](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/487) W.C.P.57 Early Appearance of Crossreactive Antibodies Specific for a Common Epitope in gp4l and HLA Class II Antigens Can Inteffere with Normal Immune Functions in AIDS Patients. LLaw..GQkjing*, G. M. Shearer, K. Hiliman, J. Manischewitz, B. Golding, *Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S~A. W.C.P.58 HIV-Infected Humans, but not Chimpanzees, Have Cytoxic T Lymphocytes That Lyse Uninfected CD4+ Cells. Patricia A. Moron*, J. M. Zarling, J. A. Ledbetter, J. W.C.P.59 Induction of Human from Chronically Infected Clones by Cytokines and Pharmacological Agents Requires Protein Kinase C Activation. AurvKne* W. Maury, G. Poli, A. S. Fauci, T. M. Folks, *National institutes of Health, Rockville, MD, U.SAl. W.C.P.60 Pathology, Auguste-Viktoria-Krankenhaus, Berlin, FederalRepublic of Germany. W.C.P.61 HIV-1 Infection of Human Fetal Central Nervous System Organotypic Cultures. William D). Lymn*~n, M. Tricoche, Y. Kress, W. Hatch, F. C. Chiu, R. Soeiro, *Albert Einstein College of Medicine, Department of Pathology, Bronx, NY, U.S~A. W.C.P.62 Use of Polymerase Chain Reaction (PCR) to Detect the Presence of HP/-i DNA in Subpopulations of Peripheral Blood Mononuclear Cells (PBMCS) in Infected Individuals. Steven M. Schnittman*, M. C. Psallidopoulos, H. C. Lane, M. Baseler, N. P. Salzman, A. S. Fauci, *NiAID, National Institutes of Health, Bethesda, MD, U.SA. W.C.P.63 HIV Infection Alters the Interaction of Macrophages with and Leishmania. D. Chester Kalter*, H. Gendelmazn, J. Orenstein, M. S. Meltzer, S. Reed, *H. M. Jackson Foundation, Bethesda, MD, US A. W.C.P.64 Infection of Human Fetal Brain Macrophages and Mixed Neural Cells in Tissue Culture by HIV-1. Ke uazk* H. Goldman, X. Q. Bai, I. Wong, M. A. Wainberg, *Mc~ill University, Montreal Children's Hospital Research Institute, Montreal, QC, Canada. W.C.P.65 General Decrease of Leukocyte Viability of AIDS Patients in Serum-Free Medium. DeieGutr*, V. Favier, M. Hardefelt, M. Adams, L. Montagnier, *Inirtitut Pasteur, Paris, France. W.C.P.66 Mechanisms of Ben Zr* T. Kaunath, K.-O. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany. W.C.P.67 CNS and Lymph Node Changes in HIV Infection. &Ltr ibeJfeld*, C. V. Parravicini, A. L. Petr~n, R. C. Gallo, *Immunopathology Laboratory, Secretion by Human Monocytes/Macrophages May Contribute to Tissue Inflammation in AIDS Patients. Phillip D. Smith*, C. L. Lamerson, S. S. Saini, L. M. Wahl, S. M. Wahl, *National Institutes of Health, Bethesda, MD, U.S.A. W.C.P.69 Altered Brain Metabolites in AIDS Dementia as Measured by Magnetic Resonance Spectroscopy. Peter C. Jensen*, B. Hubesch, R. Parks, R. Deicken, P. Krell, M. Weiner, et al., *VA Medical Center, University of California at San Francisco, San Francisco, CA, U.S.A. W.C.P.70 Induction of HIV-1 from Latently Infected CNS Derived Cells. M. Laughlin, J. M. Harouse, F. Gonzales-Scarano, *University ofPennsylvania, Medical Center, Philadelphia, PA, In Activation of Alveolar Macrophages and Lymphocytes in Spontaneous Interstitial Lung Disease Due to the Visna-Maedi Virus in Sheep. Genevieve Cordier*, J. le HIV. Jacques Leibowitch*, D. Mathez, D. Cesari, C. Poincard, Garches, France. W.C.P.73 Altered IgG-Subclass Distribution in Lymph Node Cells and Serum of Patients withHIV Infection. Fredrik Miiller*, S. *University of Oslo, Rikshospitalet, Oslo, Norway. W.C.P.74 The Effect of HIV on Membrane Lipids of Lymphocytes. Ami Klein*, P. Gordon, S. Ramcharitar, M. Wainberg, *Department of Center, W.C.P.75 Simian Bone Marrow Hematopoietic Progenitor J. Ringler, N. L. Letvin, P. A. DeLong, *Harvard Medical School, New England Regional Primate Research Center, Southborough, MA, U.S.A. W.C.P.76 Infection of Glial Cells Expressing the CD4 Molecule. Janet M. Harouse*, F. Gonzalez-Scarano, M. A. Laughlin, H. Friedman, B. Godfrey, J. Hastings, *University of Pennsylvania, Department of Neurology, Microbiology and Medicine, School of Medicine, Philadelphia, PA, U.S.A. W.C.P.77 Role of Endotoxin in Modulation of HIV Expression in a Monocytic Cell Line. Jean-Michel H. J. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. W.C.P.78 Production de TNF et d'IL-1B par les Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. W.C.P.79 HIV-2 Envelope Glycoproteins and Cell Fusion. Mark J. Mulligan*, P. Kumar, H. Hui, D. Ritter, B. Hahn, R. Compans, *University of Alabama at Birmingham, Department of Microbiology, Birmingham, AL, U.SA. 488 [Page 489](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/489) 'W.C.P.80 CMV Is not a Cofactor in the Progression of HIV Infection. Lawrence W.De* H. Brodie, W. R. Byrne, C. Graham, A. Kadakia, M. T. Williams, *Mount Zion Hospital and Medical Center, San Francisco, CA, U.ScA. W.C.P.81 Aberrant Circadian Physiologic, Immune and Rhame*, R. Sothern, L. Sackett-Lundeen, C. Suarez, W. Hrushesky, * of Minnesota, Minneapolis, MN, U.S~A. W.C.P.82 Regulation of Cytokine Receptor Expression by HIV. Allan S. Lau*, M. Dion, J. F. Livesey, *Hospital for Sick Children, Division of Infectious Diseases, Toronto, ON, Canada. W.C.P.83 Enhanced Production of Tumor Necrosis Factor in Symptomatic LIlY Infections. Allan S. Lau*, S. E. Read, S. Der, *Hospital for Sick Children, Division of Infectious Diseases, Toronto, ON, Canada. W.C.P.84 Analysis of Brain from AIDS Patients for LHlY-i DN\\A Sequences Using the Polymerase Chain Reaction (PCR). Hakan Gadler*, B. H. Hahn, G. M. Shaw, B. J. Brew, M. Rosenblum, R. W. Price, *Memarial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY, U.S.A. W.C.P.85 Effects of Tumor Necrosis Factor (TNF-a), Gamma Interferon and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) on HIV Replication in HIV-Infected Human Cell Lines. Edu~ardo Cortes*, J. P. Koeffler, J. Q2. Zhao, R. T. Mitsuyasu, * University of California at Los Angeles, Los Angeles, CA, U.SAI. W.C.P.86 Presence of HIV-1 in the Sperms of HIV-l Seropositive Individuals by DNA-Hybridization and Immunogold Methods. Bagasra*, Freund, D. Condoluci, B. Hemns, J. Weidman, J. Comida, * University of Medicine and Dentistry of New Jersey, Camden, NJ, U.SA. W.C.P.87 Presence of Tumor Necrosis Factor in the Cerebral Spinal Fluid (CSF) of AIDS Patients with HIV Encephalopathy. Victor L. Perez*, R. Janssen, T. Spira, A. S. Fauci, R. Dubois, T. M. Folks, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.SA. W.C.P.88 Detection of Unintegrated Viral DNA in HIV-1 Infection: Use of a Rapid and Easy PCR Method. Suczanne Jurriaans*, J. Geelen, L. Epstein, M. Clement, Lange, J. Goudsmit, *AMC, Department of Virology, Human Retrovirits Laboratory, Amsterdam, Netherlands. W.C.P.89 Serum Capacity to Inhibit Reverse Transcriptase In Vitro Distinguishes HIV-1 Infection from LIIV-2 or SIV Infection. Jaav of Virology, Human Retrovirus Laboratory, Amsterdamn, Netherlands. W.C.P.90 Expression of a Potential HIV Receptor on Human Gastrointestinal Epithelial Cells (GIECs). Mary Pat Moyer*, R. I. Huot, D. A. Wideman, D. W. Martin, * University of Texas Health Science Center at San Antonio, Department of Surgery, San Antonio, TX, U.S.A. 489 [Page 490](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/490) W.C.P.91 Cell-Specific Control of HIV in Cells. Volker Erfle*, W. Republic of Germany. W.C.P.92 Neutralizing and Enhancing Antibodies in Different Stages of HIV Infection. Eszter Uihelyic*, F. Tdth, B. Szabd, A. Horvdth, Bdnhegyi, et al., *National Institute of Hematology and Blood Transfusion, Budapest, Hungary. W.C.P.93 Low Plasma Cysteine and Elevated Glutamate Levels in HIV-1+ Patients May Contribute to Loss of T-cell Functions. Wulf Drye*, H.-P. Eck, H. Frey, *The German Cancer Research Center, Institute of Immunology and Genetics, Heidelberg, Federal Republic of Germany. W.C.P.94 Identification of Phenotypic Ultrastructures of Lymphocytes Reacting with H. *Biomedco Canada Inc., Montreal, QC, Canada. W.C.P.95 Longitudinal Study of HIV Antibody Responses of Infants Born to Seropositive Women in Zaire. David A. Katzenstein*, R. M. Hendry, W. Nsa, C. Ryder, C. Brown, T. C. Quinn, et al., *Laboratory of Retrovirus Research, Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A. W.C.P.96 Neutralizing Antibodies in Seropositive Subjects from Africa, South and North America against 4 Divergent Strains of HIV. David A. Katzenstein*, L. Vujcic, A. Latif, B. Galvao, N. Halsey, G. V. Quinnan, et al., *Laboratory ofRetrovirus Research, Division of Virology, CBER, Food and Drug Administration, Bethesda, MD, U.S.A. W.C.P.97 Specific Defect in Tissue Factor Expression in Monocytes from AIDS Patients. Janet L. Lathey*, J. M. Agosti, L. Corey, T. S. Edgington, M. B. A. Oldstone, J. A. Nelson, *Research Institute of Scripps Clinic, La Jolla, CA, U.S.A. W.C.P.98 Antibodies to gp41 Peptide (HIVIS, aa 583-599) do not Correlate Significantly with Protection from Disease in HIV Infection. Rachanee Cheingsong-Popov*, K. Caun, C. Panagiotidi, J. Blomberg, J. Weber, *Royal Postgraduate Medical School, Hammersmith Hospital, Department of Medicine, London, U.K. W.C.P.99 Autoimmunity against Neutrophils and Thrombocytes in Different Stages of HIV Infection. Robert J. L. Klaassen*, J. W. Mulder, A. B. J. Vlekke, J. M. A. Lange, A. E. G. von dem Borne, *Central Laboratory of the Blood Transfusion Service,Amsterdam, Netherlands. W.C.P.100 HIV Target Cells in Testes and Epididymides from AIDS Patients. Axe Ellrodt*, R. Vazeux, D. Henin, Hachouel, C. Thea*, A. Pereira, C. Sterling, G. T. K. Keusch, *New England Medical Center Hospitals, Boston, MA, U.S.A. 490 [Page 491](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/491) W.C.P.103 A Possible Block of VIP Dependent Neuronal Survival by gpl20 in AIDS Dementia Complex. Junko Kimura-Kuroda*, K. Yasui, T. Iwasaki, *Tokyo Metropolitan Institute for Neurosciences, Department ofMicrobiology, Fuchu-city, Japan. W.C.P.104 The Early Steps of T Lymphocyte Activation and Inhibition by HIV-2, STLV-III, and Different Strains of HIV-1. Bo Hofmann*, P. Nishanian, P. Insixiengmay, J. L. Fahey, *University of California at Los Angeles, School of Medicine, Department of Microbiology/Immunology, Los Angeles, CA, U.S.A. W.C.P.105 Viral Antigen Stimulation of the Secretion of Human Monokines Capable of Regulating HIV-1 Expression. Kathleen Clouse*, I. Washington, P. B. Robbins, B. Fernie, J. M. Ostrove, A. S. Fauci, *Georgetown University, Department of Microbiology, Washington, DC, U.S.A. W.C.P.106 Efficient HIV Isolation from Healthy Seropositive Individuals Using Normal Monocyte Targets: Implications for HIV Cell Tropism. Guido Poli*, F. E. Massari, S. M. Schnittman, H. C. Lane, A. S. Fauci, *National Institutes of Health, Rockville, MD, U.S.A. W.C.P.107 TNF-a Can Induce the Expression of HIV from Chronically Infected Cells in an Autocrine Fashion. Guido Poli*, J. Justement, A. Kinter, K. Clouse, T. M. Folks, A. S. Fauci, et al., *National Institutes of Health, Bethesda, MD, U.S.A. W.C.P.108 Qualitative Differences in HIV-1 and HIV-2 Infections of a Panel of CD4+ T-Cell Clones. Guido Poli*, E. Duh, A. Rabson, F. Clavel, A. S. Institutes ofHealth, U.S.A. GM-CSF Inhibition of Susceptibility of M-CSF Treated Human Monocytes to In Vitro Infection with HIV. Ferdinand Massari*, G. Poli, A. S. Fauci, *National Institutes of Health, Rockville, MD, U.S.A. W.C.P.110 Thymus Involvement in AIDS Pathogenesis: In Vitro Studies of Thymus Infection. Anita De Rossi*, M. L. Calabro, D. Bernardi, W.C.P.111 Inhibition of HIV-1 Replication with Reverse Transcriptase Inhibiting (RTI) Antibody in Lymphocyte Cultures. Tomohiko Takasaki*, D. Imagawa, M. Lee, H. Kusakabe, K. Sugita, P. Nishanian, et al., *Harbor-University of California at Los Angeles Medical Center, Torrance, CA, U.S.A. W.C.P.112 Virologic Markers of Central Nervous System HIV Infection in HIV Seropositive Homosexual Men without Neurological Symptoms. Robert W. Coombs*, A. C. Collier, K. Chloupka, J. Dragavon, H. H. Handsfield, L. Corey, *University of Washington, Virology Office, Children's Hospital, Seattle, WA, U.S.A. W.C.P.113 In Vitro Interactions of HIV with Neurons, Astrocytes and Microglial Cells. Marc Tardieu*, C. Hery, O. Boesplug, Montagnier, al., *INSERM U56, Le Kremlin-Bicetre, France. 491 [Page 492](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/492) W.C.P.114 Raised Levels of Circulating Tumour Necrosis Factor in Patients with AIDS: Pathogenetic J. Ldhdevirta, A. M. Teppo, H. Repo, *Fourth Department of Medicine, University of Helsinki, Helsinki, Finland. W.C.P.115 Anaemia and Lymphopenia in HIV Infection: Relation to Serum Levels of Tumour Necrosis Factor-. C. P. J. Maurv*, A. M. Teppo, *Fourth Department of Medicine, University of Helsi'nki, Helsinki, Finland. W.C.P.116 Replication of HTV- 1 and Insertion and Deletion Mutants in Human Cell Lines. Volker Heisig*, G. Jahn, D. Zagury, *1MM!, Hamburg, Federal Republic of Germany. W.C.P.117 JZmmunohistochemical Analysis of Germinal Centers in Rectal Biopsies of Patients with HIV- 1 Infection. PalRc\" K. Tenner-Racz, H. Schmidt, M. G. Hartmann, M. Popovic, *Institute for Tropical D iseases, Hamburg, Federal Republic of Germany. W.C.P.118 Evidence for Intrafollicular Virus Replication in Genninal Centers of Lymph Nodes of Cats Infected with FelV. Klara Tenner-Racz*, F. Noronha, H. Schmidt, P. Racz, *A.K. St. Georg, Hamburg, Federal Republic of Germany. W.C.P.119 Establishment of a Cell Line Chronically Infected but not Producing HIV-1 from an Asymptomatic Seropositive Subject. EausoLF.juti*, M. Federico, A. Borsetti, L. Verani, G. B. Rossi, *Istituto Superiore di Sanitci, Rome, Italy. W.C.P.120 Increased Production of Acid Metabolites (Prostaglandin E2 and Thromboxane B2) by Monocytes from Drug Addicts (JYDA) Infected with Human Immunodeficiency Virus. Edad P. Fernandez-Cruz*, I. M. Zabay, N. Longo, G. Gomez, J. Rosello, 1. Ramis, et al., *FHospital General the N. Habermehl, *Institute for Clinical and Experimental Virology, Free University of Berlin, Berlin, Federal Republic of Germany. W.C.P.123 HIV-Associated Changes in ta*, B. Vayuvegula, * University of California at Irvine, Irvine, CA, U.S.A. W.C.P.124 Prevalence and Significance of Antibodies to nef (p27) in HIV-1 Infection. Rachanee Cheingsong-Pooov*, C. Panagiotidi, S. Bowcock, J. Weber, *Royal Postgraduate Medical School, Hammersmith Hospital, Department of Medicine, London, U.K. W.C.P.125 Human Herpesvirus 6 (HHV-6) as a Potential Cofactor in AIDS. Paolk Lusso*, B. Ensoli, F. Negro, S. DeRocco, P. Markham, R. Gallo, et al., *National Cancer Institute, National Institutes Health, MD, D'Auriol*, Vazeux*, Cumont, Montagnier, Blocking and by an HIV Envelope-Derived Synthetic Peptide. W. John Morrow*, T. Kieber, J. Krowka, L. Wing, A. Whalley, L. Berquist, *IDEC Pharmaceuticals Corp., La Jolla, CA, U.S.A. W.C.P.129 W.C.P.130 Hypothesis: AIDS Is an Autoimmune Disease Caused by HIV Plus Allogeneic Cells. Geoffrey W. Hoffmann*, M. D. Grant, *University of British Columbia, Department of Microbiology, Vancouver, BC, Canada. W.C.P.131 Quantitation and Modulation of HIV p24 Antigen Content A. Borcich, D. P. Kotler, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. W.C.P.132 Creation of a New Target Cell Type for HIV-1. Mary Jane Potash*, D. J. Volsky, *St. Luke's-Roosevelt Hospital, Columbia University, New York, NY, U.S.A. W.C.P.133 HIV DNA Is Present in a High Percentage of Peripheral Blood Mononuclear Cells in Infected Individuals. Karen Hsia*, E. LeBlanc, S. A. Spector, *University of California at San Diego, Medical Center, San Diego, CA, U.S.A. W.C.P.134 Plasma-Associated Human Immunodeficiency Virus Type-1 (HIV) Is a Marker of Progression of HIV Infection. Robert W. Coombs*, A. C. Collier, K. Chaloupka, L. Corey, *University of Washington, Children's Hospital, Seattle, WA, U.S.A. W.C.P.135 Blocking of Antibody-Enhanced HIV-1 Infection by Recombinant Soluble CD4 (rCD4). Michael Zeira*, R. A. Byrn, J. E. Groopman, *New England Deaconess Hospital, Harvard Medical School, Boston, MA, U.S.A. W.C.P.136 HIV-2 Seroconversion in Senegal, West Africa. Phyllis Maayan, S. M'Boup, R. Marlink, K. Travers, M. Essex, et al., *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. W.C.P.137 Stress Mediated Induction of HIV Expression from a Chronically Infected Promonocytic Cell Line. Sharilvn Stanley*, T. M. Folks, A. S. *National Institutes Bethesda, MD, U.S.A. W.C.P.138 Anti-Histone H2B in HIV-Seropositive Individuals. W. John Morrow*, A. S. Whalley, C. Leahy, J. Rosenberg, R. B. Stricker, J. A. McCutchan, *IDEC Pharmaceuticals Corp., La Jolla, CA, J. Stratigos, et al., \"Ahn University Medical School, Athens, Greece. Additionnels Addi tional W.C.P.141 Experimental Infection of Cynomolgus Monkeys Per Putkonen*F, B. Bdittiger, K. Warstedt, R. Thorstensson, J. Albert, G. Biberfeld, *National Bacteriological Laboratory, Department of Immunology, Stockholm, Sweden. W.C.P.142 Effect of Whole Body Hyperthermia on Cats Infected with Feline Leukemia Virus. Dennis W. Macy*, P. W. Gasper, S. A. Oulton, N. S. Zeider, E. L. Gillette, R. J. Scott, M. L. McGee, *Colorado State University, Veterinary Teaching Hospital, Fort Collins, CO, U.S~A. W.C.P.143 Experimental Infection of Specific Pathogen-Free (SPF) Cats with U.K. Isolates of Feline Immunodeficiency Virus (FlYV). Cherida D. Hovver*, D. A. Harbour, T. J. Gruffydd-Jones, * University of Bristol, Langford, U~K W.C.P.144 A Mouse Model for Investigating HIV-1 Replication. Barney S. Graham*, N. Wetherall, *Vanderbilt University, Division of Infectious Diseases, Nashville, TN, U.SA. W.C.P.145 Analysis of Guinea Pig Dermal Hypersensitivity to HIV Whole Virus Irumunogen. Michael S. Asche r, H. Sheppard, *Caltfornia Department of Health Services, Viral and Rickettsial Disease Laboratary, Berkeley, CA, U.S~A. W.C.P.146 Growth Characteristics Kaposi's Chg.1TsL*,.J. C. Sligh, M. D. Woon, *St. Louis University School of Medicine, St. Louis, MO, U.S.A. W.C.P.1147 Development of a Study Set on the Pathololgy of Simian Retroviral Diseases. Jorge L. Ribas*, G. Baskin, N. W. King, H. M. McClure, L. J. Lowenstine, M. L. Axthelm, et al., * Walter Reed Army Institute of Research, Division of Retrovirology, Washington, DC, U.SA. W.C.P.148 Biochemical and Biomechanic Substantiation of AIDS Laser Therapy and Trials of Elaboration of Laser-Metabolic Antiviral and Anticancer Trap. V. Vasilionkaitis, Lithuanian D D Wednesday, June 7 * LeSIDA et l'individu AIDS and the Individual Session d'affichage Poster Session Counseling Counselling W.D.P.1 HIV Partner Notification within an Anonymous Testing System. Evelyn M. Blankenship*, J. M. Owen-O'Dowd, D. H. Jolly, W. J. Petz, R. A. Meriwether, *Division of Health Services, AIDS Control Program, Raleigh, NC, U.S.A. W.D.P.2 Intensive HIV Counselling Following Serostatus Notification Associated with a Low Divorce Rate in 122 Serodiscordant Zairian Married Couples. Kashama Mbuyi*, M. R. Ryder, *Projet SIDA, Kinshasa, Zaire. W.D.P.3 Recently Acquired Sexually Transmitted Diseases (STD) in Homosexuals with HIV Infection. Johannes R. Bogner*, U. Kronawitter, B. Heinrich, Goebel, Poliklinik, Universitdt of Germany. W.D.P.4 Discussing the \"Do Not Resuscitate\" Issue with AIDS Patients. Inez Madera*, L. P. J. De Caprariis, M. Stehney, J. Stiles, *Sunset Park, Family Health Center of the Lutheran Medical Center, Brooklyn, NY, U.S.A. W.D.P.5 AIDS Risk Assessment (ARA) and Counselling Behaviors of Primary Physicians in Community Medical Centers. Lila Laux*, J. Coverdale, J. Aruffo, J. Thornby, College of Medicine, Houston, TX, U.S.A. W.D.P.6 AIDS Risk Behaviors and AIDS Beliefs in HIV Seroconverters. Robert W. Wood*, C. Dunphy, L. Krueger, *Seattle-King County Department of Public Health, AIDS Prevention Project, Seattle, WA, U.S.A. W.D.P.7 Management of Psychological Distress: A Hospital Based \"Mutual Aid\" Support Group for HIV Seropositive Men. Jonathan L. Jacobs*, G. Ilaria, P. Reid, S. Miller, V. Lebowitz, *Cornell University Medical College, New York, NY, U.S.A. W.D.P.8 The Need for Counselling HIV-1 Tested Individuals in a Rural Community in Uganda. Anthony Lwegaba*, W. Naamara, M. Wawer, D. Konde-Lule, D. Serwadda, S. *AIDS Control Program, Ministry of Health, Entebbe, Uganda. W.D.P.9 Psychological Issues Presented by Self-Identified Bisexual Men with HIV Conditions. Les L. Gallo-Silver*, A. McCabe, R. Moynihan, V. Raveis, C. Kletecka, J. Segal, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. 496 [Page 497](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/497) W.D.P.10 Psychological Issues Presented by Transfusion Associated HIV-Infected Adults and Their Families. Les L. Gallo-Silver*, S. Wise-Campbell, R. Moynihan, J. M. W. Gold, V. Raveis, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. W.D.P.11 A Review of HIV Counselling in an Inner-City University Hospital. Marguerite Barbacci*, W. Wilson, R. Chiasson, *Johns Hopkins University Hospital, Baltimore, MD, U.S.A. W.D.P.12 Counselling Training-Current Needs: An Evaluation of AIDS Counselling Training Courses Looking at Change and Content. Lorraine Sherr*, A. MacCreamer, J. Green, *St. Mary's Hospital, London, U.K. W.D.P.13 HIV-precipitated Life Crises: Life Enhancing and Constricting Resolutions. Karl Zener, Walter Reed Army Medical Center, Washington, DC, U.S.A. W.D.P.14 Evaluation of Psychotherapeutic Program in HIV Seropositive Subjects. Elisa Salame*, L. Ornelas, J. de Informacidn Sobre SIDA-Sur, Mexico City, Mexico. W.D.P.15 HIV Counseling and Testing in New York State (NYS) Sexually Transmitted Disease (STD) Clinics. George T. DiFerdinando. Jr.*, H. G. Chang, D. Morse, D. Murphy, E. Tobey, *New York State Department of Health, Albany, NY, U.S.A. W.D.P.16 Helping HIV+ Mothers After the Birth of Their Babies: A Counselling Out-Patient Clinic. Francoise Weil-Halpern*, S. des Enfants Malades, Paris, France. W.D.P.17 Evaluation of a Meditation and Hypnosis-Based Stress Management Program for Men with HIV. Paul J. Kelly, Psychology Department, Toronto General Hospital, Toronto, ON, Canada. W.D.P.18 The Effects on Parents of Hospitalisation of AIDS Patients. John F. Quirk*, F. M. Pearce, *University College and Middlesex School of Medicine, Academic Department of Genito-Urinary Medicine, London, UX. W.D.P.19 Counselling HIV Asymptomatic Patients for AZT MRC/INSERM Drug Trial. Riva Miller*, R. Bor, C. A. Lee, S. C. Lim, M. Johnson, *Haemophilia Centre, Royal Free Hospital, London, U.K. W.D.P.20 Lack of Impact of HIV Counselling on Women with STD Checkups to Alter the Likelihood of Subsequent STD Visits. Gregory W. Hammond*, R. Malazdrewicz, R. Tate, V. Bhayana, K. Elmslie, *University W.D.P.21 in Cohorts of Gay/Bisexual Men and Recovering Addicts: Implications for AIDS Prevention Strategies. Johanne E. Mantell*, A. T. Di Vittis, H. B. Spivack, *Gay Men's Health Crisis Center, Department of Education, New York, NY, U.S.A. W.D.P.22 Sources of AIDS Information among Heterosexuals: Asian, Black, Latino and White College Students. Susan D. Cochran*, V. M. Mays, S. Rothspan, *California State University at Northridge, Department of Psychology, Northridge, CA, U.S.A. W.D.P.23 Prevention of HIV Infection in the Mentally Impaired, Featuring West Berlin. Monika Hachmann*, C. Matthey, E. Dieck, K. Messing, *Arbeitsgruppe AIDS Landesinstitut far Tropenmedizin, Berlin, Federal Republic of Germany. W.D.P.24 Racial and Ethnic Differences in HIV Seroprevalence in Selected United States Populations. Marta Gwinn*, R. Selik, D. Allen, L. Petersen, M. St. Louis, T. Dondero, *Centers for Disease Control, Atlanta, GA, U.SA. W.D.P.25 Recruitment, Retention and Compliance of Minority Patients and Drug Abusers in a VA Cooperative Study. Michael Simberkoff, J. Hamilton, P. Hartigan, G. Drusano, *New York VA Medical Center, New York University, School of Medicine, New York, NY, U.SA. W.D.P.26 Native American Youth and AIDS: AIDS Knowledge and Risk Behavior among Native American Students Entering College. Kathleen E. Toomey*, K. Tsouhlarakis, G. Lounsberry, L. Fox, *Division of Sexually Transmitted Diseases, Centers for Disease Control, Atlanta, GA, U.S.A. W.D.P.27 Close Encounters of an Unsafe Kind: Risky Sexual Behaviors and Predictors among Black Gay and Bisexual Men. John L. Peterson*, R. F. Fullilove, J. A. Catania, T. J. Coates, *University of California at San Francisco, Centerfor AIDS Prevention Studies, San Francisco, CA, U.S.A. W.D.P.28 Demographic Profiles of San Francisco Bay Area Black and Latin AIDS Deaths, 1985-1986. Katherine Haynes*, G. T. S. Chu, N. M. Riordan, D. Tokugawa, R. Fullilove, *MIRA, University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S A. W.D.P.29 Comparison of the Knowledge, Attitudes, and AIDS-Risk Behavior of Black and White College Students in the Southeastern United States. Janet S. St. Lawrence*, S. Betts, *Jackson State University, Jackson, MS, U.S.A. W.D.P.30 AIDS: Knowledge, Attitudes and Sexual Practices among Hispanics in Chicago: Results of a 1988 City-wide Survey. Aida L. Giachello*, O. Aguillon, J. Probst, *University of Illinois at Chicago, College of Social Work, Chicago, IL, U.S.A. 498 [Page 499](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/499) W.D.P.331 Psycho-Social Aspects of Male Prostitution in Washington, DC. Czu4Qre L. iieLL*, A. B. S. Jones, *Howard University, Washington, DC, U.S~A. W.D.P.32 Pulling Coyote's Tail: American Indian Sexuality and AIDS Education and Prevention in a Cross-Cultural Setting. 7Irv Tfovy, R. Rowell, L. Beaulieu, A. Green Rush, *National Native American AIDS Prevention Centre, Oakland, CA, U.S.A. W.D.P.33 AIDS among Hispanics in the United States. AljcL Kro1iczagk, Koba Institute, Washington, DC, U.S.A. W.D.P.34 HIV Seroprevalence Its Implications for a Transsexual Population. Din; AlnJ Guinan, L. McCallum, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. W.D.P.35 Minority Patient Populations' Knowledge about AIDS. ~oknArLuff.*, J. Coverdale, C. Vallbona, *Baylor College of Medicine, Department of Psychiatry, Housston, liX, U.S~A. W.D.P.36 HIV-Risk Related Sexual Practices among Asian Young Adults. Vickie M. Mavs*, S. D. Cochran, L. Leung, *University of California at Los Angeles, Los Angeles, CA, U.S.A. W.D.P.37 Effects of a Spanish-Language Community Intervention in Southwest Texas on Reported lIV Infection Knowledge, Attitudes and Behavior. Christine Galavotti*, C. Amezcua, A. Ramirez, A. McAlister, R. Mc~uan, C. Reed, *CentersforDisease Control,Atlanta, GA, U.S.A. Les femmes (partie 1) Women (Part 1) W.D.P.38 Psychological Aspects of the lIL Infected Women in Rio de Janeiro, Brazil. Paulo H. P. Longo*, J. L. L. Hanan, L. D. Carvalho Neto, C. A. Morais de Sd, *Gaffr~e and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. W.D.P.39 Evaluation of the WPC-333 Female Condom Barrier. Mary Ann Lp&er, M. Conrardy, J. Henderson, * Wisconsin Pharmacal, Chicago, IL, U.S.A. W.D.P.40 Differences in Stage of Presentation and Presenting Symptoms between Women and Men in a Primary Care AIDS Clinic. Denise J. Ribble*, C. Marte, A. Farber, J. Kelly, C. Keyes, J. Wolbert, *Bellevue Hospital, Community Health Project, New York, NY, U.S.A. W.D.P.41 Male Clients of Female Prostitutes in Birmingham, England: A Bridge for Transmission of HIV. Hilary R. Kinnell*, R. K. G. Grifflcths, *Community Medicine Department Central Birmingham Health Authority, Birmingham, U.K. W.D.P.42 Educational Needs Assessment for Women at Risk for HIV Through Intravenous Drug Use. Ann B3. Williams. Columbia University, New York, NY, U.SA. W.D.P.43 AIDS Outreach/Pregnant Women and Children. Patti L. Juliana*, J. H. L. Lowinson, S. Weiner, L. Finnegan, G. Weissman, K. Lewis, et al., *The Albert Einstein College of Medicine, Division of Substance Abuse, B3rox, NY, U:SA. 499 [Page 500](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/500) W.D.P.44 HIV/AIDS Public Information Campaign Targetting Women at Risk and Sexually Active Adults. Kenneth R. Williams*, F. Kroger, M. Shepard, *Centers for Disease Control, Atlanta, GA, U.S.A. W.D.P.45 Barriers to Comprehending Risk Reduction Messages among High Risk Black and Latina Women. Rani B. Eversley. University of California at San Francisco, San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.D.P.46 AIDS Risk among Women with Multiple Sexual Partners: HIV Risk Screening Data from a Family Planning Population. Rani B. Everslev*, A. Newstetter, *University of California at San Francisco, San Francisco Department of Public Health, San Francisco, CA, U.S.A. W.D.P.47 Attitudes to and Awareness of AIDS among South African Women. Dennis Sifris*, S. D. Miller, *HIV Clinic, Johannesburg Hospital, Johannesburg, South Africa. W.D.P.48 National Surveillance of AIDS in Women, 1981-1988: A Report from the Centers for Disease Control. Tedd V. Ellerbrock*, M. E. Chamberland, T. J. Bush, M. F. Rogers, *Centers for Disease Control, Atlanta, GA, U.S.A. W.D.P.49 Comparison of Black and White Women Tested for Human Immunodeficiency Virus. Bonnie Coats*, S. H. Simpson, *University of Florida, Gainesville, FL, U.S.A. W.D.P.50 Comparing Estimates of HIV Seroprevalence in U.S. Women: Childbearing Women and Military Recruit Applicants. Shari C. Wasser*, M. Gwinn, M. Pappaioanou, A. Novello, A. Willoughby, *Centersfor Disease Control, Atlanta, GA, U.S.A. W.D.P.51 Unsafe Sexual Behavior and High Risk Partners: Change over Time in a Prospective Study of Women at Risk for AIDS. Judith B. Cohen*, L. E. Dorfman, T. J. Kelly, M. Rila, D. R. Garcia, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, AWARE, San Francisco, CA, U.S.A. W.D.P.52 Emerging Patterns of Drug Use, Sexual Behavior, HIV Infection and STDs in High Risk San Francisco Areas from 1986-1989. Catherine Lyons*, J. B. Cohen, G. J. Lockett, P. A. McConnell, L. R. Sanchez, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, AWARE, San Francisco, CA, U.S.A. W.D.P.53 Behavior Changes to Reduce HIV Transmission Risk in a Prospective Study of Seropositive Women. Lauren E. Poole*, J. B. Cohen, C. A. Lyons, T. J. Kelly, C. B. Wofsy, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA, U.S.A. W.D.P.54 Epidemiological Infectiological and Immunological Results from the HIV-Ambulance of the Department of Obstetrics and Gynecology. Klaus Friese*, S. Rossol, R. Voth, G. Hess, K. H. Meyer zum Biichenfelde, G Knapstein, *University of Mainz, Department of Gynecology and Obstetrics, Mainz, Federal Republic of Germany. W.D.P.55 HIV Infection in Heterosexual Women in Copenhagen. Else Kroon, J. Gerstoft, B. Kvinesdal, L. Mathiesen, *Hvidovre Infectious Hvidovre, Denmark. 500 [Page 501](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/501) W.D.P.56 Importance of IVDA as a Risk Factor for HIV Infection in Women of Buenos Aires City. Jorge A. Benetucci*, S. Multare, Argentina. W.D.P.57 Working with High Risk Women in a National AIDS Prevention Program: The U.S., Puerto Rico and Mexico. Barbara J. Sowder*, G. Weissman, D. Hunt, V. Brown, L. Argueles, *NOVA Research Company, Bethesda, MD, U.S.A. W.D.P.58 Influence of HIV Infection on Pregnancy Decisions. AnnSunderland*, S. Holman, G, Science Center, Brooklyn, NY,U.S.A. W.D.P.59 AIDS in Women: Canadian Surveillance Program. Kimberly D. Elmslie*, P. Nault, *Federal Centre forAIDS, Ottawa, ON, Canada. W.D.P.60 A Survey of AIDS-Related Knowledge, Attitudes, Beliefs and Behaviours among Women in New York City. Angelita B. Balanon*, J. Fordyce, R. Stoneburner, E. Rautenberg, *AIDS Research Unit, New York City Department ofHealth, New York, NY, U.S.A. Consommateurs de drogues par vole Intravelneuse (partle 1) I.V. Drug Users (Part 1) W.D.P.61 Crack Use and Risk for AIDS among Black Adolescents. Robert E. Fullilove*, M. T. Fullilove, B. P. Bowser, S. A. Gross, *University of California at San Francisco Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. W.D.P.62 Relationship between HIV Risk Behaviours, Knowledge and Serostatus of Sydney Intravenous Drug Users, 1987. Alex D. Wodak*, J. Wolk, A. Morlet, J. Gold, *St. Vincent's Hospital, Sydney, Australia. W.D.P.63 The Effect of a Needle and Syringe Exchange on a Methadone Maintenance Unit. Alex D. Wodak*, J. S. Wolk, J. J. Guinan, *St. Vincent's Hospital, Sydney, Australia. W.D.P.64 HIV Risk Behaviours of Intravenous Drug Users Presenting to the Albion Street (AIDS) Centre, Sydney, Australia. Julian Gold*, A. Morlet, J. J. Guinan, S. Darke, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. W.D.P.65 A HIV-Prevention Syringe Exchange Program in Lund, Sweden. Two Years of Observations of the Attenders. Kerstin Tunving*, B. Andersson, B. Ljungberg, B. Christensson, *University of Lund, Department of Psychiatry and Neurochemistry, Lund, Sweden. W.D.P.66 Risk Taking and Risk Reduction among IV Drug Users in 4 U.S. Cities. Wayne W. Wiebel*, N. L. Altman, D. Chene, R. B. Fritz, *University of Illinois at Chicago, Chicago, IL, U.S.A. W.D.P.67 Cessation of Alcohol and Drug Use Disorders in an HIV Sample. Robert H. Remien*, J. G. Rabkin, J. B. W. Williams, J. G. Gorman, A. A. Ehrhardt, *HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A. 501 [Page 502](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/502) W.D.P.68 Demographic, Behavioral and Clinical Features of HIV Infection in New York City Intravenous Drug Users (IVDUs). Lawrence S. B rown*, A. Chu, T. Nemoto, B. I. Pri mm, *Addiction Research and Treatment Corp., Brooklyn, NY, U.S~A. W.D.P.69 Needle Sharing among IVDUs where Needles Are Available without Prescription. David W. Fleming*, B. Sibthorpe, R. McAlister, R. Kiockner, J. Gould, *Oregon Health Division, Portland, OR, U.S~A. W.D.P.70 Sexual Risk for H1V Transmission in a Gay Male Substance-Abusing Population. Ronald D. Stall*, J. P. Paul, F. Davis, * University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, U.S~A. W.D.P.71 Absence of Antibody to HIV in Long-Term, Socially Rehabilitated Methadone Maintenance Patients. David M. Nrovick*, H. Joseph, T. S. Croxson, E. A. Salsitz, G. Wang, B. L. Richman, et al., *Beth Israel Medical Center, New York, NY, U.S~A. W.D.P.72 HIV Status and Risk Behavior in Participating and Non-Participating IV Drug Patients in an HIV Testing/Education Program. Melodie 5. ciafei*, W. *Hipies Loyola Hines, IL, U.S.A. W.D.P.73 Do Male Intravenous Drug Abusers Give Consistent Responses to Behavioral Questions? Nicholas H. Wright*F, P. Akarasewi, W. Pokapanichwong, S. Vanichseni, K. Choopanya, *Departmpnt of Environmental and Community Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, U.S.A. W.D.P.74 Predicting Needle-Sharing Behavior of IVDUs in Treatment. William T. Woods*, A. Abramowitz, J. Guydish, W. Clark, N. Hearst, R. Kiefer, * University of California at San Francisco, San Francisco, CA, U.SA. WJ.D.P.75 Human Immunodeficiency Virus in Drug Users and Increased Consultation in General Practice. Carol A. Skidmore*, J. J. K. Roberts, J. R. Robertson, *Edinburgh Drug Addiction Study, Edinburgh, UX.K W.D.P.76 HIV Status and Changes in Risk Behaviour among Arrested and Detained Intravenous Drug Abusers in Stockholm 1987-88. Robert Olin*, K. Kdill, of Social Medicine, Karolinska lnstitute/Kronan Health Centre, Sweden. W.D.P.77 Observance et compliance du traitement par zidovudine (AZT) chez les toxicomanes IV infect~s par VIH. Michael J.P. Finaud*, P. Rarmbaua, P. *iHdpital Conception, Service des maladies infectieuses, Marseille, France. W.D.P.78 Reducing HIV Transmission by Providing Methadone Treatment to Intravenous Drug Users in Jail. Herman Joseyh*, S. Magura, A. Rosenblum, J. Jeffers, J. Perez, M. Wishart, *New York State Division of Substance Abuse Services, New York, NY, U.S~A. W.D.P.79 IVDU and AIDS: More Resistance to Changing Their Sexual than Their Needle Sharing Practices. Susnita Jain*, N. Flynn, V. Bailey, A. Sweha, D. Ding, W. Sloan, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A. 502 [Page 503](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/503) W.D.P.80 Use of a Fingerstick Paper-Absorbed Method (PAM) Blood Sample for HIV Serosurveys in Intravenous Drug Users (IVDU). Kathlenn A. Steger*, B. Comella, J. Forbes, R. McLoughlin, R. A. Hoff, D. E. Craven, *Boston City Hospital, Boston, MA, U.S.A. W.D.P.81 Experience with an Anonymous Drop-In HIV Testing Program for Intravenous Drug Users (IVUD) and Their Contacts. Brianne Comella*, F. Feltch, L. Kunches, J. Harris, K. Steger, D. Craven, *Project TRUST, Boston City Hospital, Boston, MA, U.S.A. W.D.P.82 Drug Use and Sexual Behavior in Male Patients at an STD Clinic: Implications for AIDS Prevention. Paul M. Gibson*, R. Kohn, G. Bolan, *Division of STD Control, Department of Public Health, San Francisco, CA, U.S.A. W.D.P.83 Prevention of AIDS in IV Drug Users and Its Consequences on the Epidemic in an Interacting Heterosexual Population. Mary E. Halloran*, C. J. Struchiner, *Harvard School of Public Health, Department of Population Sciences, Boston, MA, U.S.A. W.D.P.84 Role of HIV Infection in Alteration of Pulmonary Function in Intravenous Heroin Addicts (MIA). Valeriano Foresti*, A. Villa, G. Guareschi, E. Parisio, N. Scolari, M. Pediconi, *Fatebenefratelli Hospital, Milan, Italy. Additionnels Additional W.D.P.85 Sexual Behaviors of Intravenous Drug Users. Andrew J. Saxon*, D. A. Calsyn, S. Whittaker, G. Freeman, Jr., *Seattle VA Medical Center, University of Washington, Seattle, WA, U.S.A. W.D.P.86 Preventive and Counselling Activities of Drug Abuse Centers for HIV-Infected and Non-Infected Drug Addicts. Eva-Maria Fahrner*, J. Schumann, U. Niemeck, *Institute for Therapy Research, Munich, Federal Republic of Germany. W.D.P.87 The Use of Condoms by Prostitutes in Yaounde, Cameroon. Marcel Monny-Lobe*, D. Nichols, for 15-25 Year Olds: A Pilot Project in Stockholm County, Sweden. Viveka Urwitz*, L. Mobrandt, *Youth Project, Stockholm AIDS Prevention Programme, Stockholm, Sweden. W.D.P.89 Barriers to Continued Condom Use. Mary-Louise McLaws*, B. Oldenburg, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemology and Clinical Research, Surry Hills, Australia. W.D.P.90 Les femmes Africaines devant le Zaire. Zaire. Self-Reported Sexual Behavior in a Cohort of Homosexual Men: Cross-sectional Analysis at 6 Years. Brian Willoughby*, M. T. Schechter, B. Douglas, K. J. P. Craib, P. Constance, W. A. McLeod, et al., *The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, and Behaviour Session d'affichage Poster Session Education (partie 2) Education (Part 2) W.E.P.1 Structure of Americans' Knowledge Regarding Transmission of I{IV Infection: Implications for Targeted Education. Ydrcla &Jziln\", D. J. Schnell, 5. 0. Aral, G. S. Bowen, *Centers for Disease Control, Atlanta, G;A, U.S~A. W.E.P.2 AIDS Activism: A Means for Productive Change to Promote Clinical Research and Drug Development. William R. Bahl man, Lavender Hill Education Project, ACT UP, New York, NY, U.SA. W.E.P.3 SIDA, sexologie et culture en Afrique Centrale. Brooke Barrv*, A. Sy, I. Sarr, L. Fall, 0. programmes nationaux d'dducation pour la santd en Afrique Centrale et de Ptitgjr4\"', S. P. Sant~, GPA/NPS, Geneva, Switzerland. W.E.P.6 Computer Simulation as an Aid to Rational Problem Awareness. ~LQ~CA Gnzalez*, M. Myrtveit, L. Vavik, *Aust-Agder Central Hospital, Arendal, Norway. W.E.P.7 AIDS Prevention through Outreach Education in Public Sex Environments. David L. Beckstein*, R. Gunn-Mota, *Santa Cruz AIDS Project, Santa Cruz, CA, U.SA. W.E.P.8 A Multidimensional Approach to Promote Awareness of AIDS in the Gambia. Sekou Dibba. Medical and Health Department, Banjul, Gambia. W.E.P.9 Takin' It to the Streets: The Dynamics of Community Outreach to Combat AIDS. Patrick Biernacki*, R. S. Broadhead, * Youth Environment Study, Inc., San Francisco, CA, U.SJ.A W.E.P.1O AIDS Education and Outreach in Toronto Bath Houses. Bob Tivey, City of Toronto, Department of Public Health, Toronto, ON, Canada. W.E.P.11 \"MTS BUSTERS\": communautaire de l' QC, Canada. 504 [Page 505](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/505) W.E.P.12 Integrating AIDS Education Research into a Drug Treatment Programme. Judith Phalen*, B. F. Lewis, C. Morrison, J. McCusker, G. Cameron, *Spectrum House Inc., Westboro, MA, U.S.A. W.E.P.13 The Use of Indigenous Workers for AIDS Outreach Education/Prevention. Rebecca S. Ashery, National Institute on Drug Abuse, Rockville, MD, U.S.A. W.E.P.14 An Information, Education Workshop to Increase Condom Use among Male Bar Workers in Bangkok. Werasit Sittitrai*, R. E. Roddy, *Institute of Population Studies, Bangkok, Thailand. W.E.P.15 Education Strategies for Health Care Workers and Prisoners in Wales. Alan Michael George*, C. Griffiths, *The Welsh Office, Cardiff, U.K. d'abord. an Educational Program. Sigrid Michel. Soziopddagogisches Institut, Prien, Federal Republic of Germany. W.E.P.18 School and Community Partnership in AIDS Education. Mark J. Askew, Sydney Catholic Education Office, Sydney, Australia. W.E.P.19 Knowledge and Attitudes of Italian Youth about AIDS. Annalaura Carducci*, M. Frasca, G. Matteelli, A. Calamusa, University ofPisa, Department ofBiomedicine, Pisa, Italy. W.E.P.20 Preparing Teachers for Adolescent AIDS Prevention Education: Year Two of the Massachusetts Team Training Design. Gerald W. Davoli*, K. Cranston, S. Rosenfeld, *Massachusetts Department of Education, Quincy, MA, U.S.A. W.E.P.21 Pediatric AIDS Sourcebook. Dorothy J. Allbritten, National Association of Children's Hospitals and Related Institutions, Alexandria, VA, U.S.A. W.E.P.22 Knowledge and Attitude to AIDS Shown by Ugandan School Children, Based on a Nationwide Poster Competition. OlafMueller*, J. Lubega, J. Senoga, *League of Red Cross and Red Crescent Societies, Berlin, Federal Republic of Germany. W.E.P.23 AIDS Information in French Schools: An Experience and a Sociological View. Francois Deniaud*, M. Kalamaridas, S. Crespin, C. Livrozet, D. *Institut Pasteur, Paris, France. W.E.P.24 An HIV/AIDS Education and Training Program for Law Enforcement Officers. William Mindell*, B. Yaffe, M. Federico, D. Hancock, *City of Toronto Department of Public Health, Toronto, ON, Canada. W.E.P.25 Implementing a Mandated Curriculum. Marion Bacon*, W. McConnell, L. Hyne, A. Craven, *TV Ontario, Toronto, ON, Canada. W.E.P.26 AIDS Graduate Education: Eight Semesters, Experience in Teaching an Advanced, Interdisciplinary Course on AIDS. Robert M. Schmidt. Center for Preventive Medicine and Health Research, San Francisco University and Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A. 505 [Page 506](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/506) W.E.P.27 World AIDS Day: The Launching of an Extended AIDS Prevention Project. D.,Jyle, F. Aeberhard, J. Lebas, D. Rayon, C. Reynaud, Association pour la Prevention du SIDA, Paris, France. W.E.P.28 World AIDS Day: South Africa. Ruben Sher*, G. Christie, M. Zazayokwe, G. N. Padayachee, *School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. W.E.P.29 Readability Analysis of AIDS Brochures and Pamphlets from the U.S.A. James A. Wells*, R. A. Sell, P. DeFilippes, *Project HOPE, Center for Health Affairs, Washington, DC, U.S.A. W.E.P.30 Trends in Condom Promotion Strategies for HIV Prevention: Practical Concepts for Consideration. Susan G. Saunders*, W. A. Smith, M. L. Ramah, *Academy for Educational Development, Washington, DC, U.S.A. W.E.P.31 AIDS Information at the National Center for Health Statistics. Ann M. Hard*, R. Wilson, *National Center for Health Statistics, systhme A. Spoiden, M. A. Bertrand, *Universitd Catholique de Louvain, Brussels, Belgium. W.E.P.33 Evaluation of Prevention Components in the MTPs of Costa Rica, Panama, Trinidad and Tobago, and Uruguay. Lydia S. Bond*, D. Longshore, R. St. John, F. Zacarias, *Pan American Health Organization, World Health Organization, Washington, DC, U.S.A. W.E.P.34 Effecting Attitude and Behavior Change in Regard to HIV Infection. Ann W. Auleb*, E. Dundas, *San Francisco State University, San Francisco, CA, U.S.A. W.E.P.35 Avoiding AIDS: Preventing AIDS While Preserving Sex. Ronnv A. Shtarkshall*, E. Bargai, *The Hebrew University and Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel. W.E.P.36 AIDS Education for Adolescents: Who Responds?. Larry K. Brown*, V. J. Barone, G. K. Fritz, *Rhode Island Hospital, Brown University, Providence, RI, U.S.A. W.E.P.37 Strat6gies pour un programme pour A. Cecchini, V. M. Casillas, Paiva, M. E. L. N. Abbud, *Fundagao Estadual do Bem Estar do Menor, Sao Paulo, Brazil. W.E.P.38 Parental Viewpoints on AIDS Education in the Public Schools of Copenhagen. Merete M. Lindholm, The School Department of Copenhagen, Copenhagen, Denmark. W.E.P.39 Researching Relevant AIDS Education Material for Young People. Anna O'Sullivan*, P. A. Gillies, *University of Nottingham, Nottingham, U.K. W.E.P.40 AIDS Education for A Randomised Controlled Trial. PamelaA. Gillies*, K. U.K. 506 [Page 507](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/507) W.E.P.41 Reconciling Costs, Risk Targetting, and Probable Long-term Outcomes in Information, Education, Communities (lEG) Strategies for Preventing HIV Infections among Women. Chloe O'Gara*, J. Shelton, R. Landis, *U.S. Government, Agency for International Development, Office of Education, Bureau for Science and Technology, Washington, DC, U.S~A. W.E.P.42 An Instructional Program on AIDS Awareness and Prevention in the High School. Murray C. Newell*, a Mandated HIV/ATDS Curriculum in the Public Schools of Washington State. Gary L. Livingston*, P. Baldwin, A. Downer, *State of Washington, Office on HI V/AIDS, Spokane, A. Michel, A. Sobel, *Aparts, Paris, France. W.E.P.45 Health Education for AIDS Prevention among Students. Carlo Alberto Perucci*, P. Borgia, D. Abeni, G. Todini, Rome, Italy. W.E.P.46 \"Does AIDS Hurt?\": Educating Young Children About AIDS. Marcia J. Quackenbus9\", S. Villarreal, * University of California AIDS Health Project, San Francisco, CA, U.SA. W.E.P.47 School Based AIDS Education in a National Perspective: The Implementation and Preliminary Evaluation of the Israeli Module. Inon. I. Schenker. Hebrew University Medical Faculty, School of Public Health and Community Medicine, Jerusalem, Israel. W.E.P.48 Sex Education Materials to Prevent STD and AIDS in Adolescents. Matilde De Tafur*, C. De Martin, R. Martinez, *Fundacidn para el Desarrollo Humano y Social \"CRESALC COLOMBIA \", Bogotd, Colombia. W.E.P.49 A National Strategy Designed to Reduce Barriers Hindering the Implementation of Effective HIV Education for Youth: First Year's Achievements. Carlton Duncan*, J. Jones, L. Daily, D. Poehler, L. Kann, L. Kolbe, *Division of Adolescent and School Health, Centers for Disease Control, Atlanta, GA, U.S~A. W.E.P.5O A National Strategy for the Diffusion of Programs on School Health Education to Prevent the Spread of HIV. is A.Qqjl*\", J. Jones, W. Jubb, J. Martindale, A. Sheffield, L. Kolbe, *Division of Adolescent and School Health,~Centers for Disease Control, Atlanta, GA, U.S~A. W.E.P.51 Comparative KAP Studies and STD in Adetugbo, A. Awolowo University, Ile Ife, Nigeria. W.E.P.52 collaboration entre mddecin et France. 507 [Page 508](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/508) W.E.P.53 Comparison of AIDS Knowledge Levels and Behaviors in Sexually Transmitted Disease (STD) Clinic Patients and Alternative Testing Site (ATS) Clients. John Moye*, J. Day, B. Dillon, L. Kunches, L. Mofenson, *Massachusetts Department of Public Health, Boston, MA, U.S.A. W.E.P.54 Proposed Model of Medical Workshop on AIDS in Africa. Paolo Crocchiolo*, H. A. Attas, O. J. Khatib, N. Schinaia, A. Othman, H. M. Chwaya, *World Health Organization, Global Programme on AIDS, Geneva, Switzerland. W.E.P.55 Proposed Model of Medical Workshop on AIDS in Africa. Paolo Crocchiolo*, H. A. Attas, O. J. Khatib, N. Schinaia, A. Othman, H. M. Chwaya, et al., *Ospedale Maggiore, Milan, Italy. W.E.P.56 Cross-Cultural Obstacles to AIDS Education in the Southern African Context. Grania M. Christie*, M. Zazayokwe, R. Sher, J. Metz, *South African Institute for Medical Research, Johannesburg, South Africa. W.E.P.57 Directions for the Future: A Review of Worldwide AIDS Programs. Kathryn Carovano*, G. MacDonald, M. Helquist, *Johns Hopkins University, Academy for Educational Development, Washington, DC, U.SA. W.E.P.58 Reported Behavior Change in AIDS Risk Groups. Christine Galavotti*, A. McAlister, P. Shoemaker, P. Zbylot, D. Vacalis, C. Reed, *Centers for Disease Control, Atlanta, GA, U.S.A. W.E.P.59 A Community-wide Survey of AIDS Knowledge, Attitudes, and Preferred Information Sources. Richard J. Wolitski*, F. Rhodes, N. H. Corby, *AIDS Research and Education Project, Long Beach, CA, U.SA. W.E.P.60 How to Educate 26,000 Health Care Workers in 6 Months. Barbara Lamberto*, D. M. Evans, *Kaiser Permanente Medical Center, San Francisco, CA, U.S.A. W.E.P.61 The Judicious Use of Humor in a Condom Promotion Campaign. Ann E. Downer*, B. Kelleigh, N. Welch, T. Purdue, *University of Washington, AIDS Education and Training Center, Seattle, WA, U.S.A. W.E.P.62 SIDAIDS: A Computerized Telephone AIDS Information and Counselling Service (Telematic). Margaret Duckett*, P. R. Descout, *Visiting Scholar, McGill University, Centre for Medicine, Ethics and Law, Montreal, QC, Canada. W.E.P.63 AIDS Prevention Campaign in Healthy City Project of L6dz. Tadeusz Gdrski*, H. Kamieniak, E. Korczynski, *Sanitary-Epidemiological Station, Lddz, Poland. W.E.P.64 Extending the Role of AIDS Hotlines in AIDS Prevention Programs in Developed and Developing Countries. Susan G. Saunders*, M. Helquist, J. Stein, K. Carovano, E. De la Vega, B. Duke, *Academy for Educational Development, Washington, DC, U.S.A. 508 [Page 509](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/509) W.E.P.65 Knowledge and Perceived Risk of AIDS among the Adult Population of Kinshasa, Zaire. Sua.Hri\" J. T. Bertrand, M. Bakutuvwidi, L. N. Kinavwidi, D. Balowa, C. Chirwisa, *Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, U.S.A. W.E.P.66 Secondary School Students as AIDS Health Promoters for an illiterate Rural West African Village Population. Diane E. Bennett*, A. Demby, P. Kamara, *Global Programme on AIDS, Health Promotion Unit, Geneva, Switzerland. W.E.P.67 AIDS Education in Prisons: A Model. LQore VB..q, Educational Consultant/Private Practice, Vancouver, BC, Canada. `W.E.P.68 Risk Reduction after Outreach Intervention among Intravenous Drug Users. Mev ufa\" S. R. Friedman, A. Neaigiss, D. Goldsmith, D. C. Des Jarlais, F. L. Graves, *Narcotic and Drug Research, Inc., New York, NY, U.S.A. W.E.P.69 Niveau de connaissance du SIDA Sidi-Bel-Abbes, Algeria. W.E.P.70 Community Response to the AIDS Epidemic in Four U.S Cities: New York, San Francisco, Los Angeles and Miami. Embrv M. Howell*, R. Andrews, R. McClung, B. Preston, M. Keyes, *SysteMetrics, Mc~raw-Hill, Washington, DC, UI.S.A. W.E.P.71 Impact of Pilot Interventions to Reduce the Spread of IIIV Infection among High Risk Women in Africa. Douglas J. Nichols*, M. Monny-Lobe, B. Koumare, A. Neequaye, R. De Buysscher, K. Jesencky, S. Weir, *Family Health International, Durham, NC, U.S.A. WV.E.P.72 Social and Cultural Constraints in the Control of AIDS and HILV Infection in Sub-Saharan Africa. Valentino M.~ Lema, University of Nairobi, Nairobi, Kenya. `W.E.P.73 The AIDS-Related Knowledge, Attitudes, and Behaviors of Internists and Surgeons: A Comparative Analysis. Keith Henrv*, S. Campbell, S. Eyer, K. Willenbring, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A. W.E.P.74 AIDS and Family Planning in Adolescents. Han LEl Th*, S. Hafez, *El Menia University, Faculty of Medicine, Egypt. W.E.P.75 A S tudy of Knowledge, Attitudes and Beliefs about AIDS among Fourth Year Medical Students of Tanta University, Egypt. Ibra him Mohamad Soi Faculty of Medicine, Tanta University, Tanta, Egypt. W.E.P.76 Attitudes sur le SIDA et comportement sexuel entre le personnel de la sant6 510](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/510) Section Mercredi 7 juin S F Wednesday, June 7 Droit et 6thique Ethics and Law Session d'affichage Poster Session Recherche de traitements et de vaccins Research for Treatments and Vaccines W.F.P.1 The Study Giveth, The Study Taketh Away: The Emotional Cost of Stopping an HIV Treatment Trial. Sheila R. Enders*, N. Flynn, S. Jain, B. Siegel, *University of California at Davis, School of Medicine, Sacramento, CA, U.S.A. W.F.P.2 Ethical and Clinical Concerns in HIV Research Design. Robert Kertzner*, G. Todak, J. McKinnon, J. Gorman, A. Ehrhardt, *New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A. W.F.P.3 Ehtical and Legal Issues in Clinical Trials for HIV-Infected Children. Henry S. Sacks*, J. Martin, *Mount Sinai Medical Center, New York, NY, U.S.A. W.F.P.4 Les problbmes 6thiques pos6s par la vaccination J. Charrel, M. P. Larher, D. Reviron, C. Manuel, J. L. Marco, Sant6 Publique, Facultd de matibre de sant6 publique Preventing HIV Transmission: Religious Conflicts in Public Health W.F.P.5 Meeting the Moral Challenge of High-Risk Lifestyles: AIDS and Education. Patricia lllingworth, McGill Centrefor Medicine,Ethics and Law, Montreal, QC, Canada. W.F.P.6 The Ethics of Increasing Access to Sterile Syringes as an Approach to Reducing Perinatal HIV Transmission. Kathleen Nolan, The Hastings Center, Briarcliff Manor, NY, U.S.A. W.F.P.7 Promoting a Safer Sex. Maria E. Paalman*, A. Meyer, *Dutch Foundation for STD Control, Utrecht, Netherlands. W.F.P.8 Female Prostitution in Glasgow: Historical Studies. Stephen T. Green*, D. J. Goldberg, F. A. Green, *Infectious Diseases Unit, Ruchill Hospital, Glasgow, U.K. 510 [Page 511](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/511) Additionnels Additional W.F.P.9 et justice Ruth Murbach, Ddpartement des sciences juridiques, Universitd du Quebec a Montrial, Montreal, QC, Canada. W.F.P.10 Practical and Ethical Inadequacies of Partner Restriction as a Method of AIDS Prevention. Curtis Cole*, L. Spiegel, L. Baker, *New York Blood Center, New York, NY, U.S.A. 511 [Page 512](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/512) Section Mercredi 7 juin G Wednesday, June 7 Intemational ssues Session d'affichage Poster Session Aspects cliniques Features (Part 1) W.G.P.1 HIV, HBV, Delta-Agent and T-Pallidium Infections in Two Rural African Areas. Fausto De Lalla*, G. Rizzardini, P. L. Zeli, et du virus de l'h6patite B chez les 16preux au Congo. Francois Denis*, A. Itoua-N'Gaporo, E. Sassou-Guesseau, France. W.G.P.3 Brazil. W.G.P.4 A Survey for Unrecognized HIV Infection in a Special STD Clinic in Kuwait. Rashed Alowaish**, K. Behbehani, *Ministry of Public Health, Safat, Kuwait. W.G.P.5 About Monitoring of HIV-Spread in a Developing Country. Reinhard Bornemann*, C. Richter, F. Bschor, *Institut far Rechtsmedizin, Freie Universitlit Berlin, Berlin, Federal Republic of Germany. W.G.P.6 AIDS-associated Endemic Infectious Diseases in Mexico. Lourdes Garcia*, R. A. Morales, M. Palacios, E. Bravo, J. L. Valdespino, J. Sepulveda, et al., *General Directorate of Epidemiology, Mexico City, Mexico. W.G.P.7 The Impact of HIV Infection on Child Survival in Africa. Linda A. Valleiro, J. R. Harris, P. O. Way, *United States Agency for International Development, Washington, DC, U.S.A. W.G.P.8 The Natural History of HIV Infection in Twin Pairs Born to HIV+ Women in Kinshasa, Zaire. Susan E. Hassig*, W. Nsa, T. Manzila, M. Kashamuka, R. Ryder, *Projet SIDA, Tulane University, Kinshasa, Zaire; New Orleans, LA, U.S.A. W.G.P.9 Correlation of Hypergammaglobulinemia with Asymptomatic and Symptomatic HIV Infection in a Cohort of African Infants. MargaretJ. Oxtobv*, R. Ryder, W. Nsa, T. Manzila, S. Hassig, F. Behets, et al., *Centers for Disease Control, Center for Infectious Diseases, AIDS Program, Atlanta, GA, U.S.A. 512 [Page 513](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/513) W.G.P.1O Infection par Jourdain, Larouze, et al., * Orstom (Sant~/Urbanisation) Commission scientifique 5, Paris, France. W.G.P.11 Update on the Transition from Homosexual to Heterosexual AIDS in Trinidad and Tobago. Farlev Gte ghorn*, K. Battoo, C. Diaz, M. Francis, B. Hull, C. Bartholome~w, *The Caribbean Epidemiology Centre, Port-of-Spain, Trinidad. W.G.P.12 Clinical Manifestations of AIDS in Quito, Ecuador. Roy A. Ringenberg*, R. Semp~rtegui, J. Moreno, *Ministry of Public Health, Quito, Ecuador. W.G.P.13 A Model for AIDS Outpatient Care. Luiz Loures*, L. Rodrigues, W. Pinto, D. Cardo, D. Greco, F. Rangel, et al., *National Division of STD/AlDS, Ministry of Health, Brasilia, Brazil. W.G.P.14 Theory and Method to Develop a Revised Case Definition of AIDS from Empirical Clinical Data. Bruce G. Weniger*, M. A. Perez, C. Ismael, E. P. Quinhoes, C. F. Ramos Filho, L. A. Loures, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. W.G.P.15 Evaluation of HIV Antibody Tests in Brazil. Jairo lvo-Dos-Santos*, D. L. Campos, J. C. Couto-Fernandez, R. M. Passos, L. A. Dias-Carneiro, B. Galvao-Castro, *WHO Collaborating Centre on AIDS, Funda~ao Oswaldo Cruz, Rio Janeiro, Brazil. Facteurs de risque lies aux MTS (partie 1) STD Risk (Part 1) W.G.P.16 Prevalence of HIV Seropositivity among STD Patients in Freetown, Sierra Leone. Andrew Kosia*, T. K. Kargbo, I. D. Thorlie, N. M. Mansaray, E. J. Mackiu, J. M. Kanu, * Virus Reference Laboratory, Connaught Hospital, Freetown, Sierra Leone. WN.G.P.17 Targeting Travellers for AIDS Prevention Education. Ona A. Pela, University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine, Camden, NJ, U.SA. W.G.P.18 HIV Infection in Heterosexuals from Buenos Aires City Consulting for Venereal Disease. Martha C. Boxaca*, L. Bethi, R. Casoo, M. Gomez Carrilto, Control Study of HIV Positivity among Male Intravenous Drug Addicts in Bangkok. NichotasHW. Wright*, S. Vanichseni, P. Akarasewi, W. Pokapanichwong, D. Taylor, K. Chzoopanya, *Department of Environmental and Community Medicine, Robert Wood Johnson Medical School, Piscataway, NJ, U.S.A. W.G.P.20 Sexual Behavior and Perceived Risk for AIDS among Bank Employees and Spouses in Kinshasa. Melinda Moore*, A. Doppagne, S. E. Hassig, L. Piripiri, W. E. Bertrand, T. D. Kashala, *Zaire School of Public Health, Kinshasa, Zaire; Tulane University, New Orleans, LA, U.S.A. 513 [Page 514](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/514) W.G.P.21 Anti-HIV Antibodies in Male and Female Streetwalkers Buenos Aires City. Salvador Multare*, M. Zarate, M. Aires, Argentina. W.G.P.22 Comparison of New HIV-2 Isolates by Southern Blot and PCR. Bette Korber*, P. Kanki, F. Barin, S. M'Boup, M. Essex, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A. W.G.P.23 Tendency of Anti-HIV Antibodies in Masculine Homosexuals during the last Five in Guadalajara, Jalisco. Eduardo Vazquez-Valls*, B. M. Torres-Mendoza, M. L. Patologia Infecciosa y Experimental de la Universidad de Guadalajara, Guadalajara, Mexico. W.G.P.24 HIV Transmission among Heterosexual Couples in Mexico. Jaime Sepulveda*, C. Avila, M. Hernandez, E. Dickenson, A. Nazar, P. J. Kanki, *Direccidn General de Epidemiologia, Mexico City, Mexico. W.G.P.25 Male Bisexuality and AIDS. Present Status and Perspectives in Mexico. Lourdes Garcia*, J. A. Izazola, J. L. Valdespino, C. Magis, C. Ornelas, J. Septlveda, et al., *General Directorate of Epidemiology, Mexico City, Mexico. W.G.P.26 HTLV-I Seroprevalence Is Increased among Those Living at Low Altitude in Jamaica. Edward L. Murphy*, E. Maloney, J. P. Figueroa, W. N. Gibbs, M. Holding-Cobham, B. Cranston, et al., *San Francisco General Hospital, San Francisco, CA, U.S.A. Epid6mlologie Epidemiology W.G.P.27 HIV Seroprevalence Survey among High Risk Females at Mombasa, Kenya. Kishorchandra Mandaliva*, G. Mbugua, G. F. M. Mueke, E. Mupate, *Kenya Ministry of Health, Coast General Hospital, Mombasa, Kenya. W.G.P.28 Prevalence of HIV-1 Antibodies in STD Patients. Bekure, M. Seifu, D. Kebede, *Armed Forces Hospital, Addis Ababa, Ethiopia. W.G.P.29 HIV-1 Prevalence in Nairobi Sentinel Populations. Jackoniah O. Ndinva-Achola*, Datta, C. K Li*, E. K. Yeoh, W. Y. Lam, F. Y. Leung, Y. F. Ho, Y. H. Lee, et al., *Queen Elizabeth Hospital, Hong Kong. W.G.P.31 Approche communautaire de la lutte contre le SIDA en Haiti. Gabriel A. Thimothe, Programme National de Lutte contre le SIDA, Port-au-Prince, Haiti. W.G.P.32 The Family and Uganda. E. Maxine Ankrah*, Wednesday, June 7 Rpercussions &conomiques du SIDA The Economic Impact of AIDS Session d'affichage Poster Session Pays en vole de d6veloppement Developing Countries W.H.P.1 Costs of Treating AIDS Patients in Africa. Martv Makinen*, H. Wong, *ABTAssociates Inc., Washington, DC, U.S.A. W.H.P.2 Health-Care Cost of AIDS at a Hospital in Canary Islands. Portela Armas*, P. Jimenez, J. M. Martin, E. Gomez, J. A. Acosta, et al., *Hospital Nuestra Sefiora del Pino, Las Palmas, Spain. W.H.P.3 Direct Medical Costs of AIDS in Latin America and the Caribbean: More Cost-Effective Models. Yamil H. Kouri*, F. Zacarias, D. Shepard, *Harvard, Institute for International Development, Cambridge, MA, U.S.A. W.H.P.4 Comparative Costs of AIDS Care in Public and Private Settings. Yamil H. Kouri*, D. S. Shepard, R. Risek, J. E. Risek, S. Smith, S. Verjee, *Harvard Institute for International Development, Cambridge, MA, U.S.A. W.H.P.5 Economic Analysis of AIDS in Puerto Rico. Jose I. Alameda-Lozada*, A. Gonzdlez-Martinez, *University of Puerto Rico at Mayaguez, Mayaguez, Puerto Rico. W.H.P.6 The Economic and Social Implications of AIDS in an African Setting. Farzin Davachi*, N. Mayemba, L. Kabongo, K. Kinshasa, Zaire. M6thodologie des couts Costing Methodology W.H.P.7 HIV Case Management Utilizing Information Systems. Sylvia A. Moreno*, J. Jockush, T. Emanuele, M. T. Karpf, *Parkland Memorial Hospital, Dallas, TX, U.S.A. W.H.P.8 Direct Costs and Financing of HIV-Hospital and Community-Based Treatment. Julia Hidalgo, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A. W.H.P.9 Socio-Economic Models to Assess the Economic Impact of HIV Infection. Joan Kahn, McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. W.H.P.10 HIV Infected Hospital Patients in New York State (NYS): The Creation of Longitudinal Information from a Hospital Discharge Data System. Lloyd F. Novick*, G. I. Kaufman, J. C. Grabau, Y. Han, E. Schmidt, *New York State Department of Health, Center for Community Health, Albany, NY, U.S.A. 516 [Page 517](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/517) Modblisation math6matique et previsions Mathematical Modelling and Prediction W.H.P.11 Temporal Changes in Financing of HIV Treatment. JuliaHidalgo, AIDS Administration, Maryland Department of Health and Mental Hygiene, Baltimore, MD, U.S.A. W.H.P.12 A Production Function Approach to Estimating the Aggregate Macroeconomic Impact of AIDS on Central African Economies. Mead Over*, R. Bulatao, D. Jamison, L. Lau, *The World Bank, Washington, DC, U.S.A. W.H.P.13 A Medium-Run Model for the Analysis of the Economic Impact of AIDS in Sub-Saharan Africa. Gerard Kambou*, S. Devarajan, M. Over, *Northeastern University, Department of Economics, Boston, MA, U.S.A. W.H.P.14 The Sociocultural and Economic Impact of AIDS on Society. FransM. van den Boom*, H. C. Jager, D. P. Reinking, *The Netherlands Institute of Mental Health, Utrecht, Netherlands. W.H.P.15 Decline of AIDS Incidence in Kenya. L. N. Muthami*, N. N. Agata, G. S. Gachihi, G. G. Mbugua, T. N. Mulandi, *Kenya Medical Research Institute, Nairobi, Kenya. W.H.P.16 The Use of Random Graphs in Modelling the Transmission Dynamics of HIV Infection. Philippe Blanchard*, G. F. Bolz, T. Kriiger, *Fakultit fir Physik, Universitdt Bielefeld, Federal Republic of Germany. W.H.P.17 A Model for Evaluation of Unknown Number of HIV-Infected Persons. Anders Blaxhult*, M. Stockholm, Sweden. W.H.P.18 HIV Carriers: Non-Infectious Initial Interval Slows Up Spread of Virus. JosdJ. Gonzalez*, P. Davidsen, C. E. Moe, M. G. Koch, *AUST-AGDER Central Hospital, Arendal, Norway. W.H.P.19 Short Term Prediction of HIV Infection and AIDS: A Critique of the Cox Report. Malcolm S. Rees. Harrison Department, Radcliffe Infirmary, Oxford, U.K. W.H.P.20 Particular Features of a Lentivirus Epidemic and Their Dynamic Consequences, Such as Transients, Crescents, and a 10 Years' Moratorium for the Detection of Errors. Michael G. Koch*, J. J. Gonzdlez, D. Dorner, P. van Welck, *Vdrdcentralen, Karlsborg, Sweden. W.H.P.21 Proportion of New AIDS Case Reports Attributable to the 1987 CDC Revised Surveillance Case Definition: Canada - United States Differences. Colin L Soskolne, University of Alberta, Edmonton, AB, Canada. W.H.P.22 Changing Trends in the AIDS Epidemic in Europe. Angela M. Downs*, R. A. Ancelle-Park, J. B. Brunet, *WHO Collaborating Centre on AIDS, IMET, Paris, France. 517 [Page 518](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/518) W.H.P.23 Comparison of Epidemiological Data from the AIDS Epidemic in the USA and the FRG. Bernhard Schwartldnder*, R. Schlittgen, J. Dobberstein, M. A. Koch, *AIDS Center, Federal Health Office, Berlin, Federal Republic of Germany. W.H.P.24 It Takes Two to Tango but One Infects: Effects of Non-Disclosure on the Under-Estimation of the Perceived Risk of HIV Infection. Ronnv A. Shtarkshall*, T. Awerbuch, *The Hebrew University, Hdassah Faculty of Medicine, Department of Social Medicine, Jerusalem, Israel. W.H.P.25 Deterministic Model of the U.S.A. AIDS Epidemic. Bruce R. Buzbv*, J. W. Ramey, * University of Connecticut Business School, Brookfield, CT, U.SA. W.H.P.26 Utilizing Commercially Available PC Software for the Analysis and Management of Clinical Trials HIV Data. S. Rae. Mackay. 111*, L. Corey, J. Benedetti, *ACTU, Ministre de la solidarit6, de la sant6 et de la protection sociale de Piot du D6partement de microbiologie Institut de m6decine tropicale Belgique Perspectives et vaccination contre VIH Dani P. Bolognesi Professeur James B. Duke D6partement de Chirurgie Duke University Medical Centre Etats-Unis qui Doyen Ecole de sant6 publique University of Michigan [Page Room 407A Section juin Thursday, June 8 tpid&miologie et sant6 publique Epidemiology and Public Health Surveillance de I'6pid6mie de VIH Monitoring the HIV Epidemic Table ronde Round Table Pr6sidents Chairpersons James Chin (Switzerland) Timothy Dondero (U.S.A.) 11:00 Th.A.O.1 Program Content: * Needs and Uses of Serosurveillance * Choice of sentinel populations * Blinded versus non-blinded studies -methodologic aspects -legal and ethical considerations * Interpretation of data of non-representative populations * Serosurveys using probability samples Panelists: O. Noel Gill, London, U.K. Steve Lwanga, Geneva, Switzerland. Lloyd Novick, Albany, NY, U.S.A. 522 [Page 523](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/523) 11:00- 12:30 Salle Room 408A Section A Jeudi June 8 Round Table Pr6sidents Chairpersons et Public Health Modblisation math6matique Mathematical Modelling Roy M. Anderson (U.K.) Ron Brookmeyer (U.S.A.) 11:00 Th.A.O.2 Program Content: * Short-term prediction and back calculation * Incubation period and infectivity * Models of transmission dynamics * Demographic impact * Data needs and access to data bases * Research needs Panelists: Carlos Castillo-Chavez, Ithaca, NY, U.S.A. James Curran, Atlanta, GA, U.S.A. John Koran, Atlanta, GA, U.S.A. G. Medley, London, U.K. Andrew Moss, San Francisco, CA, U.S.A. 523 [Page 524](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/524) 11:00 - 12:30 Salle Room 408BC Section A Jeudi 8 juin Thursday, June 8 p 4id&iologieetsant6publique Epidemiology and Public Health S6ance th6matique Transmission p rinatale Specialty Session Perinatal Transmission Presidents Chairpersons R. G. Choto (Zimbabwe) Peter Piot (Belgium) Pauline A. Thomas (U.S.A.) 11:00 Th.A.O.3 11:15 Th.A.O.4 11:30 Th.A.O.5 11:45 Th.A.O.6 12:00 Vertical of HIV Infection: European Collaborative Study Update. Catherine Peckham. A. E. Ades, M. L. Newell, European Collaborative Study, Institute of Child Health, London, U.K. HIV Antibody Negative Children with Positive Virology: Observations from the European Collaborative Study. Marie-Louise Newell, C. S. Peckham, A. E. Ades, European Collaborative Study, Department of Paediatric Epidemiology, Institute of Child Health, London, U.K. Breast Feeding and HIV-1 Transmission. Subhash K. Hira*, U. Mangrola*, C. Mwale*, N. Mwansa*, C. et al., *University Teaching Hospital, Lusaka, Zambia; **Uniformed Services University of Health Sciences, Bethesda, MD, U.S.A. High Perinatal HIV Rates with Prematurity or Low Anti-gp 120. James J. Goedert*, H. Mendez**, Landesman*, *National Cancer Institute, Rockville, MD; **State University of New York Health Science Center, Brooklyn, NY, U.S.A. Early Predictors and Rate of Perinatal HIV Disease. Pauline A. Thomas, The New York City Perinatal HIV Transmission Study Group, Director, AIDS and HIV Surveillance, New York City Department of Health, New York, NY, U.S.A. Maternal Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus-1 (HIV-1). Gwendolyn B. Scott, C. Hutto, C. Mitchell, W. P. Parks, University of Miami, School of Medicine, Department of Pediatrics, Miami, FL, U.S.A. 524 [Page 525](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/525) 11:00 - 12:30 Sal4e paem 401 ABC Jeudi 8 juin Thursday, June 8 Seance th6matique Specialty Session Aspects cliniques Clinical Aspects 11:45 Th.B.O.4 Th.B.O.5 12:15 Th.B.O.6 Phase I Trial of Oral Ribavirin in High Risk Patients for AIDS. Richard B. Roberts*, R. Makuch**, K. Jurica*, *Cornell University Medical College, New York, NY; **Yale University, School ofMedicine, New Haven, CT, U.S.A. Phase Trial of Ribavirin + Isoprinosine in Asymptomatic HIV Viremic Gay Men. Richard S. Schulof*, G. L. Simon*, D. M. Parenti*, M. B. Sztein*, W. A. Meyer**, H. Paxton**, et al., *The George Washington University Medical Center, Washington, DC; **Maryland Medical Laboratory, Baltimore, MD, U.S.A. 2', 3' Dideoxycytidine (DDC) in the Treatment of Patients with AIDS and ARC. Michael S. Gottlieb*, J. Galpin*, J. Thompkins*, D. E. Wilson**, L. Medical Group, Sherman Oaks, CA; **Hoffmann-La Roche, Nutley, NJ, U.S.A. Escalating Dose Phase I Study of Intravenous and Oral 2', 3'-Dideoxyinosine (ddI) in Patients with AIDS or ARC. Robert Yarchoan. R. V. Thomas, J. M. Pluda, N. R. Hartman, D. G. Johns, S. Broder, et al., National Cancer Institute, Bethesda, MD, U.S.A. Pharmacokinetic Studies of Recombinant Soluble CD4 in Patients with AIDS and AIDS Related Complex. James O. KahA*, A. J. Davis**, L. A. Kaplan*, J. Groopman**, S. Sherwin***, *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA; **New England DeaconessHospital, Harvard Medical School, Boston, MA; ***Genentech Inc., South San Francisco, CA, U.S.A. Escalating Dose Tolerance of Recombinant Soluble CD4 in Humans. Robert T. Schooley*, D. D. Ho**, P. Gaut**, M. R. Tierney*, J. Schindler***, S. Henochowicz****, et al., *Massachusetts General Hospital, Boston, MA; **Cedars-Sinai Medical Center, Los Angeles, CA; ***Biogen, Inc., Cambridge, MA; ****NIAID, AIDS Program, Bethesda, MD, U.S.A. 525 [Page 526](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/526) 11:00 - 12:30 Salle Room 404AB Section B Jeudi 8 juin Thursday, June 8 Aspects cliniques Clinical Aspects of AIDS Test de depistage par reaction en chaine des polymbrases PCR Diagnostic Test th6matique Specialty Session Chairpersons Pedro Cahn (Argentina) Frangois Catalan (France) Denis Th.B.O.9 Th.B.O.11 12:15 Relative Amounts of HIV Proviral Sequences in PBMCS by the Polymerase Chain Reaction (PCR). Shirley Y. Kwok, D. Kellogg, J. J. Sninsky, Cetus Corp., Department of Infectious Diseases, Emeryville, CA, U.S.A. Comparison of PCR Analysis and Culture in the Detection of HIV-1 Infection in Hemophiliacs. J. Brooks Jackson*, K. Sannerud*, S. Kwok**, J. Sninsky**, J. Hopsicker*, H. H. Balfour, *University of Minnesota, Minneapolis, MN; **Cetus Corp., Emeryville, CA, U.S.A. Evaluation of the Polymerase Chain Reaction (PCR) in a Well-Characterized Cohort of Homosexual and Bisexual Men: PCR-Positive, HIV-Antibody Negative Results Are Rare. Stanley**, P. M. O'Malley*, J. Pane**, G. W. Rutherford*, P. Sohmer**, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco; **Pathology Institute, Berkeley, CA, U.S.A. Detection of HIV-1 DNA in Peripheral Blood by Polymerase Chain Reaction (PCR) and Non-Radioactive Oligonucleotide Probes. Karl E. Adler*, L. J. B. Conway**, J. C. Kaplan**, M. S. Hirsch**, *Dupont Medical Products, Billerica; **Massachusetts General Hospital, Harvard Medical School, Boston, MA, U.S.A. Simultaneous Detection of HTLV-I in AIDS Patients by PCR. Barun K. De, A. Srinivasan, Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. A Microtiter-Based DNA Sandwich Assay for the Detection of HIV-1 in Clinical Samples. George H. Keller, D. P. Huang, L. Jagodzinski, C. Overholt, D. Petersen, M. Manak, Biotech Research Laboratories, Inc., Rockville, MD, U.S.A. 526 [Page 527](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/527) 11:00 - 12:30 Salle Room 407B Section B Jeudi 8 juin Thursday, June 8 Aspects cliniques Clinical Aspects of AIDS Colloque Symposium Pr6sidents Chairpersons Infections respiratoires chez les consommateurs de drogues par vole Intraveineuse Respiratory Infection in IV Drug Users Jerome Ernst (U.S.A.) G. Visco (Italy) 11:00 Th.B.O.13 drogue Roma, Rome Italy. Mycobacterial Infections in HIV-Infected IV Drug Addicts. W. Johann Wolfgang Goethe-Universittit, Zentrum der Inneren Federal Republic of Germany. PCP and Drug Abusers: The Bronx Lebanon Experience. Jerome Ernst. The Bronx-Lebanon Hospital Center, Division of Pulmonary and Infectious Diseases, Bronx, NY, U.S.A. 527 [Page 528](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/528) 11:00 - 12:30 Salle Room 403ABC Section C Jeudi 8 juin 8 S6ance Specialty Session Recherche fondamentale (biom6dicale) Basic Research (Biomedical) base Immunology (Part 3) Jean-Claude (France) Th.C.O.2 11:30 Th.C.O.3 11:45 Th.C.O.4 Selective Signaling Defect Via the CD3/TCR Complex in T Cells from HIV-Infected Men. R. Gruters, C. J. M. van Noesel, F. G. Terpstra, P. T. A. Schellekens, R. A. W. van Lier, F. Miedema, Central Laboratory, Netherlands Red Cross Blood Transfusion Service and the University of Amsterdam, Laboratory of Experimental and Clinical Immunology, Amsterdam, Netherlands. Chemically Induced CD4 Mutants Provide Evidence for Additional Sites Involved in HIV-1 Infection and Syncytia. Hana Golding*, Monoclonal Antibodies to Variant and Conserved Epitopes of HIV Envelope Glycoproteins. James E. Robinson, D. Holton, S. Pancheco, J. Liu, H. McMurdo, Louisiana State University Medical School, Department of Pediatrics, New Orleans, LA, U.S.A. A Hybridoma Producing Human Monoclonal IgG Neutralizes the HIVIIIb Isolate In Vitro. Takashi Kawamura*, E. Robinson***, E. Petersen**, W. Mitchell***, *Teijin Institute for Biomedical Research, Tokyo, Japan; **University of Arizona Department of Hematology and Oncology, Tucson, AZ; ***Department of Pathology, Vanderbilt University, Nashville, TN, U.S.A. 4 528 [Page 529](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/529) 12:00 Th.C.O.5 12:15 of Anti-CD4 Autoantibodies the Sera HIV-Infected Using dificits immunitaires, CERVI, Paris, France. Antibody Response to the HIV-1 Regulatory Gene Products nef, vif and vpr in HIV-1 Infected juin Thursday, June 8 Colloque fondamentale (biom&dicale) Aspects pathologlques de I'infectlon par le VIH Pathological Aspects of HIV Infection Jean Latreille (Canada) Paul Racz (Federal Republic of Germany) Symposium Th.C.O.8 11:30 Th.C.O.9 11:45 Th.C.O.10 Distinct Histologic Lymph Node Changes following HIV Infection in Adults. N. L. Harris, Massachusetts General Hospital, Boston, MA, U.SA. Detection of HIV in Lymph Nodes. Paul Racz. Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Federal Republic of Germany. In situ Hybridization for Detection of HIV Genome. Peter Biberfeld, Karolinska Institute, Stockholm, Sweden. Biological Functions of Human Monoclonal Antibodies to HIV. S. Zolla-Pazner, VA Medical Center, New York, NY, U.S.A. 530 [Page 531](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/531) 11:00 - 12:30 Salle Room 41 OABC Section C Jeudi 8 juin utilisation des molecules CD-4 Drug development: Use of CD4 Molecules in AIDS Therapy Sam Broder (U.S.A.) Volker Erfle (Federal Republic of Germany) Sabih R. Khan (Canada) 11:00 Th.C.O.11 11:15 Th.C.O.12 11:30 Th.C.O.13 Retroviral Vectors Expressing Soluble CD4: A Potential Gene Therapy for AIDS. Richard A. Morgan*, D. J. Looney***, D. D. Muenchau*, F. Wong-Staal**, R. C. Gallo**, W. F. Anderson*, *Laboratory of Molecular Hematology, National Heart, Lung, and Blood Institute and **Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda; ***Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A. Specific Anti-HIV Activities of a Recombinant Human CD4-Pseudomonas Exotoxin Hybrid Toxin. Edward A. Berger*, V. K. Chaudhary**, K. A. Clouse***, D. J. FitzGerald**, Pastan**, B. Moss*, *Laboratory of Viral Diseases, NIAID; **Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD; ***Georgetown University, Washington, DC, U.S.A. Inhibition of the Infectivity of HIV-1 and HIV-2 by Soluble rCD4: Differential Sensitivity to Soluble rCD4. Hiroaki Mitsuva*, S. Hayashi*, *The Clinical Oncology Program; **Laboratory Tumor Cell Biology, National Cancer Institute, Bethesda, MD; ***Genentech, Inc., South San Francisco, HIV-Infected Cells. Mark A. Till* V. Ghetie*, Uhr*, D. Capon**, E. S. Vitetta*, *University of Texas, Southwestern Medical Center at Dallas, Department ofMicrobiology, Dallas, TX; **Genentech, Inc., South San Francisco, CA, U.S.A. Designing CD4 Immunoadhesins for AIDS Therapy. Daniel J. Capon*, S. Chamow*, J. Mordenti*, H. Mitsuya**, R. Byrn***, C. et *Genentech, Inc., South San Francisco, CA; **The Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; New England Deaconess Hospital, Harvard Medical School, Division ofHematology-Oncology, Boston, MA, U.S.A. Effect of Recombinant Soluble CD4 in Rhesus Monkeys Infected with Simian Immunodeficiency Virus of Macaques. Norman L. Letvin*, M. Watanabe*, K. A. Reimann*, T. Liu**, R. A. Fisher**, P. A. DeLong*, *Harvard Medical School, New England Regional Primate Research Center, Southborough; **Biogen Research Corp., Cambridge, MA, U.SA. 532 [Page f 0 Session Pr6sidents Chairpersons Section Jeudi 8 juin Thursday, June 8 Le SIDA et l'individu AIDS and the Individual Consommateurs de drogues par vole Intraveineuse (partle 1) Injection Drug Users (Part 1) Robert G. Covell (U.K.) Frangois Lamothe (Canada) V. What Intravenous Drug Abusers Say about Their Beliefs and Behavior: Report of a Series of Focus Group Discussions. Waranee Pokapanichwong*, D. Douglas**, N. Epidemiology, Ministry of Public Health; ****Bangkok Metropolitan Administration, Bangkok, Thailand. Temporal Pattern of Cocaine Use and AIDS in Intravenous Drug Users in Methadone Maintenance (MM). Diana Hartel. E. E. Schoenbaum, P. A. Selwyn, E. Drucker, W. Wasserman, G. H. Friedland, et al., Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, U.S.A. Effects of Changes in Drugs Injected on Drug Using Environments and on Risk Reduction among IV Users. Samuel R. Friedman*, C. Sterk*, M. Sufian*, D. C. Des Jarlais**, *Narcotic & Drug Research, Inc.; **New York State Division of Substance Abuse, New York, NY, U.S.A. Endocarditis, Subcutaneous Abscesses, and Other Bacterial Infections in Intravenous Drug Users and Their Association with Skin-Cleaning at Drug Injection Sites. John K. Watters*/**, F. Herb*, P. Case**, D. Pettiti*, *University of California at San Francisco; **Urban Health Study, San Francisco, CA, U.S.A. Methadone Maintenance and Behavior Change in Seropositive Drug Abusers: The San Francisco General Hospital Program for AIDS Counseling and Education (PACE). James L. Sorensen. S. L. Batki, D. R. Gibson, R. Dumontet, S. Purnell, San Francisco General Hospital, University of California at San Francisco, Centerfor AIDS Prevention Studies, San Francisco, CA, U.S.A. Intravenous Drug Users and Maintenance of Behaviour Change. Don C. Des Jarlais*, S. Tross**, A. Abdul-Quader**, A. Kouzi**, S. R. Friedman**, *New York State Division of Substance Abuse Services; **Narcotic and D rug Research, Inc., New York, NY, U.S.A. 533 [Page 534](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/534) 11:00 -12:300 Presidents Chairpersons Section D Jeudi 8 juin Thursday, June 8 Le SIDA et l'individu AIDS and the Individual Prostitution Prostitution Judith B. Cohen (U.S.A.) Pamela Gillies (U.K.) Ibra Th.D.O.11 12:15 Th.D.O.12 The Impact of an Educational Program on HIV Infection among Prostitutes. James R. Foreit*, A. Tejada**, J. Alarcon**, J. Piscoya**, L. Varela*, *The Population Council; **Universidad Nacional Mayor de San Marcos, Lima, Peru. Young Male Prostitutes: Safe and Unsafe Sex and AIDS Knowledge. Richard R. Pleak, H. F. L. Meyer-Bahlburg, HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY, U.S.A. Women Working as Prostitutes: Participatory/Consensus-Based Planning for Provision of Mobile Prevention, Risk Reduction, and Seroprevalence Activities. Clay P. Stephens, B. J. Hayes, R. Adams, M. Gross, Massachusetts Department of Public Health, AIDS Office, Boston, MA, U.S.A. The Agglutinating Approach to Joint STD/AIDS Prevention and Control in Female Sex Workers in the Dominican Republic. Ernesto Guerrero, S. Rosario, E. A. De Moya, C. Vdlquez, R. Alcdntara, PROCETS, Ministry of Public Health, Santo Domingo, Dominican Republic. Evaluation of Key Messages to Increase the Use of Condoms in Sex Workers. A Quasi-Experimental Study. Jose Luts Valdespino*, J. A. Izazola*, J. Ramah**, et al., *Ministry ofHealth, General Directorate ofEpidemiology; **AIDSCOM, Mexico City, Mexico. The Development of Micro-Enterprises as Work Alternatives for Female Sex Workers in the Dominican Republic. Ernesto Guerrero, M. C. Abenia, S. Rosario, E. A. De Moya, PROCETS, Ministry of Domingo, 535](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/535) Section E juin Thursday, June 8 Atelier Workshop Presidents Chairpersons Le SIDA, la soci&t6 et le comportement AIDS, Society and Behaviour Innovations en matibre de pr6vention et d'dducation au sujet du SIDA Innovations in AIDS Education and Prevention Rebecca Asmery (U.S.A.) Weraist Sittitrai (Thailand) Adolescents: Strategies for Behavior Change. Beverlie Conant Sloane, M. Dyer Chamberlain, K. Berry, R. Van Treuren, Dartmouth College, Department of Health Education, Hanover, NH, U.S.A. Developments of the National AIDS Telephone Help Line in the Netherlands, 1985-1988. Monique A. C. M. Middelhoff, J. L. Roosjen, -\"h Committee on AIDS Control (NCAB), Amsterac,.. letherlands. Equipping Kinshasa Public Buses with a Cassette Playback System Is Effective in an AIDS Prevention Campaign. Kitoto K.Kalombo*, B. N'Galy*, B. France**, T. Research Center; ****GAPPS Agency, Kinshasa, Zaire. AIDS Street Nurses. Michael L. Rekart, M. McCarthy, C. Farrow, STD Control, British Columbia Ministry ofHealth, Vancouver, BC, Canada. The Futures Workshop as a Method for Mobilization and Coordination in AIDS Prevention. Viveka Urwitz, T. Juvall, M. Ohgren, P. Sennerfeldt, Youth Project, Stockholm AIDS Prevention Programme, Stockholm, Sweden. Bleachman: A Super-Hero Teaches AIDS Prevention. Les G. Pappas, San Francisco AIDS Foundation, San Francisco, CA, U.S.A. Incorporating AIDS Education into Family Planning. Luis R. Varela, The Population Council, New York, NY, U.S.A. I 535 [Page 536](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/536) 11:00 - 12:30 Salle Room 406A Chairpersons Implications intemationales/ Aspects cliniques International Issues/ Clinical Aspects of AIDS SIDA et tuberculose AIDS and Tuberculosis Ngaly Bosenge (U.S.A.) D. Kochi (Switzerland) 12:00 Th.G.O.5 12:15 Th.G.O.6 AIDS and Tuberculosis (TB) in the USA. M. Miles Braun, W. Heyward, C. Ciesielski, R. Berkelman, R. Byers, A. Bloch, Centers for Disease Control, Atlanta, GA, U.S.A. Effect of Tuberculosis as a New AIDS Definition Criteria on Surveillance Data. Jordi Casabona, T. Salas, A. Bosch, A. Segura, Epidemiology Section, Generalitat de Catalunya, AIDS Program, Barcelona, Spain. Tuberculosis and AIDS: Our Experience. Jorge A. Benetucci, L. Astarloa, J. Gonzalez Montaner, E. Abbate, J. H. Da Bouza, et al., Hospital Francisco J. Muiiiz, Buenos Aires, Argentina. The Impact of Human Immunodeficiency Virus (HIV) on Tuberculosis in Zambia: A Cross-Sectional Study. Alison M. Elliott*, N. Luo*, G. Tembo*, G. Steenbergen**, Hospital; **Ministry of Health, Lusaka, Zambia; ***London School of Hygiene and Tropical Medicine, London, U.K. A Study of HIV Infection in Association with Tuberculosis Patients Seen in Infectious Diseases Hospital (I.D.H.), Nairobi. Daniel K. Kibuga*, S. N. Gathua*, P. P. Nunn**, *Infectious Diseases Hospital, Nairobi, Kenya; **London School of Tropical Medicine and Hygiene, London, U.K. Association of Tuberculosis and HIV Infection in Zimbabwe. William G. W, Legg, M. Mahart, S. Houston, P. Neill, C. S. Ray, E. Marowa, Harare City Health Department, Harare, Zimbabwe. 536 [Page 537](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/537) 11:00 - 12:30 Salle Room 406BC Section G Jeudi 8 juin Thursday, June 8 Implications intemrnationales International Symposium Pr6sidents Chairpersons (Canada) Edward 11:30 Th.G.O.9 11:45 Th.G.O.10 12:00 Th.G.O.11 Reliability and Validity Issues in the Assessment of Sexual Behaviour. Joseph A. Catania, Center for AIDS Prevention Research, University of California at San Francisco, San Francisco, CA, U.S.A. Sexuality Research in Zaire. Namagosi Lusakulira, Kinshasa, Zaire. Sexuality Research in Thailand. Werasit Sittitrai, Institute of Population Studies, Chulalongkorn University, Bangkok, Thailand. Sexuality Research in Brazil. Arletty Pinel, Centro de Referencia e Treinamento-AIDS, Sao Paulo, Brazil. Research on Human Sexuality in Sub Saharan Africa. Lawrence Adeokun, Global Programme on AIDS, World Health Organization, Geneva, Switzerland. 537 [Page 538](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/538) 11:00-12:30 Salle Room 411C Section H Jeudi 8 8 S6ance th6matique Speciality Session Presidents Chairpersons Re\"ercussions &aonomiques du SIDA The Economic Impact of AIDS Affectation des ressources et processus d6cisionnels Resource Allocation and Decision-Making Pierre-Marc Johnson (Canada) Denise Laberge-Ferron (Canada) Phillip Lee (U.S.A.) Th.H.O.1 11:15 Th.H.O.2 11:30 Th.H.O.3 11:45 Th.H.O.4 12:00 Th.H.O.5 Resource Allocation by Donor Countries: to High Prevalence or Low prevalence? Edward Elmendorf, The World Bank, New York, NY, U.S.A. Allocation de ressources decisions politiques et contraintes. Pierre-Marc Johnson, mddecine, dthique et droit, Montreal, QC, Canada. Data Gaps in Modeling AIDS Service Utilization and Costs. Linda Bilheimer, Mathematica Policy Research, Inc., Washington, DC, U.S.A. Comparative Evaluation of the Use of NGO's for Resource Allocation. Steven Manning. AIDS Committee of Toronto, Toronto, ON, Canada. The Financial Impact of Integrated Care Delivery. ff Morrison, The AIDS Health Service Program, University of California at San Francisco, CA, U.S.A. 538 [Page 539](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/539) 11:00 - 8 juin Thursday, June 8 1Sessionvid6o LjE J Video session Programme international-espagnol Spanish International Programme Dr. Guy Lonergan \"PUPPETS AGAINST AIDS\" Video de/Video by: Gary Friedman, African and Educational Puppetry Programme 1989 \"SIDA Instituto Familiar qui d6peint l'emploi de marionnettes g6antes pour d6crire le SIDA. Du Chili, un film gouvernemental d'information sur le SIDA et sur la transmission du VIII mettant en scene des jeunes et un m6decin. Des Atats-Unis, la transposition du SIDA sur le petit dans des t616romans les relations sociales au sein de la communaut6 latino-amdricaine. Three alternatives to community and youth education. From southern Africa, a video depicting the use of oversized puppets to describe AIDS. From Chile, a state informational video on AIDS and HIV transmission with youth and a doctor. From the United States, the dramatization of AIDS by the use of soap opera/ tele novella exploring the social intricacies of the 540](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/540) cts amfi-visuels Room 49ABC LAudio-Visual Aspects Sessions du midi La musique, les performances et les changements soclaux Noon Hour Music, Performance and Social Change Michael Callen, Musicien, Coalition des personnes atteintes du SIDA/Musician, People with AIDS Coalition, New York, NY, U.S.A. 12:55 Chanson, danse-dramatique et art la rap, danse et changement social chez les jeunes/Rap-Music, Dance and Social Change in Youth. Kevin Hicks, Quincy Delight III, Musiciens/Musicians, Los Angeles, CA, U.S.A. 13:15 Moyens d'6ducation officiels et populaires sur le et dans les autres iles des Caraibes/Formalised and Popular Mediums to Educate on AIDS in Trinidad and Other Caribbean Territories. Godfrey Sealy. Acteur/Performer, Port Rights and AIDS. Carol Leigh, and Scarlot Harlot, Activistes des droits des prostitud(e)s/Prostitutes' rights activists, Oakland, U.S.A. 13:35 La musique et le message: un exemple du Message: du monde. Appr6ciez-en le rythme. Music as means of change. The themes might stay the same but the rhythm changes. This session consists of music and performance in AIDS education from various parts of the world. Bring your lunch and enjoy the rhythms. 541 [Page 542](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/542) 14:00 - 15:30 Salle Room 407A Section A Jeudi 8 juin Thursday, June 8 Table ronde Round Table Presidents Chairpersons dpid6miologie et sant= publique Epidemiology and Public Health R6le du d6pistage et du counseling dans la prevention du SIDA The Role of HIV Testing and Counselling in AIDS Prevention Hunter H. Handsfield (U.S.A.) Sirkka-Lisa Valle (Finland) 14:00 Th.A.O.9 Program Content: * Review of data on the influence of testing and counselling on behavioural change * Differential approach and effect in different populations (e.g. men, STD clinic patients, IVDU's) * Role of testing and counselling in HIV prevention in the developing world * Further research on the efficacy of HIV testing and counselling, including possible methodologic approaches and pitfalls Panelists: Stephen Bowen, Atlanta, GA, U.S.A. Edward W. Hook, III, Baltimore, MD, U.S.A. Gloria Omelas-Hall, Mexico, Mexico. 542 [Page 543](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/543) 14:00 - 15:30 Salle Room 408A Chairpersons tpidmiologie et mdthodologle Methodologic Issues Akwasi Aidoo (South Africa) Seroconversion Experience of EIA+/WB- Individuals. Robert T. Pero, J. G. McNeil, D. S. Burke, The Walter Reed Research Group, Walter Reed Army Institute of Research, Washington, DC, U.S.A. Incidence of Pediatric AIDS in the United States: Predictions from Seroprevalence Data. Marta Gwinn*, *Centers for Disease Control, Atlanta, GA; **NICHD, Bethesda, MD, U.S.A. Relationship between Cumulative Incidence of AIDS and Prevalence of HIV in Women of Reproductive Age in the United States. Marguerite Pappaioanou*, J. Buehler*, M. Gwinn*, J. Karon*, A. Wright**, A. *Centers for Disease Control, AIDS Program, Atlanta, GA; **NICHD, Bethesda, MD, U.S.A. Evaluating the Feasibility of the National Household Seroprevalence Survey (NHSS). Geraldine M. McQuillan. T. Ezzati, J. Massey, Centers for Disease Control, National Center for Health Statistics, Hyattsville, MD, U.S.A. Application of Lot Quality Assurance (LQA) Sampling to HIV and AIDS Sentinel Surveillance. S. Lwanga, J. Chin, J. Mann, World Health Organization, Geneva, Switzerland. Methodological Considerations for Assessing the Impact of Condom, Spermicide and Oral Contraceptive Use on HIV Transmission. Ruby T. Senie, D. Kleinbaum, E. D. Eaker, N. C. Lee, H. B. Peterson, Centersfor Disease Control, Atlanta, GA, U.S.A. 543 [Page 544](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/544) 14:00 15:30 Salle408BC Room Thursday, June 8 ldf-L pid&niologie et santA publique Epidemiology Public Health S6ance th6matique Transmission sexuelle du VIH (partie 3) Specialty Session Sexual Transmission of HIV (Part 3) Presidents Chairpersons Fred Mahlu (Tanzania) Carlos Vega HIV Transmission: Confounding or Effect Modification? George R. Seage*, K. H. Mayer**, C. R. Horsburgh***, S. H. Holmberg***, G. A. Lamb*, *Boston Department of Health & Hospitals; **Fenway Community Health Center, Boston, MA; ***Centers for Disease Control, Atlanta, GA, U.S.A. The Role of Ulcerative Genital Diseases in Promoting Acquisition of HIV-1 by Homosexual Men. Mark J. Van Raden*, R. A. Kaslow*, L. Kingsley**, R. Chicago, IL, U.S.A. Syphilis Is Strongly Associated withHIV Infection in Baltimore STD Clinic Patients Independent of Risk Group. Robert O. Cannon*, T. C. Quinn*/**, A. Rompalo*/***, D. Glasser***, S. University, Baltimore; **NIAID, Bethesda; ***Baltimore City Health Department, Baltimore, MD, U.S.A. Serological Evaluation of Sexual Partners, Children, and Household Contacts of HIV Infected Persons in Yaounde, Cameroon. Marcel Study. Isabelle De Vincenzi R. Ancelle-Park, Mondiale de la Sant6-SIDA Europe, IMET, H6pital Claude Bernard, Paris, France. High Prevalence and Incidence of HIV and Other Sexually Transmitted Diseases (STD) among 801 Kinshasa Prostitutes. Marie Laga*, N. Kivuvu**, P. Piot*, R. Ryder**/***, et al., Antwerp, Belgium; **Projet SIDA, Kinshasa, Zaire; ***Centers for 15:30 Salle Rpom 401ABC Section juin Thursday, June 8 S Aspects cliniques Clinical Aspects of Dale**, A. M. Wesley**, S. Mahawar**, University of California at San Francisco, *Department ofMedicine and **Department ofNeurology, San Francisco, CA, U.S.A. Electrophysiological Investigation of Central and Peripheral Nervous System in HIV Infected Patients. Arrigo Moglia*/***, C. Zandrini*, E. Alfonsi*, Mondino; ***University of Pavia, Department of Infectious Diseases, Pavia, Italy. Study of Nerve Biopsies in 36 Patients with HIV Infection. Jean-Jacques Hauw, M.-P. ofPathology and **Department of Medicine, Berlin, Federal Republic of Germany. MR Imaging of Intracranial Manifestations of AIDS: Unenhanced and GD-DTPA Enhanced Studies. J. B. Ruf***, R. Felix*, *Free Berlin, Clinic, Department of Radiology; **Department of Neuropathology; ***Department of Internal Medicine II, Berlin, Federal Republic of Germany. The Interval between Equivocal and Definite Neurological Signs and Symptoms in the AIDS Dementia Complex (ADC). John J. Sidtis, H. T. Thaler, B. J. Brew, A. E. Sadler, J. G. Keilp, R. W. Price, et al., Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. 545 [Page 546](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/546) 14:00 - 15:30 Salle Room 404AB Thursday, 8 S6ance th6matique Specialty Session Pr6sidents Chairpersons Aspects clinrues Clinical Aspects of AIDS Les lymphokines Lymphokines Scott Hamer HIV Seroconversion: Serum 8-2 Microglobulin R. Detels, J. L. Fahey, University of California at Los Angeles, Schools of Medicine and Public Health, Department of Microbiology/Immunology, Los Angeles, CA, U.S.A. 2'-5'A Synthetase and Blastogenesis as Measures of Response to Azidothymidine (AZT). Stanley E. Read. M. Fanning, J. Osachoff, R. Coates, University of Toronto, Hospitalfor Sick Children, Toronto, ON, Canada. Power of Serum Beta-2-Microglobulin and Serum Neopterin P. J. Grob**, R. Laithy*, *University Hospital, Department of Medicine, Division of Infectious Diseases; **Division of Clinical Immunology, Zurich, Switzerland. D. Bundow, Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. High Interferon Levels Predict Subsequent Development of AIDS. Robert E. Anderson*, J. Merritt**, R. Hamilton**, S. Shiboski***, W. Winkelstein***, CA; **The Upjohn Company, Kalamazoo, MI; ***University of California, Berkeley, CA, U.S.A. Tumor Necrosis Factor (TNF) in the Plasma of Africans Infected with HIV. Steven M. Holland*, R. L. Colebunders**, H. L. Francis**, Khondi**, B. Kapita**, T. C. Quinn***, et al., *Johns Hopkins Hospital, Division of Infectious Diseases, Baltimore, MD, U.S.A.; **Projet SIDA, Kinshasa, Zaire; ***NIAID, 14:00 - 15:30 Salle Room 407B Section B Jeudi 8 juin Thursday, June 8 Aspects cliniques Clinical Aspects of AIDS Colloque Symposium Presidents Chairpersons associbs au VIH aujourd'hul et in Hemophilia: Today Epidemics. Bruce Evatt, AIDS Program, Centres for Disease Control, Atlanta, GA, U.S.A. Virucidal Methods for Clotting Factor Concentrates: Are They Effective. Pierre Manucci, University of Milano, Milan, Italy. Natural History of HIV Infection in Hemophilia. Chris M. Tsoukas, Montreal General Hospital, Division of Clinical Immunology, Montreal, QC, Canada. Rates, Markers and Cofactors of HIV-Infection and AIDS in Hemophiliacs. James Goedert, National Institutes of Health, Viral Epidemiology Section, Bethesda, MD, U.S.A. Hemophilia: Special Management Issues. Christine A. Lee, Hemophilia and Hemostasis Unit, Royal Free Hospital, London, U.K. Concentrates: Meeting the Demand. Louis M. Aledort, Mount Sinai School of Medicine, New York, NY, U.S.A. 547 [Page 548](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/548) 14:00 - 15:30 Salle Room Recherche I'AZT dans le traitement SIDA Drug Development: Use of AZT and Other Oligonucleotides in AIDS Therapy Aly Guido (Malawi) Jean-Claude P6chbre by GM-CSF, M-CSF, and A. Cooney, H. Mitsuya, D. G. Johns, S. Broder, National Cancer Institute, Bethesda, MD, U.S.A. Inhibition of HIV Replication by Novel Phospholipid Derivatives of AZT and Other Antiretroviral Nucleosides In Vitro. Karl Y. Hostetler*/**, D. D. Richman**, *Vical Inc., San Diego; **University of California at San Diego, and the VA Medical Center, San Diego, CA, U.S.A. Inhibition of HIV Expression: Enhancement of Activity of Phosphorothioate Oligodeoxynucleotides by Chemical Modification. Makoto Matsukura*, K. Mori**, G. Zon***, J. S. Cohen**, S. Broder*, *National Cancer Institute, National Institutes of Health, Clinical Oncology Program and **Medicine Branch, Bethesda, MD; ***Applied Biosystems Inc., Foster City, CA, U.S.A. 5-Halogeno-3'-Fluoro-2',3'-dideoxyuridines Are Potent Inhibitors of Retrovirus Replication In Vitro. Jan M. Balzarini*, A. Van Aerschot*, R. Pauwels*, M. Baba*, Conformational Preference of Anti-HIV and Drug Design. C. K. Chu*, P. Van Roey**, R. F. Schinazi***, E. W. Taylor*, *University of Georgia, College of Pharmacy, Athens, GA; **Medical Foundation of Buffalo, Buffalo, NY; ***Emory University School of Medicine/VA Medical Center, Atlanta, GA, U.S.A. Synthesis and In Vitro Function of Ribozymes Targeted to HIV-1 Specific RNA Sequences. John A. Zaia*, J. Rossi**, P. Chang**, D. *City of Hope Medical Center; **Beckman Research Institute of City ofHope, Duarte, 548 [Page 549](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/549) Specialty Chairpersons Recherche fondamentale (biom&dicale) Basic Research (Biomedical) Virologie Virology (Part 4) Michael John Gill (Canada) Kondou Odehouri of HIV-2 with Marked Tropism for Macrophages, One of Which is Highly Divergent and Genetically Equidistant between HIV-2ROD and SIVMAC. Helga Ribsamen-Waigmann*, Georg-Speyer-Haus; **Hoechst AG, Frankfurt am Main, Federal Republic of Germany. Characterization of a Biological Variant of HIV-1, Defective in the Ability to Modulate CD4. James A. Hoxie*, E. P. Reddy**, M. Inoue**, P. Durda***, M. Spiritos*, B. S. Haggarty*, et al., *Hospital of the University of Pennsylvania; **Wistar Institute ofAnatomy and Biology, Philadelphia, PA; ***E. I. Du Pont de Nemours & Co., North Billerica, MA, U.S.A. Murine Monoclonal Antibodies to a Synthetic Peptide of HIV-1 Have Neutralizing and Fusion Blocking Activities. Paul JL. Durda*, K. Matthews**, M. Rayner*, Pomerantz***, *E. I. Du Pont de Nemours & Co., Medical Products Department, North Billerica, MA, and Wilmington, DE; **Duke University, School of Medicine, Durham, NC; ***Massachusetts General Hospital, Infectious Diseases Unit, Boston, MA, U.S.A. Inhibition of HIV Production by Infected Cells Using Monoclonal Antibodies Marseille, France. HIV Isolates from Asymptomatic Men Are Biologically and Genetically Different from Those Isolated from AIDS Patients. Phaliuni Gupta, R. Balachandran, P. Thampatty, C. Rinaldo, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. 549 [Page 550](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/550) 14:00 - 15:30 Salle 410AB Room 8 juin Specialty glycoprot6ines Immunization Study Using HIV Glycoproteins J. Eichberg (U.S.A.) Antibodies of an HIV-1 Infected Individual. Albert T. Profy*, P. Salinas*, L. Eckler*, P. Nara**, T. Frederick, MD; ***Duke University Medical School, Durham, NC, U.S.A. Neutralization of In Vivo HIV-1 Infectivity Mediated by In Vitro Neutralizing Antibody. Emilio A. Emini*, J. Eichberg**, P. L. Nara***, J. A. Lewis*, S. Matsushita**** S. D. Putney*****, et al., *Merck, Sharp and Dohme Research Laboratories, West Point, PA; **Southwest Foundation for Biomedical Resarch, San Antonio, TX; ***National Cancer Institute/Frederick Cancer Research Facility, MD, U.S.A.; ****Kumamoto University Medical School, Kumamoto, Japan; *****Repligen Corp., Cambridge, MA, U.S.A. Studies of Hypervariable Region Deletion Mutants of HIV-1 gp120. Nancy L. Haigwood, G. K. Moore, K. A. Mann, P. T. Pruyne, P. V. Skiles, K. S. Steimer, et al., Chiron Corp., Emeryville, CA, U.S.A. Antibody Dependent Cellular Cytotoxicity (ADCC) Following Vaccination with a Recombinant HIV-1 gpl60 Vaccine. Geoffrey J. Gorse, F. Newman, R. B. Belshe, AIDS Vaccine Program, NIAID, Bethesda, MD; Marshall University School of Medicine, Department of Medicine, Huntington, WV, U.S.A. Safety and Immunogenicity of HIV-1 Recombinant gpl60 Vaccine Candidate in Normal Volunteers. Raphael Dolin*, B. Graham**, S. Greenberg**, C. Tackett**, R. Belshe**, M. Clements**, et al., *University of Rochester School of Medicine, Rochester, NY; **NIAID, AIDS Vaccine Evaluation Group; ***MicroGeneSys, Inc., West Haven, CT, U.S.A. T Cell Responses to HIV in Humans Immunized with Recombinant Vaccinia Virus Containing HIV Envelope. Elizabeth L. Cooney*, J. Zarling**, S. L. Hu**, A. Watson**, L. Greenberg*, *University of Washington, Presidents Chairpersons Section D Jeudi 8 juin Thursday, June 8 LeSIDAetl'individu AIDS and the Individual Consommateurs de drogues par voie intraveineuse (partle 2) Injection Drug Participants in the Tacoma Syringe Exchange. Hollis C. Hagan*, D. C. Des Jarlais**, D. Purchase**, T. Reid*, S. R. Friedman****, *Tacoma Pierce County Health Department, Tacoma, WA; **New York State Division of Substance Abuse Services, New York, NY; ***Point Defiance AIDS Project, Tacoma, WA; ****Narcotic and Drug Research, Inc., New York, NY, U.S.A. The Prevalence of High Risk Sexual Behaviour in Male Homosexual IV Drug Users. Diane K. Lewis*, J. K. Watters**/***, P. Case***, *University of California at Santa Cruz, Santa Cruz; **University of California at San Francisco; ***Urban Health Study, San Francisco, CA, U.S.A. Reducing HIV Transmission among Recovering Female Drug Users. Robert F. Schilling*, N. El-Bassel*, K. Gordon**, S. Nichols***, *Columbia University School of Social Work, New York; **Albert Einstein Medical College, Bronx; ***Beth Israel Medical Center, New York, NY, U.S.A. Impact of AIDS on Morbidity and Mortality among Intravenous Drug Users in a Methadone Maintenance Treatment Program (MMTP). Peter A. Selwyn, D. Hartel, W. Wasserman, E. Drucker, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A. HIV in Prisons: A Description and Evaluation of a Project Designed Specifically for Work with IVDAs in Prison. Ragnar Kvarness. S. Svensen, R. Ervik, M. Skogstad, F. Jensen, Oslo City Health and Environment Department, Oslo, Norway. AIDS Prevention through the Criminal Justice System (CJS): Referral of Intravenous Drug Abusers (IVDAs) to Drug Abuse Treatment. Robert J. Battles, C. G. Leukefeld, R. W. Pickens, National Institute on Drug Abuse, Rockville, MD, U.S.A. 551 [Page 552](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/552) 14:00 - 15:30 9 0 * Salle n Room 411A Colloque Symposium Presidents Chairpersons Section D Jeudi 8 juin Thursday, June 8 Le SIDA et l'individu AIDS and the Individual Les femmes des pays en vole de d6veloppement: O commencer? Que faire? Women in Developing Countries: Where Do We Start? What Can We Do? Maxine Issues. Eustace Muhondwa, Nuhimbili Medical Centre, University of Dar es Salaam, Dar es Salaam, Tanzania. Women with AIDS: Issues in Patient Care. Susan Allen, Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. Women as Care-Givers. Noerine Kaleeba, TASO, Kampala, Uganda. The Research Agenda for African Women. Fatia Mahmud, Bethesda, MD, U.S.A. Educational Interventions for Women. Rebecca Nvonvintono, Kampala, Uganda. 552 [Page 553](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/553) 14:00- Pr6sidents Chairpersons Section E Jeudi 8 juin Thursday, June 8 Le SIDA, la soci6t et le comportement AIDS, Society and Behaviour Politiques sociales: experiences et critiques Public Policy: Experiences and Critiques L. Malo (Canada) Andrew Mouraviekf-Apostol J. F. Mettetal, F. Fontenay, ARCAT-SIDA, CIVIS, Paris, France. Report of the Child Welfare League of America Task Force on Children and HIV Infection. Burt J. Annin, D. Pressma, V. Anderson, R. M. Horowitz, L. J. Emery, et al., Child Welfare League of America, Washington, DC, U.S.A. AIDS as a Challenge and an Innovation in Health Care and Health Policy. Knud Josephsen, Danish Positive Group, Birkerod, Denmark. AIDS and Social Politics. Arne Grnnings'eter, Norwegian Association of Social Workers, Oslo, Norway. State AIDS Legislative and Policy Trends: 1983-1988. Caitlin Ryan, George Washington University, Washington, DC, U.S.A. 553 [Page 554](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/554) 14:00 - 15:30 Salle Room 411C 8 juin Thursday, June 8 S6ance th6matique Specialty Session Implications intemalionales International issues Les femmes A risque Women at Risk B. A. The Past and the Future. J. O. Ndinvya-Achola, University of Nairobi, Department ofMedical Microbiology, Nairobi, Kenya. Population Attributable risk of Sexually Transmitted Diseases (STDs) to HIV Infection. Seth Berkeley. Uganda Ministry of Health and the Task Force for Child Survival, Kampala, Uganda. Research Needs and Priorities. Ahmad Latif. University of Zimbabwe Medical School, Department of Medicine, Harare, Zimbabwe. A Description of a National STD Control Program. Subhash Hir, University Teaching Hospital, Lusaka, Zambia. Programmatic Implications. Andrd Meheus, Programme des MST, Organisation Mondiale de PRom 406B Jeudi 8 juin Thursday, June 8 Implications International 14:00 Th.G.O.19 14:15 Th.G.O.20 The WHO's Concept of National AIDS Programme Management. Daniel Tarantola, Global Programme on AIDS, World Health Organization, Geneva, Switzerland. A Non-Governmental Independent Perspective. Meechai Viravaidhya, Harvard Institute of International Development, Cambridge, MA, U.S.A. 555 [Page 556](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/556) 14:00 - 15:30 Salle Room 404AB Section G Jeudi 8 juin Thursday, June 8 International Symposium Pr6sidents Chairpersons D6fis pos6s par la gestion de programmes Challenge of Programme Management Joshi Jones (U.K.) Fathia Mahmud on HIV Infection of Prostitutes in the Philippines. Curtis G. Hayes*, C. Manaloto*, L. Padre*, V. Basaca-Sevilla**, A. Andrada***, G. Espinosa***, et al., *U.S. Naval Medical Research Unit No. 2; **Philippine Department of Health, Manila; ***The City R. of Public Health, Boston, MA, U.S.A. Male Circumcision in Eastern and Southern Africa: Association with HIV Seroprevalence. Stephen Moses*, F. A. Plummer**, A. R. Ronald***, J. O. Ndinya-Achola**, *International Development Research Centre (IDRC); **University of Nairobi, Nairobi, Kenya; ***University of Manitoba, Winnipeg, MB, Canada. Factors Associated with Prevalent HIV-1 Infection in Pregnant Women in Malawi. Alfred J. Saah, J. Chiphangwi, E. Ndovi, G. Dallabetta, P. Miotti, N. G. Liomba, The Queen Elizabeth Central Hospital, Blantyre, Malawi; The Johns Hopkins School ofHygiene and Public Health, Baltimore, MA, U.S.A. Condom Use and Knowledge in General Population, Female Prostitutes and Gay and Bisexual Men. Josd Antonio Izazola, L. Pineda, General de Epidemiologfa, Secretarla de Salud, Mexico City, Mexico. Comparison between High Risk Practices in Female Prostitutes and Gay and Bisexual Men. Josd Antonio Izazola, C. Romero, J. L. Sepulveda, Direccidn General de Epidemiologra, Thursday, 8 SSession video [s Video session Le personnel soignant Care James Miller \"WITH Video Victoria Hospital Ann6e/Year: Les intervenants sociaux ont besoin 6voquent le role des parents d'accueil, des families, de la communaut6 homosexuelle de divers b6n6voles qui racontent comment ils ont v6cu la reaction de la soci6td au SIDA. Care providers need training, guidance and support when caring for people with AIDS. These videos depict the role of foster parents, families, the gay and lesbian community, palliative care workers, nurses and various volunteers telling their stories about society's response to AIDS. 557 [Page 558](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/558) et de I'infection au VIH: progression vers I'infection Natural History of HIV Infection: Progression in Disease Francisco Diaz (Guinea) Richard A. Goedert, W. A. Blattner, Seroconverters' Working Group, National Cancer Institute, Bethesda, MD, U.S.A. HTLV-I/II Co-Infection Is Significantly Associated with Risk for Progression to AIDS among HIV+ Intravenous Drug Abusers. Stanley H. Weiss*, J. A. Parker*, A. Lin-Greenberg***, R. Altman**, et al., *UMDNJ, New Jersey Medical School, Department of Preventive Medicine, Newark; **New Jersey Department of Health, Trenton; ***Jersey City Medical Center, Jersey City, NJ, U.S.A. Clinical Progression of HIV-related Disease in Intravenous Drug Users (IVDU) in a Prospective Cohort Study: 1985-1989. Peter A. Selwyn, D. Hartel, E. E. Schoenbaum, R. S. Klein, G. H. Friedland, Montefiore Medical Center/Albert Einstein College ofMedicine, Bronx, NY, U.S.A. Progression to Disease in Women with Known Duration of HIV Infection. Aggrey Anzala, *F. Plummer, I. Wamola, J. Ndinya-Achola, J. Kreiss, P. Waiyaki, *University of Nairobi, Kenya Medical Research Institute, Nairobi, Kenya; University ofManitoba, Winnipeg, MB, Canada; University of Washington, Seattle, WA, U.S.A. The Effect of Age on HIV Progression in Hemophiliacs. James J. Goedert, M. E. Eyster, J. E. Drummond, M. W. Hilgartner, J. L. Bray, A. R. Cohen, et al., National Cancer Institute for the Multicenter Study of AIDS in Hemophiliacs, Rockville, MD, U.S A. The Natural History of HIV Infection in a Cohort of Male Sexual Contacts of Men with HIV Disease. Randall A. Coates, J. K. Johnson, S. E. Read, J. Raboud, L. M. Calzavara, V. Farewell, et al., University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada 558 [Page 559](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/559) 16:00 - 17:30 Salle Room 408BC Section A Jeudi 8 juin Thursday, June 8 [ J p miologieetsant6publique Epidemiology and Public Health Table ronde Infection par le VIH et travailleurs de la sant6: questions actuelles Round Table HIV Infection and the Health Care Worker: Contemporary Issues Pr6sidents Chairpersons Robert J. Pratt (U.K.) Walter F. Schlech mI (Canada) 16:00 Th.A.O.28 Program Content: * Universal precautions * Occupational risks * Screening issues * Attitude and practices of health care workers concerning HIV infection * Occupational risk in the developing world * The HIV-infected health care worker Panelists: David M. Bell, Atlanta, GA, U.S.A. J. Louise Geberding, San Francisco, CA, U.S.A. Fred M. Gordin, Washington, DC, U.S.A. Bosenji Ngaly, Kinshasa, HTLV-I Retroviruses: HTLV-I William A. Blatner (U.S.A.) Guy de Laitila*, J. North Chicago, IL; **American Red Cross, Rockville, MD, U.S.A. Antibodies to HIV-1 and HTLV-I in Haiti. Robert Elie*, R. Chout**, A. Janssen*, M. Osame*, A. Igata*, H. Kubota*, H. Nishitani***, U.S.A.; University, Kagoshima; ***Utano National Sanatorium Hospital, Kyoto, Japan. HTLV-I Infection Correlates with Increased Age in Intravenous Drug Users. C. Robert Horsburgh*, D. Hartel**, R. F. Khabbaz***, M. Lairmore***, R. S. Klein**, G. H. Friedland**, *AIDS Program, Centers for Disease Control, Atlanta, GA; **Montefiore Medical Center, Bronx, NY; ***Division of Viral Diseases, Centers for Disease Control, Atlanta, GA, U.S.A. Significance of Positive and Indeterminate HTLV-I Serologic Results in Blood Donors. Rima F. Khabbaz*, M. H. Lee**, S. Critchley***, B. Atlanta, GA; **Abbott Laboratories, Chicago, IL; ***American Red Cross, Atlanta Region, Atlanta, GA, U.S.A. Prevalence of Human T-Lymphotropic Virus Type 1 in Applicants for the United States Armed Forces. Donald R. iEts*, W. Hann**, S. Alexander***, J. Damato****, J. Brundage\"\"****, D. *William Beaumont Army Medical Center, El Paso, TX; **Bowling Green State University, Bowling Green, OH; ***BioTech Research Laboratories, Rockville, MD; ****Walter Reed Army Institute of Research, Washington, DC, U.S.A. 560 [Page 561](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/561) 16:00 - 17:30 Salle Room 401ABC Section B Jeudi 8 juin Thursday, June 8 Aspects cliniques Clinical Aspects of AIDS SIDA et nutrition Nutrition and AIDS S6ance th6matique Specialty Session Presidents Chairpersons Peter Henning-Althoff (Fed. Rep. Total Parenteral Nutrition upon Body Cell Mass in AIDS. Donald P. Kotler. A. R. Tierney, J. A. Culpepper-Morgan, J. Wang, R. N. Pierson, St. Luke's-Roosevelt Hospital Center, New York, NY, U.S.A. Increased Resting Energy Expenditure in HIV-Infected Men. Miriam J. T. Hommes*, J. A. Romijn*, M. H. Godfried*, E. Endert**, S. Danner*, Sauerwein**, *Department of Internal Medicine; **Department of Endocrinology, Academic Medical Centre, Amsterdam, Netherlands. Human Immunodeficiency Virus Infection in Malnourished Children at Kenyatta National Hospital, Nairobi, Kenya. Martin Luta. G. Anabwani, M. Braddick, Department of Paediatrics, University of Nairobi, Nairobi, Kenya. Nutritional Abnormalities in Early HIV-1 Infection: I. Plasma Vitamin Levels. Richard Beach*l**, E. Mantero-Atienza*/**, F. Van Riel*/**, R. Morgan*/**, M. K. Fordyce-Baum*/**, *University of Miami School of Medicine, Department of Epidemiology; **University ofMiami, School ofMedicine, The Biopsychosocial Center on FL, U.S.A. Ileal Absorptive Function in Acquired Immunodeficiency Syndrome (AIDS). Moses S. Kavembwa, C. Bridges, A. E. A. Joseph, S. C. Fleming, G. E. Griffin, St. George's Hospital Medical School, London, U.K. Imbalance of the Amino Acids Pattern in Patients with AIDS: Special Treatment with Adapted Amino Acid Solution? Peter-Henning Althoff. Schifferdecker, H. Fdrster, B. Michels, P. Hunold, S. Klauke, et al., University Hospital, Frankfurt, Federal Republic of Germany. 561 [Page 562](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/562) 16:00 - 17:30 Salle Room Thursday, 8 S6ance th6matique Specialty Session Chairpersons Aspects cniques Clinical Aspects of AIDS Immunomodulateurs Immunomodulators Arthur A. Gotlieb (U.S.A.) Carlo A. Isaquirre HIV Infection. Victoria Davey, J. A. Kovacs, B. Herpin, J. A. Metcalf, A. S. Fauci, H. C. Lane, et al., Laboratory oflmmunoregulation, National Institutes ofHealth, Bethesda, MD, U.S.A. Immunization with Inactivated, Envelope-Depleted HIB Immunogen in HIV Infected Men with ARC: Preliminary Report of Exploratory Studies in Progress. Alexandra M. Levine*, B. E. Henderson*, S. Groshen*, R. Peters**, H. W. Shepard***, J. Salk****, et al., * University of Southern California, School of Medicine, Los Angeles; **Immune Response Corp., La Jolla; ***Department of Health Services, Berkeley; ****Salk Institute, La Jolla, CA, U.S.A. Intramuscular Poly-ICLC Administration in AIDS: Preliminary Findings. Andres M. Salazar*, J. Morales**, H. B. Levy***, P. Sarin****, L. Toro*, C. Hawkes*, et al., *Uniformed Services University of Health Sciences, Bethesda, MD and Walter Reed Army Medical Center, Washington, DC; **Ashford Presbyterian Hospital, San Juan, Puerto Rico; ***NIAID, National Institutes ofHealth; ****National Cancer Institute, National Institutes ofHealth, Bethesda, MD, U.S.A. Isoprinosine Reduced Clinical Progression in HIV Infected Patients in a Double Blind Placebo Controlled Study. Court Pedersen, E. Sandstrom, C. Sand Petersen, J. Gerstoft, G. Norkrans, K. Christensen, Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. Follow-Up Morbidity among ARC Patients on Post-Trial IMREG-1 Treatment. Marise S. Gottlieb, R. A. Zackin, A. A. Gottlieb, IMREG-1 Trial Investigators; IMREG Inc., and IMREG-1 Trial Sites at Boston, MA, Cleveland, OH, New Orleans, LA, New York, NY, Philadelphia, PA, Rancho Mirage, CA, U.S.A. The Anti-HIV Drugs Castanospermine (CSP) and Dextran Sulfate (DS) also Allow the Growth of In Vivo Infected CD4+ T Cells. Carlos A. Izaguirre, J. Drouin, University of Ottawa, Ottawa, ON, Canada 562 [Page 563](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/563) 16:00 - 17:30 Sane Room 407B Section B Jeudi 8 juin Thursday, June 8 Aspects cliniques Clinical Aspects Ruedv, St. Paul's Hospital, Vancouver, BC, Canada. Pharmacokinetics of AZT. David Barry The Wellcome Research Laboratories, Burroughs Wellcome Company, Research Triangle Park, NC, U.S.A. Intracellular Metabolism of anti HIV Nucleosides. MGH. Hitchock, Bristol Myers, Wallingford, CT, U.S.A. Pharmacological Interaction of Drugs in AIDS. Terr' Blaskv, Stanford University, CA, U.S.A. 563 [Page 564](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/564) 16:00 17:30 Salle Room 408A Section B 8 juin Thursday, June 8 L J.* Aspects clinkques Aspects of AIDS S6ance th6matique Transmembrane Synthetic Peptide in a Line Immunoassay. F. performances d'un r6actif ELISA utilisant un peptide recombinant la d6tection infections A HIV-2.F. Catalan*, A. Milovanovic*, Trechville, Abidjan, Ivory Coast. A Novel Enzyme Immunoassay to Detect Antibodies to Both HIV-1 and HIV-2. Urzsula Beckford, C. A. Roberts, R. J. S. Duncan, S. Paye, Wellcome Diagnostics, Beckenham, Kent, U.K. Comparison of Serologic Assays for Transforming Retroviruses. Chester R. Roberts, C. Romines, J. Damato, D. Burke, Walter Reed Army Institute of Research, Rockville, MD, U.S.A. Serologic Evidence of Retroviral Infection in Intravenous Abusers Wiebel**, *Rush Medical Center, Department of Immunology; **AIDS Project, University of Illinois at Chicago, School of Public Health, Chicago, IL, U.S.A. Relative Specificity of Two EIAs for Antibodies to HTLV-I. Chyang T. Fang*, Cross Blood Services, IL, 17:30 Salle Room Lymphomas (AL) Contain Shared Idiotopes (SIds) and Are Reactive with HIV Antigens. Richard M. *IDEC View; **University of California at Irvine, Irvine; ***University of California at San Francisco, San Francisco, CA, U.S.A. Anal HPV Infection and Cytologic Abnormalities in HIV-Infected Individuals. Joel Palefsky, J. Gonzales, H. Hollander, R. Greenblatt, University of California at San Francisco, San Francisco, CA, U.S.A. A Common Cell Surface Immunoglobulin Idiotype in High-Grade Lymphomas and in Prelymphomatous Reactive HIV-Infected Brian G. Herndier*, F. Khayam-Bashi*, L. Kaplan*, R. Miller**, T. Meeker***, M. S. McGrath*, *University of California at San Francisco and San Francisco General Hospital, San Francisco; **IDEC Pharmaceuticals, Mountain View; ***UCSF/Veterans Administration Medical Center, San Francisco, CA, U.S.A. Presence of Epstein-Barr Virus by In-situ Hybridization in Non-Hodgkin's Lymphomas of AIDS Patients. Jeannette Guarner, C. Del Rio, L. E. Hendrix, E. R. Unger, Emory University Hospital, Department of Anatomic Pathology, Atlanta, GA, U.S.A. Differences between Burkitt's and Non-Burkitt's High Grade Lymphomas (HGL) Associated with HIV Infection. Jean-Marie Andrieu, M. Raphael, M. Gentilini, J. M. Tourani, B. Dupont, M. Armengaud, Laennec Hospital, Paris, France. HIV-Related Tumors: A Report of comme r6servoirs du VIH-1 Role of Macrophages and Lymphocytes as Reservoirs of HIV-1 Anthony S. into Cells. J. Steven McDougall, Centers for Disease Control, Atlanta, GA, U.S.A. Role of Macrophages in Pathogenesis of HIV. S. Gartner, New Mexico State University, Primate Research Institute, Alamogardo, NM, U.S.A. Surface Recognition Structure of HIV. Angus Dalgleish, MRC Clinical Research Centre, Harrow, U.K. Cytokine Induction of HIV Expression. Anthony S. Fauci, NIAID, National Institutes of Health, Bethesda, MD, U.S.A. 566 [Page 567](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/567) 16:00 - 17:30 Salle Room 41OABC des Animal Model to Fails to Protect against Mucosal or IV Challenge. M. B. Gardner. N. Pedersen, C. V. Hanson, C. Miller, A. Gettie, M. Jennings, et al., University of California at Davis, Davis, CA, U.S.A. HIV Immunization and Challenge of HIV Seropositive and Seronegative Chimpanzees. C.J.Gibbs*, C. Mora*, R. Jensen**, D. J. J. Salk***, *National of Health, Bethesda, MD; **The Immune Response Corp.; ***The Salk Institute, San Diego, CA, U.S.A. Immunogenicity of Potential HIV Vaccines in Chimpanzees. Marc P. Girard*, M.-P. Kieny**, J. P. Lecocq**, M. HIV-1 Candidate Vaccines. Peter W. Neumann*. M. V. O'Shaughnessy*, G. Smith**, M. Cochran**, *Health and Welfare Canada, Federal Centre for AIDS, Ottawa, ON, Canada; **MicroGeneSys Inc., West Haven, CT, U.S.A. Vaccination with Live Retroviruses: The Nature of the Protective Immune Response. Ruth M. Ruprecht, R. Hom, S. Mullaney, M. A. Gama-Sosa, R. Finberg, Dana-Farber Cancer Institute, Boston, MA, U.S.A. Development of an HIV Subunit Vaccine. Scott D. Putnev*, K. Javaherian*, A. Profy*, T. Matthews**, D. *Repligen Corp., Cambridge, MA; Duke 567 [Page 16:00- June 8 S6ance th6matique Specialty Session Pr6sidents Chairpersons Le SIDA, la soci~6 et le comporement AIDS, Society and Behaviour Dimensions sociales du SIDA Social Dimensions of AIDS Ann Derval-Murray (Ireland) Manuel Lujan Swaminathan Sundararaman, S. Solomon, R. Thara, Rajkumar, th6rapeutiques a Paris sa banlieue. Jean Javanni, J. P. Cordonnier, H. Maurel, A. Michel, A. Sobel, Aparts, Paris, France. Social Organization as a Determinant in HIV Transmission. John Kreniseke, HIV Center for Clinical and Behavioral Studies, New York, NY, U.S.A. Sociological Analysis of AIDS Prevention among Homosexual Men. Robert A. P. Tielman, University of Utrecht, Utercht, Netherlands. Risk Perception, Risk-Taking and Risk Management among Intravenous Drug Users: Implications for AIDS Prevention. Margaret M. Connors. Spectrum House, Inc., Westboro, MA, U.S.A. De campagnes g6n6rales k 6thique Ethics and Law Jeudi 8 juin Thursday, June 8 Colloque Symposium Pr6sidents Chairpersons Discrimination et droits de la personne Discrimination and Human Rights Raj Anand (Canada) Susan Rai Anand, Ontario Human Rights Commission, Toronto, ON, Canada. Legal Services for Persons with AIDS (PWAs) of Predominantly Heterosexual, Poor, Minority Background.Alice Herb, D. LaGamma, Montefiore Medical Center, Bronx, NY, U.S.A. Anti-Discrimination Law and AIDS-Related Discrimination: A Philosophical Analysis. Todd Ducharme*, J. Hathaway**, *University of Alberta, Faculty of Law, Edmonton, AB; **Osgoode Hall Law School, Toronto, ON, Canada. AIDS in the U.S. Workplace: The Evolution of AIDS Litigation, Legislation, and Regulation. Verla S. Neslund. G. W. Matthews, Office of the General Counsel, Centers for Disease Control, Atlanta, GA, U.S.A. VIH et toxicomanie: aspects 6thiques. Bicetre, France. Discrimination Reflected in the Language and Diagnoses on Target HIV Client by Physicians. Robert W. Norton*, J. Schwartzbaum**, J. Wheat**, *Memphis State University; **University of Tennessee, Memphis, TN, U.S.A. Commentary. Susan Scholle-Connor. Pan American World Health Organization. Washington, DC, U.S.A. 569 [Page 570](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/570) 16:00 - 17:30 Salle Room 406A intemationales dove*, M'Boup**, T. A. F. Van Pathology of HIV Infection in Zaire. Ann Marie Nelson*/**/***; M. Kayembe*, N. Ilunga*, P. Angritt***, SIDA, Kinshasa, Zaire; ***Armed Forces Institute of Pathology, Washington, DC, U.S.A. Clinical Findings in 201 Symptomatic Children with AIDS. Farzin Davachi*, L. Kabongo*, N. Mayemba*, K. **Ministry of Health, Kinshasa, Zaire. Validation of a Case Definition for Perinatally-acquired AIDS in Africa. Wato NVsa*, T. Kinshasa, Zaire; **Centers for Disease Control, Atlanta, GA, U.S.A. Clinical Findings among HIV-Infected Individuals Attending the Dermato-Venereology Clinics. Roy D. Mugerwa. P. Nsubuga, N. Sewankambo, E. Katabira, Makerere University, Kampala, Uganda. Evaluation of Clinical Illness and Timing of Seroconversion in Sexually Transmitted Acute HIV-1 Infection. D. William Cameron*, L. J. D'Costa*, G. M. Maitha*, A. R. Ronald**, J. O. Ndinya-Achola*, F. A. Plummer**, *University of Nairobi, Nairobi City Commission, Nairobi, Kenya; **University Manitoba, Winnipeg, MB, Canada. 570 Sale Room 406C Section G Jeudi juin Thursday, June 8 Implications Chairpersons Epidemiology and Education on AIDS. Jos#-Luis Valdespino Mexico City, Mexico. Clinical-Epidemiological Characteristics of AIDS Cases in Argentina. Pedro Cahn, Buenos Aires, Argentina. Development of AIDS Programmes for Hispanic Communities in the USA. Arlettv Pinel. Sao Paulo, Brazil. AIDS Educational programmes in Sao Paulo, Brazil. Maria Eugenia Lemos Fernandes. Sao Paulo, Brazil. AIDS in Prostitutes: Experience in the Dominican Republic. Ernesto Guerrero, Santo Domingo, Dominican Republic. 571 [Page Room 406B Section G Jeudi 8 juin Thursday, June 8 Implications International Caribbean Epidemiology Centre (CAREC), Port of Spain, Trinidad. Epidemiology of AIDS in the Bahamas, August 1985 - March 1989. Kenneth Ofusu-Barko, Community Health Services Department, Ministry ofHealth, Nassau, Bahamas. AIDS in the Dominican Republic: Interventions Among Persons with High-Risk Behaviour. Ernesto Guerrero. CARE PWR, Santo Domingo, Dominican Republic. la santd, Guyana. Strategies for Prevention and Control of AIDS in Haiti. Gabriel Timothde, CARE PWR Haiti, Port-au-Prince, Haiti. AIDS Educational Strategies and Ethnic Diversity in Suriname. Ruben Del Prado, National AIDS Program, Bureau of Public Health, Paramaribo, Suriname. Challenges in Dealing with the AIDS Epidemic in Trinidad and Tobago. Beulah Duke, AIDS Programme, Eric Williams Medical Complex, Mount Hope, Trinidad and Tobago. 572 [Page 573](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/573) 16:00 - 17:30 Sane Room 411A G Jeudi 8 juin Thursday, June 8 Implications internationales International Issues Le SIDA chez I'enfant Pediatric AIDS S6ance th6matique Specialty Session Presidents Chairpersons Diane Ashley (Canada) HIV and Diarrhea in Haitian Children. Jean W. Pape, L. Oriol, S. Madhavan, Jr., W. D. Johnson, Cornell University Medical College, New York, NY, U.S.A. Pediatric AIDS in Brazil: Description and Analysis of Trends. Denise Bergamaschi*, P. Chequer*, L. Rodrigues*, E. Castilho**, *Ministry Division of STDIAIDS, Brasilia; **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil. The Effect of HIV-1 and HTLV-I Infections on Birthweight in a Population without IV Drug Abuse. Elisabeth Holt*, R. Boulos**, N. Halsey*, J. Brutus**, U. Auguste**, H. Davis**, et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A.; **Centers for Health and Development, Port-au-Prince, Haiti; ***National Cancer Institute, Bethesda, MD, U.S.A. Morbidity and Mortality in Infants of HIV-1 Infected Mothers. Pratibha P. Datta*, J. E. Embree**, M. Braddick***, J. Kreiss****, J. 0. F. A. *University Kenya; Canada; ***Middlesex Hospital, London, U.K.; ****University of Washington, Seattle, WA, U.S.A. HIV Infection as a Risk Factor for Poor Obstetrical Outcome. Marleen Temmerman*/***, N. Mirza*, F. Plummer*/**, I. Piot***, et al., *University of Kenya; **University of Manitoba, Winnipeg, MB, Canada; ***Institute of Tropical Medicine, Department of Microbiology, Antwerp, Belgium. Survie des enfants n6s de mbre positive pour HIV-1: etude t (R. P. Congo). Marc Lallemant*, Lallemant Le Coeur**, D. Cheynier***, 8 juin Thursday, June 8 La Prevention Prevention Introduction: param6dicaux, prostitu6es, homosexuels et jeunes. The nucleus of AIDS work remains prevention. From the deluge of videos submitted on the subject, this session provides an overview of prevention techniques for many target groups: drug users, health care workers, paramedics, prostitutes, gay men and youth. 575 [Page 576](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/576) Section Jeudi 8 juin A Thursday, June 8 tpid6miologie et sant6 publique Epidemiology and Public Health Session HTLV-I/HIV-1 Infection among Male Intravenous Abusers and Their Sexual Partners in Chicago. Joseph R. Lentino*, C. T. Pachucki, D. Schaaff, M. Schaefer, D. Schroer, W. Dorus, *Hines Veterans Administration Hospital, Hines, IL, U.S.A. Th.A.P.2 Screening for HTLV-I Antibodies among Finnish Blood Donors, Hemophiliacs and HIV-suspected. Pauli Leinikki*, E. Brummer-Korvenkontio, M. Kantanen, *National Public HTLV-I Jean-Marie Lemaire*, J. Coste, *GRSNTS, Centre de Transfusion sanguine, Montpellier, France. Th.A.P.4 Prevalence of HTLV-I Antibodies in HIV-1 Infected Patients in a Minority Community in the Bronx, N.Y. Stanley Bauer*, L. Amaral, J. Ernst, *The Bronx-Lebanon Hospital Center, Department of Pathology, Bronx, NY, U.S.A. Th.A.P.5 HTLV-I Seroprevalence in Patients with HIV and Neurologic Disease, Other Risk Groups, and Blood Donors in Zimbabwe. Stan Houston*, C. Thornton, J. Emmanuel, H. Smith, A. Latif, *University of Zimbabwe, Harare, Zimbabwe. Th.A.P.6 HIV-1 and HTLV-I Infections in Intravenous Drug Users (IVDU) Detroit: D. Saravolatz*, Ognjan, N. D. Pohlod, H. Lee, B. Belian, et al., *Henry Ford Hospital, Detroit, MI, U.S.A. Th.A.P.7 HTLV-I Antibodies in the Solomon Islands. Daniel B. Hardv*, J. R. Carlson, J. L. Yee, M. Y. K. Armstong, *University of California at Davis, Medical Center, Sacramento, CA, U.S.A. Th.A.P.8 Lack of HTLV-I Infection in Non-I.V. Drug Using HIV Seropositive Men in Los Angeles. David M. Aboulafia*, R. T. Mitsuyasu, D. J. Slamon, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A. Th.A.P.9 HIV-1 and HTLV-I Seroprevalence in Critically Ill Resuscitated Emergency Department Patients. Louis D. Saravolatz*, C. Lewandowski, A. Ognjan, E. Rivers, D. Pohlod, B. Hospital, MI, U.SA. 577](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/577) HIV-1 and HTLV-I Infections in Drug (IVDU) in Detroit 1985-1989. Louis D. Saravolatz*, A. Ognjan, N. Markowitz, D. Pohlod, H. Lee, B. Belian, et al., *Henry Ford Hospital, Detroit, MI, U.SA. Th.A.P.11 Prevalence of HTLV-I Antibody in Selected Women in the Los Angeles Area. Suraiva Rasheed*, S. S. Barker, P. S. Gill, *University of Southern California, School of Medicine, Los Angeles, CA, U.S.A. Th.A.P.12 HTLV-I Infection in an Inner-City Emergency Department Population. GaborD. T. DiGiovanna, L. Lofy, K. Sivertson, T. Quinn, *The Johns Hopkins Hospital, Baltimore, MD, U.S.A. Th.A.P.13 Anti-HTLV-I in New York Blood Donors (1985-1986). Patricia E. Taylor*, C. E. Stevens, H. Lee, *The New York Blood Center, Laboratory of Epidemiology, New York, NY, U.SA. Th.A.P.14 Determinants of HTLV-I F. Romano, N. Mueller, *Harvard School of Public Health, Department of Epidemiology, Boston, MA, U.SA. Th.A.P.15 Seroprevalence of HTLV-I in a Parturient Population at Risk for HIV-1 Infection. Keith Krasinski*, W. Borkowsky, A. Fidelia, D. Bebenroth, T. Moore, *New York University Medical Center, New York, NY, U.SA. Th.A.P.16 Seroprevalence of HTLV-I in Patients Attending Sexually Transmitted Diseases (STD) Clinics in the United States. Rima F. Khabbaz*, J. Douglas, R. Spiegel, M. St. Louis, W. Whittington, M. Lairmore, *Centersfor Disease Control, Atlanta, GA, U.S.A. Th.A.P.17 Risk of Development of HTLV-I-associated Myelopathy (HAM/TSP) among Persons Infected with HTLV-I. Jonathan M. Osame, A. Igata, H. Kubota, H. Nishitani, R. U.SA. HTLV-I/II Seroprevalence and HIV/HTLV Coinfection among IV Drug Abusers (DA) in the U.S. Kenneth P. Cantor*, S. H. Weiss, J. Goedert, R. Battjes, *National Cancer Institute, Bethesda, MD, U.SA. Th.A.P.19 HTLV-I and HIV-1 Infection in Intravenous Drug Jordi Tor Aguilera*, Spain. Th.A.P.20 HTLV-I Antibodies among Prison Inmates in Maryland. David Vlahov*, E. Taylor, C. Wisniewski, C. Tanner, W. Mehaffey, H. Lee, *Johns Hopkins School ofHygiene and Public Health, Baltimore, MD, U.SA. Th.A.P.21 High Rate of Confirmed HTLV-II Infection among Intravenous Drug Abusers (IVDA) from New Orleans. Helen Lee*, P. Swanson, V. Shorty, J. Zack, J. Rosenblatt, I. Chen, *Abbott Laboratories, North Chicago, IL, U.SA. Th.A.P.22 HTLV-I Infection in Spain. Vincent Soriano*, E. Abella, J. Tor, A. Flores, B. Clotet, A. Ribera, * University of Barcelona, Hospital \"Germans Courtenay Bartholomew*, F. B. Hull, K. Battoo, C. Diaz, W. Blattner, *Faculty of Medical Sciences, University of the West Indies, Port of Spain, Trinidad. Th.A.P.24 HTLV-I in Intravenous Drug Addicts (IVDA) and Gay Men in San Francisco. Ellen G. Feigal*, E. Murphy, J. Drummond, P. Bacchetti, R. Chaisson, J. S. Greenspan, et al., *University of California at San Francisco, San Francisco General Hospital, San Francisco, CA, U.S.A. Th.A.P.25 Counseling and Follow-up of Individuals Positive for HTLV-I Antibody. Harvey Dosik*, M. Kohen, L. Williams, K. Hershman, E. Silberman, M. Goldstein, *Interfaith Medical Center, Brooklyn, NY, U.SA. Th.A.P.26 Seroprevalence of HTLV-I Antibody in a Black Brooklyn Community. Harvey Dosik*, L. Williams, M. Goldstein, E. Silberman, P. Levine, R. Maloof, *Interfaith Medical Center, Brooklyn, NY, U.SA. Th.A.P.27 Prevalence of HTLV-I in Greek Blood Donors. Vassilis Georgoulias*, A. Derivianaki, E. Malliaraki-Pinetidou, *University of Crete, School of Medicine and AIDS Reference Center of Crete, Iraklion, Crete, Greece. Th.A.P.28 Seroprevalence of HTLV-I among U.S. Marines Stationed in a Hyperendemic Area. Stephanie K. Brodine*, E. C. Oldfield, A. L. Corwin, R. J. Thomas, A. B. Ryan, J. Holmberg, et al., *Naval Hospital, Infectious Diseases Division, San Diego, CA, U.SA. Th.A.P.29 Investigations on the Presence of HTLV-I Infection in Intravenous Drug Abusers and Homosexuals in the Federal Republic of Germany. Andreas Beck*, I. Ehm, G. Pauli, B. Thiele, B. Karbowiak, M. A. Koch, *AIDS-Zentrum, Berlin, of HTLV-I Infection in Blood Donors. DQ id W.Anderson*, T. H. Lee, M. Lairmore, C. Saxinger, V. S. Kalyanaraman, D. Slamon, et al., Food and Drug Administration, Division of Blood and Blood Products, Centerfor Biologics Evaluation and Research, Bethesda, MD, U.S.A. Th.A.P.32 Antibody to HTLV-I/II among Blood Donors in Four Cities of the United States. James W. Moslev*, Transfusion Safety Study Group, *University of Southern California at Los Angeles, CA, U.SA. 578 [Page 579](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/579) Questions de m6thodologie Methodological Issues Th.A.P.33 Recall Bias and Memory Failure: An Empiric Demonstration in Persons with Acquired Immune Deficiency Syndrome. Karen Gelmon*, M. T. Schechter, S. B. Sheps, R. Hershler, K. J. P. Craib, *Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital, Vancouver, BC, Tests or Testees? Sirkka-Liisa Valle*, S. Sarna, *University Central Hospital, Department of STDs, Helsinki, Finland. Th.A.P.35 Calculating HIV Incidence Rates from Seroprevalence Data. David C. Sokal*, B. Shelton, L. Kupper, *Family Health International, Research Triangle Park, NC, U.S.A. Th.A.P.36 Significance of Mean Age of Anti-HIV Positive Persons Identified in Test Programs. Gert G. Frosner*, *Max von Pettenkofer-Institut, University of Munich, Munich, Federal Republic of Germany. Th.A.P.37 Sample Sizes for Needles in a Haystack: The Case of HIV Seroprevalence Surveys in Canada. John W. Frank*, R. A. Coates, J. M. Garbutt, R. Brant, *University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. Th.A.P.38 Voluntary HIV Studies Can Underestimate Seroprevalence. Michael L. Rekart*, D. Cook, *STD Control, Ministry of Health, Vancouver, BC, Canada. Th.A.P.39 Research or Surveillance? Anonymous Seroprevalence Studies: The Quebec Experience. Catherine A. Hankins*, N. Lapointe, D. Montreal, QC, Canada. Th.A.P.40 Evaluation of Dried Blood Filter Paper Samples, Collected by Finger Stick as an Alternative to Venipuncture for HIV Seroprevalence in High Risk Adults. Havnes W. Sheppard*, J. Wiley, M. Ascher, *California Public Health Foundation, Berkeley, CA, U.S.A. Th.A.P.41 Designing Observational Studies and Field Trials of Treatments and Preventions against HIV Infection and AIDS. Mary E. Halloran*, C. J. Struchiner, J. M. Robins, *Harvard School of Public Health, Department of Population Sciences, Boston, MA, U.SA. Th.A.P.42 Validation of Sexual Histories of Homosexual Male Couples. George R. Seage*, K. H. Mayer, C. R. Horsburgh, B. Cai, G. A. Lamb, *Boston Department of Health and Hospitals, Boston, MA, U.SA. Th.A.P.43 Statistical Considerations of Misclassification of Patients at Baseline in Two AIDS Clinical Trials. Alan B. Forsvthe*, J. D. Elashoff, W. J. Dixon, *Viratek Inc., University of California at Los Angeles, School of Medicine, Costa Mesa, CA, U.SA. 579 [Page 580](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/580) Infection par le VIH chez les travailleurs de la sant6 HIV Infection among Health Care Workers Th.A.P.44 Guidelines for Prevention of Transmission of Human Immunodeficiency Virus and Hepatitis B Virus to Health-Care and Public Safety Workers. Edward L. Baker*, R. J. Mullan, M. J. Scally, P. W. Strine, *Centers for Disease Control, Atlanta, GA, U.S.A. Th.A.P.45 Zidovudine Prophylaxis for Persons with Accidental Percutaneous Blood Exposure: A Decision Analysis. David N. Rose*, H. S. Sacks, *Mount Sinai School of Medicine, New York, NY, U.S.A. Th.A.P.46 National Surveillance Program: Occupational Exposure to Human Immunodeficiency Virus (HIV-1) Infection in Canada. Kimberly D. Elmslie*, L. Mulligan, M. V. O'Shaughnessy, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. Th.A.P.47 Blood Exposures during Surgical Procedures. Adelisa Panlilio*, C. Perlino, C. Parrish, D. Foy, P. Lowry, D. Bell, *Centersfor Disease Control, Atlanta, GA, U.S.A. Th.A.P.48 Report of a Possible Laboratory Acquired HIV Infection. Charles E. Haley*, V. J. Reff, F. K. Murphy, *Dallas County Health Department, Dallas, TX, U.S.A. Th.A.P.49 The Risk of Exposure to Human Immunodeficiency Virus among Health Care Workers (HCW) at a Southern U.S. Urban Hospital. Gerge F. Risi*, R. Gaumer, S. Weeks, J. Leete, C. Sanders, *Louisiana State University Medical Center, New Orleans, LA, U.S.A. Mod6lisation math6matique et previsions Mathematical Modelling and Prediction Th.A.P.50 Census Data and Forecasting U.S. AIDS Cases. John Pickering*, J. E. Robbin, L. E. Lieb, G. W. Rutherford, N. E. Woodbury, M. J. W. Van de Laar, et al., *University of Georgia, Department of Entomology, Athens, GA, U.S.A. Th.A.P.51 Behaviorally Based Modeling of the Spread of HIV. Tim Brown, University of Hawaii at Manoa, Honolulu, HI, U.S.A. Th.A.P.52 A Dynamic Model of HIV Transmission and AIDS in San Francisco. Herbert W. Hethcote. University of Iowa, IA, U.S.A. Th.A.P.53 HIV Carriers: Increasing Infectivity with Progression to AIDS Has Important Implications for the AIDS Epidemic among Heterosexuals. Josd J. Gonzalez*, C. E. Moe, P. Davidsen, M. G. Koch, *AUST-AGDER Central Hospital, Arendal, Norway. Th.A.P.54 A Multiple Risk Group Model to Estimate and Project the Spread of HIV. Philip C. Cooley*, S. Christopher, D. Hamill, C. Van der Horst, *Research Triangle Institute, Research Triangle Park, NC, U.S.A. Th.A.P.55 HIV Dynamics in Linked Risk Groups, a Multigroup Transmission Model. Hans Van Druten*, J. C. Jager, M. J. J. C. Poos, R. A. Coutinho, E. Netherlands. 580 [Page 581](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/581) Th.A.P.56 Enhanced Computer Model of HIV Transmission Via Needle Sharing. David J. Ahlgren*, A. C. Stein, B. F. Lewis, *Trinity College, Department of Engineering and Computer Science, Hartford, CT, U.S.A. Th.A.P.57 Impact of Sexual Behaviour Change on the AIDS Epidemic. Steve P. Blvthe. Strathclyde University, Glasgow, U.K. Th.A.P.58 Modelling of Immune System Dynamics in HIV Pathogenesis: Issues in Immunomodulation. Rupert E. D. Whitaker, Boston University/Tufts, New England Medical Center Hospitals, Boston, MA, U.S.A. Th.A.P.59 The Potential for Spread of HIV in the Heterosexual Population in Norway, a Simulation Model Study. Hein Stigum*, J. K. Grnnesby, P. Magnus, J. M. Sundet, L. S. Bakketeig, *National Institute of Public Health, Oslo, Norway. Th.A.P.60 Evidence for a 16-18 Year Mean Time between HIV Viral Infection and AIDS Onset. Wilson Greatbatch*, W. S. Holmes, *Greatbatch GEN-AID, Ltd., Clarence, NY, U.S.A. Th.A.P.61 Incubation Time for AIDS in Transfusion-Associated Cases: An Estimation French Dataset. Laporte, A.-J. Valleron, Heterogeneity in the Incubation Time of AIDS: A Stochastic Serial Compartment Model. Firoze Mauji*, N. Nagelkerke, F. A. Plummer, *Kenya Medical Research Institute, Nairobi, Kenya. Th.A.P.63 Modelling Progression of HIV Infection. Victor G. De Gruttola*, N. Lange, *Harvard University School of Public Health, Boston, MA, U.S A. Th.A.P.64 \"Structured\" and \"Selective\" Mixing Formulations of Heterogenous Contact to Study HIV Transmission. James S. Kooman*, J. A. Jacquez, C. P. Simon, *University of Michigan School of Public Health, Ann Arbor, MI, U.S.A. Th.A.P.65 Simulating the Epidemic Dynamics of HIV-Infection Using Stochastic Processes over Random Graphs. Georg F. Kriiger, *Universitat Physik, Federal Republic of Germany. Th.A.P.66 A Risk Based Heterosexual Model of the Spread of HIV. James M. Hvyman*, E. A. Stanley, S. A. Colgate, S. P. Layne, *Los Alamos National Laboratory, Los Alamos, NM, U.S.A. Th.A.P.67 Challenges in Modeling HIV Infection in Low Seroprevalence Populations.John K. Watters. University ofCalifornia at San Francisco, Urban Health Study, San Francisco, CA, U.S.A. Th.A.P.68 Estimating Intravenous Drug User (IVDU) Population from AIDS Statistics in San Francisco. Patrick Biernacki*, M. Aldrich, J. Mandel, *Youth Environment Study, Inc., San Francisco, CA, U.S.A. Th.A.P.69 AIDS in the Nordic Countries: Forecasts. Bo Eriksson, Nordic School of Public Health, Guttenburg, Sweden. 581 [Page 582](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/582) Th.A.P.70 Effects of Modeling Heterogeneity of Drug Use Behavior. Joanna E. Siegel* M. C. Weinstein, D. S. Shepard, J. K. Watters, H. V. Fineberg, *Harvard School of Public Health, Boston, MA, U.S.A. Th.A.P.71 A Heterosexual Model for the Spread of HIV and the Demographic Impact of the AIDS Epidemic. Elizabeth Ann Stanley*, S. T. Seitz, P. O. Way, T. F. Curry, J. M. Hyman, P. D. Johnson, et al., *Los Alamos National Laboratory, Los Alamos, NM, U.S.A. Th.A.P.72 Estimation of the Effect of AZT on Time-to-AIDS in HIV-Infected Subjects from Observational Data. James Robins, Harvard School of Public Health, Boston, MA, U.S.A. Th.A.P.73 Simulation of HIV Transmission in a Structured Community of Intravenous Drug Users. Denton R. Peterson*, K. Willard, M. Altmann, *University of Minnesota, Laboratory of Medicine and Pathology, Division of Health Computer Science, Minneapolis, MN, U.S.A. Th.A.P.74 Reverse Extrapolation as a Method for Estimating HIV Seroprevalence. Colin L. Soskolne*, J. R. McGregor, A. N. Jaroni, *University of Alberta, Edmonton, AB, Canada. Th.A.P.75 The Prediction of the Numbers of AIDS Cases in the UK, and the Estimation of the Incubation Period of AIDS. Graham F. Medley*, R. M. Anderson, *Imperial College, Department of Biology, London, UX. Th.A.P.76 Projecting Local AIDS Incidence Using Both Surveillance and Seroprevalence Measures. Laura J. Fehrs*, T. Byers, J. LeTourneau, H. F. Hull, J. Wilson, *New Mexico Health and Environment Department, Santa Fe, NM, U.S.A. Th.A.P.77 Reliability of Estimates Based on Backcalculation. Mitchell H. Gail*, P. S. Rosenberg, R. J. Biggar, J. J. Goedert, R. Brookmeyer, *National Cancer Institute, Bethesda, MD, U.S.A. Th.A.P.78 A Review of Some Techniques for Backward Estimating the Prevalence of HIV from AIDS Case Incidence. Philip C. Cooley*, S. Reade-Christopher, D. Hamill, C. Van der Horst, *Research Triangle Institute, Chapel Hill, NC, U.S.A. Th.A.P.79 Projecting Proportions of AIDS Cases Over Time. John M. Karon*, O. J. Devine, *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Th.A.P.80 The AIDS Epidemic in Mexico. Alejandro Mohar*, V. DeGruttola, J. L. Valdespino, L. Garcia, J. Sepulveda, *Harvard School of Public Health, Boston, MA, U.S.A. Th.A.P.81 Modelling of the AIDS Epidemic in Mexico. Isabelle Romieu*, S. Sanderg, T. Awerbuch, A. Mohar, J. L. Valdespino, J. Sepilveda, et al., *Harvard University School of Public Health, Boston, MA, U.S.A. Th.A.P.82 Limitations of Official Forecasts Used in Planning Future AIDS Service Needs. Jesse Green*, M. Leigh, N. Wintfeld, *New York University Medical Center, Department ofHealth Policy Research, New York, NY, U.SA. 582 [Page 583](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/583) Histoire clinique de I'infection A VIH Natural History of HIV Infection Th.A.P.83 Genetic Epidemiology of AIDS. Leslie G. Louie*, S. Desmond, K. Gilles, B. Newman, M. C. King, *Epidemiology, School of Public Health, University of California at Berkeley, Berkeley, CA, U.SA. Th.A.P.84 Evaluation of the Immunological Staging System in a Population Based Cohort. Rachel A. Rovce*, W. Winkelstein, R. Anderson, W. Lang, *University of California at Berkeley, Epidemiology, School of Public Health, Berkeley, CA, U.S.A. Th.A.P.85 Time from First HIV Infection to Persistent Antigenemia. Joan S. Chmiel*, A. Muhoz, J. Phair, K. Macdonell, V. Carey, L. Tsung, *Northwestern University Medical School, Biometry Section, Chicago, IL, U.S.A. Th.A.P.86 Long-term HIV Infection Without Clinical Illness or Immunodeficiency: Homosexual Men Who Have not \"Progressed\". Alan R. Lifson*, S. P. Buchbinder, H. W. Sheppard, J. Wilber, N. A. Hessol, G. W. Rutherford, et al., *AIDS Office, San Francisco Department of Public Health, San Francisco, CA, U.S.A. Th.A.P.87 Defining the Interval Between Human Immunodeficiency Virus (HIV) Infection and the Appearance of HIV Antibody. Robert C. Horsburgh*, C. Y. Ou, J. M. Jason, S. D. Holmberg, T. M. Longini, H. W. Jaffe, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Th.A.P.88 Occurrence of Indeterminant Western Blot (IWB) Tests and Lack of Transmission of IWB in Persons at Low Risk for HIV Infection, Huntington, WV, U.S.A., 1986-1988. Robert B. Belshe*, A. Schindzielorz, *Marshall University School of Medicine, Huntington, WV, U.S.A. Th.A.P.89 International Registry of Seroconverters. Robert J. Biggar, Seroconverters' Registry Group, National Cancer Institute, Bethesda, MD, U.S.A. Th.A.P.90 Lack of Correlation Between Neutralizing Antibody Titers and CD4+ Decline in the San Francisco Men's Health Study. Haynes W. Sheppard*, C. Hanson, L. Miksza, R. Royce, *California Public Health Foundation, Berkeley, CA, U.S.A. Th.A.P.91 The Effect of Hepatitis B Virus Vaccination on T-Cell Subsets in HIV-1 Seropositive Men in the Baltimore MACS. Nancy J. Odaka*, J. Margolick, R. Fox, A. Muhoz, *Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, U.S.A. Th.A.P.92 Increased Rate of HIV-1 Isolation among Infected Homosexuals with Low CD4 Count. Homavoon Farzadegan*, D. Imagawa, W. Hardy, M. Lee, C. Grovit, P. Gupta, et al., *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. Th.A.P.93 Increased \"Viral Burden\" in Late Stages of HIV Infection. Donald S. Burke*, R. Redfield, A. Fowler, C. Oster, *Walter Reed Retroviral Research Group, Walter Reed Army Institute of Research, Rockville, MD, U.S.A. 583 [Page 584](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/584) Th.A.P.94 Graphical Description of Hematological Changes after HIV-1 Seroconversion in Homosexual Men. Alvaro Muioz*, J. Margolick, J. Phair, J. V. Giorgi, C. Rinaldo, *Johns Hopkins School of Public Health, Department of Epidemiology, Baltimore, MD, U.S.A. Th.A.P.95 Serologic Evidence of Epstein-Barr Virus (EBV) Reactivation Before and After HIV-1 Seroconversion. Abid Rahman*, L. A. Kingsley, C. R. Rinaldo, R. Atchison, M. Ho, M. K. Breinig, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. Th.A.P.96 Clinical Pattern and Course of HIV-Infection in 29 Patients with Seroconversion. Hans-Reinhard Brodt*, S. Zentrum Infektiologie, Federal Republic of Germany. Th.A.P.97 Immunologic Abnormalities in Anti-HIV-1 Negative (-) and Anti-HTLV-I/II Negative and Positive (+) IV Drug Abusers (IVDA) on Methadone. Nancy C. Klimas*, N. Blaney, R. Morgan, J. Simoneau, M. A. Fletcher, *University of Miami School of Medicine, Miami, FL, U.SA. Th.A.P.98 Mycobacterial Infections in Massachusetts AIDS Patients. Laureen Kunches*, L. Makarewicz, J. Day, B. Heinze-Lacey, S. Oddleifson, L. Mofenson, et al., *Massachusetts Department of Public Health, Boston, MA, U.S.A. Th.A.P.99 Ajustement de modbles chronologiques avec rupture sur une fonction Bernard Prum*, B. Picard, W. Rozenbaum, D. Garbanzadeh, C. Guihenneuc, *Universitd de Paris V, Paris, Clinical Virus (HSV) M. J. VanRaden, M. A. Deloria, S. Zeger, J. Dudley, K. Alwood, et al., *National Institute ofAllergy and Infectious Diseases, Bethesda, MD, U.S.A. Th.A.P.101 Lack of Association of T-Cell Subsets with Continuing Intravenous Drug Use and High Risk Heterosexual Sex, Independent of HIV Infection and Disease. Gerald H. Friedland*, E. E. Schoenbaum, D. Hartel, K. Davenny, R. Klein, P. Selwyn, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A. Th.A.P.102 Progression of HIV Disease in Intravenous Drug Users. Robert Gorter*, K. Kocurek, B. Brodie, P. Bachetti, E. Ross, A. R. Moss, *University of California at San Francisco, San Francisco, CA, U.SA. Th.A.P.103 A Retrospective Follow-up Study of Morbidity among HIV Infected Young Adults Prior to a Diagnosis of HIV Infection: A True Natural History. Philip 0. Renzullo*, J. G. McNeil, J. F. Brundage, *Walter Reed Army Institute of Research, Washington, DC, U.SA. Th.A.P.104 HIV Infection Increases the Frequency and Severity of Papillomavirus Induced Cervical Cytologic Abnormalities. Anat R. Feingold*, S. H. Vermund, R. D. Burk, K. F. Kelley, L. K. Schrager, R. S. Klein, et al., *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A. 584 [Page 585](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/585) Th.A.P.105 Early HIV-1 Influence on Malignancies. Eva A. Operskalski*, Transfusion Safety Study Group, University of Southern California, Los Angeles, CA, U.S.A. Additionnels Additional Th.A.P.106 Th.A.P.107 Psoriasis as a Cause of False-Positive HIV Western Blots: Detection of gag-Specific Antibodies in Virtually All Cases. Jorg Schiipbach*, A. Baumgartner, L. Bruckner-Tuderman, *Swiss National Center Double-postifs Serologic Responses to HIV-1 and -2. Mark A. Rayfield*, C. Y. Ou, J. Krebs, K. Odehouri, W. M. Heyward, G. Schochetman, et al., *AIDS Program, Centers for Disease Control, Atlanta, GA, U.S.A. Th.A.P.110 Confirmation and Virus Typing Using PCR Analysis of HTLV-1 ELISA Reactive Samples. John J. Sninsky*, J. Lipka, D. Kellogg, N. McKinney, S. Fong, S. Kwok, et al., *Cetus Corp., Emeryville, CA, U.S.A. Th.A.P.111 Detection of HIV-1 from Needles Discarded by I.V. Drug Users in Zurich and Basel Using Polymerase Chain Reaction Assessment of In Vitro Infectivity. Ines Raineri*, H. P. Luethy, M. Vogt, *University Hospital, Division of Infectious Diseases, Zurich, Switzerland. Th.A.P.112 A Comparison of IFA and EIA in Determining HTLV-I Seroprevalence in the Ivory Coast. Michel Canavaggio*, M. Verdier, E. Anderson, A. Sangare, F Denis, W. Glusic, *Abbott Laboratories, North Chicago, IL, U.S.A. Th.A.P.113 Antibodies to HIV-1 gp 120 env Epitopes Correlate with Uninfected Status of the Children Born to Seropositive Mothers. Paolo L. Rossi*, V. Moschese, P. A. Broliden, K. Ljunggren, Wahren, Immunology, Karolinska Institute, Stockholm, Sweden. Th.A.P.114 Strain-Specific DNA Probes to Study the Epidemiology of HIV Infection. Chin-Yih Ou*, R. L. Robbins, J. L. Moore, Y. Villamarzo, Jr., C. P. Horsburgh, G. Schochetman, et al., *Centersfor Disease Control, AIDS Program, Atlanta, GA, U.S.A. Th.A.P.115 The Establishment of a Routine Surveillance System for Detecting Prevalence of HIV Infection in Scotland. DavidJ. Goldberg*, J. Emslie, C. Guthrie, D. Reid, *Communicable Diseases Unit, Ruchill Hospital, Glasgow, U.K. 585 [Page Th.A.P.116 Risk B. S. Chamaret, M. Nariotti, P. Lambin, et al., *Institut national de transfusion sanguine, Paris, France. Th.A.P.117 Comparison of the Sensitivity of Various Enzyme and Substrate Systems for Western Blot Assay. Shirley Y. W. Sum*, S. L. Yap, L. Chan, *Diagnostic Biotechnology, Singapore. Th.A.P.118 A Rapid and Sensitive HTLV-I Antibody Screening Method with High Specificity. David J. Waters*, J. T. Drummond, G. L. Warner, W. A. Blattner, G. B. Braman, R. M. Thorn, *NCI-Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A. Th.A.P.119 Seroconversion: Antibody Profiles to HTLV I. Helen Lee*, A. Mann, J. Gibbs, M. Perol, G. Tegtmeier, F. Ferchal, et al., *Abbott Laboratories, North Chicago, IL, U.S.A. Th.A.P.120 Epidemiology of AIDS in the Bahamas. M. Perry Gomez*, K. Ofuso-Barko, R. Bain, *Princess Margaret Hospital, Notes [Page 588](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/588) Section Jeudi 8 juin B Thursday, June 8 Aspects cliniques Clinical Aspects of AIDS Session d'affichage Poster Session H6mophilie Hemophilia Th.B.P.1 Lymphocytes Gabriella Gamba*, S. Testa, L. Ponchio, R. Invernizzi, F. P. Fazio, G. Sofia Testa*, L. Ponchio, N. Th.B.P.4 in Argentina. Marta Beldn Bouzas*, de Medicina, Buenos Aires, Argentina. Th.B.P.5 Response to Hepatitis B Immunization in Hemophiliac Children: Relationship to Human Immunodeficiency Type I (HIV-1) Virus Infection. Wendy Chan*, M. Petric, E. Wang, G. Koren, S. Read, V. Blanchette, *Hospitalfor Sick Children, Toronto, ON, Canada. Th.B.P.6 Beneficial Effect of an Ultrapure Factor VIII Concentrate in HIV-Positive H. Medicine, Karolinska Hospital, Stockholm, Sweden. Th.B.P.7 Hemophilia, Septic Arthritis and Human Immunodeficiency Virus. Peter Jarzem*, C. Tsoukas, D. Burke, H. Strawczynski, G. Growe, M. C. Poon, *Montreal General Hospital, McGill University, Montreal, QC, Canada. Th.B.P.8 Longitudinal Analyses of HIV-Specific Antibody Responses in Hemophiliacs with Long-term HIV Infection. Abraham Pinter*, P. Flomenberg, W. Honnen, K. Revesz, M. Hilgartner, J. Conway, et al., *Public Health Research Institute, New York, NY, U.S.A. 588 [Page Histoire H6pital Paris, Progression I. Schedel, H. Deicher, *Hannover Medical School, Hannover, Federal Republic of Germany. Th.B.P.13 Clinical Signs and Death Causes in HIV+ Hemophiliacs (hem) with Progressing Disease. Guillermo Muchinik*, R. Pdrez A. Anselmo, Buenos Aires, Argentina. Th.B.P.14 Hemophiliac Population of Costa Rica from 1979 to 1989. Kirsten A. Visona*, L. Taylor, C. Montero, R. Cordero, M. C. Astua, A. Roy, et al., *Louisiana State University, International CenterforMedical Research and Training, San Josd, Costa Rica. Th.B.P.15 An Immunological Follow-up in Hemophilic Non-Converters HIV-Contaminated Sam Schulman*, E. Berntorp, *Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden. Th.B.P.16 Natural History of HIV Infection in Large Hemophilia <<Fond. Pascale)), Naples, Italy. Th.B.P.17 Natural History of HIV Infection in a Group of Hemophiliacs with Known Year of Seroconversion. Anastasia Karafoulidou*, Markakis, et al., *Laikon Hospital, Athens, Greece. Th.B.P.18 HIV-1 Infection in Children with Hemophilia A and B. A Report from the Canadian Pediatric Hemophilia AIDS Study Group. Victor S, Blanchette, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada. Th.B.P.19 Hemophiliac Age Affects Immune Functions in HIV-infected Patients. W. Abe Andes*, K. Wulff, C. Lemoine, C. Daul, J. Morgan, R. D. DeShazo, et al., *Tulane University School of Medicine, New Orleans, LA, U.S.A. 589 [Page 590](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/590) Th.B.P.20 A Prospective Study of HIV Infection in Children with Hemophilia. Kaiser Ali*, R. Card, D. Garvey, G. Growe, N. Kobrinsky, C. Tsoukas, et al., St. NF, Th.B.P.22 Pre-existing Cytomegalovirus Infection Increases the Progression towards AIDS in a Cohort of Haemophiliacs. Paul D. Griffiths*, A. Webster, C. Lee, J. E. Grundy, V. C. Emery, P. Kernoff, *Royal Free Hospital School of Medicine, London, U.K. Th.B.P.23 High Burden of Epstein-Barr Virus in HIV-Infected Hemophiliac Patients. Ciro V. Sumaya*, R. Martinez, R. Parmley, J. Drake, Y. Ench, * University of Texas Health Science Center, Department of Pediatrics, San Antonio, TX, U.S.A. Th.B.P.24 Hemophilia: Psycho-Social Th.B.P.26 Living with HIV: A Weekend Retreat for Teenagers and Young Adults with Hemophilia. Jacquelin Martin*, L. Lindner, J. Neil, *Hemophilia Assessment Clinic, The Arthritis Society, Vancouver, BC, Canada. Th.B.P.27 Responding to the Palliative Care Needs of Persons with Hemophilia and AIDS. Nena M. Nera*, R. J. Shearer, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. Th.B.P.28 Psychosocial Management of HIV Infection among Hemophiliacs in Western Canada. Wilma M. McClure*, L. Lindner, J. McDonald, C. Bell, N. Schwetz, J. Akabutu, et al., *Northern Alberta Comprehensive Hemophilia Centre, University of Alberta, Edmonton, AB, Canada. Th.B.P.29 AIDS and Hemophilia: Creating Unique Family Dynamics. Charles M. Re.y, Montreal Children's Hospital, Social Service Department, Montreal, QC, Canada. Th.B.P.30 Condom Usage Reported by Female Sexual Partners of Asymptomatic HIV Seropositive Hemophilic Men. William A. Price*, T. Merigan, T. Peterman, *Research Triangle Institute, Research Triangle Park, NC, U.S.A. Th.B.P.31 Psychosocial and Neuropsychological Status of Haemophiliacs and Gay Men with HIV Infection: A Controlled Investigation. Jos. Catalan*, I. Klimes, A. Bond, A. Garrod, A. Day, C. Rizza, *Oxford University Department of Psychiatry, Headington, Oxford, U.K. 590 [Page 591](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/591) Th.B.P.32 Risk Factors for Psychiatric Distress among Hemophiliacs Infected with HIV. Mary-Amanda Dew*, M. V. Ragni, P. Nimorwicz, *University of Pittsburgh, School ofMedicine, Pittsburgh, PA, U.S.A. Th.B.P.33 Prediction of Safer Sex Practices and Psychosocial Distress in Adults with Hemophilia at Risk for AIDS. Kathy L. Parish*, J. Mandel, J. Thomas, E. Gomperts, *Children's Hospital of Los Angeles, Behavioral Science Section, Los Angeles, CA, U.S.A. Th.B.P.34 Guidelines for Dealing with Pregnancy in Seropositive Hemophiliacs and Their Spouses. Elissa M. Kraus*, D. B. Brettler, A. Forsberg, *Worcester Memorial Hospital, Worcester, MA, U.S.A. Th.B.P.35 A Team Response to HIV/AIDS Care in Persons with Hemophilia. Nena M. Nera*, R. O'Neill, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. Maladies mycobacteriennes Mycobacterial Diseases Th.B.P.36 Tuberculosis in AIDS Patients in Rio Grande do Sul: A New Epidemic? Results. Eduardo Barroso Werneck*, R. Silva, A. M. M. Costa, N. L. Boechat, A. L. Kritski, *Institute of Physiology and Pneumology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Th.B.P.38 Thoracic X-Ray Aspects of Tuberculosis in AIDS.Helio K. Yamashita*, C. A. Accetturi, S. A. Ribeiro, Stdvale, A. M. Kambara, *Escola Paulista de Medicina, Department of Imaging Diagnosis, Sao Paulo, Brazil. Th.B.P.39 Gastrointestinal Tuberculosis in AIDS Patients: The Rio Grande do Sul Experience. Eduardo and Maria Lucia Biancalana*, W. S. Mendes, G. A. Rodrigues, H. N. Stefani, G. C. Levi, J. S. Mendonca, do Servidor Publico Estadual, Sao Paulo, Brazil. Th.B.P.41 Drug-Resistant Tuberculosis in AIDS and ARC. Mario C. Raviglione*, A. Pablos-Mendez, R. C. Battan, *Department of Medicine, Cabrini Medical Center, New York, NY, U.S.A. Th.B.P.42 Mycobacterium Kansasii Infection in HIV Infected Patients: A 5-Year Review. Gregory T. Valainis*, L. Cardona, D. Greer, *Tulane University Medical Center, New Orleans, LA, U.S.A. Th.B.P.43 Tuberculosis in HIV Patients: Correlation between Natural History, Clinical Presentation and Immunological Status. Stgphane De Wit*, M. Gerard, B. Sommereijns, N. Clumeck, *St-Pierre University Hospital, Division of Infectious Diseases, Brussels, Belgium. Th.B.P.44 Surveillance for HIV/AIDS-Related Tuberculosis (TB) in the United States (U.S.). Carol A. Ciesielski*, J. Buehler, A. Bloch, R. Berkelman, *Centers for Disease Control, Atlanta, GA, U.S.A. 591 [Page 592](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/592) Th.B.P.45 Incidence Diagnosis and Treatment of Mycobacteriosis AIDS. Walter Heise*, J. Skorde, K. Nehm, K. Arasteh, R. Habermann, M. L'Age, *Auguste-Viktoria-Hospital, II Internal Medicine Department, Berlin, Federal Republic of Germany. Th.B.P.46 Evidence of Another Epidemic: Tuberculosis and HIV in a NYC Community Hospital. Marie I. Ciacco, St. Clare's Hospital and Health Center, New York, NY, U.S.A. Th.B.P.47 Influence of Geographic Distribution on Atypical Mycobacteriosis and Isospora Belli in Rio Grande do Sul (Brazil). Matias Kronfeld*, E. Sprinz, *Universidade Federal do Rio Grande de Clinicas de Porto Alegre, Porto Alegre, Brazil. Th.B.P.48 Factors Influencing Mortality in Disseminated M. Avium (MAI) Infection in Acquired Immunodeficiency Syndrome (AIDS). Sadhana S.Sathe*, Z. Kaminski, R. Kapila, P. Kloser, L. Reichman, P. Gasione, *University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ, U.S.A. Th.B.P.49 Mycobacterium Kansasii Infection in 15 Patients with Class IV HIV Infection: Clinical and Mycobacteriologic Features. Renslow Sherer*, S. Blair, K. Muller, F. Kocka, Muthuswamy, *Cook County Hospital, Chicago, IL, U.S.A. Th.B.P.50 Seroprevalence of HIV Infection in 183 Consecutive Patients with Tuberculosis (TB) at a New York City Hospital. Robert W. Shafer*, K. D. Chirgwin, A. E. Glatt, M. A. Dahdouh, S. H. Landesman, *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S.A. Th.B.P.51 Tuberculosis as AIDS-Associated, in the Province of British Columbia (1983-1988). Steve Blackie*, S. Vedal, L. M. Lawson, J. Ruedy, J. S. G. Montaner, *St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada. Th.B.P.53 Fever, Weight Loss, Anemia, Splenomegaly and Abdominal Lymphadenopathy Are Highly Predictive of Disseminated Mycobacteriosis in Patients Who Are HIV Antibody Positive. Lawrence A. Cone*, D. R. Woodard, D. Wade, N. Curry, W. Boughton, M. Fiala, *Eisenhower Medical Center, Rancho Mirage, CA, U.S.A. Th.B.P.54 Mycobacterioses and AIDS: Therapeutic Approaches. Dirk Schiirmann*, B. Ruf, H. Mauch, H.-D. Pohle, *Second Department of Internal Medicine, Rudolf Virchow University Hospital Freie Universitdt Berlin, Berlin, Federal Republic of Germany. Th.B.P.55 Detection of Antimycobacterial Antibodies in HIV Infection. Claire-Michele Farber*, J. De Bruyn, Th.B.P.56 Clinical Immunological and Aspects HIV Patients. Giuseppe Visco*, P. Narciso, G. C. V. Tozzi, et al., *\"L. Spallanzani\" Hospital, Department of Infectious Diseases, Rome, Italy. Th.B.P.57 Tuberculose et SIDA en Espagne. Inmaculada Ocaiia*, A. De Luis, I. Ruiz, N. Martf, R. Vidal, J. M. Martinez-Vdzquez, *Autonomous University of Barcelona, Barcelona, Spain. Th.B.P.58 Generalized Infection with an Unidentified Acid-Fast Micro-organism (AFB). Nicolas Mach*, H. R. Chang, J. D. F. Portaels, R. Auckenthaler, B. Hirschel, et pathologie, Centre midical universitaire, Geneva, Switzerland. Th.B.P.59 Tuberculosis and AIDS in Frankfurt. Ruth Miiller*, K. Koller-Campert, A. Jakschik, R. Brodt, G. Frankfurt, Zentrum der Medizin, Infektiologie, Frankfurt, Federal Republic of Germany. Th.B.P.60 MNT Infection in 63 of 328 AIDS Patients in Frankfurt. Karin Koller-Lampert*, R. Brodt, A. Staszewski, A. Jakschik, Frankfurt, Zentrum der Medizin, Infektiologie, Frankfurt, Federal Republic of Germany. Th.B.P.61 Aminoglycoside Antibiotics Have Potential Value in the Treatment of Mycobacterium Avium Complex (MAC) Disease in AIDS Patients. Pattisapu R. J. Gangadharam*, L. Kesavalu, V. K. Perumal, K. Parikh, N. Ghori, *National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, U.S.A. Th.B.P.62 Plasmids Influence Virulence of Mycobacterium Avium Complex (MAC) Strains in AIDS Patients. Pattisapu R. J. Gangadharam*, V. K. Perumal, J. H. Crawford, J. H. Bates, *National Jewish Center for Immunology and Respiratory Medicine, Denver, CO, U.S.A. Th.B.P.63 Incidence of Acquired Immunodeficiency Syndrome (AIDS) in Outpatients with Tuberculosis. Sandra A. Ribeiro*, S. M. G. P. Togeiro, C. A. Accetturi, H. K. Yamashita, *Department of Preventive Medicine, Escola Paulista Hdpital Laennec, Paris, France. Th.B.P.65 Tuberculosis in AIDS Patients. J. A. Iribarren*, J. Arrizabalaga, C. Garde, I. Sefiora de Ardnzazu, San Sebastian, Spain. Th.B.P.66 Association between Tuberculosis and AIDS in Rio de Janeiro, Brazil. Carlos Alberto Morais de Sd*, W. Eyer-Silva, R. Severo, M. Guimaraes-Dias, D. Oliveira, F. S. Sion, et al., *Gaffr`e and Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. Th.B.P.67 The Clinical Impact of Mycobacterial Infections in HIV-infected Persons. Kristi L. Boldt*, L. Miedzinski, G. Taylor, G. A. Evans, S. Chomyc, *University of Alberta, Edmonton, AB, Canada. 593 [Page 594](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/594) Th.B.P.68 Poor Compliance Is the Major Obstacle in Controlling the HIV-Associated Tuberculosis (TB) Outbreak. Karen Brudney*, J. Dobkin, *Harlem Hospital, Columbia University, New York, NY, U.SA. Th.B.P.69 Successful Antituberculosis Treatment with Various Drug Regimens in Patients with HIV Infection. J.A.Carton*, V. Cdrcaba, J. A. Maradona, R. Llorente, J. al., *Hospital Universitario Oviedo, Th.B.P.70 History of Leprae and HIV Co-infection. Claude Pean*, J. W. Pape, M. M. Deschamps, M. W. Johnson, *Institut Cardinal L4ger contre la lIpre, York, NY, U.SA. Th.B.P.71 Mycobacterium Avium-Intracellulare Infection Limited to the Skin and Lymph Nodes in Patients with AIDS. Daniel J. Barbaro*, B. M. Coldiron, V. L. Orcutt, *University of Texas Southwestern Medical School, Dallas, TX, U.S.A. Th.B.P.72 Mycobacterial Infection in AIDS Patients. Andrea Antinori*, F. Damiano, M. Fantoni, G. Ventura, F. and Environmental Features of Mycobacteria Other than Tuberculosis in Germany. Malte Peters*, B. *Rudolf Virchow University Freie Universitdt Berlin, Berlin, Federal Republic of Germany. Th.B.P.74 Tuberculosis and AIDS: Rio de Janeiro, Brazil. Afranio Lineu A. Matida, B. Galvao-Castro, *Institute of Physiology and Pneumology of the Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Immunologie: m6thodologie/divers Immunology: Methodology/Miscellaneous Th.B.P.75 HIV Infection Alters Immune Response Cigarette Smoking. Rachel A. Royce*, W. Winkelstein, Jr., *University of California at Berkeley, Department of Epidemiology, School of Public Health, Berkeley, CA, U.SA. Th.B.P.76 Non-Specific Pneumonitis Lavage Marco*, M. L. Jimenez Gonzalez-Adleo, A. Gonzalez, I. Santos-Gil, F. Sanchez Madrid, M. Lopez-Botet, *Hospital de la Princesa, Madrid, Spain. Th.B.P.78 Mechanisms Underlying the Functional Impairment of Pulmonary NK Cells from Patients with HIV Infection. Carlo Agostini*, R. Zambello, V. Poletti, L. Trentin, Patients with HIV Infections Spontaneously Release Tumor Necrosis Factor. Carlo Agostini*, L. Trentin, V. Poletti, R. Zambello, and Antigen of No Diagnostic Value in Monitoring HIV-infected Patients with Pulmonary Symptoms. Marianne K. Orholm*, T. L. Neilsen, J. D. Lundren, *Department of Infectious Leucocytes Lavage (BAL) and Peripheral Blood in HIV-Infected Patients with Pneumonia. Martin Kurt Kaegi*, W. Fierz, C. Kronauer, R. Speich, E. Zurich, Th.B.P.82 Delayed in Drug Addicts. Antonio Villa*, V. Grondonna, G. Guareschi, A. M. Pediconi, F. Confalonieri, *Fatebenefratelli Hospital, Milan, Italy. Th.B.P.83 Increased Production of Soluble IL 2 Receptor in Patients with HIV Infection. Yasuko Yokota*, K. Kitamura, K. Matsuda, R. Mitsuyasu, J.-C. Chermann, M. Honda, *Department of Cellular Immunology, National Institute of Health and Department of Immunology, Tokyo, Japan. Th.B.P.84 Changes in CD16 Receptor Expression on the Neutrophils of HIV-Infected Individuals. J. George Bekesi*, P. Boros, J. P. Roboz, J. C. Unkeless, Fukuoka, Th.B.P.86 CD4+/Neopterin Ration Correlates with p24 Antigenaemia in D'Agostino, Cambid, Lymphocyte Reactivity to Anti-CD3 as a Prognostic Marker in HIV-1 Infected Homosexual Men. Mariike T. L. Roos*, F. Miedema, F. de Wolf, J. Lange, P. T. A. Schellekens, *Central Laboratory of Blood Transfusion Service, Department of Clinical (Viro) Immunology, Amsterdam, Netherlands. Th.B.P.88 Neutrophil Radical Release and Lipid Peroxidation in HIV Infected Patients. Connie Jarstrand*, G. Carlin, A. Sonnerborg, B. S. Mertins, J. Eddy, D. Venzon, T. Walsh, P. Pizzo, et al., *National Cancer Institute, Bethesda, MD, U.S.A. 595 [Page 596](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/596) Th.B.P.90 Oxidative Burst Activity and Cell Surface Antigen Expression of Monocytes from Asymptomatic HIV-infected Individuals (AHI). Ala L. Landav*, H. Kessler, C. Benson, J. Phair, L. R. Rothberg, G. Spear, et al., *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A. Th.B.P.91 Stratification of HLA Alloantigen Presenting Cell Function in Patients with AIDS. Alan L. Landav*, M. Clerici, H. Kessler, G. Shearer, *Rush Medical Center, Department of Immunology/Microbiology, Chicago, IL, U.S.A. Th.B.P.92 In Situ Demonstration of IL2 Production in Lymph Nodes of HIV-1 Positive Patients with PGL. Michel Peuchmaur*, D. Emilie, M. C. Andrd Nahmias*, T. F. Lee, C. Reimer, L. Bozeman, S. Nesheim, *Emory University School of Medicine, Atlanta, GA, U.S.A. Th.B.P.94 Impaired IgM Production and Mitogen-Induced Suppression of Immunoglobulins by Mononuclear Cells from AIDS Patients. Edw-ara Janoff~*, P. D. Smith, S. M. Wahl, *Veterans Administration Medical Center, Minneapolis, MN, U.S.A. Th.B.P.95 Increased Spontaneous Release of CD8 Antigen from CD8+ Cells Reflects the Clinical Progression of HIV-1 Infected Individuals. L George Bekesi*, F. N. Chu, P. H. Tsang, J. P. Toboz, J. I. Wallace, *The Mount Sinai School of Medicine, New York, NY, U.S.A. Th.B.P.96 HIV and Bone Marrow Progenitors Proliferation. Enrica Tamburrini*, Studies on the In Vitro Secretion of HIV-1 Specific Antibodies by Peripheral Blood Cells from HIV-1 Infected Subjects. Arlette Serre*, Th.B.P.98 Enhanced TNF Production in Peripheral Blood Mononuclear Cells of HIV-1 Infected Patients. Siegbert Rossol*, R. Voth, S. Brunner, K. Klein, M. Biittner, W. E. G. Miiller, et al., *University of Mainz, 1 Med. Klinik, Mainz, Federal Republic of Germany. Th.B.P.99 Normal and HIV-associated Fungicidal Activity of Monocytes. les phagocytes circulants of Cells to Regulation by LGL inHIV Infection. Gloria Echeverrfa de PJrez*, L. Deibis, R. Ramirez, Z. Rios, M. De Marquez, I. Blanca, et al., *Clinical Immunology, National Center, Central Th.B.P.102 Activated T-Cells (TC) and Human Immunodeficiency (HIV) Progression. R. Neal Boswell*, T. Freeman, N. Boswell, R. Hensley, C. Butzin, *Wilford Hall, USAF Medical Center, U.SA. Th.B.P.103 Decreased Lymphocyte Proliferation Towards Pokeweed Mitogen Appears as a Very Early Marker in HIV Infection. P. Henrivaux*, K. Huygen, Y. Fairon, Th.B.P.104 In Vitro B-Cell Differentiation in Normals, rGP160 Vaccinated Volunteers, and HIV+ Subjects. James M. Reuben*, L. Liang, S. Li, S. Greenberg, G. Smith, R. Couch, *University of Texas, M.D. Anderson Cancer Center, Houston, TX, U.SA. Th.B.P.105 Usefulness of Lymphoblastic Transformation Test (L.T.T.) in Asymptomatic Patients (II and II Status of CDC Classification). Claude Beuscart*, A. Coget, B. Sivery, O. Leroy, Y. In Vitro Immunoglobulin Secretion in a Pokeweed Nitrogen-Driven Cell System. Finn T. Black*, P. Tauris, C. M. Peterson, B. Moller, *Department of Medicine and Infectious Diseases, University of Aarhus, Aarhus, Denmark. Th.B.P.107 Inhibition of Lymphocyte Proliferation Induced Antigens in HIV-Infected Individuals. Rui M. M. Victorino*, V. A. J. Maria, L. A. Pinto, *Faculty of Medicine of Lisbon, Lisbon, Portugal. Th.B.P.108 Estimation of Best Absolute CD4 Count from Multiple Pairings in Two-Color Flow Cytometry. Joyce C. Niland*, Transfusion Safety Study Group, *City of Hope National Medical Center, Department of Biostatistics, Duarte, CA, U.S.A. Th.B.P.109 Identification of Multiple HIV-1 Core Proteins on Western Blot by a Monoclonal Antibody. Chi-Ming Liang*, S. Henry, J. S. Epstein, *Division of Blood and Blood Products, Food and Drug Administration, Bethesda, MD, U.SA. Th.B.P.110 Evaluation of Sensitivity and Specificity of Synthetic Peptide and Recombinant Based Anti-HIV-1 and -2 EIA. Peter W. Joller*, H. I. Joller-Jemelka, *ANAWA Laboratories Inc., Wangen, Switzerland. Th.B.P.111 Development of a Method for Correlating the Presence of HIV Antigen and Provirus. David B. Paul*, M. Bankowski, M. Kuhns, A. McNamara, A. L. Landay, G. T. Spear, *Rush University, Chicago, IL, U.SA. Th.B.P.112 Human Immunodeficiency Virus (HIV) Expression and Antigenic Stability of HIV-Infected Cells for Use in Flow Cytometric Immunofluorescence Assay (FIFA). Julie M. Sligh*, S. T. Roodman, A. P. Knutsen, C. C. Tsai, *St. Louis University School of Medicine, Department of Pathology, St. Louis, MO, U.S.A. 597 [Page 598](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/598) Th.B.P.113 Immunodosage H. Rabesandratana, A. al., *Sanofi Recherches, Montpellier, France. Th.B.P.114 Simple Laboratory Tests as Markers for the Various Clinical Manifestations of HIV Infection. Dirceu B. Greco*, U. H. M. Paulino, I. Adams, M. A. A. Vitoria, C. L. Praca, C. C. Castro, et al., ofMinas Gerais, Immunodeficiency Clinic, Minas Gerais, Brazil. Th.B.P.115 Comparison of Simultaneous Administration of Intradermal (ID) and Merieux Multitest CMI (MM) Skin Test Methods in HIV-1 Seropositive Patients. Douglas L. Mayers*, W. L. Ebbeling, D. L. Goodman, K. F. Wagner, *Infectious Diseases Division, National Naval Medical Center, Bethesda, MD, U.SA. Th.B.P.116 Phenotypic Analysis of Lymphocyte Subsets in the Syndrome Associated with HIV Infection. Silviu Itescu*, L. Brancato, J. Dalton, R. Perdue, R. Winchester, *Hospitalfor Joint Diseases, New York University Medical Center, New York, NY, U.SA. Th.B.P.117 Antibodies to Sulfamethoxazole (SMX) in Normal, Allergic, HIV-Infected, and AIDS Patients. Timothy J. Sullivan*, R. Davidson, R. Budens, S. Nightingale, *University of Texas, Southwestern Medical Center, Dallas, TX, U.S.A. Th.B.P.118 HIV-Infected Subjects Respond to Polio Vaccination Booster According to T4 Cell Count. Nurit Vardinon*, R. Handsher, V. Zackut, M. Burke, A. Hasner, I. Yust, *Tel Aviv Medical Center, Tel Aviv, Israel. Th.B.P.119 The Effect of Vaccination against Hepatitis B on the CD4+ Cell Count in Anti-HIV Positive Men. Klaus Gutfreund*, D. Cheatham-Speth, S. Rossol, R. Voth, R. Clemens, G. Hess, *University of Mainz, Mainz, Federal Republic of Germany. Th.B.P.120 Immunologic Aspects of Multiple Simultaneous Vaccinations in HIV Seropositive Subjects. Joanne Rhoads*, D. L. Birx, R. R. Redfield, D. S. Burke, *Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A. Th.B.P.121 Correlation between Histological Changes in Lymph Nodes and Alterations of Cellular Immunity in Drug Addicts at Risk for AIDS. Eduardo P. Fernandez-Cruz*, J. M. Zabay, J. Tardio, Menarguez, Interferon alpha in Anti HIV-1 Positive Patients Is Different from In Vitro Produced Interferon alpha. Rike Voth*, S. Rossol, H. P. Laubenstein, M. Buittner, W. E. G. Maller, H. G. Schr6der, et al., *University of Mainz, 1 Medizinische Klinik, Mainz, Federal Republic of Germany. Th.B.P.123 Serum Immunoglobulin Profile in HIV Infection. Luis Tavares*, J. Botas, H. Feliciano, C. Carvalho, F. Antunes, J. D. Paiva, et al., *Department of Infectious Diseases, Hospital Santa Maria, Lisbon, Portugal. Th.B.P.124 tvaluation des antighnes ph6noglycolipidique et sulfolipidique de mycobacterium le diagnostic s6rologique de tuberculose chez les malades ARC et SIDA. H. C. Berlie*, P. Cruaud, F. Papa, H. David, G. L. Daguet, *Hdpital Saint-Antoine, Paris, France. Th.B.P.125 The Composition of Circulating Immune Complexes (CIC) in HIV-Infected Individuals by Clq- and C3d-Binding ELISA. Thomas A. Schwartzer*, G. Nahass, D. J. Gocke, *Robert Wood Johnson Medical School, New Brunswick, NJ, U.S.A. Th.B.P.126 Autoreactivity in Patients Infected with HIV. R. Neal Boswell*, C. Andrzejewski, J. Benton, S. Valtier, D. Lucey, *Wilford Hall, USAF Medical Center, San Antonio, TX, U.S.A. Th.B.P.127 Complement Activation in HIV Infection Occurs through the Classical Pathway and Reflects Disease Severity. Mark Peakman*, G. Senaldi, T. McManus, E. T. Davies, D. E. H. Tee, D. Vergani, et al., *Department of Immunology, King's College School of Medicine, London, U.K. Th.B.P.128 Serum IgD Levels in the Course of HIV Infection. Jill-Patrice Cassuto*, M. Vivinus, J. F. Th.B.P.130 Adenosine Deaminase (ADA) Levels in Tears of AIDS Patients and AIDS Carriers. Kotaro Eto*, I. Tsuboi, Y. of Medicine, Fukuoka, Japan. Th.B.P.131 Bullous Pemphigoid (BP) Type Antibodies in L. Didierjean, J.-H. [Page 600](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/600) Th.B.P.132 Comparison of the Immunoglobulins (IG) Profile between White Patients (PTS) Infected in Africa (WA), White PTS Infected in Europe (WW) and Black PTS Infected in Africa (AA). B. Vandercam*, D. Zenagui, M. Cahill, M. Omar, P. Fernez, F. Zech, *Department of Internal Medicine, St-Luc University Hospital, Brussels, Belgium. Th.B.P.133 Antibodies to Endogenous Interferon- in Controls and HIV-Infected Persons in Different Disease States. Peter W. Joller*, H. I. Joller-Jemelka, *ANAWA Laboratories Inc., Wangen, Switzerland. Th.B.P.134 Complement Levels and Circulating Immune Complexes in a Controlled, Longitudinal Multicenter Study on Effects of Intravenous Immunoglobulin (IVIG) in Adults with ARC/WR5. Peter J. Spdth*, G. Mauff, *Central Laboratory, Blood Transfusion Service SRC, Bern, Switzerland. Th.B.P.135 Serum IgE Levels Vary with Absolute CD4A Lymphocyte Counts in HIV-Positive Persons. Daniel R. Lucey*, Melcher, C. Butzin, R. TX, U.S.A. Th.B.P.136 Plasma in Patients with Infection. Sampietro, M. Issi, G. Ferraro, A. Bascialla, *Division of Infectious Diseases, Varese Regional Hospital, Varese, Italy. Th.B.P.137 Serum and Salivary Immunoglobulins to Candida in HIV Positive Individuals. David Wray*, D. H. Felix, *University of Edinburgh, Department of Oral Medicine and Oral Pathology, Edinburgh, U.K. Th.B.P.138 Serum Prolactin Levels in Patients with Human Immunodeficiency Virus (HIV) Infection. Robert P. Nelson*, D. N. Wright, D. H. Russell, D. K. Ledford, R. F. Lockey, R. A. Good, *All Children's Hospital, University of South Florida College of Medicine, St. Petersburg, FL, U.S.A. Th.B.P.139 Activation of the Alternative Complement Pathway (AP) in Different Stages of HIV Infection. Eszter Uihelyi*, T. Hidvdgi, M. Kirschfink, G. Fast, D. Bdnhegyi, I. Zimony, et al., *National Institute of Haematology and Transfusion, HIV-Infected L. C. Celton, P. R. Rouger, *Institut National de transfusion sanguine, Paris, France. Th.B.P.141 Anticardiolipin Antibody (ACA) in Patients with Human Immunodeficiency Virus (HIV) Infection. Ramon A. Arroyo*, R. N. Boswell, R. Brey, J. Higgs, N. Harris, U.S.A. Th.B.P.142 CD4+ Lymphocyte Autoantibodies in Daniel*, R. Weimer, K. Schimpf, G. Opelz, *Department Republic of Germany. 600 [Page 601](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/601) Th.B.P.143 Predictive Value of IgE in HIV Disease. Francoise L~abrousse*, D. Israel-Biet, J. M. Tourani, H. Sors, J. The Relationship CD-8 Lymphocyte Counts to AIDS Progression in BIY Sero~positive Men. Robert E. Anderson*, W. Lang, S. Shiboski, N. Jewell, M. Busch, W. Winkeistein, *VifRx, Inc., San Francisco, CA, U.SA. Th.B.P.145 A Follow-up of Immune Parameters in HIV-infected Patients Treated with Low Dose Azidothymidine (AZT). An Update on the Lymphocyte Immunophenotyping Quality Assurance Program in Support of the Army HIV Studies. William J. Rickman*, M. L. J. Waxdal, C. Monical, J. D. Damato, D. S. Burke, * Walter Reed Army Institute of Research, Rockville, MD, U.S~A. Th.B.P.147 Sous-populations de lymphocytes T CD4+ avec infection VII. Chrisine Cadi\" F. Barbier, F. Touraine, J. M. Livrozet, Lymphocyte Count (ThC) in Patients with Antibodies to HIV. Predicting Value, Clinical Significance and Long-term Follow-up Variance. Bonaventura Clotet*, A. Jou, J. Tor, G. Sirera, J. M. Gimeno, et al., *Badalona Hospital \"Germans Trias i Pujol\", Clinical Correlation. G.Lcz\" I. Mezzaroma, C. Pap etti, A. M. Pesce, E. Pinter, M. Cherchi, et al., *Department of Allergy and Clinical Immunology, University of Rome, Rome, italy. Th.B.P.151. Immunological A Longitudinal Study of Lymphocyte Surface Markers in a Population of 200 HIV +ve Intravenous Drug Abusers. James A. Whzitelaw*, G. Bird, L. Mac~allum, P. Flegg, R. Robertson, *Blood Transfuision Service, Edinburgh, U.K. Th.B.P.153 Relations Leu8- Subsets among CD8- T-Lymphocytes 0. F. Kunze, R. Krasser, P. Trinkler, I. Ehm, G. Pauli, *AIDS-Zentrum, Robert-Koch Institut, Berlin, Federal Republic of Germany. 601 [Page 602](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/602) Th.B.P.154 Prediction of CD4-CD8 Ratios from O. F. Trinkler, G. Pauli, A. Beck, *AIDS-Zentrum Robert-Koch Institut, Berlin, Federal Republic of Germany. Th.B.P.155 Correlation of In Vivo Cellular Immune Function with CD4 Number and Disease Progression in HIV Seropositive Patients. Deborah L. Birx*, J. Rhoads, E. Tramont, C. Oster, D. Burke, R. Redfield, *Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, MD, U.S.A. Th.B.P.156 HIV-2 Infection and Fluid (CSF) Lymphocyte Phenotyping and HIV-1 p24 Antigen (AG) Detection in HIV-1 Infected (HIV+) Zairians with and without Neurologic Symptoms. Christopher Brown*, T. N. Lubaki, J. Immunologic of Seropositive and Negative Gay Men. Mary A. Fletcher*, N. G. Klimas, G. Ironson, A. Laperriere, Th.B.P.160 Depletion of CD16 NK Cells in HIV Infection Due to a Selective Decline in the CD16+ CD8+ Compartment. Christian Doinel*, I. Mansour, P. Bourin, J. J. Lefrere, M. C. Meyohas, C. Salmon, et al., *Institut National de transfusion sanguine, Paris, France. Th.B.P.161 AIDS Predictors. Ruben Sher, School of Pathology, University of Witwatersrand, Johannesburg, South Africa. Th.B.P.162 Dichotomy of Two in Christian Doinel*, I. Mansour, P. Bourin, H. Roquin, J. J. Lefrere, P. Rouger, *Institut National de transfusion sanguine, Paris, France. Th.B.P.163 Comparison of T4 Count, CD4%, and T4/T8 Ratio with Correlation to Clinical Stage of HIV-1. Joseph L. Malone*, K. F. Wagner, D. L. Mayers, B. B. Hendrick, E. T. Coffin, D. B. Wilson, *Naval Hospital, San Diego and National Naval Medical Center, Bethesda, MD, U.S.A. Th.B.P.164 A Longitudinal Study of Lymphocyte Surface Markers in a Population of 200 HIV+ Intravenous Drug Abusers (IVDA). James A. Whitelaw*, A. G. Bird, R. P. Brettle, J. R. Robertson, J. R. MacCallum, P. J. Flegg, *HIV Immunology Laboratory, Blood Transfusion Service, Royal Infirmary, Edinburgh, U.K. 602 [Page 603](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/603) Th.B.P.165 Blood and Cerebrospinal Fluid (CSF) Lymphocyte Phenotyping (LP) and HIV-1 p24 Antigen (AG) Detection in HIV-1 Infected (HIV+) Zairians with (N+) and without (N-) Neurologic Signs. Christopher C. Brown*, T. Quinn, M. Lubaki, J. Perriens, *Projet SIDA, Kinshasa, Zaire. Th.B.P.166 T and B Lymphocyte Subset Distributions within Clinical Stages of HIV-1 Infected Patients. Marvse Levacher*, S. Tallet, F. Hulstaert, CD4+ CD8+) in the Peripheral Blood of a Patient with AIDS. Michael Baseler*, W. Urba, C. Budzyn, R. Stevens, J. Kasper, M. Psallidopoulos, et al., *PRI, Frederick, MD, U.S.A. Th.B.P.168 T Lymphocytes (CD3/DR+),NK Cells (Leu7+/2-) and \"Unstained Cells\" in the Course of HIV Infection. Johannes R. Bogner*, A. Matuschke, Lyon, France. Th.B.P.170 Correlation of Clinical Diagnosis of HIV Infection with the Results of ELISA, Karpas Cell Test and Western Blot for Anti-HIV Antibodies. Dirceu B. Greco, Federal HIV-Infected Individuals. Qi Sun*, P. Furth, D. Archibald, *University of Maryland Dental School, Baltimore, MD, U.S.A. Th.B.P.172 IgG Subclass Antibodies against Synthetic Peptides of HIV-1 Proteins in HIV-1 Infected Individuals. Bernhard Schwartldnder*, B. Bek, R. O. F. Kunze, G. Pauli, *AIDS-Zentrum, Bundesgesundheitsamt, Berlin, Federal Republic of Germany. Reactivity in Low and High HTLV-I Seroprevalence Groups: Resolution of Indeterminate Immunoblot Radioimmunoprecipitation Assay. Trudie M. Hartley*, R. F. Khabbaz, R. O. Cannon, J. E. Kaplan, M. D. Lairmore, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. Th.B.P.174 Salivary IgA to HIV in Patients with or at Risk of AIDS. Kdroly Nay*, A. Voevodin, E. Drexler, *Institute of Isotopes of the Hungarian Academy of Sciences, Budapest, Hungary. Th.B.P.175 Class-Specific Antibodies to Human Immunodeficiency Virus-1 (HIV) in Small Intestinal Fluids from AIDS Patients. Edward Janoff*, P. D. Smith, S. M. Wahl, *Veterans Administration Medical Center, Minneapolis, MN, U.S.A. 603 [Page 604](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/604) Th.B.P.176 Antibodies to Human in Rapid Test. Cileste Chenet-Monte*, C. H. Riggin, *Cambridge Bioscience Corp., Worcester, MA, U.S.A. Th.B.P.177 Differing Sensitivity of Three HIV-1 Antigen-Capture Assays to the Presence of HIV-1 Antibody. James E. Drummond*, D. J. Waters, L. O. Arthur, J. W. Bess, W. A. Blattner, *NCI-Frederick Cancer Research Facility, Program Resources Inc., Frederick, MD, U.S.A. Th.B.P.178 Distribution of Anti-nef Antibodies in 26 HIV Seronegative Stable Sexual Partners of HIV Seropositive Patients: Epidemiological Correlation. Yves Mouton*, B. Western Blot and PCR Reactivity Patterns in Individuals at High Risk for HIV Exposure. Richard T. Davey*, J. Metcalf, M. Easter, V. Vasudevachari, M. Psallidopoulos, H. C. Lane, et al., *National Institute of Allergy and Infectious Diseases, Bethesda, MD, U.S.A. Th.B.P.180 Positive HIV Western-Blot Reactions in Serum Samples from LED Patients Non-Infected by HIV. Nicolas Burgisser, HIV-Antigen, Various Antibodies and T4 Cell Counts as Markers of Clinical Progression in HIV Infection. Andrea Kleinschmidt*, A. Matuschke, D. Schuster, S. Schewe, Frdsner, fur Molekulare Zellpathologie, between HIV-1 p24 Antigenemia, Anti-p24 Antibody and Neutralizing Antibody Response in All Stages of HIV-1 Infection. J. George Bekesi*, P. H. Tsang, F. N. Chu, P. Mason, Y. Sei, J. I. Wallace, et al., *The Mount Sinai School of Medicine, New York, NY, U.S.A. Th.B.P.183 Prospective Multicenter Cohort Study in Homosexual Men in FRG. Observation of Immunological Parameters in a 4-Year Follow-up. Bernhard Schwartlmnder*, J. Koch, G. Pauli, *AIDS-Center, Federal Health Office, Berlin, Federal Republic of Germany. Th.B.P.184 Relation of Antigenaemia, Loss of Antibodies to Human Immunodeficiency Virus Reverse Transcriptase (RT) and Impairment of Cellular Immunity to Development of AIDS in Drug Addicts. Eduardo P. Fernadez-Cruz*, M. Garcia-Montes, N. Longo, B. Gonzalez, A. Fernandez, J. M. Zabay, *Hospital General Gregario Marafion, Complutense University, Brockmeyer, for Medical Virology and Immunology, University ofEssen, Medical School, Essen, Federal Republic of Germany. Th.B.P.186 Prevalence of HIV-1 p24 Antigen (AG) in Different Populations at Risk for HIV-1 Infection in Zaire: A Comparison of Three Commercial AG Assays. Christopher Brown*, L. Stibu, R. Kline, R. Ryder, A. Nelson, T. C. Quinn, et al., *Projet SIDA, Kinshasa, Zaire. 604 [Page 605](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/605) Th.B.P.187 HIV Antigenemia in Various Clinic al S tages of HIV Infection in African Patients. P1.il ioo Legage, Department of Pediatrics, Centre hospitalier de Kigali, Kigali, Rwanda. Neurologie: generalit~s Neurology: General Th.B.P.188 The Spectrum of Altered AIDS and ARC. Re~ aoP G..Jacquette, J. Dobkin, J. C. M. Brust, *Harlem Hospital Center, Columbia University, New York, NY, U.S~A. Th.B.P.189 Acquired Inimunodeficiency Syndrome: Neurologic Complication in 44 Cases. M. Jikti'er, A. C. 0. Favoretto, C. Andrd, C. A. Peixoto, S. A. Novis Pereira, * Universidade Federal do Rio de Janeiro, Hospital Universitdfrio Neurology, Rio de Janeiro, Brazil. Th.B.P.190 Orthostatic Hypotension (OH) in HIV+ Patients May Represent Generalized Autonomic Nervous System (ANS) Dysfunction. Jefiv AliL..Coheint, L. Miller, L. Polish, * University of Colorado School of Medicine, Denver General Hospital, Denver, CO, U.S~A. Th.B.P.191 Possible Pathogenetic Role of Immune Complexes in HIV-Related Neuropathy. Franco Confalonieri*, A. Parisio, N. Scolari, *Fateberefratelli Hospital, Milan, Th.B.P.192 Two Years Neurological Follow-up HIV-Positive C. Bruzki, K. Wirtz, et al., * University Clinic, Department of Neurology, Bonn, Federal Republic of Germany. Th.B.P.193 Incidence of the AIDS Dementia Complex as the First Manifestation of AIDS: A Prospective Study. Losev, Sarro, I Provincial, University of Barcelona, Barcelona, Spain. Th.B.P.194 Myelopathy as Presentation of AIDS: Treatment with AZT. Clr L. Caggese, I. Schlacht, Granda Hospital, Milan, Italy. Th.B.P.195 Neuropsychological Follow-up of Subjects on AZT Licensing Trial: San Diego Cohort. Jacqueline Dav*, I. Grant, J. H. Atkinson, L. Brysk, J. McCutchan, R. K. Heaton, et al., *University of California at San Diego and San Diego State University, San Diego, CA, U.SA. Th.B.P.196 Peripheral Neuropathies and Neurologie, Hdpital de la Salpt~triktre, Paris, France. Th.B.P.197 A System for Staging the AIDS Dementia Complex: Correlations with Neurological and Neuropsychological Assessments. RidiardW. jce *, B. I. Brew, J. J. Sidtis, A. Sadler,.J. Kielp, W. Wolf, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.SA. Th.B.P.198 Pharmacokinetic Analysis of the Enhanced Distribution of Zidovudine into Rabbit Cerebrospinal Fluid Caused by Probencid. of Disease Activity and Response Therapy. Lrc. BLryj, W. Hardy, B. Poiesz, G. Ehrlich, M. Larimore, R. W. Price, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. Th.B.P.200 Neuropsychological Follow-up of 1,787 Participants in the Multicenter AIDS Cohort Study. Barbara R. Visscher*, E. Miller, P. Satz, J. McArthur, 0. Selnes, B. Cohen, et al., *School of Public Health, University of California at Los Angeles, Los Angeles, CA, U.S~A. Th.B.P.201 The Epidemiology of AIDS-Related Neurological Diseases. Maf.y.L Wilson*, G. F. Lemp, D. Neal, A. Vlamis, D. D. Ferguson, G. W. Rutherford, *California Department of Health Services, San Francisco, CA, U.S~A. Th.B.P.202 N'europsychological Follow-up in Patients Who Have Progressed to AIDS: The Multicenter AIDS Cohort Study (MACS). Ola A. Selnes*, E. N. Miller, I. C. McArthur, B. Cohen, J. T. Becker, A. Saah, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S~A. Th.B.P.203 Neurological Involvement in Group IV HIV+ Patients: Neurophysiological Clinical Data. Massimo Di Pietro*, P. F. Mazzotta, F. Pinto, Malattie Infettive, Florence, Italy. Effect of Mannitol IV Infusion on Distribution of Zidovudine between Plasma and Cerebrospinal Fluid in Rabbits. Yanfeng Wang*, M. A. Hedaya, R. J. Sawchuk, * University of Minnesota, Minneapolis, MN, U.S~A. Th.B.P.205 Cranial Neuropathies in AIDS Patients. Edwin S. Mahawar, A. M. Wesely, D. E. Bredesen, * University of Cali/'ornia at San Francisco, San Francisco, CA, U.SA. Th.B.P.206 Neurologic Abnormalities among HIV-1 Seropositive Intravenous Drug Users. Roval*, M. Updike, D. R. Cornblath, 0. A. Selnes, L. Solomon, D. Vlahov, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.SA. Th.B.P.207 Subclinical Neuropsychological and Peripheral Abnormalities in HIV+ Cahn*, C. Mangone, H. Pdrez, A. A ires, Argentina. Th.B.P.208 Multivariate Statistical Determination of Incidence and Character of Cognitive Impairments in HIV Patients. Pim Brouwers*, E. Mohr, M. Hendricks, J. Claus, M. Young, P. Pierce, *National Cancer Institute, Pediatric Branch, Bethesda, MD, U.S.A. Th.B.P.209 Peripheral Facial Palsy as a Predictive Indicator of HIV Infection in Central Africa. Laurent Belec*F, P. M. V. Martin, E. Vuillecard, D. Di Costanzo, E. Schuller, A. J. Georges, *Institut Pasteur, Bangui, Central African Republic. Th.B.P.210 Declining Incidence of AIDS Dementia Complex and HIV-1 Antigen Detection in the Cerebrospinal Fluid following Systematic Zidovudine Treatment. Pe rLore g*s, J. De Gans, M. M. A. Derix, S. A. Danner, J. M. A. Lange, J. Goudsmit, * University of Amslterdam, Academic Medical Center, Amsterdam, Netherlands. 606 [Page 607](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/607) Th.B.P.211 A Case Definition of AIDS Dementia Complex for Use in African Patients. Joseph H. Perriens*, M. Mussa, M. Luabeya, K. Kayembe, Prospective F. Thuillard, G. Assal, Vaudois, Lausanne, Switzerland. Th.B.P.213 CNS Lesions in AIDS: of 44 Patients. Roberto Luzzati*, E. Concia, L. Bontempini, M. Malena, R. Mazzi, D. Bassetti, *Institute of Infectious University of Verona, Civil Hospital, Verona, Italy. Th.B.P.214 Guillain-Barre Syndrome in HIV Infection: Experience from an African Center. Charles A. Thornton*, A. S. Latif, *University of Zimbabwe School of Medicine, Department of Medicine, Avondale, Zimbabwe. Th.B.P.215 Long-term Effects of Treatment with Zidovudine on Neuropsychological Functions in Subjects with ADC. Ivar Reinvang*, S. S. Frland, A. J. Lundervold, * Department Psychosomatic Medicine, Rikshospitalet, Oslo, Norway. Th.B.P.216 Prevalence, Treatment, and Costs of Mental Disorders among Persons with AIDS. Julia Hidalgo*, F. Schaerf, D. B. Larson, *Department of Health and Mental Hygiene, AIDS Administration, Baltimore, MD, U.S.A. Th.B.P.217 Neurological Disturbances Associated with HIV Infection: Experience at an African Center. Charles A. Thornton*, A. S. Latif, S. Houston, *University ofZimbabwe School ofMedicine, ofMedicine, Avondale, Th.B.P.218 Effects of Azidothymidine on Neuropsychological Performance in Asymptomatic and Symptomatic HIV-1 Infection: The Multicenter AIDS Cohort Study. Justin C. McArthur*, E. N. Miller, O. A. Selnes, J. Becker, B. A. Cohen, D. Starky, et al., *Johns Hopkins Medical Institutions, Baltimore, MD, U.S.A. Th.B.P.219 Natural History of Central Nervous System (CNS) Impairment in HIV Infection. Christine Katlama*, P. Duneton, F. Paris, France. Th.B.P.220 Neurological Manifestations in HIV Infection. Analysis of 217 Patients. Giuseppe Visco*, S. Galgani, G. Piazza, Narciso, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy. Th.B.P.221 Neuropsychiatric Findings in HIV-infected Patients at an Infectious Disease Clinic in Kinshasa, Zaire. Mesu'a-Kabwa Luabeya*, K. Kayembe, M. Mussa, K. A. L. Kayembe, K. A. Izzia, T. D. Kashala, *Tulane le LCR Neurology: Markers of HIV Infection in the CNS. Sonia Zeriav*, D. Jevtovic, B. Brmbolic, V. Suvakovic, M. Sasic, *Institute for Infectious and Tropical Diseases, Virological Laboratory, Belgrade, Yugoslavia. Th.B.P.223 Cytokines and Immunoglobulins (Ig) in Cerebrospinal Fluid (CSF) of Anti-HIV-1 Positive, Anti-HTLV-I Negative Asymptomatic Men. Nancy C. Klimas*, J. Berger, S. Spector, H. Friedman, M. Ashman, M. A. Fletcher, *University of Miami School of Medicine, Department of Medicine, Miami, FL, U.S.A. Th.B.P.224 Serotonin Metabolite Deficiency in HIV Infection and AIDS. Carolyn B. Britton*, S. Kranzler, A. Naini, L. Co6t, *HIV Center, Columbia University College of Physicians and Surgeons, New York, NY, U.SA. Th.B.P.225 Intrathecal Synthesis of Free Light Chains in Human Immunodeficiency Virus Type I Infected Patients. Paolo Gallo*, S. Pagni, M. G. Piccinno, A. De Rossi, L. B. *Institute of Neurology, University of Padua, Padua, Italy. Th.B.P.226 Activation of the Cellular Immune System in the CNS of HIV-1 Infected Individuals. Anders B. Sonnerborg*, L. V. Von Stedingk, L. O. Hansson, 0. Strannegard, *Department of Virology, Central Microbiological Laboratory, Stockholm, Sweden. Th.B.P.227 Lack of Relationship between Tryptophan and Neurological Disease in HIV-1 Infected Individuals. Bruce J. Brew*, M. Heyes, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. Th.B.P.228 Cerebrospinal Fluid Findings in Two Patients with Human Immunodeficiency Virus. R. Alvarado*, R. Andrade-Arzabe, M. A. Pacheco, V. Bartos, R. De La Vega, J. Auza, *San Gabriel Hospital, La Paz, Bolivia. Th.B.P.229 Longitudinal CSF Cell and Protein Levels in 258 HIV-Infected US Air Force Personnel. Douglas W. Marshall*, R. L. Brey, C. A. Butzin, R. A. Zajac, R. N. Boswell, *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A. Th.B.P.230 Intrathecal Production of IgG in a Longitudinal Study of 258 HIV-Infected US Air Force Personnel. Douglas W. Marshall*, R. L. Brey, C. A. Butzin, D. R. Lucey, R. N. Boswell, *Wilford Hall USAF Medical Center, San Antonio, TX, U.S.A. Th.B.P.231 Intrathecal Antibody Production Assayed by Recombinant Antigens, gpl20 RIPA. Thomas Weber*, Luke, W. Republic of Germany. Th.B.P.232 Quinolinic Acid Concentrations Are Increased in Plasma and Cerebrospinal Fluid in AIDS and Correlates with AIDS Dementia Complex. Melvvn P. Heves*, B. J. Brew, S. P. Markey, A. Martin, R. W. Price, D. Rubinow, et al., *National Institute of Mental Health, Bethesda, MD, U.S.A. 608 [Page 609](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/609) Th.B.P.233 CSF B2 Microglobulin as a Marker of the Presence and Severity of AIDS Dementia Complex. Bruce J. Brew*, R. Bhalla, M. Paul, M. Schwartz, R. W. Price, *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. Th.B.P.234 Adenosine Deaminase (ADA) Values in Clotet*, Pujol\", Barcelona, Spain. Th.B.P.235 Detection HIV Markers in Cerebrospinal Fluid. Henri Agut*, A. Devillechabrolle, C. Katlama, P. Duneton, Pitid-Salpetridre, Paris, Th.B.P.236 Cerebrospinal Fluid and Blood Markers in HIV Seropositive Individuals with and without Neurologic Complications. Wallace W. Tourtellotte*, E. J. Singer, K. Syndulko, P. J. Ruane, R. Mitsuyasu, *Veterans Administration Medical Center Wadsworth, University of California at Los Angeles, Los Angeles, CA, U.S.A. Th.B.P.237 Serotonin Metabolite Deficiency in HIV Infection and AIDS. Carolyn B. Britton*, S. Kranzler, A. Naini, L. C6dt, *HIV Center, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A. Th.B.P.238 Increasing CSF Abnormalities in HIV-Infected Individuals with Declining Systemic Immune Status. Justin C. McArthur*, J. H. McArthur, C. Herman, H. Farzadegan, J. Margolick, A. Saah, *Johns Hopkins Hospital Medical Institutions, Baltimore, MD, U.S.A. Th.B.P.239 Antibody Dependent Cellular Cytotoxicity (ADCC) in Blood and Cerebrospinal Fluid (CSF) of HIV-1 Infected Zairian Patients. Christopher Brown*, J. Perriens, N. Lubaki, A. Men. Nanc G. Klimas*, J. Berger, L. LaVoie, M. A. Fletcher, *University of Miami School of Medicine, Department Medicine, Miami, FL, U.S.A. Th.B.P.241 CRF, B-Endorphin and ACTH Are Significantly Decreased in Cerebrospinal Fluid of AIDS Patients. Catherine Rougeot*, J. Lebas, A. Sobel, S. Everaere, F. Dray, *Institut Paris, France. Th.B.P.242 Brain Radiological, Neurological and Neuropsychological Follow-up in Relation to Intrathecal Immune Response in HIV Infection. Irina Elovaara*, E. Raininko, L. Valanne, A. Virta, J. Ldhdevirta, *University of Helsinki, Department of Virology, Helsinki, Finland. Th.B.P.243 CSF Changes in Different Stages of HIV Infection. Lorenzo Minoli*, R. Brustia, R. Maserati, M. Furione, D. Franciotta, G. L. Melzi d'Eril, * University of Pavia, Department of Infectious Diseases, Pavia, Italy. Th.B.P.244 Neopterin and B2-Microglobulin in Cerebrospinal Fluid in HIV Infection. Frank D. Goebel*, J. R. Bogner, B. Junge-Halsing, Einhaupl, *Med. [Page 610](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/610) Th.B.P.245 The CSF-HIV Markers in the Different Stages Infection. Raffaele Pristerd*, 0. Moling, E. Kafmann, A. Castegna, M. Marchesi, L. Grimaldi, et al., *Bolzano General Hospital, Infectious Diseases Department, Bolzano, Italy. Th.B.P.246 Cerebrospinal Fluid Analysis in Opportunistic Modifications biologiques du LCR au cours de l'infection par VII. Thierry Saint-Marc*, A. Vergne, C. Caudie, F. Touraine, J. M. Pathological Studies Th.B.P.248 Productive Infection by 11W of Human Central Nervous System (CNS) Tissues. iH~erbr Bda University of Vienna, Neurological Institute, Vienna, Austria. Th.B.P.249 Clinical-Pathological Features of HTLV-I Associated Myelopathy (HAM) in AIDS. &jw.cL t. Be.~, M. R. Rosenblum, H. A. Aro now, W. Hardy, K. Cronin, R. W. Price, *Memnorial Sloan-Kettering Cancer Center, New York, NY, U.SA. Th.B.P.250 Can Alone Induce resonance des cerdbrales au de Trotot*, C. Sandoz-Tronca, R. Levillain, Vazeux, L. Mathiesen, *Irstitut Paris, France. Th.B.P.254 Apport de l'IRM au diagnostic precoce des complications enc~phaliques du SIDA. Pierre M. T2rotot*, C. Sandoz-Tronca, M. Thibierge, A. E. Cab~fe, R. Lavayssitre, M. et M. A. Rosci, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy. 610 [Page 611](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/611) Th.B.P.256 Brain Magnetic Resonance Imaging (MRI) Findings in HIV Infection. Giuseppe Visco*, V. Tozzi, R. Ciciani, S. V. Volpini, et al., *L. Spallanzani Hospital, Department of Infectious Diseases, Rome, Italy. Th.B.P.257 Cerebral Atrophy in HIV-Infected Patients: Relationship to Neurological and Neuropsychological Measures. Howard Aronow*, J. G. Kielp, B. J. Brew, R. W. Price, J. J. Sidtis, A. E. Sadler, et al., *Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. Th.B.P.258 Autoradiographic Analysis of AIDS Brain Lesions with an Omega 3 (Peripheral Type Benzodiazepine) Binding Site Radioligand. Jean-Jacques Hauw*, Cerebral Metabolic (PET), Neuropsychologic and Neurologic Abnormalities in Patients with AIDS. Wilfred G. Van Gorp*, M. Mandelkern, J. Ropchan, G. Evans, W. Blahd, F. Flynn, et al., *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A. Th.B.P.260 HM-PAO Spect and GD-DTPA Enhances MR Imaging in CNS-Manifestations AIDS. Michae Cordes*, H. Henkes, J. Hunger, R. W. Heise, R. Felix, *Universitdtsklinik Rudolf Virchow, Department ofRadiology, asymptomatique Neurology: Neurological Involvement in Asymptomatic HIV Th.B.P.261 Absence of Neurological Disease Early in HIV Infection. Karen Marder*, K. Bell, G. Dooneief, J. Gorman, G. Todak, R. Mayeux, *HIV Centerfor Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, NY, U.S.A. Th.B.P.262 Neuropsychological Change in CDC II, HI and IV Persons after 6 to 12 Months: Evidence for Decline. IgorGrant*, R. K. Heaton, T. Jernigan, J. Hesselink, J. H. Atkinson, J. Weinrich, et al., *University of California at San Diego, Department ofPsychiatry, La Jolla, CA, U.S.A. Th.B.P.263 T4 Lymphocyte Counts and the Presence of Abnormalities on Neurological Examination in Asymptomatic HIV Seropositive Subjects. Joseph R. Berger*, M. McCarthy, L. Resnick, M. A. Fletcher, N. Klimas, L. Pall, et al., *University of Miami School of Medicine, Department of Neurology, Miami, FL, U.S.A. Th.B.P.264 Neurologic Findings in Early HIV Infection. Michael Coats*, A. M. Salazar, A. Martin, B. Jabbari, C. Geyer, D. Burke, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A. Th.B.P.265 Major Dysfunction and Cognitive Disturbances in 50 Clinically Asymptomatic HIV-Infected Patients with Normal MRT-Scans. of Germany. 611 [Page 612](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/612) Th.B.P.266 Choice Reaction Time Measures and Cognitive Dysfunction in Persons with HIV Infection. Michael Perdices*, D. A. Cooper, *NHMRC Special Unit in AIDS Epidemiology and Clinical Research, Surry Hills, Australia. Th.B.P.267 Incidence of Mild Neuropsychiatric Abnormalities in HIV-Infected Patients in Kinshasa, Zaire. Mesu'a-Kabwa Luabeva*, K. Kayembe, M. Mussa, K. A. L. Kayembe, K. Izzia, W. E. Bertrand, *Tulane University SPHTM, New Orleans, LA, U.S.A. Th.B.P.268 Uncommon Neurologic Manifestations in HIV-1 Infected Patients without AIDS. Aleio Erice*, J. Fortin, J. M. Hermida, R. Nash, L. Buzdn, *Hospital Ramdn y Cajal, University of Alcald Medical School, Madrid, Spain. Th.B.P.269 Neuropsychometric Function in Early HIV Positive Patients Compared with a Matched HIV Negative Population. David B. Clifford*, J. P. Miller, W. Seyfried, M. Glicksman, R. Jacoby, *Washington University School of Medicine, St. Louis, MO, U.SA. Th.B.P.270 Central Nervous System Findings and Neurologic (N) Correlates of HIV Infection in Men with CDC Group II/III HIV Disease. Ann C. Collier*, C. Marra, B. Coombs, W. Cohen, K. Claypoole, H. Handsfield, et al., *University of Washington, Harborview Medical Center, Seattle, WA, U.SA. Th.B.P.271 Neuropsychological Abnormalities among Asymptomatic IV Drug Users: No Relationship with HIV-1 Serostatus. Ola A. Selnes*, T. V. Proctor, W. R. Royal, C. Herman, D. Vlahov, J. C. McArthur, et al., *Johns Hopkins Medical Institutions, MD, U.S.A. Neurologle: Divers (depistage, of AIDS Dementia Complex: Subjects. Maurizio Department of Infectious Diseases, Pavia, Italy. Th.B.P.273 EEG Background Slowing Appears in HIV-Infected Patients in the Absence of Metabolic Derangements or Other Cerebral Involvement. MichaelJ. Borucki*, K. Norcross-Nechay, S. J. Borucki, R. B. Pollard, *The University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX, U.S.A. Th.B.P.274 The Neurophysiology of Sleep Destruction in Patients with CNS-Manifestations of AIDS. Klaus Terstegge*, H. Henkes, B. Ruf, G. Scholz, S. Kubicki, *Free University Berlin, Department of Clinical Neurophysiology, Rudolf Virchow Clinic, Berlin, Federal Republic of Germany. Th.B.P.275 Comparison of EEG Findings in HIV-Infected et *Free University Berlin, Department of Neurology, Klinikum Rudolf Virchow, Berlin, Federal Republic of Germany. 612 Th.B.P.276 Quantitative Vibration Threshold Testing (QVTT) and Computer-based Neurobehavioral Testing (NES) of Persons Infected with HIV. Alfred Franzblau*, R. E. Letz, D. Hershman, P. Mason, J. Wallace, J. G. Bekesi, *Mount Sinai Medical Center, New York, NY, U.SA. Th.B.P.277 Neurotoxicity Battery for Phase I HIV Drug Assessment: Initial Applications. Elizabeth S. Parker*, T. P. Bridge, L. Ingraham, E. Eaton, P. N. R. Heseltine, *Center for Neuropsychology, Newport Beach, CA, U.S.A. Th.B.P.278 Cognitive Abnormalities as a Function of HIV-1 Clinical Status and Use of Azidothymidine (AZT): The Multicenter AIDS Cohort Study (MACS). Eric N. Miller*, O. A. Selnes, B. Cohen, J. Becker, L. Park, B. Visscher, et al., *University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S.A. Th.B.P.279 Decision-Making Speed in Early Human Immunodeficiency Virus (HIV) Infection. Howard E. Edelstein*, E. Martin, L. Robertson, *VA Medical Center, Martinez, CA, U.S.A. Th.B.P.280 Abnormalities of EEG and Otoneurologic Tests in Asymptomatic HIV Infected Homosexuals: A Prospective Controlled Study. I/gr Koralnik*, Beaumanoir, R. A. Universitaire de Gendve, Geneva, Switzerland. Th.B.P.281 EEG Findings and Cognitive Performance in 82 HIV-Infected Patients. Lorenzo Minoli*, A. Parisi, G. Bono, E. Sinforiani, M. Turla, G. Nappi, *IRCCS Matteo, Micoud, Grenoble, France. Th.B.P.283 Prospective Evaluation of an Algorithm for the Diagnosis of AIDS-Related Neurologic Illness: Experience with Over 200 Patients. Robert M. Levy*, S. Grohmann, B. Cohen, J. Von Roenn, R. Murphy, *Northwestern University Medical School, Chicago, IL, U.S.A. Th.B.P.284 Patterns of Neuropsychological Dysfunction in a Select Group of HIV+ Individuals in Comparison to Psychiatric Controls. Alex Martin*, A. M. Salazar, D. Kampen, J. Williams, W. Law, C. Gomez, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A. Th.B.P.285 Current Perception Threshold in HIV-Positive Patients. Jefferson J. Katims*, D. N. Taylor, J. I. Wallace, J. G. Bekesi, J. C. Masdeu, *Cabrini Medical Center, New York, NY, U.S.A. Th.B.P.286 Neuropsychological Evidence for Early Involvement of the Basal Ganglia Region in a Subgroup of HIV+ Individuals. Alex Martin*, D. Kampen, A. M. Salazar, J. Williams, W. Law, T. Roller, et al., *Walter Reed Army Medical Center, Washington, DC, U.S.A. 613 [Page 614](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/614) Th.B.P.287 Prospective Neurological and Neurophysiological Assessment in a Cohort of Homosexual Men. Ruth H. McAllister*, M. J. G. Harrison, G;. B. Griffin, C. J. Fowler, S. P. Newman, M. V. Hems, et al., * University College and Middlesex School of Medicine, London, U.K. Th.B.P.288 Changes in Performance on the Trail-Making Test before and after HIV-1 Seroconversion and Diagnosis of AIDS: The Multicenter AIDS Cohort Study. Eric N. Miller*, 0. A. Selnes, B. Visscher, J. C. McArthur, P. Satz, J. Dudley, * University of Cal Wornia at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S~A. Th.B.P.289 Neurop sychologic al Performance in HIV- 1 Immunocompromi sed Patients. Wilfred G. Van Gort,*, E. Miller, P. Satz, B. Visscher, * University of California at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S~A. Th.B.P.290 Antisaccadic Eye Movement Abnormalities in Asymptomatic HlY Seropositive Individuals. Ton NV. Currie*, B. M. Ramsden, J. M. Lynch, C. L. McArthur, E. M. Benson, M. Perdices, et al., *Mental Health Research Institute of Victoria, Melbourne, Australia. Th.B.P.291 Sequential Autonomic Function Tests in HIV Infection. Gir4&nLR.. 5.c.QLL, D. J. Ewing, A. Piaggesi, *Edinburgh Royal Infirmary, Edinburgh, U.K. Th.B.P.292 Neuro-Performance Measurement and Memory Profiles of Disability in HIV Seropositive Individuals. Wallace W. Tourtellotte*, K. Syndulko, E. Singer, P. Ruane, B. Fahy-Chandon, G. V. Kondraske, * Veterans' Administration Medical Center Wadsworth, University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S~A. Th.B.P.293 Latency of P300 and Pattern Visual-Evoked Potential Are not Sensitive to Early HIV-Related Neurologic Disease. Wallace W. T~ourtllote* K. Syndulko, E. Singer, P. Ruane, B. Chandon, * Veterans' Administration Medical Center Wads-worth, University o~fCal Wornia at Los Angeles, Los Angeles, CA, U.SA. Th.B.P.294 Computerized Screening for HIV-Related Cognitive Decline: Cross-Sectional Analyses and One-Year Follow-up. Eric N. Miller*, P. Satz, W. Van Gorp, B. Visscher, J. Dudley, * University of Cal Wornia at Los Angeles, Neuropsychiatric Institute, Los Angeles, CA, U.S~A. Th.B.P.295 Event-Related Potential Measures of Dementia in HIV Disease. Chrkstirie L..QLI2\", R. Johnson, J. Grafman, L. Govoni, D. Rubi now, P. Bridge, *Nationol Institute for Mental Health, Bethesda, MD, U.S~A. Th.B.P.296 Clinical Validation of a Bedside Antisaccadic Test for the Assessment of AIDS Dementia. Elizabeth M. Benson*, J. N. Currie, B. M. Ramsden, J. M. Lynch, C. L. McArthur, D. A. Cooper, *Monosh University Medical School, Alfred Hospital, Melbourne, Australia. Th.B.P.297 Multimodality Evoked Potentials in HIV Infected Subjects: A Longitudinal Study. Costanzo Gala*, A. Ducati, R. Donati, L. Vianello, M. Mansi, S. Martini, * University of Milan Medical School, Department of Psychiatry, Milan, Italy. 614 [Page 615](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/615) Nutrition Nutrition Th.B.P.298 Body Composition in Asymptomatic HIV-Positive Men. Christooher Olivez~I, J. Gold, B. J. Allen, N. Blagojevic, A. Rose, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. Th.B.P.299 Nutritional Status in AIDS Patients. Daniel Scevola*, G. Barbarini, A. Zambelli', G. Bottari, * University of Pavia, Institute of Infectious Diseases, Pavia, Italy. Th.B.P.300 Less Diarrhea Seen in HIV-Positive Patients on Low-Fat Elemental Diet. Alison B. Kin g*, G. McMillan, J. St. Arnaud, T. T. Ward, *Norwich Eaton Pharmaceuticals, Inc., a division of Procter and Gamble, Norwich, CT, U.S~A. Th.B.P.301 Identification des besoins d'information en par Michi~l LLsett, CLSC Centre-Ville, Montreal, Th.B.P.302 AIDS Nutrition Network (A]NN). William F. Horn*, D. F. Moore, S. L. Matheny, *San Jose State University, Nutrition Services Consulting, HRSA, PHS, DHHS, San Jose, CA, U.S~A. Th.B.P.303 Evaluation of the Zinc Taste Test (ZTT) in AIDS Patients. SadaM Johnson*, B. S. Peters, G. Johnson, G. M. Hems, A. J. Pinching, *St. Mary's Hospital, London, U.K. Th.B.P.304 Garlic as an Antimicrobial and Immune Modulator in AIDS. Tanga L.AkduIhh*, D. V. Kirkpatrick, L. Williams, J. Carter, *Akbar Research Foundation, Panama City, FL, U.S~A. Th.B.P.305 Protein Turnover and Substrate Cycling in AIDS Patients. L.JPeiez Stein*. D. Condoluci'. C. Nutinskv. C. E. Bodwell. * University ot Medicine and Dentistry of New Jersey. Newark. NiJ. U.S.A. Th.B.P.306 Early Predictors of Nutritional Status in HIV Infection. R~ichard S.BJj*~, E. Mantero-Atienza, F. Van Riel, R. Morgan, M. K. Fordyce-Baum, * University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S~A. Th.B.P.307 Dietary Intake in HIV Infection: Relative Caloric Deficiency in Patients with AIDS. Rowan T. Chlebowski*, M. Grosvenor, S. Kruger, L. Bulcavage, K. G. Beall, *Harbor..UCLA Medical Center, Torrance, CA, U.S.A. Th.B.P.308 Dietary Intervention in ARC Patients. &i#.l ~hal, S. Sears, Medica, Homestead, FL, Von Roenn*, R. Murphy, *Northwestern University, Chicago, JL, U.S~A. Th.B.P.310 Nutritional Abnormalities in Early HIV-1. Infection II: Trace Elements. Marianna K. Fordyce-Baum*, E. Mantero-Atienza, F. Van Riel, R. Morgan, R. S. Beach, * University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.S~A. 615 [Page 616](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/616) Warrier, J. I. Lybanon, R. Sharma, University School of Medicine, New Orleans, LA, U.SA. Th.B.P.312 Effect of Enteral Nutritional Therapy upon Body Cell Mass in AIDS. Robert Ferraro*, D. P. Kotler, P. Cuff, A. R. Tierney, S. Heymsfield, *St. Luke's-Roosevelt Hospital Center, New York, NY, U.SA. Th.B.P.313 Low Vitamin B6 Levels and Immune Dysregulation in HIV-1 Infection. Emilio Mantero-Atienza*, R. Beach, F. Van Riel, M. A. Fletcher, R. Morgan, C. Eisdorfer, et al., *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.SA. Th.B.P.314 Nutritional Knowledge, Health Beliefs, and Practices in the HIV Infected Patient. Emilio Mantero-Atienza*, M. Fordyce-Baum, F. Van Riel, R. Beach, *University of Miami School of Medicine, Department of Epidemiology, Miami, FL, U.SA. Th.B.P.315 The Role of Zinc in HIV-Induced Immunosuppression. Julian M. Falutz*, C. M. Tsoukas, G. Deutsch, *Montreal General Hospital, McGill University, Montreal, QC, Canada. Th.B.P.316 Functional Correlates of Decreased Serum Zinc in Human Immunodeficiency Virus (HIV) Disease. Julian M. Falutz*, C. M. Tsoukas, G. Deutsch, *Montreal General Hospital, McGill University, Montreal, QC, Canada. Th.B.P.317 Exocrine Pancreatic Function in Human Immunodeficiency (HIV) Infection in London and Kampala Patients. Moses S. Kapembwa*, S. C. Fleming, N. Sewankambo, G. E. Griffin, K. Caun, A. J. Pinching, et al., *St. George's Hospital Medical School, London, U.K. Th.B.P.318 Nutritional Status Parameters Associated with Psychosocial Well-Being Seen in AIDS/ARC Clients at an Outpatient Clinic in San Francisco. Bonnie Broderick*, J. K. Nesset, *Better Health Programs, San Francisco, CA, U.SA. SIDA buccal Oral AIDS Th.B.P.319 Single-Dose Therapy for Esophageal with A Pilot Vaudois, Division of Infectious Diseases, Lausanne, Switzerland. Th.B.P.320 Sites and Relative Prevalence of Hairy Leukoplakia, Pseudomembranous Candidiasis and Erythematous Candidiasis. Deborah L. MacPhail, S. Miyasaki, J. S. Greenspan, *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.SA. Th.B.P.321 Oral Findings in Patients with Asymptomatic HIV Disease. Engelbert Schulten*, R. W. Ten Kate, I. Van der Waal, *Free University Hospital, Department of Oral Pathology, Amsterdam, Netherlands. Th.B.P.322 Single-Dose Therapy for Oral Candidiasis with Fluconazole in HIV-Infected Adults. Angela Caiot*, Swiss Group for Clinical Studies on AIDS, *Centre Hospitalier Universitaire Vaudois, Division of Infectious Diseases, Lausanne, Switzerland. 616 [Page 617](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/617) Th.B.P.323 The Identification and Tracking of Candida Albicans Isolates from Oral Lesions in HIV-Seropositive Individuals. Shelley H. Miyasaki*, I. Polacheck, J. Hicks, D. Greenspan, J. S. Greenspan, *University of California at San Francisco, Oral AIDS Center, San Francisco, CA, U.SA. Th.B.P.324 Oral Mucosal Lesions in Infants of HIV+ve and HIV-ve Mothers. Peter Wanzala*, P. Datta, J. Pindborg, H. Kariuki, N. Kisumbi, *Kenya Medical Research Institute, Nairobi, Kenya. Th.B.P.325 Oral Mucosal Lesions and Lymphadenopathy in HIV-1 Seropositive Patients. Peter Wanzala*, F. Manji, F. Plummer, J. J. Pindborg, *Kenya Medical Research Institute, Nairobi, Kenya. Th.B.P.326 Erythematous Candidiasis: Early Clinical Manifestations in HIV-Reactive Patients. Pedro E. Cahn*, Z. Casariego, H. Perez, A. Early Marker of HIV-Disease Progression. Daniel X. Pagerols, A. Romeu, F. Gudiol, of Barcelona, Barcelona, Spain. Th.B.P.328 Itraconazole vs. Ketoconazole in the Treatment of Mucocutaneous Candidosis. Don E. Smith*, M. Allan, G. M. Connelly, J. Migley, B. G. *St. Stephen's Hospital, London, Th.B.P.329 Oral Candidiasis (OC) Determined by a Quantitative Method: Correlation to Marker of the Immunologic System. Andreas Plettenberg*, E. Reisinger, U. Lenzner, Kern, W. Meigel, *Allgemeines Krankenhaus St-Georg, Hamburg, Federal Republic of Germany. Melanotic Macules in Patients Infected with HIV-1. E. Adler-Storthz, D. Gaglioti, R. Di Pietro, *University of Florence, Division of Maxillofacial Surgery, Florence, Italy. Th.B.P.331 Local Destruction of Labial Surface of Mandibular Teeth by Direct Application of Cocaine in Drug Users with AIDS. Arthur M. Quart*, C. B. Small, R. S. Klein, *North Central Bronx Hospital, Albert Einstein College ofMedicine, Bronx, NY, U.S.A. Th.B.P.332 Immunohistochemical Studies of Oral Scratches in HIV-Infected Patients. R. O. A. Reichard, *Freie Universitat Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany. Th.B.P.333 Recurrent Oral Aphthae in HIV-Infected Homosexual Males. Francina I. Lozada-Nur*, M. Huang, S. Silverman, *University of California at San Francisco, School of Dentistry, San Francisco, CA, U.SA. Th.B.P.334 Fluconazole in the Treatment Just*, M. Frankfurt, Zentrum der Inneren Medizin, Th.B.P.335 Carriage of Oral Candida Albicans: Correlations with HIV Infections and Cellular Immunity in Heroin Abusers. Roberto Muga Bustamante*, J. Tor, R. Marc Pulik*, E. Oksenhendler, H. Lida, A. Gaulier, P. Clauvel, *Hopital V. Dupouy, Argenteuil, France. Th.B.P.337 Oral Pathology in HIV Infected Patients. Rita de Cassia Bertazzoli*, A. C. Rissi, R. C. Rissi, M. P. Lima, S. B. Bellucci, *Centro Corsini, Campinas, Sao Paulo, Brazil. Th.B.P.338 Correlation of HIV in Gingival Crevicular Fluid with HIV in Serum. James R. Winkler*, P. A. Murray, C. K. French, J. A. Lippke, K. K. Vaccaro, *University of California at San Francisco, Department of Stomatology, San Francisco, CA, U.SA. Th.B.P.339 An Immunohistochemical and Ultrastructural of V. Rienzo, of Infectious Diseases, Modena, Italy. Th.B.P.340 Oral Kaposi's Sarcoma: The Sequence of Appearance with Respect to Other AIDS Complications. Caroline L. Dodd*, D. Greenspan, G. Overby, D. W. Feigal, H. Hollander, J. S. Greenspan, et al., * University ofCalifornia at San Francisco, Department ofStomatology, San Francisco, CA, U.SA. Th.B.P.341 Clinical Aspects and Treatment Oral/Oropharyngeal Kaposi's Sarcoma. Sol Silverman*, G. Ficarra, F. Lozada-Nur, A. M. Berson, J. M. Quivey, C. A. Migliorati, et al., *University of California at San Francisco, San Francisco, CA, U.S.A. Th.B.P.342 Oral Hyperpigmentation Associated with HIV Infection. Angelika Langford*, Pohle, *Freie Universitdt Berlin, Department of Oral Surgery, Berlin, Federal Republic of Germany. Th.B.P.343 Oral Leukoplakia: Clinical Behavior and Treatment Results. Giuseppe Ficarra*, Gaglioti, M. Di Pietro, P. Paci, A. Ravina, *University of Division of Maxillofacial Surgery, Florence, Italy. Th.B.P.344 Salivary SLgA and HIV Infection. R. Raiteri, G. Marietti, *Institute Savoia\" Hospital, University of Turin, Turin, Italy. Th.B.P.345 Occurrence of Oral Pathology among Different Risk Groups of HIV Infected Patients. Stdphane De Wit*, I. Loeb, F. Prieels, N. Clumeck, *Division of Infectious Diseases, St-Pierre University Hospital, Brussels, Belgium. Th.B.P.346 Oral Manifestations of HIV Infection in Abidjan, C6te d'Ivoire. Sopiato Likimani*, K. DeCock, T. L. Green, J. S. Greespan, K. Odehouri, et al., *World Health Organization, Center for Disease Control, Abidjan, Ivory Coast. 618 [Page 619](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/619) Th.B.P.347 Natural History of HIV-Associated Salivary Gland Disease. Scid~ D. Greenspan, C. Dodd, D. Chernoff D. Wara, P. Leggott, et al., * University of California at San Francisco, Oral AIDS Center, San Francisco, CA, U.S~A. Th.B.P.348 Treatment of HJV+ Patients with Oropharyngeal and/or Qesophageal Candidiasis: The Results of a D.B. rto Esvosito*, C. Uberti Foppa, M. Cernuschi, *Clinic of Infectious Diseases of the University of Milan, Milan, Italy. Th.B.P.349 Carbon Dioxide Laser Treatment of Oral Kaposi's Sarcoma. ReelLJ Hadderingh*, F. W. Van der Meulen, * University of Amsterdam, Academic Medical Center, A msterdam, Netherlands. Th.B.P.350 Predominant Microflora of HIV-Related Periodontitis. Mazio Andriolo*, T. E. Rams, D. Feik, S. N. Abel, T. M. Mc~ivern, J. Slots, *St. Clare's Hospital and Health Center, New York, NY, U.S~A. Th.B.P.351. In Situ Characterization of the Inflammatory Infiltrate in HIV Associated Periodontitis. Mcae Ut 121*, P. A. Murray, J. R. Winkler, C. Williams, J. S. Greenspan, *University of California at San Francisco, OralAIDS Center, San Francisco, CA, U.SA. Th.B.P.352 Periodontal Disease in Heterosexual Patients with AIDS. Arthur M. Qygif\" C. B. Small, R. S. Klein, *North Central Bro nx Hospital, Albert Einstein College of Medicine, Bronx, NY, U.S.A. Th.B.P.353 Salivary Inhibition of HIV-1 Infectivity in Seronegative Men, Women, and Children and Seropositive Men. Phil C.o\" A. Wolff, C.-K. Yeh, J. C. Atkinson, B. J. Baum, *CIPCB, National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S~A. Th.B.P.354 Disinfection/S terilization Protocols Recommended by Impression Manufacturers. IL es QQ.LLQLtoeJ, P. Dinyarian, * University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S~A. Th.B.P.355 Fluconazole Lim*, C. A. Lee, M. Hales, M. O'Doherty, M. Winter, P. B. A. Kernoff, *Haemaphilia Centre and Haemostasis Unit, Academic Department of Haematology, Royal Free Hospital, London, U.K. Th.B.P.356 Oral Bacterial Flora: Role in the Infectivity of HIV. D.Ai4c..zk~vc\" Q. L. Liu, S. Gold*, J. J. Guinan, A. Morlet, L. Virtue, *Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. Th.B.P.359 Evolution of the CD4 4B4 and CD4 M. Canill, F. Zech, M. Omar, P. Fernez, et al., *Department of Internal Medicine, St-Luc University Hospital, Brussels, Belgium. 619 [Page 620](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/620) Th.B.P.360 Intra Laboratory Evaluation of a Cryoprotected Doubled Preparation for Flow Cytometry. Fr Bergeron, B. McCulloch, M. V. O'Shaughnessy, *Bureau of Laboratories and Research Services, Health and Welfare Canada, Ottawa, ON, Canada. Th.B.P.361 A Rapid Verification of Monocyte Enrichment/Depletion Technique Utilizing Flow Cytometry. Francis Mandv*, A. Sherring, V. M. O'Shaughnessy, *Bureau of Laboratories andResearch Services, Health and Welfare Canada, Ottawa, ON, Canada. Th.B.P.362 Leukoagglutination in Patients with Hemophilia. Guillermo Felippo, E. Rickard, Bianco, M. M. Medicina, Buenos Aires, Argentina. Th.B.P.363 Blood-Brain-Barrier Total IgG Synthesis in Patients with Human Immunodeficiency Virus Infection. Atm ndo5.ea\"~, V. Sena, F. Lisbon, Th.B.P.364 Incidence of Autoantibodies in HIV Infection. Pierre Dellamonica*, J. F. Q2uaranta, M. De Matteis, C. cours de l'infection par VII. Christiane Caudie*, A. France. Th.B.P.366 Study of Predisposing Factors on the Susceptibility of Individuals to Infection by HIV. D.Ai A dkv*c, Q. L. Liu, R. Phase of the HIV-1 Infection. Vlastimil Maver*, P. Schmidtmayerovd, Academy of Sciences, Bratislava, Czechoslovakia. Th.B.P.368 HIV-1 IgG Antibodies in Breast Milk: Detection Methods and Correlation with Serum Markers. A4dreaJL RiffP, H. Farzadegan, J. Marzouka, R. Buolos, A. Saah, N. Halsey et al., *Johns Hopkins University, School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S~A. Th.B.P.369 Comparison of Eight Anti-HIV Enzymeimmunoassays, 3 HIV Antigen and Two Westemn Blots on a Seroconverter Panel. Allison Imzk*\", D. A. Cooper, *Center for Immunology, St. Vincent's Hospital, Sydney, Australia. Th.B.P.370 Detection of HIV Antigen and HIV Core Antibody During Seroconversion. Allison A. Imrie*, D. A. Cooper, G. Doherty, *Center for Immuno~logy, St. Vincent's Hospital, Sydney, Australia. Th.B.P.371 Sensitive Detection of HIV-1 Antibody with a Peptide-B ased ELISA in Two Seroconversion Panels. MartialLacroix*, Th.B.P.372 Immunocompetent Cells in Livers of Children with AIDS. M. Alba Greco*, P. A. Thomas, E. Kahn, M. Magid, V. Mahnovski, V. Anderson, *New York University, Department of Pediatric Pathology, New York, NY, U.S.A. Th.B.P.373 Serial Immunologic Studies as an Indicator of Progression to AIDS in a Cohort of Male Sexual Partners of Men with HIV Disease. Stanley E.Read*, R. Coates, V. Farewell, M. Klein, D. MacFadden, L. Calzavara, et al., *Hospitalfor Sick Children, Toronto, ON, Canada. Neurologle Neurology Th.B.P.374 Neurological Manifestations in Patients with Human Immunodeficiency Virus Infection. Beng T. Goh*, S. Estreich, G. E. Forster, C. Kennard, M. Swash, *The London Hospital, London, UK. Th.B.P.375 AIDS-Related Neurological Illness in Two U.S. Cities: A Comparison of Similar Populations. Rober M. Levy*, S. Grohmann, D. Bredesen, M. Rosenblum, B. Cohen, J. Von Roenn, et al., *Northwestern University Medical School, Chicago, IL, U.S.A. Th.B.P.376 Impaired Motor Performance of HIV-1 Infected Patients Is not Due to Simple Fatigue. John G. Keilp*, A. E. Sadler, L. Wolf, B. J. Brew, R. W. Price, J. J. Sidtis, *Memorial Sloan-Kettering Cancer Center, Department ofNeuropsychology, New York, NY, U.S.A. Th.B.P.377 Expressions neuropyschiatriques du SIDA au S6n6gal. L. Nutrition Nutritional Factors Associated with AIDS. Sally A. Zumwalt*, R. M. Schmidt, *Pacific Presbyterian Medical Center, Center for Preventive Medicine andHealth Research, University ofSan Francisco, San Francisco, CA, U.S.A. Th.B.P.379 The Challenge of Nutritional Care of Patients with AIDS. Sonia A. Chrvsomilides*, *St. Paul's Hospital, Vancouver, BC, Canada. Th.B.P.380 Nutritional Aspects of AIDS Patients in an Inner City Clinic. Jihad Slim*, C. Forrester, S. Koller, G. Perez, E. Perez, *Saint Michael's Medical Center, Newark, NJ, U.S.A. Th.B.P.381 Dietary Intervention in Kaposi's Sarcoma Patients. Barry Sears*, (Biomedical) Role Bahraoui, *H6pital de la Pitid-Salpe^tridre, Paris, France. Th.C.P.2 High Level Expression of Native Reverse Transcriptase and Mutants Affecting the Enzyme Activity. Erwin Soutschek*, M. H. Wolf, *Max von Pettenkofer Institute, Ludwig Maximilian University, Munich, Federal Republic of Germany. Th.C.P.3 HTLV-I Binds not only to Human T Lymphocytes, but also to B Cells and Monocytes. Subhash Dhawan*, P. Casali, H. Z. Streicher, L. M. Wahl, A. L. Notkins, *National Institute of Dental Research, National Institutes of Health, Bethesda, MD, U.S.A. Th.C.P.4 Protease Activation during HIV Infection in a CD4 Positive Cell Line. Giuseppe Piedimonte*, P. G. Petronini, Instituto di Patologia Generale, Parma, Italy. Th.C.P.5 Concomitant Infection with Human T Cell Lymphotropic Virus II (HTLV-II) and HIV-1. William W. Hall*, M. H. Kaplan, M. Coronesi, S. Z. Salahuddin, N. Oyaizu, K. Nagashima, et al., *North Shore University Hospital, Division of Infectious Diseases, Manhasset, NY, U.S.A. Th.C.P.6 Envelope Cross-Reactivity between HIV-1 Bacteriological Laboratory, Department oflmmunology, Stockholm, Sweden. Th.C.P.7 Prospective Study of Newborns to HIV Seropositive Mothers: Prognostic Value of Antigenemia and Antibodies Western-Blot M. J. Mayaux, C. Jacomet, S. Blanche, C. Griscelli, French HIV Infection Newborns Collaborative Study *Laboratoire microbiologie, J. Launay, *Swiss National Center of Retroviruses, University of Zurich, Zurich, Switzerland. 622 [Page 623](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/623) Th.C.P.9 The HIV-1 Production in Peripheral Blood Mononuclear Cells is Inhibited by Anti-B2 Microglobulin Monoclonal Antibodies. Pierre Corbeau*, C. Devaux, F. Kourilsky, J. F. Schulz, K. Moelling, M.-T. Knoop, *Institute for Cancer Research, London, U.K. Th.C.P.11 Isolation of HIV-2 Strains with Different Neutralization Patterns. Thomas F. Schulz*, D. Whitby, H. Whittle, R. A. Weiss, *Chester Beatty Laboratories, Institute for Cancer Research, London, U.K. Th.C.P.12 Inhibition of Envelope Oligosaccharide Processing Diminishes N. Vander Heyden, Ratner, U.S.A. Th.C.P.13 1,25(OH)2 Vitamin D3 (1,25D) Enhances HIV-1 Replication in a Monocyte Cell Line. Paul R. Skolnik*, M. Wang, T. Rota, S. Krane, M. Hirsch, *New England Medical Center, Tufts University, Division of Infectious Diseases, Boston, MA, U.S.A. Th.C.P.14 Stimulation of HIV Expression in B Lymphocytes by B Cell Growth Factor. Phalguni Gupta*, P. Thampatty, R. Balachandran, C. R. Rinaldo, *University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, U.S.A. Th.C.P.15 Cellular Control but not Entry Down-Regulate HIV-1 Expression in Neural Cells. Yaffa Mizrachi*, F. Sinangil, D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A. Th.C.P.16 Latent/Induced Expression of HIV-1 in Glial Cells. Helen Shahabuddin, Y. Mizrachi, D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A. Th.C.P.17 Differences among HIV Isolates in Cellular Entry and Fusogenicity as Measured by Fluorescence Dequenching D. J. Volsky, *St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, U.S.A. Th.C.P.18 The Role of the vpu Gene in HIV-1 Life Cycle. Zene Matsuda*, M. Matsuda, M. Essex, T. H. Lee, *Harvard School of Public Health, Department of Cancer Biology, Boston, MA, U.S.A. Th.C.P.19 Molecular Interactions between HHV-6 and HIV-1 in Coinfected CD4+ T-Cells Lead to Increased HIV-1 Gene Expression. Barbara Ensoli*, P. Lusso, F. Schachter, J. Rappaport, S. Josephs, F. Wong-Staal, et al., *Laboratory ofTumor Cell Biology, National Cancer Institute, National Institutes ofHealth, Bethesda, MD, U.S.A. Th.C.P.20 Induction of Human Immunodeficiency Virus Expression by Ultraviolet Light. Reza M. Sadaie*, E. Tschachler, K. Valerie, M. Rosenberg, G. N. Pavlakis, F. Wong-Staal, et al., *Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A. 623 [Page 624](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/624) Th.C.P.21 Isolation of HIV in a HIV-1-HIV-2 Dual Seroconverted Child Infected by Blood Transfusion in 1984 in France: Characterization with PCR. Christine ROUZi~oux*, M. Burgard, V. France. Th.C.P.22 Binding Characteristics of III-1 and HIV-2: Differences in Binding Inhibition by Soluble CD4 and Dextran Sulfate. Dai.Loe\" H. Mitsuya, G. Franchini, S. Broder, R. Redfleld, F. Wong-Staal, * Walter Reed Army Institute of Research, Division of Retrovirology, Rockville, MD, U.S~A. Th.C.P.23 Characterization of nef Genes from SIN and 1{IV-2. Harry W. Kestler*, Y. Li, M. D. Daniel, C. V. Butler, R. C. Desrosiers, *New England Regional Primate Research Center, Harvard Medical School, Southbo rough, MA, U.S.A. Th.C.P.24 In Situ Hybridization Analysis of HIV RNA Induction in Ul Cells Treated with Phorbol Ester. Maulrice J. Rosenstraus*, H. Russo, W. Maltzman, B. Sellers, A. Saunders, J. Laurance, *Enzo Bi'ochem Inc., New York, NY, U.S.A. Th.C.P.25 Non-Radioactive Immunoprecipitation Confirmatory Test for Virus. Chn-hi a\" S. Alexander, E. Lilleho], R. C. Ting, *Biotech Research Laboratories Inc., Rockville, MD, U.S.A. Th.C.P.26 Purification of HIV in an Aqueous Two-Phase System Retains the Infectious Titer and Gives a Yield of gpl2O. Lena Hammar*, G. Gilljam, Sweden. Th.C.P.27 Complementation of HIV-1 rev mutants by rex Protein of HThV-1 but not by rex of BLV. Barbara K. Felbe r*, D. Derse, A. Athanassopoulos, G. N. Pavlakis, *Natjopgjl Cancer Institute, Frederick Cancer Research Facility, BRI-Basic Research Program, Frederick, MD, U.S.A. Th.C.P.28 Analysis of Unintegrated Viral DNA and Cytopathic Effect (CPE) Induced by HIV. Takao Masuda*, S. Harada, *Kyoto University, Institute for Virus Research, Kyoto, Japan. Th.C.P.29 Interferons (IFN) and Bacterial Lipopolysaccharide (LPS) Prevent by Blocking Provinis Formation. Rkbha4 &K. airnlLL~th, P. S. Oh, I. R. Munis, P. H. Cleveland, D. D. Richman, * University ofCalfornia atSan Diego, and the VeteransA dministration Medical Center, La Jolla, CA, U.S.A. Th.C.P.30 Characterization of HTLV-1 Cell Lines Derived from U.S. Patients with Spastic Paraparesis. Michael D. Lairmore*, B. K. De, R. Khabbaz, R. Janssen, J. Kaplan, T. Folks, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. Th.C.P.31 Generation of Hybrid Immunodeficiency Viruses. Alagarsamv Srinivasan*, S. Kalyanaraman, S. M. Desai, S. G. Devare, J. Jannoun-Nasr, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. 624 [Page 625](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/625) Th.C.P.32 Factors Influencing Homologous Recombination between HIV DNAs in Cultured Human Cells. Alagarsamv Srinivasan*, S. Kalyanaraman, R. Jannoun-Nasr, R. Baine, J. Benson, D. Swan, *Centersfor Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. Th.C.P.33 Localization of the Defect in HIV Proviral DNA by Homologous Recombination. Alagarsamv Srinivasan*, S. Kalyanaraman, D. Butler, R. Jannoun-Nasr, D. York, B. De, *Centers for Disease Control, Retrovirus Diseases Branch, Atlanta, GA, U.S.A. Th.C.P.34 Human Antibodies to HIV-1 gp160 Inhibit Attachment to CD4. Nicole K. T. Back*, C. Thiriart, L. Van Der Hoek, C. Bruck, J. Goudsmit, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands. Th.C.P.35 Distinction between HIV-1 and HIV-2 Infection Using Antibody Response to Accessory Gene Products. Jaap Goudsmit*, T. Dekker, C. Boucher, A. De Ronde, C. Debouck, F. Barin, *AMC, Department of Virology, Human Retrovirus Laboratory, Amsterdam, Netherlands. Th.C.P.36 Expression of Eight Human Immunodeficiency Virus Genes in Escherichia Coli for Use in Diagnostic Tests. Sushil G. Devare*, S. Desai, J. Casey, R. Aneja, D. Kramer, K. Rupprecht, et al., *Abbott Laboratories, Abbott Park, IL, U.S.A. Th.C.P.37 Discrimination of HIV-2 Infection by Western Blot and Radioimmunoprecipitation Analysis (RIPA). Timothy J. Holzer*, R. G. Allen, C. A. Heynen, M. M. Kennedy, D. A. Paul, G. J. Dawson, *Abbott Laboratories, North Chicago, IL, U.S.A. Th.C.P.38 Pseudotypes of Human Immunodeficiency Virus (HIV) with the Envelope of Vesicular Stomatitis Virus (VSV) or Herpes. Steve Chen*, Z. Zhu, A. S. Huang, *The Children's Hospital, Division of Infectious Diseases, Boston, MA, U.S.A. Th.C.P.39 HIV Positive Sera Identified with Synthetic Peptide Analogs of env, gag, tat, and nef. Dale A. McPhee*, S. Cumming, B. Kemp, R. Doherty, *Fairfield Hospital, NHMRC Special UnitforAIDS Virology, Fairfield Hospital, Fairfield, Australia. Th.C.P.40 HIV-1 Infection on Human Monocytes is Inhibited by Antisera to HIV-1 or by LPS Activation of the Cells. David A. Katzenstein*, S. A. Grace, E. W. Carrow, P. Vial, D. S. Webb, G. V. Quinnan, *Food and Drug Administration, Laboratory of Retrovirus Research, Division of Virology, Centerfor Biologics Evaluation and Research, Bethesda, MD, U.S.A. Th.C.P.41 Growth Kinetics of HIV in HTLV-I Transformed Cells. Rosemary E. Kiernan*, D. A. McPhee, J. A. Marshall, R. R. Doherty, *NHMRC Special Unitfor AIDS Virology, Fairfield Hospital, Fairfield, Australia. Th.C.P.42 Monoclonal Antibody Identifies a Conserved Epitope of the HIV-1, HIV-2 and HTLV-I Core Proteins. Chi-Ming Liang*, S. Henry, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A. 625 [Page 626](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/626) Th.C.P.43 Role of Oligosaccharides on the Processing Glycoproteins from Human T-Cell Lymphotropic Retroviruses. Ranajit Sarngadharan, *Bionetics Research, Inc., Rockville, MD, U.S.A. Th.C.P.44 Mapping of the Immunoreactive Epitopes of the HIV-1 Endonuclease Protein by Means of Recombinant Proteins. Cristina Vinga-Martins*, N. *Klinikum des Mikrobiologie und Hygiene, Homburg/Saar, Federal Republic of Germany. Th.C.P.45 A Human Monoclonal Antibody against Envelope Glycoprotein of HIV-1 Enhances HIV-1 Infection In Vitro. W. Edward Robinson*, D. Lake, D. C. Montefiori, Y. Masuho, T. Kawamura, W. M. Mitchell, et al., *Vanderbilt University Medical Center, Department of Pathology, Nashville, TN, U.S.A. Th.C.P.46 Correlation Study Involving the Detection of HIV-1 in Samples from AIDS Patients Using Co-Culture, p24 ELISA, and TAS- and PCR Gingeras*, J. D. Richman, G. R. Davis, *The Salk Institute Biotechnology/Industrial Associates, Inc., La Jolla, CA, U.S.A. Th.C.P.47 Expanded Host Range of HIV Acquired through Modification of gp 120. Deborah Seto*, C. Cheng-Mayer, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. Th.C.P.48 Replication of HIV-1 in a Variety of Animal Fibroblast Cells Using Phenotypically Mixed Viral Particles. Martine Canivet*, A. Hoffman, D. Hardy, J. Sernatinger, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. Th.C.P.49 The Antibody Response to Immunodeficiency Virus: Neutralization vs. Enhancement. Jacques Homsv*, M. Meyer, C. Cheng-Mayer, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.SA. Th.C.P.50 Are There Multiple Strains of HIV in an Infected Individual? Li-Zhen Pan*, J. A. Levy, C. Cheng-Mayer, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. Th.C.P.51 Parameters Involved in the Cell Fusion Induced by the Human Immunodeficiency Virus. Shen-Bei Tang*, J. A. Levy, *University of California at San Francisco, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. Th.C.P.52 Growth of HIV-1 and T Cell Subsets in Sequential Blood Samples Taken from a HHV-6 Patient before, during, and after Infection. Paul M. Feorino*, D. Warfield, K. Sanderlin, Grewe*, H. R. Gelderblom, *Robert Koch Institute, Berlin, Federal Republic of Germany. 626 [Page 627](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/627) Th.C.P.54 Characterization of Proteins Associated with Two Novel Retroviruses Isolated from AIDS-Associated Lymphoma Tissue. YaklereI..LVg*, F. Khayam-Bashi, J. Marsh, M. S. Mccrath, * University of Calijfornia at San Francisco, San Francisco General Hosp ital, San F~rancisco, CA, US A. Th.C.P.55 Diagnosis of HIV-2L or HIV-1/HIV-2 Double Infection with Synthetic Peptides as an Additional Confirmatory Assay. Cees L. Van der Poel*, N. Lelie, H. Reesink, M. Cot, H. Hutisman, *Red Cross Blood Bank, Amsterdam, Netherlands. Th.C.P.56 Superinfection with Infectious lil-i of Defective lIlY-i Producing Cell Clones. Kazuvoshi Ikuta*, M. Yunoki, H. Imai, S. Miyake, K. Hirai, S. Kato, *OsaJka University, Osaka, Japan. Th.C.P.57 Association of Human Herpes Virus 6 (HHV6) and HIV Infections in Africa. DailA ct\" N. T. Constantine, *US Naval Medical Research Unit No. 3, WHO Collaborating Centre for AIDS, Cairol, Egypt. Th.C.P.58 SI~smm: A Possible Progenitor of frin.Li*F, Y. M. Naidu, H. W. Kestler, P. Fultz, M. D. Daniel, R. C. Desrosiers, \"Hrvr Medical School, New England Regional Primate Research Center, Southborough, MA, U.S~A. Th.C.P.59 Mapping of Seven HIV-i Anti-p24 Monoclonals Using a Series of Overlapping Peptides. R. Bridget Ferns*, J. C. Partridge, R. S. Tedder, R. P. Spence, * University College and Middlesex Medical School, Department of Medical Microbiology and Virology, London, U.K. Th.C.P.60 Lectin Binding Pattern of HIV Envelope Glycoprotein. Tohn-Erik ~1Lansen*, C. M. Nielsen, C. Nielsen, P. Heegaarrd, L. Mathiesen, J. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. Th.C.P.61 Inhibition of Syncytium Formation with Lectins. John-Erik S. Hansen*, C. M. Nielsen, C. Nielsen, P. Heegaard, L. Mathiesen, J. Nielsen, *Hvidovre Hospital, Department of Infectious Diseases, Hvidovre, Denmark. Th.C.P.62 Electron Microscopic Evidence for Coinfection and Replication of Herpesvirus and HIV-l in the Same N. Iyer, MA, U.S~A. Th.C.P.63 Co-Infection of a Human T-Lymphocyte Cell Line with HIV-l and a Newly Identified Virus-like Infectious Agent (VLIA). Dennis M.j4{Pjjg, J. B. Benish, S. C. Lo, *Armned Forces Institute of Pathology, Was~hington, DC, U.S~A. Th.C.P.64 Chemical Inducers of Cell Differentiation Inhibit HIV Replication In Vitro. Dimitri Viza*, A. Aranda-Anzaldo, D. Ablashi, S. Z. Salahuddin, * Universit6' de Paris V, Facult6 de rn~decine, Paris, France. Th.C.P.65 Brain and Blood HIV-l Isolates from the Same Individual Have Different Biological Properties. Carol D. Weiss*, C. Cheng-Mayer, D. Seto, J. A. Levy, * University of California, School of Medicine, Cancer Research Institute, San Francisco, CA, U.S.A. 627 [Page 628](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/628) Th.C.P.66 Inhibition Th.C.P.67 HIV Down-Regulates Its Receptor Two Different Mechanisms. Patrick Salmon*, R. Y. Rividre, Th.C.P.68 Productive HIV-1 Infection of Hepatocellular Carcinoma Cell (HCC) Lines In Vitro. Yunzhen Cao*, A. E. Friedman-Kien, Y. X. Huang, X. L. Li, M. Mirabile, D. Zucker-Franklin, et al., *New York University Medical Center, New York, NY, U.S.A. Th.C.P.69 Quantification and Cellular Distribution of HIV Proviral DNA in Buffy Coats from HIV Seropositive Haemophiliacs. Peter Simmonds*, J. F. Peutherer, A. J. Leigh-Brown, J. O. Bishop, C. A. Ludlam, * University of Edinburgh, Department of Genetics, Edinburgh, U.K. Th.C.P.70 HIV-1 DNA Sequences Detected by PCR in Seronegative, yet Anti-nef Positive, Individuals. Laure*, *CHU Paris, France. Th.C.P.71 Sequence Analysis of a Highly Cytopathic Strain of HIV- 1: Correlation between Biological and Genomic Marseille, France. Th.C.P.72 Susceptibility to HIV-1 Infection a Human B-lymphoblastoid Cell Line, DG75, Transfected with Subgenomic DNA Fragments. D. S. Josephs, Z. Salahuddin, *Hebrew University, Jerusalem, Israel. Th.C.P.73 Processing of gag and pol Polypeptides as In Vitro Model for Protease Inhibition Studies in Eucaryotic Target Ludwig Maximilian University, Munich, Federal Republic of Germany. Th.C.P.74 Biological and Molecular Pattern of Different HIV Isolates from Zidovudine (AZT) Treated and Untreated AIDS Patients. Alfredo A. Garcia-Salz*, A. Bernal, L. Muiioz, S. Sanchez-Palomino, J. M. Rojas, Ndjera, s6quentiels des Archinard, Virologie, URA CNRS, Tours, France. Th.C.P.76 Differential Susceptibility to AZT of HIV-1 Variants Grown in EBV-Transformed B Cell Lines. Michel Tremblay*, M. A. Wainberg, *Lady Davis Institute, Montreal, QC, Canada Th.C.P.77 Molecular Characterization of Two Non-Infectious HIV-1 Isolates. Stdphane Bour*, F. B. Boulerice, A. V. Lvovich, M. A. Wainberg, *Jewish General Cot*, M. Barrd-Sinoussi, *Diagnostics Pasteur, Marnes-la-Coquette, France. Th.C.P.79 Dideoxynucleosides Prevent Formation of Provirus during Single Infection of Macrophages. James R. Munis*, R. S. Kornbluth, D. D. Richman, *Veterans Administration Medical Center, Infectious Diseases, San Diego, CA, U.S.A. Th.C.P.80 Quantification of gpl60 from HIV by a \"Capture\" ELISA. Lennart S. Akerblom*, T. Fridberger, M. Villacres, *Swedish University of Agriculture Science, Department of Veterinary Microbiology, Section of Virology, Uppsala, Sweden. Th.C.P.81 Sequencing of PCR-amplified HIV-1 Related Sequences Found in the DNA of Insects from Central Africa. Maurice L. J. Moncany*, L. Montagnier, J. L. Becker, *Unitd d'Oncologie virale, Paris, France. Th.C.P.82 Improved Assays Polymerizing Enzymes, by the Use of 5-125 I-Iododeoxyuridine Triphosphate, Illustrated by Direct Quantification of HIV-RT Antibody (AB). J. Simon Gronowitz*, M. Neumiiller, A. R. Karlstrdm, C. F. R. Kallander, *University of Uppsala, Department of Medical Virology, Uppsala, Sweden. Th.C.P.83 Multiple Sclerosis and Retrovirus: Screening with Retroviral Probes of a cDNA Library Constructed with Poly A+ RNA from Active Lesions. Suzie Lefebvre*, J. F. Bureau, S. Chirinian, M. Single-Tube, One-Step Purification and Assay for the Analyses of Reverse Transcriptase Activity (RT) in Crude Specimens and Some Applications with Reference to HIV. J. Simon Gronowitz*, M. Neumilller, R. Bhikhabhai, T. Unge, C. F. R. Kdllander, *University of Uppsala, Department of Medical Virology, Uppsala, Sweden. Th.C.P.85 Characterization of an HIV-2 Related Virus with a Smaller Sized Envelope Precursor. Bernard Krust*, M. A. Rey, A. G. Laurent, D. Guitard, L. A. G. virale, Paris, France. Th.C.P.86 New Tests Using Synthetic Peptides in the Diagnosis and Typing of HIV Infections in Humans. Jacques Martin*, S. Bettinger, D. Adda, P. K. Tsai, C. Richardson, G. Somme, *CLONATEC, Paris, France. Th.C.P.87 Infection and Replication of HIV-1 in Human Broncho-Alveolar and Peripheral Blood Monocytes-Macrophages. Marie Suzan*, D. Salaun, G. Hans-Jiirgen Stellbrink*, R. 629 [Page 630](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/630) Th.C.P.89 Expression of Viral and Cellular Genes in Cells Infected by the Human Immunodeficiency Virus, LII-1 and the Simian Immunodeficiency Virus, SIV/Mne. Mic1e G.Ktz\" W. R. Morton, R. E. Benveniste, K. Foy, L. Corey, M. Agy, * University of Washington, Department of Microbiology, Primate Research Center, Seattle, WA, U.S~A. Th.C.P.90 Identification of HIV-1 Packaging Signals. Andrew M. L. Lever*, H. Gottlinger, W. Haseltine, J. Sodroski, *Dana47arber Cancer Institute, Boston, MA, U.S~A. Th.C.P.91 Differential Inhibition of HIV Variant Induced Syncytium AreRbnti\" E. Steinhauer, R. Sangsakphisarn, 0. Einstein College of Medicine, Bronx, NY, U.S~A. Th.C.P.92 HIV-1 Infection of Human Monocyte Cultures: Implications for Silent Infection. Antonio Valentin*,.J. Albert, E. M. Feny6\", B. Asj6\", *Karolinska Institute, Department of Virology, Stockholm, Sweden. Th.C.P.93 Effect of Calcium Channel Blocker on HIV-1 Expression in Lymphoid Cells. Mary A. Harbison*, S. Kim, D. Baltimore, S. Hammer, *New England Deaconess Hospital, Infectious Diseases Section, Boston, MA, U.SA. Th.C.P.94 A Rapid and Sensitive Plaque Assay of HI V-i on C8166 Cells. Kezwncih Mclntosh*, Z. Zhu, S. Chen, R. A. Weiss, *Children's Hospital, Boston, MA, U.S~A. Th.C.P.95 Processing and Assembly of HIV-1 Core Antigens Expressed by Recombinant Vaccinia Virus. Shui-Lok Hu*~, B. M. Travis, P. J. Garrigues, *Oncogen, Seattle, WA, U.SA. Th.C.P.96 Characterization of HIV-1 Proteins Expressed by Vaccinia Virus and E. Coli. Atsushi A. Yasucda*, A. Kojima, Okamoto, J. Chiba, Co., Ltd., Kawasaki -S hi, Japan. Th.C.P.97 HIV-1 Specific Antibodies in Cerebrospinal Fluid Mediate Cellular Cytotoxicity and Neutralization. Francesca Chiodi*, K. Ljunggren, P. Norkrans, M. Jondal, E. M. Feny3\", *Krlnk Institute, Department of Virology, Stockholm, Sweden. Th.C.P.98 In vitro, une heure d'exposition a une micromole d'AZT France. Th.C.P.99 Detection of the nef Cellular Protein by Synthetic Monoclonal Antibody from HIV Infected Subjects. Mgj.L Pezzelha~, A. M. Anastasi, N. Vonesch, S. D. DeSantis, \"La Sapienza\", Institute Infectious J. L. Spouge, M. Dembo, * University of California, Los Alamos National Laboratory, Los Alamos, NM, U.S~A. 630 [Page 631](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/631) Th.C.P.101 Host Cell Tropism of HIV Strains: Comparison of Replication in Peripheral Blood Lymphocytes and Monocyte-Derived Macrophages. Ronald G. Collman*, H. Friedman, S. Douglas, R. Walker, N. Hassan, B. Godfrey, et al., *University of Pennsylvania Medical Center, Philadelphia, PA, U.S.A. Th.C.P.102 Specificity of Murine Antibodies towards Epitopes of HIV-1. Rula F. R. Khuzaie* A. Bernatowicz, S. Pingel, H. J. Streckert, *Ruhr University, Department of Medical Microbiology and Virology, Bochum, Federal Republic of Germany. Th.C.P.103 Single Amino Acid Substitutions Identify Amino Acids Critical for RNASE H Activity and Replication of HIV. Francois Clavel*, R. Repaske, T. D. Maudru, *National Institutes of Health, Bethesda, MD, U.S.A. Th.C.P.104 HIV Detection in Plasma of Patients with Retrovir. WeiLuc*, A. Venet, J. M. Andrieu, D. Israel-Biet, J. M. Tourani, M. Stern, et al., *Hdpital Lainnec, Paris, France. Th.C.P.105 HTLV-I Antibody Screening in IV Drug Misusers, Haemophiliacs, Homosexuals and Blood Donors in Edinburgh, Scotland. Sheila M. Burns*, F. D. Hargreaves, P. L. Yap, A. Jordan, J. Tosswell, G. Leadbetter, et al., *Regional Virus Laboratory, City Hospital, Edinburgh, U.K. Th.C.P.106 The Killing Effect of 65C Temperature on HIV-1 in Dried Blood: Decontamination of Lab Instruments/Equipment. Homayoon Farzadegan*, W. B. Tepper, P. Goldenbaum, A. Saah, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. Th.C.P.107 Fusions of Simian Immunodeficiency Virus (SIVmac) with Ghosts. Charles E. Larsen*, D. R. Alford, L. Young, K. D. Lee, T. McGraw, N. Diizgiines, *University of California, Cancer Research Institute, San Francisco, CA, U.S.A. Th.C.P.108 Monoclonal Antibodies to HTLV-I and HTLV-II gag Proteins. Cathy L. Heffner-Barrett*, A. J. Bodner, S. Alexander, Z. Salahuddin, M. Lipsky, A. Corrigan, *Biotech Research Laboratories Inc., Rockville, MD, U.S.A. Th.C.P.109 Additional Characterization of Unusual Human Immunodeficiency Isolates from Two Cameroonians (ANT 70 and ANT 70 NA). Robert J. De Levs*, B. Vanderborght, L. Brys, M. Vanden Haeselvede, H. Van *Innogenetics N.V., Antwerp, Belgium. Th.C.P.110 Expression of the gag/pol Gene Products of Human Immunodeficiency Virus by Recombinant Vaccinia Virus Vector. Tatsuo Shiodq*, K. Hirose, H. Sawada, H. Shibuta, *University of Tokyo, Institute of Medical Science, Tokyo, Japan. Th.C.P.111 Detection of HIV Genome in Seronegative Homosexual Men. Mario Pezzella*, E. S. Sturchio, P. C. F. Cordiali-Fei, N. V. Vonesch, E. G. Gentili, F. C. Caprilli, *University of Rome \"La Sapienza\", Institute of Infectious Umberto I, Rome, Italy. 631 [Page 632](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/632) Th.C.P.112 A Quantitating Infectious HIV Particles. Enok Tita*, B. Grinde, *National Institute of Public Health, Department of Virology, Oslo, Norway. Th.C.P.113 Diminutive Utilization of CD4 Entry Pathway for Infection by Putative Neuropathic HIV-1 Isolates. Rita Anand*, S. Nayyar, *National Institute of Mental Health, St. Elizabeth's Research Hospital, Washington, DC, U.S.A. Th.C.P.114 Viral Gene Expression Assessed by PCR in HIV-1 Infected H9 Cells. Indira K. Hewlett*, M. Ruta, S. J. Geyer, C. A. Hawthorne, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Center for Biologics Evaluation and Research, Bethesda, MD, U.S.A. Th.C.P.115 Purification and Analysis of the HTLV-I Envelope Glycoprotein gp46 Using an Anti-Carboxyl-Terminal Synthetic Peptide Serum. Erik Lillehoj*, N. Nguyen, C. Tai, S. Alexander, *Biotech Research Laboratories, Rockville, MD, U.S.A. Th.C.P.116 Biological Heterogeneity among HIV-1 Isolates. Barbara E. Moore*, A. R. Hart, M. W. Cloyd, *University of Texas, Medical Branch, Department of Microbiology, Galveston, TX, U.S.A. Th.C.P.117 Clonal Heterogeneity of HIV-1 Bour, R. Geleziunas, M. A. Wainberg, *Lady Davis Institutefor Medical Research, Jewish General Hospital, Montreal, QC, Canada. Th.C.P.118 A Rapid, Direct Assay for Reverse Transcriptase Activity in HIV-Infected Cell Culture Supernatants. Sharon J. Geyer*, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Retrovirology, Bethesda, MD, U.S.A. Th.C.P.119 Simultaneous Detection of HIV-1 and HTLV-I Infections by Co-Amplification Using PCR. Martin Ruta*, I. K. Hewlett, C. A. Hawthorne, J. S. Epstein, *Food and Drug Administration, Division of Blood and Blood Products, Bethesda, MD, U.S.A. Th.C.P.120 Variability of HIV-1: Computer Analysis of Data Base. Hirofumi poi, Division of Biological Information Science, IIAS-SIS, Fujitsu Ltd., Ohta-ku, Japan. Th.C.P.121 Development of a Novel Quantitative Assay to Study Membrane Fusion Mediated by gpl20/gp41. M. Bud Nelson*, Y.-H. Zhang, D. Rekosh, M.-L. Hammarskjdld, *State University of New York at Buffalo, Departments of Biochemistry and Microbiology, Buffalo, NY, U.S.A. Th.C.P.122 Expression and Characterization of HIV-1 Envelope Proteins Synthesized from a SV40 Vector. Bijrn P. Hammarskiald*, M.-L. Hammarskj6ld, D. Rekosh, M. B. Nelson, *State University of New York at Buffalo, Departments of Biochemistry and Microbiology, Buffalo, NY, U.SA. Th.C.P.123 Purified Reverse Transcriptase (RT) from HIV-1, HIV-2 and EIAV Share Structural and Immunologic Properties. Anthony L. DeVico*, T. Copeland, S. Oroszlan, R. R. Cloning, Preliminary Characterisation and Expression of Gene Fragments of a European HIV-2 Isolate (ANT 53). David Parker*, M. Vanden Haesevelde, B. Vanderborght, A. Driver, *Wellcome Diagnostics, Beckenham, U.K. Th.C.P.125 Kinetics of Appearance and Specificity of Neutralizing Antibodies in Patients with Primary HIV Infection. Jan Albert*, K. Ljunggren, K. Nagy, B. Abrahamsson, E. M. Feny6, *National Bacteriological Laboratory, Stockholm, Sweden. Th.C.P.126 Evaluation of Three Methods for HIV Detection in Culture in Haemophilia-A Patients. Selma Rebus*, D. Beatson, J. Stewart, C. M. Steel, R. J. G. Cuthbert, C. A. Ludlam, et al., *University of Edinburgh, Department of Bacteriology, Edinburgh, U.K. Th.C.P.127 Recognition of Antibodies in HIV-1 Positive Sera by Peptides Derived from Different Viral Proteins. Otakar Mach*, M. Reinis, J. Kaminkovd, Z. Vacek, J. Krchndk, *Institute of Molecular Genetics, Prague, Czechoslovakia. Th.C.P.128 Measurement of Antibody to HIV-1 Reverse Transcriptase. Clive Lovedav, H. Williams, R. S. Tedder, I. V. D. Weller, J. N. Weber, * University College and Middlesex School of Medicine, Department of Virology, London, U.K. Th.C.P.129 Complement Receptor Type 2 (CR-2) Is a Receptor for In Vitro Complement-Mediated, Antibody-Dependent Enhancement (C'-ADE) of HIV-1 Infection. W. Edward Robinson*, D. C. Montefiori, W. M. Mitchell, *Vanderbilt University Medical Center, Department of Pathology, Nashville, TN, U.S.A. Th.C.P.130 Processing of the HIV-1 gag-pol Precursor Protein. Velissarios Karacostas*, B. Moss, *Howard Hughes Medical Institute, Laboratory of Viral Diseases, National Institutes of Health, NIAID, Bethesda, MD, U.SA. Th.C.P.131 Double Reactive Sera for HIV-1 and HIV-2 Antibodies and HIV Variant Strain from West Africa. Francois Simon*, S. Mas, M. C. Dazza, V. Bichat-Claude Bernard, Paris, France. Th.C.P.132 Frequent Isolation and Molecular Identification of Human T-Cell Leukemia Virus Type-2 (HTLV-II) in Three U.S. Population Centers. Ira Gore*, T. L. Snyder, W. D. Decker, B. H. Hahn, E. S. Parks, S. H. Weiss, et al., *University of Alabama at Birmingham, Birmingham, AL, U.S.A. Th.C.P.133 Quantitative HIV Blood Cultures. Robert H. Redfield*, A. Fowler, C. Oster, O. S. Burke, *Walter Reed Army Institute of Research, Department ofRetroviral Research, Rockville, MD, U.S.A. Th.C.P.134 A Host-Range Mutant of HIV Which Can Infect Fibroblast-like Cells Derived from Human Brain. Yasuhiro Takeuchi*, H. Hoshino, *Gunma University School of Maebashi, Japan. 633 [Page 634](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/634) Th.C.P.135 Erfle*, W. Comparison Between Jmmunocytofluorographic Analysis (ICE) and In Situ Hybridization (ISH) in Detection of HIV Infection of Monocyte-Macrophages. Suzanne M. Crowe*, T. Elbeik, N. McManus, P. Lekas, M. Mccrath, J. Mills,*Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Fairfield, Australia. Th.C.P.138 Quantitation of HIV-1 in Plasma and Peripheral Blood Mononuclear Cells (PBMC) of Seropositive Persons. DaQi~. Hoc, M. Alam, T. Moudgil, S. Liu, * University of California at Los Angeles, School of Medecine and Cedars-Sinai Medical Center, Los Angeles, CA, U.SJ.A Th.C.P.139 The Binding Of HIBsAg to Human T4 Lymphocytes Indicates the Possibility of the Antigen to Function as Oligopeptide Antagonist to HIV Primary Infection of T4 Lymphocytes. Lakew Gebreselassie. National Research Institute of Health, Addis Ababa, Ethiopia. Th.C.P.140 Analysis of a Functional HIV-2 Gene. Sylvie Kimitaka Katagiri, H. Natori, M. M. *Kurumne University, School of Medicine, Department of Immunology, Kurume, Japan. Th.C.P.142 Characterization of Monoclonal Antibodies Reactive with Different Proteins of HIV-1-NDK Strain. Chrristian D~evalux*, V. Robert, M. Tatsumi, J. Th.C.P.143 IgA Antibodies against Pneumocystis Carinii Antigens in AIDS Patients Measured by ELISA and Western Blot. Peder B. Nielsen*, A. G. Poulsen, C. Koch, B. Hofmann, Mojon, *Department of Clinical Microbiology, Copenhagen, Denmark. Th.C.P.144 B-Cell System Activation and HIV-1 Infection. Alberto Amadori*, R. Zamarchi, E. Francavilla, A. Barelli, A. Borni, of Padua, Institute of Oncology, Padua, Italy. Th.C.P.145 Fine Structure of Inside the Viral Envelope of the HIV-1. Ichiro T.akahtsi\"i, A. M. Ladhoff, M. Takama, D. Scholz, *Central Laboratory Electron Microscopy, Itaboshi -Ku, Japan. 634 [Page 635](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/635) Th.C.P.146 Some Observations on the Latent HIV Infection Period. Mario Pezzella*, E. Mannella, M. A. Rosci, M. Mirolo, M. Miceli, N. Vonesch, *University of Rome, Institute of Infectious Diseases, Policlinico Umberto I, Rome, Italy. Th.C.P.147 HJV-1 Does not Replicate in Human Vaginal Epithelial Cells. Lamis C. Sunstrum*, C. Meriwether, J. Sobel, * Wayne State University, Detroit. MI, U.SA. Th.C.P.148 Excretion of Human Immunodeficiency- Virus in Body Fluids. Mark Cordierv*, Y. Barrett, S. O'Shea, J. E. Banatvala, C. Bradbeer, *FSt. Thomas' Hospital, Department of Virology, London, U.K. Th.C.P.149 Molecular Characterization of a Defective Human Immunodeficiency Virus. Masahiro Inoue*, I. A. Hoxie, Grewe*, A. Beck, H. R. Gelderblom, *Robert Koch Institut, Berlin, Federal Republic of Germany. 635 [Page 636](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/636) I W section Jeudi 8 juin S O Thursday, June 8 Le SIDA et 'individu AIDS and the Individual Session d'affichage Poster Session Les femmes (partle 2) Women (Part 2) Th.D.P.1 HIV Antibody and High Risk Behaviours among Non-Intravenous Drug Using Women Obtaining Abortions in the South Bronx, New York City. Mavris P. Webber*, E. E. Schoenbaum, L. S. Stern, E. Drucker, H. Gayle, *Montefiore Medical Center, AIDS Research Department, Epidemiology and Social Medicine, Bronx, NY, U.S.A. Th.D.P.2 HIV Infection in Women: Effect of Counselling on Risk-Associated Behavior. Charles C. J. Carpenter*, S. Danforth, *Brown University, The Miriam Hospital, Providence, RI, U.S.A. Th.D.P.3 Glasgow Street Prostitutes: A Study of Sexual Behaviour and Injected Drug Usage. Stephen T. Green*, D. J. Goldberg, A. Thomson, D. H. Kennedy, J. A. Emslie, *Infectious Diseases Unit, Ruchill Hospital, Glasgow, U.K. Th.D.P.4 Sexual Partner Notification: Attitudes and Actions of HIV-Infected Women. Stanley H. Weiss*, J. L. Chervenak, *University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Department of Preventive Medicine, Newark, NJ, U.S.A. Th.D.P.5 Perception of AIDS Risk among Women Sexual Partners of IV Drug Users in San Francisco. Laurie A. Wermuth*, J. Ham, *University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. Th.D.P.6 An Ethnographic Study of High Risk Sexual Behaviour in 96 Women Using IV Heroin, Cocaine and Crack in the South Bronx. Ernest Drucker*, D. Worth, K. Eric, B. Chabon, A. Pivnick, K. Cochrane, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S.A. Th.D.P.7 The Women's Center: A Model Peer Support Program for High Risk IV Drug-and Crack-Using Women in the Bronx. Ernest Drucker*, K. Eric, D. Worth, B. Chabon, A. Pivnick, K. Cochrane, *Montefiore Medical Center, Albert Einstein College ofMedicine, Bronx, NY, U.S.A. Th.D.P.8 Discrimination against HIV Positive Women by Abortion Clinics in New York City. Katherine M. Franke. New York City Commission on Human Rights, AIDS Discrimination Division, New York, NY, U.S.A. Th.D.P.9 Differences between Symptomatic HIV+ Female and Male Patients. Patricia J. Kelly*, V. Graham, L. Hall, A. Kitchens, A. Bastien, J. DeHovitz, *King's County Hospital Center, Brooklyn, NY, U.S.A. 636 [Page 637](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/637) Th.D.P.10 Selected Gynecological Issues in Women with HIV Infection. Jean R. Anderson*, J. Horn, R. King, J. Keller, B. Herbert, M. Barbacci, *The Johns Hopkins University School of Medicine, Baltimore, MD, U.S A. Th.D.P.11 College Women's Sexual Behavioural Intent and Perception of Risk of HIV Infection for Self and Peers. Donna L. Richter*, F. Sy, T. Theocharis, D. Summers, J. Hussey, *University of South Carolina, School of Public Health, Columbia, SC, U.S.A. Th.D.P.12 Female Sex Partners of IV Drug Users: A Study of Socio-Psychological Characteristics and Needs. Lourdes Argiielles*, A. M. Rivero, C. J. Reback, N. H. Corby, *University of California at Los Angeles, School of Social Welfare, Los Angeles, CA, U.S.A. Th.D.P.13 Gender Differences in \"Maturing Out\" of Intravenous Drug Use. Patrick Biernacki*, J. S. Mandel, M. R. Aldrich, *Youth Environment Study, Inc., San Francisco, CA, U.S.A. Th.D.P.14 Access and Utilization of Services for Women with AIDS in Poor Minority Communities. Melinda A. Cuthbert. Yale University, New Haven, CT, U.S.A. Th.D.P.15 Female Family Members as Mediators of Utilization of Health and Social Services. Stephen Crystal*, N. Schiller, E. Dejowski, S. Hansell, C. Merzel, P. Beck, *Rutgers University, Institute for Health, New Brunswick, NJ, U.S.A. Th.D.P.16 HIV Infection among Females Entering New York State Prisons. Perry F. Smith*, J. Mikl, B. Truman, E. Lord, R. Broaddus, D. Morse, *New York State Department of Health, AIDS Epidemiology Program, Albany, NY, U.S.A. Th.D.P.17 Determinants of Sexual Risk Reduction in Female IV Drug Users Recruited from the Street. Susan Tross*, A. Abdul-Quader, D. C. Des Jarlais, A. Kouzi, S. R. Friedman, E. McCoy, *Narcotic and Drug Research Inc., New York, NY, U.S.A. Th.D.P.18 Differences in HIV/AIDS Counselling for Women and for Men. Judith Hutterer*, P. Blaas, C. Oberauer, M. Ogris, B. Pec, M. St6gerer, et al., *Austrian AIDS Foundation, Vienna, Austria. Th.D.P.19 Pratiques de risque et parmi les prostitu6es R. Usieto*, J. Sastre, J. Torres, H. Anabitarte, R. De Andres, J. Menor, *Universit6 Internationale Menendez Pelayo, Spain. Th.D.P.20 STD Patients' and Prostitutes' Knowledge on AIDS: Modification of Sexual Practices and Education Needs. F, Soyinka*, M. Z. Hossain, O. Onayemi, *Obafemi Awolowo University, Ile Ife, Nigeria. Th.D.P.21 \"Twilight Phenomena\": A Project Concerning Men as Buyers of the Services of Prostitutes as a Risk Factor. Elizabeth Pettersson*, J. Larsson, G. Mellberg, B. Pettersson, B. Group, Gothenburg Social Services, Gothenburg, Sweden. Th.D.P.22 HIV Infection and Prostitution in Yaounde, Cameroon. Marcel Monnv-Lobe*, D. Nichols, L. HIV Infection in the Potential of HIV Transmission. Klaus Friese*, S. Rossol, C. Klein, G. Hess, K. H. Meyer zum Biischenfelde, G. Knapstein, *University of Mainz, Department of Gynecology and Obstetrics, Mainz, Federal Republic of Germany. Th.D.P.24 A Descriptive Analysis of Patients Attending the Women's HIV Clinic at the Johns Hopkins Hospital. Janet Horn*, J. Anderson, J. Atkinson, K. Alwood, S. Cohn, R. Chaisson, *Sinai Hospital of Baltimore, Johns Hopkins Hospital, Baltimore, MD, U.S.A. Th.D.P.25 AIDS and Women: Change in Sexual Behaviour. Francisco S. Sy*, D. Richter, T. Theocharis, J. Hussey, D. Summers, * University of South Carolina, School of Public Health, Columbia, SC, U.S.A. Th.D.P.26 Serosurvey of Women of Childbearing Age in Texas, USA. Christie M. Reed*, E. G. Thompson, L. Suarez, K. B. Buchanan, B. L. Therrell, *Texas Department of Health, AIDS Division, Austin, TX, U.S.A. Th.D.P.27 The Women and AIDS Resource Network (WARN). Saint Cvr-Delpe, Women and AIDS Resource Network, Brooklyn, NY, U.S.A. Th.D.P.28 Medical-Psychological Counselling for Braun-Falco, *Dermatological Department of Ludwig-Maximilians University, Munich, Federal Republic of Germany. Th.D.P.29 An AIDS Prevention Program Consisting of Education, Confidential Testing, and Condom/Spermicide Distribution in Rwanda: Does It Change Behavior? Susan Allen*, A. Serufilira, P. Vandeperre, F. Nsengumuremyi, J. Tice, et al., University of California at San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, U.S.A. Consommateurs de drogues par vole intraveineuse (partie 2) IV Drug Users (Part 2) Th.D.P.30 Risk-Taking Behaviour of Intravenous Drug Users. Frederick R. Snyder*, M. H. Myers, *NOVA Research Company, Bethesda, MD, U.S.A. Th.D.P.31 Risk Factors for HIV Seropositivity among IV Drug Abusers (IVDA) in France: Evidence of a Change in Behaviour. Philippe Chossegros*, P. Barlet, J. Ritter, V. *INSERM U271, Lyon, France. Th.D.P.32 The Impact of Law and Policy on Needle Exchange Programmes in Canada. Anne Duffie*, A. Orkin, *McGill Centre for Medicine, Ethics and Law, Montreal, QC, Canada. Th.D.P.33 Increasing Crack Use among Drug Users in an AIDS Epicenter: San Francisco. Joseph R. Guvdish*, A. Abramowitz, W. Woods, W. Clark, * University of California at San Francisco, Centerfor AIDS Prevention Studies, San Francisco, CA, U.S.A. Th.D.P.34 Sharing Needles: Risk Reduction among Intravenous Drug Users in San Francisco. Joseph R. Guydish*, A. Abramowitz, W. Woods, J. Newmeyer, W. Clark, J. Sorenson, *Center for AIDS Prevention Studies, University of California at San Francisco, San Francisco, CA, U.S.A. 638 [Page 639](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/639) Th.D.P.35 Modification du Lebouc, I. Exchange Program in Lund, Sweden: Two Years of Observations of the Attenders. Kerstin Tunving*, B. Ljungberg, B. Andersson, B. Christensson, E. Johnsson, * University of Lund, Departme nt of P~sychiatry and Neurochemistry, Lund, Sweden. Th.D.P.37 An AIDS Intervention Program for the Black Out-of-Treatment Intravenous Drug User. CL rles.Haleu*, J. Valentine, A. Thomas, M. Krepcho, D. Johnson, A. Freeman, *Dallas County Health Department, Dallas, TX, U.SA. Th.D.P.38 The Needle and Syringe Exchange Pilot Program in New York City. Kevin J. Mahonev*, M. Zweig, C. Eaton, S. Schultz, S. Joseph, *New York City Department of Health, New York, NY, U.S~A. Th.D.P.39 Risk of AIDS in Seroconverter Drug Injectors: A Comparison with Other Risk Groups. Giovanni Rezza*, F. Menniti-ippolito, A. Lazzarin, G. Angarano, A. Sinicco, U. Tirelli, *AiDS Unit, Department of Social Medicine, Ministry of Health, Rome, Italy. Th.D.P.40 AIDS Incidence and Risk Factors for Disease Progression in a Cohort of Seroconverter Drug Injectors. Giovanni Rezza*, F. Menniti-Ippolito, A. G. Angarano, U. Tirelli, et al., *FAIDS unit, Department of Social Medicine, Ministry of Health, Rome, Italy. Th.D.P.41 11W Infection in Intravenous Drug Addicts. Walentvna B. Gluska, *Medical Academy, institute of Venereology, Warsaw, Poland. Th.D.P.42 Risk Behavior and Attitudes among Recovering IV Drug Users. Robert F. Schilling*, N. El-Bassel, S. P. Schiuke, G. Botvin, M. Orlandi, S. Nichols, *Columbia University, School of Social Work, New York, NY, U.S~A. Th.D.P.43 AIDS Beliefs and Behavior Change in Minority IV Drug Users. Mildred && Baw1nistL*, M~. D. Anderson, G. A. D. Smereck, *Personalized Nursing Corp., Detroit, MI, U.S~A. Th.D.P.44 Cocaine Use and Sexually Transmitted Diseases Including 11W. Howard L;. Minkofplc, S. McCalla, I. Delke, R. Stevensc, M. Salwen, J. Feldman, *State University of New York, Health Science Center at Brooklyn, Department of Obstetrics and Gynecology, Brooklyn, NY, U.SAl. Th.D.P.45 The Epidemiology of AIDS among New York State Prison Inmates. Qalk L Moi&e*, B. Truman, J. Mikl, P. Smith, R. Broaddus, B. Maguire, *N~ew York State Department ofHealth, Albany, NY, U.SA. Th.D.P.46 11W Fernandez, Buenos Aires, Argentina. Th.D.P.47 Sexual Activities of IV Drug Users with Multiple Sex Partners. H. Virgina McCoy*, E. J. Trapido, J. A. Inciardi, D. C. McBride, C. Y. McKay, *Florida International University, North Miami, FL, U.SA. 639 [Page 640](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/640) Th.D.P.48 Mobility, Risk Cities, Risk Behavior, and HIV Status of IV Drug Users. Clyde B. McCov*, D. D. Chitwood, J. B. Page, *University of Miami School of Medicine, Miami, FL, U.S.A. Th.D.P.49 Generational Differences in HIV Risk Behaviors and Sero-Prevalence Rates among IV Drug Users. Duane C. McBride*, J. A. Inciardi, C. B. McCoy, D. D. Chitwood, H. V. McCoy, *Andrews University, Behavioral Sciences Department, Berrien Springs, MI, U.S.A. Th.D.P.50 IVDU Characteristics Associated with Needle Sharing. Wallace Mandell*, D. Vlahov, S. Cohn, *The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, U.S.A. Th.D.P.51 Cocaine, Marijuana and Alcohol as Risk Factors for HIV Infection in Homosexual Men: A Pilot Study. Allen J. McCutchan*, S. Loue, L. Brysk, P. Spechko, J. Weinrich, C. Molgaard, *University of California at San Diego, San Diego Medical Center, San Diego, CA, U.SA. Th.D.P.52 AIDS-Related Knowledge, Attitudes and Behaviours in IDUs Attending a Toronto Treatment Facility. Margaret E. Millson*, R. Coates, P. Devenyi, T. Franklin, J. Rankin, *University of Toronto, Department of Preventive Medicine and Biostatistics, Toronto, ON, Canada. Th.D.P.53 Mode of HIV Transmission among Seroconverted Intravenous Drug Users (IVDUs): 1987 and 1988 Cohort Study. Lawrence S. Brown*, T. Nemoto, B. J. Primm, K. Foster, A. Chu, *Addiction Research and Treatment Corporation, Brooklyn, NY, U.S.A. Th.D.P.54 Inpatient Group Work with Inner-City Minority Drug-Using AIDS/ARC Patients: It Can Be Done. Rachel A. Pousson*, V. Graham, A. Kitchens, *King's County Hospital AIDS Team, Brooklyn, NY, U.S.A. Th.D.P.55 The Disinfectant Potential of Vinegar Solutions Used by Glasgow IDUs to Prepare Heroin for Injection. David J. Goldberg*, N. Flynn, S. T. Green, S. Jain, H. Watson, E. Keddie, *CD(S)U Ruchill Hospital, Glasgow, U.K. Th.D.P.56 Seroprevalence and Demographic Results of Intravenous Drug Users among Individuals at Risk for HIV Infection in a Community-based Study in Winnipeg, Manitoba, Canada. Gregory W. Hammond*, D. Buchanan, R. Malazdrewicz, R. Tate, L. Selka, V. Bhayana, *Cadham Provincial Laboratory, University of Manitoba, Winnipeg, MB, Canada. Th.D.P.57 Information on HIV-1 Transmission and Sexual Behaviour in Couples of Intravenous Drug Abusers (IDAs). Jordi Spain. Th.D.P.58 HIV Seroprevalence in Two Methadone Drug Treatment Programs in Los Angeles County, 1988. Peter R. Kerndt, W. Ford, I. Strantz, J. Keasler, T. Rose, *Los Angeles County Department of Health Services, Los Angeles, CA, U.S.A. 640 [Page 641](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/641) Th.D.P.59 Low HIV Seroconversion and Change in High Risk Behaviour in Intravenous Drug Users (IVDUs) from 1985-88 in the Bronx, N.Y.C. Din are\" E. E. Schoenbaum, P. A. Selwyn, R. S. Klein, G. H. Friedland, *Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, U.S~A. Th.D.P.60 Social, Sexual and Drug Use Profile of LHl (+) and l{IV (-) Women with PID. &ILe Heasg*n, T. Dotson, 0. Abulafla, S. Tross, D. Desi~alans, S. Landesman, et al., *State University of New York, Health Science Center at Brooklyn, Brooklyn, NY, U.S~A. Th.D.P.61 Access to IV Drug Users (lYDUs) through Combined Efforts of a Public Health Department and Indigenous Outreach Workers. Frances Feene.y, T. Brewster, A. Davidson, S. Koester, G. Burke, D. Cohn, *Denver Disease Control Service, Denver, CO, U.S.A. Th.D.P.62 Modification of Needle Use in Out-of-Treatment Intravenous Drug Users. Harvey W. Feldman*, P. Biernacki, T. Knapp, E. Margolis, *Youth Environment Study Inc., San Francisco, CA, U.S.A. Th.D.P.63 Risk Behaviour Is Common among Drug Users despite Knowledge of Transmission Routes, Access to Sterile Syringes and 11W Antibody Testing. Ann j4kilC, I. Lundin Kvalem, B. Nilsen, *Department of Epidemiology, National Institute of Public Health, Oslo, Norway. Th.D.P.64 Predictors of Attempted Sexual Behaviour Change in a Street Sample of Active Male IV Drug Users in New York City. Abu Abdul-Ouader*, S. Tross, D. C. Des.Jarlais, A. C. Kouzi, S. R. Friedman, E. McCoy, *Narcotic and Drug Research Inc., New York, NY, U.S.A. Th.D.P.65 Street Outreach Strategies for Intravenous Drug and Crack Users, Their Sexual Partners and Addicted Prostitutes at Risk for HIV. Ioltn4a Serrano*, D. Goldsmith, *Association for Drug Abuse Prevention and Treatment, Brooklyn, NY, U.S.A. Th.D.P.66 Organizing Intravenous Drug Users against AIDS. Yolanda Serrazno*, S. R. Friedman, L. Torres, M. Sufian, P. Nelson, F. Tardalo, *Association for Drug Abuse Prevention and Treatment, Brooklyn, NY, U.S.A. Th.D.P.67 Long-term Follow-up of a Cohort of Drug Abusers of the Area of Reggio Emilia (North Italy). Segi Gaf'*, M. Seropositive IYDAs with Deaths among Seronegative IVDAs: The HIV Prevalence and the Sero-Conversion Rate among JYDAs. Christian Sohlberg*, P. Kittelson, F. Jensen, P. Magnus, *Oslo City Health and Environment Department, Oslo, Norway. Th.D.P.69 Methadone Maintenance inHKIV Infected IV Drug Addicts: Medical and Psychological Effects. Peter Walger*, P. Baumgart, G. Wilke, U. Kupfer, The Use of Sterile Syringes among IVDUs That Had Gone through Detoxicating Treatment at Home Directed by a Center of Health Promotion in Madrid. Pilar Estebanez*, J. C. Martinez Barrios, P. Vitores, R. Wall, *Madrid City Council, Health Department, Madrid, Spain. Th.D.P.71 Survey of the Methadone Treatment Programme of the Outpatient Clinic of the Vienna Psychiatric University Hospital. Judith Hutterer*, O. Presslich, V. Pfersmann, D. Pfersmann, E. *Austrian AIDS Foundation, Vienna, Austria. Th.D.P.72 AIDS-related Behaviour and Attitudes among IV Drug Users in Greece. A. Kokkevi*, S. Alevizou, C. Stefanis, *Athens University Medical School, Department of Psychiatry, Athens, Greece. Th.D.P.73 Street-Based Needle Exchange Programs: The Next Step in HIV Prevention. Research Prevention Group Point, Independent Community-Based Research Group, San Francisco, CA, U.S.A. Th.D.P.74 Historical Account of the Tacoma Syringe Exchange. DavidPurchase*, H. Hagan, D. C. Des Jarlais, T. Reid, *Point Defiance AIDS Project, Tacoma, WA, U.SA. Th.D.P.75 AIDS Education and the Transition from Non-Injecting Drug Use to Injecting Drug Use. Don C. Des Jarlais*, C. Casriel, S. R. Friedman, A. Rosenblum, E. Rodriguez, E. Khouri, *New York State Division of Substance Abuse Services, New York, NY, U.S.A. Th.D.P.76 The Effects of AIDS Education on the Knowledge and Attitudes towards AIDS by Substance Abusers in a Drug Detoxification Setting. John Weber*, L. Dengelegi, S. Torquato, S. Yancovitz, A. Kolakathis, *Beth Israel Medical Center, New York, NY, U.S.A. Th.D.P.77 Needle Sharing Patterns of Intravenous Drug Users. Donald A. Calsyn*, A. J. Saxon, S. Whittaker, G. Freeman, *Seattle Veterans Administration Medical Center and University of Washington, Seattle, WA, U.S.A. Th.D.P.78 Use of Clinical Criteria to Predict HIV Antibody Status among Intravenous Drug Users (IVDU) in a Prospective Cohort Study. Peter A. Selwyn*, D. Hartel, E. E. Schoenbaum, R. S. Klein, D. Buono, G. H. Friedland, *Montefiore Medical Center, Albert Einstein College ofMedicine, Bronx, NY, U.S.A. Th.D.P.79 Clinical Symptoms and Medical Histories of a Cohort of IV Drug Users: Correlation with HIV Seroprevalence. Kenrad E. Nelson*, D. Vlahov, L. Solomon, A. Lindsay, N. Chowdhury, *Department ofEpidemiology, Johns Hopkins University, Baltimore, MD, U.S.A. Th.D.P.80 Risk Factors for Transmission and Changes in Risk Behaviour among IV Drug Addicts (IVDAs) in Geneva. Claude F. Robert*, B. Hirschel, J. J. Deglon, *University Hospital, Division of Infectious Diseases, Geneva, Switzerland. Th.D.P.81 The Use of a Minimal Behavioural Intervention as Part of a Risk Reduction Strategy among Intravenous Drug Users. Anna Stallard*, M. G. T. Dow, *Counselling Clinic, Psychology Department, Ruchill Hospital, Glasgow, U.K. 642 [Page 643](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/643) Th.D.P.82 A Comparative Analysis of HIV Infection among IV Drug Users in Treatment and on the Street. Clyde B. McCov*, D. D. Chitwood, J. B. Page, *University of Miami School ofMedicine, Miami, FL, U.S.A. Th.D.P.83 Comparison of Sexual Behaviors among White IVDU and Non-IVDU (NIVDU) Heterosexuals in Southeastern New England. Kenneth H. Maver*, S. Zierler, L. Feingold, D. Laufer, C. Carpenter, *Memorial Hospital, Brown University, Pawtucket, RI, U.S.A. Th.D.P.84 Psychoeducational Group Approach to AIDS Prevention with Drug Abusers in Residential Treatment: Impact 6 Months after Intervention. James L. Sorensen*, D. R. Gibson, C. Heitzmann, R. Dumontet, M. Costantini, I. Melese-D'Hospital, et al., *University of California at San Francisco, General Hospital, San Francisco, CA, U.S.A. Th.D.P.85 AIDS and Substance Use Education and Prevention: A Community-Based Approach. Diane M. Riley*, M. McCrimmon, K. Sheyka, *Municipality of Metropolitan Toronto, Toronto, Canada. Th.D.P.86 Management of HIV-Infected Female IVDAs. Axel Eck, B. Schwartldnder, Friedmann, *Freie Universitdt Berlin, Department of Obstetrics and Gynecology, Berlin, Federal Republic of Germany. Th.D.P.87 Additionnels Additional Th.D.P.88 Changes in the Sexual Behavior of HIV-Infected Patients Participating in a Group Process. Luisa Rossi*, L. Garcia, E. Salame, AIDS. Eleonora Quinhoes*, M. C. Rachid de Lacerda, J. L. L. Hanan, P. H. Longo, E. M. M. Moura, *Gaffrde Guinle University Hospital, University of Rio de Janeiro, Rio de Janeiro, Brazil. Th.D.P.90 HIV-AIDS Counselling: A Collaborative Project. Gweneth Gowanlock*, J. Findlay, M. Carballo, *Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada. Th.D.P.91 AIDS Prevention in the Legalized Sex Industry. Cheryl M. Overs*, A. P. Hunter, *Prostitutes Collective of Victoria, St. Kilda, Melbourne, Australia. Th.D.P.92 Survey of Physicians' Needs. Marg Hulin*, M. Grondin, *City of Toronto, Department of Public Health, Toronto, ON, Canada. 643 [Page 644](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/644) Section lasoci&t~etlecomportement ~j~J~~UUD Behaviour Session Tendances demographiques, tendances de Ia fertliit6 Demography and Fertility Patterns Th.E.P.1 Contraceptive Utilization In and Out of the Marital Setting: Implications for the Transmission of HIV in Kinshasa. &isa&&..ffcxrig', A. Doppagne, M. Moore, L. Piripiri, R. W. Ryder, W. E. Bertrand, *Tulane University, New Orleans, LA, U.S~A., Zaire School of Public Health. Th.E.P.2 Modelling the Spread of HIV/AIDS and Its Demographic Impact: A Review of Approaches. Larry Heligman*, A. Palloni, 'Uie Nations, Population Division, New York, NY, U.S~A. Th.E.P.3 Risk Factors for IJIV-2 Infection. Phyllis Kanki*, B. De Zalduando, T. Siby, R. Marlink, M. Essex, S. M'Boup, *Ha,.vard School of Public Health, Department of Cancer Biology, Boston, MA, U.S~A. Th.E.P.4 Determinants of Contraceptive Practices among Intravenous Drug Users in New York City. Anth1Lny...C.KQ1zi*, D. C. Des Jarlais, S. F. Friedman, S. Tross, A. Abdul-Quader, *Narcotic and Drug Research Inc., New York, NY, U.S~A. Th.E.P.5 Characteristics of Men in the National Mortality Followback Survey Who Died of AI1)S. Eve Powell-Griner*, K. Trent, laioa Center Th.E.P.6 anti-HIV-2 Monde, Francoise Aeberhard*, J. Lebas, B. Masse, A. Bedossa, M. C. Coignet, *M~decins du Monde, ONG France, Paris, France. Th.E.P.8 Estimating the Percentages of High Risk Groups Which Have Been Tested and Counseled for HIV by 1988. Franklyn NY. Judson*, J. M. Douglas, A. Davidson, *Denver Public Health, University of Colorado, Denver, CO. U.S~A. Th.E.P.9 Emotional Impact of Voluntary HIV Antibody Testing. 5.atuiel W. Perrv*, L. Jacobs berg, B. Fishman, A. Frances, A. Novick, R. Rein, *Cornell Medical Center, New York, NY, U.S.A. 644 [Page 645](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/645) Th.E.P.10 HIV Antibody Testing by Canadian General Practitioners and Family Physicians. Thomas J. Elmslie*, J. Shearman, N. Busing, *University of Ottawa, Ottawa, ON, Canada. Th.E.P.11 Telephone Screening of Men at Risk of HIV Infection. Charles E. Lewi*, H. Freeman, K. Montgomery, *University of California at Los Angeles, Department of Medicine, Los Angeles, CA, U.S.A. Th.E.P.12 Campagne de promotion pour le d6pistage Lyon-France. *MWdecins du Monde, Lyon, France. Th.E.P.13 Anonymity Sought in HIV Antibody Testing. James W. Dillev*, J. M. Moulton, B. E. Havassy, *University of California at San Francisco, School ofMedicine, Department of Psychiatry, AIDS Health Project, San Francisco, CA, U.S.A. Th.E.P.14 Assessing the Ethical and Policy Implications of Testing Surgical Patients for HIV Antibody in the USA. A. Gene Copello. Vanderbilt University, Nashville, TN, U.SA. Th.E.P.15 Preliminary Evaluation of an Admission, HIV Antibody, Voluntary Screening Program in a Large Private Hospital. Richard L. Harris*, E. Boisaubin, P. Salyer, D. Semands, *The Methodist College of Medicine, Houston, TX, U.S.A. Th.E.P.16 tvolution des motifs de prescription de s6rologie en m6decine g6n6rale en Aquitaine, France, 1981-1988. S. Maurice, G. Poumerol, C. B. Tilly, *Dipartement 2, centre de d6pistage anonyme H6pital Pellegrin-Tripode, France. Th.E.P.18 Characteristics of Patients Submitted to HIV Serology in a Clinic for Sexually Transmitted Diseases of Downtown Montreal. Michel Alar*, J. Castel, C. Olivier, S. L. Hanan*, E. M. M. Moura, C. A. Morais de Brasileiro de Cooperacao Intercdmbio de Sociais, Janeiro, Brazil. Th.E.P.20 Funk and Epidemiology: Viral Dialectics in the Soul Music of Prince. MarkHarrington*, D. Barr, R. Vazquez, R. Deagle, *ACT UP/NY, New York, NY, U.S.A. Th.E.P.21 Study of the Prevalence in an HIV Testing Center. Danielle Sondag-Thull*, J. Defourny, M. Paulo): Vilma Lucia Carmona Goncalves*, R. M. P. Dos Anjos, M. C. O. Gomes, T. Ramos, *Conjunto Hospitalar [Page 646](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/646) Th.E.P.23 Social Acceptability of HIV Screening among Pregnant Women. Jean-Paul Moatti*, C. Le Predictors of People Who Fail to Return for Their HIV Test Results. Joseph A. Catania*, M. Kegeles, T. Coates, *University of California, San Francisco, Centerfor AIDS Prevention Studies, San Francisco, CA, U.SA. Th.E.P.25 A Confidential Public Health HIV Testing Clinic as an Acceptable Alternative to Anonymous Testing. Michael L. Rekart*, D. Cook, W. Black, *STD Control, Ministry ofHealth, Vancouver, BC, Canada. Th.E.P.26 Factors Affecting the Decision to Refuse HIV Testing among Haitian Immigrants in Montreal. Alix Adrien*, C. A. Hankins, Y. santd l'H6pital General de Montreal, Montreal, QC, Canada. Th.E.P.27 Anxiety and Attitudes to HIV Testing in an Ante-Natal Clinic. Lorraine Sherr*, C. Victor, A. Stevens, *St. Mary's Hospital, London, U.K. Th.E.P.28 HIV Testing and Counselling Practices in the U.S.A.: A Descriptive National Study. Felissa L. Cohen, University of Illinois, College of Nursing, Chicago, IL, U.S.A. Th.E.P.29 Impact of Experience with AIDS on HIV Testing Patterns: An Analysis of Minnesota and U.S. Hospitals. Scott Campbell*, J. R. Thurn, M. Maki, K. Willenbring, K. Henry, *St. Paul-Ramsey Medical Center, Section of Infectious Diseases, St. Paul, MN, U.S.A. Th.E.P.30 Characteristics and Responses of Men Seeking HIV Antibody Test Results. David G. Ostrow*, J. Joseph, E. Beltran, J. Chmiel, J. Phair, * University of Michigan, Institute for Social Research, Ann Arbor, MI, U.SA. Th.E.P.31 Premarital Screening for Antibodies to HIV-1 in the U.S. Carol R. White*, L. Petersen, *Centers for Disease Control, Atlanta, GA, U.SA. Th.E.P.32 The Effect of Mandatory AIDS Education on Voluntary HIV Testing in Prisons. Jon K. Andrus*, D. Fleming, C. Knox, R. McAlister, J. Horan, L. Foster, *Centers for Disease Control, Atlanta, GA, U.SA. Th.E.P.33 A Report on a Newly Developed AIDS Intervention Programme in Montreal. Marlene Yuen-Boyer*, F. Bates, C. Paquin, G. Schoel, *CLSC Metro, Montreal, QC, Canada. Anthropologie Anthropology Th.E.P.34 Sexuality and HIV Transmission in Kagera Region, Tanzania. George K. Lwihula, Faculty of Medicine, Dar es Salaam, Tanzania. Th.E.P.35 Sexualit6 et connaissance du SIDA chez les lyc6ens Role of IV Drug Withdrawal Symptoms and Symptom Anticipation in AIDS Risk Reduction. Margaret M. Connors, SpectrumiHouse, Inc., Westboro, MA, Perspective on AIDS-Risk-Related Sexual Behaviors as Depicted in Art throughout History. Tune M. Reinisch*, M. Ziemba -Davis, S. A. Sanders, *The Kinsey Institute for Research in Sex, Gender, and Reproduction, Bloomington, IN, U.S~A. Th.E.P.38 Traditional Healers and AIDS among the Yorubas in Nigeria. M. K..Jinadu*, B. Ajuwon, D. A. Jaiyeoba, *Obafemi Awolowo University, Ile-Ife, Nigeria. Th.E.P.39 AIDS Knowledge, Attitude and Practice in a Deprived Urban Area of Nairobi, Kenya. Doris M. W. Kinuthia*, V. Orinda, I. P. Brady, J. S. Meme, *Department of Pediatrics, University of Nairobi, Nairobi, Kenya. Th.E.P.40 SIDA: Repr~sentations et pratiques Schoepf, *Wooc~ Hole, MA, U.S~A. R6le de Ia religion Role of Religion Th.E.P.41 Religious Organizations Respond to a Community Mffected by HIV. Rodney I. De Martini*, C. Hartquist, A. Rose, *Archdiocese of San Francisco, Office of AIDS Education, San Francisco, CA, U.S~A. Th.E.P.42 Involving the Religious Community: A Statewide Model. Tiaddiis A. Bennett*, D. Wood, C. Carnahan, *AJDS Ministries Program, Episcopal Diocese of Connecticut, Hartford, CT, U.S~A. Th.E.P.43 Religion as a Tool in Preventing the Spread of HIV in Uganda. MuhamedMusaar*, F. Namaganda, *MIDS Control Program, Entebbe, Uganda. Th.E.P.44 How Organized Religion Impacts on the AIDS Pandemic in Prevention, Education, and Prejudice. Henry J. Yeager. The Dwight Foundation, New York, NY, U.S~A. Th.E.P.45 Mobilization of Volunteers for Control of the HIV Epidemic. Charles E. Car&, Tampa Veterans Administration Hospital, Tampa, FL, U.SA. Sociologie du SiDA Sociology of AIDS Th.E.P.46 attitudes relativement Sucesso, Lisbon, Portugal. Th.E.P.47 Where Are People in England and Wales Dying from AIDS? Ann &. etiiedy.\", G. A. Ellam, J. D. H. Porter, *CommunicabJle Disease Surveillance Centre, Public Health Laboratory Service, London, U.K. Th.E.P.48 Pratiques de risque et SIDA parmi R. Usieto*, J. Sastre, H. Anrabitarte, J. Torres, R. De Andres, M. C. Contreras, *Universit~ Internationale Menendez Pelayo, Madrid, Spain. Th.E.P.49 AIDS Treatment Deficits: An Ethnographic Study of the Management of the AIDS Epidemic, the Ontario Case. Ge ge W.. Smithi, Ontario Institute for Studies in Education/AIDS ACTION NO WI, Toronto, ON, Canada. 647 [Page 648](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/648) Th.E.P.50 AIDS as an Emergent Field: Lessons from a Comparison with Perinatal Medicine and Geriatrics. Debbie Indyk, Mt. Sinai School of Medicine, New York, NY, U.S.A. Th.E.P.51 The Impact of AIDS on the Homosexual Clone Community in New York City. Martin P. Levine, Bloomfield College, Department of Sociology, Bloomfield, CT, U.S.A. Th.E.P.52 Connaissance, attitudes et croyances sur Pasteur, Bangui, Central African Republic. Th.E.P.53 AIDS as a Challenge to Physicians' Professional Identity. Kathryn M. Taylor*, J. K. Eakin, M. J. Kelner, *University of Toronto, Department of Behavioural Sciences, Toronto, ON, Canada. Th.E.P.54 A Model Comparing Condom Use vs. Partner Reduction Strategies. Lra L. Reiss*, R. K. Leik, *University of Minnesota, Department of Sociology, Minneapolis, MN, U.S.A. Th.E.P.55 AIDS in an Aging Society: Ethical and Psychosocial Considerations. Robert M. Schmidt*, R. H. Kenen, *Centerfor Preventive Medicine and Health Research, San Francisco University and Pacific Presbyterian Medical Center, San Francisco, CA, U.S.A. Th.E.P.56 Health Professionals' Views of Social Distance from Persons with AIDS and Other Conditions. Felissa L. Cohen*, R. Mudro, *University of Illinois, College of Nursing, Chicago, IL, U.S.A. Th.E.P.57 Guardianship Status and Supportive Relationships as Co-Determinants of Enrollment of HIV-Positive Children in a Placebo-Controlled Study. Katherine E. Steinberg*, T. Calvelli, J. Kashkin, A. Willoughby, L. Bernstein, A. Rubinstein, *Albert Einstein College of Medicine, Bronx, NY, U.S.A. Th.E.P.58 Perinatal Study Compliance of HIV-Infected Women: Significance of Risk as a Determinant. A. Willoughby, *Albert Einstein College of Medicine, Bronx, NY, U.S.A. Th.E.P.59 Changes in Sexual Behavior of a Cohort of Female Health Care Workers during the AIDS Era. Charles T. Leach*, S. Viker, T. Kuhls, N. Parris, J. Cherry, P. Christenson, *University of California at Los Angeles, School of Medicine, Los Angeles, CA, U.S.A. Th.E.P.60 Social Aspects of AIDS: An Analysis of Attitudes and Awareness. S. Shanmuganandan*, P. T. K. Subramanian, *Department of Geography, Madurai Kamaraj University, Madurai, India. Les arts Arts Th.E.P.61 Our Lady of AIDS: The Talismanic Design of Andr6 Durand's Plague Icon \"Votive Offering\". James L. Miller, University of Western Ontario, London, ON, Canada. Th.E.P.62 Back to Basics: Use of Popular Theatre in AIDS Awareness Campaign. Rodreck S. Mupedziswa. University of Zimbabwe, School of Social Work, Harare, Zimbabwe. 648 [Page 649](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/649) Th.E.P.63 Private/Public Sector Cooperation in AIDS Downer*, C. Bishop, P. Hillard, C. Granat, *University of Washington, AIDS Education and Training Center, Seattle, WA, U.S.A. Th.E.P.64 1989 Partnership in Caring Calendar. Diane McMenamin*, C. Hostetter, *Department of Health and Human Services, Rockville, MD, U.S.A. Th.E.P.65 The Rural Theatre Project: AIDS Education in the Villages of Trinidad and Tobago. Michael Helquist*, O. Besly, R. John, C. Almedal, *Academy for Educational Development, Washington, DC, U.S.A. Th.E.P.66 Physician-Patient Relationships in AIDS Dramas. Howard C. Rubin*, G. Nakajima, *Mount Sinai School of Medicine, New York, NY, U.SA. La communaut6 (partle 2) Community (Part 2) Th.E.P.67 The \"Fundaci6n SIDA de Puerto Rico\" Experience. Jose Toro-Alfonso*, M. Rodrtguez, A. Nigaglioni, A. Meaux, *Fundaci6n SIDA de Puerto Rico, Inc., San Juan, Puerto Rico. Th.E.P.68 Le Comit6 SIDA Aide Montr6al et ses Montreal, QC, Canada. Th.E.P.69 HIV Related Services: A Model for Community Service Provision. Nicholas A. Rango, New York State Department of Health, AIDS Institute, Albany, NY, U.S.A. Th.E.P.70 Contributions of the International Gay Community to AIDS Research. Lawrence A. Falk*, W. A. Verick, *Committee for a Nobel Endeavor, Chicago, IL, U.S.A. Th.E.P.71 London Lighthouse: A Continuum of Care. Christopher Spence*, H. MacGregor, S. Malach, S. J. Mansfield, U. O'Brien, M. Pipes, et al., *London Lighthouse, London, U.K. Th.E.P.72 Cr6er un milieu (partie 3) Education (Part 3) Th.E.P.73 The Stop-AIDS Model for Community Change: Acceptability in a Low-Incidence Area for AIDS. Carolyn G. Beeker*, T. Rose, *New York State Department of Health, AIDS Institute, Albany, NY, U.S.A. Th.E.P.74 Educational Intervention in a Cohort of Homo/Bisexual Men towards a Change in High Risk Behavior for HIV Infection: An Assessment of the Process. Carlos F. Caceres*, F. Mariscal, E. De La Vega, E. Gotuzzo, M. Ramah, *Instituto de Medicina Tropical Alexander Von Humboldt, U. P. Cayetano Heredia, Lima, Peru. Th.E.P.75 Resources for Educating about Married Homesexual and Bisexual Men: A Facilitator's Kit in Action. John W. Molenaar. Gay and Married Men's Association, Ministry of Education, Box Hill, Australia. Th.E.P.76 STD Patients' and Prostitutes' Knowledge on AIDS: Modification of Sexual Practices and Education Needs. Femi Sovinka*, M. Z. Hossain, juin F ~ Thursday, June 8 Droit et ~hique Ethics and Law Session d'affichage Poster Session Discrimination et droits de Ia personne Discrimination and Human Rights Th.F.P.1 AIDS and Ethics. Guido Carlos Levi*, A. 0. L. Barros, *Hospit-jl to Prevent and Resolve HIV-related Discrimination: Five Case Studies. Anne M. Guthrie*, L. Sherwood-Fab~re, R. J. Steele, S. E. Karsten, B. F. Lorenz, J. L. Ritter, *Offl~ce of the Assistant Secretary for Health, U.S. Public Health Service, Washington, DC, U.S.A. Th.F.P.4 Equality Rights for People with AIDS: Mandatory Reporting of HIV Infection and Contact Tracing in Ontario. William F. Flanagan. Columbia University School of Law, New York, NY, U.S.A. Th.F.P.5 Governments' Duty to Provide Financial Assistance and Compensation to Persons Who Have Become Infected with HIV through Blood Transfusions and Blood Products. Jacques J. M. Shore, Heenan Blaikie, Montreal, QC, Canada. Th.F.P.6 Providing High Quality, Low Cost Legal Services to People with AIDS: A Discrimination Law Project. MaLk Btn\"', D. M. Greenberg, *Colurpbia University School of Law, AIDS Law Clinic, New York, NY, U.SAl. Th.F.P.7 AIDS Policies of Canadian Universities. Donald~ C. Savage*, M. Blanchette, *Canadian Association of University Teachers, Ottawa, ON, Canada. Th.F.P.8 Forum for Civil and Human Rights Bodies Active in AIDS Work. The B.C. Civil Liberties Association, Vancouver, BC, Canada. Th.F.P.9 HIV-Antibody Testing: Is Consent the Legal Issue? Dai Harris, The Terrence Higgins Trust Legal Centre, London, U/.K. Th.F.P.1O A Bill of Rights for Persons with AIDS. Lebr ZR..5ier*, C. Taylor, *New York University, New York, NY, U.S.A. Th.F.P.11 Catastrophic Rights. Z&1L1LQ~ixQI, The B.C. Civil Liberties Association, Vancouver, BC, Canada. 650 [Page 651](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/651) Th.F.P.12 The Influence of AIDS on Individual Rights and the Dignity of People. Carmen Arredondo Miguel*, F. Conde, A. Coronado, E. Gil, *Ministerio de Sanidad y Consumo, Madrid, Spain. Th.F.P.13 Development of Community-Based Legal Services for Persons with HIV Infection. Clint Hockenberrv*, M. Zavos, *AIDS Legal Referral Panel, San Francisco, CA, U.SA. Th.F.P.14 Legal Needs Assessment of HIV-Infected Men and Women. Brian R. Saltzman*, D. C. Perlman, J. Clayton, P. Colligan-Levine, C. Lane, L. Comeau, et al., *Beth Israel Medical Center, New York, NY, U.SA. Th.F.P.15 HIV Antibody Testing of \"Canada World Youth\" (CWY) Applicants. R. Morisse*, D. J. Roy, J. Jobin, J. Joubert, *H6tel-Dieu de Montreal, Clinical Research Institute of Montreal, Canada World Youth, Montreal, QC, Canada. 651 [Page 652](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/652) Section Jeudi 8 juin GThursday, June 8 Implications International Issues Session d'affichage Poster Session Aspects cliniques (partle 2) Clinical Features (Part 2) Th.G.P.1 HIV and HTLV-I Infection among Homosexual and Bisexual Men in Kingston, Jamaica. Edward L. Murphy*, W. N. Gibbs, J. P. Figueroa, B. Bain, L. Lagrenade, B. Cranston, et al., *San Francisco General Hospital, San Francisco, CA, U.S.A. Th.G.P.2 Risk Factors for HTLV-I Infection in Pregnant Haitian Women. Andrea J. Ruff*, E. Holt, S. Wiktor, R. Boulos, W. Blattner, N. Halsey, et al., *Johns Hopkins University School of Hygiene and Public Health, Department of International Health, Baltimore, MD, U.S.A. Th.G.P.3 HIV Infection among Prostitutes and Transvestites in Brazil. Francisco H. Aoki*, J. N. Lima, W. B. Abreu, D. T. Monteiro, M. H. P. Pavan, R. J. Pedro, *Hospital de Clinicas, Unicamp, Grupo de AIDS, Campinas, Brazil. Th.G.P.4 Seamen: Risk Population Mar, Chile. Th.G.P.5 Preventive Intervention for HIV in STD Clinics in Zambia. Subhash K. Hira*, P. Matondo, * University Teaching risque Ii~s aux MTS (partle 2) STD Risk Factors (Part 2) Th.G.P.6 Detection of HIV-1 from Filter Paper by Polymerase Chain Reaction (PCR). Shlomit Orgad*, B. Korber, R. Marlink, M. Kanki, M. Essex, *Department of Cancer Biology, Harvard School of Public Health, Boston, MA, U.S.A. Th.G.P.7 Liaison entre la densit6 optique en ELISA et le r6sultat du Western Blot chez les donneurs de sang de Brazzaville (Congo). MichelRosenheim*, P. M'Pele, A. Salpetridre, Paris, France. Th.G.P.8 Rapid Method for Detection of HIV-1 and HIV-2 Infections: Evaluation of Sensitivity and Specificity. Daniel Th.G.P.9 Modified Western Blot Assays for Infection. Sunil K. Arora*, S. Sehgal, *Department oflmmunopathology, Postgraduate Institute 652 [Page 653](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/653) Th.G.P.10 FDA Reform: An Activist Perspective on the Need for Legal and Regulatory Change. Mark Harrington*, J. Eigo, M. McCarthy, I. Long, D. Z. Kirschenbaum, *ACT-UP/NY, New York, NY, U.S.A. Th.G.P.11 Blinded by Science: DHPG and the Conflict between \"Clean Data\" and Care. Mark Harrington*, K. Wiley, J. Eigo, *ACT-UP/NY, New York, NY, U.S.A. Th.G.P.12 National Institutes of Health/NIAID-WHO AIDS Research and Reference Reagent Program. Susan A. Stern*, L. Muul, G. Milman, *National MD, U.S.A. Th.G.P.13 Phase-I Study of Recombinant Peptide Corresponding to the gp41 Transmembrane Protein of the HIV-1 Virus Coupled to Ficoll. Manfred Dietrich*, S. Schwander, D. Hanson, B. Letwin, J. Schindler, *Bernhard-Nocht Institutefor Tropical Medicine, Clinical Department, Hamburg, Federal Republic of Germany. Th.G.P.14 African HIV Education Mobilized through a Public-Private Workshop. Lester N. Wright*, H. Elder, R. Hart, *Oregon Health Division, Portland, OR, U.S.A. Th.G.P.15 The Role of Female Prostitution in the Heterosexual AIDS Epidemic in South Africa. Barry David Schoub*, D. Martin, A. N. Smith, S. F. Lyons, G. N. Padayachee, S. Naidoo, *National Institute for Virology, Sandringham, Transaal, South Africa. Epid6mlologle Epidemiology Th.G.P.16 Attitudes Explaining Desertion and Non-Use of Condoms in Gay Men in Mexico. Jose-Antonio Izazola*, R. Basafez, J. L. Valdespino, M. *Direccidn General de Epidemiolog(a, Secretar(a de Salud, Mexico City, Mexico. Th.G,P.17 HIV Infection in Pregnant Women and Their Infants in Argentina. Arnaldo D. Casiro*, F. Uranga Imaz, A. Infectolog(a, Buenos Aires, Argentina. Th.G.P.18 Lessons from AIDS Surveillance and Prevention in Uganda. Ikwaras S. Okware*, S. F. Berkley, W. Naamara, W. D. Sutherland, *Uganda National AIDS Control Programme, Entebbe, Uganda. Th.G.P.19 AIDS and African Women. E. Maxine Ankrah, Makerere University, Kampala, Uganda. Th.G.P.20 Connaissances, attitudes et comportement a l'egard du SIDA de la population Rwandaise. G. Muligande* N. Ndibisheye, D. Nzaramba, P. Lehman, M. Carsel, *Sociological and Behavioural Research, Global Program on AIDS, World Health Organization, Geneva, Switzerland. Th.G.P.21 Heterosexual Transmission of HIV Infection in Hemophiliacs. Ema Muchinik, M. Th.G.P.22 HIV A General Overview. Fernando V. De La Cruz*, J. A. X. Barreto, C. A. D. Paiha de Soissa, L. Barquet, A. J. R. Cabral, J. Selvamani Samulndi Sankari*, L. Anantha Subramanian, Subramanian, C. Saikumar, *Madras University Madras Medical College, Government K. G. Hospital, Madras, India. Th.G.P.25 Hijras: A Cult Susceptibility for AIDS. Ishwarvrasad S. Gilada, Indian Health Organization, J. J. Hospital, Bombay, India. Th.G.P.26 Epidemiological Findings of lill Infection among Women in Sao Paulo, Brazil. Ana Carolina I. Ferreira*, J. L. Grandi, M. E. Fernandes, C. Accetturi, W. Pinto, *Refereni.e and Training for AIDS, Sao Paulo, Brazil. Th.G.P.27 Epidemiological Features of Pediatric AIDS in the Caribbean.,iai P. Narain*, S. Mahabir, I. Hospedales, D. Bassett, Center, Port-of-Spain, Trinidad. Th.G.P.28 Increasing Problem of Heterosexually-Acquired AIDS in the English-Speaking Caribbean Suriname. LaiLL....aruiM', *Caribbean Port-of-Spain, Trinidad. Th.G.P.29 Modification of High Risk Heterosexual Behaviour after Education and Counselling in Nairobi. D. William Cameron.*, L. J. D'Costa, A. M. Maingi, J. 0. Ndinya-Achola, A. R. Ronald, F. A. Plummer, *Ottawa General Hospital, Ottawa, ON, Canada. Th.G.P.30 Transmission of HIV in Mansa, Zambia. Peter L. Perine*, S. K. Hira, G. J. Bhat, K. Mutkelabai, NV. N. Pearsall, C. Chishemba, et al, * Uniformed Services University of the Health Sciences, Bethesda, MD, US A. 654 [Page 655](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/655) Notes [Page 656](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/656) Section Jeudi 8 juin H Thursday, June 8 R4pecussions economiques du SIDA The Economic Impact of AIDS Session d'affichage Poster Session Affectation des Canada. Th.H.P.2 The Economic Impact of AIDS: A Patient Perspective. Lois A. Jackson*, M. M. Fanning, *Toronto General Hospital, CCRW, Toronto, ON, Canada. Th.H.P.3 Distribution and Characteristics of AIDS Hospitalizations in the U.S., 1986-87. Judy K. Ball*, B. J. Turner, *U.S. DHHS, National Centerfor Health Services Research, Rockville, MD, U.S.A. Th.H.P.4 The Economic Impact of AIDS on the Health Care System in Switzerland. Maurice R. H. Pedergnana, University of St. Gallen, St. Gallen, Switzerland. Th.H.P.5 Hospital Utilization and Hospital Expenditures for Patients with HIV Diagnoses: United States, 1984-1987. Mary Moien*, L. J. Kozak, *National Center for Health Statistics, Hyattsville, MD, U.SA. Th.H.P.6 Impact and Distribution of Hospitalized HIV Disease in a Low-Incidence Area of Canada. Geoffrey D. Taylor*, L. J. Miedzinski, *University of Alberta, Edmonton, AB, Canada. Th.H.P.7 A Systemic Approach to AIDS Economic and (Social) Development Impact Analysis. Samuel Bounya-ypee. University of Yaounde, Department of Economics, Yaounde, Cameroon. Th.H.P.8 The Canadian AIDS Research Contribution: A Critique. Allan R. Ronald, University of Manitoba, Department of Internal Medicine, Winnipeg, MB, Canada. Th.H.P.9 Labor Productivity Losses to Nevada's and the American Economy Resulting from Premature Death Due to AIDS. Vicky L. Carwein*, C. G. Ray, *Department ofNursing, University of Nevada at Las Vegas, Las Vegas, NV, U.S.A. Th.H.P.10 Study on Consumption of Care of HIV-Positive Patients. Harriet E. Malmquist*, B. R. Nilsson, K. Lidman, *National Swedish Board of Health and Welfare, Stockholm, Sweden. Th.H.P.11 Medical Consumption of HIV Patients Outside Hospitals in France: An Analysis in Terms of Gravity Level. Annie Triomphe*, Y. A. Flori, G. 657](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/657) Th.H.P.12 A Comprehensive and Cost-Effective Approach to the Management of AIDS Patients in an Outpatient Facility: The Results of a Patient Survey. Raul Benitez*, J. Sotomayer, *San Juan AIDS Institute, Hato Rey, Puerto Rico. Th.H.P.13 Enlisting the Support of Traditional Healers in AIDS Education Campaign. E. Sivile*, B. U. Chirwa, *Ministry of Health, Lusaka, Zambia. Th.H.P.14 Pays en vole de d6veloppement - divers Developing Countries - Miscellaneous Th.H.P.15 The Fear of AIDS in Young Women. George latrakis*, G. Sakellaropoulos, G. Kourounis, E. Argyroudis, *Department of Obstetrics and Gynecology, Athens, Greece. Th.H.P.16 ttude du temps moyen de survie des patients atteints SIDA a I. Phillips, L. Varela, *Universidad Nacional Mayor de San Marcos, Lima, Peru. Th.H.P.18 Utilisation d'un test rapide au latex pour prevenir la transmission du HIV par transfusion dans les Kinshasa, Prevalence HIV in Namibian Teenagers. Gersimos Lecatsas*, J. J. Joubert, C. H. J. Schutte, M. B. Taylor, C. Swanevelder, *Medical University of South Africa, Pretoria, South Africa. Th.H.P.20 AIDS and Migration in Jalisco, Mexico: Their Relation with Risk Factors. David Diaz-Santana*, A. *Consejo Estatal para Jalisco, Guadalajara, Mexico. Th.H.P.21 HTLV-I Infection in Sexually Active and HIV-1 Infected Subjects in the Philippines. Ofelia T. Monzon*, F. J. E. Paladin, S. S. Mohammad, C. Lazo, J. M. Capellan, *Research Institute for Tropical Medicine, Manila, Philippines. Th.H.P.22 Mode de contamination des enfants a Pointe-Noire (Congo). Jo'lle Nicolas-Randegger*, L. B. *Hdpital Paradox or Concealment of Information? Pedro E, Cahn*, H. M. Perez, A. D. Casiro, N. S. Grinberg, G. Muchinik, M. B. Argentina. Th.H.P.24 Typology, Behavior, Bisexuality and HIV Infection of Homosexual Men of Costa Rica, 1985-1988. Leonardo J. Mata*, E. Ramirez, J. Badilla, E. Mata, *Instituto de Investigaciones en Salud, University of Costa Rica, San Pedro, Costa Rica. 657 [Page 658](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/658) Th.H.P.25 HIV-1 and HIIV-2 Serological Study Carried Donors from Guinea Bissau. ~S~r ~io *abta, M. Ghidinelli, A. Mendez, F. Diaz, *Ospedale Maggiore, Bologna, Italy. Th.H.P.26 AIDS Surveillance in Sichuan, China. D gyagoypaj*, L. Chen, B. Lu, P. Deng, *Health and Anti-Epidemic Center of Sichuan Province, Chengdu, China. Th.H.P.27 Prevention of Transfusion-associated 11W Transmission in Kinshasa, Zaire. Helmut Jaeger*, K. Nseka, J. Perriens, C. in Egypt: An Epidemiological Study. Samir Mohamed WassW\"r, A. B. Mobarak, A. S. Rashid, 0. M. Wassif, *Faculty of Medicine, Zagazig U/niversity, Zagazig, Egypt. Th.H.P.29 AIDS Education for Commercial Sex Workers in Honduras. Barbara Lanzwyitz*, M. Coello, P. Bailey, K. Clarke, *Family Health International, Research Triangle Park, NC, U.S~A. Th.H.P.30 AIDS Prevention and Its Countercurrents in Asia. &hahl.Hamee EftkW'im\" D. Hilsorst, *Bicol Christian College Medicine, Europ~en France Directeur le SIDA Canada Richard A. Comit6 programme Prdsident VIe Confdrence internationale sur le SIDA San Francisco Lars OlofKallings Prdsident International AIDS Society Minist~re de la sant6 Prdsidente, FONDATION ]Etats-Unis 662 [Page 663](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/663) Chairman: Plenary Speakers: Ivan Head Conference Chairman President, International Development Research Centre The Honourable Perrin Beatty Minister of Health and Welfare Canada Mohammed Abdelmoumene Deputy Director-General World Health Organization John Ziegler Chairman VI International Conference on AIDS San Francisco Lars Olof Kallings President International AIDS Society Ministry of Health and Social Affairs Sweden Message from Danielle Mitterrand President FONDATION FRANCE-LIBERTfS Randy Shilts National Correspondent San Francisco Chronicle U.S.A. Closing Ceremony Friday June 9 663 [Page 664](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/664) Index des pr6sentateurs Presenting Authors Index A 64 Abdullah, Tariq H. ThB P.304 Th.B.O.36 Alexander, L MDJP.17 Alger, L. M.B.P.12 Ali, Kaiser Th.B P20 Allan, Davis J. TB P.303 Allbritten, Dorothy J. Allen, David M. Robert E. WA.P26, W.B.O.16 Allen, Susan ThD.020 Allerton, TE.P33 Ancelle-Park, Rosemary WA.P.S15 Anderson, Daniel C. W.C.O.45 Anderson, David W. ThAP.31 Anderson, Elizabeth S. T.H.02, T.H.P.12 Anderson, Jean R. ThD.P.10 Anderson, Robert E. T.BP.85, Anderson, Roy T.B.P.101 Atkinson, J. Hampton WB.P233 Atkinson, William T.A.P.SO August, Sharon M. Bach, Michael C. MB.P247 Bachelerie, B. WDP WE.0.19 Barton, MA~ PliS 665 Index pr~sentateurs MJJ.O.1 7, MJLPJ 7 Bennett, Diane B. W.E.P.66 Bennett, Thaddeus A. Th.E.P.42 Benson, Elizabeth M. Th)J'2~P~96 Bentwich, Zvi H. W.C.0.29, W.CJ-.129 Bergamaschi, Denise Th.G.0SO M~A.P.90, Wi) PSi, Bemard B. Wi).P.71 Finn T. Thi).P.106 Black, John R. Ti) J'.30 Blackie, Steve Thi)J'PS2 Blair, Edward D. T.C.P 101 M~i.P~33, Blakeney, Thi)J'.18 Blankenship, 1 Terry Thi).0 52 666 [Page 667](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/667) Index Blower, Sally Mildred S. ThD.P.43 Elizabeth C. James W. TB.P.121 Brettle, Raymond P. Burgess, Mary J. TDP26 Burke, Donald S. ThAP.93 Burke, Michael T.A.P2 Bums, J. A. ThAP.69 K. Th.C.021 Chun, Peter K. T.B.P.125S Church, John A. MD.P.92 Church, Joseph A. T.B.P213 Ciacco, Marie I. Th.B.P.46 Ciesielski, Carol A. Th.B.P.44 Clark, Charles F. Th.E.P4S Clark, Edward A. T.C.P.10O Clark, MAP.113, ThA.027 Coates, Thomas Coats, Michael Th.B. P264 M.B.P.94 L. W.B.P.183 Cohen, Eric A. T.C.0.49, W.C.0.34 Cohen, Felissa L ThE.P28, ThEP.56 Cohen, WDP51 Cohen, Lucie T.CP.118 Cohen, Sarale T.B.P.1 83 Cohen, Stuart M.CPSO Cohn, David L. M A.PY76, TAAPS2, T D.0.6 Cohn, Jonathan W.B.P353 Cole, Curtis W.FP.1O Nanette L. T.A1. 73 A. Confalonieri, Franco Th.B.P.191 Conley, J. T Conly, John M. MJHIP.16 Connelly, Mark C. WB.P.46, W.BP.47 Connor, Susan Elizabeth L. H. WB).P.81 C. M.C P.61, W.B.O.47 Cooper, Cowan, Frances M. MB.P.3, WiBP.317, WB.P.371 Cowan, Morton J. T B P227 [Page 671](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/671) Index des pr6sentateurs Presenting Davidson, Bruce L. MA.0.39 Davidson, Susan J. TA.0.14 Davies, Peter M. TD.P.19, TD.P.20 Davis, Iris L. WA.P307 Davis, Jeffrey P. MA.P22 Davoli, Gerald W. WE.P.20 Th.AP.63 Jong, La Fernando V. De Lalla, Fausto W.G.P1 De Leys, Robert J. Th.C.P.109 De Maria, Andrea TB.P252 De Martini, Rodney J. Th.E.P.41 De Moya, E. Antonio Denis, Frangois Denning, David W., WB.P.10 Dennis, Macy W. Giovanni, Cleto WA.P213 Di John, David Dodd, Caroline L. ThABP.340 Dodd, Roger Y MA.P29 Doerr, J. Downie, Jean WITP22 M.H.P.12 T.CP.74 Edelmann, Frederic Edelstein, Howard E. Th.B.P279 Edlin, Brian R. M.C.P.116 Edmonson, Paul F. W.C.P.12 Patricia Harvey W. ThD.P.62 Fenger, P.361 Ferreira, I. M.B.P.108, Amrnold Fox, Philip C. ThB.P.353 Donald P. MA.O.19, WA.028 675](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/675) Index P.169 Fridland, Gardner, Th.C..0 45 Jon R. George, Michael WE.PS15 George, James R. TA.022 675 [Page 676](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/676) Index des pr6sentateurs Presenting Authors Index Gibson, Paul M. WD.P. 82 Giesecke, J. WA.0 Noel P4 Gill, Parkash Gillies, Pamela A. M.CP.34 Gilson, Irene L. MB.0.7, TJI.P.13 Peter William C. TDP.59 Grade, Margaret M. MD.P.42 Graham, Barney S. M.CP.19, Igor W.B.P230, Grant, John H. T.C.020 Haigwood, Nancy H. F. W.C.P.32 Hammett, Ann M. WA.026, W.&~P.31 Hardy, Daniel B. Th~AP.7 Hardy, lain Richard L. P.24 Hart, Clyde E. T.CP.83 677 [Page 678](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/678) Index des pr6sentateurs Presenting Hartel, B. A. W.B.P251 Helquist, Michael ThE.P66S Herb, Herbert, Barbara L. A. TE.P.3S Herbert, Daniel T.E.O.5 Herek, Gregory M. ME.P3 Herman, Bruce WA.P.101 Hemrnandez, 50 678 [Page 679](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/679) Index des pr6sentateurs Presenting T.B.P.117, T.B P.122, T.BP.148 Holm, F. Th.B.P302 Horsburgh, C. Robert, Jr. ThA.0.32, Horton, Th.C.025S Hoy, Jennifer F. M.BP.124, T.B.P311 W.C.P.133 Hu, Dale J. ME.P.4 Hu, Shiu-Lok W.C.PO10, Th.C.P.95 Jackson, Lois A. ThJI.P2 Jackson, Rudolph E. T.E.P.11 Jackson, Susan T.C.P64 Jacob, K. S. M.B.P.381 Jacobs, ME.P64, Jacobs, Raymond Jacobsberg, Lawrence W.B.P210 Jacobsen, Paul B. W.B.P332 MD.P.75 Jacobson, Jennings, Myra B. WC.P.18 Jensen, Brigitte Nybo TB.P.S9 L. John P. TB.P.210, T.B.P.220 Johnson, Margaret A. TC.P.8 Johnson, Michael P. TB.P.318 Johnson, Philip R. WC.0.50 Johnson, Pierre-Marc Th.HI.02 Johnson, Sandra M. ThJ.B.P303 Johnson, Sylvia S. TG.P.18 Johnson, Victoria Anne M.CP.97 Johnson, Warren D. WG.0.8, WG.O.11 Johnston, B. Lynn W1B.P.381 L. Th.B.P285 Index Harold, P. MDJ'.16 Katsivo, M. N. W.G. 0 22 Katz, Deborah G. T.El'S) Katze, Michael G. Th.C.P.89 Katzenstein, David Keller, Th~.B..12 Kelley, Patrick W. M~A.P.4 Kelly, Ann M~.DP308, WB.P.379 Kelly, Chester J. W~A.02S Kelly, Jeffrey A. M~D P22 Kelly, Patricia J. Th~D.P.9 Th~E~P47 Kenny, M~A.P.S7 Kenny, Frank T. W~A.P.76 Kensil, Charlotte R. M.CP.2 Keogh, Pauline M. T.E. 0 3 Kemdt, Peter R. Th~D.P.S8 Kertzner, Robert W.F.P.2 W.F. Knox, Michael D. M~DY.6 Knutsen, Alan P. TB.BP2S3 Ko, Richard J. W.D.O.S Kobayashi, Joyce S. Wi) P. 182 Koblin, Beryl A. TA.P219 681 [Page 682](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/682) Index des pr6sentateurs Presenting Authors Index Koch, Michael G. WJ.P.20 Koch, Thomas K. TB P.177 Kochen, Michael M. Kocsis, Leibowitch, Jacques L. Guido Carlos T.BP.317, Th.F.P.1 Levine, Alexandra M. ThB.O.44 Levine, Carol ME.P29, TF.O.13, WF.0.8 Levine, James D. WB.P328 Levine, Martin Levine, Robert J. WB.O.51, WF.O.1 Levitt, Nirvair T.HP.11 Levy, Jack WA.P.49 Levy, Jay M.C.O.1 Levy, Robert M. ThB P2 83, Th P.3 F. TA.P35, Diane K. ThD.O.14 Lewis, Dorothy E. M.CP.20, M.CP.124 Lewis, Edwin M. Th.B.P205 Li, Patrick C. K. Li, Yen Th.C.P.58 Th.BP.109, M.F.P.11 Long, Susan, K. ThJ.P.34 Ly, T. D. TBP 113 Lyman, William D. W.CP.61 Lyons, Catherine WD-P.52 Lyons, Robert W. T.H.P21 [Page 685](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/685) Index des Authors 0 3 24 Malek, Adel N. David J. T.EP.1 Martin, Isabelle, M. G. T.C.P 107 Martin, Jacqueline Thi~P~26 Martin, Jacques Th.C.P.86 Martin, Jean M.F.0.13 Martin, Malcolm T.C.024 Martin, Olivia S. Wi).P. 137 Martin, Paul M. T. C.P22 Martin, Steven R. T.B.P249 Martinez-Barrios, Juan Carlos McBride, Duane McCamish, C. ME.P.70 McCoy, Clyde B. ThD.P.48, Th.DP.82 McCoy, Virgina Th.C.O.41 McFarland, WA.P.8 McGee, Juli M.CP.15 McGee, Susan A. WB.P 175 McGuigan, Chris M.CP. 70 McIntosh, Kenneth Th.C.P.94 McMenamin, Diane ThEP.64 McNeamrney, A. M.C.0.16 WA.P.77 Mildvan, Donna Th.B.P278, Th.B P288, Th.B.P294 Miller, James L. ThE P.61 Miller, Kenneth P. TD.P.15 Miller, Laurel A. TB.P.43, W.B.P.345 Miller, Richard A. 687](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/687) des pr6sentateurs Presenting Authors Timothy E. WA.P.111 Miller, Veronica E. M.C.O.29 Millson, Margaret T.B.P.70 Morais de SA, Carlos Alberto M.B.P257, ThB.P.66 Morales, Edward S. TD.O0.12 Moran, John S. T.A.024 Moran, Patricia A. W.CP.S8 Mordaunt, John ME.027 Moreno, Jose N. T.B.P320 Moreno, Sylvia A. W.HJP.7 Morfeldt-Manson, R. Linda T.B.P.372 Morgan, TD.P.7 Morris, Scott K. M.B.P237 Morrison, Cliff Th.H.0.5 Morrison, Ken A. WE.0.12 Morrow, John W.C.P.128, WC.P Morse, Dale L. Morton, T.C.0.14 Moses, Th.G.027 Mosier, Donald Mosley, James W. ThAP.32 Moss, Andrew R. TA.O.11, TA.0.31 B. T.A.P88 W.G.P.21 687 [Page 688](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/688) Index des pr6sentateurs Presenting Authors Index Mundy, Thomas Th.C.P.S4 Ngugi, M.G.O.32 Nichols, David L. Th.B.O.58 Nichols, Douglas J. W.E.P.71 Nichols, Larry C. L. Park, Lawrence Neil T. T.CP.87 TD Patricia M.B.0.6 Gustavo T.B.P.1 93 Alvarez Lucia T.B P229 Perez, Victor L. W.CJ.87 Perine, Peter M~A.0S,M~A~P32 Peterson, Denton R. Th~AP.73 Peterson, Eskild A. WI).P287 Peterson, John L. W~DP.27 Peterson, [Page 691](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/691) pr6sentateurs Presenting Authors Index T.B.P247 Plaeger-Marshall, T.C.P31 W.C.P.141 Putney, MEP.S9, Filho, Celso Ramos, TB.022, WAP.66, Reed, Christie M. Rhodes, Fen Rizzi, Marco MA.P.9S Robb, Merlin Robert, Claude F. ThD.P.80 Robert, Jean TF.O.15, WG.O.40 Roberts, Chester R. ThB.O.57 Roberts, James W. MIB.P273 Roberts, Michael TC.P.13S Roberts, Richard B. M.C.P.88, Th.B.O.1 Robins, James ThA P.72 Robinson, James E. Edward Th.C.P.4S, Index des pr6sentateurs Loree V. W.EP.67 Rose, Thanne P. Th.C.P24 Rosenthal, T.E.O.16 Rosenthal, Jonathan H. M.B.P.84 Rosenthal, Kenneth L. M.C.P.21 Ross, Lawrence A. T.BP267 Ross, Paul A. T.HP29 J. M.F.O.3, W.H.O.11 Rowell, Ronald M. T.D.O.13 Rowley, Jane T. E T.H.O.16 Roy, Charles M. Th.B.P29 Roy, David J. T.F 0.10 Roy, Denis WA.P.83 Roy, Sophie T.C.027 Royal, Walter Rutherford, George T.A.0.32, W. M.A.O.35, MB P.31, T.BP.181 Ryder, Robin M.G.O.21 S Patrick H616ne M.C.P.57 Savage, Donald ThB.P.198 Sawyer, Leigh A. T.B.P281 Saxinger, Carl MA.O.17 Saxon, J. Daniel Scott, Daniel A. Th.C.P57 MG..0.33 Sharer, Leroy R. W.CP.3O Sharp, Erica S. M~A.P.17 Sharp, Victoria L. T.B J'18 Sharpton, Thonias E. T.BP64, WDP.55 Smith, George W. ThE.P.49 Smith, James R. M.B.P292 Smith, James W. M.C.P.46 Smith, Marilyn S. M.C.P82 Smith, Mark MH.0.6 Smith, Perry F. T.A.P.80, ThDP.16 D. Stephen C. J. ThA P.110 Frederick R. ThD.P30 Snyder, Harry W. WB.P310 Sobel, Alice W.B.P367 Specht, Norbert T.FP.9 Spence, Christopher Spencer, Brenda E. Spencer, Nancy E. WA.021 Sperling, Rhoda S. MA.P.56 Spiers, R. ThFPP.10 Spina, S. St. Louis, Michael E. MA.02, MD.P.1 Staats, pr6sentateurs Presenting Authors Index Stanley, Elizabeth Ann ThA.P.71 Stanley, W.B.O.23 Stein, Barry S. T.C.O.38 Stein, Robert E. MF.O0.18 Stein, T. Peter Th.B.P.305 Steinberg, E. ThEP.E57 Stellbrink, Claire E. WD.O.S Stern, Adam C. MJ.P.6, TH.0.3 WB.0.25 Sullivan, Timothy J. Th.B.P.117 Judith Y. W. ThA.P.117 Sumaya, Ciro V. Th.B.P23 Sun, Di Th. Cheryl Elaine Sweeney, Patricia A. WD.0.1 Sweet, Raymond W. WC.0.12 Geoffrey D. Thll.P.6 697 [Page 698](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/698) Index des prdsentateurs Presenting Authors Index Taylor, Kathryn M. MDP.78, ThE P5S3 Taylor, Patricia E. ThA.P.13 Taylor, Roger T.B.P.142 WA.O.9 H. L. TB P.57 Thomas, Steven G. TD.O.3 Thompkins, Jennifer E. lan L. MB.P278 Thompson, Imani P. T.EP.17 Johannes C. T.G~P8 Devanter, Nancy L. E.P.1 Huib Raden, Mark J. Th~A..1 7 Van den WII~PJ4 Th.B~P107 Vienne, Patricia Gregory A. Walker, Bruce D. W.C.0.43 Walker, T.C.0.32 Wallace, Joyce I. M.B.P.184, Walrond, Errol J. WA.P.114 Waweru, Samuel E. N. Peter O. M.GJP.11 J. T.E.P.36 P. Laurence T.C.P.3 A. W.B.P.120, Mercedes C. MD.O.10, J. A. Welsh, Gregory M. Bruce Peggy A. W.CP.8 Wermuth, Laurie A. ThD.P.5 West, Gary R. Ulf M.C.P.32 Wetherall, Neal T. W.C.P.31 Whitaker, Rupert E. D. ThA.P.58 White, Carol R. ThEP.31 White, Nick D. M.HP.22 Whitelaw, James A. Th.B.P 164 Whittaker, Bill H. W. L. Wilks, David T.CP.11 Williams, Alan E. MB.P.146 Williams, Ann WD P.42 Williams, Bryan T.CP.98 Williams, Ekanem E. Y. W.B.P.373 R. [Page Presenting Willoughby, Brian W.B.0.13, WD.P.92 Wilson, David Richard Wolters, Pamela T.H.0.7 Wong-Staal, Flossie Woo, Stephen ME.P.S8 WB.P.196, WB.P.261 Wood, Robert Wright, Nicholas H. WD.P.73, W.G.P.19 Wu, Albert W. WB.P254 Wu, Ping WB.P 133 Wykoff, Randolph F. WA.P.87 Yamamoto, Janet K. WCP.11 Michele S. WB.P57 701 [Page 702](https://quod.lib.umich.edu/c/cohenaids/5571095.0005.001/702) Index video Video Index Aboriginal Medical Service WJ.V.14 Balser, Michael and Andy Fabo T.I.V.4 Blais, Robert T.I.V.IO British Medical Association MJ.V.1 Burke, Andre WJ.V.6 Carlomusto, Maggenti MJ.V.9 Child Welfare League of America ThJ.V.4 Coward, Lynn ThJ.V.7 Current, David and Anne Ruthledge Henry, Thompson, Tuff, HahnWer du Centre World "}